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ABSTRACT 
 This thesis is centred on the application of Ru-based complexes as a promising alternative to 
cis-platin in cancer chemotherapy. Cis-platin is known to be the most prescribed chemotherapy which 
has more than 70% application in cancer cases especially the testicular cancer. An insight is provided in 
Chapter One and Two into the literatures reports on the application of Ru(II)-based complexes in 
cancer chemotherapy. In order to address some of the pressing challenges in rational design of Ru-
based anticancer complexes, section 3.3 and 3.4 deal with efforts to elucidate the complication of their 
chemistry and instability while in section 3.5 efforts are made to find solution to the lack of proper 
knowledge of their targets using different theoretical approaches as presented in Chapter Three. In 
addition to the theoretical study, this thesis also comprises of the synthesis of the bis-pyrazole 
derivatives type of ligands and the derivatives of their Ru(II)-based complexes as provided in Chapter 
Four and Five respectively. Also the computational methods were used to elucidate the structural and 
spectroscopic properties of the synthesised ligands and their Ru(II)-based complexes. 
 The geometrical and electronic properties are studied in relation to the stability and the reported 
anticancer activities of Ru(II)-based complexes in section 3.3. In subsection 3.3.1, several quantum 
properties including the natural energy decomposition analysis (NEDA) and quantum theory of atoms 
in a molecule (QTAIM) are computed on three models of RAPTA-C complexes using DFT with hybrid 
functional and basis set with ECP and without ECP. The higher stability of  Carbo-RAPTA-C and 
Oxalo-RAPTA-C over RAPTA-C comes from the lower exchange repulsion and higher polarization 
contributions to their stability which gives insight into experimental observation. A similar study was 
carried out in subsection 3.3.2 on half-sandwich Ru(II)-based anticancer complexes with 6-toluene 
and 6-trifluorotoluene. The trifluorotoluene and the hydrated models are characterised with higher 
charge transfer, polarizability, synergistic effect of ligand fragments, stronger and higher HB 
interactions that support their reported experimental anticancer activities and the mechanism of their 
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activation by hydrolysis. Also in the subsection 3.3.3, the factors that determine the stability and the 
effects of non-covalent interaction on the two models of these half-sandwich 6-arene ruthenium 
anticancer complexes and their respective hydrated forms were investigated using DFT method. Lastly 
in section 3.3, the subsection 3.3.4 deals with the intramolecular properties of five sets of ruthenium 
based anticancer complexes using DFT method. 
 The spectroscopic and the non-linear optical properties of selected Ru(II) anticancer complexes 
are shown in Section 3.4. In subsection 3.2.1, DFT method was applied to study the thermodynamic 
and spectroscopic properties of three Ru-based complexes in order to give possible reasons for the 
reported experimental stability of complexes 1 and 2 with bidentate chelating ligands than complex 3. 
A further study was carried out in Subsection 3.4.2 where computational method was used to gain 
insight into the correlation between the chemistry of the hydrolysis and the anticancer activities of 
selected Ru(II)-based complexes. Lastly in this section, subsection 3.2.3 deals with application of 
different density functional methods (DFT) to optimize and study the chemistry of five potential 
anticancer complexes in terms of their electronic, conductive and spectroscopic properties. The 
carboxylic and pyrazole units are found to significantly enhance the polarizabilities and 
hyperpolarizabilities of the complexes while the chloride only improves the polarity of the complexes. 
 The possible targets of Ru(II)-based anticancer complexes are predicted using docking methods 
as presented in section 3.5 of this thesis. In subsection 3.5.1, the interactions of selected Ru(II)-based 
complexes with different cancer receptors are carried out using computational docking. The study 
focuses more on finding alternative protein targets other DNA for some Ru(II)-based complexes using 
computational docking. A further study on addressing the problem of the improper knowledge of of the 
targets of Ru-based anticancer complexes was carried out in subsection 3.5.2. Some promising 
anticancer complexes of Ru(II) such as RAPTA based complexes formulated as [Ru(η6-p-
cymene)L2(pta)] and those with unusual ligands are docked against receptors using Autodock, Glide 
and Gold. Lastly in section 3.5, docking packages Molegro and Autodock were applied in subsection 
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3.5.3 to predict the anticancer activities of selected Ru(II) complexes against twelve anticancer targets. 
Introducing the quantum calculated atomic charges of the optimized geometries is found to 
significantly improve the docking predictions of these anticancer metallocompounds.  
 In section 4.3-4.6, the spectroscopic and the geometric properties of ligands with pyrazole,  
methylpyrazole, bipyridine and phenanthroline derivatives were studied at both experimental and 
computational levels. The computational results are perfectly in agreement with the experimental 
results especially in terms of the spectroscopic properties.  The spectroscopic analyses as well as the 
computed properties were used to establish the successful synthesis of the ligands. Many of the 
functional groups in these ligands are found to be Raman active which also help in their spectroscopic 
elucidation. 
 Lastly in chapter five, the method used for the synthesis of forty Ru(II)-based complexes were 
presented with their experimental spectroscopic features being elucidated using theoretical methods. A 
very high correlation was observed between experimental and theoretical characterisation of the 
complexes which is an indication of successful synthesis of the complexes. 
1 
CHAPTER ONE 
1 INTRODUCTION 
1.1 Introduction 
 Cancer is known medically as a malignant neoplasm [1-4] which means a progressively worse 
growth or abnormal proliferation of cells that result in an abnormal mass of tissue. These cells divide 
and grow uncontrollably, forming malignant tumours, and metastasised by invading other parts of the 
body. There are more than 200 different types of cancer that are known and vary in nature from one site 
to another. The causes of many cancers are not completely understood as the origin of many can neither 
be traced to bacterial nor to viral infection. A primary cancer can be treated by surgery but when it is 
metastasised into a systemic problem, chemotherapy is the best method of treatment. The most efficient 
drug recognised for the treatment of more than 70% of cancer cases is cis-platin [5, 6]. Many promising 
potential anticancer drugs of metal-based complexes have been proposed to have better activities than 
the most commonly used platinum chemotherapy against cancer but their targets remain unknown [5-
14]. There are evidences that proteins are the most likely targets for organometallic anticancer 
complexes other than Deoxyribonucleic acid (DNA) which is an established cis-platin target. 
Ruthenium antitumor agents generally display lower reactivity towards double-stranded DNA and their 
cellular mechanisms of action are not known [15]. In an effort to address the present problems in 
cancer therapy like non-selectivities of the cytotoxic cancer drugs, ineffectiveness towards many 
metastasised cancer cells, drug resistance and toxicity, many researchers are focusing on the design of 
metal-based anticancer complexes with better selectivity. The motivation behind metal-based 
anticancer design is due to the recorded success of cis-platin above all the available organic anticancer 
counterparts despite its nonselectivity [13, 16-18]. Dyson and co-researchers designed different 
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derivatives of Ru-based complexes containing a kinetically favourable 1,3,5-triaza-7-
phosphaadamantane (PTA) group with many derivatives of the type [(η6-arene)RuCl(PTA)2], [(η
6
-
cymene)RuCl(PTA)2], [CpRuCl(PTA)2] and [Cp*RuCl(PTA)2] which are generally referred to as 
RAPTA complexes and are characterised by strong in vivo but weak in vitro activity [5-7, 18, 19]. 
Another group in this field is Sadler and co-researchers [20-35] who are working on Ru-based 
complexes called the ―piano-stool‖ [36, 37] that are often characterised with bidentate nitrogen donor 
atoms (e.g. ethylenediamine) coordinating with the metal. Both group of researchers are exploring the 
use of cyclic π-ligand with other ligands coordinated to the Ru metal centre as potential anticancer 
agents. It has been observed that metal in a way has been enhancing and even inducing some 
pharmacological properties into ligands as some non-cytotoxic ligands in metal complexes lead to 
compounds with significant anticancer activities [38-40].  
 Our research effort is directed towards proposing the possible target of anticancer 
organometallic complexes of ruthenium(II) using docking methods and designing more selective 
anticancer agents by focusing more on cancer peculiar proteins other than DNA. We are interested in 
designing complexes that will display higher activity at lower dose because most of the current 
compounds with potential anticancer are only effective at high dose [19]. The search for the alternative 
targets for Ru-based complexes is a research challenge as the targets of many of these complexes can 
not be ascertained [5, 8-11]. There has been some controversy about similarities and differences in the 
anticancer chemistry of cis-platin and Ru(II) complexes with some suggesting that Ru(II) complexes 
probably function in a different manner from cis-platin while other stated that they mimic cis-platin 
[41]. However, organometallic Ru(II) anticancer complexes are reported to be more similar to cis-platin 
than to inorganic Ru(II) compounds [41]. The lack of proper understanding of the targets of Ru-based 
complexes is hindering their rational design [10] and its the major factor that is hindering the national 
cancer institute (NCI) approval of Ru-based complexes like indazolium trans-[tetrachloridobis(1H-
3 
indazole)ruthenate(III)] (KP1019), and imidazolium trans-[tetrachlorido(1H-imidazole)(S-dimethyl 
sulfoxide)ruthenate(III)] (NAMI-A) [7].  
 There has been a great deal of research directed towards generating novel complexes for 
anticancer testing but the rational design has been hampered due to lack of understand of their mode of 
actions [10]. Many of these organometallic complexes have been reported to be unstable and have 
complicated ligand exchange chemistry [5]. However, some ruthenium organometallics have displayed 
high water- and air-stability [8, 42]. There have been many experimental reports on the anticancer 
activities of metal-based complexes without any detail understanding of electronic structural properties 
in relation to the observed activities and the instability of some complexes [5]. The theoretical methods 
have been used enough to complement and sometimes even to challenge experimental data in areas like 
predicting the geometries, vibrational frequencies, bond dissociation energies, and other chemically 
important properties [43]. In drug design there is need for a clear understanding of the physicochemical 
properties of the drug candidates [44] which will enhance their rational design.  
 Another significant part of this project is the experimental synthesis of the proposed complexes 
from computation and the study of their anticancer activities. 
 
1.2 Methods of cancer treatment and need for alternative metal-based anticancer 
agents  
 There are four standard methods of treating cancer which are surgery, chemotherapy, radiation 
therapy, immunotherapy and biological therapy [45]. Surgery is taken to be the first and the best 
approach for external tumours and primary cancer that have not been metastasised. Radiation therapy 
uses high-energy radiation from X-rays, gamma rays, and radioactive particles to shrink tumours and 
kill cancer cells. Chemotherapy deals with application of drugs which is found to be the best means of 
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controlling metastasised cancer and also found useful for many primary cancers even before any 
attempt of surgery. Water-soluble organometallics based on radioactive elements such as 99mTc, 188Re 
and 186Re are applicable for diagnosing and to potentially treat cancer. The radioactive metal centre 
will provide the activity while the ligands that are attached to the metal centre will determine the 
selectivity and efficiency of these compounds to target diseased cells [5]. Also, some drugs like Bexxar 
combine both the radioactive and chemical properties together. Bexxar is a radioactive tositumomab 
that is linked covalently with iodine-131. Bexxar binds to CD20 and also directs radioactivity to B-
cells. The function of CD20 is not clear but it is known as a B cell-specific surface antigen that plays 
role in B cell activation and proliferation [46]. Another example is Zevalin (Yttrium-90 ibritumomab 
tiuxetan) which is a radioactive antibody directed against CD20 on B lymphocytes. It is analogous to 
iodine-131 tositumomab. Zevalin is a tissue-selective agent against both normal and malignant B cells 
which induces apoptosis in CD20+ B-cell lines and also send the radiation from Y-90 to induce cellular 
damage in the target and neighbouring cells [46]. However, the focus of this thesis is on chemotherapy 
aspect of cancer treatment. 
 The goal of the National Cancer Institute (NCI) is to eliminate suffering and death due to cancer 
by year 2015 [47]. The possible means of achieving this aim by using chemotherapy anticancer drugs is 
suggested to be in the combination of the three classes of chemotherapeutic anticancer drugs which 
entails: 
i. Cancer-specific targets  
ii. Universally-vital targets but with selective protection of normal cells and 
iii. Tissue-specific targets [47]. 
Each of these classes of chemotherapeutics for cancer treatment is associated with limitations as the 
cancer-selective agents are limited to rare Kinase-addictive cancers, semi-selective agents are not 
effective alone, cytotoxic agents are too toxic alone, and tissue-selective agents are reported to be 
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accidental [46]. Several efforts have been made in the past 30 years to elucidate the specific targets for 
cancer therapy and find the mechanisms of their actions. One of the first cancer targets identified is 
Bcr-Abl Kinase with the inhibitors gleevec and imatinib developed to treat Bcr-Abl-positive-leukemia 
[47]. Despite the growing rate of research on cancer therapy and the number of drugs as anticancer 
agents, yet the rate of the survival (65.3 per 100000 people) of cancer infection is far less than the rate 
of cancer death (181.3 per 100000 people) which is an indication that more efforts are needed to 
address the issue. Out of the list of more than 100 drugs that have been approved as anticancer agent 
from the NCI [48], it is only cis-platin and its derivatives that are metal-based drugs. The cis-platin is 
known since the history of cancer treatment as the most notable anticancer therapeutic drug [49]. The 
superior activities of cis-platin are traceable to the opportunities that are offered by metal in drug 
design such as ability to go beyond the coordination number four in carbon atom, act as glue to attach 
different ligands that may act in a synergistic fashion with each part, exploit endobiotic metal transport 
pathways to give a degree of tumour cell targeting, redox properties offer tumour cell selectivity and 
also accord some unique properties like structural diversity, adjustable ligand exchange kinetics, fine-
tuned redox activities and distinct spectroscopic signatures [7, 49]. Because of several binding 
geometries that are possible using metal atom which gives it an improved ability to build many 
structures, it is referred to be serving as a stable imaginary ‗‗hypervalent carbon‘‘ [49]. 
 Cis-platin and its derivatives are the only metal-based anticancer drugs that are at present in 
clinical usage and continue to be used in up to 70% of all cancer patients [5, 6]. They have been used to 
treat many cancerous cells and organ including ovarian, oropharyngeal, bronchogenic, cervical and 
bladder carcinomas, lymphoma, osteosarcoma, melanoma, neuroblastoma [18] and testicular cancer 
which prior to the introduction of these drugs, 90% of patients usually died [7]. Despite their 
tremendous success, they still suffer some disadvantages like being inefficient against platinum-
resistant tumours especially their inactivity against many cancer cell lines and metastasis (secondary) 
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cancers [6] and are associated with severe side effects such as nephrotoxicity due to their high general 
toxicity [8]. Cis-platin protein interactions are often considered to be random and non-specific, with 
cis-platin being particularly susceptible to interactions with sulfur-containing residues such as cysteine 
and methionine. They also offer very little possibility for rational improvements to increase its tumour 
specificity because of its particular structure.  
 There are three metal-based antineoplastic chemotherapeutics of Pt compounds namely cis-
platin, carbo-platin, and oxalo-platin, which are approved for worldwide clinical practice. However, 
they are frequently accompanied by severe side effects, and their activity is limited in many widespread 
tumours due to acquired or intrinsic resistance [14]. As a result of the limitations of cis-platin, many 
other metallic and organometallic anticancer drugs have been suggested and some are already passing 
through the phase II clinical test. There is also the cruel consequence of cancer development after 
approximately 10 years of cis-platin therapy because of cis-platin-induced DNA lesions which lead to 
incentives to develop therapies that do not target DNA [7]. The cancer-induction is believe to be the 
result of the irreversible binding of cis-platin to DNA but metal like ruthenium has been discovered to 
bind to DNA reversibly. Another disadvantage of DNA target compared to protein targets is that DNA 
is present in both healthy and cancerous cells including eventual tumours and their metastases while 
protein targets provide the possibility of obtaining selective drugs as many of the proteins are diseases 
peculiar [7]. Examples of metallic anticancer drugs are metallocenes. All medicinally important bent 
metallocenes have a cis-dihalide motif which is similar to the cis-dichloro motif of the well-established 
anticancer drug cis-platin [8]. Besides platinum, other metals like Fe, Ga, Ti, Ir, Co, Ru, Au, Os and Rh 
are the most often screened metal-based complexes as anticancer agents but Ru in the oxidation state of 
+2 and +3 is taking the lead. In the quest for metal compounds to extend the spectrum of activity of 
metallodrugs, ruthenium complexes have been identified to be the most promising alternatives to Pt 
complexes [14]. A very important organometallic anticancer drugs of recorded efficiency against cancer 
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cells are ruthenium-based antitumor drugs. The idea of using ruthenium-containing organometallics as 
anticancer agents was first developed by Tocher et al. [50]. Ruthenium complexes have a stronger 
affinity for cancer tissues more than normal tissues due to its ability to bind readily to transferrin 
molecules in plasma where it is transported to the tumour tissues. Then the ruthenium-transferrin 
complex is internalized into tumour cells through transferrin receptors to accumulate specifically in 
cancer tissues [51, 52]. Besides KP1019, and NAMI-A which are Ru-based drugs in clinical test, many 
other promising Ru complexes such as RAPTA (R = Ru, A = 6-arene, PTA = 1,3,5-triaza-7-
phosphaadamantane) and piano-stool form of complexes have been found to have high inhibitory 
activities against tumours. These type of cancer therapy can not be classified as cytotoxic and also they 
are non-toxic to healthy cells because the ruthenium may mimic iron in binding to biological molecules 
such as serum transferrin and albumin [5], they have been found to inhibit cancer metastasis and have 
only mild effects on the primary tumour [8]. PTA ligand in RAPTA complexes confers water solubility 
and is of critical importance for it could facilitate the administration and transportation of the drugs and 
exhibit the pH-dependent DNA damage [5, 9]. One of the limitations of RAPTA complexes is that they 
are prone to hydrolysis and would have to be administered in saline to suppress the cleavage of the 
chloride ligands. One of the suggested means of circumventing this problem is the synthesis of RAPTA 
with bidentate ligands to replace the labile chloride ligands. Some ruthenium-arene complexes are 
unstable and have complicated ligand exchange chemistry. Increasing their stability might provide 
better drug candidates [5].  
 
1.3 Methods of improving anticancer activities of metal-based drugs and proposing 
their targets 
 Recent studies on several cytotoxic metallodrugs revealed that their biological and 
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pharmacological actions are independent of DNA contrary to the initial opinion that the mechanism of 
their action relies on direct DNA damage [8, 9]. Dyson and Sava [6] in their study observed that the 
discovery of innovative agents that will address the tumour malignancy lies not simply assuming that 
DNA is the only relevant target of metal-based drugs but focus must be on how these organometallic 
cancer drugs could match and pharmacologically interact with protein targets of significant function to 
cancer existence. Another strategy that is being used in designing organometallic drugs is attaching an 
organometallic fragment to compounds of known biological function [5, 6]. This alternative approach 
to the discovery of new metallodrugs involves binding an organic compound of known therapeutic 
value to a metal-containing fragment which results in the metal-drug synergism in which the metal acts 
as a carrier and stabilizer for the drug until it reaches its target, while the organic drug fragment carries 
and protects the metal, preventing side reactions in its transit toward a second target of biological 
action [53]. This is gaining recognition because of its ability to endow existing drugs with new 
properties which include overcoming drug resistance. This was reported to be used by Brocard and co-
workers to modify the chloroquine series of drugs, to produce a ferrocenyl derivative called ferroquine 
which has been proven to be effective against chloroquine resistant malaria parasites and is now 
completing phase II clinical trials [6, 8, 54]. Also in a research, Rajapakse et al [53] found out that the 
potency of Ru(II) complexes of chloroquine against malarial resistant parasites is consistently higher 
than that of chloroquine. The compounds also inhibited the growth of colon cancer cells, independently 
of the p53 status and of liposarcoma tumour cell lines with increased sensitivity. Also, ruthenium 
complexes were discovered as protein Kinases and HIV-1 reverse transcriptase inhibitors [55] 
 The activities of any potential pharmaceutical compound as representative of their in vivo 
behaviour can be predicted through the study of their effects on cell culture. The growing of cells in 
vitro is made possible because of the genetic modifications that take place in the diseased cells like 
cancer cells since the normal cells do not grow in tissue culture [5]. Due to the complexity of 
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mammalian cells, it is not possible to identify all the in vivo interactions of the biomolecules with the 
drugs using in vitro study [5]. The complexity of cancer in human patients can not be completely 
represented by in vitro studies nor entirely modelled by one in vivo system but through the combination 
of appropriate in vitro and in vivo models [56]. The metabolism of many diseased cell are altered, 
which results in a lower oxygen concentration, reduced pH and elevated levels of glutathione in the 
cancerous tissues. This promotes a reducing environment which helps in the activation of many 
anticancer drugs [5] especially the Ru-based drugs. Sava et al [7] suggested that protein inhibition 
assays should become the first screening step in metal-based drug development. Although there are 
many in vitro promising metal-based complexes, yet they have a relatively low representation in the 
clinic because most of the drugs with good in vitro properties fail to show any therapeutic effect in 
vivo. This has been reported to be due to pharmacokinetic limitations, cross-reactivity, general toxicity, 
low initial efficacy and rapid development of drug resistance [7]. 
 Cancer progression is known to start from the primary tumours and migrate to metastasised 
tumours which become a systemic problem that is very much difficult to treat. The process of 
metastases was explained to involve tumour cells migration from the primary tumour to enter the 
circulation (intravasation), detachment of tumour cells from the local primary tumour, invasion of 
intercellular matrices, penetration of basement membranes of blood vessels, resist anoikis that initiate 
cells apoptosis when out of their cellular contact, circulation while undergoing homotypic aggregation, 
extravasation, immune escape, induction of new blood vessels (angiogenesis), proliferate and 
successfully grow into a clinically relevant metastatic lesion [56, 57]. Access to primary tumour has 
made it possible to carry out in vivo sensitivity testing and to obtain tissue for studying the therapeutic 
mechanism and molecular changes in response to treatment [58].  
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1.4 The mechanism of anticancer activities and proposed targets.  
 There are many proteins that are proposed to play some significant roles in cellular tumour 
invasion apart from DNA. Some of them are urokinase plasminogen activator receptor (uPAR) [59], 
cathepsins B [59], topoisomerase I and II (top I & II) [58, 60], HER-2 [58], the tumour suppressor 
protein p53 and its regulators (including c-Jun NH2-terminal Kinase (JNK)) [13], hypoxia-
scolaroinducible transcription factor-1 (HIF-1) is also another attractive target for enhancing the 
therapeutic efficacy against many tumour cells especially non-small cell lung cancer (NSCLC) cell 
lines [61]. Several studies have shown that an elevated level of HIF-1 is associated with radio-
resistance and chemo-resistance which leads to a poor prognosis especially in lung cancer that is still 
the leading cause of cancer deaths worldwide. It is found to be related with more aggressive 
phenotypes of tumour cells and the therapeutic resistance of tumour cells. HIF-1 is a heterodimer 
composed of HIF-1 alpha and HIF-1 betal subunits and is one of the most important regulatory 
molecules that respond to hypoxia for cell survival. Therefore, down-regulation of HIF-1 was 
associated with proteosomal degradation and decreased Akt phosphorylation [61]. However, it is not 
easy to find them because HIF-1 is a transcriptional factor, which is not a conventional target of drugs. 
 The interaction of metallodrugs with plasma proteins is also relevant, as platinum and 
ruthenium compounds may bind to proteins such as serum transferrin and albumin, which are normally 
used to deliver iron to the cells [5]. Different methods have been used to improve the effective delivery 
of anticancer drugs to tumour tissue in order to improve their selectivity and consequently, reduce side 
effects. This has lead to enhancement of the intracellular concentration of drugs in cancer cells, usually 
without being blocked by P-glycoprotein, a protein responsible for multidrug resistance [62]. Serum 
albumin has been exploited as a drug-delivery system as albumin conjugates for the delivery of 
anticancer agents and albumin nanoparticles for drug encapsulation because of its accumulation in solid 
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tumours. Albumin conjugates with methotrexate and a doxorubicin derivative and an albumin 
paclitaxel nanoparticle (nab-paclitaxel; abraxane) have been evaluated in clinical trials. Also albumin 
conjugates of the platinum(II) anticancer drug carbo-platin were shown to be as, or more, effective and 
even in some cases, were less toxic than carbo-platin in reducing the tumour size of nude mice bearing 
human breast tumours [62]. In another attempt to improve the physicochemical properties and 
bioavailability of organometallic anticancer, researchers have coupled cyclin-dependent Kinase (Cdk) 
inhibitors with organometallic moieties [62]. Stepanenko et al [62] have synthesized the complexes of 
[RuCl(η6-arene)(L)]Cl in which the arene is 4-formylphenoxyacetyl-η6-benzylamide and L is a Cdk 
inhibitor [3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines and indolo[3,2-d] benzazepines to 
evaluate the antiproliferative activity and bioavailability. Some of the promising effects of these 
complexes are increased solubility in physiologically relevant media and synergistic effects from metal 
and ligand leading to highly cytotoxic species [62]. A report has revealed that conjugation of the 
ruthenium moiety to modified rHSA was realized via hydrazone bond formation and cleavage of the 
hydrazone bond under acidic conditions has been exploited for drug release in cancer cells [63]. 
 However, since there are many enzymes or proteins that have been discovered to play some 
vital role in cancer growth and metastasis, it is not feasible to consider all in a single project. But it is 
interesting to know that some drugs that are designed against cancer associating prominent enzymes 
like top II can also significantly hinder the expression of some of the other enzymes. There are reports 
on inhibition of hypoxia-induced HIF-1 protein accumulation in tumour cells through the 
administration of individually camtothecins, topotecan and etoposide which are Top II inhibitors [61, 
64] and a better effect was even observed when topotecan and etoposide were combined [61]. It has 
been experimentally shown that the modulation of the HIF-1 expression by Top inhibitors requires the 
expression of Top [61]. 
 Even though cell apoptosis through drugs that are cytotoxic is the main approach in cancer 
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treatment yet the use of multi drug therapy is necessary especially to administer cytotoxic with other 
drugs that have the ability to deactivate the activities of some enzymes that will prevent cell apoptosis. 
Many common chemotherapeutic drugs and other inducers of DNA apoptosis result in activating NF-
κB nuclear translocation and its DNA-binding. Because some of the anthracyclines such as 
daunorubicin that induce DNA-damage through inhibiting topoisomerase II also undergoes redox 
cycling to produce oxygen free radicals, it was initially believed that production of oxygen free radicals 
is responsible for the activation of NF-κB binding to DNA until it was recently disproved [65]. Many 
proteins or enzymes have been proved to be significant in tumour growth and metastasis. The 
connection between the level of expression of these enzymes in the tumour cell and the degree of 
apoptosis has been demonstrated experimentally. In one of the studies, the higher apoptosis level 
discovered in patients with breast cancer who responded to anthracyclines such as daunorubicin, 
doxorubicin and aclarubicin [65] treatment showed that top II levels declined in responsive tumours 
[58]. Some additional ezymes or proteins of interest to us in this project as potential target in cancer 
therapy are: 
i). Ribonucleotide reductases (RNR): The action of this enzyme is responsible for the synthesis of 
DNA from the corresponding building blocks of RNA. These enzymes convert ribonucleotides (a base 
and phosphate group linked to a ribose sugar) into deoxyribonucleotides (a base and phosphate linked 
to deoxyribose sugar) [66]. 
ii). Histone Deacetylase (HDAC7): Histones are proteins that assist in the packaging of DNA into 
chromosomes as well as in gene regulation and are effective through acetylation and deacetylation. The 
inhibition of this becomes the drug target because without its function of removing acetylated groups, 
the signalling switches will become stuck in one position and loses their effectiveness [66]. Histone 
deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth arrest, differentiation 
and apoptotic cell death [67]. 
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iii). Cathepsins B: Cathepsin B has been reported to play significant roles in glioma invasion which is 
a complex primary brain disease of tumour invasion [59]. Cathepsin B (CatB) is an enzyme that is 
involved in cellular metabolism and it is implicated to take part in the tumour progression and 
metastasis processes which makes it a suitable target for the design of anti-metastatic drugs [68]. The 
use of Cat B inhibitors has been reported to reduce both the in vitro tumour cell mobility and 
invasiveness [9]. 
iv). Topoisomerase II (Top II): This plays an important role in replication, transcription, 
recombination and segregation of chromosomal pairs during cell division. Topoisomerase IIa (top IIa) 
has been reported experimentally as a known molecular target for anthracyclines and it is found to be 
frequently co-amplified with HER-2 in breast cancer [58]. In the absence of drug, Top1 plays a key role 
in relaxing supercoiled DNA for replication and transcription [60]. It is also involved in maintaining the 
structural organization of the mitotic chromosomal scaffold [52]. 
v). Thioredoxin reductase (TrxR): TrxR system (TrxR reductase, and NADPH) is an ubiquitous 
flavoenzyme of thiol oxidoreductase system that regulates cellular reduction/oxidation (redox) status 
[9, 69]. It is a large homodimer with a glutathione reductase-like structure. TrxR is a likely 
pharmacological target for a range of metallodrugs because its active site selenolate group manifests a 
large propensity to react with ―soft‖ metal ions after its reduction [9]. Human TrxR has a conserved 
dithiol active site, Cys32-Gly-Pro-Cys35, and contains three structural cysteine residues (Cys62, 
Cys69, and Cys73) [70]. 
vi). Thymidylate synthase (TS): Thymidylate synthase (TS) gene is located on chromosome 18p11.32 
and it is a critical enzyme in maintaining a balanced supply of deoxynucleotides required for DNA 
synthesis and repair [71]. Thymidylate synthase and dihydrofolate reductase are choice targets of 
chemotherapy to test the vulnerability of cancer cells to the inhibition of TMP synthesis [66]. 
vii). Recombinant Human albumin (rHA). This has been reported [36] as the most abundant protein 
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in blood (ca. 0.6 mm) which plays a significant role in the pharmacokinetic availability of a wide range 
of drugs, including metallodrugs and consequentially determines their bioavailability and toxicology. 
Serum proteins can play a divergent role either in delivery of metal-based anticancer drugs to their 
cellular targets or in deactivating them even before reaching the target(s) [38].  
viii). DNA gyrase: This is included in this project to know the possibility of anticancer agents also 
acting as antimalarial agents which can be relevant since bacterial infections are known to be 
opportunistic infections. DNA gyrase controls the topological state of DNA [72] and uses the free 
energy of ATP hydrolysis to catalyze the negative supercoiling of double-stranded circular DNA [73]. 
Since the relaxation of DNA is essential for DNA replication and transcription, therefore the inhibition 
of DNA gyrase blocks relaxation of supercoiled DNA, which makes gyrase a suitable target for 
antibacterial agents [72, 73].  
ix). BRAF Kinase: Among the RAF isoforms, BRAF Kinase represents an excellent target for 
anticancer drug development because it differs significantly from CRAF and ARAF as a major 
activator of MEK1/2 and requires fewer regulatory events for activation [74]. These BRAF mutations 
are found in a variety of cancers which includes 67% of melanomas, 30-50% of thyroid cancers, 30% 
of ovarian cancers, 5-20% of colorectal cancers, and 1-3% of other cancer types [74].  
x). Histone Protein in Nucleosome core particle (HP-NCP): NCP has been pointed out as a basic 
repeating element of histone-packaged DNA comprising chromatin. Chromatin has become one of the 
potential superlative therapeutic targets for metallodrugs and other compounds because of its 
abundance and primary regulatory function of histone proteins in DNA sites [15]. 
 
1.5 Computer-aided drug design application 
  The major focus of computational science is to transform theories into computer algorithms and 
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use it to understand the science of its systems. This computational method helps to solve problems 
whose difficulty or complexity places them beyond analytical approach or human endurance [75].  
 In the pre-clinical drug discovery, an indispensable computational method that is commonly 
used is docking of ligands into the target protein binding site in order to understand their mode of 
interaction, find the correct conformation of a ligand and its receptor and to screen the library of 
ligands through their binding energy. This is used as one of the important tools of high-throughput 
virtual screening to generate ―hits‖ and enrich compound libraries. It is also used to optimize ―hits‖ into 
lead series which includes testing of structure-activity relationship (SAR) hypotheses as well as 
evaluation of novel scaffolds and core templates [76]. 
 The first step in structural based drug design is to find out the structure and the enzymes or the 
proteins that are unique to the life-cycle and functions of the responsible pathogens. The most sensitive 
work of the researcher in this step is to be sure that the enzymes that are identified as significant to the 
pathogens are not having strong hit with any of the human proteins [77]. Computational chemistry is 
applicable at the early stage of drug research to reduce the number of possible ligands and also at the 
end during lead-optimization stages in an effort to reduce experimental costs and times [78]. Though it 
is possible to get the detail structures of biological macromolecules such as protein experimentally, it is 
hard to study the change on a short time scales as individual structures of the molecules functions. 
Also, experiment alone cannot study the molecular mechanisms of fast processes such as chemical 
reactions in enzymes or ion transport through membranes. These problems are solved through the use 
of fundamental physics theorems which are used in modelling how proteins and other biomolecules 
move, fluctuate, interact, react and function. Through simulation, structures can be analysed in atomic 
detail and experimental data can be interpreted in terms of atomic level interaction to show the 
mechanisms of biomolecular function rather than providing pretty pictures as in experiment. Also, it 
reduces the cost and the time of new drug to reach the market. For instance in in less than 2 years from 
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the start a novel, potent, and selective anti-anxiety, anti-depression 5-HT1A agonist reached the stage 
for clinical trials with less than 6 months of lead optimization and synthesis of only 31 compounds 
[79]. The development of more accurate and reliable algorithms in computational chemistry has made 
it a significant method that is used to exploit the opportunities of potential new drug targets emerging 
from genomic and proteomic initiatives and to screen the large libraries of small compounds now 
readily available through combinatorial chemistry [78]. 
 The best known success stories of computer-aided drug design are in HIV and flu drugs. Since 
the early success in the application of computational modelling, it has become an integral part of drug 
discovery and almost every recent drug from big pharmaceutical companies to market has involved 
some sort of collaboration with computational chemistry. Computational modelling plays a salient role 
in drug discovery mostly because no drug is created solely in silico [80]. Though high-throughput 
screening are now available in both academic laboratories and drug companies, the cost of random 
screening of very large collections of compounds can be prohibitive. Therefore, where possible in silico 
or virtual screening has become a significant tool in drug discovery to filter down the number of 
compounds used in real screens to solve the problem of delay and expense in synthesis [81].  
 Compared to organic compounds, organometallic complexes are rarely studied computationally 
due to difficulties of optimizing and computing metal complexes [68]. Taking an instance of RAPTA 
complexes, there are little computational studies of these complexes such as in clarifying the 
experimental data on pKa values [82], docking to cancer macromolecules [51], QM/MM study of the 
interaction of Ru(II)-based complexes to macromolecules [68], DFT study of the interaction of the 
complexes with residues that characterise the binding sites of cancer macromolecules [41]. Also, there 
have been several successful applications of molecular docking studies in rational drug design but they 
have limited application to study metal complexes [9] mostly due to the lack of appropriate force fields 
to take care of metal atoms [83] and their relativity properties. 
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CHAPTER TWO 
2 LITERATURE REVIEW 
2.1 Metal based complexes as promising anticancer agents  
 Since 1960s when Rosenberg discovered that cis-platin inhibits cell division in bacteria, it was 
subsequently identified as a potent anticancer agent in 1970 and quickly became the most widely used 
cancer chemotherapeutic drug [16]. Cis-platin entered clinical trials in 1971 and, within a relatively 
short time, became the most widely used anticancer medicine [13]. Cis-platin is extremely effective 
against several cancers like testicular and ovarian cancers [16]. Its application is also accompanied by 
severe side effects, like nausea, vomiting and hearing loss, and many tumours show intrinsic or 
acquired resistance against the drug [16]. Its application is also limited by its activity in a few numbers 
of tumours [17], severe toxicity, and also by drug resistance which may be natural resistance to cis-
platin or a developed resistance after initial treatment [13]. Other cis-platin derivatives that are 
developed as a result of these limitations are carbo-platin and oxalo-platin (Table 2.1) which defer from 
cis-platin mainly in terms of their rate of aquation and therefore their overall reactivity [16]. Other drug 
that have been developed to treat cis-platin resistant cancers are complexes of ruthenium, gallium, 
titanium and gold [17]. These drugs exhibit a different mode of action compared with platinum-based 
drugs and are found to treat cis-platin resistant cancers [17]. 
 Since the last 30 years, many experimentalists together with theoreticians have been partaking 
in the design and evaluation of the antitumour properties of a wide selection of metal-organic 
compounds against cancer targets with the aim of getting better potent therapies for cancer cells. The 
significant impact of metal-based drug (cis-platin) in clinical application and the limitations associated 
with its uses have motivated extensive investigations into alternative metal-based cancer therapies. The 
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investigations to produce drugs that will be widely used as cis-platin and its derivatives have not been 
successful even though many other drug targets have been identified along the way [13] as well as 
many potential anticancer agents. This is what call for further research efforts to discover other metal-
based drugs that will address the limitations that are associated with the use of cis-platin and its 
derivatives. Besides the carbo-platin and oxalo-platin derivatives of cis-platin that are approved for 
worldwide usage, there are other platinum-based drugs that have been approved for regional uses. 
Nedaplatin is approved in Japan, heptaplatin in South Korea, lobaplatin in China (Table 2.1) [84]. 
Report has shown that the first ever marketed transition organometal drug was ferrocerone that was 
clinically approved in the USSR as antianeamics [8]. Organometallic complexes offer aspects for 
medicinal chemistry that are not available with organic drugs, in particular because of their 
coordination and redox properties [85]. The quest for alternative anticancer drugs, resulted in a variety 
of cytotoxic organometallics, of which (arene)-ruthenium complexes occupy a prominent position 
because of their unique combination of lipophilic and hydrophilic properties [51]. Many of the 
ruthenium potential drugs are characterised by low general toxicity, which is attributed to the ability of 
ruthenium to accumulate specifically in cancer tissues, possibly via the transferrin pathway [51]. 
 In the field of cancer chemotherapy, the cyclopentadienyl complex, [Cp2TiCl2] has been in 
clinical trials and a ferrocene derivative of tamoxifen is also in clinical trials for breast cancer therapy 
[37]. Since metal-based drugs tend to undergo activation following administration, they are then being 
considered as prodrugs that are activated in vivo [17]. The mechanism of their action comprises simple 
hydrolysis/aquation and subsequent reaction with proteins or DNA [17]. Many promising compounds 
which include derivatives of the clinically tested titanocene dichloride (Table 2.1), ferrocene-modified 
established drugs, square-planar gold drugs, and ruthenium–arene and osmium–arene complexes 
appear to have the potential to overcome the limitations of current chemotherapeutics [17]. Among the 
most prominent potential anticancer candidates today are KP1019 [12, 86], NAMI-A [87-92] and 
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[dichlorido(η6-toluene)(PTA)ruthenium(II)], where PTA is 1,3,5-triaza-7-phosphaadamantane 
(RAPTA-T) [16] (Table 2.1). NAMI-A and RAPTA-T seem to be highly effective against metastases, 
whereas KP1019 shows good activity towards primary tumours. Also, several other Ru-based 
complexes have been synthesised and characterised as anticancer agents [41, 93-124]. 
 
Table 2.1 The metal-based drugs that are already in clinical use, in clinical trial and in research level 
[84]. 
Structure/Name/level of application Structure/Name 
 
Cis-platin 
The first and the best metal-based anticancer drug 
in clinical use worldwide 
 
Titanocene 
This entered clinical trials as an anticancer agent 
in 1990s  
 
Carbo-platin 
Derivative of cis-platin in clinical use worldwide 
 
KP1019 
In clinical trial 
 
Oxalo-platin 
Derivative of cis-platin in clinical use worldwide 
 
NAMI-A 
In phase II clinical trial 
 
Heptaplatin 
Heptaplatin is a derivative of cis-platin approved 
in South Korea only 
 PTA =  
RAPTA-B 
Still at laboratory research level 
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Lopaplatin 
Lobaplatin derivative of cis-platin approved in 
China only 
 
RAPTA-T 
Still at laboratory research level 
 
Nedaplatin 
Nedaplatin is a derivative of cis-platin approved in 
Japan only 
 
RAPTA -C 
Potential anticancer drugs from Dyson et al. 
 
Ferrocerone 
Ferrocerone (sodium salt of O-carboxybenzonyl 
ferrocene) is the first ever marketed transition 
organometal drug that was clinically approved in 
the USSR to treat iron-defficiency anemia 
(antianemics). 
 
 
Carbo-RAPTA-C 
Still at laboratory research level 
 
Ferrocifen 
This is a metal-based derivative of the anticancer 
drug tamoxifen. It is shown to inhibit proliferation 
of both hormone-dependent and hormone-
independent forms of breast cancer 
 
 
Oxalo-RAPTA-C 
Still at laboratory research level 
 
Ferroquine 
Found to be highly active against chloroquine-
resistant strains of the malaria parasite. 
 
Piano-Stool Ru-Complex 
Potential Anticancer drugs of Ru(II) arene 
ethylenediamine derivatives (refers to as ―piano 
stool‖) from Sadler et al Lab 
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 It is very important in drug design to make a careful choice of the chemical reactivity of the 
complexes so as to balance the inertness required for the drug to reach its target site (e.g., DNA) and 
minimize attack on other sites (side effects) yet allow the activation necessary for binding to the target 
[37]. Hydrolysis has been seen as an important activation mechanism of reactions of Ru complexes 
with biomolecules. Therefore, the factors that control the aqueous chemistry of organometallic 
complexes are proposed as tools that may allow the design of effective anticancer agents. The presence 
of an arene in Ru(II) complexes has been found to greatly stabilize Ru(II) compared with Ru(III) even 
though ruthenium has a rich redox chemistry. It has also been reported that the reactions of chloro 
Ru(II) arene complexes with nucleotides appear to involve initial aquation, and also Ru–OH2 bonds 
appearing more reactive than Ru–OH bonds [37]. There is a high chloride concentration in blood 
plasma (the concentration of chloride in blood plasma or culture medium is ~104 mM and in the 
cytoplasmic is ~22 mM). The hydrolysis rate decreases in the order Cl ~ Br > I. Hydrolysis of cis-platin 
has been shown to be of rate constants of 7.56x10
-5
 and 6.32 x10
-5
 s-1 for the first and second chloride 
ligands respectively [37]. 
 Among new classes of Ru-based antitumor drugs emerging as alternative to the platinum-based 
anticancer therapy are: Ru(III) complexes such as trans-Ru(imidazole)2Cl4 and trans-Ru(dimethyl-
sulphoxide)(imidazole)Cl4 as anti-metastatic agents [68]. Presently, research focus is on the anticancer 
potency of Ru(II) due to research evidences that the Ru(III) pro-drug will interact with biological 
reductants in human system to form Ru(II) before it accomplishes its biological activity [68]. 
 
 
22 
2.2 Inherent advantages of Ru-based anticancer complexes 
 Research interest has focused on organometallic compounds specifically on ruthenium(II)-arene 
compounds, which show excellent antiproliferative properties both in vitro and in vivo [125]. Cytotoxic 
drugs based on ruthenium have shown the greatest potential and remain the subject of extensive drug 
discovery efforts [51]. Ruthenium coordination compounds have been high lighted as most prominent 
non-platinum-based anticancer agents, with two representatives namely NAMI-A (Table 2.1) and 
KP1019 (Table 2.1) completed phase I clinical trials [13,17, 126]. The qualities of Ru metal that makes 
it the centre of research attraction as a substitute for cis-platin are further stressed in terms of the 
extensively developed chemistry of its coordination particularly with ligands of biological relevance; 
the preferred octahedral coordination for the common +2 and +3 oxidation states in aqueous solution, 
the adequate substitution rates, redox potentials for biological interactions and a demonstrated low 
toxicity [53]. Recently, Ru(II) is gaining more research attention as the mechanism of activation of 
known Ru(III)-based complexes like K1092 and NAMI-A is believe to be through the process of 
activation-by-reduction from Ru(III) as pro-drug to Ru(II) before accomplishing their biological 
activity [68].  
 There have been several excellent in vivo antitumor activities of ruthenium complexes but the in 
vitro activities are approximately 10 times lower than that of cis-platin [13]. More specifically, 
ruthenium complexes containing indazole heterocycles coordinated to the metal centre through 
nitrogen have been shown to act as cytostatic and cytotoxic drugs in colorectal tumour cells both in 
vivo and in vitro [13]. The process of their entering into the cells is suggested to be probably via 
interactions with transferrin [13]. However, the cellular molecular mechanisms of apoptosis induction 
the signalling pathways are yet unknown. Another Ru complexes is ruthenium(II)–arene complexes 
containing a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand. These have been shown to have 
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moderate anticancer activity in various cell lines and an excellent activity with regard to reducing the 
number and weight of solid metastases but do not affect the primary tumour [13, 51]. These compounds 
show high selectivity toward cancer cell lines in vitro, and in vivo. They are reported to effectively 
reduce lung metastases in mice without significantly affecting the primary tumour. Out of many 
derivative of RAPTA that have been identified, synthesized and characterised, [Ru(η6-p-
cymene)Cl2(pta)] (RAPTA-C) (Table 2.1) is the best anticancer compound [13]. Experimentally, it has 
been shown that there is a reduced likelihood of RAPTA-C developing some types of drug resistance 
because the anticancer effect of RAPTA-C is mediated via different molecular pathways [13]. RAPTA-
C was reported to exhibit effective cell growth inhibition by triggering G2/M phase arrest and 
apoptosis in cancer cells of Ehrlich ascites carcinoma (EAC) bearing mice [13]. In another study, the 
platinum compounds were demonstrated to be less reactive and considerably less selective in protein 
binding than RAPTA-C, which showed a high affinity towards ubiquitin and cytochrome c, but not 
superoxide dismutase [126]. 
 Many derivatives of [(η6-arene)RuCl(PTA)2], [(η6-cymene)RuCl(PTA)2], [CpRuCl(PTA)2] and 
[Cp*RuCl(PTA)2] have been synthesized by Dyson et al. [127-141]. Many of these compounds have 
been reported to be similar because they display only weak in vitro activity but RAPTA-C shows 
excellent in vivo characteristics comparable to those of NAMI-A, which is only achieved at higher 
doses [19]. There is still several research efforts in place to derive compounds of π-ligand, PTA and 
halide ligands, of more cytotoxic at lower doses that will reduce tumour mass in vivo [19]. Compound 
of the type [(Cp′OR)RuCl(PTA)2] are found promising with two orders of magnitude more active than 
a close model structure and also show excellent activity in a cis-platin resistant cancer cell lines [19]. 
Another cytotoxic RAPTA compounds especially in A2780 human ovarian cancer cells and also 
significantly more cytotoxic than other simple RAPTA compounds is [Ru(η6-C6H5CF3)(pta)Cl2], 
termed RAPTA-CF3, with the electron-withdrawing a,a,a-trifluorotoluene ligand [17]. This compound 
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has significantly lower pH, to achieve higher selectivity in the treatment of cancer and it has been 
found to associate with a more pronounced degree of decomposition of the oligonucleotide compared 
with RAPTA-C. It is observed that the biomolecule reaction mixtures of RAPTA-CF3 contained mostly 
[Ru(pta)]–biomolecule adducts which were not observed in the protein or DNA binding studies of 
[Ru(pta)(arene)] adducts typical of other RAPTA compounds [17]. Therefore, the facile arene loss is 
proposed to be responsible for the increased cytotoxicity of RAPTA-CF3 [17]. This can be another 
breaking ground for using RAPTA as a conveyor of notable cancer drugs into the cancer sites. 
 Despite the high volume of the in vitro, in vivo and theoretical studies on the behaviour of the 
RAPTA based compounds, their mechanism of action are not well known [68] and thus affect their 
further development. The poor correlation between the binding of RAPTA compounds to DNA and 
their cytotoxicity suggested that these compounds act through a mechanism different from the classical 
platinum anticancer drugs [68]. The mechanisms of action of ruthenium-based anticancer compounds 
are comparatively yet to be explored. It is predicted that ruthenium compounds might directly interfere 
with specific proteins involved in signal transduction pathways and/or alter cell adhesion and migration 
processes [126]. 
 The best studied organometallic compounds are based on the ruthenium–arene scaffold and bear 
monodentate and bidentate ligands which include halides or dicarboxylates as leaving groups and 1,2-
ethylenediamine (en), pta, pyrone, and paullone derivatives, and others as activity-determining moieties 
[17, 142-153]. It has been shown analytically, that most of the ruthenium-based drug candidates 
mentioned are capable of binding strongly to biological nucleophiles especially those bearing halides, 
mostly chloride, proceed via their replacement with soft donor atoms, such as the imidazole of 
histidine, the thiol of cysteine, or the thioether of methionine in the case of proteins or with N7 of 
purine bases, predominantly guanine, in the case of DNA. The bonding between Ru and N7 (guanine) 
is considered the predominant mode of action with DNA for Ru antitumor compounds [154]. It was 
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earlier established that compounds of RAPTA show a very favourable biological and pharmacological 
profile and a strong preference for protein binding over DNA [7, 9]. Their mechanism of action is 
DNA-independent and substantially different from cis-platin and related anticancer platinum drugs [9]. 
Both metallodrugs, cis-platin and RAPTA-C have affinities for the same amino acid residues on protein 
binding [126]. Metallation of specific amino acid residue affects the function of biologically crucial 
proteins through the formation of strong coordinate covalent bonds. The possibility of the combined 
ligands competing for the same binding site was revealed through the experimental observation that  
RAPTA-C competes with cis-platin for the same binding sites on three selected proteins, ubiquitin, 
cytochrome c and superoxide dismutase [126]. 
 The unique function of ruthenium based complexes that distinguished them from cis-platin is 
the proposed function of binding protein targets more preferably than DNA which promotes their 
apoptosis function in wider tumour cells than cis-platin. To substantiate the hypothesis that DNA might 
not be the primary target for ruthenium-based complex, its adduct formation with DNA has been shown 
to proceed more slowly compared with cis-platin [16]. Triruthenium clusters are reported to be very 
active compared to ruthenium compounds. The predicted reason behind the higher biological activities 
of triruthenium clusters is traced to their known ability to form supramolecular interactions with arenes 
and other functions [125]. Such interactions may possibly be playing important roles in their mode of 
biological activity. Rhodium and Osmium analogues were evaluated in HT29 colon carcinoma, A549 
lung carcinoma and T47D breast carcinoma cell lines in vitro and found to display activities that are not 
too dissimilar from the related ruthenium(II)-arene complexes [125].  
 Several works have been done on ruthenium-based antiumor, chelated RAPTA compounds [51], 
RAPTA with labile chloride ions [18], RAPTA chelated with potential Cdk inhibitors [62], the 
cytotoxic of diruthenium complex [(p-MeC6H4Pri)2Ru2(SC6H4-p-Me)3]
+
 which is shown to efficiently 
catalyze oxidation of the thiols cysteine and glutathione to give the corresponding disulfides [85]. In an 
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attempt to develop drugs that could resist hydrolysis in aqueous media, research attention has been 
given to the organometallic arene-capped ruthenium-(II) 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane 
(RAPTA) complexes bearing chelating carboxylate ligands. Some of the new complexes, Ru(η6-
cymene)(PTA)(C2O4) (i.e. Oxalo-RAPTA-C, Table 2.1) and Ru(η
6
-cymene)(PTA)(C6H6O4) (i.e. Carbo-
RAPTA-C, Table 2.1), were found to be highly soluble and kinetically more stable than their RAPTA 
precursor that contains two chloride ligands in place of the carboxylate ligands [51]. 
 The mechanism of Ru-based complexes is understood to be through hydrolysis where one of the 
chloride ion is replaced with water molecule, but that of the bidentate without any chloride ion is not 
well known but believe to be through ring-opening reactions [37]. The possibility of bidentate 
complexes following the same mechanism of hydrolysis for activation was also reported for Ru(II)- and 
Os(II)-arene complexes with alkoxycarbonylmethyl-3-hydroxy-2-pyridone ligands [38]. The highlight 
on the possible hydrolysis of these metal-hydroxypyr(id)ones was shown using the 
1
H-NMR and ESI-
MS on the incubated complexes with Gly, Ala, His, Met, and Cys [38]. There were observed signals 
that indicate the reaction of respective amino acid replacing the used bidentate hydroxypyridone within 
which Cys takes the lead by decomposing the Ru complex within minutes (the reason is suggested to be 
probably due to strong trans-effect of the thiol functionality) then followed by Met and His which also 
released pyridone ligand within 24 h [38]. The reason for the activity of Met and His to release the 
pyridone ligand is suggested to be due to the ability of both amino acids to act as bidentate or tridentate 
chelating ligands (with the thioether of Met and N1 or N3 atoms of the imidazole moiety of His as third 
donors in addition to NH2 and COOH) [38]. Many chelate metal-arene complexes with chloride ion of 
the type [M(η6-arene)-(XY)Cl]n+ where M = Ru, Os; XY = bidentate of N,N-, N,O-, O,O- or S,O- 
chelating ligand; n = 0, 1 have shown promising cytotoxicity profiles [38]. Their significant feature for 
the cytotoxicity of metal complexes is their hydrolysis. Their complexes were found to hydrolyse 
rapidly upon dissolution in water by exchange of the chlorido ligand with a neutral water molecule and 
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exist predominantly as the charged monoaqua species of the general formula [M(cym)-(XY)(OH2)]
+
.  
 The choice of ligands is important because a ligand that binds too strongly could render the 
drug inactive, while a labile ligand could be easily hydrolysed or replaced. In order to obtain 
hydrophilic metal-based complexes, ligands with hydrophilic properties are often used as one of the 
most common approaches. One of those ligands of high solubility in water that is gaining research 
attention is the cage-like tertiary phosphane 1,3,5-triaza-7-phospha-adamantane (PTA) among water-
soluble phosphanes due to extensive participation of its three nitrogen atoms in hydrogen bonding 
interactions with water molecules [155]. PTA has in recent years become a highly appreciated ligand 
because of its high water solubility properties and the catalytic applications of its metal complexes 
[156]. The RAPTA complexes with labile chloride atoms are prone to hydrolysis and would have to be 
administered in saline to suppress the cleavage of the chloride ligands. The problems that are associated 
with hydrolysed complexes are that they are often difficult to characterise and would be problematic for 
pharmacokinetics studies which can consequently affect the clinical trial [51]. The notable ligands that 
have been used to resist hydrolysis are bidentate carboxylate ligands. These were used to endow cis-
platin derivatives, namely carbo-platin and oxalo-platin with high aquatic solubility and resistance to 
hydrolysis. Though carbo-platin is active in the same range of tumours as cis-platin, it has been found 
to be much less toxic than cis-platin and may be administered at higher doses. The derivative, oxalo-
RAPTA-C has been shown to completely resist hydrolysis while carbo-RAPTA-C is susceptible to 
hydrolysis [51].  
 The hypothetical reasons why ruthenium-based complexes are becoming promising anticancer 
drugs than cis-platin and its derivatives are due to the facts that the cancerous cells have more 
chemically reducing environment than healthy ones [10]. Thus favouring the reactivity of ruthenium-
based anticancer as Ru(II) rather than Ru(III) whereas platinum-based drugs does not follow reduction. 
In contrast to cis-platin, Ru compound (NAMI-A) which was recently launched in the clinic shows 
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remarkably low general toxicity. Ruthenium complexes have been shown to specifically accumulate in 
tumour cells and thereby reduce general toxicity of NAMI-A compared to platinum drugs which could 
be due to ruthenium selectivity [18]. Ruthenium complexes have a stronger affinity for cancer tissues 
than normal tissues because ruthenium binds readily to transferrin molecules in plasma forming 
ruthenium-transferrin complex and is transported and internalized into tumour cells through transferrin 
receptors which are abundantly expressed on the surface of tumour cells [52]. Among the metal atoms 
used in anticancer metal complexes, ruthenium is most unique [52, 53]. It is a rare noble metal 
unknown to living systems and has a strong complex-forming ability with numerous ligands [52]. The 
properties that accord ruthenium drugs all the promising advantages are summarised in the rate of 
ruthenium ligand exchange, the range of accessible oxidation states of the metal and the ability of 
ruthenium to mimic iron in binding to certain biological molecules [11]. RuCl2(C6H6)(dmso) was 
reported to completely inhibit DNA relaxation activity of topoisomerase II and form a drug-induced 
cleavage complex [52]. 
 Also, functional group modification of the ligands can significantly affect the activities of the 
entire complexes. It has been reported that modifications on the PTA ligands through functionalization 
of the PTA phosphane like [1-R-PTA](where R = Me,Et, (CH2)4I, CH2Ph, CH2py (pymePTA), di-N-
methylated, di-N-acylated (DAPTA) or di-N-formylated (DFPTA), N-boranyl adduct 1-BH3-PTA, 
affect their chemical properties, and many have been found to improve the water-solubility, as well as 
the DNA binding properties and antimicrobial activity [156]. There have been many functionalized 
PTA phosphanes but very less research on the chemistry of the metal complexes of these ligands [156]. 
Many of the complexes of the functionalize PTA with hydridotris(pyrazolyl)borate (Tp) ruthenium(II) 
complexes were also reported [156].  
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2.3 Review of some Ru-based complexes 
 Among the metal atoms used in anticancer metal complexes, ruthenium has been defined to be 
the most unique [52, 53]. In some complexes of Ru-based, Ru metal has been proved to be significant 
and suggested to take part in the anticancer activity since substitution with another metal resulted in 
lower anticancer activity (e.g. NAMI-A, RM175) [157]. The possibility of metal in a complex not 
directly involve in interaction but acts as an holder for ligands interaction with receptors has been 
reported in the literature [157] though the metal has significant electronic effect on the ligands 
interactions and stability. The greatest limitation in effective design of the Ru-based complexes is the 
absence of convincing data on the fine mechanism of their actions and lack of clear knowledge of their 
target [157]. Functional group has significant effect on the cytotoxicity of Ru-based complexes as 
Sadler et al [158] reported the loss of cytotoxic activity of Ru arene organometallics upon oxidation of 
their amine ligand such as o-phenylenediamine (o-pda) to the corresponding imine ligand o-
benzoquinonediimine (o-bqdi). Several derivatives of Ru-based complexes have been screened as 
potential anticancer agents as shown in Table 2.2. 
 
Table 2.2 Selected mononuclear Ru(0), Ru(II) and Ru(III) complexes that have been screened as 
anticancer agents except where otherwise stated. 
 
N(
1) NAMI-A [157] 
 
 
 (2) KP418 [157] 
 
 
(3) KP1019 [157] 
 
 
 (4) RDC11 [157] 
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(5) DW1 [157, 159]  
 
(6) (arene)-Ru(II) complexes 
from Sadler et al [160]. 
 
 
(7) Ru-(arene) o-
phenylenediamine (o-pda) 
complex from Sadler et al 
lab [158] 
 
 
(8) Ru-(arene) o-
benzoquinonediimine (o-
bqdi) complexfrom Sadler et 
al lab [158] 
 
 
(9) Ruthenium(II) Arene 
Phenylazopyridine 
Complexes from Sadler lab 
[161] 
RM17 
 
(10) (Piano Stool) [157] 
 
 
(11) [162] Not screened as 
anticancer agent 
 
 
(12) [162] Not screened as 
anticancer agent 
 
 
(13) [163] 
 
 
(14) RAPTA- [B (R1 = H, R2 
= H); T (R1 = H, R2 = CH3), 
C (R1 = CH3, R2 = 
CH(CH3)2)] [51] 
 
 
(15) Carbo-RAPTA-C [51] 
 
(16)Oxalo-RAPTA-C [51] 
 
 
(17) RAPTA-NAMI form 
Dyson et al lab [164]. 
 
 
(18) Cp-Ru complex from 
Dyson et al lab [19]. 
 
 
 
(19) [17] 
 
 
(20) Dwyer compound [165] 
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(21) (from Dyson Lab) [62] 
 
 
(22) 
Ru(II)−DMSO−Cl−Chalcone 
Complexes [166] 
 
 
(23) Ru(II) Arene Cp 
Complexes [167] 
 
 
(24) [156] 
 
(25) [38] 
 
 
(26) Pgb Inhibitor [8] 
 
 
 
(27) [8] 
 
 
(28) CORM-3 for Cardio-
protective action [5] 
 
 
(29) [168] 
 
 
(30) There is no anti-cancer 
screening information on this 
molecule [169]. 
 
 
(31) This is not screened as 
anticancer agents. It is only 
the photoconductive 
properties that are determine 
[170]. 
 
 
(32) This is not screened as 
anticancer agents. It is only 
the photoconductive 
properties that are determine 
[170]. 
 
 
(33) [53, 171] 
 
 
(34) [8, 53] 
 
 
(35) [8, 53] 
 
 
 
 
 
 The key concept in the design of anticancer complexes of metal is summarised as optimization 
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of chemical reactivity to allow facile attack on the target site like DNA but yet avoid attack on other 
sites associated with unwanted side effects [37]. Some of the unique properties of interest in the 
designing of metal complexes as potential anticancer and anti-metastasis are the ability of the metal-
based complexes to exhibit water solubility and the capacity to link to nucleobases, DNA fragments, 
aminoacids, peptides, and proteins [155]. Therefore, besides the modification of functional groups, 
there is still a wide chemical space in terms of the choice of ligands in complex with the metals.  
 
2.4 Limitations of ruthenium and other organometalic anticancer therapies and the 
way forward. 
 Current inorganic drugs such as cis-platin have been successfully used in the treatment of many 
cancers, including testicular, ovarian, oropharyngeal, bronchogenic, cervical and bladder carcinomas, 
lymphoma, osteosarcoma, melanoma and neuroblastoma [18]. But the inherent limitations with cis-
platin, primarily its high toxicity, unwanted side effects, low administration dosage [51], and drug 
resistance [18] have shifted researchers attention towards Ru-based anticancer to address the problems 
that are associated with metal-based drugs. Currently, the action of ruthenium complexes is still 
hypothetical with two main theories that ruthenium compounds target DNA or unknown proteins. Till 
date, there is relatively little rational design or work aimed at elucidating the modes of action of these 
complexes even though there is a great deal of research which has been directed at generating novel 
complexes for testing [10]. This is a major limitation in ruthenium drug discovery. 
 The ruthenium based drugs have shown promising clinical applications showing modest and 
reversible DNA adduct formation leading to apoptosis activation of the metastasised tumour but not 
primary tumour and they do not induce significant in vitro cytotoxicity [7]. Two of ruthenium drugs in 
clinical trial are KP1019 and NAMI-A. The targets of KP1019 and of NAMI-A remain unknown after 
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more than 15 years of their discovery which is posing difficulties to their study and hampers the 
possibility to explore new analogues of KP1019 or of NAMI-A with superior pharmacological profiles 
[7]. Numerous studies have been focused on the interaction of KP1019 with serum proteins, and the 
intracellular fate of KP1019 and KP1339 after uptake into tumour cells is widely unknown [12]. The 
ultimate targets of many bioorganometallics still remain unclear and controversial but the essential 
mode of action is considered to be the mono-functional covalent binding accompanied by a hydrogen 
bond to DNA nucleobases [38]. 
 Three ongoing research approaches to address the ruthenium and other metals therapy 
limitations have been summarised [10]: 
i). The first approach is to generate large numbers of different compounds to screen against 
different targets and cell lines without a thorough understanding of their biological targets [10]. Many 
organometallic potential anticancer drugs including Rh(III) and Ir(III) have been reported in the 
literature targeting different potential biomolecules but their exact mode of cytotoxic action is still 
unknown even though it was shown that these compounds were indeed targeting the desired 
biomolecules [8]. 
ii). The second is directing research attention to elucidate the mode of action and the behaviour in 
biological media of existing ruthenium which is a progressive step towards rational design of 
ruthenium anticancer drug [10]. Research effort are now directed toward linking the medicinal 
properties of inorganic drugs to specific biological properties in an attempt to elucidate their 
mechanism step by step in order to use the information to design improved drugs with increased 
potency and reduced side effects. The mechanism of many inorganic drugs are complex and the exact 
route of activity for many of them remains unknown [11]. The advantage of this rational drug design 
approach is that there are a number of direct assays that can be performed looking at both specific 
interactions and drug activity in whole cells, which are not possible if the target is unknown [5]. 
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Because of the possibility to clone topoisomerase II from number of sources and to make it 
recombinantly, it has provided an easily accessible, pure and homogeneous source for characterization 
and the effect of the drug on enzyme activity can be probed directly. By using gel electrophoresis 
ruthenium compounds have been shown to inhibit topoisomerase II [5 and ref there in]. 
iii). Lastly, the generation of further complexes in which ruthenium is chemically linked to an 
‗organic directing molecule‘ (ODM) mostly notable drugs of known biological target [10] or known 
organic protein binders [49, 172], in which an organic molecule binds to the active site of an enzyme 
and the attached ruthenium ion binds to a nearby residue of the same protein [10]. The advantages in 
this aspect are that molecular recognition will be combined with properties that are unique to metal 
complexes, such as photophysical signatures or catalysis, in order to create compounds with novel and 
unprecedented properties [49]. 
 Another related ODM is what is called metal-drug synergism as an alternative approach to the 
discovery of new metallo-drugs which involves binding an organic compound of known therapeutic 
value to a metal-containing fragment [53]. This results in the metal acting as a carrier and stabilizer for 
the drug until it reaches its target and also the organic drug carries and protects the metal which prevent 
side reactions in its transit toward a second target of biological action. The mechanism of action of 
metal-drug complexes especially that of metal-CQ (where CQ is chloroquine) has been investigated to 
show the role of the metal fragment as an alteration of the structure, the basicity, and most importantly 
the lipophilicity of CQ to make it less recognizable to the parasite‘s defense mechanism [53]. For 
instance, the activity of organic antimicrobial drugs has been enhanced by binding the organic molecule 
to a ruthenium centre of which the resulted complex are found overcoming resistance that the parasite 
has developed to the organic compound alone [11]. Also, Polypyridyl-containing half-sandwich 
complexes with Ru(II) and Rh(III) central atoms and hexamethylbenzene or 
pentamethylcyclopentadienyl ligands have been reported to show stable intercalative binding with 
35 
DNA and exhibited excellent cytotoxic activities [8 and the ref there in]. 
 Ferrocifen is a derivative of the anticancer drug tamoxifen in which a phenyl group is replaced 
by a ferrocene moiety. Tamoxifen is the front-line chemotherapeutic agent for patients with hormone-
dependent breast cancer whose activity depends on its competitive binding to the estrogen receptor, 
ERa, thus repressing the estradiol-mediated DNA transcription in the tumour tissue [49]. Therefore 
ferrocifen is also believed to act in the same manner but recent findings have shown a more effective 
strength of ferrocifen to act against tumour cells that lack this estrogen receptor although the mode of 
action is yet unknown. Isostructural ruthenocene derivative also acts as an antiestrogen in hormone-
dependent breast cancer cells but lacks the antiproliferative effect of ferrocifen against hormone-
independent cells [49]. 
 Many nanomolar and even picomolar ATP-competitive ruthenium-based inhibitors for different 
protein Kinases have been discovered, some of them by combinatorial chemistry, some by rational 
design, or a combination of both [49]. New Ru(II) chloroquine complexes [Ru(η6-arene)(CQ)Cl2] (CQ) 
chloroquine; arene) p-cymene, benzene), ([Ru(η6-p-cymene)(CQ)(H2O)2][BF4]2, [Ru(η6-p-
cymene)(CQ)(en)][PF6]2(en = ethylenediamine), and [Ru(η6-p-cymene)(η6-CQDP)][BF4]2 (CQDP = 
chloroquine diphosphate)) have been found to show a consistent higher potency against resistant 
parasites than that of the standard drug chloroquine diphosphate [53]. 
 
2.5 The metal coordinating ligands of interest and their functionalization 
2.5.1 Half-sandwich and heterocyclic nitrogen coordinating ligands 
The synthesis of both sandwich and half-sandwich complexes were made available through the 
experimental works of Bennett [173-199]. Ru-arene complexes especially those with cyclopentadienyl, 
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ruthenocene, benzenoid 6-electron donor ligands are all experimentally feasible using Bennett‘s 
synthetic method [200]. Since then, several Ruthenium half-sandwich complexes have been 
synthesised [17, 200-202] and found numerous applications as catalysts for organic transformations, in 
the supramolecular field, solar cell and medicinal chemistry [203-228]. However, the ruthenium half-
sandwich complexes seem to be widely screened as anticancer agents [142-153, 229-241]. In the 
synthesis of anticancer Ru-based complexes, Dyson experimental team members combined the features 
of half-sandwich and PTA ligands in many of their synthesised anticancer complexes of ruthenium [9, 
13, 16, 17, 51, 54, 63, 127-141, 242-257] while Sadler team members are known to combine the half-
sandwich with N-N bidentate or tridentate ligands [20-37, 258-272]. 
 In addition to the half-sandwich features, our interest is equally in Ru complexes of heterocyclic 
nitrogen coordinating ligands to possibly mimic the feature of the best anticancer complex called cis-
platin which is characterised with two units of NH2 ligand. In addition to the complexes from Sadler's 
research group that are most often characterised by heterocyclic nitrogen containing ligands, many 
other researchers have equally characterised the Ru-based complexes that contained 1,10-
phenanthroline [273-280], bipyridine [281-284], terpyridine [285-293], bis(pyrazoly-l-yl) [294-300] for 
different purposes like electro-chemiluminescence, catalyst, photochemical and anticancer complexes. 
However, the application of these type of ruthenium complexes as potential anticancer are predominant 
[259, 301-312]. 
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2.6 Justification of the work 
 This research is targeted towards addressing some of the existing gaps in cancer chemotherapy. 
There are over 100 existing anticancer drugs in clinical application but limited to some specific 
anticancer cells while many remained incurable. The targets of organometallic anticancer agents like 
ruthenium complexes that have been found to be promising anticancer candidates that are 
competitively active as cis-platin remained unknown even though it is established that other target 
proteins are the most likely points of interaction for organometallic anticancer agents besides the 
establish cis-platin target called DNA [5, 7-14]. In the clinical trials ruthenium compounds may provide 
a less toxic and more effective alternative to platinum therapy but there is no enough investigation and 
understanding of modes of action of different ruthenium compounds. There are many designed 
promising anticancer metal-based drugs but yet to come to clinical uses except cis-platin and its 
derivatives because of limitation in ascertaining their targets. Cis-platin and its derivatives as the only 
metal-base drugs and the most widely used clinically is also suffering from resistance and 
ineffectiveness toward metastases cancer cells. Due to problems suggested like pharmacokinetic 
limitations, cross-reactivity, general toxicity, low initial efficacy and rapid development of drug 
resistance, many in vitro promising metal-based complexes as alternative to cis-platin have a relatively 
low representation in the clinic because many with good in vitro properties fail to show any therapeutic 
effect in vivo. [7]. In another way, several Ru-based complexes have shown excellent in vivo antitumor 
activities comparable to cis-platin but are found to be approximately 10 times lower than that of cis-
platin in their in vitro activities [13] which is hindering their rational design. Selectivity and 
cytotoxicity are the unique properties of an ideal cancer drugs, but most of the highly effective cancer 
drugs are cytotoxic i.e. they mediate their effect principally via genotoxicity (cytotoxicity) and are 
therefore clinically criticized because of some associated sever side effects [7, 46, 47]. There is yet to 
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be any single cancer drug that is effective against over 200 types of cancer in existence and all of the 
cancer drugs in existence have limited and selected cancer cells or tissues they target while many 
cancer cells are incurable or have developed drug resistant. The investigations to produce drugs that 
will widely be used as cis-platin and its derivatives have not been successful even though many drug 
targets have been identified along the way [13] and many potential anticancer agents have been 
synthesised.  
 Based on our interest in the synthesis of organometallic derivatives of Ru(II)-based anticancer 
complexes, as well as understanding their biological activities, we are attempting first the theoretical 
study of Ru(II)-based anticancer complexes utilizing quantum and docking calculations to investigate 
their possible activities as inhibitors of notable enzymes that are significant in cancer growth and 
metastases. The project will contribute to addressing these challenges in two different ways which are: 
studying the interaction of Ru-based organometallic cancer complexes against some possible enzymes 
of interest to suggest the possible in vivo target using mostly computational approach and a little 
experimental approach and designing new complexes from the scaffold of organometallic Ru-based 
complexes and studying their binding affinity computationally and experimentally. With this we hope 
to understand better the mechanism of Ru-based organometallic drugs which will enhance the rational 
approach of designing better efficient drugs. More over, we hope to discover a better derivative of Ru-
based organometallic drugs that are pharmacokinetically and pharmacologically effective against some 
forms of cancer including the metastasised and cis-platin resistant cancer cells.  
 There are clear evidences on the need for further research on ruthenium-based cancer drugs that 
will result to an effective delivery of anticancer drugs to tumour tissue, improve their selectivity and 
consequently reduce drug side effects. Our efforts therefore are toward obtaining more effectively Ru-
based anticancer drugs if their targets can be predicted.  
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2.7 Statement of problem 
 The grave challenge in cancer therapies is treatment of metastasised cancers [6] since medical 
surgery is limited to primary cancer. Cis-platin and its derivatives are the only metallic anticancer drugs 
that are already in clinical use but are associated with some side effects and are limited to some cancer 
cells and metastasised platinum resistant cancer cells. Other promising anticancer drugs is the Ru 
metallic drugs like KP1019 and NAMI-A [51] that have reached the phase II clinical test [164] but are 
yet to pass the NCI test [6] because the mode of their actions are yet to be fully understood in order to 
allow better rational design for improved therapy and selectivity. There is therefore urge for better 
cancer drugs and researchers have found Ru organometallic drugs as the most promising one. However, 
the anticancer mechanism of Ru-based organometallic drugs is yet to be understood in terms of what 
their main targets are, even though they have been found effective in vitro and in vivo. Therefore some 
of the questions that this research seeks to answer include: how can the possible targets of Ru(II)-based 
metal complexes be predicted through computational methods?, how can we find a better Ru-based 
organometallic anticancer that can address the limitation of the known cis-platin drug?, can we design 
some Ru(II) complexes that are active as the promising RAPTA complexes that are still at research 
level and also overcome their limitations? Can a more selective Ru(II) complexes be predicted through 
docking considering proteins as their targets just as it was proposed that RAPTA complexes have a 
strong preference for protein binding over DNA [7]? Can computational docking better predict the 
experimental behaviour of Ru-based complexes using some proteins that are peculiar to cancer growth? 
 The possibility of reducing the toxicity of cancer therapy is to increase their selectivity, but 
selectivity usually limits the range of the application of the drugs since there will always be cancer cells 
where the selected targets will not be present, therefore the interest of this research is how toxicity can 
be reduced and at the same time increase the effectiveness and application? Rational drug design is the 
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only and the most promising way if the mechanism of the cancer growth and metastases including the 
mode of action of the available cancer therapy can be fully comprehended.  
 Another important question we are trying to address is that if addition of metal to chloroquine 
has been found to improve the effectiveness of the drug notably [53], can the same thing be apply to 
some of these cytotoxic anticancer drugs that are natural product in order to increase their effectiveness 
and selectivity? 
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2.8 Aims 
 The aims of this work are to computationally predict the most likely possible biological targets 
of the ruthenium-based anticancer complexes and to synthesize new forms of ruthenium-based 
antitumor in an attempt to increase their cytotoxicity. 
2.9 Objectives 
i). Build new forms of ruthenium-based anticancer complexes starting from the existing complexes 
that have been screened by researchers as anticancer agents. This attempt is to increase the cytotoxicity 
and effectiveness. This will involve functional group manipulations on the ligands. 
ii). The pharmacokinetic studies using ADMET properties and by docking of the complexes to 
Human serum albumin (HAS) (PDB ID 1BM0) to determine their binding energy. Understanding the 
metal coordination chemistry of albumin (HSA) become crucial because of its significant role in drug 
transport and metabolism [36]. 
iii). Quantum calculation of the kinetics of the organometallic drugs for the change in their free state 
to the substrate binding [41]. Kinetic study of the hydrolysis of the Ru-Cl bond of the prodrug to 
generate an active [(η6-arene)Ru(en)(H2O)]
2+ 
[41]. Detailed kinetic studies showed that the Ru-Cl bond 
hydrolysis can be strongly influenced by the nature of the coligands as well as the nature of the metal 
ion. We will seek to relate some of the quantum thermodynamic and electronic properties to the 
anticancer effect of the potential drugs. 
iv). The theoretical study of our anticancer agents by utilizing quantum and docking calculations to 
determine the quantum properties of some existing Ru(II) complexes as anticancer and the new model 
of the complexes built. The quantum calculation is relevant to comprehend the quantum properties that 
determine their stability and effectiveness while docking will be used as a tool to predict their possible 
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targets. Some of the enzymes that will be used in this research are Topoisomerase II (top II), 
Thioredoxin reductase (TrxR), Cathepsin B (Cat B), Ribonucleotide reductases (RNR), Histone 
Deacetylase (HDAC7) and Recombinant Human albumin (rHA). Since the target of many anticancer 
metallodrugs can not be ascertained [8, 9], then we chose many cancer enzymes of significant function 
to cancer growth to discover the most likely target of these complexes. 
v). Synthesize some of the promising complexes which have shown significant anticancer activities 
against some selected protein targets through docking. 
vi). Characterization of the synthesized complexes. 
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CHAPTER THREE 
3 COMPUTATIONAL STUDY OF RUTHENIUM(II)-BASED COMPLEXES 
 
3.1 Background of the chapter 
 This chapter is made up of computational works carried out on ruthenium complexes which 
have been reported in the literatures and proposed new models. For easy understanding, this chapter is 
grouped into three sections: Section 3.3 deals with the geometrical and the electronic properties of 
selected Ru complexes in relation to their stability and available anticancer activities, Section 3.4 deals 
with the spectroscopic properties and their possible applications as non-linear optical materials and 
Section 3.5 deals with the computational docking of the selected ruthenium complexes to different 
receptors that have been reported to play significant roles in cancer invasion, progression and 
metathesis as mentioned in Section 1.3 of this thesis. This chapter is a combination of all ten 
manuscripts that have been written on the computational studies of ruthenium complexes of which 
eight are already published [313-320] and two are under review. However, in order to reduce the 
volume of this thesis, the details are avoided but can be found in the reference papers cited at the 
beginning of each subsection. 
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3.2 Computational methods 
3.2.1 Computational methods for geometric and the electronic properties  
 The methods shown here are the summary of the computational approaches used in this section 
but does not contain all the variations of the methods used in each of the subsections. The 
computational simulations were done using FIREFLY 7.1.G [321], Gaussian 03/09 [322, 323] and 
AIMAll 12.06.03 [324]. Firefly QC package [321], which is partially based on the GAMESS (US) 
[325] source code, was used for for all the NBO and NEDA analysis. The geometries of the complexes 
were optimized twice with PBE0 [326] functional and a mixed basis sets SBKJC VDZ that have 
effective core potential (ESP) [327] approximation and 6-31G* or 6-31+G(d,p) basis set. In the first 
optimization, the ECP basis set SBKJC VDZ is applied on the Ru and Cl atoms where applicable while 
other atoms in the complexes are treated with basis set 6-31G* which shall subsequently be referred to 
as ECP(Ru,Cl)[6-31G*]. In the second optimization, the SBKJC VDZ is limited to only the ruthenium 
atom while the scaled up basis set 6-31+G(d,p) was applied on other atoms in the complexes which 
shall subsequently be referred to as ECP(Ru)[6-31+G(d,p)]. Other properties of the complexes are 
computed at B3LYP hybrid functional [328] level of theories using other higher basis set like DGDVZP 
applied on Ru atom while others are treated with 6-31G* or 6-31+G(d,p) referred to as 
DGDVZP(Ru)[6-31G*] or DGDVZP(Ru)[6-31+G(d,p)]. We also considered the accuracy of 
computing the properties using the minimal basis set 3-21G [329] applied uniformly on all the atoms of 
the complexes which can be helpful for the treatment of large molecules. External basis set are obtained 
from EMSL Basis Set Library [330, 331] which were incorporated into the input file in a format that 
each FIREFLY and Gaussian programs can read. The choice of SBKJC VDZ ECP basis set with PBE0 
is as a result of a large number of electrons and configurations to be treated and due to the past records 
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of their effectiveness in computational study of metal clusters [332, 333] and because it incorporates 
relativistic corrections for the metal atoms [334].  
 The Bader‘s quantum theory of atoms in a molecule (QTAIM) analysis were done mainly using 
the wavefunction obtained form using B3LYP hybrid functional [328] and basis sets either ECP(Ru)[6-
31+G(d,p)] or DGDVZP(Ru)[6-31+G(d,p)] or a minimal all electron basis set 3-21G [329]. A 
topological analysis was performed in order to calculate the charge density () and its second Laplacian 
derivative of charge density () for the bond critical points (BCP). AIMAll 12.06.03 package was 
used for QTAIM analysis [324] while the NBO 5.0G program [335] as implemented in FIREFLY 08 
was used for the natural bond orbital (NBO) analysis [336] and natural energy decomposition analysis 
(NEDA) [337]. 
 
3.2.2 Computational method for the spectroscopic and non-linear optical properties 
 The ruthenium atom was treated with SBKJC VDZ ECP as described in the previous section. 
The choice of SBKJC VDZ ECP basis set is necessary for large systems of our type which also contain 
heavy metal like ruthenium. This functional has been reported to improve the accuracy of excitation 
energies and charge transfer bands in metal complexes both in gas phase and in solution [338]. Also, 
the ECP basis set has been pointed out as a viable method for accurate calculations of transition metal 
polarizabilities [339]. All of the computed properties were done using Becke‘s three- parameter 
exchange [328] and Lee-Yang-Parr‘s correlation non-local functional which is usually denoted by 
B3LYP, combined with different combination of basis set. The properties of the systems optimize with 
PBE0/ECP(Ru)|6-31+G(d,p) are computed with the combination of DGDZVP basis for ruthenium 
atom and 6-31+G(d,p) basis set for other atoms which will be further referred to as DGDZVP(Ru)|6-
31+G(d,p). The properties of the same set of the optimized systems are also computed with the same 
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combinations of basis set as was used for the optimization (ECP(Ru)|6-31+G(d,p)). The properties of 
all the systems optimized with lower basis sets ECP(Ru,Cl)|6-31G* were computed with the same 
combination of basis sets as those used for their optimization (ECP(Ru,Cl)|6-31G*) and also computed 
with minimal all electron basis set 3-21G [329] applied on all atoms. The external SBKJC VDZ ECP 
was obtained from EMSL Basis Set Library [330, 331] and incorporated into input files in a readable 
format for Gaussian 09 [323] suite of programs used for the computation. The NMR and one-bond 
NMR spin-spin coupling constants J(A,B) [340, 341] were computed in Gaussian package using the 
GIAO method. The wavefunction (WFX) files for the computation of QTAIM properties were obtained 
at the same level of theory through the fchk generated files using the AIMAll program package [324]. 
Intra- and inter-atomic properties were computed by the Proaim integration approach, as implemented 
in the AIMAll suite of programs. The accuracy of the integration process was guaranteed by keeping 
the atomic integral of the one-electron density Laplacian below the 10
-4
 a.u. within all atomic basins. In 
addition, the summation of all basin energies was compared with the total electronic energy of the 
molecule, calculated independently at the above-mentioned computational level, to check that the 
differences remain below the 1 kcal/mol. 
 The thermodynamic properties like Zero-point correction (ZPE), Zero-point energy (E0 = Eelec + 
ZPE), Total energy (E = E0 + Erot + Etran), Enthalpy (H = E + RT), Gibb free energy (G = H – TS), 
constant volume molar heat capacity (CV) and entropy (S) are computed for each complex. 
Infrared (IR) stretch spectra, i.e. wavenumbers (ν) in cm-1 and intensities (I) in km/mol, of complexes 
were obtained using vibrational frequencies calculated at hybrid functional PBE0. The NMR isotropic 
shielding (σ) were calculated using the Gauge-Including Atomic Orbitals (GIAO) [342] method and the 
one-bond NMR spin-spin coupling constants J(A,B) [340, 341] associated with atoms A and B are also 
determined. 
 The proton, the carbon and nitrogen chemical shifts of the ligands are computed theoretically 
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using a direct method and a fitting equation. In a direct method, the isotropic shielding of the proton, 
carbon and nitrogen are subtracted directly from that of a reference compound (tetramethylsilane 
(TMS) for 
1
H and 
13
C and CH3NO2 for 
15
N [343, 344]) while in the fitting method, the following 
equations are used as reported in the literature [343]:
1H = 31.0 – 0.97 *1H
13C = 175.7 – 0.963 *13C
15N = -152.0 – 0.946*15N 
where *1H, *13C and *15N represent the computed isotropic shielding tensor of proton, carbon and 
nitrogen respectively. 
 The different terms in the energy of a molecule that is subjected to a static electric field (F) are 
computed. This type of energy (E) can be expressed as [338]:  
E= E0−μi F i−
1
2
αij F i F j−
1
6
βijk F i F j F k−
1
26
γ ijkl F i F j F k F l− ...  
where E
0
 = is the energy of the molecule in the absence of an electronic field 
ithe component of the dipole moment vector 
ij = the linear polarizability tensor, 
ijk and ijkl are first and second hyperpolarizability tensors where i, j, and k label are 
the x, y, and z components respectively [338]. 
 All these terms are computed except the second hyperpolarizability tensor (ijkl) to understand 
the polarizability and the hyperpolarizability properties of the ligands.  
The dipole was computed using: 
 = (x + 

y + 

z)
1/2
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The anisotropy polarization was calculated using 
<> = 1/3 (xx + yy + zz)
 = 1/2 (xx + yy) – zz
 = {1/2 [(xx - yy)
2
 + (xx - zz)
2
 - (yy – zz)
2
 + 6 (2xy + 
2
xz + 
2
yz)]}
1/2
 = [(

 – (
 
 In addition to the mean polarizability (<>) and polarizability anisotropies (1, ), the 
polarizability exaltation index () was also evaluated as:
 = (mol) – ii where
(mol) = mean polarizability of a molecule 
 ii = summation of the atomic polarizability of the atoms which constitute the molecule.  
 The values of have been employed to estimate relative aromaticity of furan homologues and 
stabilities of atomic clusters [345]. A large negative  value denotes a very stable structure.  
 The accurate single values of first static hyperpolarizability (ß) of the ligands were computed 
using Quasi-Pythagorean equation [346] on the 10 components of the 3 x 3 x 3 matrix as βxxx, βxxy, 
βxyy, βyyy, βxxz, βxyz, βyyz, βxzz, βyzz, βzzz respectively from G09 output as: 
 
 
where ßx = (ßxxx + ßxyy + ßxzz), ßy = (ßyyy + ßyxx + ßyzz) and ßz = (ßzxx + ßzyy + ßzzz). 
The atomic units (a.u.) of ß in G09 were converted into electrostatic units (esu) (1a.u. = 8.6393 x 10
-33
 
esu).  
βtot= (βx
2+βy
2 +βz
2)
1
2
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 The relative stability and reactivity of series of compounds can be predicted from the molecular 
property of their hardness () [345, 347]. The values of  is given in terms of difference in the 
ionization energy (IE) and electron affinity (EA), which can be approximated by highest occupied 
molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies (), 
respectively:  
η=
1
2
(IE− EA)≈
1
2
(εHOMO –εLUMO)  
 
3.2.3 Computational methods for the docking study 
 There are limitations in the application of docking to metal-based complexes which results in 
very few reports in the literatures compared to organic compounds due to lack of appropriate force 
fields to take care of the metals [83] and their relativities and the difficulty of optimising the initial 
structures. In this research, the geometries of the Ru-based complexes used were first optimized using 
Firefly package [321] or Gaussian 03/09. The optimized structures which are the first criteria for any 
possible successful docking of metal-based complexes were used. Different docking packages that have 
been used are Autodock 4.2 suit [348], GOLD (Genetic Optimisation for Ligand Docking) 5.1 [349], 
Molegro [350] and the Glide 5.8 [351] as part of Maestro 9.3 suite of programs. The molecular 
graphics and other analyses were performed with the UCSF Chimera package [352]. 
 In Autodock, the Lamarckian genetic algorithm is chosen because it as been pointed out to be 
most efficient, reliable and successful than others like simulated annealing (SA) and a genetic 
algorithm (GA) methods in autodock [353, 354]. For the Ru atom charge, we applied the native charge 
of +2 which is general and can be applied to any complex/receptor interaction study though it may not 
be as accurate as using an optimized charge which is more specific to the type of the system as it was 
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reported for the docking of the metalloenzymes that contain Zn atom [83]. The active site was defined 
using AutoGrid version 4 and the grid size was set to 60 × 60 × 60 points with a grid spacing of 0.375 
Å centred on the selected residues of the binding site of each receptor. The grid box includes the entire 
binding site of the enzyme and provides enough space for the ligand translational and rotational walk. 
Step sizes of 2Å for translation and 50
o
 for rotation were chosen and the maximum number of energy 
evaluations was set to 1,750, 000. Twenty runs were performed and for each of the 20 independent 
runs, a maximum number of 27,000 GA operations were generated on a single population of 100 
individuals. Default values for the operator weights for crossover (0.80), mutation (0.02) and elitism 
(1.00) parameters were used. 
 The obtained trial version of GOLD (Genetic Optimisation for Ligand Docking) 5.1 [349] was 
used for the docking. The Hermes visualiser in the GOLD Suite was used to further prepare the metal 
complexes and the receptors for docking. The region of interest used for Gold docking was defined as 
all the protein residues within the 5 Å of the reference ligands that accompanied the downloaded 
protein complexes except for the protein complex with no accompanied ligand where the binding site 
was defined from the list of protein residues reported in literatures to characterised their binding site. 
Default values of all other parameters were used and the complexes were submitted to 10 genetic 
algorithm runs using the GOLDScore fitness function. 
 In Molegro, the docking scoring function of MolDock which make use of piece-wise linear 
potential (PLP) was used. The maximum interation was set to 2500 against the default 1500 and the 
population number also increased from default values of 50 to 100. Five maximum posses were 
selected and a more stringent re-scoring applied on them for a better prediction of the binding activities 
of the metallocompounds. MolDock scoring considers the hydrogen bonding, inter molecular protein-
ligand and intra molecular ligand interactions and has been successfully applyed for molecular docking 
[355]. Since the Molegro docking package is designed for the ligand-protein interaction, the simple 
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trick employed to consider the ligand-DNA interaction is to include DNA as a cofactor of the protein. 
This is achieved by incorporating protein into the DNA pdb file 3LPV (named DNA-1) or using pdb 
4DL7 input which contain both DNA and protein (named DNA-2) obtained from protein data base 
[356].  
 The trial version of Glide [351, 357] which is part of the Maestro 9.3 suite of programs was also 
used for docking. The method use in Glide docking is referred to as funnel approach where a series of 
ligand conformations are initially created by Glide and then removing the unfavourable ones [358]. 
After this, refinement is performed by energy minimization followed by a restricted Monte Carlo 
search on the lowest energy conformations to refine the initial structure. The protein structures in mol2 
format were prepared using the protein preparation wizard with default values and the incomplete 
residues of the receptors were corrected using Prime package [359]. Since, Glide ligand preparation 
package lack the force field to take care of metal-based complex, then protein preparation wizard was 
manipulated to prepare the metal-based complexes for docking as if the Ru(II) metal is a part of the 
protein. The Grids for the prepared protein were generated using 25 Å box with the centre of the grid 
being defined by using the ligand that is on the binding site of the protein and the force field used is 
OPL2005 which recognizes the metal atom. The default parameters in Glide for standard precision 
(SP) docking mode were used. In both Autodock and Glide dockings, flexibility of the complexes was 
allowed. The correlation table was derived using the statistical tool R (http://www.R-project.org). 
 
3.3 The geometric and the electronic properties  
 In the subsection 3.3.1, we studied RAPTA-C and its two derivatives carbo- and oxalo-RAPTA-
C (Figure 3.1) which have been reported as potential anticancer agents [5, 13, 51]. Both carbo-and 
oxalo-RAPTA-C are reported to resist hydrolysis [8] and have high anticancer activities similar to the 
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parent complex RAPTA-C. However, oxalo-RAPTA-C is known to completely resist hydrolysis while 
carbo-RAPTA-C can moderately be hydrolysed [51]. Also, carbo-RAPTA-C is known to show higher 
anticancer activity than oxalo-RAPTA-C [13, 51]. These two bidentate are reported stable while their 
native complex RAPTA-C is kinetically unstable [5, 51]. Many of the Ruthenium-arene complexes of 
these types have been reported to be unstable and have complicated ligand exchange chemistry [5]. In 
drug design there is a need for a clear understanding of the physicochemical properties of the drug 
candidates [44] which will enhance their rational design. Therefore, it is of prime importance to us to 
explore the electronic properties of the carbo-RAPTA-C, oxalo-RAPTA-C and their parent complex 
RAPTA-C (Figure 3.1) which have been proposed as anticancer agents [13, 51].  
 In subsection 3.3.2, we have selected RAPTA-T (complex 1 in Figure 3.4) and a model with 
electron-withdrawing a,a,a-trifluorotoluene ligand [Ru(η6-C6H5CF3)(pta)Cl2] (i.e. RAPTA-CF3) 
(complex 3) [17] to give the feature of the interatomic properties of these complexes, the factors that 
determine their stability and the properties of their hydrolysed forms (complexes 2 and 4) respectively 
(Figure 3.4). The complexes that hydrolyse rapidly have been shown to be active over cancer cells than 
those that do not aquate easily [37] indicating that the significant feature of these cytotoxic metal 
complexes is hydrolysis [38]. This section presents the unique features, natures and magnitudes of the 
electronic properties with the intra-molecular interactions that influence the stability of four Ru-based 
complexes in relation to their reported anticancer activities. Researches have shown that these type of 
compounds can be characterised with favourable interactions between electron-rich and π-deficient 
groups [360]. Complex 3 has been found to be most cytotoxic RAPTA compounds especially in A2780 
human ovarian cancer cells and also significantly more active than other simple RAPTA compounds 
[17]. The biomolecule reaction mixtures of complex 3 has been observed to contain mostly [Ru(pta)]–
biomolecule adducts which were not observed in the protein or DNA binding studies of 
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[Ru(pta)(arene)] adducts typical of other RAPTA complexes [17]. Therefore, this facile arene loss is 
proposed to be responsible for the increased cytotoxicity of complex 3 [17].  
 In the subsection 3.3.3, we have selected two of the model compounds (Figure 3.7) which are 
[Ru(η6-p-benzene)Cl2(pta)] (RAPTA-H named as complex 1 and 2) and [Ru(η
6
-p-cymene)Cl2(pta)] 
(RAPTA-C named as complex 3 and 4) reported by Dyson et al as anticancer agents [13]. The hydrated 
form of these complexes which are [Ru(η6-p-benzene)Cl(H2O)(pta)] named complexes 2 and [Ru(η
6
-p-
cymene)Cl(H2O)(pta)] named complex 4 (Figure 3.7) are considered since activation of Ru complexes 
are known to occur through hydration [8, 17, 37, 38]. In order to improve their anticancer activities and 
obtain better lead compounds, their stability must be improved [5]. In this study, we have used the 
quantum theory of atom in a molecule (QTAIM) to understand the effects of non-covalent interactions 
on the stability and hydration of these complexes.  
 In the subsection 3.3.4, five ruthenium half-sandwich complexes are selected for theoretical 
studies. These have the feature similar to the type of complexes that have gained researcher attention of 
the Sadler et al laboratory [20-26] but there are little differences because of the carboxylic and/or 
pyrazole unit(s) (Figure 3.10) that are introduced into the complexes. Ruthenium based complexes 
seems to have attracted serious research attentions than any other metal complexes [12, 86-92] as 
potential anticancer agents. Even though there is yet to be any approved anticancer complexes that 
match the anticancer activities of cis-platin, many of the promising anticancer ruthenium complexes 
have been synthesised and analysed [93, 94, 95, 96, 97, 98]. Other notable anticancer complexes still at 
laboratory level are the RAPTA complexes from Dyson et al [9, 13, 16, 17, 51, 54, 63, 127-129]. These 
five complexes have been theoretically compared to the RAPTA complexes against many anticancer 
receptors and are predicted to be promising [318]. 
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3.3.1 The effects of bidentate coordination on the molecular properties of RAPTA-C 
based complexes using theoretical approach 
3.3.1.1 Natural orbital analysis 
 The hybridization of Ru(II) metal (Table 3.1) for all the three complexes (Figure 3.1) shows that 
the 4d
7
 orbitals are used preferentially in complex formation compared to the 5s
1
 orbital as the 
computed occupancy of s-orbital ranges from 0.13 to 0.40 which is far less than one. This further 
confirms that the 4d orbitals are lower than that of 5s. The natural Lewis structure description in terms 
of the percentage of the total electron density confirm the stability of the complexes with three 
complexes having more than 97% Lewis electrons (Table 3.1). Also, valence non-Lewis orbitals 
(description of antibonds or electron delocalization) play a relatively important role in the stability of 
the complexes as it is associated with relatively significant percentages compared to the extra-valence 
orbitals (i.e. Rydberg) in the slight departures from a localized Lewis structure model. 
 The features of the metal-ligand interaction and bonding (Table 3.2 and 3.3) indicate that there 
is metal to ligand charge transfer (MLCT) in all the three complexes. This is evidence from the 
assymetric polarization of the bonding electron in the natural bond orbital (NBO) analysis of Table 3.2 
where bonding electrons are directed towards the ligand atoms. Metal complexes are known to posses 
intense, low energy metal ligand charge transfer (MLCT), ligand metal charge transfer (LMCT), or 
intraligand charge transfer (ILCT) excitations [346]. The feature of the HOMO and the LUMO in 
Figure 3.2 also shows that the Ru atom and the bidentate ligands dominate the HOMO while the arene 
unit which is a π-ligand are predominantly the LUMO which further confirm the electron transfer from 
metal to arene carbon atoms. Different from what is obtained in the bidentate complexes, the HOMO in 
monodentate is dominated with the PTA ligand. There is a significant electron transfer from the Ru(II) 
lone pair into the carbon atoms of arene unit which range from 0.44596e
 
to 0.48942e in the three 
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complexes considered. In this NPA analysis, the Ru atom interaction with arene C atoms are suggested 
as adjacent bonded atom (vicinal, "v"), or a more remote ("r") site since each of the three complexes 
are split into two different units made of of arene unit and all other atoms taking as second unit (Table 
3.3). 
 The strength of these intramolecular interaction obtained using the bond order analysis (Table 
3.4) of ligand atoms that are in direct bonding with metal is in good agreement with the result obtained 
from the QAIM analysis. The bond order of the metal-ligand atoms are in the order of Ru-Cl > Ru-P > 
Ru-O > Ru-C where the carbon atoms are from the arene ligand. The highest bond order of Ru-Cl up to 
0.967 and lower bond order of Ru-P and Ru-C coupled with the topological analysis done with AIMAll 
(Table 3.5) show that the Ru-Cl is a strong ionic bond while the rest of metal-ligand bond should be 
dative bond. We observed that the strength of the bond order is not in direct relation with the bond 
distance for the Ru-Cl in complex 3 which have the highest bond distance also have the highest bond 
order (Table 3.4). 
3.3.1.2 Natural energy decomposition analysis 
 In the NEDA calculation, charge transfer (CT) is found to make a significant contribution to the 
Ruthenium-Ligand (Ru-L) interaction for all model studied (Table 3.6). The magnitude of CT is far 
higher than the electrical interactions which include both the electrostatic (ES) and polarization (POL) 
contributions. The POL with CT and SE which may make largest individual contributors to strong 
attractions that are necessary for binding to overcome the strong CORE repulsions at the equilibrium 
geometry of H-bonding (far inside van der Waals contact) resulting in the final net H-bond stabilization 
energy (E). The results from NEDA analysis shows that 1 and 2 have higher hydrogen bond stability 
(Table 3.6) than the precursor complex 3 which is the direct effect of their higher polarizabilty than 
complex 3. Interestingly also, the feature of the intramolecular interation of atoms obtained from 
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AIMALL also shows that complex 1 has higher hydrogen network (Figure 3.3 and Table 3.5) than the 
other two complexes just as NEDA rated to have the highest hydrogen bond stability (Table 3.6). This 
is in good agreement with the reported experimental results where 1 and 2 were found to be highly 
soluble and kinetically more stable than their precursor complex 3 that contains two chloride ligands in 
place of the carboxylate ligands [51]. The higher solubility of the two bidentate complexes 1 and 2 
should also be the direct effect of their higher intramolecular hydrogen bond (HB) interaction which 
will enhance their interaction with the polar solvent environment. HB has been described to be based 
on two different effects which are electrostatic field effect and orbital delocalization effect [166].  
3.3.1.3 Atoms in molecules analysis using B3LYP/3-21G functionals 
 The atoms in molecular analysis of complexes using AIMAll confirmed the presence of both 
strong and weak noncovalent interactions. In interpreting the features of the quantum theory of atoms 
in molecules (QTAIM) topology, the critical points density ( gives information about the existence 
of bonds, while the sign of the Laplacian of the density ( at that point reflects the kind of 
interaction which if it is negative is a critical point for covalent interactions (open shells), and if it is 
positive is a closed shell interactions, such as hydrogen bonds [361] or ionic bond or Van der Waals 
interaction [362]. The Laplacian features of each complex electron density ( are shown using the 
contour plot along the plane of the P, Ru and Cl or O in the bidentate complexes (Figure 3.3) and many 
of the atoms of the complexes are found on the chosen plane. All the ligand-ligand bonds are 
characterised with negative (dash lines) while the metal-ligand bonds are characterised with 
positive  (solid lines) which further confirmed that they are covalent and non-covalent interactions 
respectively.  
 The typical nature of covalent bond which is an open shell interaction is high negative value of 
(r), higher (r) value, low kinetic energy per electron and higher magnitude of the ratio of potential 
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to kinetic energy (V/G) [363]. The covalent bonds have higher negative values of V, high (r), higher 
negative values of (r), higher negative value of V/G and lower kinetic G. The  values for the 
BCP of M-L bonds are positive but far higher than that of exiting hydrogen bonds (HB) which are 
characterised with low +ve value of  as shown in (Table 3.5).The high +ve  values of BCP for 
M-L and the corresponding high values of (r) is an indication of strong non-covalent bonds [362]. 
This gives the reason why the bond order for M-L bonds are relatively low (Table 3.4) except for Ru-Cl 
of complex 3 that is suggested to be ionic bond. This further highlights the NBO analysis that indicates 
d-orbitals of the metal as the orbital which carries highest percentage of bonding to ligand atoms. Also, 
the feature of the Lewis bonding and non-Lewis antibonding in Table 3.2 shows that one of the Ru-O 
bond is missing for complex 1 and the bond order in Table 3.4 also shows that the Ru-O bonds of 
complex 1 are associated with longer unequal bond which will further enhance its hydrolysis compared 
to 2. 
3.3.1.4 The correlation of the computed bond properties 
 The relationship that exist between the computed bond properties can be comprehended using 
the correlation Table 3.7 that is constructed over all existing bonds in the three complexes. From this 
table, a high value of (r) should have a high negative value of (r) except where there is a stronger 
non-covalent bond as in M-L bonds. The values of (r) appear to be strongly related with the values 
of V/G which is an indication that a stronger bond should be characterised with stronger potential 
energy density than Lagrangian form of kinetic energy density. A very flat electron density region that 
is usually characterised with very low average values for (r)and (r) are usually found to have a 
relatively high ellipticity [364] which can be interpreted that ellipticity is inversely proportional to 
(r)and negative values of (r). The correlation of the ellipticity of all the bonds in the three 
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complexes with (r)and negative (r) shows that it is inversely proportional and averagely high. The 
correlation values of ellipticity with (r)as shown in Table 3.7 are -0.57,-0.72 and -0.65 while with the 
negative values of (r) are 0.57, 0.65 and 0.60 for complexes 1, 2 and 3 respectively. The implication 
is that a high negative value (r) and high positive values of (r) which is a picture of strong open 
shell covalent bond are characterised with lower ellipticity while the close shell interaction of low 
positive (r) as in HB are characterised with higher ellipticity. Therefore the Ru-Ligand bonds (Table 
3.5) are characterised with higher ellipticity than covalent bonding within the ligands which is a further 
indication that the metal-ligand bonds are closed shell interaction. The higher ellipticity values of the 
ruthenium monodentate bonds in complex 3 and ruthenium bidentate bonds in complexe 1 than 
complex 2 further supports the reported hydrolysis of complex 1 and 3 while complex 2 completely 
resist hydrolysis [8, 51]. Also, bonds with relatively high ellipticity are those with higher bond 
stretching (BPL-GBL_I) with correlation of 0.51, 0.93 and 0.74 in complexes 1, 2, and 3 respectively 
(Table 3.5).  
3.3.1.5 The intraatomic properties of the complexes 
 As expected for all the heavy atoms with largely core electrons, the population of each atom is 
highly localized (Table 3.8) while electron density of all the H atoms is strongly delocalized and 
therefore can easily be perturbed by external influences such as an electric field [363]. The properties 
of some of the selected atoms of interest which are directly bonded to Ru metal are shown in Table 3.8. 
All the atomic basins have integrated Laplacian values L(A) of approximately equals to zero (Table 
3.8), indicating satisfactory numerical integration [363]. As clearly shown in Table 3.8, the arene 
carbon atoms become more electronegative as a result of MLCT. The complex HB bonds network 
observed in the complexes as shown in Figure 3.3, are direct consequence of one centre being 
electronegative than the other as the atoms that are involved in HB are of different atomic charges 
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(Table 3.8).  
 Taking a critical look at the molecular sum total of the atomic properties for the complexes 1, 2, 
and 3, we observed that the total K(A) are 6045.16, 5891.34 and 6432.41 while the total V(A) 3603.91, 
3116.36 and 3069.81. It is interesting to point out that the higher total values of K(A) of complexes 3 
and 1 over complex 2 is in the order of their reported anticancer activities [13]. 
3.3.1.6 Atoms in molecules analysis using PBE0/6-31G*(SBKJC VDZ ECP) functionals 
 When ECP basis set was applied on P, Ru and Cl atoms where applicable, the intramolecular 
features in QTAIM topology shows that there is Non-Nuclear Attractor (NNA) Critical Point (CP) i.e. 
(3,-3) CP but this NNA disappeared when all electron basis set was applied on the three complexes. A 
typical feature for the complex one is shown in Figure 3.3 as 1a and 1b when ECP basis set and all 
electron basis set were used respectively. In making use of the ECP, even though we obtained similar 
features when all electron basis set was used yet there is a higher number of RCPs because of the 
introduction of NNA into complex 1a (pink sphere in Figure 3.3 (1a)). The computed feature of the 
topology when the ECP was applied on Ru and P atoms shows that there is a common NNA between 
the Ru-P bond in the three complexes which is very closed to P atom characterised with of 3.22, 
3.22 and 3.18 for P-NNA bond and 0.11, 0.12 and 0.11 for NNA-Ru bond in the complexes 1, 2 and 3 
respectively. The higher values of for P-NNA and lower for NNA-Ru is an indication that the 
electronic configuration of metal atom was well represented with the ECP basis set. Also, the contour 
plot in Figure 3.3 for complex 1a shows that the NNA is within the negative contour (dash lines) 
around P atom which further confirms that the NNA was introduced to compensate for the deficiency 
of electrons around P due to application of ECP.  
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Complex 1 (carbo-RAPTA-C) 
 
Complex 2 (oxalo-RAPTA-
C) 
 
 
 
 
 
 
 
 
Complex 3 (RAPTA-C) 
 
Figure 3.1: The schematic structures of complexes 1, 2 and 3 
 
 
 
 
 
Complex 1 HOMO 
 
Complex 1 LUMO 
Complex 2 HOMO 
 
Complex 2 LUMO 
 
Complex 3 HOMO 
 
Complex 3 LUMO 
 
Figure 3.2: The HOMO and the LUMO of complexes 1, 2, and 3 in a ascending order. 
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Complex 1a 
 
Complex 
1b 
 
 
Complex 2 
 
Complex 
3 
(3,-1) bond critical points (BCPs) are shown as small green spheres, (3,+1) ring critical points (RCPs) as small red spheres, 
and (3,+3) cage critical points (CCPs) as small blue spheres and the Non-Nuclear Attractor (NNA) in complex 1 as a large 
pink sphere. 1a and 1b stand for when ECP basis was used and when all electron minimal basis was used for complex 1. 
 
Figure 3.3: Laplacian of the electron density in a plane containing P, Ru and Cl or O nuclei (positive 
contours as solid and negative contours as dash lines are drawn from 0 to ±800) and bonds (strong 
bonds in solid and HB in dash lines) for complexes 1, 2 and 3.  
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3.3.2  Computational properties of 6-toluene and 6-trifluorotoluene half-sandwich 
Ru(II) anticancer complexes  
3.3.2.1 The geometries of the complexes 
 The geometries of the complexes (Figure 3.4) were optimized to their lowest ground state 
energy characterised with zero imaginary frequencies. The obtained bond distances and angles are 
within the experimental ranges [365]. The computed Ru-arene bond distances of complex 3 ranges 
from 2.197 to 2.257 Å which is very close to the reported experimental range of 2.151-2.169 Å. 
Comparing the computed geometries of the complexes to the experimental reports (in bracket), the 
range of bond distances (in Å) for Ru-P is 2.419-2.443 (2.279-2.297), Ru-Cl is 2.481-2.496 (2.410-
2.434) while the bond angles (in degree) ranges for Cl-Ru-Cl is 89.73-90.75 (87.25-87.88) and Cl-Ru-P 
is 79.96-82.75 (82.61-87.86). All the bond distances of the ruthenium-ligand (Ru-L) with their 
respective bond orders are shown in Table 3.9 (for the systems treated with B3LYP/DGDZVP(Ru)|6-
31+G(d,p)). The bond order of the two chloride atoms in each of complex 1 and 3 are relatively the 
same. This indicates that any one of the two chloride atoms can be a leaving group in their hydrolysis 
to complexes 2 and 4 respectively (Table 3.9). After the hydrolysis, the possibility of the last chloride 
atom becoming a leaving group is rare [255] as the bond order of chloride atom increases from the 
unhydrolyzed complexes (1 and 3) to the hydrolysed ones (2 and 4) while that of the Ru-P decreases. 
Therefore for any possible covalent interactions of the central metal atom with biological residue as 
proposed experimentally [38, 68, 126], the water molecule has to be a leaving group and possibly the 
PTA ligand. The bond order analysis recognised the existence of the hydrogen bond (HB) that exists 
within each of the complex. The fluorination in complexes 3 and 4 respectively seems to have very 
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little effect on the bond order of the complexes with a little improvement in the Ru-P and Ru-Cl bond 
order. 
 In all the complexes, the natural bond order (NBO) and NEDA properties computed with ECP 
(PBE0/ECP(Ru, P, Cl)|6-31G*) (Table 3.14)) and the QTAIM properties computed with minimal basis 
set 3-21G (Table 3.18, 3.20 and 3.21) are in a close range with those computed with higher basis sets 
where Ru atom is treated with DGDZVP basis set and other atoms treated with 6-31+G(d,p) basis set 
(Table 3.6 - 3.11) (referred to as B3LYP/DGDZVP(Ru)|6-31+G(d,p) systems). This is an indication that 
the properties computed with minimal basis set 3-21G for these type of complexes is reliable enough 
and can be helpful to treat large system. 
3.3.2.2 Natural bond orbital analysis 
 The 4d
7
 orbitals are used in bond interactions preferentially to 5s orbitals in all the four models 
(Figure 3.4). The Lewis carries the highest percentage (ranges from 97.68% to 98.11%) which is an 
indication that the structure is stable. The effect of the non-Lewis orbitals is relatively significant 
(ranges from 1.71% to 2.16%) as a measure of the backbonding interactions in the complexes. The 
polarization (cA) of the bonding atoms and the percentage of the NBO (cA-squared) on each hybrid 
(Table 3.10) is in favour of the coordinated ligand atoms as they are associated with higher values. This 
suggests the possibility of metal to ligand charge transfer (MLCT) transitions. The better feature of the 
charge transfers is observed when second perturbation energies (E
(2)
) of the delocalized orbitals were 
computed as shown in Table 3.11. The higher value of E
(2)
 is an indication of higher stability ascribed 
to contribution due to delocalization. A critical observation of the common charge transfer (CT) from 
the Ru atom to the arene C=C double bonds shows that the stabilization energy (E
(2)
) of this CT 
decreases upon the hydrolysis of the complexes and fluorination of the complexes (Table 3.11). 
However, the values of the E
(2)
 are not the direct measure of the magnitude of charge transfer from the 
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Ru atom to the arene carbon atoms because higher charge transfer are observed from the Ru atom to the 
arene carbon atoms (Table 3.12) in the hydrolysed complexes (i.e. complexes 2 and 4) and fluorinated 
complexes (i.e. complexes 3 and 4). It is interesting to point out that both hydrolysis and fluorination 
significantly leads to the lower energy values of the antibonding orbitals of the complexes which 
enhances both the MLCT and LMCT properties of the complexes. This should also be responsible for 
the higher electrical energy (EC) contribution and charge transfer (CT) of the hydrolysed and 
fluorinated complexes from the NEDA analysis of the complexes (Table 3.13). Also from NEDA 
analysis, we observed the total charges transferred from the Ru lone pairs to the ligand lone pairs or 
Ru-L bonds (after all the transferred from the ligand atoms have been subtracted) to be 0.494, 0.472, 
0.533 and 0.409 e for complexes 1, 2, 3 and 4 respectively which is an indication that hydrolysis 
decrease the MLCT while fluorination increases it. 
 The nature of the HOMO and the LUMO of the complexes (Figure 3.5) further confirmed 
mixed features of the MLCT and LMCT in the complexes. HOMO is predominantly the Ru, Cl and 
PTA atoms while the arene ligand atoms including also the Cl and Ru atoms dominate the LUMO. The 
hydrolysis of the complexes results to lower HOMO contribution of Ru atom in the complexes 2 and 4 
which is the effect of the significant backbonding of electron from the oxygen atom of the water 
molecule to the antibonding orbital of the Ru atom (Table 3.12). Fluorination of the arene reduces the 
HOMO contribution of the chloride atoms in the complexes which result to HOMO being 
predominantly characterised with only the Ru and the PTA atoms (complexes 3 and 4) which further 
confirm the features obtained from NEDA analysis. 
3.3.2.3 Natural energy decomposition energy analysis 
 The results obtained from the NEDA analysis of the complexes are shown in Table 3.13 and 
Table 3.14. The high values of charge transfer (CT) further shows its significance contribution to the 
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stability of the complexes. CT is the most significant factor that determines the stabilization of the un-
hydrolysed complexes while POL is the most important factor in the hydrolysed complexes (Table 
3.15). A significant increase in the value of hydrogen energy (E) from un-hydrolysed complexes to the 
hydrolysed complexes is an evidence of improved stability which may be responsible for the reported 
activation of these complexes by hydrolysis [8, 37]. The presence of trifluorotoluene in complexes 3 
and 4 lead to increase in the CT and Electrical properties of the complexes but lower overall hydrogen 
interaction energy (E). 
 The synergistic effect of fragments in complexes on each other through the decomposition 
analysis of the complexes can be seen from Table 3.15. Both the synergistic properties of the induced 
energy and dipole increases as a result of presence of the trifluorotoluene in complexes 3 and 4 which 
could be responsible for the reported better anticancer activities of these complexes than complexes 1 
and 2 [17]. The overall strong synergistic effects of ligand units that are coordinated to metal centre in 
all the complexes can lead to highly cytotoxic species as it was experimentally suggested [62]. 
3.3.2.4 The QTAIM analysis of bonds 
 Further analysis of the electron density wavefunction through the quantum theory of atoms in a 
molecule (QTAIM) as implemented in AIMAll package give a better features of the interatomic 
interaction in the complexes. The QTAIM properties obtained from combination of higher basis sets 
DGDZVP(Ru)|6-31+G(d,f) (Table 3.16, 3.19) is very similar to the properties computed using minimal 
basis set 3-21G (Table 3.18 and 3.21).  
 In QTAIM analysis of the complexes, all the inter-atomic bonds within each of the ligand are 
characterised with covalent bonds which is an open shell interaction with negative value of (r) 
(Figure 3.6), higher (r) value, low kinetic energy per electron (K) and higher magnitude potential to 
Lagrangian kinetic energy ratio [363]. A positive (r) characterised all the metal-ligand bonds 
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(dotted lines in the contour plots of Figure 3.6) and the HB (Tables 3.16 and Table 3.18) which is an 
indication of a closed shell interactions typical of hydrogen bonds [361] or dative or ionic or van der 
waals bond [362]. The very high positive (r) is an indication that the metal-ligand bonds in these 
complexes are dative bond [362] except Ru-Cl bonds that may be suggested to be ionic bond. Also, all 
the HB bonds have the same properties of M-L bonds but lower values of (r) and (r) [361] and are 
weaker than the dative bond that exist within the M-L bonds (Table 3.18).  
 The communication of electron through hydrogen bond (HB) interactions between the arene 
and PTA units which are remote to each other improved significantly due to fluorination. All the four 
complexes are associated with intramolecular HB interaction some of which are unusual [366-368]. In 
complex 1 and 2 there is unusual HB between the C of arene and one H atoms of the PTA which is as a 
result of the arene unit acting as charge acceptor since it is a -ligand that is characterised with electron 
deficiency. In all the complexes, the strongest HB exist in the hydrated complexes between the Cl and 
the H atoms of water molecule (Figure 3.6) which were also confirmed by the bond order analysis and 
higher values of (r) and (r) (Tables 3.35). Fluorination in complexes 3 and 4 significantly 
improved their HB network and can be ascribed to the higher charge transfer and electrical properties 
but lower overall hydrogen interaction energy observed for these complexes (Table 3.13 and Table 
3.14). This may be responsible for the reported higher anticancer activities of the fluorinated complexes 
as a result of increase in number and strength of HB which can lead to increase in the sensitivity of 
some of the atoms and stability of complexes.  
 The correlation table was constructed for all the bond parameters computed during the QTAIM 
analysis (Table 3.17) over all the existing bonds in each of the four complexes. This is to understand 
the relative effect of these parameters on the strength of all atomic bond interactions in the complexes. 
The values of the density ((r)) are shown to be highly inversely proportional to the Laplacian values 
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of the density ((r)) which is an indication that a bond with high (r) values will be associated with 
very high negative values of (r) which is typical of strong covalent bonds except the metal-ligand 
bonds with high positive (r).  
3.3.2.5 The QTAIM analysis of intra- and inter-atomic properties 
 The properties of selected atoms of interest which participate in the M-L bond, HB and nitrogen 
atoms of the PTA are presented (Table 3.19, 3.21). All the atoms (except H atoms) in the complexes are 
more localized with higher %Loc(A) while H atoms are characterised with higher %Deloc(A,A') which 
is an indication that the H atoms of these complexes can easily be perturbed by external influences such 
as an electric field [363]. Atoms such as Cl, Ru and P have the highest Vol(A) in a descending order 
which consequently resulted in lower (r)and (r) bond interactions for the Ru-Cl and Ru-P bonds 
(Table 3.16 and Table 3.19) that involve the interaction of two atoms of large V(A). The changes in the 
atomic properties of Ru metal give insight into the hypothesis of the activation of these complexes by 
hydrolysis. The charge distribution on the arene carbon atoms (Table 3.9 and 3.21) shows that these 
atoms are charge acceptor centre which further explains the observed MLCT.  
 In order to understand the chemistry of each atom in the complexes, the correlation of all the 
computed atomic properties is constructed over all the atoms present in each complex (Table 3.20). The 
electronic kinetic energy of each atom (K(A)) is significantly affected by the magnitude of the bond 
dipole moment of each atom (|Bond(A)|) and the total dipole of each atom (|(A)|). The -Bond(A) is 
the main determinant factor of the total dipole (|(A)|) and also have high effect on all the computed 
atomic properties except its poor correlation with the atomic charge (q(A)).  
 The sum total of all the intra- and inter-atomic properties computed over all the atoms in each 
complex is presented in Table 3.22. The sum over of the total dipole () and K(A) of the 
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trifluorotoluene complexes 3 and 4 is higher than that of complexes 1 and 2 which may contribute to 
the reported higher anticancer activities of the fluorinated complexes. Comparing the properties of the 
hydrolysed complexes to the unhydrolysed complexes, there is decrease in the LI(A), K(A) and dipole 
properties while there is a increase in the DI(A,A')/2. 
3.3.2.6 QTAIM analysis using PBE0/ECP(Ru, Cl, P)|6-31G* 
 The topological features using the mixed basis set where the SBKJC VDZ ECP basis set is 
applied on Ru, P and Cl atoms of the complexes as explained in the computational method referred to 
as PBE0/ECP(Ru, Cl, P)|6-31G*, shows a common Non-Nuclear Attractor (NNA) Critical Point (CP) 
i.e. (3, -3) between the Ru-P bond which was never observed when all electron higher basis sets 
DGDZVP(Ru)|6-31+G(d,P) and when minimal basis set 3-21G were used. This is an indication that the 
presence of NNA in these complexes is just a computational artefact of ECP basis set which could not 
effectively account for all the electrons density around the atoms.  
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Figure 3.4: The schematic feature of complexes 1, 2, 3 and 4 
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1. HOMO 1. LUMO 2 HOMO 2 LUMO 
3 HOMO 3 LUMO 4 HOMO 4 LUMO 
 
Figure 3.5: The HOMO and the LUMO of complexes 1, 2, 3 and 4 with arrow showing the direction of 
the dipole moment 
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(3,-1) bond critical points (BCPs) are shown as small green spheres, (3,+1) ring critical points (RCPs) as small red spheres, 
and (3,+3) cage critical points (CCPs) as small blue spheres 
 
Figure 3.6: Laplacian of the electron density in a plane containing P, Ru and Cl or O nuclei (positive 
contours as solid and negative contours as dashes lines are drawn from 0 to ±800 a.u) and bonds 
(strong bonds in solid and HB in dash lines) for complexes 1, 2, 3 and 4.  
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3.3.3 Insights into the intramolecular properties of 6-arene-Ru based anticancer 
complexes using quantum calculations 
 Stable stationary geometries were obtained for the four complexes (Figure 3.7) which are 
characterised by zero imaginary number from the thermodynamic calculation. When the geometries of 
the complexes were further optimized from PBE0/ECP(Ru,P,Cl)|6-31G* to PBE0/ECP(Ru)|6-
31+G(d,p), the highest contraction of bond lengths up to 0.05 Å was observed for Ru-Cl bonds (Table 
3.23). There is also a slight change in bond orders up to 0.1 when comparing the two steps of 
optimization. Applying uniform basis set 3-21G on all atoms of the complexes, there are no significant 
changes in the total energies from the first optimization (-6307.84, -5925.61, -6464.66 and -6082.04 
A.U. respectively) to the second optimization (-6307.84, -5925.61, -6464.26 and -6082.04 a.u.). The 
bond orders of the Ru-Cl bonds increase in the hydrated complexes 2 and 4 which suggest that the 
possibility of displacing the second Cl atom with aqua ligand will be difficult [255]. But on the order 
hand, the Ru-P bond order decreases upon hydration of the complexes. The properties computed using 
combination of higher basis sets DGDVZP(Ru)|6-31+G(d,p) and those computed using lower basis sets 
3-21G follow the same trend which is an indication that lower basis sets can give insight into the trend 
though it either underestimate or overestimate the computed properties.  
3.3.3.1 The natural bond orbitals (NBO) analysis 
 The polarization features of some visible Ru-L bonding orbitals are shown in Table 3.24, while 
Table 3.25 shows the nature of the electron delocalization orbitals with their second-order perturbation 
energy (E
(2)
). The number of the electron transfer into each of the acceptor orbitals in Table 3.25 are 
shown in Table 3.26 with the values of their energy level. The bonding polarizations of the Ru-L are 
directed towards the ligand atoms (Table 3.24). The reverse is the case in all the antibonding orbitals 
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interactions as a result of backbonding of electrons into the antibonding lone pair of ruthenium atom. 
The features of the charge transfer is clearly seen from the delocalized orbitals that have notable 
interaction with the Ru atom or bonds and have significant stabilization energy (E
(2)
) equal or greater 
than 10 kcal/mol as presented in Table 3.25. There are many bond to bond, atoms to bond and atom to 
atom delocalization of electrons in the complexes. The most significant feature is the presence of metal 
to ligand charge transfer (MLCT) from the lone pair of Ru to the antibonding lone pair of arene C 
atoms in all the complexes. There is also an observed MLCT from the lone pair of ruthenium to the 
bonding lone pair of the same arene C atoms in complex 2 and 3. From the NEDA analysis, if the total 
charge transfer from ligand to the lone pair of ruthenium metal (LMCT) is subtracted from that of 
metal to ligand (MLCT), the overall features shows that complexes 1 and 4 are predominantly 
characterised by LMCT with respective total charges of -0.56209 and -0.47667 transfer to the lone pair 
of ruthenium atom from ligand atoms while complexes 2 and 3 are predominately characterised with 
MLCT of total charges of 0.37489 and 0.45986 transfer from the Ru lone pair to the ligand atoms on 
bonds. These features are typical nature of π ligand metal complexes with intense intramolecular CT 
between metal and ligand (MLCT or LMCT) transitions and associated with π back-bonding [369, 
370]. 
 The features of the electronic orbitals in Figure 3.8 give an insight observed MLCT and LMCT 
observed in the complexes. The ruthenium atom is characterised as part of both HOMO and LUMO as 
a result of bonding electron contribution of metal and the backbonding contribution of the ligands. The 
PTA ligand dominates the HOMO orbitals of the hydrated complexes 2 and 4 compared to the Ru and 
Cl atoms which characterise the HOMO of the un-hydrated complexes 1 and 3. The arene ligand is 
predominantly the LUMO which confirm the existence of MLCT between the Ru atom and the -
orbital of the arene moiety of the ligand. The HOMO nature of the Ru and the Cl atom in complexes 1 
and 3 significantly reduced upon being hydrolysed to complexes 2 and 4 respectively.  
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3.3.3.2 Natural energy decomposition analysis 
 The results obtained from the NEDA analysis are shown in Table 3.27. The complexes 1, 2, 3 
and 4 are fragmented into four, three, two and six units respectively. The respective fragmentations of 
complexes 1, 2, 3 and 4 are shown in Table 3.28 except the last two fragments of complex 4 which are 
the two hydrogen atoms of the aqua ligand that have negligible zero contribution. The number of the 
fragmentations in the complexes significantly correlates with their total interaction energy (Table 3.27). 
The strength of the interaction energy does not correlate with the number of hydrogen bond in the 
complexes. There are two, one, four and five hydrogen bonds in complexes 1, 2, 3 and 4 respectively as 
shown in Figure 3.9. The result shows that either polarization (POL) (complexes 1, 2, and 3) or charge 
transfer (CT) (complex 4) has the greatest contribution to the stability of the complexes. The significant 
values of the POL and ES result to the electrical energy having the highest contribution to the stability 
of the complexes (Table 3.27). The hydrated complex 4 has the highest interaction energy as a result of 
its significant high CT, ES and POL. On the contrary, the hydrated complex 2 has lower interaction 
energy compared to its unhydrated complex 1. The high stability of interaction energy of RAPTA-C 
(i.e. hydrated complex 4) should significantly contribute to its experimentally reported higher 
anticancer activity than the other RAPTA complexes [13]. 
3.3.3.3 The bond critical points analysis  
 The bond properties from both the B3LYP/DGDVZP(Ru)|6-31+G(d,p) treated systems (Table 
3.29) and B3LYP/3-21G (Table 3.30) methods of computation were obtained from the quantum theory 
of atoms in a molecule (QTAIM) analysis of their respective electron density wavefunction. The r 
and r of all theRu-L bonds are shown in Table 3.29 and 3.30. All the Ru-L bonds of the 
complexes are characterised by positive but higher  (Table 3.29, 3.30 and Figure 3.9) than hydrogen 
bonds confirming that they are closed shell interactions like dative, hydrogen, ionic and van der waals 
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bonds [361, 362]. The features of the bonds are shown using the contour plot of the along the plane 
of the P, Ru and Cl or O atoms where the hydrated complexes are considered (Figure 3.9).  
 Complex 1, 2, 3 and 4 have two, one, four and five hydrogen bonds respectively (Figure 3.9). In 
literatures, there have been reports of unusual alkyl and halogen H-bonds [371-377] which are also 
observed in these complexes. There are unusual H-bonds between the alkyl C atoms of the cymene unit 
of complexes 3 and 4 and also H-bonds between the chloride atoms and H atom of aqua, PTA and arene 
ligands which contribute significantly to the H-bond networks of complexes 1, 3 and 4. The higher HB 
network in complexes 3 and 4 indicates that many of the atoms in these complexes will be sensitive to 
macromolecular interactions and should be responsible for their experimental reports of high cytotoxic 
activities than complexes 1 and 2 [13]. The hydrated form (complexes 2 and 4) are characterised with 
extra and stronger HB suggesting that the activation mechanism of these complexes by hydration [8, 
17, 37, 38] can possibly be the result of increase in the sensitivity of the atoms as a result of increased 
networks of HB and electronic interactions. There is a unique HB that exists between Cl and H atoms 
of the water molecules in the hydrated forms that is stronger than any other existing HB based on a 
higher value of (r) and(r) (Figure 3.9). The values of the ratio of the magnitude of potential 
energy (P.E) and the kinetic energy (K.E) of the electrons (|V|/G) in Tables 3.29 and 3.30 is relatively 
low indicating a balance between a stronger bond interactions and high density in the regions [363]. A 
high value of |V|/G corresponds to higher density and stronger bonds except were the (r) is small 
(Table 3.29, 3.30 and correlation Table 3.31). 
 The strength of the two Ru-Cl bonds in terms of the  and  is not equal in complex 3 
compared to complex 1 (Table 3.29 and 3.30) which is also observed in their bond order (Table 3.23). 
The imbalance features of the two Ru-Cl in complex 3 can enhance the aqua substitution of the weaker 
Ru-Cl to form Ru-OH2 which may also play significant role in the reported higher anticancer of 
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RAPTA-C since easy hydration has direct correlate with the higher anticancer activity [37]. 
 The relationships between the computed factors of the bonds are constructed over all the 
existing bonds in the complexes (Table 3.31). A very high negative value of (r) is an indication of 
strong covalent bond while a high positive value corresponds to a strong non-covalent bond. The 
general relation is that high negative values of (r) is directly proportional to high (r), high Ven, 
lower bond stretch (BPL-GBL_I), lower kinetic energy (K), high negative values of potential energy 
(V), lower ellipticity () and relatively high value of |V|/G. The higher electronic kinetic energy (K) is 
an indication of lower values of (r),  and potential energy (V) but a higher value of (r) (Table 
3.31). These observed correlations further confirmed the reported nature of a very flat electron density 
region that is characterised by very low average values for (r), (r) which is usually found to have a 
relatively high  [364].  
3.3.3.4 The intraatomic properties  
 The properties of some selected atoms in each of the four complexes are presented in Table 3.32 
and Table 3.33. The integrated Lagrangian values L(A) of all the atomic basins are approximately 
equals to zero, which is an indication of satisfactory numerical integration [363]. The distribution of the 
atomic charges shows that the arene C atoms have gained charges confirming the existence of MLCT. 
For all the atoms in the complexes other than H atoms, the values of the percentage localization 
(%(A)) are higher than the percentage delocalization (%(A,A')).  
  The features of the relation within the computed intramolecular properties can be seen from the 
constructed correlation correlation Table 3.34. Higher K(A) is found to be as a result of higher bonding 
dipole moment contribution of the atoms (bond(A)|), high number of electron and relatively low 
Vol(A) that is poorly correlated. The high values of bond(A)| is an indication of low %(A,A'), high 
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%(A) and high Vol(A) of atoms. The atoms that are characterised with bigger volume will be 
associated with higher negative values of the zz. The atomic energy contribution (Ee(A)) to the virial 
energy of the system depend significantly on the number of the electrons and the number of localized 
electrons. The out of plane magnetizability (zz) is proportional to the number of the atomic localized 
electrons and inversely proportional to the atomic delocalized number of electrons. 
 The sum total of the intraatomic properties computed over all existing atoms show the changes 
in the computed atomic properties from one complex to another (Table 3.35). The decrease in the 
values of the atomic energy contributions like Ee(A) and KScaled of the respective hydrated complexes 
shows the significant contribution of the Cl atom to the total energy of the systems. The average values 
of the percentage electron delocalization over all the atoms increases in the respective hydrated 
complexes while the average electron localization decreases which correspond with the theory of 
activation of this complexes by hydration. Also, the average electron delocalization and the three types 
of dipole moments in complexes 3 and 4 are higher than complexes 1 and 2 which further distinguishes 
RAPTA-C complex of reported better anticancer activities.  
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Figure 3.7: The schematic structures of complexes 1, 2, 3 and 4 
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Figure 3.8: The HOMO and the LUMO of complexes 1, 2, 3 and 4 in a ascending order. 
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Figure 3.9: Laplacian of the electron density in a plane contains P, Ru and Cl or O nuclei (positive 
contours as dash and negative contours as solid lines are drawn from 0 to ±800 and bonds (strong 
bonds in solid and HB in dash lines).  
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3.3.4 Interatomic properties of ruthenium half-sandwich anticancer complexes 
containing Ru-N bonds  
 The optimization and computation of the properties for these complexes were done twice, first 
applying ECP SBKJC VDZ basis set on Ru and Cl atoms where applicable and all other atoms treated 
with 6-31G* basis set while in the second method the ECP is limited to only the ruthenium atom and 
the other atoms in the systems are treated with 6-31+G(d,p) basis set which will subsequently be 
referred to as PBE0/ECP(Ru,Cl)[6-31G*] and PBE0/ECP(Ru)[6-31+G(d,p)] respectively. All the 
stationary geometries of the complexes studied are obtained using the PBE0ECP(Ru,Cl)[6-31G*] and 
PBE0/ECP(Ru)[6-31+G(d,p)] and the respective thermodynamic properties obtained from these are 
shown in Table 3.36. Change of the functionals significantly affects the total energy of these complexes 
than changes in the basis sets (Table 3.37). The functional B3LYP in all the cases over estimate the 
energy of the system while PBE0 gives values closed to higher perturbation method of MP2 as show in 
Table 3.37. This further support the literature reports that metal complexes are better optimized using 
PBE0 with ECP basis sets [332, 333]. However, the NBO, NEDA and QTAIM properties of the 
complexes were computed using B3LYP functional because it is one of the most used functionals in 
computational studies and also shown to behave well in computing QTAIM properties [378]. 
Considering the functional B3LYP only, there is a much closed relationship in the energy values 
computed by scaling up the basis set to a limit of aug-cc-pVTZ-DK as shown in Table 3.37. The 
energies are computed following the scaling: 3-21G → ECP(Ru,Cl)[6-31G*] → ECP(Ru)[6-
31+G(d,p)] → DGDZVP(Ru)[6-31G*] → DGDZVP(Ru)[6-31+G(d,p)] → aug-cc-pVTZ-DK. The 
basis set aug-cc-pVTZ-DK and the functional MP2 are prohibitively expensive for computing the 
properties of these type of metal complexes with atoms ranging from 36-45, therefore the energy values 
provided for functional MP2 and basis set aug-cc-pVTZ-DK in Table 3.37 are the unconverged values. 
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The QTAIM properties of the complexes are computed using 3-21G, DGDZVP(Ru)[6-31+G(d,p)] and 
ECP(Ru)[6-31+G(d,p)] basis sets but the NBO and NEDA analysis a limited to only the higher 
combination of basis set DGDZVP(Ru)[6-31+G(d,p)]. In line with the literature reports, we observed 
that all methods can either overestimate or underestimate QTAIM properties (Table 3.45, 3.46 and 
3.47) [378]. 
 An interesting aspect of this work is to understand the chemistry of these five Ru(II)-based 
anticancer complexes based on their intramolecular interactions, strength of the Ru-N bonds and the 
stability of these complexes in relation to their proposed anticancer behaviours [318].  
3.3.4.1 Thermodynamic and the geometry properties  
 The schematic geometries of the five complexes studied in this work are shown in Figure 3.10. 
These are half-sandwich complexes with bidentate (complexes 1, 2, and 3) and tridentate (complexes 4 
and 5) ligands. Both complexes 4 and 5 have no chloride atom as ligand and there is no carboxylic unit 
in complex 4 among all other complexes. The high negative values of the energy, enthalpy and the free 
energy of the complexes at both level of theories (Table 3.36) shows that they are thermodynamically 
stable complexes. The values of the thermodynamic properties of the complexes at the two level of 
theories ECP(Ru,Cl)[6-31G*] and ECP(Ru)[6-31+G(d,p)] as applied for their optimization are shown 
in Table 3.36.  
 All the present metal-ligand bonds in the complexes with their bond order obtained through 
NBO analysis are shown in Table 3.38. The ruthenium-nitrogen (Ru-N) bonds are the shortest bonds in 
all the complexes ranges from 2.00 to 2.162 while their bond orders ranges from 0.361 to 0.424 which 
are relatively within the bond order of Ru-Carene bonds. Compared to the available experimental Ru-N 
bond lengths, the computed Ru-Nbpyr bonds in complex 2 (where subscript bpyr indicates ruthenium-
bipyridine bonds) are both 2.09 Å while Ru-Nphn in complex 3 (where subscript phn indicates 
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ruthenium-phenanthroline bonds) are both 2.138 Å which are closed to the experimental range of 
values for Ru-Nbpyr (2.040 to 2.056 Å) and for R-Nphn (2.073 to 2.087 Å) bonds [379]. In very good 
agreement with the experimental reports typical of Ru-Nbpyr and R-Nphn, the Ru-Nbpyr bonds in complex 
2 is shorter than the R-Nphn bonds in complex 3. The bond order (Table 3.38) with the Laplancian 
values (2(r)) of the electron density of the bonds (Table 3.45) also indicate that the Ru-Nbpyr is 
stronger than the R-Nphn in perfect agreement with the experimental report [379]. The computed N-Ru-
N angle of complex 2 is a little lower than complex 3 which agrees with the experimental order and 
range of values 78.9 and 79.5 to 80.1 typical of Nbpyr-Ru-Nbpyr and Nphn-Ru-Nphn respectively [379]. 
The Ru-Carene bonds ranges from 2.222 (in complex 1) to 2.289 Å (in complex 5) and their bond orders 
ranges from 0.35 (in complex 2) to 0.435 (in complex 4). The Ru-Cl bonds distances range from 2.39 
to 2.396 and their bond order ranges from 0.996 to 1.052. Both the computed Ru-Carene and Ru-Cl 
bonds are within the experimental ranges of 2.197 to 2.257 Å for Ru-Carene and 2.410 to 2.434 for Ru-
Cl as reported for RAPTA complexes [365]. The features of bond orders suggest Ru-Cl to be strongest 
(Table 3.38) but disapproved from the QTAIM analysis (Table 3.45) which shows it is weaker than 
other bonds and will be a good leaving unit for the activation of these complexes by hydrolysis [8, 17, 
38]. 
 The HOMO of the complexes is predominantly the metal atom and the chloride atom where 
applicable which indicate the electrons being pulled away from metal orbital by the coordinated ligand 
and also electron being back-bonded into the metal's low lying orbital from the coordinated ligand 
atoms which are responsible for the metal atom being also part of the LUMO (Figure 3.11).  
3.3.4.2 The features of H-bonding and Ru-N bonds 
 Hydrogen bond is the most widely studied noncovalent interaction in chemical and biological 
systems because of it is significance important to the stability and biological functions of compounds 
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[380-383]. It is reported to be undoubtedly the most important weak interaction in nature [382]. To the 
best of our understanding, this is the first time the intramolecular H-bonding of this type of complexes 
is reported. All the H-bonding in the complexes are shown in Table 3.39 while the properties of the 
hydrogen donor mostly C-H with another C-H which are not involved in H-bonding but are in the same 
chemical environment with those involved in H-bonding are shown in Table 3.40. The classical effect 
is observed in complex 1 as the C5-H24 and C15-H29 that are involved in H-bonding are weaker with 
Laplacian (2(r)) of -1.106 and -1.105 compared to C11-H30 and C21-H35 with 2(r) of -1.107 and 
-1.107 respectively which are in the same ligand chemical environment (Figure 3.12 and Table 3.40). 
The bond length of the two C-H bonds that are involved in H-bonding also are found to increase and 
consequentially have higher bond extension than the rest of the C-H bonds. The higher H-bonding of 
the H24···O2 than the H29···O2 is reflected in their receptive C-H as that of the formal is shorter than 
the later (Table 3.40). The H atoms that are involved in the H-bonding become more electropositive 
while the C atoms of the C-H bonds become less electropositive compared to carbon in the same 
chemical environment [Figure 3.12]. The C=O unit of the carboxylic group in complexes 1 and 3 
contributes significantly to the H-bonding networks of the complexes and the total hydrogen stability 
energy of the complexes 1, 2, 3 and 5 with carboxylic unit (Table 3.44). There is every possibility that 
the near contact effect of the two carboxylic unit contribute to the observed H···H hydrogen bond 
observed in complex 2. This type of interaction is not completely strange as it was observed in the H2-
HH non-covalent interaction [381, 382]. Interestingly also, these complexes have the highest 
stabilization energy (Table 3.44) which are in a closed range compared to other complexes.  
 Considering the strength of the H-bonds formed (the 2(r) in bracket) in complexes 1 (+0.038 
and +0.039), 2 (+.040) and 3 (+0.061 and +0.063), the strongest one is in complex 3 while that of 
complex 1 is the lowest (Table 3.39). The H···H interaction in complex 2 has greater ellipticity and 
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bond stretching than other H-bonds in other complexes yet its strength is still a bit higher than H-bonds 
in complex 1 considering their 2(r) values (Table 3.39). Other interesting features of the C-H that 
acts as proton donor in complexes 1 and 2 is that its C atom becomes less electropositive and its 
electronic volume appreciate while proton becomes more electropositive and its electron volume 
depreciate when compared to another C-H in the same chemical environment. This further indicates the 
elongation and weakening of the C-H bonds as a result of the H-bonding (Table 3.40).  
 In all the complexes, the strength of the Ru-N bonds is higher than the Ru-C bonds and Ru-Cl 
bonds in the complexes. Considering the mid Ru-N bonds in complexes 4 and 5, the order of the Ru-N 
bonds in the five complexes is 5 > 2 > 4 > 3 > 1 which agrees with the experimetal report of stronger 
Ru-N bonds of the metal-bipyridine than metal-phenanthroline [379]. 
3.3.4.3 The nature of the charge transfer and stability of the complexes 
The lowest percentages of non-Lewis Rydberg and highest percentages of Lewis orbital indicates that 
there geometries are stable. Also, relatively significant percentages of the Valence non-Lewis orbitals 
shows the importance of charge transfer which can be metal to ligand (MLCT) or ligand to metal 
(LMCT) in determination of the stability of the complexes. In Table 3.41, the donor and the acceptors 
NBO that have the perturbation stabilization energy (E
(2)
)  10.00 kcal/mol are presented and the 
amount of the electron (e) transferred into the anti-Lewis orbitals of the acceptors are presented in 
Table 3.42. The features of the perturbation energy presented in Table 3.41 for the five complexes show 
that they are dominated by back-bonding of electrons from the lone pair of the ligand atoms to the anti-
Lewis lone pair (LP) orbitals of the Ru atom. The amount of electrons that were transferred into all the 
anti-Lewis orbitals (acceptors) with the energy level of the orbitals is shown in Table 3.42. There is a 
significantly high amount of electron transfer into the anti-Lewis lone pair orbitals of metal atom. From 
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the NEDA, it is observed that the features of LMCT overshadowed the presence of MLCT. The lone 
pairs in the metal atom (both Lewis and non-Lewis) are the main orbitals that are involved in the 
charge transfer.  
 The fragmentation of the complexes into different units (Table 3.43) gives the features of the 
synergistic effect of the metal coordinated fragments on each other. It is observed that the stability of 
the ligand units of these complexes were strongly enhanced through the synergistic effects where the 
bidentate unit in complexes 1, 2 and 3 and tridentate unit of complexes 4 and 5 (fragment unit two in 
all the complexes) are the most enhanced. The next to this is the arene unit (fragment unit three in 
complexes 1, 2, and 5, fragment unit four and two in complexes 3 and 4 respectively) which is also 
characterised with lower energy minimum.  
 It is obvious from the features of the NEDA analysis (Table 3.44) that polarizability (POL) is 
the predominant factor that determines the stability of these complexes except in complex 2 where 
charge transfer (CT) is a little prevalent than POL. Electrostatic energy (ES) also contribute 
significantly to the stability of the complexes after the effects of the POL and CT. Complexes 2 and 3 
are significantly stable than the rest of the complexes and complex 4. However, the main reason for the 
lower stability energy of complex 4 can be traced to the low magnitude of CT due to the absence of 
carboxylic unit in the complex compared to other complexes.  
3.3.4.4 The bond properties from QTAIM analysis 
 The bond properties of the complexes are computed through QTAIM analysis using AIMAll 
package. For the systems optimized with PBE0/ECP(Ru,Cl)[6-31G*], the properties were computed 
using functional with all electron minimal basis set B3LYP/3-21G while the properties of the systems 
that were optimized with PBE0/ECP(Ru)[6-31+G(d,p)] were computed using both the 
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PBE0/ECP(Ru)[6-31+G(d,p)] and B3LYP/DGDZVP(Ru)[6-31+G(d,p)] functional and basis sets. The 
bonds properties are presented for the B3LYP/DGDZVP(Ru)[6-31+G(d,p)] in Table 3.45 for B3LYP/3-
21G and PBE0/ECP(Ru)[6-31+G(d,p)] in Table 3.46 and 3.47 respectively. The features of Laplacian 
plots of electron density for all the complexes using B3LYP/DGDZVP(Ru)[6-31+G(d,p)] basis sets is 
shown in Figure 3.12. Also, the correlation among the computed bonds properties are shown in Table 
3.48 (for B3LYP/DGDZVP(Ru)[-31+G(d,p)] only). The first thing that was observed is the 
disappearance of the NNCP in the topological surface of these complexes when the ECP basis set is 
limited to only ruthenium atom but appears especially in complexes 1, 2, and 3 when the chloride atom 
was also treated with ECP as explained for the optimization. The change in bond distance in the 
complexes from the PBE0/ECP(Ru,Cl)[6-31G*] to PBE0/ECP(Ru)[6-31+G(d,p)] optimized systems is 
less than 0.1 hatree and atomic properties obtained using a higher basis set DGDZVP(Ru)[6-
31+G(d,p)] (Table 3.45 and 3.49) and minimal basis set 3-21G (Table 3.46 and 3.50) are in very close 
proximities which is an indication that there is no serious change in the geometries of the systems when 
they were optimized with higher basis set (ECP(Ru)[6-31+G(d,p)]) and lower basis set (ECP(Ru,Cl)[6-
31G*]) respectively. Another implication is that all electron minimal basis set 3-21G is good enough 
for the construction of topological features of complexes especially when the system in big. However, 
the values of the Hamiltonian form of kinetic energy density (K) are under estimated using 3-21G basis 
set (comparing Table 3.45 with Table 3.45). The bond properties of the complexes obtained when the 
system was treated with ECP(Ru)[6-31+G(d,p)] (Table 3.47) are very similar to that obtained from all 
electron basis set DGDZVP(Ru)[6-31+G(d,p)] (Table 3.45) but ECP is found to underestimate the 
atomic properties (comparing Table 3.49 with Table 3.51) which is an indication that constructing the 
topological features with ECP may not accurately provide both intra and inter atomic properties of the 
complexes though it provides the same trends of values. 
 The bond distances (GBL_I) computed for complex 1 at the two method of optimization (Table 
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3.45 and Table 3.46) are very similar but there is a significant change in the dihedral angles of the 
carboxylic unit which resulted to one H-bonding in the system optimized with ECP(Ru,Cl)[6-31G*] 
but two when optimized with ECP(Ru)[6-31+G(d,p)]. The Laplacian plot of the electron density of 
complex 2 (Figure 3.12(2)) shows that many of its atoms are on the same plane. In complex 3, there is 
also no traceable changes in the geometries and the topologies from both 3-21G (Table 3.46) and 
DGDZVP(Ru)[6-31+G(d,p)] (Table 3.45) and two H-bonding are recognised in both methods (Figure 
3.12(3), Table 3.45 and Table 3.46).  
 All the ruthenium-ligand (Ru-L) bonds are characterised with positive (r) and a lesser value 
of (r) (within the range of 0.07 to 0.10) compared to the covalent bonds that exist within the atoms of 
each coordinated ligands (Table 3.45 and Figure 3.12) which are characterised with negative (r) and 
higher (r) values (within the range of 0.2 to 0.41).  
 The features of the metal-chloride bonds in complexes 1, 2, and 3 that contain coordinated 
chloride indicates that the chloride will be a good living group where necessary in their biological 
interactions which has been suggested to proceed through hydrolysis [8, 17, 37, 38]. The Ru-Cl bonds 
are characterised with lowest (r)and (r) indicating it is weaker than other Ru-L bonds but 
associated with lower stretching and lower ellipticity (Table 3.45).  
 The correlation of the bond properties constructed over all the existing bonds in the complexes 
(Table 3.48) gives a clear picture of the factors that define a strong bond and their relationship. A strong 
bond with a high negative values of (r) (i.e. covalent bond) or high positive values of (r) (i.e. 
non-covalent bond) should also be characterised with high values of (r) These strong bond should 
also be associated with lower ellipticity, lower bond length and bond stretching. The correlation of 
potential energy density (V) and the Lagrangian form of kinetic energy density (G) on the strength of 
bonds greatly become significant when considering their ratio (|V|/G). The values of K is highly 
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correlated with the electron density ((r)) of each atom (0.89, 0.88, 0.90, 0.90 and 0.88 respective 
complexes) and also have higher effect than G on the values of (r), ellipticity and bond distance 
(Table 3.48).  
3.3.4.5 Intra- and inter-atomic properties  
 The properties of the atoms in each of the five complexes which are coordinated to metal are 
presented in the Table 3.49. The integrated Lagrangian values L(A) of all the atomic basins are 
approximately equals to zero, which is an indication of satisfactory numerical integration [363]. For all 
the atoms in the complexes other than H atoms, the values of the percentage localization (%Loc(A)) are 
high while the percentage delocalization (%Deloc(A,A')). The reverse nature of the %Loc(A) and 
%Deloc(A,A') of the H atoms indicates they can be easily perturbed by an external electric field [363].  
  The correlation of the computed atomic properties in Table 3.52, gives the summary of the 
changes in the properties in relation to each other. The atoms that are highly electronegative in the 
complexes are associated with higher bonding dipole, total dipole and higher volume of atomic density. 
The high number of electrons or of localized electron significantly favours the bonding dipole, total 
dipole and volume of electron density of the complexes while high de-localization has reverse effects. 
The total dipole of each atom is significantly determined by its bonding dipole than the contribution of 
its intra atomic dipole. 
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1. Radibpza  
 
2. RadPya 
 
3. Raphendia 
 
4. RAbpz-py 
 
 
5. RAterpya 
RA = Ruthenium-6-arene); phendia = phenanthroline-diacetic; dpya = di(pyridine-acetic) bpza = bis(pyrazol-1-ly)acetic, 
bpz-py = bis(pyrazol-1-ly)pyridine, terpya = terpyridine-monoacetic 
Figure 3.10: The schematic structures of the five complexes 
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Figure 3.11: The HOMO and the LUMO of the complexes  
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Complex 5 
 
(3,-1) bond critical points (BCPs) are shown as small green spheres, (3,+1) ring critical points (RCPs) as small red spheres, 
and (3,+3) cage critical points (CCPs) as small blue spheres. 
 
Figure 3.12: Laplacian of the electron density plots in the plane of N, Ru and N nuclei (positive 
contours as solid and negative contours as dashes lines are drawn from 0 to ±800) showing the features 
of bonds (strong bonds in solid and HB in dash lines) for five complexes.  
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3.4 The spectroscopic and non-linear optical properties of some Ru(II)-based 
complexes 
 This section is made up of three subsections on the spectroscopic and non-linear optical 
properties of Ru(II)-based complexes. Two of these subsections have been published in the literatures 
[316, 317]. Section 3.4.1 illustrates the chemistry of the three model of RAPTA-C (r = Ru, a = 6-
arene, PTA = 1,3,5-triaza-7-phosphaadamantane and C means the ligand unit arene is cymene) which 
will enhance the experimental means of increasing their stability that is suggested as a means of getting 
better drug candidates [5]. The models considered in this work are the RAPTA-C and its bidentate 
forms which are oxalo-RAPTA-C and carbo-RAPTA-C (Figure 3.13). The chelate effect on oxalo-
RAPTA-C has lead to a structure that completely resists hydrolysis while there is a possible hydrolysis 
of carbo-RAPTA-C [51]. The possible application of Ru(II) complexes as photocatalysts or 
photoinitiators has been reported [384]. In this work, electric dipole moments, hyperpolarizabilities, 
isothropic and anisotropi C-NMR properties of these selected Ru(II)-based complexes are calculated. 
The goal of this work is to investigate the physicochemical nature of the intramolecular non-bonded 
forces that drive the stability in relation to their anticancer behaviour. For this purpose, in addition to 
the thermodynamic properties, we have computed the IR, NMR shifts, spin-spin coupling constants and 
nonlinear optical (NLO) properties like hyperpolarizability.  
 In Section 3.4.2, computational method was applied to compute the properties of four different 
forms of organometallic Ru(II) anticancer complexes known as RAPTA-H (complex 1), RAPTA-C 
(complex 3), RAPTA-T (complex 5) [8] and RAPTA-CF3 (complex 7) [17] with their respective 
hydrated complexes 2, 4, 6 and 8 to understand the properties that enhance their activation by 
hydrolysis (Figure 3.16). There are reported kinetic study of the hydrolysis of the Ru-Cl bond of the 
prodrug to generate active complexes of the form [(η6-arene)Ru(en)(H2O)]
2+ 
[41]. The kinetic studies 
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showed that the Ru-Cl bond hydrolysis can be strongly influenced by the nature of the coligands as 
well as the nature of the metal ion. What is of interest to us is the possible changes in the properties of 
these complexes upon hydrolysis that is responsible for their activation using the electronic and the 
quantum theory of atoms in a molecule (QTAIM). Based on the knowledge that these type of the 
complexes should be characterised with an intense intramolecular CT between metal and ligand 
(MLCT or LMCT) which will definitely lead to a very large value for hyperpolarizability ( [369] as a 
consequence of the π back-donation in the complexes [369, 370], the non-linear optical (NLO) 
properties were also computed to understand their correlation to the anticancer activities and the 
possibility of using the complexes alternatively as NLO materials. To the best of our knowledge, these 
type of correlation studies of the electronic and spectroscopic properties of these complexes with their 
anticancer activities have not been considered in the literatures. 
 In the section 3.4.3, the complexes of interest (Figure 3.19) have similar structures with the 
types of half-sandwich ruthenium anticancer complexes designed and studied under Sandler research 
team [20-29]. The interest of this research work is to compute the chemical properties of these 
complexes in relation to the unique features of the carboxylic or pyrazole units, total stability, 
conductivity and reactivity either as anticancer or NLO materials. There is little known information 
about the hyperpolarizabilities of ruthenium metal complexes but many of the computed properties in 
this study have not been reported for these types of metal complexes to the best of our knowledge. The 
complexes used in this work are designed to play a dual role as anticancer and non-linear optical 
(NLO) materials.  
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3.4.1 Theoretical study of the electronic and spectroscopic properties of Ru(II)-based 
complexes of RAPTA-C derivatives  
 The electronic, electrochemical and structural properties like thermodynamic, nonlinear optical 
(NLO), NMR and spin-spin coupling constant of complexes 1, 2 and 3 are computed using DFT 
method. There have been no previous considerations on the correlation of these properties to the 
biological activities of the complexes to the best of our knowledge. The conceived interest is to know 
the possible correlation to the anticancer activities of these complexes since they have been reported to 
have complex chemistry [5] and to also envisage other alternative applications of these complexes. 
3.4.1.1 The geometry, thermodynamic and infra red (IR)  
 The geometries of the three complexes are presented in Figure 3.13 with their bond distances in 
atomic unit (au). Ru-P bond distances in angstrom (Å) for complexes 1, 2 and 3 (experimentally 
available values in parenthesis) are 2.43, 2.43 (2.31) and 2.42 respectively; Ru-arene carbon bonds 
ranges from 2.21 to 2.23 in complex 1, from 2.22 to 2.23 in complex 2 while it ranges from 2.20 to 
2.24 in complex 3. The two Ru-O bond distances for the bidentate complex 1 are 2.10 and 2.12 while 
complex 2 has approximately the same distance of 2.09 (2.09, 2.10). The two Ru-Cl bonds for complex 
3 are ~ 2.50. A closer look at the bond distances of complexes 1, 2 and 3 with the available 
experimental values from literature [51] in parenthesis shows strong similarities in the complexes. The 
common bond angle O-Ru-O for complexes 1 and 2 are 84.56° and 79.47° (78.43°) while the unique 
bond angle Cl-Ru-Cl for complex 3 is 89.64°(89.16°). According to Ang et. al [51], the significantly 
smaller than 90° for 1 and 2 six-membered and five-membered metallacycles respectively is an 
indication that they are strained. The close values of our computation to the available experimental 
values obtained from literature [51] is an indication that the geometries of the complexes are well 
optimized with DFT functional PBE0 and mixture of basis set 6-31G* and SBKJC VDZ with ECP 
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which further confirm the efficacies of this PBE0 functional with ECP basis set in computing the 
structural properties of metal-based complexes according to literatures [332-339]. 
 A critical look at the thermodynamic properties in Table 3.53 shows that the effect of the 
rotational and translational energy (Erot + Etran = E
0
-E) is very low as they are found to be 0.08, 0.08, 
0.07 KJ/mol for the three complexes 1, 2 and 3 respectively. It is not appropriate to compare the 
thermodynamic properties between the three complexes since each complex contains different number 
of atom but the individual thermodynamic nature shows that they are characterised with negative Gibbs 
free energy and have relatively high entropy which indicate they are thermodynamically stable. 
 The low intensities at 3040-3051 cm
-1
 region as shown in Figure 3.14 are ascribed to (C-H) 
antisymmetric stretches while the high intensity bands at 1242-1303 cm
-1
 regions were characterised as 
(C-H) bend of CH2 of the ligands. The sharp frequencies at 2975- 2992 cm
-1
 region are assigned to 
(C-H) of the arene alkyl CH3 side chain. The arene (C-H) stretches as a low intensity frequencies at 
1427-1450 cm
-1
 which is close to the experimentally assigned for arene (C-H) stretches of 1614 cm-1 
[53]. The high intensity at 1633-1727 cm
-1 
region are ascribed to the (OCO) of the carboxylate units 
of the bidentate complexes as it is absent in the complex 3 without the bidentate as shown in Figure 
3.13 which is close to the experimentally reported (C=O) 1612-1628 cm-1 of the similar complex 
[154]. The common frequencies within 933-1020 cm
-1
 are assigned to the C-C, C-O and C-N vibrations 
in three complexes. The lowest frequencies in 480-680 cm
-1
 region are assigned to (Ru-P) and Ru-Cl 
where applicable which is very close to experimental value 424-428 cm
-1
 assigned to (Ru-S) [154]. 
There is significant upper (red) shift of bidentate (OCO) vibration from 1 to 2 and significant change 
in the intensity of the picks are observed in the complexes. The intensity of (C-H) bend at 1242-1303 
cm
-1
 region is very high in 1 and very low in 3 which further shows the higher number of CH2 in 1 than 
the other two complexes.  
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3.4.1.2 The hyperpolarizability 
 We observed that there are other important factors like higher isotropic polarizability that can 
possibly define the higher hyperpolarizability of complex 1 above 2 and 3 despite its contradicting 
higher band gap and lower dipole moment (Table 3.54). The hyperpolarizability of the complexes 2 and 
3 are very close to each other and lower band gap is found to favour complex 3 while higher dipole 
moment favours complex 2. The lowest band gap of 3 is an indication that there is a better electron 
communication within this complex which could also be responsible for its reported activity as the best 
anticancer among the three [13]. Interestingly, there is high possibility that high conductive properties 
of these complexes may likewise contribute to their anticancer activities since it can enhance their 
binding to receptors' residues.  
 We observed that these complexes that were originally designed as anticancer complexes are 
found having higher hyperpolarizability than many of the reported complexes that were originally 
designed as NLO materials. They are found to be better NLO material than reported high 
hyperpolarizability materials like ruthenium complexes with redox-switching non-innocent ligands 
(NILs) [338], far better than NLO reported for 5-monocyclopentadienylnitrilecobalt complexes [370] 
and very competitively close to some of the high first static hyperpolarizabilty values reported for 
bimetallic complexes [369] and that of the nitrogen bound low valent (M
0
) group six metal carbonyls 
[346]. The implication is that systems with intense intramolecular CT between metal and ligand 
(MLCT or LMCT) transitions will lead to a very large value for  [369] which is also the consequence 
of the π back-donation in the complexes [369, 370].  
3.4.2 The Ramsey terms and nuclear spin-spin coupling (Jru-A) 
 We make use of four Ramsey terms Fermi contact (FC), spin dipole (SD), diamagnetic spin 
orbit (DSO), paramagnetic spin orbit (PSO)) leading to total nuclear spin-spin coupling (J) [385]. The 
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result obtained by using all electron basis set, give a better picture of the contribution of different 
factors to the total nuclear spin-spin coupling J(HZ) (Table 3.55, 3.56). The spin-spin coupling, J(HZ), 
of Ru-C bonding where the C atoms are from arene ligand is far less deshielded (i.e. highly shielded) 
than the J(HZ) for Ru-P and Ru-O where the P atom is from PTA ligand and O are the two bonding 
oxygen of the bidentate ligand. Also, the higher less negative values of J(HZ) Ru-C in complex 3 
shows that there is higher shielding of arene ruthenium bonding in complex 3 than in complex 2. Both 
Ru-Cl and the Ru-P are highly deshielded in complex 3 which suggest the possibility of both to be 
labile unit even though only the Cl atom has been experimentally reported to be labile for this complex 
[5]. The Ru-O bonding in complex 2 is associated with high J(HZ) shielding which further explain the 
reason why it is experimentally found to completely resist hydrolysis [51]. Also, the reported 
correlation of the change in each factor with the change in J(HZ) as shown in Table 3.57, further 
confirm the significant effect of the hyperfine function FC. The results that we obtained from using 
ECP basis set significant underestimate the FC and PSO effect (Table 3.58). The reason is that the core 
electrons that were represented with pseudopotential were not properly accounted for during the spin-
spin computation, and this consequentially leads to lower FC since the core electrons also play 
important role in determining FC. Contrary to all electron basis set (Table 3.55, 3.56), all the four 
parameters using ECP (Table 3.58) are very small with PSO having the highest contribution and 
correlation follow by SD.  
 The results of the correlation of isotropic, anisotropic and charges of all atoms are present in 
complexes 2 and 3 with the four Ramsey terms for atomic coupling properties with Ru atom (Table 
3.57). There has been reported change in NMR isotropic shieldings (σ) with change in the electron 
density of atoms [386]. We observed a low correlation in the distribution of atomic charges and their 
NMR isotropic shielding (Table 3.57). There are some unique differences and similarities in the 
properties of complex 2 and 3. Isotropic is poorly correlated with anisotropic properties in complex 2 
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but a very high correlation is observed in complex 3 when both 3-21G and and 3-21G** basis sets were 
used. There is an average relation between the isotropic properties of atoms in the complexes and their 
total nuclear spin-spin coupling with ruthenium atom (Jru-A) (Table 3.57). In complex 2 there is a very 
high correlation of the Isotropic with Ramsey term FC while it is strongly correlated with SD and PSO 
in complex 3. The total nuclear spin-spin coupling of Ru atom with all the atoms in the complexes (Jru-
A) is significantly characterised with FC and followed by SD term. PSO term has a very negligible 
effect on the value of Jru-A in complex 2 compared to complex 3.  
3.4.2.1 The analysis of the magnetizabilities and  NMR shielding properties using 
AIMAll 
 The correlation of all the magnetic properties computed is presented in Table 3.59. The atomic 
charge q(A) appears to have average effect on the intraatomic magnetizability contribution of each 
atom (Intra_Iso(A)) which consequentially cause its relatively high correlation with the total 
magnetizability contribution of each atom (Iso(A)). When we consider the correlation of q(A) with 
intraatomic shielding tensor (Iso(A,A)) and total magnetic shielding tensor of each atom (Iso(A)) as 
found in a literature [386], there exist an averagely good and inverse correlation in complex 3 but very 
low correlation in complex 2. Iso(A,A) and Iso(A) are significantly inversely correlated with 
Intra_Iso(A) and Iso(A) and are also directly correlated with bonding magnetizability contribution of an 
atom (Bond_Iso(A)). What determine the total magnetic shielding tensor of each atom (Iso(A)) is the 
intraatomic Iso(A,A) which is a function of the intraatomic electrons. The total dipole (A) is found to 
depend more on the bonding dipole moment contribution (Bond(A)) than intraatomic dipole moment 
contribution Intra(A) while the total magnetic shielding tensor (Iso(A)) depends more on the 
intraatomic Intra_Iso(A) than bonding Bond_Iso(A). The Iso(A',A) is inversely correlated with 
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Bond_Iso(A). Bond_Iso(A) correlated averagely and inversely with Bond(A) and (A). 
 The charges, dipole, magnetizabilities and NMR shielding of some selected atoms in complexes 
2 and 3 are presented in the Table 3.60. In the computed isotropic shielding complex 1 and its atomic 
charge which are not presented, we observed that the two bonding bidentate oxygen atoms to Ru atom 
are more electronegative with high shielding tensor than what is observed in complex 2. Also, there is a 
very high imbalance in the shielding of these two bonding bidentate oxygen atoms of complex 1 which 
can possibly enhance the process of ring opening as suggested means of hydrolysis of bidentates [37] 
and could probably be responsible for the reported better hydrolysis of 1 than 2 [51]. We observed that 
there is relatively high similarities in the atomic charges, dipole, magnetizabilities and  NMR shielding 
properties of similar atoms like N atoms from PTA and C atoms from arene unit of complexes 2 and 3 
(Table 3.61, 3.62). Table 3.60 give the sum over of all the magnetizabilities and the shielding tensor. 
Just as the correlation indicated, the higher value of the sum over of the total dipole of complex 2 is 
higher than 3, then there is corresponding higher negative value of the sum over of Bond_Iso(A) of 2 
than 3. Also, since the Iso(A,A) and Iso(A) of complex 2 is far less than 3 then the negative value of 
the sum over of Intra_Iso(A) of 2 is also higher than that of 3. The implication of these is that the major 
factor that determines the NMR shielding tensor of each atom is their intraatomic magnetizability 
contribution rather than ordinary charge. The intraatomic shielding tensor (Iso(A,A)) in complex 3 is 
far greater than complex 2 which consequentially resulted to higher total magnetic shielding tensor 
(Iso(A)) of the complex (Table 3.60). A more critical look at the complexes shows that the higher the 
shielding the more sensitive the atoms as the N atoms of the PTA (223.15, 226.89, 222.53 for complex 
2 and 221.04, 220.35, 216.69 for complex 3) are found to be highly shielded which are reported to be 
significant in the kinetic of the potential drugs as they act as hydrogen bonding acceptors [9]. The 
hydrogen bonding of this chloride further gives the reason why complex 3 which as been 
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experimentally reported to be less kinetically stable is also found to be a transition state structure as 
given in Table 3.53.  
 The feature of the contribution of bond between atom A and Atom B (Bond(A|B)) to total 
bonding magnetizability contribution of each atom Bond(A) is shown in Figure 3.15. The atoms that are 
directly bonded to metal centre have the highest atom-atom magnetizabilities and the total shielding 
compared to others. In the two complexes we found that the Ru atom is contributing more to Bond(A|B) 
that exist between it and the electron depleted pi ligand of arene. The analysis of the contribution to 
bonding magnetizability show that Ru atom contribution ranges from 2.75 to 2.91 and 2.77 to 3.18 in 
cgs-ppm for complexes 2 and 3 respectively in bonding to arene ligand which is higher than any 
contribution of the C atoms of the arene ligand. These further suggest that there exist metal to ligand 
charge transfer (MLCT) between the Ru atom and the electron depleted arene ligand which is 
commonly reported to metal complexes [346].  
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1. Carbo-RAPTA-C 
 
2. Oxalo-RAPTA-C 
 
3. RAPTA-C 
 
Figure 3.13: The geometric structures of complexes 1, 2 and 3 with their bond distances shown in 
angstrom (Å). 
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Figure 3.14: The IR spectral of complexes 1 (purple), 2 (green) and 3 (red). 
 
 
 
Complex 2 
 
Complex 3 
 
Figure 3.15: The contribution of each atom to the bond magnetizability. 
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3.4.3 Electronic, conductivities, and spectroscopic properties of hydrolysed Ru(II) 
anticancer complexes 
3.4.3.1 The geometrical and the infra red properties 
The optimized geometries of the complexes (Figure 3.16) were obtained using PBE0 hybrid functional 
and two mixed basis sets that comprises of SBKJC VDZ basis set with ECP that was applied on the Ru, 
Cl and P atoms and all electron basis set 6-31G* that was applied on the remaining atoms of each 
complex. All the Ru-Cl bond distances through all the complexes are within the range of 4.67 to 4.73 
(a.u.), the Ru-O where the O atom is from water molecule is within the range of 4.21 to 4.25 (a.u.). The 
bond angle Cl-Ru-Cl in complexes 1, 3, 5 and 7 are 90.42
O
, 89.64
O
, 90.75
O
 and 89.73
O
 respectively 
while the bond angle Cl-Ru-O of their respective hydrated complexes 2, 4, 6 and 8 are 79.99
O
, 76.65
O
, 
76.99
O
 and 77.02
O
 respectively.  
 The features of the infra red (IR) (Figure 3.17) show that complexes share many common bands 
which indicate that the overall structures of the complexes are not very different. Large spectra 
differences are observed only when each of the complexes hydrolysed to their respective complexes. A 
further difference is also observed when the methyl group on the arene units of complexes 5 and 6 are 
substituted with trifloromethyl group to form complexes 7 and 8. From the knowledge of the reported 
experimental IR value for the Ru-O stretching frequency at 580 cm
-1
 [387], we can allocate the 
computed Ru-O strength in the hydrated complexes 2, 4, 6 and 8 to the observed absorption at 645, 
636, 626
 
and 638 cm
-1
 respectively which is not obvious in the unhydrated complexes 1, 3, 5 and 7 
(Figure 3.17). In the hydrated complexes 2, 4, 6 and 8, there is a peculiar vibration at 1622, 1617, 1617 
and 1616 cm
-1
 respectively which can be assigned to the activities of the water molecules that donate at 
least one hydrogen bond to the complexes in line with a range of 1600-1700 cm
-1
 that have been 
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experimentally proposed for such kind of water molecule activities [388]. While two other unique 
stretching vibrations of each hydrated complexes 2 (3635, 3309 cm
-1
), 4 (3623, 3292 cm
-1
), 6 (3636, 
3304 cm
-1
) and 7 (3640, 3308 cm
-1
) can be assigned to O-H from water molecule having two different 
modes due to the formation of hydrogen bond. In another reported experimental IR information, Ru-P 
is assigned 280 cm
-1
, (C-H) or (C-H) of the benzene ring 3057-3024 cm-1 or 1035-1000 cm-1, the (C-
H) of the CH3 is assigned 2932-2874 cm
-1
 [389]. Therefore the Ru-P is assigned to be the prominent 
lowest frequencies at 274 cm
-1
 in complexes 1 and 2, 280 cm
-1
 in complexes 3 and 4, 262 cm
-1
 in 
complexes 5 and 6 and at 262 cm
-1
 in complexes 7 and 8. Also a shoulder like stretching vibrations 
observed at 3045 cm
-1
 for all the complexes of which the unhydrated is higher than the hydrated are 
assigned to the (C-H) of the arene units. The sharp and very prominent bands found at 2987, 2980, 
2978, and 2988 cm
-1 
in the unhydrated complexes 1, 3, 5 and 7 and in the hydrated complexes 2, 4, 6 
and 8 at 3002, 3005, 3003 and 3014 cm
-1
 are assigned to (C-H) of the CH3 on the arene units. 
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Figure 3.16: The optimized geometries of complexes 1, 3, 5, 7 (left) and their hydrolysed 2, 4, 6, 8 
(right) respectively 
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a). IR for complexes 1 (red) and 2 (green) as 
indicated in the plot 
 
 
b). IR for complexes 3 (red) and 4 (green) as 
indicated in the plot 
 
c). IR for complexes 5 (red) and 6 (green) as 
indicated in the plot 
 
 
d). IR for complexes 7 (red) and 8 (green) as 
indicated in the plot 
 
Figure 3.17: IR plot of the complexes as indicated in the figures 
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3.4.3.2 The thermodynamic properties 
 The thermodynamic properties of the complexes are shown in Table 3.63 using the functional 
and mixed basis sets used for the optimization. Many of the complexes are found to be stable minimum 
geometries except 2, 3 and 5 that have single imaginary. However, this observation is not strange as 
there have been reported instability of some of these complexes [5, 51]. A critical look at the 
thermodynamic properties as shown in Table 3.63 indicates that the effect of the rotational and 
translational energy (Erot + Etran = E
0
-E) is very low as their values ranges from 0.048 to 0.066 Kjmol
-1
 
through all the complexes. The thermodynamic natures of the complexes show that they are 
characterised with negative Gibbs free energy (G), negative enthalpy (H) and have relatively high 
entropy (S) which indicate they are thermodynamically stable. 
 We consider the change in the thermodynamic properties during the process of hydrolysis of 
complexes 1, 3, 5 and 7 to their respective hydrolysed complexes 2, 4, 6 and 8 as shown in Table 3.64. 
There have been little study on the thermodynamic change for the hydrolysis of Ru(II) complexes of 
the type [Ru(6-arene)(en)Cl]+ but that of the [Ru(6-arene)(pta)Cl2] in relation to the variation of their 
anticancer activities has not been considered to the best of our knowledge [41]. The simple method 
used in computing the thermodynamic changes follow from a simple equation: 
rec_Cl + H2O → prod_H2O + Cl
X = X(prod_H2O + Cl) - X(rec_Cl + H2O) 
where rec_Cl represent complexes 1, 3, 5 and 7 which contain the leaving Cl atom and prod_H2O 
represent the hydrated complexes 2, 4, 6 and 8 with a water molecule. 
 The results (Table 3.64) shows that the hydration of the complexes are not spontaneous but 
require some energy like high temperature in the system before the hydrolysis can take place as the H 
and G are positive. The possibility of the hydration taking place in the blood before reaching the cell 
107 
[5] or the possibility of the hydration taking place only in the cell due to high chloride concentration in 
the blood [8] depend on other reaction activities in the blood or in the cell respectively that will initiate 
the hydrolysis. The complexes that hydrolyse very slowly have been reported to have very poor 
anticancer activities
 
[37]. However, the strong anticancer effect of complex 7 above complex 5 despite 
the unfavoured thermodynamic of its hydrolysis can be traced to the reported formation of [Ru(pta)]–
biomolecule adducts (the arene unit being separated) which were not observed in the protein or DNA 
binding studies of other [Ru(pta)(arene)] adducts of RAPTA compounds [17]. This unique arene 
separation in complex 7 may enhance its hydrolysis and consequently improve its anticancer properties.  
3.4.3.3 Conductive properties 
 The conductive properties of these complexes in the form of the NLO hyperpolarizability were 
computed to determine any possible correlation with their anticancer activities and also the possibility 
of using them as NLO materials. The NLO properties of the complexes are computed as the first static 
hyperpolarizability (ß) (Table 3.64). The hydrolysed complexes 2, 4, 6 and 8 are accompanied with 
higher hyperpolarizability and consequential lower band-gap than their respective complexes 1, 3, 5 
and 7 (Table 3.65). This suggests that the mechanism of activation by hydrolysis can be as a result of 
increase in the conductive strength of the hydrolysed complexes which will enhance easy charge 
transfer and interaction.  
 The hyperpolarizability of complex 7 and its hydrated complex 8 are higher with lower band-
gap compared to complex 5 and its hydrated complex 6 respectively. This further gives another 
possible reason why complexes 7 and 8 are better anticancer compared to complexes 5 and 6. The 
hyperpolarizability of complex 3 is a little higher than that of complex 1 but reverse is the case when 
comparing their hydrolysed complexes 4 and 2 respectively. However the isotropic polarizability 
polarization of complexes 3 and 4 is higher than that of complexes 1 and 2 which further suggest 
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possible effect of the higher conductive effect of complexes 3 and 4 to their higher anticancer activities. 
 It is interesting to point out that these complexes that were originally design as anticancer 
complexes are found to have high first static hyperpolarizability (ß) than many of the reported 
complexes that were originally designed as NLO materials [338, 346, 369, 370].  
3.4.3.4  Ramsey properties of Nuclear magnetic resonance (NMR) 
 The NMR Ramsey properties of some selected bonds in the complexes and that of their 
respective hydrolysed complexes are shown in Tables 3.66.  
 The Ru-Cl bond has the highest PSO and SD values but the lowest values of the DSO and FC 
than other Ru-L bonds. This bond is also characterised with higher J(HZ) values except for Ru-P bond 
that is characterised with the highest coupling constant. Upon hydrolysis, the Ramsey parameters of 
Ru-Cl of the retained Cl atom are lower compared to the Ramsey parameters of Ru-Cl in the 
unhydrated complexes but the J(HZ) of all the Ru-P and Ru-C bond increases upon hydrolysis. Despite 
the significant difference in the arene unit of the unhydrated complexes 1, 3, 5 and 7, the Ramsey 
properties of their Ru-Cl, Ru-P and Ru-C are relatively the same.  
 In order to understand the most significant factors that determine the J(HZ), we computed the 
correlation within all the Ramsey factors over all bonds that exist in the complexes (Table 3.67). The 
FC is found to be the most significant factor as it has the highest correlation with the J(HZ) ranging 
from 0.88 to 0.96 in all the complexes. The next significant factor is SD which has a correlation range 
from 0.74 to 0.87, typical in nature of systems [166]. The PSO and DSO correlations with the J(HZ) 
are negligible. We also observed that in all the hydrolysed complexes, high correlation exists between 
the FC and SD. 
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3.4.3.5 NMR bond properties using QTAIM analysis 
 The features of the first-order net current vector obtained using the QTAIM analysis as 
implemented in the AIMAll shows that the highest part of these induced currents are out of plane 
(J_ZZ) and the hydrolysed complexes are characterised with the highest values compared to their 
respective unhydrolysed complexes (Table 3.68). Also, complexes 3 and 4 are characterised with higher 
values than complexes 1 and 2 and likewise complex 7 is characterised with higher values than 
complex 5 which correlate with their reported anticancer activities. 
 The bonding magnetizability between Atom A and Atom B (Bond(A|B)) of some selected atoms 
are shown for the complexes in Figure 3.18. We observed that the Bond(A|B) give some interesting 
feature to the existing HB interactions in the complexes. All of the HB are significantly characterised 
by different atomic contribution of Bond(A|B) along their line of HB interaction which is an indication 
that each atomic Bond(A|B) may play significant role in determining the possibility of HB interaction 
between two atoms. However, there is no significant difference in the Bond(A|B) of two atoms that 
formed a real bond which implies that the Bond(A|B) is negligible in determining real bonds. 
3.4.3.6 NMR atomic properties using QTAIM analysis 
 The atomic charges (q(A)), magnetizability contribution (Iso(A)), dipole (A)) and magnetic 
shielding tensor (Iso(A)) were computed using QTAIM analysis as implemented in AIMAll (Table 
3.69-3.75). The bonding magnetizability contribution of each atom (Bond_Iso(A)) in cgs-ppm is found to 
be higher than the intraatomic magnetizability contribution of each atom (Intra_Iso(A)) for the Ru, C, 
and P atoms but reverse is the case for the Cl, N and O atoms. The H atoms from arene, PTA and water 
molecule which are involved in HB interaction are included in Table 3.69-3.75. The general 
observation is that the H atoms from water molecule are characterised with high Iso(A,A) and 
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consequently high total magnetic shielding tensor of each atom (Iso(A)) than any other H atoms from 
arene and PTA units. 
  Interestingly, we observed that complexes 3 and 4 which are known to be the best anticancer 
[13] are having the highest magnitude of Intra_Iso(A) and the lowest Iso(A) compared to the rest of the 
unhydrated and hydrated complexes respectively. However, complex 7 which is expected to have 
higher Intra_Iso(A) and lower Iso(A) than complex 5 because of its reported better anticancer activity 
[17] does not follow, which is an indication that the experimentally found unique feature of the arene 
separation in its adduct interaction should be responsible for its higher anticancer activity as we have 
discussed in the thermodynamic properties (Table 3.63 and 3.64).  
 The sum total of all the computed properties over all the existing atoms in each complexes 
(Table 3.76) can only make sense when comparing the hydrated complexes and the unhydrated 
complexes separately because of the significant differences in the ruthenium-ligand (Ru-L) bonds. We 
can then state that high values of Intra_Iso(A) are directly related to their anticancer activities as the 
value for the unhydrated complex 3 is having the highest value and also complex 7 as expected is at 
this point correlate with its anticancer activity as it is characterised with higher Intra_Iso(A) than 
complex 5. Also, as expected, the hydrated complex 4 is having the highest value of Intra_Iso(A) 
compared to all other hydrated complexes. 
3.4.3.7 Correlation of the NMR atomic properties 
 The possible correlations within the computed properties are also considered (Table 3.77). The 
atomic charge (q(A)) is averagely correlated with the Intra_Iso(A) which happen to be its best recorded 
correlation. The Intra_Iso(A) is also found to be the most significant factor that determined the values of 
Iso(A) than the contribution from the Bond_Iso(A). The Bond_Iso(A) is found to be most significantly 
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correlated with the anisotropy of the atoms. The Intra_Iso(A) has better inverse correlations with 
Iso(A,A) and Iso(A) while the Bond_Iso(A) has better inverse correlations with the Iso(A,A'). The 
Iso(A) is found to have the best correlation with the Bond(A) and A) than any other computed 
properties. The values of Iso(A) is significantly determined by the values of Iso(A,A) and are both 
strongly correlated with the anisotropy though inversely. 
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Figure 3.18: The Contribution of each atom to the bonding magnetizability between Atom A and Atom 
B (Bond(A|B)) 
113 
3.4.4 The spectroscopic and conductive properties of Ru(II)-based complexes as 
potential anticancer  
3.4.4.1 The geometry and the IR spectroscopic  
 The geometry of the complexes (Figure 3.19) are optimized twice using the combined basis set 
ECP(Ru,Cl)|6-31G* for the first optimization and ECP(Ru)|6-31+G(d,p) for the second optimization. 
The zero imaginary obtained for the five complexes during the two methods of optimization is an 
indication that both methods detect the minimum geometry of the complexes except for complex 4 that 
was predicted during ECP(Ru,Cl)|6-31G* as transition with single imaginary frequency. There is no 
significant changes in the bond lengths (>>0.01 Å), angles (>> 2.0
O
) and the conformations (>> 0.1) of 
the complexes when optimized with ECP(Ru,Cl)|6-31G* and with higher basis set ECP(Ru)|6-
31+G(d,p) (Table 3.78). The little significant change observed is in the conformational change of the 
carboxylic units of complex 1 which is responsible in having the highest recorded RMSD of 0.068 
(Table 3.78) when the geometries from the two optimizations are matched.  
 Differences in the complexes and their respective IR spectra were used to suggest the 
corresponding bond vibrations. The Ru-Nitrogen (Ru-N) bonds are assigned to indicate the differences 
in the vibration of ruthenium bonded to pyrazole or pyridine or phenanthroline units. The peculiarity of 
weak vibrations around 700 cm
-1
 for the complexes 1, 2 and 3 with chloride ligands which are not 
obvious in other complexes without chloride is an indication of Ru-Cl vibration around this region. The 
Ru-Carbon (Ru-C) bonds are assigned to vibration at 797 cm
-1 
which is common to all the complexes. 
The assigned Ru-C vibrations are within the possible Metal-C vibrations (548-829 cm
-1
) reported for 
carbonyl metal bonds [390] and of that which was specifically reported for the Ru-C vibration (838 cm
-
1
) [391]. The common vibrations around 1419 cm
-1
 that is peculiar to complex 4 and that at 1477 cm
-1
 
for other complexes are assigned to the possible C-C, C-N vibrations and can be equally suggested to 
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be as a result of Ru-ligand (Ru-L) charge transfer [392]. All the vibrations at 3600-3625, 1758-1784, 
1050-1150 and 735-745 cm
-1
 are all peculiar to the complexes with carboxylic unit and are assigned to 
different modes of vibrations as indicated in Table 3.79. 
 
 
 
 
 
 
 
 
 
Figure 3.19: The schematic features showing all the bidentate ligands of complexes 1, 2, 3 and 
tridentate ligands of complexes 4 and 5. 
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Figure 3.20: The IR spectra of the indicated complexes showing the variation in their vibrational modes 
 
 
 
3.4.4.2 Spin Spin Coupling (J(HZ)) of Ru-Ligand bonds 
 The Ramsey Terms are computed with different combinations of basis sets. The properties 
computed with DGDZVP(Ru)|6-21+G(d,p) and 3-21G are shown in Table 3.80 while those computed 
with ECP(Ru)|6-21+G(d,p) and ECP(Ru,Cl)|6-21G* are shown in the Table 3.81. The FC and SD 
represent the spin polarization densities while DSO and PSO represent orbital current densities [385].  
 The Ramsey terms computed with only minimal basis set 3-21G are in a close relationship with 
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the one computed with higher basis set DGDZVP(Ru)|6-21+G(d,p) but it underestimates the values of 
the FC, SD and consequentially the values of the total spin spin coupling constant (J(HZ)) (Table 3.80) 
while the magnitude of PSO and DMO remains virtually the same. However, the same trends of values 
obtained with 3-21G and DGDZVP(Ru)|6-21+G(d,p) (R-square = 0.9864, P-value = 2.20E-016, F-
statistic = 3192) is a clear indication that the minimal basis set can equally reproduce a good feature of 
the Ramsey terms of these complexes. All the Ramsey properties computed with basis sets either when 
only the Ru atom is treated with ECP (ECP(Ru)|6-21+G(d,p)) or when Ru and Cl atoms are treated 
with ECP (ECP(Ru,Cl)|6-21G*) significantly underestimate the Ramsey terms except the DSO which 
appears to be unaffected with core electron approximation with ECP (Table 3.81). The trend and the 
values of the total spin spin coupling constant (J(HZ)) of the ECP(Ru)|6-21+G(d,p) systems improved 
(R-square = 0.7781, P-value = 7.28E-016, F-statistic = 155.3) compared to the ECP(Ru,Cl)|6-2G* 
systems (R-square = -0.007818, P-value = 0.4215, F-statistic = 0.6587).  
 The Ramsey term which has the greatest magnitude is the FC term followed by the PSO while 
the DSO is the smallest. The least magnitude of DSO further support the report that DSO is the least 
interesting and also the least investigated mechanism [166].  
 The chloride atoms in complexes 1, 2 and 3 have the lowest magnitude of the FC and DSO but 
highest SD and PSO which consequentially lead to the highest magnitude of the J(HZ) compared to 
other coordinated atoms of the ligands. The relatively the same values of the spin spin coupling of the 
chloride atoms in complexes 1, 2 and 3 is an indication that there is no serious effect on the coupling 
strength of the chloride to the ruthenium metal atom due to changes in their chemical environment 
(Table 3.80).  
 In complexes 1, 2 and 3 where there is chloride atom, a very high correlation of the SD with the 
PSO (0.93, 0.89 and 0.98 respectively) are observed but no such high correlation is observed for 
complexes 4 (0.32) and 5 (0.08) without the chloride atoms. The effect of SD on the total spin-spin 
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coupling (J(HZ)) was also high on the three complexes with chloride (Table 3.82) while the effect of 
the FC on the spin spin coupling constant significantly improved in complexes 4 and 5 without the 
chloride atoms. Generally, the Ramsey terms which have the highest effects on the total spin spin 
coupling constants are FC and PSO while SD and DSO are average and depend on the type of the 
complexes (Table 3.82). Even though the magnitude of DSO is the least in all the complexes (Table 
3.80), yet it has a significant effect in complexes 4 and 5 (Table 3.82) which have no chloride ligand. 
3.4.4.3 NMR properties of the complexes 
 The computed NMR properties using the combined basis set DGDZVP(Ru)|6-31+G(d,p) (Table 
3.83) and a single minimal basis set 3-21G are in a close range (Table 3.85) but when the ECP(Ru)|6-
31+G(d,p) basis was used, the isotropic NMR shielding tensor of Ru atom was underestimated which 
equally affect the values obtained for other atoms (Table 3.86). The magnitude of the magnetizabilities, 
isotropic NMR shielding and many other atomic properties computed with the minimal basis set 3-21G 
and DGDZVP(Ru)|6-31+G(d,p) are relatively close. This observation further supports the view that the 
isotropic magnetizability is generally insensitive to electron correlation corrections and vibrational 
corrections [393].  
 The hydrogen atoms that are involved in HB are characterised by higher magnetizability bond 
contribution (Bond(A)), lower intra atomic magnetizability and lower shielding tensor than any other 
hydrogen atoms in the complex (Figure 3.21). The QTAIM properties obtained from the highest 
combination of basis set DGDZVP(6-31+G(d,p)) (Table 3.83) will be considered for further discussion. 
The magnitude of the total bonding magnetizability (Bond_Iso(A)) of Ru atom is higher than other atoms 
in the complexes but it is not the case for its total bonding isotropiC-NMR shielding (Iso(A',A)) 
contribution. The highest among each of the bonding magnetizability contribution (Bond(A|B)) of Ru to 
all the coordinated atoms is to arene carbon atoms (Ru-C bonding) except in complex 3 where the 
118 
highest contribution is towards the Ru-Cl bonding. The lowest values obtained for the Cl atom 
interatomic magnetizability (Bond_Iso(A)) (Table 3.83) is an indication that it could be ionic bond. It has 
been demonstrated that inter-atomic magnetizability (bond magnetizability) is able to verify the exact 
nature of aromaticity/antiaromaticity among different molecules and also distinguish the correct 
aromaticity order among the sets of aromatic/antiaromatic molecules [394]. 
 The selected correlation of the computed QTAIM NMR atomic properties with the isotropic 
magnetizabilities and NMR shielding are shown in Table 3.84. Besides those shown in Table 3.84, the 
values of Anisotropy is highly correlated with intra-atomic magnetizabilities (Intra_Iso(A)) with the 
correlation values of 0.69, 0.62, 0.68, 0.96, 0.89 for the respective complexes while it is inverse 
correlation with inter-atomic magnetizabilities (Bond_Iso(A)) with correlation values of -0.80, -0.79, -
0.83, -0.86 and -0.80 for the respective complexes. It is interesting to point out that, there is a very 
strong correlation of atomic charges with the intra-atomic magnetizabilities as was previously observed 
in the literature [394] but low with inter-atomic magnetizabilities (Table 3.84). Also, the correlation of 
the atomic charges with the intra-atomic isotropic shielding is very low.  
 The high correlation obtained from the computed atomic properties makes us to proposed a 
model for easy computation of NMR properties of molecules.  
The proposed model equation is:
Iso(A) = C0 + C1*ABS(X1) + C2*X2 + C3(X3
2
) + C4*X4 + C5*X5  
Where X1 = q(A), X2 = K(A), X3 = K_Scaled(A), X4 = LI(A) and X5 = DI(A,A')/2 
 The Ci values, the level of the correlation and the significance of the QTAIM properties (Xi) 
used to model the NMR isotropic shielding are shown in Table 3.87. From the values of the R
2
, there is 
a clear indication that a very high correlation of the NMR shielding with the computed electronic 
kinetic energy of atoms (K(A)), number of electrons localized in atoms (Loc(A)), approximation to 
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virial-based total energy of atoms (K_Scaled(A)) and number of electron delocalization from atoms 
(Deloc(A,A')). However, despite the high correlation, wide residual ranges are observed for complexes 
1, 2, 3 and 5 with carboxylic units. The carboxylic group is responsible for a wide margin as the 
oxygen and the hydroxyl units are very poorly fitted among all the atoms in each of the complexes. 
3.4.4.4 Polarizability and hyperpolarizabilities of the complexes 
 In addition to the hyperpolarizability, mean polarizability (<>), polarizability anisotropies (1, 
), we evaluated the polarizability exaltation index (), which is determined as  = (mol) - 
ii, where (mol) is the mean polarizability of a molecule and ii is the summation of the 
atomic polarizability of the atoms which constitute the molecule. According to literature [345], 
calculated  values have been employed to estimate relative aromaticity of furan homologues and 
stabilities of atomic clusters. A large negative  value denotes a very stable structure.  
 The calculated hardness ( values are included in Table 3.88 with all other conductive 
properties of the complexes. In agreement with the relative energies, the most stable isomer is predicted 
to be the hardest one [345]. However, the molecules having a small energy gap are known as soft and 
having a large energy gap are known as hard molecules [347]. 
 In both cases of ECP basis sets ECP(Ru,Cl)|6-31G* and ECP(Ru)|6-31+G(d,p), the computed 
conductive properties are overestimated beside the dipole (), polarizability exaltation index (Band 
gap and hardness ( that were underestimated. However, ECP(Ru)|6-31+G(d,p) give better results that 
follows the same trend with the basis set DGDZVP(Ru)|6-31+G(d,p). The trend of the results obtained 
from 3-21G are very similar to the best result obtained from DGDZVP(Ru)|6-31+G(d,p) basis sets but 
there is a little overestimation of the values of and underestimation of other properties. Complex 2 
have the highest value of the first hyperpolarizabilities (while complex 5 have the least. The trend of 
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the magnitude of computed conductivity properties of the complexes for Dipole, 
<, and Band gap (or  are 3 < 1 = 2 < 5 < 4; 5 < 3 < 2 < 4 < 1; 2 < 5 < 3 < 4 < 
1; 5 < 2 < 3 < 4 < 1; 4 << 5 < 1 < 3 < 2; 2 < 3 < 5 < 4 < 1; 2 << 3 < 1 < 4 < 5 and 1 < 4 < 5 < 2 < 3 
respectively. The computed values of  using different basis sets do not follow the same trend which 
is an indication that the values of are very sensitive to the type of the basis sets. Since the values of 
can be used to predict the stability of the complexes , therefore complexes 2 and 3 may 
probably be the most stable and coupled with their lowest band gap (very soft) will make them very 
reactive [395] which may eventually help in their anticancer activities. Also, complex 2 and 3 having 
the highest values of is an indication that they are the best NLO materials which may eventually help 
in their anticancer activities.  
 
 
 
 
 
 
 
 
 
 
121 
  
 
 
 
 
Figure 3.21: The optimized geometries of the complexes showing the isotropiC-NMR shielding of 
selected atoms computed with DGDZVP(Ru)|6-31+G(d,p) 
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3.5 Computational docking of the selected ruthenium complexes 
 In this section, three different sets of docking results from Ru(II)-based complexes are reported 
and all the results of this section have been published respectively as three different articles [318-320]. 
In subsection 3.5.1, our effort is directed towards proposing better selective anticancer agents by 
focusing more on cancer peculiar proteins other than DNA and also predicts complexes that display 
higher activity at lower dose because most of current potential anticancer complexes are only effective 
at high dose [19]. The search for the alternative targets for Ru-based complexes is a research challenge 
as the targets of many of these complexes can not be ascertained [5, 8, 9, 11, 396]. The lack of proper 
understanding of the targets of Ru-based complexes is hindering their rational design [396] and it is the 
major factor that is hindering the NCI approval of Ru-based complexes like Indazolium trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019), and imidazolium trans-[tetrachlorido(1H-
imidazole)(S-dimethyl sulfoxide)ruthenate(III)] (NAMI-A) [7]. In our attempt to predict the possible 
target and the mechanism of the anticancer activities of Ru(11)-based complexes (Figure 3.22), ten 
different receptors of various relevance in cancer chemotherapy targets are considered. The receptors 
used are Recombinant Human albumin (rHA), Thymidylate synthase (TS), Ribonucleotide reductases 
(RNR), Histone Deacetylase (HDAC7), Cathepsin B (CatB), Topoisomerase 11 (Top 11), Thioredoxin 
reductase (TrxR), BRAF Kinase and Histone Protein in Nucleosome core particle (NCP) and DNA-
gyrase was included to study the possibility of anticancer complexes also acting as antimalarial agents. 
Their respective pdb files 1BM0, 2G8D, 4R1R, 3C0Z, 1CSB, 1QZR, 1H6V, 3Q4C, 3MNN and 1AJ6 
were obtained from protein data base (pdb) [356].  
 In subsection 3.5.2, some of the different models of RAPTA complexes that have been reported 
in the literatures [13, 17, 51] are used with other proposed structures especially the unusual metal-based 
complexes (Figure 3.24). In order to predict the possible targets and reasons for some of the traceable 
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ineffectiveness of these metal-based complexes, ten protein targets are used as potential targets of the 
Ru(II)-based complexes. Also, DNA gyrase was included to study the possibility of anticancer 
complexes also acting as antimalarial agents.   
 In the section 3.5.3, another docking package called Molegro which sufficiently recognise the 
ruthenium atom as metal centre than Glide, Gold and Autodock was used. Unlike the organic 
counterparts, there is a very serious limitation in making use of docking tools for metal complexes 
mainly due to lack of proper force fields to take care of the metal centre [83]. Also, we have enhance 
the prediction of our docking results by introducing the atomic charges of each metallocompound 
obtained from their optimized structures in quantum calculation (Figure 3.26). In addition to the 
number of receptors considered in our previous works [318, 319], we have also included DNA as part 
of targets to see the possibility of some of these metallocompounds having favourable interaction 
properties like that of cis-platin.  
 
3.5.1 The inhibitory activities and possible anticancer targets of Ru(II)-based 
complexes using computational docking method 
 
 In this subsection, we focus our interest on predicting the best targets for some of the Ru(II)-
based complexes as anticancer agents which as being a great research challenge [5-9, 11-14, 396] and 
also try to compare the newly predicted hypothetical anticancer complexes with the known RAPTA 
complexes. The structure of the complexes that were docked into the binding sites of the proposed ten 
targets using Autodock and Glide docking are shown in Figure 3.22.  
 The analysis of the results obtained from Glide docking (Table 3.89) gives the picture of the 
predicted inhibitory strength of the Ru(II)-based complexes used. According to the results obtained 
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through Glide docking, many of the complex-receptor binding activities preferentially predicted our 
newly proposed structures especially 9 and 10 to bind more favourably compared to the RAPTA type of 
complexes. The strongest bindings among all the complex-receptor interactions are the inhibitory 
interaction of 9 and 10 with RNR. Also, these two complexes happens to be the best predicted 
inhibitors of RNR and also the best two inhibitors of TrXR in a reverse order. Combination of same 10 
with 7 is predicted as the best inhibitors of Kinases above every other complex considered. The 
complex 9 with 8 or 11 are predicted as the best for HP-NCP or DNA-Gyrase respectively. The same 9 
followed by 6 are predicted as the best inhibitors of Cat B. For HDAC7, 10 and 6 are also predicted as 
the best inhibitors. The complex 3 is taking to be the best inhibitor of Top11 followed by 9, 6 and 5. 
The complex 11 followed by 6 or by 3 are predicted the best for rHA or TS respectively. The best 
targeted receptors of the complexes with the highest activities are RNR (because of strong interaction 
of 9 and 10 only), Kinase (due to strong interaction of 10, 7, 2, 11, 8 and 1 in a decreasing order), 
Top11 (predicted as good target of most of the complexes except 1 and 2 where no activity is recorded) 
and Cat B (mainly 9, 11, 6, 3 and 5), followed by HP-NCP, TS (but is a poor target of 1 and 4), DNA-
Gyrase and TrXR are average targets while HDAC7 and rHA are predicted to be relatively poor targets. 
The general features of the Glide docking shows that 9 and 10 followed by 6 are predicted as the best 
inhibitors of most of the receptors considered using Glide. The feature of the interaction of the 
complexes with Cat B shows that besides our proposed 9, 11, and 6 the best of the RAPTA complexes 
are predicted to be 3, 5 and 4 but 1 predicted poor.  
 The suggested targets as most favourable of the complexes from the Autodock docking (Table 
3.90) are Cat B, HP-NCP, HDAC7 (except 9, 10, 11), Kinase and DNA-Gyrase. Those suggested as 
average targets are TS (still one of the best targets for 1 and 2), TrXR (the best target for 10) and rHA 
(the best target for 11) while RNR (part of the best target for 10 and 11) and Top11 (but still a good 
target for 10) are suggested as poor targets for most of the complexes. In line with the reported 
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experimental results, Cat B is still the best predicted target of the RAPTA complexes in the order of 1, 2 
and 4 which is an indication that prediction of Autodock agree better with the experimental finding than 
Glide as 4 is experimentally proposed as having the best anticancer activity and interaction with Cat B 
than many other RAPTA's complexes [9, 13]. This shows 1 and 2 as derivative of 4 can resist 
hydrolysis [5] interact more competitively with Cat B than the parent complexes. However, 8 among 
our complexes is predicted a better inhibitor of Cat B than RAPTA complexes. Also, a critical look at 
the best predicted activities of the complexes across the best targets shows that complex 8 is predicted 
best inhibitor for Cat B, HP-NCP, HDAC7 while 1 and 2 are predicted better inhibitors than 8 for 
DNA-Gyrase which is a suggestion that RAPTA complexes can equally act as antimalarial [72, 73]. 
Therefore, in most cases the order of activities of the complexes follows as 8, 1, 2 and 4 as the best 
inhibitors.  
 There is good agreement between the predicted behaviour of the receptors toward the 
complexes as predicted by the Autodock and Glide packages. Both predicted Cat B and Kinases as 
good targets of most of the complexes and TS as average target. While DNA-Gyrase, TrXR, HP-NCP 
are either predicted as an average or one of the best by each of the two methods. These are in good 
agreement with the experimental findings as Cat B [9], HP-NCP [15] and Kinase [74] have been 
suggested as possible targets of Ru(II)-based complexes. Also, the prediction of TrXR as less preferred 
target compared to Cat B by both Glide and Autodock docking agree well with experimental report 
especially for RAPTA's complexes [9]. The correlation of ranking order of the complexes from 
Autodock and Glide in Table 3.91 further gave a clear picture of the disparity in their ranking as most 
of the correlation determined for each receptor are highly negative which is an indication that the 
ranking of the complex activities by the two method are nearly reverse of each other. However, the 
comparison between the activities of the complexes predicted by the two methods of docking are not of 
interest, but the interest is to understand and to predict the optimal orientation and conformation of the 
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complexes embedded in a proteins which is the primary objective of all the research efforts in the area 
of protein-ligand interactions, development of many different techniques and the associated software 
tools [354].  
 In order to gain better insight into the binding site interaction and orientation of the complexes, 
a more critical look is presented in Table 3.92 for the best two inhibitors of each receptor in terms of 
hydrogen bond (HB) and Metal-Receptor (MR) possible interactions with residues within the range of 
4.5Å. The result from Glide docking shows that, the orientation of the best two inhibitors of Cat B are 
alike with the carboxylic unit forming hydrogen bond with carboxylic unit of the GLU 122E. A 
likewise orientation also occur in the binding of the best two predicted inhibitors of DNA-Gyrase as the 
two inhibitors have common hydrogen bond interaction with ASP 73. The complex predicted as first of 
this two has no residue within the 4.5 Å of the metal radius that would possibly suggest any MR 
relationship. In HP-NCP the two complexes are characterised with single HB and MR with one oxygen 
unit of the COO group of 8 interacting with the NH unit of the imidazole group of HIS 106 H. In 
interaction of complexes with Kinase, complex 7 that is ranked second is found to penetrate further into 
receptor and characterised with many possible MR interactions (some are presented in the Table 3.92) 
than 10 that was ranked first. The binding sites located on rHA by the two best ranked (11 and 6) are 
very widely separated from each other. The relative importance of MR interactions and other possible 
interactions with HB interaction is shown in the interaction of 6 with rHA where there is only single 
HB with higher MR compared with 11 (Table 3.92) where there is higher HB and yet their interacting 
energy is very close as shown in Table 3.89.  
 Also, the observations from Autodock further give insight into the binding site interaction of the 
complexes. A critical look at the interacting feature of the complexes with HDAC7 in relation to Cat B 
(Table 3.92) indicates that though the inhibitory activities of their best two inhibitors are very close 
(Table 3.90) yet the HDAC7 inhibitors are characterised with very few HB and MR which is an 
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indication that there are other factors that are playing significant role on the inhibitory activities of 
complexes. In HP-NCP there is the possibility of a very strong MR interaction as the side group of ASP 
65A (i.e. CH2COO) is having a closed and free space interaction with the Ru(II) metal. The sites of 
binding of the best two inhibitors of Top II are widely separated from each other suggesting two 
possible binding sites. The high inhibitory activities of the best two inhibitors of DNA-Grase and 
HDAC7 despite very few numbers of HB and MR interaction coupled with the best for TS where there 
is no recorded HB and MR shows the significant effects of other types of possible interactions. 
  There is further similarity between Autodock and Glide in the best two inhibitors that are 
predicted for some of the receptors as 8 is commonly predicted for receptor HP-NCP, 11 for rHA, 10 
for RNR and 10 for TrXR (Table 3.92 and Figure 3.23). A more critical look at these four receptors 
with the same complexes predicted among the best two, the binding site located by Autodock for the 
complexes are different form Glide predicted binding site in HP-NCP, rHA and TrXR but the same in 
RNR as shown in Figure 3.23a, b, d, & c respectively. The orientation of 10 on the binding site of RNR 
as predicted by Autodock and Glide is very similar with the carboxylic units contributing to the 
stability by forming HB as shown in Figure 3.23(c). As shown in Figure 3.23, all the four interactions 
of complexes with receptors are characterised with multiple HB (represented by orange and cyan 
cylinder shape). The different binding sites suggested by Autodock and Glide for the interaction of 
some complexes with some receptor give the possibility of having more than one binding site as it is 
even observed within the same package when Glide suggested different site for the best two inhibitors 
of rHA and Autodock suggest widely separated binding sites for the best two inhibitors of Top II. This 
is not far from the experimental report of multiple binding sites for Ru-(II)-based complexes with HP-
NCP [15] and Kinase [74]. However, the possible reason for the observed disparities in the ranking of 
the Glide to that of Autodock methods was suggested in another part of our work to possibility result 
from the bias of the Glide docking of the metal complexes toward the steric hindrance. 
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= 1,3,5-triaza-7-phosphaadamantane; Cp = cyclopentadienyl, bk = -diketone, piano = model of piano-stool] 
 
 
Figure 3.22: The structures of the Ru(II)-based complexes as anticancer agents 
 
 
129 
 
 
a). The interaction of etdiaglydmso with HP-NCP 
(in surface mesh) using Autodock and Glide. 
 
b). The interaction of raphendioic with rHA (in 
surface mesh) using Autodock and Glide. 
 
c). The interaction of radipyrdioic with RNR (in 
surface mesh) using Autodock (Cyan) and Glide. 
 
 
 
 
 
d). The interaction of radipyrdioic with TrXR (in 
surface mesh) using Autodock and Glide. 
 
Figure 3.23: The binding site interactions of one of the best two inhibitors of HP-NCP, rHA, RNR and 
TrXR as predicted by the Autodock (right with C atoms in Cyan) and Glide (left with C atoms in 
Magenta) showing hydrogen bond (orange cylinder form). 
 
 
 
 
130 
3.5.2 Comparative study of the suitability of Autodock, Gold and Glide for the docking 
and predicting the possible targets of Ru(II)-based complexes as anticancer 
agents 
  
 In this subsection, the binding modes, the best possible targets and binding site interactions of 
Ru-based complexes with ten receptors were predicted using Glide, Autodock and Gold docking. Even 
though a little comparison of the ranking obtained from the three methods are considered but the 
interest is to understand and to predict the optimal orientation and conformation of the complexes 
embedded in proteins which is the primary objective of all the research efforts in the area of protein-
ligand interactions, development of many different techniques and the associated software tools [354]. 
The results of the docking presented in this work is the best binding results out of the 20 favourably 
predicted by Autodock, 10 predicted by Gold and 26 predicted by Glide. The structures of all the metal-
based complexes that were used in the docking study are presented in Figure 3.24.  
 The general features from the prediction of glide docking (table 3.93) show that the best 
predicted targets for most of the complexes are Top II followed by Kinase, RNR and Cat B accordingly. 
Some of the complexes like 6, 5, 13, 9, 16 and 21 respectively bind to Kinase preferentially than many 
other possible targets that are considered in this research. Also, 17, 8 and 5 prefer to target TS than 
many other targets. Some of the least targeted receptors are rHA (except complex 21), HDAC7, DNA-
Gyrase, TrxR (except complex 21).  
 The results obtained from the docking of these metal-based complexes with the ten choice 
receptors using Gold package are presented in the Table 3.94. The Gold docking results are reported in 
terms of the values of fitness which means the higher the fitness the better the docked interaction of the 
complexes unlike the other two docking packages (Glide and Autodock) which are reported in terms of 
131 
the docking energy score which means the lower the score the better the interaction. The most targeted 
receptors from Gold results are Top II, Cat B and Kinase respectively. This is in good agreement with 
the prediction from the Glide package which equally suggested Top II and Cat B as part of the most 
probable targets for the complexes. The receptors that are moderately targeted are TS, TrxR, rHA and 
DNA-Gyrase. The receptors that are predicted to be least targeted by the complexes are HP-NCP, RNR 
(except 1 and 5) and occasionally HDAC7 especially by 1, 5, 11, 12 and 17. The prediction of Cat B as 
a better target than TrxR is in good agreement with experimental finding [9].  
 The receptors that are recorded to be the most targets by many of the metal-based complexes 
from Autodock prediction (Table 3.95) are Cat B followed by HDAC7, DNA-Gyrase, HP-NCP and 
Kinase except 6 and 7 that bind poorly with most of the receptors while TS and rHA are predicted as 
average targets. The receptors that are predicted to be least targeted by the complexes are Top II (with 
the exception of 5, 17), RNR and TrxR (with the exception of 21, 5, 20, 4 accordingly). In all cases, 
Glide, Gold and Autodock commonly predicted Cat B as one of the most possible target of the 
complexes and TrXR as far less target compared to Cat B which is in good agreement with reported 
experimental results [9]. Also, Glide/Gold included Top II and Gold/Autodock included Kinase as one 
of the best targets. There is very close relationship in the predictions through the three packages except 
for the receptors Top II and RNR which are predicted as rarely targeted by Autodock but predicted to 
be one of the most targeted by Glide/Gold and Glide respectively. There is further agreement between 
Autodock and Gold as TS, rHA and DNA-Gyrase are either predicted as one of the best or average 
targets for most of the metal-based complexes. The complexes that are predicted to have the best 
activities against most of the chosen targets are 1, 5, 3, 2, 4, 17, 8, 12, 20, 10 and 14 accordingly. The 
metal-based complexes that are predicted to have poor activity against most of the receptors are 6, 7, 18 
and 21. Just like the activities of the hydrated complexes are predicted to be highly enhanced using 
Glide and Gold, so also are 8, 12, 20 and 19 predicted to be more active than the respective parent 
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complexes.  
 A critical look at the general behaviour of the complexes towards the targets according to the 
Glide prediction shows that 6 is predicted as the best inhibitor of Kinase than any other complexes 
considered, while 8, 13, 17 and 20 respectively predicted as the best inhibitors of Top II than any other 
complexes. The feature of the Gold prediction shows that 4, 3, 16, 11 and 12 are respectively predicted 
to have the best activities toward the Top II.  
 There is a very good agreement between our docked results and the reported experimental 
behaviour of some of the RAPTA as inhibitors of Cat B and TrxR [9]. Selecting the RAPTA complexes 
that are common with our models, the reported experimental results shows that the inhibitory strength 
against TrxR starting from the greatest to lowest are in this order: 1, 5, 11 and 14 respectively with little 
or no effect of 7 on TrxR. While that of the Cat B are in this order: 14, 11 and 1 respectively with little 
or no effect of 5 and 7 on Cat B [9]. Also, the inhibition of Cat B is predicted to be high with RAPTA 
complexes than TrxR which is in agreement with the results from all the three packages used. 
According to Autodock prediction the inhibition of Cat B follows this order: 3, 4, 1, 5, 12, 20 and 8. 
Also 14 and 11 recorded significant effect far better than 7 which is in line with the experimental 
findings. Compounds 5, 20, 17, 4, 1, 8 and 12 are predicted as TrxR inhibitors in that order. Gold 
predicted 1, 4, 15, 16, 7 and 10 for Cat B while the general behaviour of inhibitors toward TrxR are 
very low compared to Cat B just as it was in the reported experimental result. From Glide, the 
inhibition of Cat B by the inhibitors considered is low compared to some other receptors like Top II. 
However, 20, 19, 18, 8, 7 are predicted to take the lead accordingly. While TrxR inhibition is reported 
to be very poor by most of the complexes except 21.  
 In summary, combining the three methods together, just as in the experimental result, 1, 5, 12 
and 20 are included as part of the best TrxR inhibitor and 1 is specifically rated among the best 
inhibitors of TrxR by the three docking methods which is in good agreement with the experimental 
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report. Also, almost all the experimentally found inhibitors of Cat B such as 1, 12 and 20 are included 
except 5 which is predicted as one of the better inhibitors contrary to the experimental finding.  
 Further analysis of the interactions of some Ru(II)-based complexes with the receptors is 
presented in Table 3.96 where the binding site interactions of the two best ranked complexes for each 
receptor are shown in terms of the noticeable hydrogen bond (HB) and metal-receptor residues (MR) 
interactions. The two best ranked complexes are 5 and 12 for TrxR respectively are almost 
superimposed and the site of their binding is buried inside the receptor. The stronger interaction of 1 
with TS (without any noticeable HB and MR) than complex 5 that is ranked second which has two HB 
suggests that the metal may not necessarily has direct interaction with the receptor residues but just act 
as holder of ligands for better and stronger ligand-receptor interactions which may include van der 
Waals, electrostatic, steric and others. A critical look at the interaction from Gold prediction (Table 
3.96) give further insight into the mode of the complex-receptor interaction and the reason while some 
are rank better inhibitor than the others. The binding site located by the three docking suites are the 
same for many of the receptor with that of Gold and Autodock docking specifically in Cat B almost 
having superposition of the 1 (Figure 3.25). The structures with NH2 like 10 and 4 which are ranked 
either first or second as inhibitors of rHA, TrxR and HDAC7 respectively show that there is very strong 
metal to receptor residues interactions as the NH2 group was seriously pushed off for better direct 
interaction of Ru atom with the CH3 part of S(CH3) group of MET 87A, arene part of phenol group of 
TYR 200 and arene of PHE 679A respectively. But in the case where there is an existence of HB 
between the NH2 and receptor as in Top II where one of the H atom of NH2 and O atom of CO group of 
ASN 129 are interacting through hydrogen bond, the NH2 is well fixed in a right position with metal. 
This suggest that NH2 can be a good leaving group where it does not make any HB contribution to the 
binding of the metal complexes. Another interesting feature indicates the significance of other form of 
interactions order than HB and MR that are analysed (Table 3.96) as in the case of RNR where 1 which 
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was ranked first has no HB while the second ranked complex 5 as five noticeable HB interactions. In 
Glide, the first two ranked complexes as inhibitors of rHA namely 21 and 17 locate two different 
binding sites. The presence of more than one binding sites observed in our docking studies is not far 
from the experimental report of multiple binding sites for Ru(II) complexes with HP-NCP [15] and 
Kinase [74]. 
 The similarity in the three methods of predicting the interaction is also demonstrated from the 
binding site interaction of complexes 1, 3, 4, 20 with Cat B, Top II, Gyrase and Kinase respectively as 
shown in Figure 3.25. Taking a critical look at complex 1 in Figure 3.25(a), the cyclobutyl di-
carboxylate of the three predictions are towards the boundary of the hydrophilic and hydrophobic part 
of Cat B but the arene and PTA direction of the Glide is different from that of Autodock and Gold. 
Further agreement is seen in the prediction of Autodock (Cyan) and Gold (Magenta) as the PTA groups 
are directed toward an inner hydrophilic large pocket of Cat B and the arene groups of the complex are 
toward the hydrophilic end. The three packages predicted almost the same binding site interaction for 
complex 3 with Top II residues as shown in Figure 3.25(b) while there is a difference in the prediction 
of the interaction of complexes 4 and 20 with Gyrase and Kinase respectively (Figure 25c & d).  
 Very good agreement has been observed in the structural interaction of the complexes with the 
receptors using the three methods but the ranking of the three methods are not the same. On the 
average, there is a better agreement between the ranking of the docked metal-based complexes using 
Autodock and Gold (Table 3.97) with correlation of one of the receptors (i.e. RNR) up to 0.76. The 
correlation of the Glide with both Autodock and Gold is poor mainly because Glide did not recognise 
the Ru atom properly and most of the complexes geometrical orientations on the binding sites of the 
receptors vary significantly from that of Autodock and Gold as in Figure 3.25(a).  
 In order to further understand the properties that are prevalent in the determination of the 
docking score of Glide and the possible causes for wide difference in ranking from the other two 
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methods, the COMSIA properties was also carried out using the Field-based QSAR in Maestro (Table 
3.98). The major defining factor of the docking score of Glide is predicted to be gaussian steric 
property which defines the steric hindrance of the molecule. Another property that define the docking 
score of the Glide for the metal-based complexes is the hydrogen bond followed by electrostatic 
property. The predicted activities agree well with the docked activities based on the statistical 
properties of significantly high value of R
2
-value ranges from 0.49 to 0.72, high stability ranges from 
0.31 to 0.94 and very low P-value ranges from 1.83E-011 to 1.07E-004 (Table 3.98). 
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Figure 3.24: The structures of the metal-based complexes
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a). Complex 1 in Cat B 
 
b). Complex 3 in Top II 
 
c). Complex 4 in Gyrase 
 
d). Complex 20 in Kinase 
 
Figure 3.25: The binding site interaction of complexes 1, 3, 4 and 20 with Cat B, Top II, Gyrase and 
Kinase respectively using Autodcock (Cyan), Gold (Magenta) and Glide (yellow) Docking Predictions. 
The colouring of Cat B Surface is from the hydrophilic (red) to hydrophobic (blue) and the HB is 
represented with green cylinder in the figures.  
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3.5.3 Insight into the anticancer activities of Ru(II) based metallocompounds using 
docking methods 
3.5.3.1 General features of the binding activities of the metallocompounds 
 In this subsection, the binding affinities and conformations of 30 metallocompounds including 
their hydrolytic forms are presented. The 30 metallocompounds (Figure 3.26) are docked against 
twelve receptors using relax Molegro, constraint Molegro and Autodock docking approaches. The 
summary of 72 poses of the best two metallocompounds in their interaction with the receptors are 
shown in Table 3.99 indicating the hydrogen bonding (HB) interactions with the binding sites receptor 
residues and the possible metal-receptor (MR) interactions. The results obtained from the docking of 
metallocompounds to twelve receptors using Autodock, relax Molegro without metal-residue covalent 
constraint and constraint Molegro with covalent constraint are shown in Table 3.100(a&b), 3.101(a&b) 
and 3.102(a&b) respectively. The docking results obtained from both relax and constraint Molegro 
docking (Table 3.101(a&b) and 3.102(a&b)) gives a better ranking than the Autodock which cannot not 
be easily ranked since many of the Autodock values (Table 3.100(a&b)) are within its standard error 
margin of ~2.177 kcal/mol [354, 353]. Table 3.100(a), 3.101(a) and 3.102(a) contain binding affinities 
of non-hydrolytic complexes while Tables 3.100(b), 3.101(b) and 3.102(b) contain the affinities of their 
respective hydrolytic complexes. The hydrolytic complexes are named after their respective non-
hydrolytic type with suffix ―a‖. Generally, we observed that some of the new metallocompounds like 
complexes 1, 1a, 8, 8a, 9, 9a, 10, 10a, 11 and 12 (Table 3.101(a&b)) are found to have better binding 
affinities than the co-crystallized compounds of Cat B, HDAC7, TS and BRAF Kinase receptors. 
Though co-crystallized compounds bind better in TrXR, Top II, RNR and Gyrase than all the 
metallocompounds (Table 3.101(a&b) and 3.102(a&b)), yet many of our modelled metallocompounds 
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(occasionally the bidentate RAPTA complexes 2 and 3) are found to be highly competitive to the co-
crystallized compounds in their binding affinities (Table 3.101(a&b) and 3.102(a&b)). The newly 
modelled metallocompounds especially 1 & 1a, 9 & 9a, 10 & 10a, 11 and 12 followed by the bidentate 
RAPTA (2 and 3) and hydrated RAPTA (13a, 14a, 15a and 16a) complexes are predicted to have 
stronger binding affinity to many of the receptors (Table 3.101(a&b) and 3.102(a&b)).  
 The proposed mechanism of activation of the metallocompounds through hydrolysis [8, 17, 37, 
397] is further confirmed through the docking results. In most of the receptor interactions, autodock 
indicates an enhanced binding energy with receptors for all the hydrolytic complexes (Table 
3.100(a&b)). The same is observed for the covalent constraint docking of metallocompounds to DNA-
1,DNA-2, Cat B, RNR and TrXR and also for relax Molegro docking to DNA-1 and DNA-2 (Table 
3.100(a&b) and 3.101(a&b)). In other receptors, only few hydrolytic metallocompounds increase 
binding energy as a result of the hydrolysis which depends on the type of receptor targets. The binding 
activities of the hydrated forms of RAPTA complexes are found to be greatly enhanced. Also, the 
bidentate form of RAPTA complexes are suggested to competitively bind strongly to receptors as the 
hydrated forms of RAPTA complexes especially metallocompound 14a though their activities are still 
lower than the modelled metallocompounds using the results of the three docking methods (Table 
3.100(a&b), 3.101(a&b) and 3.102(a&b)). In many of the receptor interactions, metallocompounds 16 
and 16a are predicted to have better binding affinity than 15 and 15a (Table 3.101(a&b)) except for 
receptors RNR which further support the experimental report for higher anticancer activities of the first 
pair [17].  
 In many instances, the binding of the relax Molegro docking are stronger than the constrained 
Molegro docking, also the relax Molegro agree better with the available experimental reports (Table 
3.103(a&b)) and the experimentally proposed activation of metallocompounds by hydrolysis (Table 
3.101(a&b) and 3.102(a&b)).  
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 All docking methods clearly indicate that the best target of the hydrolytic cis-platin (Cisp-W1 
and Cisp-W2) is DNA as they are found having higher binding energy with DNA compared to other 
receptors. The hydrolytic cis-platin especially the doubly hydrolized (Cisp-W2) has the highest DNA 
binding compared to the other forms of cis-platin which further confirm the need for hydrolysis before 
activation [37, 51]. However, in protein receptors, there is decrease in binding affinity of hydrolytic cis-
platin compared to its non-hydrolytic type which further confirms that protein is not its target. 
Considering the ranking of both relax and constrained Molegro docking, the best targets of the metallo 
complexes follow the order HDAC7 > DNA-1 > rHA > Cat B > DNA-2 > Gyrase > TrXR > Top II > 
TS > RNR > HiS > Kinase except in few cases like complex 12 that prefers Cat B to rHA. The poorest 
binding affinity of the complexes is observed in the covalent constrained docking to rHA receptor.  
3.5.3.2 The interacting poses of the best two metallocompounds in the receptor 
binding sites. 
 To have a better understanding of the binding site orientation poses and interaction of the 
metallocompounds with the residues of each receptor, we have selected two metallocompounds 
predicted by relax Molegro, covalent constraint Molegro and Autodock methods to have the best 
binding to each of the receptors (Table 3.99). The binding site interactions are elaborated in terms of 
the hydrogen bonds (HB) and the metal-residues (MR). The MR considers possible covalent bonding 
interaction of the metal with a nucleophilic centre of receptor residue which was considered during the 
constrained docking. There is the possibility of metal-residue (MR) interaction of complex 4a with 
DNA-1 according to Autodock prediction [Table 3.99]. The relax Molegro and Autodock dockings 
suggest different binding sites from that of constrain docking in the binding of metallocompound to 
DNA-1 (Figure 3.27(a)). Interestingly, the suggested conformation of complex 12 binding to DNA-2 
from both relax and covalent constrain dockings is perfectly superimposed (Figure 3.27(b)). There is 
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also an interesting feature of possible intercalation of complex 12 with the two based pair nitrogen 
atoms (N7) of the Guanine in DNA-2 by both relax and constrained docking as shown in Figure 
3.27(b). The tridentate ligand part of metallocompound 12 in the relax Molegro docking (cyan) and 
Autodock (magenta) perfectly fits into the hydrophobic pocket of the Cat B as shown in Figure 3.27(c) 
which was not the case in the constrained docking (green). This further suggest the possible reason why 
the binding affinities of the relax docking are higher than that of the constrained docking.  
 Both relax and constrained Molegro docking show a superimposed comformation for complex 
10a of which the arene unit pointing toward the mouth of the inner pocket of the HDAC7 while the 
Autodock preferentially locate the outer pocket (Figure 3.27(d)). Complex 1a is rated to have the best 
binding affinity to HP-NCP in relax Molegro docking but it has no visible H-bond nor metal-receptor 
interaction. The conformation of complex 1a as suggested by the relax Molegro docking fits in totally 
into one side of the binding site pockets than the conformation suggested by the constrained Molegro 
and Autodock docking to HP-NCP. In Figure 3.27(e), the experimental conformation from the crystal 
structure of RAPTA complex 14a in the HP-NCP binding site is compared to the conformation 
obtained from the docking results.  
 In Autodock docking of complex 10 to rHA we observed possible covalent interaction of 
ruthenium with the NH3 unit of residue LYS 195A characterised by a distance of 1.78 (Table 3.99). The 
three docking methods suggest either the hydrolytic complex 10a or non-hydrolytic complex 10 as the 
best binding metallocompound to rHA. The conformation suggested for the docking of RAPTA 
complex 3 to RNR is shown in Figure 3.27(f), both Autodock and Molegro suggest a very close 
position for the ruthenium atom but different position for its coordinated ligands. In the constrained 
docking of complexes 9a and 8a to TrXR, there is the possibility of ruthenium atom forming covalent 
bond with the bridged sulfur (SG) residue CYS 64A or strong close contact van der Waal interactions 
with the two bridged sulfur (SG) atoms of the residues CYS 64A and CYS 59A.  
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3.5.3.3 The binding affinity of the metallocompounds to DNA  
 An insight into the interaction of the metallocompounds with two types of DNA (DNA-1 and 
DNA-2) is given for the Autodock (Table 3.100(a&b)), relaxes Molegro (Table 3.101(a&b)) and 
constrained Molegro (Table 3.102(a&b)). There is improvement in the binding of many of the 
complexes to DNA-1 and DNA-2 due to their hydrolysis. Typical examples are complexes 1a, 8a, 9a, 
10a and all the hydrolytic RAPTA complexes. In agreement with literatures [5, 6], the best target of 
Cis-platin is DNA as their binding affinity decrease significantly in protein receptors compared to 
DNA-1 and DNA-2. The features of cis-platin in all the dockings show that their activities significantly 
increase when it is doubly hydrolized (Cisp-W2) than when it is singly hydrolyse (Cisp-W1). The 
newly proposed model complexes appear to have strong DNA interaction which suggests DNA as part 
of their possible targets. Most of the RAPTA complexes will target Cat B or HDAC7 preferentially to 
DNA. The spectrum of the interactions of RAPTA complexes with DNA ranges from -116.96 to -49.53, 
while Cat B ranges from -124.88 to -60.05 and HDAC7 ranges from -127.16 to -55.13, considering 
both the relax and constrained docking further confirm that RAPTA complexes will target proteins 
preferentially to DNA [9, 15].  
3.5.3.4 The binding affinities of the metallocompounds to Cat B and TrxR 
 The results obtained from relax Molegro and Autodock docking (Table 3.100(a&b) and 
3.101(a&b)) shows that 12, 1 & 1a, 10 & 10a, 9 & 9a and 11 bind strongly to Cat B than its co-
crystallized compound. The experimental activities of the RAPTA complexes against Cat B follow the 
order 15, 14, 2 while 3 and 13 rarely show any appreciable binding affinity and that of TrXR followed 
the order 2, 3, 14 and 15 while 13 has the lowest activity (Table 3.103) [9]. Selecting only the 
metallocompounds that have experimental values, the predicted binding affinities of the 
metallocompounds against TrXR using Molegro agree better with the experimental order of their 
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inhibitory activities as metallocompound 13 is rated least in activities toward TrXR follow by 
metallocompound 15. Contrary to the experimental report, metallocompound 3 was predicted to bind 
strongly to Cat B. However, ranking of metallocompounds 14a and 15a among those that have the best 
binding to Cat B and metallocompound 13 rated least agrees well with the experimental results (Table 
3.103). The rating of both hydrated and non-hydrated forms of metallocompound 14a among those that 
bind strongly to Cat B, further give insight into the experimental findings as the best anticancer among 
the RAPTA complexes [13]. The three docking methods show that the interaction of the 
metallocompounds with Cat B is stronger than with TrXR which agree well with the experimental 
report [9]. The binding affinities of the hydrated metallocompounds with Cat B and TrXR are 
significantly enhanced (Table 3.100(a&b), 3.101(a&b) and 3.102(a&b)). 
3.5.3.5 The binding affinity of the metallocompounds with Gyrase, HDAC7, HP-NCP, 
BRAF Kinase, rHA, RNR, Top II and TS  
 The features of the binding affinities of the metallocompounds against Gyrase from both 
docking methods show that co-crystallized compounds still preferentially bind to Gyrase than any of 
the metallocompounds even though the activities of the new modelled metallocompounds are 
competitively close to that of its co-crystallized analogues. The metallocompounds that have the best 
binding to Gyrase using Molegro are 1 & 1a, 9 & 9a, 10 & 10a, 11 and 12 (Table 3.101(a&b) and 
3.102(a&b)). Autodock included the hydrated metallocompounds 14a, 13a and 15a immediately after 
metallocompounds 12, 9a, 10, 4a, 8a, 1a, 10a and 5a (Table 3.100(a&b)). The binding affinities of the 
metallocompounds to HDAC7 show that the model 1, 12, 11, 10, 9 and their respective hydrolytic 
forms (where applicable) have the best binding than its co-crystallized compound. This is also 
applicable to the RAPTA complexes. 
 There are experimental reports on HP-NCP also being a possible target of RAPTA complexes 
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[15], but the new model metallocompounds 1, 9, 10, 11, 12 and their hydrolytic forms (where 
applicable) are predicted to bind better than RAPTA complexes in all the three docking methods. The 
crystal structure of HP-NCP shows RAPTA-C (metallocompound 14a) binding to two different sites on 
chain G and H of the receptor (Figure 3.27(e)). In order to make parallel comparison of the poses of 
metallocompound 14a with the available experimental crystal structure, its docking features is shown in 
Figure 3.27(f). The constrained Molegro and Autodock docking of complex 14a gives preference to the 
first binding site which suggest that complex 14a will bind preferentially to the first site than the 
second. Also, the constrained Molegro docking shows that the PTA unit of this metallocompound locate 
the same receptor pocket as the crystal structures (Figure 3.27(e)). The new models of 
metallocompounds 1, 9, 10, 11, 12 and 8 (include their hydrated forms) are predicted among those that 
have the best binding to BRAF Kinase (Table 3.101(a&b)). The rHA is predicted as an average target 
suggesting that many of the Ru(II)-based complexes that are considered will be on the average 
kinetically favourable which further support the experimental findings [13, 17, 51].  
 In the interaction of the metallocompounds with RNR, the co-crystallized compound is found to 
bind preferentially to all the metallocompounds. The predicted best binding metallocompounds to RNR 
are 1, 10, 8, 11, 12 and 9 including the bidentate RAPTA complexes 3, 2 and hydrated 14a. The 
suggested best binding metallocompounds to Top II after the co-crystallized compound are 1, 10, 9, 12, 
11 and the RAPTA complexes 2, 3, 14a and 16a. Commonly predicted best binding metallocompounds 
to TS by the three methods of docking are 12, 10, 11, 9 and the bidentate RAPTA complexes 2 and 3 
while only Molegro rated 1 as part of the best for TS. 
3.5.3.6 Metal-Receptor residues covalent interaction using constraint Molegro docking 
  In this study, based on the available information on the binding site residues of each receptor, a 
nucleophilic atom was selected as centre of covalent interaction with the metal centre of the 
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metallocompounds. Cysteine sulfur atom (SG) was selected for the Cat B (Cys A 29) [398], BRAF 
Kinase (CYS A 531) [74], RNR (CYS B 439) [399], TrXR (CYS A 59) [400] and TS (CYS A 198) 
[401]; histidine nitrogen atom was used for the HDAC7 (HIS A 709) [402], HP-NCP (HIS H 106) 
[403] and Top II (HIS B 20) [404]; while for the Gyrase [73] and rHA [405] where none of the HIS, 
CYS and MET are within the binding site residues, nucleophilic nitrogen atom of ASN A 46 and ARG 
A 144 were used respectively. For the DNA (4DL7) [406], the nitrogen atom (N7) of the Guanine (DG 
T 7) was used.   
 The general features is that the binding affinity is lower when the covalent constraint is applied 
(Table 3.102(a&b)) compared to when it is not (Table 3.101(a&b)). This therefore shows that the 
ruthenium metal in many of the metallocompounds will prefer positioning the ligands for optimum 
receptor interactions than forming covalent bonds with the residues of protein receptors. However, the 
binding affinities of some metallocomponds against targets like DNA-1, DNA-2, HDAC7, HIS and 
RNR during the covalent constrained docking is competitively high as that of the relax docking 
indicating the possibility of the ruthenium atom forming covalent interaction with the receptor residues. 
 In summary, the new models especially complexes 1, 9, 10 and 12 (and their respective 
hydrolytic form where applicable) are predicted by all the methods of docking among the best two 
inhibitors of all the receptors. Also, complex 11 is rated among the best three by the relax docking for 
Gyrase and the constrained docking for Cat B and HDAC7. However, none of the RAPTA complexes 
appearing among the best two proposed inhibitors of the receptors considered in this work using the 
three docking methods (Table 3.99) except in rHA and RNR where the first and the second ranked 
complexes are the non-hydrolytic and hydrolytic forms of the same compound (Table 3.101(a&b) and 
3.102(a&b)). This suggests the possibility of the new models acting as better anticancer agents than the 
RAPTA complexes. 
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3.5.3.7 The correlation of factors that determined the binding activities of the 
metallocompounds 
 The docking method of Molegro gives a more comprehensive insight into the factors that 
determine the binding affinities of the metallocompounds. Their correlations Tables 3.104(a&b) are 
constructed using the statistical package R [407]. The most significant factors that influence the 
metallocompounds interaction with the DNA and many of the protein receptors are intra-molecular van 
der Waal (E.Intra.vdw.), pose energy, steric and long range electrostatic interaction (ElectroLong in 
Table 3.104(a&b). In all the protein receptors, the inter protein-ligand and the pose energies 
significantly determine the total binding energy of the metallocompounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147 
 
1. PPpyrazoic 
1
a. PPpyrazoic 
 
2. Carbo-RAPTA-C 
 
3. Oxalo-RAPTA-C 
 
4. piano 
 
4a. piano 
 
5. RAgly 
 
5a. RAgly 
 
6. etdiaglydmso 
 
6a. etdiaglydmso 
 
7. rCpBkdmso 
 
8. RAdipyrazoic 
 
8a. RAdipyrazoic 
 
9. RAdiPyrdioic 
 
9a. RAdiPyrdioic 
 
10. RAphendioic 
 
10a. RAphendioic 
 
11. Rapyrdipyrazole 
 
12. RAterpyrnic 
 
13. RAPTAB 
 
13a. RAPTAB-H2O 
 
14. RAPTA-C 
 
14a. RAPTA-C-H2O 
 
15. RAPTAT 
 
 15a. RAPTAT-H2O 
 
16. RAPTAT-CF3 
 
16a. RAPTAT-CF3-H2O 
 
Cis-platin 
 
Cisp-W1 
 
Cisp-W2 
  
The PP = 4-Phenylpyridine, RA = Ruthenium-(6-arene); etdia = ethylenediamine, phen = phenanthroline; pyr = pyridine; 
pyraz = pyrazole, PTA = 1,3,5-triaza-7-phosphaadamantane; Cp = cyclopentadienyl, Bk = -diketone, piano = model of 
piano-stool 
 
Figure 3.26: The schematic structures of the anticancer metal-based complexes  
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Figure 3.27: The receptor binding site interaction of the selected best binding metallocompounds from 
Autodock (magenta), Molegro unconstrained (cyan), constrained (green) and the experimental crystal 
structure in yellow.  
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CHAPTER FOUR 
4 SYNTHESIS OF LIGANDS AND THEIR COMPUTATIONAL PROPERTIES 
 
4.1 Background of the chapter 
 This chapter describes the synthesis and theoretical properties of the ligands that were used for 
the synthesis of Ru(II)-based complexes in Chapter Five. The atomic, molecular, spectroscopic and 
non-linear properties of the ligands and their derivatives were elucidated through molecular simulation 
using DFT methods of computation. For ease of comparison, the ligands are grouped into four sections 
4.3, 4.4, 4.5 and 4.6. These sections describe the synthesis and computational studies of 
methylpyrazole, pyrazole, pyridine and phenathroline derivatives. 
 Sections 4.3 and 4.4 are respectively the studies on methylpyrazole (Figure 4.1) and pyrazole 
(Figure 4.6) derivatives which are usually referred to as scorpionates and have become one of the most 
versatile types of tridentate/bidentate ligands that can coordinate to a wide variety of elements ranging 
from early to late transition metals [408, 409]. These type of compounds have a wide application 
especially in the field of transition metal carbonyl chemistry [408]. Since the introduction of the 
scopionates compounds by Trofimenko more than 30 years ago [410, 411], several subset of these types 
have been synthesised where the R–B–R moiety has been changed to R–C–R [409]. There have been 
synthesis of several scopionates derivatives which are not necessarily linked with boron atom but with 
different organic linkers like CHCOOH, CH2 and pyridine derivatives [412, 409]. Many of the 
pyrazoles derivatives are designed as bidentates, tridentates and tetradentates [413, 294-300]. The 
dimethypyrazole derivatives are significantly important in the formation of several metal complexes 
through the available lone pair of electron on the N atom [408, 414-416]. There have been syntheses of 
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many metal complexes of pyrazole derivatives especially that of ruthenium complexes [294-300] for 
various applications. Therefore in the two sections, we have considered the spectroscopic and the 
electronic properties of the methylpyrazole and pyrazole derivatives using both experimental and 
computational tools. The changes in the properties of the lone pair of electron on N2 atom which may 
affect its coordination to metal atom were probed theoretically. The four ligands considered in section 
4.3 are shown in Figure 4.1. The ligands of interest in section 4.4 are pyrazole (pz), bis(pyrazol-1-
yl)methane (bpzm), bis(pyrazol-1-yl)acetic (bpza) and bis(pyrazol-1-yl)pyridinic (bpzpya) as shown in 
Figure 4.6. 
 In section 4.5, another seven derivatives of pyrazole (Figure 4.11) were studied in order to show 
the effect of methyl, carboxylic, pyridine and phenyl on the stabilities, conductivity, availability of the 
nitrogen atom of pyrazole for metal coordination (denoted as *N) and the strength of the *N-N bonds 
of the pyrazole. Effort was also made to correlate the theoretical spectroscopic properties with the 
experimental values in an attempt to get the distinguishing features from the IR, Raman, 
1
H-NMR, 
13
C-
NMR, 
15
N-NMR and UV of the derivatives. We envisage that the information provided from 
experimental and theoretical studies will be of tremendous help in the design of pyrazole based 
organometallic complexes for specific uses in biomedical and non-linear optical (NLO) applications.  
 Lastly in section 4.6 of this chapter, we carried out a study on the pyridine (pyr) and 
phenanthroline (phn). The pyridine and phenanthroline derivatives are the most widely used bidentates 
ligands in metal coordination. They have received research attention in the application of their metal 
complexes as electro-chemiluminescence, catalyst, photochemical and anticancer [273-279, 417, 281-
284]. Due to the wide application of pyr and phn derivatives, it is imperative to understand their 
relative properties in order to bring about a more rational combination in metal complexes. The interest 
of this section is to give at a glance the spectroscopic and electronic properties of pyr and phn 
derivatives. The schematic representation of the six ligands is shown in Figure 4.16. 
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4.2 Experimental Synthesis of the ligands 
4.2.1 Chemicals and solvents 
The chemicals and solvents used for the synthesis of the ligands were purchased from Sigma aldrich 
and were used as purchased without any further purification. The chemicals used for the synthesis of 
the ligands are pyrazole, 3,5-dimethylpyrazole, 3-phenylpyrazole and dibromoacetic acid. The solvents 
used during the synthesis are dichloromethane, tetrahydrofuran (THF), acetone, diethyl ether (Et2O) 
methane and acetonitrile. 
 
4.2.2 Physical measurements 
The physical methods used for the characterisation of the ligands are IR, Raman, UV, NMR and 
Elemental analyser. 
4.2.2.1 The IR measurement 
The Fourier Transform Infra Red (FTIR) spectra of the ligands were measured using a Brukers Vector 
22 spectrophotometer and the values are given in cm
-1
. The solid samples of the ligands were used in 
all the IR analysis. 
4.2.2.2 The Raman measurement 
The Raman spectra were obtained for the ligands using Bruker Fourier Transform Raman spectrometer 
(model FRA 106). The solid samples of the ligands were also used. 
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4.2.2.3 The UV measurement 
The absorption spectroscopic properties of the ligands were determined using Hewlett–Packard 8452A 
diode array spectrophotometer. The solids were dissolved in methanol. 
4.2.2.4 The NMR measurement 
The NMR chemical shifts of the ligands were determined using Bruker-AVANCE NMR spectrometer 
at 600 MHz. The samples were dissolved in deuterorated methanol (CD3OD) or DMSO (DMSO-D6). 
Both 
1
H-NMR and 
13
C-NMR chemical shifts are reported in δ relative to tetramethylsilane (TMS) as 
reference. 
4.2.2.5 The elemental analysis 
The elemental analyses of the ligands were performed using Perkin Elmer 2400 Series II CHNS 
Elemental analyzer. 
 
4.2.3 Synthesis of bis(3,5-dimethylpyrazol-1-ly)acetic (bdmpza) 
 The method employed for the synthesis of this ligand is very similar to the method reported in 
the literature [408]. Both 3,5-dimethylpyrazole (40 mmol, 3.84 g) and dibromoacetic acid (20 mmol, 
4.355 g) were added to THF solvent with K2CO3 (75.7 mmol, 10.45 g), KOH (77.7 mmol, 4.35 g) and 
BTEA (1.0 g) as phase transfer agent. The reaction was refluxed for 5-6 hours. The product was dried 
in vacuo, 80 ml of water was added and then acidified with half diluted HCl first to a pH of 7.0 and 
extracted with Et2O (200 mL). It was further acidified to pH 1.0 and extracted twice with Et2O (2 x 150 
mL). The organic solvent was dried with Na2SO4 and evaporated in vacuo. Acetone was added to the 
oily product and then dried in vacuo to afford a white powder which was further recrystalized with 
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acetonitrile.  
4.2.4 Synthesis of bis(methylpyrazol-1-ly)methane (bdmpzm) 
 The same method employed for the synthesis of bis(methylpyrazol-1-ly)methane is similar to 
that reported in the literature [418] with slight modification. Methylpyrazole (40 mmol, 3.84 g) was 
added to CH2Cl2 solvent for the synthesis. The same process as in bdmpza was equally followed for the 
separation of the product.  
 
4.2.5 Synthesis of bis(pyrazol-1-ly)methane (bpzm) 
 Ligand bpzm was prepared as described in the literature [418]. Pyrazole (40 mmol, 2.725 g) 
was dissolved in dichloromethane solvent with K2CO3 (75.7 mmol, 10.45 g), KOH (77.7 mmol, 4.35 g) 
and BTEA (1.0 g) as phase transfer agent were added. The reaction mixture was refluxed for 5-6 hours. 
The product was dried in vacuo, 80 mL of water was added and was acidified with half diluted HCl 
first to a pH of 7.0 and extracted with Et2O (200 mL). It was further acidified to pH 1.0 and extracted 
twice with Et2O (2 x 100 mL). The organic solvent was dried with Na2SO4 and evaporated in vacuo. To 
the oily product was added acetone and dried in vacuo to afford white microcrystals of bpzm. 
 
4.2.6 Synthesis of bis(pyrazol-1-ly)acetic (bpza) 
Ligand bpza was prepared as reported in the literature [408]. Both pyrazole (40 mmol, 2.725 g) and 
Dibromoacetic (20 mmol, 4.355 g) were added to THF with K2CO3 (75.7 mmol, 10.45 g), KOH (77.7 
mmol, 4.35 g) and BTEA (1.0 g) as phase transfer agent. The reaction mixture was refluxed for 5-6 h. 
The product then dried in vacuo, 80 mL of water was added and then acidified with 50% HCl first to a 
pH of 7.0 and extracted with Et2O (200 mL). The reaction mixture was further acidified to pH 1.0 and 
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extracted twice with Et2O (2 x 100 mL). The organic solvent was dry with Na2SO4 and evaporated in 
vacuo. To the oily product was added acetone and dry in vacuo to afford a white powder which was 
further recrystalized with acetonitrile. 
 
4.2.7 Synthesis of 3,5-diaceticpyrazole (dcpz) 
The ligand 3,5-dicarboxylpyrazole (dcpz) was synthesised by oxidation of the 3,5-dimethylpyrazole. 
The method used is similar to that method reported for the oxidation of the methyl group of 4-methyl-
1,10-phenanthroline [280]. 3,5-dimethylpyrazole (1 g) was refluxed for 4 h with selenium oxide (2.5 g) 
in dioxane containing 4% water and filtered through celite 521 while hot. The aldehyde obtained was 
oxidized with HNO3 to give 3,5-dicarboxylpyrazole (dcpz).  
 
4.2.8 Synthesis of bis(phenylpyrazol-1-ly)acetic (bphpza) 
The method used for the synthesis of bis(phenylpyrazol-1-ly)acetic is as reported in the literature [408] 
with slight modification. Both phenylpyrazole (40 mmol, 5.76 g) and dibromoacetic (20 mmol, 4.355 
g) were added to THF solvent in a conical flask. The reaction mixture was reflux for 5-6 h. The product 
was dry in vacuo, 80 mL of water was added and was acidified with 50% HCl first to a pH of 7.0 and 
extracted with Et2O (200 mL). It was further acidified to pH 1.0 and extracted twice with Et2O (2 x 100 
mL). The organic solvent was dry with Na2SO4 and evaporated in vacuo. To the oily product was added 
acetone and dry in vacuo to afford a white powder which was further recrystalized with acetonitrile. 
 
4.2.9 Synthesis of bis(pyrazol-1-ly)pyridine (bpzpy) 
The method employed for the synthesis of bis(pyrazol-1-ly)pyridine is a combination of different 
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methods reported in the literatures [413, 418] with slight modifications. The method used here is a bit 
similar to the method used for the synthesis of bis(pyrazo-1-ly)acetic [408]. Pyrazole (30 mmol, 2.044 
g) and dichloropyridine (5.21 mmol, 1.235 g) were added to THF with K2CO3 (75.7 mmol, 10.45 g), 
KOH (77.7 mmol, 4.35 g) and BTEA (1.0 g) as phase transition. To allow complete replacement of the 
bromides, a 6:1 moles of pyrazole:bromopyridine was used. The reaction mixture was refluxed for 24 
h. The product was dried in vacuo, 80 mL of water was added and was acidified with HCl to form 
precipitate which was filtered and washed with water. 
 
4.2.10 Synthesis of bis(methylpyrazol-1-ly)pyridine (bmpzpy) 
The same method as described for the synthesis of bis(pyrazo-1-ly)pyridine (bpzpy) was employed. In 
the synthesis of bis(methylpyrazol-1-ly)pyridine, methylpyrazole (30 mmol, 2.88 g) was reacted with 
dichloropyridine (5.21 mmol, 1.235 g). 
 
4.3 Spectroscopic and electronic properties of 3,5-dimethylpyrazole based ligands 
using the experimental and computational methods 
4.3.1 The infra red spectral  
 The schematic representation of 3,5-dimethylpyrazole based ligands are shown in Figure 4.1. 
The results of the experimental Raman, IR and the theoretical IR are shown in Figure 4.2 with the 
assigned vibrations. The assignment of the IR vibration was done based on potential energy distribution 
(PED) contributions using the package VEDA [419] as explained in the literatures [ 420, 421]. The best 
two vibrations which define all the prominent peaks in the ligands are shown in Table 4.1. The 
prominent peaks at 2927.75 cm
-1
 (dmpz), 2923.89 cm
-1 
(bdmpzm), 2929.68 cm
-1 
(bdmpza) which can 
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be ascribed to (C-Hpz) are highly Raman active and are very weak peaks in the experimental IR 
spectra but relatively stronger in the theoretical IR. Peculiar to Raman spectra is the strong vibrational 
peaks at 590.00 cm
-1
 (assigned to out of plane CCNN) and around 1000 cm
-1 
(assigned to bending of 
either CNN or CCN) in the three ligands. Another Raman active vibration common to dmpz, bdmpzm 
and bdmpza are the peaks around 1425.48 cm
-1 
which are ascribed to the bending vibration of CH3 
deformation. A prominent experimental and theoretical IR vibration at 1739.00 cm
-1 
is peculiar to only 
bdmpza and bdcpzm but absent in dmpz and bdmpzm is assigned to the (C=O) vibration in agreement 
with literature on a similar ligand [408].  
4.3.2 The NMR properties 
 The experimental proton and carboN-NMR for bdmpzm and bdmpza with the proton for dmpz 
are presented in Table 4.2. The available values as reported in the literatures are shown in bracket. The 
two synthesised derivatives bdmpzm and bdmpza has no proton shift at 11.99 that is observed in the 
precursor dmpz indicating that the hydrogen atom at N1 has been successfully substituted with CH2 
and CHCOOH in the two derivatives respectively. The observed C-NMR shift at 169.71 is an 
indication of the formation of the CHCOOH group of ligand bdmpza which is absent in the complex 
bdmpzm which as CH2 as linking unit of the two dmpz. Experimental 
1
H-NMR shift for the CH3 ranges 
from 1.703 to 2.49, the CH2 or CHCOO of the linking ranges from 6.13 to 7.27, CHpz ranges from 5.73 
to 5.88, COOH is found at 7.45 while the highest shift is found in dmpz at 11.99 which is ascribed to its 
NHpz unit. 
  The results obtained are shown in Tables 4.3 and 4.4. Using the direct method, 
1
H-NMR shift 
for the CH3 ranges from 1.68 to 2.52, the CH2 or CHCOO of the linking ranges from 5.62 to 7.39, CHpz 
ranges from 5.94 to 7.03, COOH ranges from 5.76 to 6.56 while the highest shift is found in dmpz at 
8.68 which is ascribed to proton shift of its NHpz unit. The fitting method gives the 
1
H-NMR shift for 
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the CH3 ranges from 2.15 to 2.97, the CH2 of CHCOO of the linking ranges from 5.97 to 7.69, CHpz 
ranges from 6.29 to 7.34, COOH ranges from 6.11 to 6.88 while highest shift of 8.94 is also obtained 
for the NHpz proton shift that is present in dmpz.  
 The experimental 
13
C-NMR shift for all the CH3 ranges from 11.13 to 13.54, CH2 was found at 
60.46, the Cpz ranges from 104.37 to 148.58 and the highest shift is 169.71 for COOH. Using the direct 
method, the 
13
C-NMR shift for all the CH3 ranges from 11.87 to 15.67, CH2 or CHCOOH ranges from 
63.10 to 76.5, the Cpz ranges from 101.37 to 148.40 and the highest shifts also predicted for COOH 
ranges from 151.70 to 166.00. The fitting method for the 
13
C-NMR shift predicted 3.082 to 6.747 for 
CH3, 52.50 to 67.20 for CH2 or CHCOOH, 89.08 to 134.5 for Cpz and 137.7 to 152.00 for COOH. 
 The values obtained for the Rasey terms and the spin-spin coupling (J-coupling) are shown in 
Table 4.5. As indicated in Table 4.5, among the four Ramsey terms, FC term has the highest 
magnitudes followed by the PSO while the SD and DSO have the smallest. The magnitude of FC in the 
bonded *N-N are higher in bdmpzm than the precursor dmpz while bdcpzm has the lowest. The SD has 
the highest magnitude in the precursor dmpz than the derivatives. The order of the magnitude of the 
*N-N J-coupling in the four ligands are bdmpza > bmpm > bdcpzm > dmpz. Though bdcpzm have 
relatively lower FC and SD but it has the highest magnitude of PSO properties due to its higher 
conjugative features. The non-bonding *N···*N interaction in bdcpzm has the highest coupling 
properties which may be attributed to the electronic field effects on the *N atoms from the nearby 
carboxylic units. 
4.3.3 The geometries  
 The changes in the *N-N bonds from the precursor to the derivatives are computed using the 
QTAIM method as shown in Table 4.6. Comparing *N-N bond in the precursor dmpz to the derivatives, 
there is a slight elongation in bdmpzm and bdmpza which result to a weaker feature of the bond as 
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indicated with a lower magnitude of the Laplacian of electron density (2(r)) (Figure 4.3). A pair of 
*N-N bond in each bdmpzm, bdmpza and bdcpzm indicate that there is a slight variation within each 
pair (Figure 4.3). It is interesting to point out that within a pair of *N-N in each ligand, the one with 
shorter distance is associated with higher magnitude of 2(r), (r) and V indicating the characteristic 
features of a stronger bond. The variations within a pair of *N-N bonds of each derivative is an 
indication that there will be significant difference in the properties of the two *N atoms that are 
available for the metal coordination of the derivatives. The ring electron density (in red) of the pyrazole 
unit are observed to have significantly changes from the precursor to the derivatives in the order dmpz 
< bdmpzm < bdmpza < bdcpzm (Figure 4.3). 
 As shown in Table 4.7, the *N atoms that are available for metal coordination are characterised 
with lower atomic charge (q(A)), intraatomic magnetizability (Intra_Iso(A)), bonding magnetizability 
(bond_Iso(A)), total magnetizability (Iso(A)), bond isotropic shielding tensor (Iso(A',A)) and energy 
level compared to N atoms that are not accessible for metal coordination. These *N atoms are also 
characterised by higher magnitude of intraatomic dipole of an atom (intra(A)), bonding dipole of an 
atom (bond(A)), total atomic dipole (A)), atomic volume (Vol(A)), out of plane magnetizability of 
atoms (zz(A)), intraatomic isotropic shielding tensor (Iso(A,A)), total shielding tensor of an atom 
(Iso(A)) (except in dmpz), electron occupation and an extremely higher anisotropic values.  
 The characteristic properties of the *N atoms in the ligands suggest the possibility of poor metal 
coordination of bdcpzm compared to the others. This observation is further confirm with the lower 
number of localized electrons on the *N atoms of the ligand bdcpzm compared to other ligands (Figure 
4.3). Considering the total values of the computed properties as shown in Table 4.7, the dipole 
properties of the ligands varies in the order of dmpz < bdmpzm < bdmpza < bdcpzm.  
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4.3.4 The hydrogen bonding  
 H-bonding is known to be the most widely studied non-covalent interactions in both chemical 
and biological systems due to its significant roles in the stability and biological functions of compounds 
[380-383]. The molecule bdmpza has the highest number of intramolecular H-bonding networks (Table 
4.8 and Figure 4.3). There are no intraatomic H-bonding in the precursor dmpz but two are found in 
bdmpzm, five in bdmpza and two in bdcpzm. There is one unusual H-bonding in bdmpzm (H24···H28) 
and two in bdmpza (C2···C7 and H28···H33). This type of unusual interaction is not completely 
strange as H-bonding was found present in H2····HH non-covalent interaction [381, 382]. The unusual 
H-bonding of H···H in both bdmpzm and bdmpza have relatively high bcp which is a clear indication 
that it is not a van der Waals interaction since it lies within the range proposed for H-bonding 
interactions [382].  
4.3.5 The UV absorption and electronic transition  
 The experimental max of the UV absorption for dmpz, bdmpza and bdmpza are found at 
273.00, 270.00 and 269.00 nm respectively. The theoretical max UV absorption are found at 213.36 
(0.0241), 227.46 (0.0092), 272.98 (0.027) and 282.21 (0.0099) nm for the dmpz, bdmpzm, bdmpza and 
bdcpzm respectively (the oscillatory strength are in bracket). Contrary to the red shift observed in the 
experimental UV absorption, the theoretical method predicted a blue shift from dmpz to bdmpza 
(Figure 4.4). The computed triplet states have zero oscillatory strength (f) which is an indication that 
the excitation of the electrons are mostly into the singlet excited states in all the ligands. As shown in 
Figure 4.4 and Table 4.9, only two singlet excited states are visible for bdmpzm and bacpza among 
three predicted singlet states while one is visible in dmpz and bdmpza. In this case, the experimental 
absorption for dmpz at 273.00 is found theoretically to be predominantly characterised by HOMO to 
LUMO+1 transition, that of bdmpzm at 270.00 is found to be HOMO to LUMO while that of the 
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bdmpza at 269.00 is as a result of HOMO-1 to LUMO transition (Table 4.9). Both the experimental and 
theoretical max UV absorption of bdmpza are in very good agreement and the features of the isodensity 
of its three HOMO and three LUMO energy levels are shown in Figure 4.5. The isodensity surface in 
Figure 4.5 gives a more comprehensive features of the levels of HOMO and LUMO contributions of 
the two *N atoms. Just as shown in Table 4.9, the first of the two *N atoms significantly determine the 
HOMO-4 (53%) while the second determine the HOMO-5 orbital (50%) (Figure 4.5). The 
experimental absorption of bdmpza at 269.00 can best be explained as the excitation of electron from 
one of the pyrazole ring that dominates HOMO-1 to the carboxylic unit that dominates the LUMO.  
 In order to further illustrate the variations in the properties of the two *N atoms that make up a 
pair of bidentate properties of the ligands, the contribution of each *N atom to the electronic transition 
are illustrated in Table 4.10. The *N atom in dmpz make highest contribution to the occupied low 
energy level H-2 (70%) and unoccupied higher energy level L+3 (26%). The two *N atoms in bdmpzm 
contribute to different energy levels where *N12 contributes to H-5 (50%) and L+3 (26) and *N14 
contributes to H-4 (53%) and L-5 (53%).  
4.3.6 The conductive properties of the ligands 
 The values of  calculated with other computed polarizabilities and hyperpolarizabilities are 
shown in Table 4.11. In agreement with the relative energies, the most stable isomer is predicted to be 
the hardest one [345]. However, the molecules having a small energy gap are known as soft and having 
a large energy gap is known as hard molecules [347]. 
 The NLO properties of the derivatives are enhanced compared to the precursor. The computed 
properties show that bdmpza is the best NLO materials out of the four ligands because of its lower band 
gap and higher hyperpolarizabilities. Despite the higher number of H-bonding found in bdmpza, it has 
the lowest percentage of non-Lewis orbital while bdcpzm have the highest. However, the precursor is 
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predicted as the most stable based on the highest value of its   but not the most reactive because 
of its higher band gap (very hard) [395]. The NLO properties therefore follow the order of bdmpza < 
bdmpzm < bdcpzm < dmpz which is also the order obtained for the magnitude of the *N-N J-coupling. 
 
 
 
 
 
 
1. dmpz 
 
2. bdmpzm 
 
3. bdmpza 
4. bdcpzm 
 
 
Figure 4.1: The schematic diagram of methylpyrazole (dmpz), bis(dimethylpyrazol-1-yl)methane 
(bdmpzm), bis(dimethylpyrazol-1-yl)acetic (bdmpza) and bis(diaceticpyrazol-1-yl)methane (bdcpzm). 
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Figure 4.2: The experimental IR and Raman (in red) with the theoretical IR (in black) spectral of the 
ligands 
163 
 
 
 
1. dmpz 
2. bdmpzm  
3. bdmpza 
 
 
4. bdcpzm  
 
Figure 4.3: The features of the QTAIM properties of the ligands showing the atomic localized 
electrons, Laplacian of electron density of the bonds and the ring electron density. 
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Figure 4.4: The experimental and theoretical UV absorption of the ligands in nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Electronic isodensity surface of six levels of HOMO and LUMO of bdmpza 
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4.4 Synthesis of pyrazole derivatives and their spectroscopic properties  
 The geometrical structures of the Ru complexes that were studied are shown in Figure 4.6. 
Comparing the computed geometries of bpza with the reported experimental crystal structure [408] (in 
bracket), the bond distance N9-C11 is 1.457 (1.468), N10-C11 is 1.457 (1.467), C11-C13 is 
1.451(1.554), C13-O12 is 1.222 (1.215), C13-O14 is 1.353 (1.318) and the bond angle N9-C11-N10 is 
114.08 (111.82). This shows a very good agreement between the computed geometry and the crystal 
structure of bpza. 
4.4.1 The infra red spectra 
 The potential energy distribution (PED) contributions are employed for the assignment of the 
spectra using VEDA [419] as explained in the literatures [420, 421]. The experimental and theoretical 
IR vibration help to distinguished bpza from the rest of the ligands with a unique vibration at 1720 cm
-1
 
(assigned for (C=O)) which is very close to the reported 1761 cm-1 in the literature [408]. The Raman 
spectra also distinguishes bpza from bpzm with the a weak vibration at 1720 cm
-1
 (i.e. C=O vibration) 
and a moderate vibration at 2990 cm
-1 
ascribed to the C-H vibration of the CHCOOH unit of bpza. 
Peculiar to bpza is the vibration at 3750 cm
-1
 (theoretically found at 3610 cm
-1
) which is assigned to O-
H vibration. The theoretical and experimental IR further distinguished bpza from other ligands with the 
strong vibration at 1100 cm
-1
 which is assigned to C-O vibration. Another distinguishing feature in the 
Raman spectra that is peculiar to bpza only is the vibration at 380 cm
-1
 assigned to the CCO which is 
completely absent in bpzm. The Raman active vibrations are 1400 cm
-1
(assigned to the vibration of NC 
and CCN as shown in Table 4.12), the strongest peaks 1150 cm
-1
 (NN vibration) in bpzm and at 1300 
cm
-1
 (NC vibration) in bpza. In bpza, there is a strong Raman peak at 1100 cm
-1
 which corresponds to 
both experimental and theoretical IR vibrations assigned to the stretching vibration of the OC. Also, all 
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the vibrations found within 500 to 1000 cm
-1 
which are assigned to the vibrations OCO, HOCC, CCN, 
NC and HCCN as shown in Figure 4.7 and Table 4.12 are not Raman active vibrations. The 
experimental N-H vibration in pz lies within the broad vibration of C-H but has a very sharp feature 
which distinguishes pz from bpzm and bpza. The theoretical comparison of bpza with bpzpya shows a 
red shift in most of the IR vibrations in bpzpya due to the presence of the pyridinic linking unit.  
4.4.2 The NMR properties  
 The experimental protoN-NMR clearly shows that in bpzm and bpza, there is no high shift of 
12.81 ascribed to N-H in pz which is an indication that the respective linking units CH2 and CHCOOH 
have been successfully introduced into the bidentate ligands. The proton chemical shift at 7.20 in bpza 
also indicate the presence of carboxylic unit and CHCOO at 7.22 which is very close to the reported 
value 7.27 in the literature [408]. Most of the proton and carbon chemical shift obtained are very closer 
to the previously reported shift in the literatures which are shown in bracket in Table 4.13 [418, 408]. 
 The theoretical proton chemical shifts obtained using the two methods are shown in Table 4.14 
while that of the carbon chemical shifts are shown in Table 4.15 for each of the ligand. The H-bonding 
in bpza that involves H19 and H20 results in higher proton shifts compared to other hydrogen atoms in 
the ligands (Table 4.14). 
 The experimental protoN-NMR shift of C3-H is found within the range of 7.60 to 7.65, C4-H 
within 5.89 to 6.37, C5-H within 7.28 to 7.81, CH2 at 6.41, CHCOO at 7.22, COOH at 7.20, N-H at 
12.81. Using the direct method, the protoN-NMR shift of C3-H is found within the range of 7.58 to 
7.97, C4-H within 6.34 to 6.67, C5-H within 7.07 to 8.37, CH2 within 5.83 to 6.51, CHCOO at 7.29, 
COOH within 6.52 to 7.02, N-H at 9.51 and the Hpy in bpzpya within 6.89 to 7.93. By making use of 
the fitting equation, the protoN-NMR shift of C3-H is found within the range of 7.87 to 8.26, C4-H 
6.67 to 6.99, C5-H within 7.38 to 8.64, CH2 within 6.18 to 6.84, CHCOO at 7.59, COOH within 6.85 to 
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7.34, N-H at 9.75 and the Hpy in bpzpya within 7.20 to 8.22. It is evidently clear that the two theoretical 
methods give a perfect correlation with the experimental proton chemical shift but direct method gives 
values which are much closer to the experimental than the fitting method except for the COOH and N-
H where fitting method is closer. 
 The experimental 
13
C-NMR shift of Cpz is found within the range of 104.67 to 133.85, CH2 at 
77.00, CHCOO at 74.18 and COOH at 140.94. Using the direct method, the 
13
C-NMR shift of Cpz is 
found within the range of 101.65 to 140.64, CH2 at 68.41, CHCOO at 76.49, COOH within 160.13 to 
166.09 and Cpy in bpzpya within 101.05 to 152.00. Using the direct method, the 
13
C-NMR shift of Cpz 
is found within the range of 89.54 to 127.09, CH2 at 57.53, CHCOO at 65.31, COOH within 145.86 to 
151.60 and Cpy in bpzpya within 88.96 to 138.02. There is a perfect correlation also between the 
experimental and computed 
13
C-NMR shift. The direct method equally gives values close to the 
experimental than fitting method except for the COOH where the fitting method performed better.  
4.4.3 The nuclear spin-spin coupling 
 The Ramsey terms are considered for the bonding *N-N and none bonding *N-*N where *N is 
the nitrogen available for metal coordination and N is the one not available for metal coordination 
(Table 4.16). The J-coupling of the *N-N bonds are stronger in the derivatives than the precursor pz 
and the two bonds in bpza have the highest values. The J coupling between the two *N atoms of the 
pyrazole unit in bpza is higher than what is found in bpzm and bpzpya. However considering the J-
coupling of the *N atoms with the Npy of the pyridinic unit (*N-Npy) in bpzpya, the value is 
significantly higher than what is found in *N-*N coupling. It is interesting to observe in bpza a kind of 
symmetry in the properties of the two *N-N bonds which is not observed in the bpzm and bpzpya. 
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4.4.4 The bond properties  
 The bond properties of the *N-N are presented in Table 4.17. There is a gradual increase in the 
*N-N bonds from the precursor pz to the derivatives (GBL_I) which consequentially results to a 
weaker nature of these bonds in derivatives indicated with a lower Laplacian values of their electrons 
(2(r)). Generally, the features of *N-N in the ligands show that as the bond length increases from the 
pz to bpzpya, there in a corresponding decrease in electron density, strength of the bonds in term of the 
values of the Laplacian of electrons (2(r)) and the magnitude of the ratio of potential energy and 
Lagrangian kinetic energy (|V/G|). Only bpza have two intramolecular H-bonding while other ligands 
have none. The two H-bonding are also found to have NMR J-coupling of -2.58E-001 which is stronger 
than what is observed for the *N-*N coupling (Table 4.16). 
4.4.5 The intra- and inter-atomic properties  
 There is also a unique pattern of the symmetrical features in both intra- and inter-atomic 
properties of the two *N atoms in bpza when compared to other ligands (Table 4.18). Comparing the 
*N with the N atoms in all the ligands, the *N atoms are characterised with lower atomic charge (q(A)), 
bonding magnetizability (bond_Iso(A)), total magnetizability (Iso(A)), bond isotropic shielding tensor 
(Iso(A',A)) (except in bpzpya) and lower energy level. These *N atoms are also characterised with 
higher magnitude of intraatomic dipole of an atom (intra(A)), bonding dipole of an atom (bond(A)), 
total atomic dipole (A)), atomic volume (Vol(A)), intraatomic isotropic shielding tensor (Iso(A,A)), 
total shielding tensor of an atom (Iso(A)) (except in pz), electron occupation and also have an 
extremely higher anisotropic values. The number of the localized electron on the *N is higher than that 
of the N atoms (Figure 4.8). A lower energy level of the *N atoms and their higher charges, bond(A), 
Intra_Iso(A), Iso(A,A) and Iso(A) can be responsible for observed bond strength in the order bpzpya > 
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bpza > bpzm > pz. Also the total molecular dipole properties (intra(A), bond(A), (A)) follow the order 
bpzpya > bpza > bpzm > pz. 
4.4.6 The Excitation properties 
 The experimental max is found at 211.00, 275.00 and 275.00 for pz, bpzm and bpza 
respectively. The theoretical is found at 205.26, 214.20, 248.42 and 338.64 for pz, bpzm, bpza and 
bpzpya respectively (Figure 4.9 and Table 4.19). There is a blue shift in both the experimental and 
theoretical UV from pz to bpza. A much more blue shift is observed in the theoretical study of bpzpya. 
The theoretical max for the ligands are underestimated compared to the experimental. Considering the 
theoretical max in relation to the experimental max, the type of the transitions is predicted as shown 
in Table 4.19. The experimental absorptions at 211.00, 275.00 and 275.00 are as a result of the 
predominant nature of HOMO-1→LUMO+1, HOMO-1→LUMO and HOMO-2→LUMO respectively 
for pz, bpzm and bpza.  
 Comparing energy level contribution of the coordinating point *N in pz with N, it contributes 
significantly to the HOMO than N and contributes 77% of the electrons occupying HOMO-2 energy 
level when compared to other atoms in the ligand. Interestingly, in all other ligands except in bpzpya, at 
least one of the *N atom makes significant contribution to the HOMO energy level. Also, comparing 
the two coordinating centre of *N atoms in bpzm and bpza as bidentate and three in bpzpya as 
tridentate, there are different contribution to the molecular energy levels (Table 4.20). The contributions 
of the *N atoms in bpzm, bpza and bpzpya are very similar. Their highest contribution are found at 
HOMO-4 and HOMO-5 where the two in bpzm contributes 73% in both energy levels, the two in bpza 
contribute 37% and 39% respectively, while the three in bpzpy contribute 36 to HOMO-4 and 28 and 
47 to HOMO-5 (Table 4.20). The electronic isodensity surface of bpzm is shown in Figure 4.10. The 
isodensity feature of the HOMO-4 and HOMO-5 shows that the coordinating *N atoms dominate the 
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surface. It is interesting to also point out that one of the two pyrazole units in bpzm dominates the 
HOMO while the second dominate the LUMO (Figure 4.10). The variation in the properties of the *N 
atoms in both bidentate (bpzm and bpza) and tridentate (bpzpya) indicates the possibility of differences 
in the affinity for metal coordination of the *N atoms within a ligand. 
4.4.7 The electrical properties 
 In agreement with literature [345], the most stable ligand (i.e. pz) is also the hardest ligand 
characterised with the highest magnitude of and . However, the most stable are less valuable 
material in terms of the NLO properties based on its lower hyperpolarizability (ß). The possible 
application of the ligands as NLO material is in order of bpzpya > bpza > bpzm >pz according to the 
values of their hyperpolarizability (Table 4.21). The order of their band gap and ii also agree with 
the order of their hyperpolarizability. It is interesting to point out that the tridentate bpzpya is more 
stable in terms of higher magnitude of than bpza and bpzm and yet is better NLO material in terms of 
the higher ß and lower band gap. 
1. pz 
 
2. bpzm 
 
 
3. bpza 
4. 
bpzp
ya 
 
Figure 4.6: The schematic diagram of pyrazole (pz), bis(pyrazol-1-yl)methane (bpzm), bis(pyrazol-1-
yl)acetic (bpza) and bis(pyrazol-1-yl)pyridinic (bpzpya). 
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Figure 4.7: The experimental IR and Raman (in red) with the theoretical IR (in black) spectral of the 
ligands 
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1. pz 2. bpzm 
3. bpza 
4. bpzpya 
 
Figure 4.8: The features of the QTAIM properties of the ligands showing the atomic localized 
electrons, Laplacian of electron density of the bonds and the ring electron density. 
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Figure 4.9: The experimental and theoretical UV absorption of the ligands in nm. 
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Figure 4.10: Electronic isodensity surface of six levels of HOMO and LUMO of bpzm 
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4.5 The substituent effects on the spectroscopic and electronic properties of 
pyrazole derivatives using experimental and computational approaches 
4.5.1 The IR and Raman spectra 
 The experimental and theoretical IR spectra of the ligands (Figure 4.11) are shown in Figure 
4.12. The spectra of the ligands are assigned as shown in Table 4.22 using the method of the potential 
energy distribution (PED) contributions as implemented in package VEDA [419] and explained in the 
literatures [420, 421]. Besides the OH and NH vibrations which are theoretically overestimated, there is 
a very strong correlation betweeen the theoretical and the experimental spectra (Figure 4.12) which 
help to establish the successful synthesis of the ligands. Starting from the ligands dcpz, there is an 
evidence of successful oxidation of the methyl group of the 3,5-dimethylpyrazole with the presence of 
C=O vibration at 1750 cm
-1
. In bphpza, the distinguishing features theoretically and experimentally is 
the C=O vibration at 1750 cm
-1
 which is observed to be Raman inactive. In the presence of the C=O 
vibration in ligands like dcpz, bphpza and bdcpzpy, the C=C vibrations around 1600 cm
-1 
remain 
invisible in the experimental and theoretical IR but very strong in the experimental Raman spectra. 
Other vibrations in the ligands bphpza, bpzpy and bdmpzpy which were found to be Raman active are 
CH, HCC, CC, NC, NN, CCN, CCNCout and CCC as shown in Figure 4.12 for the ligands bphpza, 
bpzpy and bdmpzpy. A distingushing feature of the tridentate bpzpy and bdmpzpy from bidentate 
bphpza is the experimental Raman vibration within 270 to 300 cm
-1
 which are assigned to the CCN and 
CCNCout respectively. In both theoretical and experimental IR, the C-H vibration around 3100 cm
-1
 is 
very weak in bpzpy.  
 
4.5.2 The 13C-NMR shift 
 There is a perfect correlation between the 
13
C-NMR shifts obtained from the experimental 
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(Table 4.23) and from the two theoretical methods (Table 4.24). In the ligand bdmpzpy, the 
experimental carbon shift of CH3 ranges from 13.72 to 14.89, direct methods gives a range of 15.11 to 
15.49 while fitting method gives 6.20 to 6.57. The experimental ranges of 
13
C-NMR shift of C4 are 
105.04 to 109.79, C5 is 125.19 to 138.99 and C3 is 132.23 to 140.79. The theoretical direct method 
gives 101.91 to 105.71 for C4, 122.80 to 136.64 for C5 and 139.60 to 151.20 for C3 while the fitting 
method gives the ranges 89.79 to 93.45, 109.91 to 123.24 and 126.08 to 137.20 respectively for same 
set of carbon shifts. In many of the 
13
C-NMR shifts, the direct method gives better values within the 
experimental ranges than the fitting method.  
 The order of the chemical shift of C4 within the ligands is phpz < dphpzm < dphpza < dcpz < 
bpzpy < bdmpzpy < bdcpzpy. The order of 
13
C-NMR shift in tridentate ligands bpzpy, bdmpzpy and 
bdcpzpy which are made up of two pz and one pyr units are C4 < Cpy-meta < C5 < Cpyr-para < C3 < Cpyr-
ortho except in bdmpzpy where Cpyr-para of pyr is lower than C5 of pz. The order in the two bidnetate 
bphpzm and bphpza with phenyl (ph) and two pyrazole (pz) units is CH2 < CHCOOH < C4 < Cph-ortho < 
Cph-para < Cph-meta < C5 < Cph < C3 < CHCOOH. When considering all the carbon atoms across the 
seven ligands, CH3 has the lowest chemical shift while CHCOOH has the highest. 
4.5.3 The 1H-NMR shift 
 There is very high correlation between the experimental (Table 4.25) and theoretical (Table 
4.26) proton shifts. The theoretical direct method gives a range of 2.07 to 2.52 for the proton shift of 
CH3, the fitting gives the range 2.53 to 2.96 while the experimental values obtained is within 2.317 to 
2.673 for ligand bdmpzpy. The direct method shift for the COOH unit of bphpza is 6.56, the fitting 
method gives 6.89 while the experimental is 6.452. The order of the proton shift does not directly 
follow the order of the corresponding carbon atoms. Considering the level of proton across the ligands, 
the lowest shift is observed in CH3 of bdmpzpy followed by those from CH2 linking unit. The proton 
shift in the bidentate bphpzm and bphpza follows the order CH2 < COOH < C4-H < CHCOO < Cph-para-
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H < Cph-meta-H < 
f
Cph-ortho-H < C5-H < 
c
Cph-ortho-H except for C5-H that is lower than Cph-para-H and C5-
H' lower than Cph-ortho-H in bphpzm (the superscript ―c‖ and ―f‖ on Cph-ortho mean close to and far from 
the nitrogen which is the coordination centre of the pyrazole). In tridentates bpzpy, bdmpzpy and 
bdcpzpy, the proton shift follow the order CH3 < COOH < C4-H < Cpyr-meta-H < Cpyr-para-H < C5-H < 
C3-H except in bdcpzpy where the Cpyr-para-H is lower than one of the Cpyr-meta-H that is closed to the 
coordinating centre nitrogen atom due to twisting of one of the pyrazole units (Figure 4.13). 
4.5.4 The 15N-NMR shift 
 The nitrogen shift of the nitrogen atom that is not available for metal coordination (N) is far 
higher than that of the coordinating centre that is available for metal coordination (*N) as shown in 
Table 4.27 which indicates that the N are more shielded than the *N atoms. In the tridentate, which 
contain an extra coordinating centre on pyridine, the nitrogen shift of the coordinating centre on 
pyridine (
pyr
N) is higher than the other two in pyrazole units. The two *N coordination centre on two pz 
units of bidentate and tridentate ligands have equal shift only bpzpy and bdmpzpy but different shift in 
other ligands with the highest difference observed in bdcpzpy. The *N atom of the pz units in bdcpzpy 
with the higher shift from the reference is the one that face the pyridine nitrogen while the one twisted 
away is lower. Across the ligands, the nitrogen shift of *N atoms is in the order of bdcpzpy < dcpz < 
bpzpy < bdmpzpy < bphpza < bphpzm < phpz. This order shows that carboxylic and pyridine units 
have significant de-shielding effect on the *N atoms of the pyrazole units. 
4.5.5 The nuclear spin-spin coupling  
 In all the ligands, the FC is the most significant Ramsey term that determines the J-coupling of 
the *N-N bonds. The two *N-N bonds in the bidentate ligands bphpzm and bphpza have significantly 
different Ramsey terms and J-coupling compared to those in tridentates bpzpy, bmpzpy, bdcpzpy (Table 
4.28). The FC and J-coupling of *N-N in the ligands are in the order of bpzpy > bdmpzpy > bphpza > 
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bphpzm > bdcpzpy > phpz > dcpz if the highest value is considered in each ligand. The H-bonding 
N···C interactions in bdcpzpy have J-coupling of -1.41E-001 while O···H H-bonding in bphpza have 
the J-coupling of -2.18E-001 which are higher in magnitude than the non-bonding *N-*N J-coupling. 
The corresponding strength of interactions of the three H-bonding in the bdcpzpy and bphpza are 
predicted to be 0.051 and 0.038 from the QTAIM properties (Figure 4.13 and Table 4.29). The J-
coupling and the corresponding strength of H-bonding interactions are not in the same order. 
4.5.6 The bond and atomic properties 
 The geometrical features with the strength of selected bonds and the amount of localized 
electrons on the selected atoms which are obtained through QTAIM analysis are shown in Figure 4.13. 
The strength of the *N-N bonds of the pyrazole unit in the ligands is in the order of dcpz > bdcpzpy > 
phpz > bphpzm > bphpza > bpzpy > bdmpzpy (Figure 4.13 and Table 4.29). The stronger *N-N bonds 
are also associated with shorter bond distance (GBL_I), bond stretch (BPL – GBL_I) and higher 
electron density ((r)) as shown in Table 4.29. Considering the Laplacian of the electron density on the 
pyrazole ring in the ligands, the order is bdcpzpy > bphpza > bphpzm > bdmpzpy > bpzpy > dcpz > 
phpz. One intramolecular H-bonding is found in both bdcpzpy and bphpza while others have none. The 
strength of the H-bonding ranges from 0.038 to 0.051 which is within the suggested range of H-
bonding in the literature [382]. 
 Generally, the coordinating centre *N atoms are distinguished from the other N atom with the 
characteristic features of higher magnitude of intraatomic dipole (intra(A)), bonding dipole (bond(A)), 
total dipole ((A)), atomic volume (Vol(A)), intraatomic magnetizability (Intra_Iso(A)), intraatomic 
shielding tensor (Iso(A,A)), total isotropic shielding tensor (Iso(A)), anisotropy, total electron 
occupation (Occ) but lower atomic charge q(A), bonding magnetizability (bond_Iso(A)), total 
magnetizability (Iso(A)), bonding shielding tensor (Iso(A',A)), energy level (Table 4.30). The sum 
total of the computed atomic QTAIM properties over all the atoms in each of the ligands shows that 
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bdcpzpy and bphpza are having the highest dipole properties (intra(A), bond(A) and (A)) while phpz 
have the lowest (Table 4.30). 
4.5.7 The electronic spectral 
 The experimental and theoretical UV absorption for the ligands are shown in Figure 4.14. A 
very broad experimental absorption was observed for bpzpy but found theoretically to be two distinct 
peaks (at 283.79 and 327.49 nm) of almost the same strength within the range of the broad 
experimental spectra. Experimentally, we observed a bathocromic (blue) shift from bphpza to bpzpy 
but red shift from bpzpy to bdmpzpy. In the theoretical absorption, there is a blue shift in themax in 
the order of bdmpzpy > bphpza> bdcpzpy >bpzpy > bphpzm > phpz > dcpz. The experimental max 
observed for dcpz, bphpza, bpzpy and bdmpzpy at 276.00, 286.00, 308.00 and 288.00 nm respectively 
can be ascribed to the theoretical max at 257.58, 299.56, 283.79 and 331.82 nm (Table 4.31). These 
experimental max absorption are found to be dominated with H-2→LUMO, HOMO→L+1, 
HOMO→L+1 and HOMO→LUMO for the bphpza, bpzpy and bdmpzpy respectively (Table 4.31). 
Also, in ligand phpz, bphpzm and bdcpzpy which are considered only theoretically, the max 
absorption are predominately HOMO→LUMO, H-1→LUMO and HOMO→L+1 respectively.  
 The level of the contribution of the *N atoms to the energy level are also considered for each of 
the ligands (Table 4.32). The *N atoms contributes significantly to the HOMO levels than the N atoms. 
Most of the orbital contributions of the *N atoms are found at the HOMO-4 or HOMO-5 except in 
ligand bdcpzpy where the highest *N atoms contribution is found at HOMO-1. The features of the high 
contribution of the *N atoms to HOMO and 
py
N to the LUMO is shown in Figure 4.15 for ligand 
bpzpy. It is obvious from Figure 4.15 that the HOMO-5 are predominantly the *N atoms of the 
pyrazole while the LUMO is predominantly the pyridine unit.  
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4.5.8 The conductive properties 
 The conductive properties of the ligands are shown in Table 4.33. The ligand bdmpzpy have the 
highest molecular dipole moment while bphpza have the lowest. The trend of the conductive properties 
of the ligands in terms of the hyperpolarizability is bdmpzpy > bpzpy > bphpza > phpz> bdcpzpy > 
bphpzm > dcpz. It is obvious that the tridentate bdmpzpy and bpzpy have more potential for the 
application as non-linear optical (NLO) materials than the rest of the ligands. The most stable ligand is 
phpz which is characterised by the highest magnitude of  but it is not the hardest ligand since its  is 
lower than that of dcpz contrary to the expectation [345]. 
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7. bdcpzpy 
 
Figure 4.11: The schematic diagram of 3,5-dicarboxylpyrazole (dcpz), 3-phenylpyrazole (phpz), bis(3-
phenylpyrazol-1-yl)methane (bphpzm), bis(3-phenylpyrazol-1-yl)acetic (bphpza), bis(pyrazol-1-
yl)pyridine (bpzpy), bis(3,5-dimethylpyrazol-1-yl)pyridine (bdmpzpy), bis(3,5-dicarboxylpyrazol-1-
yl)pyridine (bdcpzpy) 
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Figure 4.12: The experimental IR and Raman (in red) with the theoretical IR (in black) spectral of the 
ligands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. dcpz 
 
 
 
 
 
 
 2. phpz 
3. bphpzm  
4. bphpza  
5. bpzpy  
6. bdmpzpy 
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7. bdcpzpy 
 
 
Figure 4.13: The features of the QTAIM properties of the ligands showing the atomic localized 
electrons, Laplacian of electron density of the bonds and the ring electron density. 
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Figure 4.14: The experimental and theoretical UV absorption of the ligands in nm. 
 
 
 
 
 
 
Figure 4.15: Electronic isodensity surface of six levels of HOMO and LUMO of bpzpy 
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4.6 The spectroscopic and the QTAIM properties of pyridine and phenanthroline 
derivatives using experimental and computational methods  
4.6.1 The IR spectra 
 The structures of the ligands bpyr, dmbpr, dcbpyr, phn, dmphn and dcphn are shown in Figure 
4.16 and their IR spectra in Figure 4.17. The spectra were analyzed in terms of the potential energy 
distribution (PED) contributions using the package VEDA [419] as explained in the literatures [420, 
421]. The best peaks based on the level of the intensity and their corresponding best two vibrations are 
presented in Table 4.34. The unique difference in the experimental IR of the bpyr and dmbpyr 
compared to the phn and dmphn is the vibration around 1730 cm
-1
 which is ascribed is still assigned to 
the C=C vibration. The unique features in all the ligands bpyr, dmbpyr, dcbpyr, phn, dmphn and dcphn 
is the C=C vibration around 1500 - 1620 cm
-1 
but found experimentally in pyr and dmbpyr around 1730 
cm
-1
. The C-H vibrations in the ligands are found experimentally to be a weak vibration but theoretical 
found to be strong vibrations. Also, C-H vibrations in pyr derivatives are found experimentally around 
3000 while the phn derivatives are found around 3400 cm
-1
.  
4.6.2 The 1H-NMR shift 
 Both the experimental (Table 4.35) and theoretical 
1
H-NMR chemical shift of the ligands 
bmpyr, phn and dmphn (Table 4.36) are in perfect agreement. It is interesting to point out that both 
experimental and theoretical methods clearly show that the proton chemical shift of CH3 is higher in 
dmphn than dmbpyr. Also the range of proton shift on Cpx-meta-H in dmbpyr, phn and dmphn using the 
direct method is 7.15 to 7.64 and that of the fitting method is 7.45 to 7.93 which are very close to the 
experimental range of 7.27 to 7.77. The 
1
H-NMR chemical shift follows the same trend as observed for 
the 
13
C-NMR shift in both bpyr and phn derivatives except for the proton atom of the COOH group 
which is characterised to have the lowest shift. The order of proton shift in pyr derivatives is CH3 < 
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COOH < Cpyr-meta-H < Cpyr-para-H < Cpyr-ortho-H while that of phn derivatives is CH3 < COOH < Cphn-meta-
H < Cbase-H < Cphn-para-H < Cphn-ortho-H. The little exception to the order of proton chemical shift in phn 
derivatives is the Cphn-meta in dcphn which is found higher than the Cbase and Cphn-para due to the presence 
of carboxylic group on its Cphn-ortho.  
4.6.3 The 15N-NMR shift 
 The values of the 
15
N-NMR chemical shift computed using the direct and the fitting methods 
are shown in Table 4.37. The experimental nitrogen shift observed for dmbpyr in the literature is -81.60 
[344] but the direct method in our calculation gives a lower shift of -64.74 while the fitting method 
gives a higher shift of -91.24. In another type of dmphn in the literature [344] though the methyl 
substituent position is completely different, the experimental nitrogen shift is reported to be -76.00 but 
the direct method gives -68.36 while the fitting method gives -94.67. The direct method gives values 
lower than the experimental while the fitting gives values higher than the experimental. The order of 
the nitrogen chemical shift in the six ligands is dmphn > dmbpyr > phn > bpyr > dcphn > dapyr. The 
implication of this order is that the nitrogen atoms of the phn derivatives are more shielded than those 
of the pyr derivatives.  
4.6.4 The 13C-NMR shift 
 The theoretical 
13
C-NMR of the six ligands are shown in Table 4.38. The 
13
C-NMR chemical 
shifts in the three bipyridine (bpyr) and three phenanthroline (phn) derivatives follow predictable 
trends. The carbon atoms around the nitrogen atom in each of the rings in bpyr and phn derivatives will 
be considered as ortho, meta and para for easy explanation while the last two carbon atoms at the base 
of phenathroline (i.e. C5 and C6 from conventional numbering) will be referred to as Cbase. Considering 
the pyr derivatives, the order of the carbon shift is CH3 < Cpyr-meta < Cpyr-para < Cpyr-ortho < 
c
Cpyr-ortho < 
COOH where the superscript ―c‖ represent the ortho carbon that connect the two units of pyridine. A 
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wide difference is observed between the shifts of Cpyr-ortho and 
c
Cpyr-ortho.  
 The 
13
C-NMR shift observed in the derivatives of phn is in the order of CH3 < Cphn-meta < Cbase < 
c
Cphn-meta < Cphn-para < 
c
Cphn-ortho < Cphn-ortho < COOH where the superscript ―c‖ on the Cphn-meta and Cphn-
ortho indicates the one connected with another ring. The presence of the carboxylic unit on the Cphn-ortho 
of the dcphn does not make significant change on its chemical shift (145.38 and 145.97) when 
compared to the parent compound phn (147.21 and 147.22) but the presence of methyl group results in 
a longer chemical shift of Cphn-ortho (157.20).  
 It is worth pointing out that the order observed in both bpyr and phn derivatives for the 
13
C-
NMR is in perfect agreement with the experimental order observed for the similar bpyr and phn in the 
literature [344]. 
4.6.5 The Ramsey terms and the total nuclear spin-spin coupling 
 The most significant Ramsey term is the PSO in the six ligands followed by the FC. The values 
of the PSO and FC of the pyr derivatives are higher than the phn derivatives except in dcphn where FC 
is a little competitively high as that of pyr derivatives (Table 4.39). The J-coupling of the dcphn is 
significantly low compared to the remaining ligands. The values of the SD are also very significant 
compared to the values of the DSO which appear to be the less important in all the C-N bonds. 
Contrary to the bonding C-N interaction, FC is the most significant Ramsey term in the non-bonding 
N-N which also determines the total J-coupling. The Ramsey term FC and J-coupling of N-N are lower 
and positive in values compared to the C-N that are higher and negative. The order of the J-coupling 
for the C-N bonds is phn > dmphn > dcbpyr > bpyr > dmbpyr > dcphn while that of the N-N bond is 
dcbpyr > dmbpyr > bpyr > dmphn > phn > dcphn.  
4.6.6 The bond and atom QTAIM properties  
 The Laplacian of the bond and ring electron density with the number of the localized electrons 
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are shown in Figure 4.18. There is an unusual H-bonding H···H in ligand dcbpyr which has the 
smallest bcp electron density, yet the value is a clear indication that it is not a van der Waals interaction 
since it lies within the range proposed for H-bonding interactions [382]. There is a gradual decrease in 
C-N bond strength from the phn to dmphn and to dcphn. In pyr derivatives, the strongest C-N bond is 
in dmbpyr while bpyr have the lowest. There is an increase in the Laplacian of the ring electron density 
from bpyr < dmbpyr < dcbpyr. Likewise in phn derivatives, the Laplacian of the ring electron density 
also follows the same trend as phn < dmphn < dcphn but little higher than what was found in pyr 
derivatives.  
 The details of the QTAIM properties of the two C-N bonds in each of the ligand and the linking 
C-C bonds are shown Table 4.40 while that of the selected atoms are shown in Table 4.41. In all the 
ligands, the C-N bond lengths are in a close range of 2.555 to 2.569. Likewise also the electron density 
((r)) and Laplacian of electron density (2(r)) of the C-N are in a very close range. Considering the 
sum total of the computed QTAIM properties over all the atoms in each of the ligand (Table 4.41), the 
ligands dcbpyr and dcphn with carboxylic unit have the highest magnitude of the sum total of the 
QTAIM atomic properties except for the bond_Iso(A), Iso(A,A), Iso(A',A) and Iso(A) where the 
ligands dmbpyr and dmphn with methyl group are taking the lead. The implication is that the 
carboxylic units in the ligands result to increase in the dipole and anisotropic properties of the 
molecules while the methyl group result to increase in the isotropic shielding tensor of the molecules. 
4.6.7 The UV absorption 
 There is a very high correlation between the experimental and theoretical UV absorptions as 
shown in Figure 4.19. The experimental max of ligands bpyr, dmbpyr, phn and dmphn are found at 
309.00, 299.00, 307.00 and 310.00 nm while the theoretical are found at 292.28, 286.60, 321.38 and 
349.04 nm. It is interesting to point out that both the experimental and theoretical values indicate a red 
shift in the absorptions of bpyr to dmbpyr but a blue shift from phn to dmphn. The ligands dcbpyr and 
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dcphn are only considered theoretically are their respective max is found at 348.79 and 358.76 nm. 
The phn derivatives are characterised with broader and higher wavelength of absorption than the pyr 
derivatives (Figure 4.19). The features of the electronic excitation which define the observed 
absorptions are shown in Table 4.42 and the contributions of the N atoms to each of the energy levels 
are shown in Table 4.43.  
 The experimentally observed max for the ligands bpyr, dmbpyr, phn and dmphn are found 
through the theoretical methods to be predominantly defined with electronic excitations of the type 
HOMO-2→LUMO, HOMO→LUMO, HOMO-1→LUMO and HOMO→LUMO respectively (Table 
4.42). The max of ligands dcbpyr and dcphn that were treated only theoretically are found to be 
predominately HOMO→LUMO and HOMO→LUMO respectively. The features of the electron 
excitations in the ligands show that most of the significant electron excitations are from either HOMO-
2, HOMO-1 or HOMO to the LUMO of the ligands. The nitrogen atoms which served as the 
coordinating centres on the ligands contributes significantly to the HOMO energy levels of the ligands 
than the LUMO has shown in Table 4.43. A typical feature of the contributions of the atoms to the 
different energy levels of the ligand dmbpyr is shown in Figure 4.20. The features of the isodensity 
surface of the dmbpyr show that the N atoms significantly determine the surface of the HOMO-1 and 
HOMO-2. 
4.6.8 The conductive properties 
 The order of their non-linear optical properties (NLO) is dcphn > dmphn > dcbpyr > dmbpyr > 
bpyr > phn. As seen in Table 4.44, the hyperpolarizability tensor of dcphn is far higher than other 
ligands. Interestingly also, dcphn has the lowest band gap and also appear to be the most stable based 
on the its high negative value of . Contrary to the expectation, ligand dcphn that is the most stable is 
not the hardest [345]. In addition, the ligands dcphn and dmphn which are predicted as the best NLO 
material are also characterised with the highest values of Dipole and polarization 
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( except for the properties which is low in dmphn.  
 
 
 
 
 
1. bpyr 
 
 
 
2. dmbpyr 
 
 
 
3. dcbpyr 
 
 
 
4. phn 
 
 
 
5. dmphn 6. dcphn 
Figure 4.16: The schematic diagram of 2,2'-bipyridine (bpyr), 4,4'-dimethyl-2,2'-bipyridine (dmbpyr), 
4,4'-dicarboxyl-2,2'-bipyridine (dcbpyr), phenanthroline (phn), 2,9-dimethylphenanthroline (dmphn), 
2,9-dicarboxylphenanthroline (dcphn) 
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Figure 4.17: The experimental IR with the theoretical IR (in black) spectral of the ligands 
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Figure 4.18: The features of the QTAIM properties of the ligands showing the atomic localized 
electrons, Laplacian of electron density of the bonds and the ring electron density. 
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Figure 4.19: The experimental and theoretical UV absorption of the ligands in nm 
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Figure 4.20: Electronic isodensity surface of six levels of HOMO and LUMO of dmbpyr 
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CHAPTER FIVE 
5 SYNTHESIS, CHARACTERISATION AND COMPUTATIONAL ELUCIDATION OF 
RUTHENIUM(II) COMPLEXES 
5.1 Background of the chapter 
 In this chapter, the synthesis, characterisation and computational spectroscopic properties of 
forty Ru(II)-based (C1-C40) complexes and four precursor (ST1-ST4) complexes are presented. The 
computational models were used to confirm the successful synthesis of the complexes and were also 
used to elucidate and interpret the experimental spectroscopic properties of the synthesised complexes. 
The different ligands that were used in this project are shown in Figure 5.1. Four different methods 
were used in the synthesis of the complexes based on the type of the starting materials as presented in 
Table 5.1. The method used was based on each starting material as detailed in the experimental section. 
All the syntheses were carried out in vacuum and the cationic complexes are precipitated using 
NH4PF6. The unique target in all our synthesised complexes is to have the pyrazole (pz) derivatives or 
have cymene (cym) unit or combination of both. The intention in all the pyrazole derivatives with the 
linker CHCOOH (i.e. bpza, bdmpza and bphpza) is to make sure the carboxylic unit is not coordinated 
to the metal but free for biological interactions. It is very rare to prevent the carboxylic unit of pyrazole 
derivatives participating in metal coordination. In fact, we have only come across one in the literature 
[422] where this was done compared to many other publications using the conventional method of 
forming tridentate through coordination of the carboxylic group. To afford the free carboxylic unit of 
the pyrazole derivatives, no deprotonation was allowed before or during their synthesis which is similar 
to the method reported in the literature [422]. 
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5.2  Experimental methods for the synthesis of Ru-based complexes 
5.2.1 Chemical and solvents for the synthesis of R(II)-based complexes 
The ruthenium salt RuCl3·3H2O, p-phenanthroline and the solvents dichloromethane, tetrahydrofuran 
(THF), DMSO, DMF, acetone, diethyl ether (Et2O) and methanol and acetonitrile were used as 
purchased from Aldrich Chemical. Also the ligands 2,2'-bipyridine, 4,4'dimethyl-2,2'-bipyridine, 1,10- 
phenanthroline and 2,9-dimethyl-1,10-phenanthroline were used as purchased from Aldrich Chemical. 
The other ligands that were used for the sysnthesis of the Ru(II)-based complexes were synthesised as 
discribed in section 4.2 of this project. The synthesised ligands are bis(3,5-dimethylpyrazol-1-ly)acetic, 
bis(3,5-dimethylpyrazol-1-ly)methane, bis(pyrazol-1-ly)acetic, bis(pyrazol-1-ly)methane and bis(3-
phenylpyrazol-1-ly)acetic. 
5.2.2 Physical measurements 
The same physical methods used for the characterisation of the ligands as described in subsection 4.2.2 
are also used for the characterisation of the ruthenium complexes. 
5.2.3 Synthesis of ruthenium complexes 
 The starting material RuCl2(dmso)4, [(cym)RuCl2]2, Ru(bdmpzm)Cl4 and Ru(bpzm)Cl4 were 
synthesised and used as precursors for the synthesis of the different forms of Ru complexes. The 
number of moles and the percentage yields of complexes are shown in Table 5.1. The complexes C1 to 
C4 and C5 to C8 were synthesised directly from the reaction of RuCl3·3H2O with equivalent of 3.1 and 
2.1 mmol of ligands respectively. 
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 The method used for the synthesis of the precursor RuCl2(dmso)4 and all the Ru complexes 
synthesised from its application as starting material are shown below. The starting material 
RuCl2(dmso)4 was synthesised from the RuCl3.3H2O (2 g, 7.62 mmol) added to 7 mL DMSO and 
reflux for 10 min. The solvent was reduced to half of its volume in vacuum and 40 mL acetone was 
added to give yellow precipitate which was filtered, wash with acetone and Et2O and dry in vacuum 
[423]. All the Ru complexes synthesised from RuCl2(dmso)4 as starting material follow the same 
method as reported in literature [280]. As given in Table 5.1, a mixture of indicated amount of 
RuCl2(dmso)4 and equivalent 1.05 each of the two ligands L1 and L2 were heated for 6-12 h in DMF 
(except otherwise state) to form the different complexes as shown in Table 5.1. The DMF solvent was 
dried in vacuum and the product re-precipitated in CH2Cl2 and Et2O. 
 
 
 
 
 
 
  
 
The preparation of both Ru(bdmpzm)Cl4 and Ru(bpzm)Cl4 follow similar way as reported in the 
literature [280]. The indicated mmol of RuCl3.3H2O together with 1.18 equivalents of the respective 
ligands bdmpzm and bpzm (Table 5.1) are added to 70 mL of 1 N HCl and allow the reaction to stand 
over night. In all the complexes where Ru(bdmpzm)Cl4 was used as starting material, the stated mmol 
of the starting material with 1.05 equivalent of the ligand were dissolved in 50 mL of DMF (except 
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otherwise state) and refluxed 6-12 h under a nitrogen atmosphere [280]. The solid products were 
obtained by drying the solvent in vacuum and the product washed with solvents like acetone and Et2O. 
 
 
 
 
 
 
 
 The precursor [(cym)RuCl2]2 was synthesised by reacting RuCl3·3H2O (1.834 g, 7.016 mmol) 
and p-phellandrene (7.646 g, 56.129 mmol) in ethanol (70 mL). The method used is similar to the 
literature report [201] except that 8.0 mmol equivalent of p-phellandrene was used instead of 
approximately 10 mmol equivalent in the literature [201]. The precursor [(cym)RuCl2]2 was used for 
the synthesis of [(cym)RuLCl2], [(cym)RuLCl]
+
 or [(cym)RuL]
2+
 derivatives. The synthesis of 
(cym)RuL derivatives followed a similar method used for the synthesis of RAPTA complexes [9, 424]. 
As stated for each of the (cym)RuL derivatives in Table 5.1, the stated mmol of the precursor 
[(cym)RuCl2]2 was mixed with 2.2 mmol equivalent of the ligand in the respective solvents as shown in 
the table and reflux for 6-12 h. 
 
 
  
 
5.3 Characterisation and elucidation of the structures 
 The synthesised Ru complexes were analysed using Elemental Analysis, IR, ProtoN-NMR and 
290 
31
P-NMR. In order to have a better understanding of the structures, all the complexes were 
characterised theoretically using the computed IR, 
1
H-NMR, 
13
C-NMR, 
15
N-NMR and 
99
Ru-NMR. The 
chemical shift were computed for the 
1
H-NMR and 
13
C-NMR using TMS as reference, for 
15
N-NMR 
using CH3NO2 [343, 344] and for 
99
Ru-NMR using [Ru(CN)6]
4-
 [334] as reference in place of 
K4Ru(CN)6 [425, 426] which is difficult to compute [426].  
 
5.3.1 The elemental analysis and mass spectroscopic 
 Directly from the elemental analysis (Table 5.2), there is an evidence that 25 complexes C2-C4, 
C6, C8-C15, C17-C20, C25, C27, C28, C30-C32 and C34-C36 are pure enough while 11 complexes 
C1, C5, C7, C16, C21-C23 and C37-C40 appears not to be pure enough. The starting materials ST1-
ST4 appear also to be pure enough. There is no result for 4 complexes C24, C26, C29 and C33 
because of their instability of their mass during the analysis. Since the interest is to interpret the 
complexity of these organometallic using the computational methods, the Ru complexes that appears in 
the elemental analysis to be uncertain were still further purified and analysed.  
 
5.3.2 The IR spectra 
 Both the experimental and theoretical IR spectra are shown in parallel for each of the complexes 
in Table 5.3 and Figure 5.2. There is a very high similarity and correlation between the observed 
experimental and theoretical IR. Interestingly, much peaks intensity is reproduced theoretically. The 
major differences between the experimental and theoretical are the OH vibration which is observed 
theoretically at higher frequency and well separated from the CH vibration. Also, the theoretically 
predicted high intensity of vibration around 2600 to 2700 cm
-1
 in complexes like C6, C8, C9 and C11 
which are experimentally found to be very weak. Peculiar to only the experimental spectra is the 
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vibration found within 2300 to 2400 cm
-1 
as found in complexes like C1, C22, C24, C26, C29 which 
can be interpreted to associate with the anionic PF6
- 
in the cationic complexes except for complex C22. 
 The assignment of all the prominent peaks is shown in Table 5.3 while the peaks that are 
associated with the Ru atom are shown in Table 5.4. The IR vibrations that are dominantly strong in the 
complexes are stretching (SO), (C=O), (C-O) (NN), (CH), (NC), (CC), (OH), bending 
(OCO), (HOC), (HCC) and torsional (HCSRu), (HCCO), (HCCC), (HCCN), (HOCC). In the 
starting complexes ST3-ST4, the (RuCl) IR vibration is very strong but its intensity in the complexes 
is lower. The carbonyl (C=O) vibrations are found within 1700 to 1860 cm-1 in the complexes while 
(C-O) is found within 1050 to 1400 cm-1 (Table 5.3). The (CO) are also found at very low frequency 
around 664 as found in complex C27. Many of the IR vibrations that are associated with Ru atom are 
found to be low frequency and weak vibration with low intensity (Table 5.4). However, some 
ruthenium vibrations like out(NRuNC) or out(CNRuN) as in complexes C6, C9-C11, C15 are among 
the prominent vibrations. Also, in complexes with cymene unit (C25 to C40), the vibrations like 
(HCCRu) are found to occur at high frequencies (around 1370 to 1000 cm-1) though with low 
intensity. As shown in Table 5.4, in many of the complexes, the RuN vibrations are weaker and found 
at lower frequency than RuCl.  
5.3.3 The 1H-NMR chemical shift of the complexes 
 The theoretical and the experimental 
1
H-NMR shifts of the complexes are shown in Table 5.5. 
The computational values were obtained through direct subtraction of the proton isotropic shielding 
tensor of the TMS from that of the each of the proton in the complexes while the fitting values were 
obtained using the fitting equation. The experimental and theoretical 
1
H-NMR shifts for many of the 
complexes are in good agreement. The computation gives significant insight into the NMR spectra of 
the complexes. The general observation is that the proton that are directed towards the Ru metal centre 
are characterised with more shielding effect which results in lower shift while reverse is the case of the 
292 
protons that are directed towards the chloride or carbonyl group. The common trend in the proton shift 
of the complexes follow the order CH3 < Ccym-H < Ccym-arene-H < CH2 < C4-H < Cpz-H < COOH < 
Cbpyr-H < CHOO < NH. In some complexes the strong effect of the Ru atom shielding effect and Cl or 
carbonyl deshielding effect cause a change in the order. In many of the complexes, the proton shift of 
the CH2 linker of the pyrazole derivatives are low and very close to that of the methyl shift except 
where any of the protons is directed toward the Cl atom. The proton shifts of the CH2 group in 
complexes C10 and C21 are having a very wide variation as a result of one of the two hydrogen atoms 
being very close to the Cl atom. The proton shift of the CHCOO in complex C6 is found be far higher 
theoretically (11.4349, 12.0581) than what is observed experimentally (8.5) because the theoretical 
model is pointing toward the Cl atom. Also, in many other complexes like C9, C11, the proton shift of 
CHOO is very high when directed toward the Cl atom. The reverse is the case for the proton shift of the 
CHOO and Hmeta (i.e. C3-H) which are sometimes found lower than the C4-H because of their close 
range to metal atom especially in complexes like C2 without Cl atom. Also very low proton shift is 
observed in precursor complex ST3 for the methyl H atom that is pointed towards Ru atom while those 
pointing towards the Cl atom have a very high shift. Likewise in complex C36 a higher proton shifts 
(>4.00) were observed for some of the methyl group protons because of being directed towards the Cl 
atom. In the complexes with the pyrazole derivatives with CHCOOH as linker, the proton shift of the 
CHCOO and COOH are within a close range of which either of the two can be smaller than the other.  
 There are many peculiar features observed in some of the complexes. In the experimental 
proton shift of complex C8, only the methyl and hydroxyl shift are very obvious while the rest are not 
observed. This observation can best be explained from the computed theoretical shift which shows that 
there is a very high possibility that the other proton shifts are within the same value of the OH. In 
complex C19, the methyl H atom that is pointing towards the C=O have higher proton shift compared 
to the one pointing toward the Cl atom. We observed in complex C7 that if the H atom of the methyl is 
pointing towards the Ru atom, then a very low shift is usually observed which could be responsible for 
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the lower shift observed experimentally (as low as 0.5318) for some of the methyl H atoms. This lower 
proton shift as a result of being close to the Ru atom is observed theoretically and experimentally in 
complex C3 where the methyl H atoms pointing towards the Ru atom have a very low shift (theor. 
0.0440, exp. 0.4400). The strong singlet shift at 6.60 observed experimentally in the precursor complex 
ST4 is an indication that one of the linking CH2 hydrogen atom is very close to the Ru but those of the 
theoretical method are very close to the Cl atoms leading to a higher shift (11.1008 and 18.5331). The 
computational proton shift of the Ccy-H in complex C38 is lower than the experimental because it is 
pointing towards the direction of the Ru atom which enhances its shielding. There is possibility that the 
experimental proton shift for COOH in complex C38 is pointing toward the direction of the Ru atom 
which result to its experimental shift being lower than the theoretical. The proton shift of the CH3 and 
also that of the CH in cym group is lower than those of bdmpzpy group as observed in complexes C40. 
Also, the proton shift of the CH in cymene ring of complex C39 are within the range of 5.00 to 6.50 
while the CH of bpzpy unit is having the highest shift of 7.30 to 8.94. The CH of the para proton of the 
phenyl group and the ortho of the pz group of the bphpza are having the highest proton shift in complex 
C32. In complexes C25-C27, possibly the experimental NH is pointing towards Ru atom which 
resulted in significant lower proton shift compared to the theoretical. 
 
5.3.4 31P-NMR chemical shift 
The phosphorus chemical shift of some of the synthesised cationic complexes were carried out 
experimentally only to confirm successful stabilization of the cationic complexes with PF6
-
 ion. The 
31
P-NMR shift obtained for the complexes C2-C4, C28 and C30-C40 are -144.5958, -144.6007, -
144.6131, -144.5888, -144.6079, -144.6171, -144.6129, -144.6127, -144.6026, -144.6019, -144.6138, -
144.6138, -144.6145, -144.6137 and -144.6153 respectively. This is a clear indication that the cationic 
complexes were successfully synthesised and stabilized with PF6
-
 counter ion. The values obtained for 
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31
P-NMR shift of the cationic ruthenium complexes are very similar to what have been reported in the 
literature for the cationic complexes stabilized with PF6
-
 [427]. 
 
5.3.5 13C-NMR chemical shift 
 Since a very high correlation was observed between the theoretical and experimental proton 
shift, the structures of the complexes were further elucidated using the theoretical 
13
C-NMR chemical 
shift as shown in Table 5.6. Just as was observed in the proton shift, the Ru atom causes a lower shift 
effect of carbon atoms that are directed toward it while the Cl or carbonyl atom causes a higher shift. 
Despite the effects of the Ru, Cl and carbonyl group on the carbon shift, these effects do not 
significantly alter the order of the carbon shifts which make the 
13
C-NMR more predictable than the 
1
H-NMR. The carbon shifts commonly follow the order CH3 < Ccym-H < CH2 < CHCOOH < Ccym-arene 
< Cpyr-meta < C4 < C3 < C5 < Cothers < CHCOOH. There are little exceptions to the given order. The 
carbon shift of C3 in the complex C8 is having the highest shift while COOH carbon shift is in between 
the C3 and C5 shifts. Just as shown in the order, the Cpyr-meta atoms that are at meta position of the 
pyridine unit of the tridentates as found in complexes C23 and C24 are having shift lower than the C4 
of the pyrazole unit. The methyl group of the precursor complex ST1 have the highest carbon shifts 
among all the methyl group in the complexes. As can be seen in complex C15, the methyl group results 
to the de-shielding of its anchoring C atom which consequentially results to high 
13
C-NMR shift. The 
two methyl group in complex C13 have the same carbon shift as the two C4 of complex C12.  
 
5.3.6 15N-NMR chemical shift 
 In order to study the differences in the shielding of the nitrogen atoms based on their chemical 
environment, we have computed the nitrogen shift of the coordinating nitrogen on pyrazole derivatives 
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(*N), on the phn or pyr derivative (**N) and the nitrogen on the pyrazole derivatives that are not 
available for metal coordination (N). The general observation as presented in Table 5.7 is that in many 
of the complexes the nitrogen shift of the N atoms are higher in magnitude than both *N and **N 
atoms which is an indication that N is more shielded than the coordinating *N and **N atoms. 
However, in complexes with tridentates ligands (bdmpzpy and bpzpy), there are variation to the 
observation. The **N coordinating centre on the pyridine unit of the tridentates are having the highest 
magnitude of nitrogen shift (more shielded) among all the nitrogen atoms presence in cymene 
containing Ru complexes (C39 and C40) while the reverse is the case in the Ru complexes without 
cymene as found in complexes C23 and C24. The coordinating **N of the other bidentates like the 
dmbpyr, bpyr, dcbpyr, phn, dmphn and dcphn are having the nitrogen shift lower in magnitude (highly 
de-shielded) than both non-coordinating (N) and coordinating (*N) of the pz derivatives.  
 
5.3.7 99Ru-NMR chemical shift 
 The 
99
Ru-NMR chemical shifts of the complexes are shown in Table 5.8. The interesting 
features of the ruthenium chemical shift is that the ST3 and ST4 which have four chloride atoms have 
the highest shielding of the Ru atom which consequentially leads to lower chemical shifts. Also, the Ru 
atom of the complexes with the cymene group (i.e. C25-C40) are more shielded (characterised with 
lower shift) while those with bdmpza, bdmpzm and bphpza have the lowest shielding of Ru atom 
which consequentially lead to their highest shift of 
99
Ru-NMR. 
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Figure 5.1: The representation of the ligands which where used in the syntheses of the Ru complexes 
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Figure 5.2: The IR plots of the complexes showing the correlation of the experimental (red) and the 
theoretical (black). 
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CHAPTER SIX 
6 SUMMARY, CONCLUSION AND RECOMMENDATION 
 
6.1 Summary 
 In this thesis, the literature review of the Ru-based complexes as promising alternative to cis-
platin were presented in Chapter One and Two. In addressing some of the pressing challenges like lack 
of proper knowledge of the targets of Ru-based complexes, complication of their chemistry and 
instability, we have adopted different theoretical methods to elucidate the geometrical stability, 
spectroscopic properties and predicting the possible targets through docking as presented in Chapter 
Three. The experimental methods use for the synthesis of the ligands used for the synthesis of all our 
Ru complexes and their computational studies are presented in Chapter Four while Chapter Five gives 
information about the experimental synthesis, characterization and theoretical elucidation of the 
synthesised complexes. 
 In subsection 3.3.1, several quantum properties including the NEDA and QTAIM are computed 
on three models of RAPTA-C complexes using DFT with hybrid functional and basis set with ECP and 
without ECP. Several interesting correlations within the observed properties and also with the reported 
experimental behaviours of these complexes including their biological activities presented. The study 
shows that the stability of the two complexes with bidentate ligands is associated with their high 
hydrogen bonding stability and existence of stronger non-covalent metal-ligand bonds. The energy 
decomposition analysis indicated that inter-atomic interactions in the three forms of RAPTA-C 
complexes and their stability are governed by the charge transfer term with significant contributions 
from polarization and electrostatic terms. The higher stability of complex 1 and 2 over 3 comes from 
the lower exchange repulsion and a higher polarization contributions to their stability which agree 
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perfectly with the experimental observation. Our results provide insight into the nature of 
intramolecular forces that influence the structural stability of the three complexes [313]. 
 In subsection 3.3.2, the computational properties of the 6-toluene and 6-trifluorotoluene half-
sandwich Ru(II) anticancer complexes and their respective hydrated complexes were computed using 
DFT method and the quantum theory of atoms in a molecule (QTAIM) analysis. The interatomic 
properties that are crucial in understanding the non-covalent interactions and the stability of these 
complexes were considered. We observed that high polarization, charge transfer and strong networks of 
intramolecular hydrogen bond (HB) interactions significant influenced the stability of these complexes. 
The trifluorotoluene and the hydrated models are characterised with higher charge transfer, 
polarizability, synergistic effect of ligand fragments, stronger and higher HB interactions that support 
their reported experimental anticancer activities and the mechanism of their activation by hydrolysis. 
The complexes are predominantly characterised with metal to ligand charge transfer [314]. 
 In subsection 3.3.3, the factors that determine the stability and the effects of non-covalent 
interaction on the 6-arene ruthenium anticancer complexes are determined using DFT method. The 
intramolecular and intra-atomic properties were computed for two models of these half-sandwich 
ruthenium anticancer complexes and their respective hydrated forms. The results showed that the 
stability of these complexes depends largely on the network of hydrogen bonds (HB), strong nature of 
charge transfer, polarizability and electrostatic energies that exist within the complexes. The hydrogen 
bonds strength was found to be related to the reported anticancer activities and the activation of the 
complexes by hydration. The metal-ligand bonds were found to be a closed shell systems characterised 
by high positive Laplacian values of electron density. Two of the complexes are found to be 
predominantly characterised with LMCT while the other two are predominately characterised with 
MLCT [315]. 
 In subsection 3.3.4, the intramolecular properties of five sets of ruthenium based anticancer 
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complexes have been theoretically studied using DFT method. The values of the energies show that 
PBE0 functional is good for the optimization of the metal complexes. The computed properties with 
minimal basis set or ECP basis sets reproduce the orders in reference higher basis set. The results 
shows that these complexes are thermodynamically stable and the stability is significantly enhanced 
through the high level of polarizability (POL), charge transfer (CT) and electrostatic (ES) contributions 
which may contribute to their biological effects. The presence of carboxylic unit waS found to enhance 
the contributions of these factors. The QTAIM atomic properties of ruthenium changed significantly 
with changes in the chemical environment of the complexes. The NEDA analysis shows that these type 
of complexes are predominantly characterised with ligand to metal charge transfer (LMCT).  
 DFT method was applied to study the thermodynamic and spectroscopic properties of three Ru-
based complexes in Subsection 3.4.1. Possible reasons for the reported experimental stability of 
complexes 1 and 2 with bidentate chelating ligands over complex 3 were explained using the computed 
properties. The results show that the trend in their thermodynamic, hyperpolarizabilities, 
magnetizabilities and the NMR isotropic shielding agree well with many of their experimental 
properties which can be used to explain the reported differences in their stability, hydrolysis and 
anticancer activities. We also found out that these complexes that were originally designed as 
anticancer agents have high hyperpolarizabilities which suggest that they can also act as good non-
linear optical (NLO) materials [316]. 
 In subsection 3.4.2, computational method was used to study the correlation between the 
hydrolysis and the anticancer activities of selected Ru(II)-based complexes. Interestingly, the 
mechanism of activation by hydrolysis and their consequential anticancer activities was found to be 
associated with favourable thermodynamic changes, higher hyperpolarizability (ß), lower band-gap and 
higher first-order net current. The Fermi Contact (FC) and Spin Dipole (SD) were found to be the two 
most significant Ramsey terms that determine the spin-spin couplings (J(HZ)) of most of the existing 
bonds in the complexes. Many of the computed properties give insights into the change in the 
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chemistry of the complexes due to hydrolysis. Besides strong correlations of the computed properties to 
the anticancer activities of the complexes, using the quantum theory of atoms in a molecule (QTAIM) 
to analysed the spectroscopic properties shows a stronger correlation between the spectroscopic 
properties of Ru atom to the reported anticancer activities than the sum over of the spectroscopic 
properties of all atoms in the complexes [317]. 
 In subsection 3.4.3, different density functional methods (DFT) were used to optimize and study 
the chemistry of five potential anticancer complexes in terms of their electronic, conductive and 
spectroscopic properties. Many of the computed properties in addition to the IR and QTAIM analysis of 
the NMR are dipole moment vector (i), linear polarizability tensor (ij), first hyperpolarizability 
tensors (ijk), polarizability exaltation index () and chemical hardness () of the complexes. A stable 
low energy geometries were obtained using basis set with effective core potential (ECP) approximation 
but in the computation of atomic or molecular properties, the Ru metal atom is better treated with 
higher all electron basis set like DGDZVP. The spectroscopic features like the IR of the metal-ligand 
bonds, the isotropiC-NMR shielding tensor of the coordinated atoms are significantly influenced by the 
chemical environment of the participating atoms. The carboxylic and pyrazole units were found to 
significantly enhance the polarizabilities and hyperpolarizabilities of the complexes while the chloride 
only improves the polarity of the complexes. Fermi contact (FC) have the highest effect followed by 
the PSO among all the four Ramsey term which defined the total spin-spin coupling constant J(HZ) of 
these complexes. 
 In subsection 3.5.1, the interactions of selected Ru(II)-based complexes with different cancer 
receptors were carried out through computational docking. In an effort to search for better alternatives 
to cis-platin and its derivatives that are nonselective cytotoxic anticancer agents, many metal based 
complexes especially that of Ru(II)-based complexes with potential alternative targets other than 
universal target like DNA have been suggested. This subsection focus more on finding alternative 
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protein targets other than DNA for some Ru(II)-based complexes using computational docking as a 
means of addressing commonly reported research challenges on the lack of proper understanding of the 
anticancer targets of Ru-based complexes. The observed interactions through our docking study show 
that, besides predicted targets like Cat B, HP-NCP and Kinase which is in good agreement with what 
they have been experimentally suggested as possible target of Ru-based anticancer agents, other targets 
like RNR and HDAC7 were proposed. The fast majority of the complexes are on the average have 
good interaction with rHA which will enhance their pharmacokinetic properties and some of the 
complexes also are suggested to have the potential for dual roles of acting as anticancer and as 
antimalarial agents because they are found to bind favourably with DNA-Gyrase [318].  
 In subsection 3.5.2, some promising anticancer complexes of Ru(II) such as RAPTA based 
complexes formulated as [Ru(η6-p-cymene)L2(pta)] and those with unusual ligands were docked 
against receptors using Autodock, Glide and Gold. Cat B and Kinases receptors have been 
experimentally confirmed as possible targets of the complexes and are also predicted by the three 
methods as one of the most targeted receptors while Top II and HDAC7 are predicted by two and one 
of the methods as the best targets. The interesting features of the binding of the complexes show that 
some of the complexes preferentially target specific macromolecule unlike the other which is an 
indication of their specificity and probable therapeutic combination without severe side effect that may 
come from competition for the same target. Also, introduction of unusual ligands were found to 
significantly improve the activities of most of the complexes studied. Strong correlations were 
observed for the predicted binding sites and the orientation of the complexes within the binding site by 
the three methods of docking. However there were observable disparities in the ranking of the 
complexes by the three method of docking especially that of Glide [319]. 
 In subsection 3.5.3, Molegro and Autodock were used to predict the anticancer activities of 
selected Ru(II) complexes against twelve anticancer targets. Unlike the organic molecules, reports on 
docking of metal complexes are very few mainly due to inadequacy of force fields in docking packages 
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to appropriately characterised the metal atoms which thus hinder their use in rational design of metal-
based drugs. We observed that introducing the quantum calculated atomic charges of the optimized 
geometries significantly improved the docking predictions of these anticancer metallocompounds. Most 
of our newly proposed metallocompounds were found theoretically as better anticancer 
metallocompounds than all the experimentally proposed RAPTA complexes. An interesting features of 
strong interactions of new modelled of metallocompounds against both base edge of DNA strands 
suggest similar mechanisms of anticancer activities to cis-platin. There is possibility of covalent 
bonding between the metal centre of the metallocompounds and the residues of the receptor DNA-1, 
DNA-2, HDAC7, HIS and RNR. However, the results suggest the possibility of metals positioning the 
coordinated ligands for optimal receptor interactions and synergistic effects rather than forming 
covalent bond [320].  
 In section 4.3, the spectroscopic and the geometric properties of four ligands with pyrazole unit 
were studied at both experimental and computational levels. The computational results are perfectly in 
agreement with the experimental results especially in terms of the spectroscopic properties. The 
spectroscopic features as well as the computed properties were used to establish the successful 
synthesis of bdmpzm and bdmpza ligands. The theoretical and the experimental IR and Raman spectra 
significantly help in distinguishing the four ligands. The results show that the Raman spectra is better 
applicable in characterising the CH3 deformation, the C-H, CNN and CCNNout of the ligands but 
vibrations like N-H in dmpz and O-H, C=O in bdmpza were observed to be Raman inactive. 
Significant variations were observed among the two available *N atoms characterising the bidentate 
features of bdmpzm, bdmpza and bdcpzm which indicate possible different affinities for metal 
coordination. Also the result suggest that bdmpza will be the best starting material for NLO application 
than other while bdcpzm is predicted to have potential of been a poor coordinating ligand. 
 In section 4.4, two pyrazole (pz) derivatives (bpzm and bpza) were synthesised and 
characterised by spectroscopic analysis. Many of the functional groups in these ligands were found to 
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be Raman active which also helps in their spectroscopic elucidation. The electronic, spectroscopic and 
conductivity properties of pz, bpzm, bpza and bpzpya were further studied using DFT methods. The 
computed properties such as the IR, 
1
H-NMR, 
13
C-NMR and UV are found to be highly correlated with 
the experimental values. Many of the computed properties like the dipole, band gap, hyperpolarizability 
and reactivity are in the order of bpzpya > bpza > bpzm > pz.  
 In section 4.5, the electronic and spectroscopic properties of seven pyrazole derivatives were 
studied. Four out of the seven ligands were synthesised and characterised experimentally. The 
excitation properties computed using the TDDFT shows that most of the experimentally observed 
absorptions of the ligands are predominantly from either the HOMO or HOMO-1 to LUMO or 
LUMO+1. The characteristic features of the *N atoms (i.e. metal available coordinating centre) shows 
that the carboxylic unit may possibly decrease the metal affinity of the pyrazole unit while the pyridine 
unit will increase the affinity. The conductivity properties of the seven ligands are in the order of 
bdmpzpy > bpzpy > bphpza > bdcpzpy > phpz > dcpz. 
 In section 4.6, the experimental and theoretical properties of six ligands comprising of three 
bipyridine and three phenanthroline derivatives were studied. The carboxylic units in the ligands result 
to increase in the dipole and anisotropic properties of the molecules while the methyl group result to 
increase in the isotropic shielding tensor of the molecules. Most of the observed UV max in the 
ligands are predominantly excitation of electrons from the HOMO-2 or HOMO-1 or HOMO to the 
LUMO of the ligands. The ligand dcphn is predicted to be the best starting material for non-linear 
optical (NLO) application due to its far higher first static hyperpolarizability tensor compared to other 
ligands and its lowest band gap.  
 In Chapter Five, forty Ru(II) complexes were synthesised from four ruthenium precursors and 
their spectroscopic features are elucidated using theoretical methods. A very high correlation was 
observed between experimental and theoretical characterisation of the complexes which is an indication 
of strong agreement between the experimentally synthesised and theoretically predicted complexes. 
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The theoretical approach significantly helps to elucidate and give more detail insight into the 
complicated chemistry of the complexes. The experimentally observed IR peaks are reproduced 
theoretically for many of the complexes. All the peaks including the fingerprint region that is know to 
be relevant for the structural peculiarities and equally known to be difficult are successfully assigned 
using the potential energy distribution (PED) method. The general trend in the 
1
H-NMR chemical shift 
is CH3 < Ccym-H < Ccym-arene-H < CH2 < C4-H < Cpz-H < COOH < Cbpyr-H < CHOO < NH; in 
13
C-NMR 
is CH3 < Ccym-H < CH2 < CHCOOH < Ccym-arene < Cpyr-meta < C4 < C3 < C5 < Cothers < CHCOOH, in 
15
N-NMR N > **N > *N while the 
99
Ru-NMR chemical shift in Cymene containing complexes are 
lower than the complexes without Cymene group. However, the presence of Ru atom in the complexes 
results to a more shielding effect and consequential lower shift of the 1H-NMR and 13C-NMR of the 
respective H and C atoms that are pointing toward the Ru atom while reverse is the case of those that 
are directed towards the Cl and carbonyl groups in the complexes. 
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6.2 Conclusion 
 In the subsection 3.3.1, an insight into the molecular properties like NBO, NEDA and QTAIM 
analysis of three Ru-based complexes named RAPTA-C derivatives were provided using DFT method. 
From the NBO analysis, we observed that the three complexes are characterised mainly with MLCT 
specifically from the Ru atom to the lone pair C atoms of arene π-ligand. The NEDA analysis shows 
that the stability of the complexes is most significantly determined by charge transfer followed by 
strong polarization and electrostatic. There is a high synergistic effect of the metal coordinated ligands 
on each other resulted to high induced dipole and induced stabilization energy which further support 
the reported differences in their stability and anticancer activities. The QTAIM analyses show that the 
metal-ligand bond are characterised with non-sharing bonds. We equally found out that the presence of 
NNA in our system with ECP basis set is a complete computational artefact which suggests the 
application of ECP will be appropriate in computing intramolecular properties if limited to metal atom 
only in these complexes. In addition to the significant effect of the bonds (r) and (r), bond 
ellipticity and the ratio of the potential energy density and Lagrangian form of kinetic energy density 
(V/G) are found to significantly influence the reported differences in the hydrolysis of the complexes. 
The intraatomic properties computed show that the atomic electrons are largely localized except for the 
H atoms which are highly delocalized and can be easily perturbed. The atomic volume V(A) of the Ru 
atom is found higher in complex RAPTA-C than complexes carbo-RAPTA-C ans oxalo-RAPTA-C 
derivatives which can further enhance its reported higher hydrolysis and anticancer activities.  
 The computed geometrical properties of the ruthenium complexes named RAPTA-T, RAPTA-
CF3 and their hydrated models in subsection 3.3.2 give additional features. The hydrolysed complexes 
are characterised with higher values of induced dipole and hydrogen bond stabilization energy which 
gives a rational behind the reported activation of the complexes by hydrolysis. The complexes with 
trifluorotoluene are found to be characterised with stronger and higher number of intramolecular HB 
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interactions which consequently resulted in higher charge transfer, polarizability and synergistic effects 
(higher induced dipole and induced wavefunction) of the different units of ligands that made up the 
complexes. The synergistic effects can lead to highly cytotoxic species as it was experimentally 
suggested [62]. The computed properties of four ruthenium complexes named RAPTA-B and RAPTA-
C and their respective hydrated forms were also studied in subsection 3.3.3. The hydrated form of 
RAPTA-C have the highest interaction energy as a result of its significant high CT, ES and POL which 
gives a possible distinguishing features that can contribute to its reported higher anticancer activities 
above the other [13].  
 The results obtained in subsection 3.3.4 for five different complexes shows that the PBE0 
functional combined with ECP basis set is the most appropriate for the geometry optimization of these 
type of metal complexes in agreement with the literature [332, 333] because it gives the energy values 
closed to that of higher perturbation MP2 method. The set of complexes considered here can be 
described in terms of ligand to metal charge transfer (LMCT). The strength of the Ru-N bonds in the 
complexes follows the order 5>2>4>3>1 if only the mid Ru-N bond is considered in complexes 4 and 5 
which agrees with the experimental report of stronger Ru-Nbpyr bonds than R-Nphn [379]. The presence 
of the carboxylic unit in the ligands significantly contributes to the H-bonding networks and the total 
hydrogen stability of the complexes. 
 In subsection 3.4.1, we have been able to establish the possible relationship between the 
reported experimental properties of three RAPTA complexes and the computed properties like the 
thermodynamic, magnetizabilities, spin-spin coupling,  NMR shielding, dipole moment and 
hyperpolarizabilities. More significantly, inferences are made to the reported anticancer activities of the 
three complexes based on the correlation of the computed properties to the trend of their anticancer 
activities. The possibility of these complexes also acting as good NLO materials was also suggested 
giving indication that higher polarizability may play significant role in their anticancer activities. In 
subsection 3.4.2, the electronic, conductive and spectroscopic properties of the eight Ru(II)-based 
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complexes were computed. Also, we point out significant changes in the computed properties from the 
unhydrated to the hydrated complexes as a known mechanism of activation of ruthenium anticancer 
complexes. Other properties computed are the magnetizability contribution (Iso(A)), dipole ((A)) and 
magnetic shielding tensor (Iso(A)) using QTAIM analysis as implemented in AIMAll. There is a high 
relation between the anticancer activities and the conductivities of the complexes as the activated 
complexes which are the hydrated forms are characterised with higher hyperpolarizability (ß) and 
lower band-gap. We observed that the properties of the Ru atom in each of the complexes like higher 
Intra_Iso(A) and lower magnitude of Iso(A) correlate significantly with their reported anticancer 
activities. Similarly, five different ruthenium complexes were studied in subsection 3.4.3. The 
difference in the IR features of these complexes shows that there is either bathochromic or 
hypsochromic shift in the IR vibration modes of the metal-ligand bonds like Ru-N as a result of the 
change in the chemical environment of participating atoms. Among the Ramsey terms, the FC was 
found to have the greatest values and also have the highest effect on the computed spin-spin coupling 
constant J(HZ) followed by the PSO and SD while the DSO is least. Complexes 2 and 3 are predicted 
as the most stable characterised with the highest value of  and the most reactive with lowest 
band gap (very soft) [395].  
 In subsection 3.5.1, metal complexes are docked against receptors using Autodock and Glide 
docking packages. The general feature of the docking shows that the inhibitory activities do not directly 
depend on the number of the HB nor number of the MR but on their strength and other possible 
interactions that could not be directly accounted for. Also, there is preference for better HB in the 
interactions of the complexes with receptor residues than assuming an orientation that would allow 
close MR interaction. Autodock and Glide docking give preference to some of the newly proposed 
complexes like 8, 9, 10 and 11 as inhibitors of most of the receptors than many of the RAPTA's 
complexes. One of the observed reasons for the preferential binding of the newly proposed structures is 
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observed to be as a result of enhanced HB especially through the presence of carboxilic group in some 
of the new complexes. Besides experimentally established possible anticancer target of Ru(II)-based 
complexes like Cat B, other suggested targets are HDAC7, Kinase, TS and HP-NCP. Also, RNR as a 
rare anticancer target of many complexes is predicted as alternative anticancer target for the newly 
proposed complexes 9 and10. A similar study was carried out in subsection 3.5.2 using Autodock, 
Glide and Gold on different sets of ruthenium complexes in relation to RAPTA complexes. Cat B was 
found to be the most possible target for these complexes as predicted by the three packages. Also, Top 
II and Kinase are predicted by two of the packages as some of the best targets while HP-NCP, HDAC7, 
DNA-Gyrase and RNR are suggested by one of the packages as part of the best targets. It is equally 
interesting to point out the three docking packages clearly show that the activities of the RAPTA 
complexes are enhanced when hydrolysed which is in good agreement with the experimental reports [8, 
17, 37, 38]. Predictions from Autodock and Gold correlate better with experimental and each other than 
Glide. Also in subsection 3.5.3, we have presented the binding affinities of new model 
metallocompounds and that of RAPTA complexes using Molegro and Autodock methods of docking. 
Making use of the atomic charges of the metallocompounds obtained from the optimized quantum 
calculation significantly improved the predicted activities and ranking of the metallocompounds which 
strongly agree with the available experimental results. In summary, the new models are predicted by all 
the methods of docking among the best two inhibitors of all the receptors. Considering the ranking of 
both relax and constrained Molegro docking, the best targets of the metallocompounds are of the order 
HDAC7 > DNA-1 > rHA > Cat B > DNA-2 > Gyrase > TrXR > Top II > TS > RNR > HiS > Kinase 
except in few cases like complex 12 that prefers Cat B to rHA. The RAPTA complexes are suggested to 
target protein like Cat B and HDAC7 better than DNA which further confirms the experimental 
suggestion that DNA may not be the target of RAPTA complexes [9].  
 In section 4.3-4.6 of chapter four, the electronic and spectroscopic properties of the different 
sets of ligands were studied experimentally and computationally. Very strong agreements were 
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observed between the experimental and theoretical results. The finger print region of the IR and Raman 
spectra helps in distinguishing the ligands. Some of the vibration which are very prominent in Raman 
spectral are CH3 deformation, the C-H, CNN and CCNNout of the ligands. However, some vibrations 
like N-H in dmpz and O-H, C=O in bdmpza is observed to be Raman inactive. Both the experimentally 
and theoretical obtained proton and carbon shifts significantly distinguishes the ligands. Using both the 
direct method and fitting methods, the calculated 
1
H-NMR shift agrees strongly with the experiment. 
Also, the experimental values of the 
13
C-NMR shift were better reproduced using the direct method but 
the fitting method underestimate the shifts. The most contributing part of the Ramsey terms to the J-
coupling of the bonds is the FC followed by the PSO while the SD and DSO have the smallest 
contribution. The stronger *N-N bond within a pair is characterised with shorter bond length, higher 
magnitude of 2(r), (r), V and Ven and lower ellipticity (). The usual H-bonding are 
characterised with negative values of J-Coupling compared to the unusual types that have positive 
values. In many of the ligands, the absorptions are found to be the result of the predominant nature of 
HOMO→LUMO, HOMO-1→LUMO+1, HOMO-1→LUMO and HOMO-2→LUMO.  
 In the Chapter Five, we have reported the successful synthesis of forty Ru(II)-based (C1-C40) 
complexes from four precursors (ST1-ST4). Their spectroscopic with the geometrical properties are 
elucidated using the computational methods. A very strong agreement between the experimental and 
theoretical IR and 
1
H-NMR which further confirm that the expected Ru(II)-based complexes were 
successfully synthesised. Deeper insights into the complicated chemistry of the complexes are obtained 
through the theoretical studies of their 
13
C-NMR, 
15
N-NMR and 
99
Ru-NMR. Interestingly, many of IR 
peak intensities which were observed experimentally were also reproduced theoretically. The major 
difference between the experimental and theoretical is the OH vibration which is observed theoretically 
at higher frequency and well separated from the CH vibration compared to the experimental. Also, the 
theoretical predicted high intensity of vibration around 2600 to 2700 cm
-1
 in complexes like C6, C8, 
C9 and C11 are experimentally found to be very weak. With the application of potential energy 
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distribution (PED) methods on the theoretical IR, the experimentally observed peaks including the 
difficult fingerprint region are fully assigned. The IR vibrations that are dominantly strong in the 
complexes are stretching (SO), (C=O), (C-O) (NN), (CH), (NC), (CC), (OH), bending 
(OCO), (HOC), (HCC) and torsional (HCSRu), (HCCO), (HCCC), (HCCN), (HOCC). In the 
starting complexes ST3-ST4, the (RuCl) IR vibration is very strong but its intensity in the complexes 
C1-C40 is lower. Both experimental and theoretical 
1
H-NMR shift are in good agreement as found in 
many of the complexes. The general observation is that the protons that are directed towards the Ru 
metal centre are characterised with more shielding effect which results to lower shift while the reverse 
is the case of the protons that are directed towards the chloride or carbonyl group. The common trend 
in the proton shift of the complexes follow the order CH3 < Ccym-H < Ccym-arene-H < CH2 < C4-H < Cpz-
H < COOH < Cbpyr-H < CHOO < NH. However, in some complexes the strong effect of the Ru atom 
shielding effect and Cl or carbonyl deshielding effect cause a change in the order. In many of the 
complexes, the proton shift of the linker CH2 of the pyrazole derivatives are low and very close to that 
of the methyl shift except where any of its protons is directed toward the Cl atom.  
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6.3 Recommendation for further study 
 One of the major barrier in the rational design of the Ru(II)-based complexes as anticancer 
agent is the lack of the proper knowledge of their targets. Also many of the complexes that are found to 
be active in vivo are not active in vitro. It is therefore recommended that beyond the cytotoxic 
screening of the Ru(II) complexes to determine their anticancer activity, there should be more detail 
screening of the complexes against enzymes like Cat B, Top II, BRAF Kinases, HDAC7 which have 
been found in this study as probably the best possible targets. 
 This study shows that there is high possibility of improving the anticancer activities of Ru(II)-
based complexes by the introduction of functional group like carboxylic unit. It is therefore recommend 
that more research effort need to be concentrated on the functionalization of the promising Ru(II)-based 
complexes, synthesis and study of their anticancer activity. 
 Many of the originally designed Ru(II)-based anticancer complexes have very high 
hyperpolarizability properties and lower band gap which are found to correlate with some of their 
anticancer activities. It will be necessary to study the electronic properties like the conductivity of some 
of these complexes which may shed some light about their potentials as anticancer agents.  
 In this study, it was established that stability of the complexes are greatly influence by 
properties like charge transfer, polarizability and electro static interactions. It is recommended that 
electronic properties be put into consideration in the design of Ru(II)-based complexes for application 
in cancer chemotherapy. 
 In addressing the problems associated with complicated chemistry of Ru(II)-based complexes, 
this study has found out that computational models can be useful tools to better understand the 
chemistry and interpretation of the spectroscopic properties of the complexes. It is therefore 
recommended that the computational modelling of the Ru(II)-based complexes should be given priority 
328 
in the rational design of potential anticancer compounds in order to understand their chemistry and get 
lead compounds. 
 There is a clear evidence that despite the limitations of docking methods to accurately predict 
the activities of metal complexes unlike their organic counterparts due to lack of appropriate force 
fields to represent heavy metal atoms, relativity problem of heavy metal and their polarizability, this 
study has been able to show that very good experimental correlation of the activities of these 
complexes can be found theoretically especially if the quantum parameter like the atomic charge is 
introduced into the docking. It is recommended that more research be carried out on the application of 
docking packages for the prediction of biological activities of metal-based complexes. 
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Appendix 
Table 3.1: Hybridization and Lewis properties in terms of percentage total electron density distribution 
of the complexes 
Molecule 
Ru(II) Valence 
rating Total Lewis Val non-Lewis 
Rydberg non-
Lewis 
1 4d7 < 5s1 
97.536% of 
138 2.28% 0.18% 
2 4d7< 5s1 
97.384% of 
123 2.44% 0.18% 
3 4d7< 5s1 
97.692% of 
118 2.17% 0.14% 
 
 
Table 3.2: The polarization of the bonding and the antibonding interaction of Ru(II) with ligand atoms  
Com
p. 
Lewis 
Bonding  
 (cA-squared) cA → (cA-squared) cA Non-
Lewis 
Antibondi
ng 
 (cA-squared) cA ← (cA-squared) cA 
1 (Ru-P)  (33.77%) 0.5811*→ (66.23%) 0.8138* 
 
(Ru-O)  (66.23%) 0.8138* ← (33.77%) -0.5811* 
  
 (Ru-O)  (23.78%) 0.4876* → (76.22%) 0.8731*
    
 
(Ru-O)  (76.22%) 0.8731* ← (23.78%) -0.4876* 
  
2 (Ru-O)   (21.12%) 0.4595*→ (78.88%) 0.8882* (Ru-O)  (78.88%) 0.8882* ← (21.12%) -0.4595*
  
 (Ru-O)  (21.12%) 0.4595* → (78.88%) 0.8882* 
 
(Ru-O)  (78.88%) 0.8882* ← (21.12%) -0.4595*
  
 (Ru-P)  (27.65%) 0.5258* → (72.35%) 0.8506*
    
 
(Ru-P)  (72.35%) 0.8506* ← (27.65%) -0.5258* 
3 (Ru-P)  (31.47%) 0.5610*→(68.53%) 0.8278* 
 
(Ru-P)  (68.53%) 0.8278*Ru ← (31.47%) -
0.5610*  
 (Ru-Cl)  (25.01%) 0.5001* → (74.99%) 0.8660*(Ru-Cl)  (74.99%) 0.8660* ← (25.01%) -0.5001*
  
 (Ru-Cl)  (24.81%) 0.4981* → (75.19%) 0.8671*
    
 
(Ru-Cl)  (75.19%) 0.8671* ← (24.81%) -0.4981* 
 Polarization coefficient cA is the values with starred superscript and the square of it is percentage of the NBO (cA-squared) 
on each hybrid orbitals (in parentheses). 
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Table 3.3: The delocalization orbitals with their second perturbation energies (E
(2)
) and the principal 
delocalizing acceptor orbitals associated with each donor NBO 
 
Co
m
p. 
Delocalization of Electrons Delocalization donor orbitals Delocalization acceptor orbitals 
 Donor → Acceptor E
(2) 
kcal/m
ol 
Donor occ E   Pda Acceptor   e
-
 gain   E 
1 1. (Ru-O) → 14. 
*(Cu=Ou)  
15.28 1. (Ru – O)  0.91961 -0.40736 14(v) 8. LP*(Ru)  0.18716e 0.62863  
 2. LP(Ru) → 10. 
LP*(C) 
 22.72 2 LP(Ru)  0.87731 -0.24553 5(r) 10. LP*(C)  0.46262e -
0.16897  
 3. LP(Ru) → 9. LP*(C)  22.81 3. LP(Ru)  0.86880  -0.24643 9(r) 11. LP*(C)  0.44596e -
0.15605  
 3. LP(Ru) → 11. 
LP*(C) 
 16.20 5. LP(C)  0.49558 -0.17000 10(v) 12. *(Ru-P)  0.24037e 0.09092  
 4. LP(O) → 8. LP*(Ru)  28.12 6. LP(C)  0.47745  -0.15262 11(v) 13. *(Ru–
O) 
 0.23514e -
0.02340  
 5. LP(C) → 13. *(Ru-
O) 
 43.01 7. LP(C)  0.49089  -0.16396 10(v) 14. *(Cu 
=Ou) 
 0.11939e 0.05793 
 6. LP(C) → 12. *(Ru-
P) 
 22.70         
 7. LP(C) → 8. LP*(Ru)   10.43        
2 1. (Ru-O) →13. 
*(Ru–O) 
 11.05  1. (Ru-O)  0.95924 -0.45566  14(g) 12. *(Ru-O)  0.19245e 0.15949 
 1. (Ru-O) →14. 
*(Ru–P) 
 16.36 2. (Ru-O)  0.95720 -0.45611  14(g) 13. *(Ru-O)   0.19124e 0.16517 
 2. (Ru-O) →12. 
*(Ru-O) 
 11.16 3. (Ru-P)  0.93212  -0.37226 13(g) 14. *(Ru-P)  0.16022e 0.37628 
 2. (Ru–O) →14. 
*(Ru-P) 
 16.63 4. LP(Ru)  0.87205  -0.24879  11(r) 9. LP*(C)  0.47318e -
0.16517 
 3. (Ru-P) →12. 
*(Ru-O) 
 18.88  5. LP(Ru)  0.86829   -0.25044  9(r) 10. LP*(C)  0.46416e -
0.16617 
 3. (Ru-P)→13. 
*(Ru-O) 
 19.15  6. LP(C)  0.47536  -0.16503 10(v) 11. LP*(C)  0.46586e -
0.16623 
 3. (Ru-P) → 14. 
*(Ru-P) 
 10.82 7. LP(C)  0.48942   -0.17244  8(v) 7. LP(C)  0.48942e -
0.17244 
 4. LP(Ru) → 7. LP(C)  10.60 8. LP(C)  0.48061 -0.17301  7(v) 8. LP(C)  0.48061e -
0.17301  
 4. LP(Ru) → 11. 
LP*(C) 
 20.77        
 5. LP(Ru) → 8. LP(C)  12.47         
 5. LP (3)Ru → 9.  15.31         
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LP*(C) 
 5. LP (3)Ru → 10. 
LP*(C) 
 13.19        
 6. LP (1) C →12. 
*(Ru-O) 
 19.17        
 7. LP (1) C →13. 
*(Ru-O) 
 22.04        
 8. LP (1) C →12. 
*(Ru-O) 
 20.45         
3 1. (Ru-P) → 13. 
*(Ru-Cl)  
19.10 1. (Ru-P)  0.93656 -0.37418 13(g)  12. *(Ru-P) 0.17416e 0.25537 
 1. (Ru-P) → 14. 
*(Ru-Cl) 
 18.99 2. (Ru-Cl)   0.96973 -0.35980  12(g) 13. *(Ru-
Cl) 
 0.18941e 0.18579  
 2. (Ru-Cl) → 12. 
*(Ru-P)  
15.19 3. (Ru-Cl)   0.97066 -0.36016 12(g) 14. *(Ru-
Cl) 
 0.18893e 0.19315  
 2.  (Ru-Cl) → 14. 
*(Ru-Cl) 
 10.97 4. LP(Ru)   0.88393  -0.24641  6(r) 6. LP(C)  0.47037e -
0.16731 
 3.  (Ru-Cl) →12. 
*(Ru-P) 
 15.34  5. LP(Ru)  0.85983  -0.24181  9(r) 7. LP(C)  0.48229e -
0.17163 
 3. (Ru-Cl) → 13. 
*(Ru-Cl) 
 11.19 6. LP(C)  0.47037  -0.16731  8(v) 8. LP(C)   0.47524e -
0.16572 
 4. LP(Ru) → 6. LP(C)  14.58 7. LP(C)  0.48229  -0.17163  6(v) 9. LP*(C)   0.46719e -
0.16497 
 4. LP(Ru) → 10. 
LP*(C) 
 10.36  8. LP(C)  0.47524  -0.16572  6(v) 10. LP*(C)  0.46930e  -
0.15866 
 4. LP(Ru) → 11. 
LP*(C) 
 10.12     11. LP*(C)  0.46202e -
0.15019  
 5. LP(Ru) → 7. LP(C)   16.75         
 5. LP(Ru) → 8. LP(C)   11.72         
 5. LP(Ru) → 9. LP*(C)  22.31        
 6. LP(C) → 14. *(Ru-
Cl) 
 16.80         
 7. LP(C) →13. *(Ru-
Cl)  
19.99        
 8. LP(C)→ 14. *(Ru-
Cl)  
 20.25        
The orbital analyses in the table are defined in terms donor orbital, acceptor orbital, second perturbation energy or stability 
energy (E(2) in kcal/mol), occupancy (occ), principal delocalizing acceptor (Pda), quantity of electron gain (e
- gain) and 
energy level (E). The topological relationship to the NBO if attached to the same atom (geminal, "g"), to an adjacent bonded 
atom (vicinal, "v"), or to a more remote ("r") site. The amount of electron loss is calculated on the basis of NPA at the same 
level. The supercript ―u‖ is on atoms that are not bonded to metal atom. 
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Table 3.4: Bond Order shows other atoms in the molecule that are interacting with the metal centre. 
 Complex 1 Complex 2 Complex 3 
 Bond length   Bond order Bond length  Bond order  Bond length  Bond order 
Ru-P 2.430   0.590  2.429  0.594   2.420  0.725  
Ru-C 2.211  0.439  2.230  0.382  2.231  0.416 
 2.233  0.423 2.225  0.390 2.205  0.441 
 2.266   0.348  2.232  0.413 2.198  0.446 
 2.249  0.429  2.241  0.411 2.205  0.452  
  2.213  0.433 2.239  0.429 2.236  0.392 
 2.232  0.425  2.231  0.442  2.295  0.332 
Ru-Cl   2.500  0.966    
   2.496  0.947    
Ru-O  2.100  0.659 2.090  0.682    
 2.119  0.667 2.086  0.673   
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Table 3.5: Electron density critical point analysis of selected bonds in the complexes 
Complex 1 
 Bonds (r)  Ellipticity K 
BPL-
GBL_I V G L V/G 
pta Ru1-P16 0.073 0.155 0.186 0.017 0.011 -0.072 0.055 -0.039 -1.300 
arene Ru1-C9 0.077 0.265 0.214 0.011 0.010 -0.089 0.078 -0.066 -1.146 
 Ru1-C14 0.071 0.291 1.009 0.008 0.029 -0.089 0.081 -0.073 -1.098 
 Ru1-C19 0.068 0.277 2.574 0.007 0.027 -0.083 0.076 -0.069 -1.091 
 Ru1-C24 0.072 0.256 0.400 0.009 0.013 -0.083 0.073 -0.064 -1.129 
 Ru1-C31 0.071 0.295 1.647 0.007 0.046 -0.088 0.081 -0.074 -1.088 
 Ru1-C29 0.077 0.262 0.331 0.011 0.010 -0.089 0.077 -0.066 -1.149 
bidentate Ru1-O8 0.086 0.379 0.215 0.011 0.005 -0.118 0.106 -0.095 -1.107 
 Ru1-O27 0.083 0.351 0.296 0.012 0.001 -0.112 0.100 -0.088 -1.121 
HB O8-H35 0.006 0.032 0.259 -0.002 0.009 -0.004 0.006 -0.008 -0.627 
 C11-H49 0.003 0.013 1.235 -0.001 0.028 -0.002 0.003 -0.003 -0.723 
 O30-H47 0.008 0.039 0.090 -0.002 0.016 -0.005 0.007 -0.010 -0.687 
 H42-H54 0.005 0.019 0.213 -0.001 0.026 -0.002 0.003 -0.005 -0.608 
 H58-H62 0.003 0.011 0.603 -0.001 0.133 -0.001 0.002 -0.003 -0.681 
 O30-H61 0.010 0.047 0.672 -0.002 0.096 -0.007 0.009 -0.012 -0.739 
Complex 2 
pta Ru1-P17 0.073 0.162 0.166 0.016 0.010 -0.073 0.057 -0.041 -1.287 
arene Ru1-C2 0.073 0.281 0.767 0.009 0.017 -0.088 0.079 -0.070 -1.114 
 Ru1-C6 0.074 0.265 0.397 0.010 0.016 -0.086 0.076 -0.066 -1.129 
 Ru1-C5 0.074 0.274 0.561 0.010 0.015 -0.088 0.078 -0.069 -1.125 
 Ru1-C7 0.072 0.272 0.627 0.009 0.023 -0.085 0.077 -0.068 -1.113 
 Ru1-C10 0.073 0.274 0.414 0.009 0.018 -0.087 0.078 -0.068 -1.121 
 Ru1-C8 0.071 0.282 0.865 0.008 0.027 -0.087 0.079 -0.071 -1.103 
bidentate Ru1-O12 0.090 0.383 0.194 0.013 0.003 -0.122 0.109 -0.096 -1.121 
 Ru1-O16 0.091 0.386 0.196 0.013 0.004 -0.123 0.110 -0.096 -1.122 
HB C15-H41 0.007 0.027 1.073 -0.001 0.057 -0.004 0.005 -0.007 -0.740 
 H45-H51 0.003 0.011 0.200 -0.001 0.015 -0.001 0.002 -0.003 -0.572 
Complex 3 
pta Ru1-P13 0.076 0.149 0.143 0.018 0.008 -0.073 0.055 -0.037 -1.327 
arene Ru1-C6 0.074 0.278 0.691 0.010 0.017 -0.089 0.079 -0.070 -1.121 
 Ru1-C9 0.077 0.290 0.425 0.011 0.017 -0.094 0.083 -0.072 -1.130 
 Ru1-C10 0.077 0.282 0.266 0.012 0.014 -0.094 0.082 -0.071 -1.141 
 Ru1-C14 0.077 0.269 0.263 0.012 0.013 -0.091 0.079 -0.067 -1.149 
 Ru1-C16 0.072 0.277 1.380 0.008 0.030 -0.086 0.077 -0.069 -1.106 
mono Ru1-Cl19 0.056 0.182 0.203 0.005 0.002 -0.055 0.050 -0.046 -1.094 
 Ru1-Cl20 0.056 0.184 0.169 0.005 0.001 -0.056 0.051 -0.046 -1.095 
HB C2-H29 0.006 0.019 0.854 -0.001 0.121 -0.003 0.004 -0.005 -0.768 
 Cl20-H43 0.010 0.034 0.911 -0.001 0.113 -0.006 0.007 -0.009 -0.814 
 Cl20-H46 0.010 0.032 0.043 -0.001 0.006 -0.005 0.007 -0.008 -0.775 
(r) is electron density,  is the Laplancian of (r), BPL – GBL_I is Bond strain, V is virial field (potential energy 
density), G is Lagrangian form of kinetic energy density, K is hamiltonian form of kinetic energy density, L (i.e. K – G) is 
lagrangian density which is (-1/4)  while ―Ratio‖ is V/G i.e. PE/KE (the higher its magnitude the stronger the Bond). 
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Table 3.6. The summary of the natural energy decomposition analysis showing the components of 
interaction energy in kcal/mol. 
 
Mol. CT   ES   POL  XC   DEF  SE  Electrical   Core   E 
CraptaC -402.36  -157.67  -169.20 -176.52  834.49  82.1   -244.77 575.87   -71.26  
OraptaC -1079.81  -151.05  -162.92  512.35  810.4  78.58   -235.39  1244.16  -71.04 
raptaC -819.55  -162.03  -133.42 28.28 818.81  63.52  -231.93 983.58  -67.90 
The components of energy are defines in terms of charge transfer (CT), electrostatic interaction (ES); polarization (POL); 
electrical self-energy (SE); exchange interaction (XC); deformation energy (DEF), Electrical (ES+POL+SE), Core 
(XC+DEF-SE) and Total Interaction energy which is the final net H-bond energy (E = Electrical + Core + CT) 
 
 
Table 3.7: The correlation in the properties of the electron density critical point analysis of complexes 
1, 2 and 3
(r)#  Ellipticity K BPL.GBL_I V G L Ratio 
1 -0.85 -0.57 0.96 -0.62 -0.86 0.39 0.85 -0.71 
2 -0.83 -0.72 0.96 -0.74 -0.83 0.36 0.83 -0.64 
3 -0.92 -0.65 0.98 -0.60 -0.95 0.23 0.92 -0.80 
 Ellipticity K BPL.GBL_I V G L Ratio  
1 0.57 -0.81 0.47 0.54 0.09 -1.00 0.90  
2 0.65 -0.76 0.62 0.45 0.16 -1.00 0.88  
3 0.60 -0.95 0.43 0.82 0.13 -1.00 0.90  
Ellipticity# K BPL.GBL_I V G L Ratio   
1 -0.53 0.51 0.41 -0.06 -0.57 0.48   
2 -0.62 0.93 0.46 -0.07 -0.65 0.57   
3 -0.61 0.74 0.56 -0.05 -0.60 0.55   
K# BPL.GBL_I V G L Ratio    
1 -0.53 -0.93 0.51 0.81 -0.60    
2 -0.62 -0.92 0.52 0.76 -0.50    
3 -0.51 -0.96 0.19 0.95 -0.77    
BPL.GBL_I
# V G L Ratio V# G L Ratio 
1 0.46 -0.20 -0.47 0.48 1 -0.79 -0.54 0.31 
2 0.49 -0.13 -0.62 0.57 2 -0.81 -0.45 0.16 
3 0.55 -0.29 -0.43 0.44 3 -0.46 -0.82 0.59 
G# L Ratio L# Ratio     
1 -0.09 0.29 1 -0.90     
2 -0.16 0.40 2 -0.88     
3 -0.13 0.37 3 -0.90     
The parameters that are denoted with ―#‖ shows they are in correlation with every other parameters that are in that row 
except where ―#‖ appears again. 
 
 
 
 
 
Table 3.8: Selected atomic properties derived through the quantum theory of atoms in molecules 
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analysis of the complexes 
 
Complex 1 
 Name q(A) L(A) K(A) 
K_Scaled(
A)
Intra(A
)
Bond(
A) (A) N(A) 
%Loc(A
) 
%Deloc
(A,A') 
Vol(A), 
0.001 
 Ru1 0.86 9.73E-04 4402.36 -4426.58 0.30 1.64 1.34 43.14 94.18 5.82 98.66 
arene C9 -0.11 -4.40E-05 37.63 -37.83 0.22 0.20 0.21 6.11 65.89 34.11 72.17 
 C14 -0.14 4.30E-05 37.62 -37.83 0.24 0.11 0.17 6.14 65.99 34.01 76.94 
 C19 -0.08 7.00E-06 37.63 -37.83 0.21 0.40 0.59 6.08 64.89 35.11 59.57 
 C24 -0.10 -1.72E-04 37.62 -37.83 0.09 0.27 0.18 6.10 64.87 35.13 61.55 
 C29 -0.12 -1.13E-04 37.65 -37.85 0.26 0.36 0.62 6.12 66.00 34.00 71.17 
 C31 -0.12 4.70E-05 37.62 -37.83 0.25 0.18 0.23 6.12 65.96 34.04 76.32 
pta P16 0.89 2.52E-04 338.04 -339.90 1.03 0.56 1.59 14.11 86.02 13.98 102.66 
Bident
ate O8 -0.95 -7.00E-06 74.55 -74.96 0.13 0.79 0.85 8.95 86.36 13.64 93.88 
 O27 -0.95 1.75E-04 74.54 -74.95 0.17 1.01 1.14 8.95 86.87 13.13 96.01 
Complex 2 
 Ru1 0.85 -1.02E-04 4402.39 -4426.23 0.37 1.83 1.65 43.15 94.12 5.88 99.40 
arene C2 -0.11 -1.10E-04 37.62 -37.82 0.24 0.18 0.10 6.11 65.99 34.01 75.24 
 C5 -0.12 -1.64E-04 37.63 -37.83 0.22 0.16 0.11 6.12 65.92 34.08 73.72 
 C6 -0.07 -1.78E-04 37.61 -37.82 0.16 0.30 0.16 6.07 64.86 35.14 61.43 
 C7 -0.08 -3.30E-05 37.63 -37.83 0.19 0.20 0.05 6.08 64.80 35.20 58.62 
 C8 -0.14 -8.80E-05 37.62 -37.82 0.22 0.11 0.14 6.14 65.93 34.07 76.13 
 C10 -0.15 -6.10E-05 37.62 -37.83 0.20 0.10 0.13 6.15 65.89 34.11 74.16 
pta P17 0.82 -3.60E-05 338.07 -339.90 1.05 0.21 1.18 14.18 85.99 14.01 106.82 
Bident
ate O12 -0.92 1.64E-04 74.54 -74.95 0.14 0.97 1.05 8.92 86.23 13.77 95.79 
 O16 -0.92 1.57E-04 74.54 -74.95 0.15 1.02 1.10 8.92 86.23 13.77 96.49 
Complex 3 
 Ru1 0.64 -7.21E-04 4402.59 -4424.39 0.37 1.39 1.48 43.36 94.05 5.95 107.89 
arene C6 -0.09 -2.56E-04 37.62 -37.80 0.12 0.17 0.05 6.09 64.84 35.16 61.85 
 C9 -0.13 -1.78E-04 37.62 -37.81 0.23 0.11 0.14 6.13 65.90 34.10 74.95 
 C10 -0.11 -3.14E-04 37.63 -37.81 0.24 0.17 0.10 6.11 65.85 34.15 73.23 
 C14 -0.12 -1.86E-04 37.63 -37.81 0.23 0.18 0.09 6.12 65.84 34.16 71.88 
 C16 -0.12 -1.28E-04 37.63 -37.81 0.23 0.18 0.11 6.12 65.87 34.13 72.90 
 C17 -0.06 4.70E-05 37.61 -37.80 0.19 0.05 0.15 6.06 64.88 35.12 59.93 
pta P13 0.86 -2.50E-05 338.02 -339.70 1.02 0.11 0.96 14.14 85.74 14.26 99.49 
mono Cl19 -0.58 9.80E-05 456.63 -458.89 0.14 1.40 1.54 17.58 96.71 3.29 237.25 
 Cl20 -0.57 7.60E-05 456.63 -458.89 0.14 0.66 0.79 17.57 96.55 3.45 231.48 
 q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %Loc(A) is percentage of average number of electrons localized in 
atom A, K_Scaled(A) is approximation to virial-based total energy of atom A, Intra(A) is magnitude of Intraatomic dipole 
moment of atom A, Ee(A) is contribution of atom A to electronic energy of molecule, %Deloc(A,A') is the percentage of 
electron delocalization index of atom A and Vol(A) is the volume bounded by an isosurface of the electron density 
distribution (0.001) and by interatomic surfaces of atom A. 
 
 
Table 3.9: Bond Order shows the metal-ligand bonds for the B3LYP/DGDZVP(Ru)|6-31+G(d,p) 
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treated systems 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
 Bonds  
Bond 
distance 
(Å) 
Bond 
Order Bonds 
Bond 
distance 
(Å) 
Bond 
Order Bonds 
Bond 
distance 
(Å) 
Bond 
Order Bonds 
Bond 
distance 
(Å) 
Bond 
Order 
arene Ru-C6 2.198 0.424 Ru-C2 2.221 0.396 Ru-C6 2.215 0.4 Ru-C6 2.223 0.383 
 Ru-C9 2.216 0.407 Ru-C3 2.218 0.446 Ru-C8 2.213 0.411 Ru-C8 2.241 0.42 
 Ru-C10 2.246 0.331 Ru-C7 2.229 0.415 Ru-C12 2.197 0.4 Ru-C12 2.182 0.418 
 Ru-C14 2.235 0.41 Ru-C8 2.272 0.35 Ru-C17 2.254 0.329 Ru-C17 2.277 0.361 
 Ru-C16 2.235 0.343 Ru-C13 2.181 0.463 Ru-C21 2.2 0.412 Ru-C21 2.18 0.446 
 Ru-C19 2.209 0.409 Ru-C14 2.261 0.328 Ru-C22 2.257 0.32 Ru-C22 2.283 0.31 
PTA Ru-P11 2.419 0.781 Ru-P12 2.435 0.744 Ru-P14 2.423 0.798 Ru-P14 2.443 0.754 
Others Ru-Cl2 2.496 0.834 Ru-O11 2.251 0.41 Ru-Cl11 2.483 0.875 Ru-O11 2.239 0.416 
 Ru-Cl20 2.493 0.834 Ru-Cl20 2.481 0.908 Ru-Cl23 2.487 0.854 Ru-Cl23 2.475 0.928 
 
 
 
1 Table 3.10: The polarization of the bonding interaction of Ru(II) with ligand atoms 
using B3LYP/DGDZVP(Ru)|6-31+G(d,p)  
 
Complex 1 
 Bond cA-squared cA Atom  cA-squared cA Atom  
(1) Ru-Cl2 22.71% 0.4765* Ru 77.29% 0.8792* Cl2 
(1) Ru-P11 28.37% 0.5326* Ru 71.63% 0.8463* P11 
 Ru-Cl20 22.58% 0.4752* Ru 77.42% 0.8799* Cl20 
Complex 2 
(1) Ru-P12 33.18% 0.5761* Ru 66.82% 0.8174* P12 
(1) Ru-Cl20 23.42% 0.4839* Ru 76.58% 0.8751* Cl20 
Complex 3 
(1) Ru-Cl11 23.55% 0.4853* Ru 76.45% 0.8744* Cl11 
(1) Ru-P14 29.82% 0.5461* Ru 70.18% 0.8377* P14 
(1) Ru-Cl23 23.41% 0.4838* Ru 76.59% 0.8752* Cl23 
Complex 4 
(1) Ru-P14 34.92% 0.5909* Ru 65.08% 0.8067* P14 
(1) Ru-Cl13 24.37% 0.4937* Ru 75.63% 0.8696* Cl23 
Polarization coefficient cA is the values with superscript ―*‖ and its percentage NBO is ―cA-squared‖ on each hybrid 
orbitals. 
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Table 3.11: The delocalization orbitals for the charge transfer with second perturbation energies (E2) 
greater than or equals to 10 Kcal/mol 
 
Complex 1 
Donor Acceptor 
E
2
 
Kcal/mol 
94 n(2) Ru 101 n(1) C9 15.66 
94 n(2) Ru 108 n*(1) C14 33.35 
94 n(2) Ru 417*(2) C10-C16 26.01 
95 n(3) Ru 101 n(1) C9 32.66 
95 n(3) Ru 103 n(1) C19 39.92 
95 n(3) Ru 107 n(1) C6 73.57 
95 n(3) Ru 108 n(1) C14 27.19 
13(1) C6-C9 396*(1) Ru-Cl20 15.32 
23(1) C10-C16 395* Ru-p11 12.79 
24(2) C10-C16 395* Ru-P11 39.25 
34(1) C14-C19 394* Ru-Cl2  14.99 
101 n(1) C9 396* Ru-Cl20 44.44 
103 n(1) C19 394* Ru-Cl2 46.59 
Complex 2 
91 n(2) Ru 93 n(1) C2 17.27 
91 n(2) Ru 104 n*(1) C7 22.37 
91 n(2) Ru 418*(2) C8-C14 23.14 
92 n(3) Ru 93 n(1) C2 25.99 
92 n(3) Ru 94 n(1) C3 45.94 
92 n(3) Ru 104 n(1) C7 19.22 
92 n(3) Ru 105 n(1) C13 52.84 
3(1) C2-C3 400*(1) Ru-Cl20 14.54 
18(1) C7-C13 103 n*(4) Ru 14.17 
19(1) C8-C14 399*(1) Ru-P12 10.73 
20(2) C8-C14 399*(1) Ru-P12 43.33 
93 n(1) C2 399*(1) Ru-P12 12.04 
93 n(1) C2 400*(1) Ru-Cl20 51.77 
94 n(1) C3 400*(1) Ru-Cl20 60.44 
97 n(2) O11 103 n*(4) Ru 51.84 
Complex 3 
2(1) Ru-P14 423*(1) Ru-Cl11 10.92 
2(1) Ru-P14 425*(1) Ru-Cl23 10.91 
98 n(2) Ru 101 n(1) C6 51.02 
98 n(2) Ru 119 n*(1) C8 31.34 
98 n(2) Ru 458*(2) C17-C22 20.1 
99 n(3) Ru 119 n*(1) C8 25.77 
99 n(3) Ru 448*(2) C12-C21 38.13 
25(1) C12-C21 423*(1) Ru-Cl11 16.13 
26(2) C12-C21 423*(1) Ru-Cl11 52.33 
35(1) C17-C22 424*(1) Ru-P14 12.46 
36(2) C17-C22 424*(1) Ru-P14 36.97 
101 n(1) C6 425*(1) Ru-Cl23 39.08 
Complex 4 
94 n(2) Ru 100 n(1) C8 18.7 
94 n(2) Ru 116 n*(1) C6 49.12 
94 n(2) Ru 464*(2) C17-C22 15.43 
95 n(3) Ru 100 n(1) C8 12.15 
95 n(3) Ru 106 n(1) C12 50.7 
360 
95 n(3) Ru 117 n*(1) C21 77.09 
15(1) C6-C8 430*(1) Ru-Cl23 13.46 
26(1) C12-C21 115 n*(4) Ru 14.63 
35(1) C17-C22 429*(1) Ru-P14 10.5 
36(2) C17-C22 429*(1) Ru-P14 40.48 
100 n(1) C8 430*(1) Ru-Cl23 66.76 
106 n(1) C12 115 n*(4) Ru 45.44 
106 n(1) C12 429*(1) Ru-P14 22.62 
105 n(2) O11 115 n*(4) Ru 53.44 
E(2) in kcal/mol is the second perturbation energy or stability energy, ―n‖ is lone pair and ―‖ is sigma bond 
 
 
Table 3.12: The principal delocalizing acceptor orbitals associated showing only the non-Lewis charge-
transfer acceptors from the for B3LYP/DGDZVP(Ru)|6-31G+(d,p) systems 
 
 Complex 1 
Acceptor 
orbital e- gain 
Energy 
(Hatree) 
394*(1) Ru-Cl2  0.31608 -0.02839 
395*(1) Ru-P11 0.29782 0.01188 
396*(1) Ru-Cl20 0.31292 -0.027 
108 n*(1) C14 0.96795 -0.17992 
417*(2) C10-C16 0.33081 -0.00328 
 Complex 2    
103 n*(4) Ru 0.349 -0.12843 
399*(1) Ru-P12 0.37892 -0.18713 
400*(1) Ru-Cl20 0.37243 -0.20633 
 Complex 3    
423* Ru-Cl11 0.30699 -0.03781 
424* Ru-P14 0.29048 0.0009 
425*(1) Ru-Cl23 0.31061 -0.03811 
119 n*(1) C8 0.96704 -0.19129 
448*(2) C12-C21 0.43603 -0.036 
 Complex 4    
115 n*(4) Ru 0.33789 -0.13532 
429*(1) Ru-P14 0.37099 -0.20007 
430*(1) Ru-Cl23 0.36914 -0.21941 
116 n*(1) C6 0.94061 -0.31983 
117 n*(1) C21 0.91202 -0.32273 
464*(2) C17-C22 0.31585 -0.15262 
―n‖ is lone pair and ―‖ is sigma bond 
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Table 3.13: The summary of the natural energy decomposition analysis (NEDA) showing the 
components of interaction energy in kcal/mol for the B3LYP/DGDZVP(Ru)|6-31+G(d,p) treated 
systems 
 
  Complex 1 Complex 2 Complex 3 Complex 4 
Electrostatic ES -202.73 -238.05 -199.29 -232.16 
Polarizabilit
y POL -617.07 -759.26 -622.79 -755.71 
 XC -178.19 219.22 -180.5 -178.96 
 DEF 1331.71 1635.67 1360.91 2119.7 
 SE 304.74 372.58 306.57 355.55 
Electrical 
ES+POL+S
E -515.06 -624.73 -515.51 -632.33 
Charge 
Transfer CT -374.59 -955.54 -394.74 -1041.52 
Core 
XC+DEF-
SE 848.77 1482.33 873.84 1585.19 
Total 
Interaction E -40.87 -97.94 -36.4 -88.66 
The components of energy are defines in terms of electrostatic interaction (ES); polarization (POL); electrical self-energy 
(SE); exchange interaction (XC); deformation energy (DEF), Electrical (ES+POL+SE), Core (XC+DEF-SE) and Total 
Interaction energy which is the final net H-bond energy (E = Electrical + Core + CT) 
 
 
Table 3.14: The summary of the natural energy decomposition analysis (NEDA) showing the 
components of interaction energy in kcal/mol for the PBE0/ECP(Ru, Cl, P)|6-31G* treated 
systems 
 
  1 2 3 4 
Electrostatic ES  -160.57  -157.95 -180.9 
Polarizabilit
y POL  -129.94  -134.23 -209.87 
Exchange 
interaction XC  251.3  266.41 -391.41 
lectrical self-
energy DEF  818.35  845.39 1550.57 
lectrical self-
energy SE  61.96  63.7 87.98 
Electrical  
ES+POL+S
E -228.55  -228.47 -302.78 
Charge 
Transfer CT  -844.65  -880.49 -883.95 
Core 
XC+DEF-
SE 1007.7  1048.09 1071.19 
Total 
Interaction E -65.5  -60.88 -115.55 
The components of energy are defines in terms of electrostatic interaction (ES); polarization (POL); electrical self-energy 
(SE); exchange interaction (XC); deformation energy (DEF), Electrical (ES+POL+SE), Core (XC+DEF-SE) and Total 
Interaction energy which is the final net H-Bond energy (E = Electrical + Core + CT) 
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Table 3.15: The induced energy (Hatree) and dipole values (Debye) due to synergistic effect of 
fragments on each other for B3LYP/DGDZVP(Ru)|6-31+G(d,p) treated systems 
 
 Fragments 
Induced 
Energy 
Induced 
Dipole 
Complex 1 
1 C6H12N3PCl -0.602871 1.38 
2 C7H8 -1.519335 0.78 
Complex 2 
1 C6H12N3PCl -0.740521 10.70 
2 C7H8 -1.404810 1.23 
3 H2O -0.461211 0.56 
Complex 3 
1 C6H12N3PCl -0.628114 2.34 
2 C7H5F3 -1.540632 0.84 
Complex 4 
1 C6H12N3PCl -1.484898 33.56 
2 C7H5F3 -1.422444 1.07 
3 H2O -0.470609 0.57 
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Table 3.16: Electron density critical point analysis of selected bonds in the four complexes using 
combined basis sets DGDZVP(Ru)|6-31+G(d,p) (all the data in atomic units) 
Complex 1 
Bonds
(r) 
(e/bohr
3
) (r)  K 
BPL - 
GBL_I V G L 
GBL_I 
(bohr) |V/G| 
Ru1 - C6 0.081 0.248 0.545 0.016 0.012 -0.095 0.079 -0.062 4.154 1.209 
Ru1 - C9 0.077 0.267 1.555 0.014 0.023 -0.094 0.081 -0.067 4.187 1.171 
Ru1 - C14 0.076 0.251 1.805 0.013 0.030 -0.090 0.076 -0.063 4.225 1.176 
Ru1 - C19 0.078 0.259 0.952 0.014 0.025 -0.093 0.079 -0.065 4.176 1.180 
Ru1 - P11 0.080 0.143 0.205 0.021 0.008 -0.077 0.056 -0.036 4.572 1.365 
Ru1 - Cl2 0.058 0.183 0.173 0.006 0.006 -0.057 0.051 -0.046 4.717 1.111 
Ru1 - Cl20 0.058 0.184 0.209 0.006 0.005 -0.058 0.052 -0.046 4.711 1.111 
Complex 2 
Ru1 - C2 0.077 0.254 1.321 0.014 0.023 -0.092 0.078 -0.064 4.197 1.182 
Ru1 - C3 0.077 0.248 0.707 0.014 0.017 -0.090 0.076 -0.062 4.192 1.187 
Ru1 - C7 0.076 0.252 1.974 0.013 0.021 -0.089 0.076 -0.063 4.213 1.172 
Ru1 - C13 0.083 0.239 0.353 0.019 0.013 -0.097 0.078 -0.060 4.123 1.237 
Ru1 - P12 0.080 0.127 0.183 0.021 0.003 -0.073 0.052 -0.032 4.602 1.396 
Ru1 - O11 0.055 0.313 0.505 -0.004 0.004 -0.071 0.075 -0.078 4.254 0.950 
Ru1 - Cl20 0.060 0.192 0.338 0.006 0.003 -0.060 0.054 -0.048 4.688 1.115 
Complex 3 
Ru1 - C6 0.078 0.269 2.184 0.014 0.035 -0.095 0.081 -0.067 4.186 1.171 
Ru1 - C8 0.078 0.252 0.773 0.015 0.015 -0.092 0.078 -0.063 4.181 1.187 
Ru1 - C12 0.080 0.276 0.927 0.016 0.019 -0.100 0.085 -0.069 4.152 1.185 
Ru1 - C21 0.080 0.252 0.592 0.016 0.014 -0.095 0.079 -0.063 4.158 1.202 
Ru1 - P14 0.081 0.132 0.181 0.021 0.006 -0.075 0.054 -0.033 4.580 1.392 
Ru1 - Cl11 0.060 0.184 0.184 0.006 0.005 -0.059 0.052 -0.046 4.692 1.121 
Ru1 - Cl23 0.059 0.184 0.193 0.006 0.002 -0.058 0.052 -0.046 4.700 1.117 
Complex 4 
Ru1 - C6 0.078 0.260 3.049 0.014 0.058 -0.093 0.079 -0.065 4.201 1.175 
Ru1 - C8 0.072 0.255 1.593 0.012 0.023 -0.087 0.075 -0.064 4.234 1.153 
Ru1 - C12 0.082 0.282 0.947 0.016 0.017 -0.102 0.086 -0.071 4.123 1.185 
Ru1 - C17 0.069 0.237 6.641 0.010 0.122 -0.079 0.069 -0.059 4.303 1.140 
Ru1 - C21 0.085 0.235 0.420 0.019 0.013 -0.098 0.078 -0.059 4.118 1.248 
Ru1 - P14 0.080 0.113 0.176 0.021 0.003 -0.071 0.050 -0.028 4.615 1.428 
Ru1 - O11 0.057 0.324 0.475 -0.004 0.003 -0.073 0.077 -0.081 4.231 0.950 
Ru1 - Cl23 0.061 0.191 0.279 0.007 0.003 -0.061 0.055 -0.048 4.677 1.123 
(r) is electron density, (r) is the Laplancian of Rho, BPL – GBL_I is Bond strain, V is virial field (potential energy 
density), G is Lagrangian form of kinetic energy density, K is hamiltonian form of kinetic energy density, L (i.e. K – G) is 
lagrangian density which is (-1/4)(r) while |V/G| is the ratio of PE to KE and the higher its magnitude the stronger the 
Bond. 
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Table 3.17: Correlation among the computed QTAIM Bond properties for the systems using combined 
basis sets DGDZVP(Ru)|6-31+G(d,p) 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
 
(r
)  |V/G| 
(r)  |V/G| 
(r)  |V/G| 
(r)  |V/G| 
(r) -0.94 -0.70 0.74 -0.91 -0.62 0.74 -0.90 -0.46 0.69 -0.88 -0.39 0.70 
(r) 1.00 0.71 -0.87 1.00 0.64 -0.85 1.00 0.58 -0.87 1.00 0.44 -0.85 
 0.71 1.00 -0.58 0.64 1.00 -0.55 0.58 1.00 -0.43 0.44 1.00 -0.33 
K -0.96 -0.70 0.73 -0.97 -0.61 0.72 -0.84 -0.49 0.59 -0.88 -0.40 0.63 
BPL - 
GBL_I 0.41 0.65 -0.39 0.27 0.34 -0.29 0.46 0.42 -0.40 0.54 0.83 -0.46 
V 0.86 0.65 -0.56 0.89 0.55 -0.58 0.60 0.35 -0.31 0.66 0.32 -0.37 
G 0.01 -0.07 -0.38 0.01 0.05 -0.40 0.09 0.05 -0.34 0.10 0.01 -0.34 
L -1.00 -0.71 0.87 -1.00 -0.64 0.85 -1.00 -0.58 0.87 -1.00 -0.44 0.85 
GBL_I 0.94 0.68 -0.88 0.93 0.61 -0.90 0.93 0.44 -0.84 0.91 0.37 -0.85 
V/G -0.87 -0.58 1.00 -0.85 -0.55 1.00 -0.87 -0.43 1.00 -0.85 -0.33 1.00 
 
 
 
Table 3.18: Electron density critical point analysis of selected bonds in the four complexes using 3-21G 
(all the data in atomic units) 
 
Complex 1 
 Bond (r) (r)  K 
BPL - 
GBL_I V G L 
GBL_I 
(Hatree) V/G 
arene Ru1-C6 7.83E-02 2.72E-01 2.17E-01 1.22E-02 1.16E-02 
-9.23E-
02 8.01E-02 
-6.79E-
02 4.15 -1.15 
 Ru1-C9 7.48E-02 2.90E-01 5.81E-01 9.87E-03 1.94E-02 
-9.22E-
02 8.23E-02 
-7.24E-
02 4.19 -1.12 
 Ru1-C10 7.00E-02 2.82E-01 
2.72E+0
0 6.97E-03 3.78E-02 
-8.45E-
02 7.75E-02 
-7.05E-
02 4.24 -1.09 
 Ru1-C14 7.38E-02 2.73E-01 5.92E-01 9.60E-03 1.65E-02 
-8.75E-
02 7.79E-02 
-6.83E-
02 4.22 -1.12 
 Ru1-C16 7.21E-02 2.74E-01 9.95E-01 8.55E-03 2.03E-02 
-8.57E-
02 7.72E-02 
-6.86E-
02 4.22 -1.11 
 Ru1-C19 7.57E-02 2.81E-01 3.54E-01 1.06E-02 1.64E-02 
-9.15E-
02 8.09E-02 
-7.03E-
02 4.17 -1.13 
mono Ru1-Cl2 5.65E-02 1.83E-01 1.55E-01 4.95E-03 2.54E-03 
-5.56E-
02 5.06E-02 
-4.57E-
02 4.72 -1.10 
 
Ru1-
Cl20 5.67E-02 1.84E-01 1.84E-01 5.02E-03 2.03E-03 
-5.59E-
02 5.09E-02 
-4.59E-
02 4.71 -1.10 
pta Ru1-P11 7.59E-02 1.46E-01 1.34E-01 1.84E-02 1.02E-02 
-7.33E-
02 5.50E-02 
-3.66E-
02 4.57 -1.33 
HB 
Cl2-
H25* 9.96E-03 3.37E-02 9.72E-01 
-1.35E-
03 8.95E-02 
-5.72E-
03 7.07E-03 
-8.43E-
03 5.30 -0.81 
 
C18-
H37* 5.18E-03 1.81E-02 7.60E-01 
-8.48E-
04 6.10E-02 
-2.82E-
03 3.67E-03 
-4.52E-
03 5.65 -0.77 
Complex 2 
arene Ru1-C2 7.49E-02 2.75E-01 5.25E-01 1.04E-02 1.61E-02 
-8.95E-
02 7.91E-02 
-6.87E-
02 4.20 -1.13 
 Ru1-C3 7.46E-02 2.67E-01 2.88E-01 1.05E-02 1.75E-02 
-8.77E-
02 7.72E-02 
-6.68E-
02 4.19 -1.14 
 Ru1-C7 7.43E-02 2.69E-01 6.75E-01 9.89E-03 1.93E-02 -8.70E- 7.71E-02 -6.72E- 4.21 -1.13 
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 Ru1-C8 6.73E-02 2.64E-01 
2.17E+0
0 6.52E-03 3.51E-02 
-7.90E-
02 7.24E-02 
-6.59E-
02 4.29 -1.09 
 Ru1-C13 8.10E-02 2.67E-01 1.17E-01 1.38E-02 1.44E-02 
-9.43E-
02 8.05E-02 
-6.67E-
02 4.12 -1.17 
mono Ru1-O11 6.04E-02 2.94E-01 3.42E-01 7.36E-03 3.85E-03 
-8.83E-
02 8.09E-02 
-7.36E-
02 4.25 -1.09 
 
Ru1-
Cl20 5.88E-02 1.89E-01 2.37E-01 5.98E-03 3.66E-03 
-5.91E-
02 5.32E-02 
-4.72E-
02 4.69 -1.11 
pta Ru1-P12 7.46E-02 1.30E-01 1.22E-01 1.81E-02 5.04E-03 
-6.88E-
02 5.07E-02 
-3.26E-
02 4.60 -1.36 
HB 
Cl20-
H41* 2.35E-02 8.97E-02 4.45E-01 
-1.78E-
03 1.30E-02 
-1.89E-
02 2.06E-02 
-2.24E-
02 4.35 -0.91 
 C6-H33* 4.17E-03 1.51E-02 6.57E-01 
-7.83E-
04 3.90E-01 
-2.21E-
03 2.99E-03 
-3.78E-
03 5.84 -0.74 
 
H23-
H26* 3.63E-03 1.35E-02 4.72E-01 
-9.30E-
04 5.36E-02 
-1.51E-
03 2.44E-03 
-3.37E-
03 4.79 -0.62 
Complex 3 
arene Ru1-C6 7.51E-02 2.91E-01 6.36E-01 9.79E-03 1.82E-02 
-9.24E-
02 8.26E-02 
-7.28E-
02 4.19 -1.12 
 Ru1-C8 7.54E-02 2.73E-01 3.22E-01 1.06E-02 1.38E-02 
-8.95E-
02 7.88E-02 
-6.82E-
02 4.18 -1.13 
 Ru1-C12 7.82E-02 3.03E-01 2.97E-01 1.16E-02 1.47E-02 
-9.89E-
02 8.74E-02 
-7.58E-
02 4.15 -1.13 
 Ru1-C17 6.93E-02 2.70E-01 
1.80E+0
0 7.11E-03 3.16E-02 
-8.18E-
02 7.47E-02 
-6.76E-
02 4.26 -1.10 
 Ru1-C21 7.76E-02 2.76E-01 2.42E-01 1.17E-02 1.35E-02 
-9.24E-
02 8.06E-02 
-6.89E-
02 4.16 -1.15 
mono 
Ru1-
Cl23 5.78E-02 1.82E-01 1.56E-01 5.45E-03 7.20E-04 
-5.65E-
02 5.10E-02 
-4.56E-
02 4.70 -1.11 
 
Ru1-
Cl11 5.85E-02 1.83E-01 1.56E-01 5.68E-03 2.50E-03 
-5.70E-
02 5.13E-02 
-4.57E-
02 4.69 -1.11 
pta Ru1-P14 7.62E-02 1.36E-01 1.19E-01 1.88E-02 8.93E-03 
-7.15E-
02 5.27E-02 
-3.39E-
02 4.58 -1.36 
HB 
Cl11-
H32* 9.90E-03 3.30E-02 
1.23E+0
0 
-1.25E-
03 1.60E-01 
-5.76E-
03 7.01E-03 
-8.26E-
03 5.34 -0.82 
 
F18-
H34* 5.78E-03 3.76E-02 5.42E-02 
-2.87E-
03 1.05E-02 
-3.65E-
03 6.52E-03 
-9.39E-
03 4.83 -0.56 
 F7-H34* 4.47E-03 2.93E-02 2.03E-01 
-2.37E-
03 2.57E-02 
-2.59E-
03 4.95E-03 
-7.32E-
03 5.04 -0.52 
 F7-H25* 3.89E-03 2.71E-02 2.93E-01 
-2.22E-
03 3.13E-02 
-2.33E-
03 4.55E-03 
-6.77E-
03 5.05 -0.51 
Complex 4 
arene Ru1-C6 7.50E-02 2.77E-01 7.88E-01 9.97E-03 1.68E-02 
-8.93E-
02 7.93E-02 
-6.93E-
02 4.20 -1.13 
 Ru1-C8 7.03E-02 2.70E-01 6.29E-01 8.31E-03 2.23E-02 
-8.41E-
02 7.58E-02 
-6.75E-
02 4.23 -1.11 
 Ru1-C12 7.97E-02 3.03E-01 2.87E-01 1.23E-02 1.79E-02 
-1.00E-
01 8.81E-02 
-7.58E-
02 4.12 -1.14 
 Ru1-C17 6.72E-02 2.49E-01 9.69E-01 7.13E-03 2.17E-02 
-7.65E-
02 6.93E-02 
-6.22E-
02 4.30 -1.10 
 Ru1-C21 8.19E-02 2.61E-01 1.65E-01 1.43E-02 1.31E-02 
-9.39E-
02 7.96E-02 
-6.53E-
02 4.12 -1.18 
mono Ru1-O11 6.19E-02 3.02E-01 3.19E-01 7.61E-03 3.00E-03 
-9.07E-
02 8.30E-02 
-7.54E-
02 4.23 -1.09 
 
Ru1-
Cl23 5.98E-02 1.87E-01 1.91E-01 6.38E-03 4.32E-03 
-5.96E-
02 5.32E-02 
-4.68E-
02 4.68 -1.12 
366 
pta Ru1-P14 7.44E-02 1.18E-01 1.18E-01 1.83E-02 4.66E-03 
-6.61E-
02 4.78E-02 
-2.95E-
02 4.62 -1.38 
HB 
Cl23-
H42* 2.35E-02 9.06E-02 4.70E-01 
-1.81E-
03 1.41E-02 
-1.90E-
02 2.08E-02 
-2.26E-
02 4.34 -0.91 
 
F18-
H34* 4.77E-03 3.16E-02 8.86E-02 
-2.52E-
03 1.79E-02 
-2.85E-
03 5.37E-03 
-7.89E-
03 4.96 -0.53 
 F7-H34* 4.68E-03 3.14E-02 1.15E-01 
-2.50E-
03 2.63E-02 
-2.83E-
03 5.34E-03 
-7.84E-
03 4.98 -0.53 
 F7-H25* 4.01E-03 2.82E-02 3.89E-01 
-2.29E-
03 4.10E-02 
-2.47E-
03 4.76E-03 
-7.04E-
03 5.03 -0.52 
(r) is electron density, (r) is the Laplancian of Rho, BPL – GBL_I is Bond strain, V is virial field (potential energy 
density), G is Lagrangian form of kinetic energy density, K is hamiltonian form of kinetic energy density, L (i.e. K – G) is 
lagrangian density which is (-1/4)(r) while V/G is the ratio of PE to KE and the higher its magnitude the stronger the 
Bond. 
 
 
 
 
 
 
Table 3.19: Selected atomic properties derived through the quantum theory of atoms in molecules 
analysis for the four complexes using combined basis sets DGDZVP(Ru)|6-31+G(d,p) (all the data 
in atomic units) 
 
Complex 1 
 q(A) L(A) K(A) 
K_Scaled
(A) 
|Intra(
A)| 
|Bond(A
)| |(A)| N(A) LI(A) 
%Loc(
A) 
DI(A,A'
)/2 
%Deloc
(A,A') 
Vol(A),
0.001 
Ru1 0.78 -3.86E-04 4435.17 -4445.88 0.43 1.39 1.55 43.22 40.56 93.85 2.66 6.15 110.75 
C6 -0.06 -7.00E-05 37.85 -37.94 0.11 0.14 0.07 6.06 3.96 65.39 2.10 34.61 71.16 
C9 -0.08 -9.20E-05 37.85 -37.94 0.10 0.04 0.08 6.08 3.98 65.43 2.10 34.57 73.61 
C10 -0.05 -6.70E-05 37.84 -37.93 0.14 0.12 0.08 6.05 3.97 65.54 2.08 34.46 74.57 
C14 -0.05 -5.00E-06 37.85 -37.94 0.06 0.04 0.02 6.05 3.90 64.47 2.15 35.53 60.56 
C16 -0.05 -1.36E-04 37.84 -37.93 0.13 0.13 0.08 6.05 3.96 65.46 2.09 34.54 72.87 
C19 -0.07 2.28E-04 37.86 -37.95 0.10 0.10 0.07 6.07 3.97 65.43 2.10 34.57 71.83 
P11 0.94 -5.00E-04 340.20 -341.02 1.11 0.46 0.72 14.06 12.03 85.53 2.04 14.47 99.10 
Cl2 -0.59 9.30E-05 459.38 -460.49 0.12 1.20 1.29 17.59 17.00 96.62 0.60 3.38 243.78 
Cl20 -0.59 9.90E-05 459.38 -460.49 0.12 1.23 1.31 17.59 17.00 96.62 0.59 3.38 244.32 
Complex 2 
Ru1 0.78 -1.21E-04 4435.16 -4446.25 0.37 0.64 0.78 43.22 40.65 94.07 2.56 5.93 113.29 
C2 -0.06 -2.82E-04 37.85 -37.94 0.10 0.06 0.09 6.06 3.97 65.44 2.09 34.56 71.86 
C3 -0.07 -2.94E-04 37.84 -37.94 0.12 0.08 0.08 6.07 3.97 65.52 2.09 34.48 73.55 
C7 -0.05 -4.15E-04 37.85 -37.94 0.09 0.14 0.21 6.05 3.90 64.55 2.14 35.45 59.94 
C8 -0.05 -4.40E-05 37.84 -37.93 0.11 0.07 0.05 6.05 3.97 65.58 2.08 34.42 74.85 
C13 -0.06 -1.12E-04 37.86 -37.96 0.10 0.11 0.09 6.06 3.97 65.45 2.09 34.55 69.95 
C14 -0.03 1.90E-05 37.83 -37.93 0.14 0.13 0.05 6.03 3.95 65.56 2.08 34.44 73.59 
P12 0.75 -2.42E-04 340.29 -341.15 1.01 0.57 0.44 14.25 12.18 85.46 2.07 14.54 106.96 
O11 -1.16 6.70E-05 75.20 -75.39 0.32 0.87 0.70 9.16 8.22 89.77 0.94 10.23 119.81 
Cl20 -0.56 4.80E-05 459.40 -460.55 0.07 1.31 1.25 17.56 16.92 96.39 0.63 3.61 233.67 
Complex 3 
Ru1 0.79 6.95E-04 4435.15 -4446.40 0.43 1.92 2.14 43.21 40.53 93.79 2.68 6.21 109.65 
C6 -0.06 -1.17E-04 37.84 -37.93 0.14 0.15 0.04 6.06 3.96 65.40 2.10 34.60 72.23 
C8 -0.05 -2.00E-04 37.84 -37.94 0.12 0.20 0.09 6.05 3.96 65.41 2.09 34.59 71.76 
C12 -0.04 -1.08E-04 37.89 -37.99 0.14 0.10 0.23 6.04 3.89 64.47 2.14 35.53 57.49 
C17 -0.04 -1.49E-04 37.84 -37.93 0.13 0.15 0.08 6.04 3.96 65.51 2.08 34.49 73.39 
367 
C21 -0.05 -4.57E-04 37.85 -37.95 0.14 0.23 0.10 6.05 3.95 65.38 2.09 34.62 69.96 
C22 -0.04 -9.00E-06 37.83 -37.93 0.15 0.15 0.08 6.04 3.95 65.51 2.08 34.49 74.06 
P14 0.92 2.71E-04 340.21 -341.07 1.07 0.64 0.45 14.08 12.03 85.44 2.05 14.56 98.55 
Cl11 -0.58 9.90E-05 459.39 -460.55 0.12 1.17 1.23 17.58 16.97 96.57 0.60 3.43 241.92 
Cl23 -0.58 9.90E-05 459.38 -460.54 0.10 1.41 1.46 17.58 16.97 96.54 0.61 3.46 241.45 
Complex 4 
Ru1 0.79 5.90E-04 4435.13 -4446.80 0.37 0.98 1.24 43.21 40.63 94.03 2.58 5.97 112.26 
C6 -0.04 -1.39E-04 37.84 -37.94 0.14 0.14 0.03 6.04 3.95 65.42 2.09 34.58 70.42 
C8 -0.06 -3.21E-04 37.84 -37.94 0.14 0.09 0.07 6.06 3.97 65.56 2.09 34.44 74.48 
C12 -0.04 1.36E-04 37.90 -38.00 0.11 0.10 0.05 6.04 3.90 64.52 2.14 35.48 56.69 
C17 -0.05 3.00E-06 37.84 -37.94 0.10 0.09 0.05 6.05 3.97 65.57 2.08 34.43 73.76 
C21 -0.03 -1.56E-04 37.85 -37.95 0.13 0.19 0.06 6.03 3.95 65.44 2.09 34.56 68.14 
C22 -0.02 -4.80E-05 37.83 -37.92 0.15 0.15 0.06 6.02 3.95 65.59 2.07 34.41 74.92 
P14 0.72 7.66E-04 340.30 -341.20 0.96 1.13 0.25 14.28 12.20 85.42 2.08 14.58 106.84 
O11 -1.16 7.30E-05 75.20 -75.40 0.32 0.86 0.67 9.16 8.22 89.74 0.94 10.26 119.23 
Cl23 -0.54 8.90E-05 459.39 -460.60 0.08 1.27 1.19 17.54 16.89 96.32 0.65 3.68 231.84 
q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %Loc(A) is percentage of average number of electrons localized in 
atom A, K_Scaled(A) is approximation to virial-based total energy of atom A, Intra(A) is magnitude of Intraatomic dipole 
moment of atom A, %Deloc(A,A') is the percentage of electron delocalization index of atom A and Vol(A) is the volume 
bounded by an isosurface of the electron density distribution (0.001) and by interatomic surfaces of atom A. 
2  
3  
Table 3.20: Correlation among the computed QTAIM Intra- and inter-atomic properties for the systems 
using combined basis sets DGDZVP(Ru)|6-31+G(d,p) 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
 |(A)| Vol(A),0.001 |(A)| Vol(A),0.001 |(A)| Vol(A),0.001 |(A)| Vol(A),0.001 
q(A) -0.07 -0.04 0.22 0.29 -0.05 -0.04 0.18 0.23 
L(A) -0.79 -0.78 -0.74 -0.76 0.91 0.88 0.89 0.88 
K(A) 0.87 0.83 0.83 0.81 0.89 0.84 0.86 0.82 
K_Scaled(A) -0.87 -0.83 -0.83 -0.81 -0.89 -0.84 -0.86 -0.82 
|Intra(A)| 0.97 0.98 0.97 0.99 0.97 0.98 0.97 0.99 
|Bond(A)| 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.99 
|(A)| 1.00 0.99 1.00 0.99 1.00 0.99 1.00 0.99 
N(A) 0.99 0.98 0.98 0.98 0.99 0.99 0.99 0.99 
LI(A) 0.99 0.97 0.98 0.97 0.99 0.98 0.99 0.98 
%Loc(A) 0.98 1.00 0.98 1.00 0.98 1.00 0.99 1.00 
DI(A,A')/2 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 
%Deloc(A,A') 0.96 0.99 0.97 0.99 0.96 0.99 0.97 0.99 
Vol(A),0.001 0.99 1.00 0.99 1.00 0.99 1.00 0.99 1.00 
 
 
 
 
 
 
Table 3.21: Selected atomic properties derived through the quantum theory of atoms in molecules 
analysis for the four complexes using 3-21G basis set (all the data in atomic units) 
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Complex 1 
 Atom q(A) L(A) K(A) 
K_Sca
led(A) 
|Intra(
A)| 
|Bond(
A)| |(A)| N(A) LI(A) 
%Loc(
A) 
DI(A,
A')/2 
%Delo
c(A,A'
) 
Vol(A)
, 0.001 
 Ru1 0.65 
7.41E-
04 
4402.6
4 
-
4424.0
4 0.39 1.56 1.71 43.35 40.77 94.03 2.59 5.97 107.30 
arene C6 -0.11 
-
1.39E-
04 37.61 -37.80 0.25 0.21 0.07 6.11 4.02 65.90 2.08 34.10 73.62 
 C9 -0.13 
-
2.10E-
05 37.62 -37.80 0.23 0.12 0.12 6.13 4.04 65.93 2.09 34.07 75.60 
 C10 -0.09 
-
6.60E-
05 37.60 -37.78 0.27 0.23 0.07 6.09 4.02 66.01 2.07 33.99 76.65 
 C14 -0.09 
-
1.80E-
04 37.61 -37.79 0.12 0.16 0.04 6.09 3.95 64.85 2.14 35.15 61.84 
 C16 -0.10 
-
7.10E-
05 37.61 -37.79 0.26 0.23 0.07 6.10 4.02 65.97 2.07 34.03 75.11 
 C19 -0.11 
-
1.02E-
04 37.62 -37.80 0.24 0.18 0.08 6.11 4.03 65.88 2.09 34.12 73.86 
 C18* -0.06 
-
1.91E-
04 37.52 -37.70 0.21 0.22 0.09 6.06 4.05 66.79 2.01 33.21 74.52 
mono Cl2# -0.57 
8.10E-
05 456.64 
-
458.86 0.14 1.13 1.26 17.57 16.99 96.69 0.58 3.31 235.93 
 Cl20 -0.57 
8.00E-
06 456.64 
-
458.85 0.14 1.38 1.51 17.57 16.99 96.70 0.58 3.30 236.66 
pta P11 0.86 
2.75E-
04 338.03 
-
339.67 1.02 0.18 0.90 14.14 12.13 85.74 2.02 14.26 100.02 
 N5 -0.85 
6.70E-
05 54.40 -54.66 0.38 0.47 0.85 7.85 6.07 77.36 1.78 22.64 74.29 
 N7 -0.86 
-
9.00E-
05 54.41 -54.68 0.37 0.49 0.84 7.86 6.08 77.33 1.78 22.67 74.16 
 N15 -0.85 
1.55E-
04 54.40 -54.67 0.38 0.47 0.84 7.85 6.07 77.35 1.78 22.65 74.23 
 H25* 0.12 
7.50E-
05 0.56 -0.57 0.15 0.44 0.50 0.88 0.34 38.92 0.54 61.08 39.83 
 H37* 0.06 
6.20E-
05 0.59 -0.59 0.16 0.10 0.09 0.94 0.39 41.62 0.55 58.38 44.45 
Complex 2 
 Ru1 0.68 
5.60E-
05 
4402.5
7 
-
4424.8
0 0.31 0.72 0.78 43.32 40.83 94.25 2.49 5.75 108.66 
arene C2 -0.11 
-
1.36E-
04 37.62 -37.81 0.24 0.13 0.13 6.11 4.03 65.93 2.08 34.07 74.20 
 C3 -0.12 
-
1.65E-
04 37.61 -37.80 0.24 0.15 0.12 6.12 4.04 66.06 2.08 33.94 76.49 
 C7 -0.09 
4.00E-
05 37.62 -37.81 0.16 0.07 0.20 6.09 3.95 64.93 2.13 35.07 61.27 
369 
 C8 -0.11 
-
3.00E-
06 37.60 -37.79 0.24 0.14 0.12 6.11 4.04 66.11 2.07 33.89 78.02 
 C13 -0.11 
-
1.04E-
04 37.63 -37.82 0.24 0.18 0.11 6.11 4.03 65.94 2.08 34.06 72.67 
 C14 -0.08 
3.80E-
05 37.59 -37.78 0.27 0.22 0.09 6.08 4.01 66.02 2.06 33.98 76.20 
 C6* -0.06 
-
8.30E-
05 37.52 -37.71 0.25 0.20 0.24 6.06 4.06 66.96 2.00 33.04 75.28 
 H26* 0.06 
7.20E-
05 0.58 -0.58 0.16 0.09 0.23 0.94 0.39 41.93 0.55 58.07 45.74 
mono O11 -0.93 
-
1.50E-
05 74.48 -74.86 0.13 0.67 0.75 8.93 7.88 88.24 1.05 11.76 99.90 
 Cl20# -0.53 
5.40E-
05 456.65 
-
458.95 0.11 1.21 1.31 17.53 16.91 96.49 0.62 3.51 230.54 
 H41* 0.51 
7.00E-
05 0.40 -0.40 0.15 0.35 0.41 0.49 0.10 20.38 0.39 79.62 20.69 
pta P12 0.73 
-
2.28E-
04 338.10 
-
339.80 0.94 0.43 0.51 14.27 12.24 85.74 2.03 14.26 107.07 
 N15 -0.85 
1.70E-
05 54.41 -54.68 0.36 0.46 0.81 7.85 6.06 77.21 1.79 22.79 73.77 
 N16 -0.85 
7.90E-
05 54.41 -54.69 0.35 0.45 0.81 7.85 6.06 77.21 1.79 22.79 73.70 
 N5 -0.85 
1.49E-
04 54.41 -54.68 0.36 0.45 0.81 7.85 6.06 77.21 1.79 22.79 73.69 
 H23* 0.07 
7.40E-
05 0.58 -0.58 0.16 0.12 0.09 0.93 0.39 41.41 0.55 58.59 45.34 
 H33* 0.07 
7.20E-
05 0.58 -0.58 0.16 0.10 0.08 0.93 0.38 41.11 0.55 58.89 44.11 
Complex 3 
 Ru1 0.65 
5.60E-
05 
4402.6
2 
-
4424.5
4 0.40 1.85 2.08 43.35 40.74 93.97 2.61 6.03 107.21 
arene C6 -0.10 
-
5.10E-
05 37.60 -37.79 0.28 0.22 0.07 6.10 4.02 65.88 2.08 34.12 74.51 
 C8 -0.09 
-
2.25E-
04 37.60 -37.79 0.26 0.25 0.02 6.09 4.01 65.89 2.08 34.11 74.30 
 C12 -0.11 
-
2.55E-
04 37.69 -37.88 0.10 0.12 0.21 6.11 3.97 65.03 2.14 34.97 60.38 
 C17 -0.09 
-
9.60E-
05 37.60 -37.79 0.26 0.29 0.05 6.09 4.02 65.98 2.07 34.02 75.66 
 C21 -0.08 
-
1.20E-
05 37.60 -37.79 0.29 0.30 0.03 6.08 4.01 65.84 2.08 34.16 72.40 
 C22 -0.08 
-
1.35E-
04 37.59 -37.78 0.28 0.23 0.11 6.08 4.01 65.98 2.07 34.02 76.36 
 F7* -0.52 
1.54E-
04 98.81 -99.30 0.07 0.53 0.47 9.52 8.88 93.30 0.64 6.70 83.90 
 F18* -0.50 1.61E- 98.81 -99.30 0.07 0.68 0.61 9.50 8.86 93.28 0.64 6.72 83.31 
370 
04 
 F9 -0.49 
9.10E-
05 98.84 -99.34 0.08 0.77 0.69 9.49 8.87 93.45 0.62 6.55 81.17 
mono Cl11# -0.55 
7.60E-
05 456.64 
-
458.92 0.14 1.10 1.23 17.55 16.96 96.62 0.59 3.38 234.34 
 Cl23 -0.55 
7.80E-
05 456.63 
-
458.91 0.14 1.33 1.46 17.55 16.96 96.61 0.59 3.39 234.96 
pta P14 0.84 
-
6.90E-
05 338.04 
-
339.72 0.98 0.50 0.48 14.16 12.13 85.66 2.03 14.34 100.28 
 N15 -0.85 
1.20E-
05 54.41 -54.68 0.37 0.47 0.84 7.85 6.07 77.32 1.78 22.68 74.20 
 N13 -0.86 
3.70E-
05 54.41 -54.68 0.37 0.47 0.83 7.86 6.08 77.33 1.78 22.67 74.23 
 N2 -0.85 
-
3.00E-
06 54.40 -54.67 0.38 0.47 0.84 7.85 6.07 77.34 1.78 22.66 74.19 
 H25* 0.07 
5.60E-
05 0.58 -0.58 0.16 0.18 0.29 0.93 0.38 41.38 0.54 58.62 44.22 
 H32* 0.11 
6.20E-
05 0.57 -0.57 0.15 0.34 0.39 0.89 0.35 39.21 0.54 60.79 40.25 
 H34* 0.08 
5.20E-
05 0.58 -0.58 0.15 0.26 0.37 0.92 0.37 40.73 0.54 59.27 41.12 
Complex 4 
 Ru1 0.69 
4.50E-
04 
4402.5
5 
-
4425.3
1 0.32 0.97 1.16 43.31 40.80 94.21 2.51 5.79 108.44 
arene C6 -0.08 
-
1.21E-
04 37.60 -37.79 0.27 0.22 0.06 6.08 4.00 65.89 2.07 34.11 73.07 
 C8 -0.10 
-
8.50E-
05 37.60 -37.79 0.27 0.18 0.09 6.10 4.03 66.06 2.07 33.94 77.22 
 C12 -0.11 
-
5.10E-
05 37.70 -37.90 0.06 0.07 0.03 6.11 3.97 65.04 2.13 34.96 59.54 
 C17 -0.11 
-
7.00E-
06 37.61 -37.80 0.22 0.17 0.08 6.11 4.04 66.11 2.07 33.89 77.18 
 C21 -0.07 
-
2.77E-
04 37.61 -37.81 0.28 0.28 0.04 6.07 4.00 65.92 2.07 34.08 71.17 
 C22 -0.06 
3.00E-
05 37.58 -37.77 0.30 0.24 0.10 6.06 4.00 66.02 2.06 33.98 77.52 
mono O11 -0.93 
6.50E-
05 74.48 -74.87 0.13 0.66 0.74 8.93 7.87 88.20 1.05 11.80 99.59 
 Cl23# -0.51 
7.20E-
05 456.65 
-
459.01 0.11 1.17 1.26 17.51 16.88 96.41 0.63 3.59 229.50 
 H42* 0.51 
1.20E-
05 0.40 -0.40 0.15 0.35 0.40 0.49 0.10 20.29 0.39 79.71 20.62 
pta P14 0.70 
-
2.19E-
04 338.10 
-
339.85 0.91 0.94 0.19 14.30 12.25 85.70 2.04 14.30 107.80 
 N15 -0.85 
-
7.40E-
05 54.42 -54.70 0.35 0.45 0.80 7.85 6.06 77.16 1.79 22.84 73.62 
 N13 -0.85 
2.90E-
05 54.41 -54.69 0.35 0.46 0.81 7.85 6.06 77.19 1.79 22.81 73.73 
371 
 N2 -0.85 
-
7.50E-
05 54.41 -54.69 0.35 0.45 0.80 7.85 6.06 77.17 1.79 22.83 73.68 
 F18* -0.49 
1.35E-
04 98.80 -99.31 0.07 0.69 0.62 9.49 8.85 93.23 0.64 6.77 83.61 
 F7* -0.51 
8.30E-
05 98.80 -99.31 0.07 0.58 0.52 9.51 8.87 93.25 0.64 6.75 83.67 
 F9 -0.47 
8.40E-
05 98.83 -99.34 0.08 0.75 0.67 9.47 8.84 93.33 0.63 6.67 81.07 
 H25* 0.09 
7.00E-
05 0.57 -0.58 0.15 0.16 0.26 0.91 0.37 40.70 0.54 59.30 42.95 
 H34* 0.10 
6.30E-
05 0.57 -0.58 0.15 0.27 0.37 0.90 0.36 40.12 0.54 59.88 40.55 
q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %Loc(A) is percentage of average number of electrons localized in 
atom A, K_Scaled(A) is approximation to virial-based total energy of atom A, Intra(A) is magnitude of Intraatomic dipole 
moment of atom A, %Deloc(A,A') is the percentage of electron delocalization index of atom A and Vol(A) is the volume 
bounded by an isosurface of the electron density distribution (0.001) and by interatomic surfaces of atom A. 
 
 
 
 
Table 3.22: The sum total of computed atomic properties derived through the quantum theory of atoms 
in molecules analysis for the four complexes using two methods (all the data in atomic units)  
DGDZVP(Ru)|6-31+G(d,p) 
 q(A) L(A) K(A) K_Scaled(A) 
|Intra(A)
| 
|Bond(A
)| |(A)| N(A) Loc(A) 
DI(A,A'
)/2 
Vol(A), 
0.001 
1 0.00 -1.59E-03 6360.99 -6376.34 9.67 11.59 11.52 212.00 163.28 2314.08 48.72 
2 1.00 -1.26E-03 5977.39 -5992.34 9.63 10.63 9.08 204.00 154.43 2332.33 49.57 
3 0.00 2.10E-03 6657.18 -6674.07 10.68 16.01 13.77 236.00 187.60 2455.78 48.40 
4 1.00 4.52E-03 6273.56 -6290.06 10.64 15.26 11.33 228.00 178.76 2475.23 49.23 
3-21G 
1 0.00 1.43E-03 6316.25 -6346.95 10.91 12.03 11.43 212.00 163.62 48.37 2626.01 
2 1.00 -2.10E-04 5934.77 -5964.72 10.95 10.86 9.23 204.00 154.54 49.46 2523.74 
3 0.00 -3.80E-04 6610.15 -6643.07 11.06 15.26 13.29 236.00 187.63 48.37 2669.61 
4 1.00 -5.95E-04 6228.64 -6260.83 9.61 14.35 11.01 228.00 178.54 49.46 2572.07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.23: Bond lengths and Orders of the Ruthenium-ligand bonds in the complexes when optimized 
with PBE0/ECP(Ru,P,Cl)|6-31G* and PBE0/ECP(Ru)|6-31+G(d,p) 
372 
PBE0/ECP(Ru,P,Cl)|6-31G* 
Complex 1 Complex 2 Complex 3 Complex 4 
Bond Length Order Bond Length Order Bond Length Order Bond Length Order 
Ru-C2 2.206 0.451 Ru-C6 2.224 0.427 Ru-C6 2.231 0.416 Ru-C6 2.211 0.445 
Ru-C3 2.249 0.375 Ru-C9  2.223 0.467  Ru-C17 2.205 0.441  Ru-C19 2.217 0.468  
Ru-C4  2.210 0.444  Ru-C7  2.196 0.482 Ru-C9 2.198 0.446  Ru-C10  2.228 0.440 
Ru-C6 2.250 0.374 Ru-C18  2.277 0.391 Ru-C14 2.205 0.452  Ru-C21  2.304 0.366 
Ru-C7 2.210 0.444 Ru-C14  2.183 0.492  Ru-C10  2.236 0.392 Ru-C11  2.176 0.483  
Ru-C9  2.206 0.451  Ru-C17 2.265 0.359 Ru-C16  2.295 0.332  Ru-C18 2.252 0.373 
Ru-P11 2.406 0.727 Ru-P11 2.433 0.706 Ru-P13 2.420 0.725  Ru-P12 2.437 0.712 
Ru-Cl5 2.490 0.967  Ru-O8 2.244 0.503 Ru-Cl19 2.500 0.966  Ru-O16 2.253 0.509  
Ru-Cl17 2.490 0.967 Ru-Cl19 2.480 1.024 Ru-Cl20 2.496 0.947  Ru-Cl23 2.486 1.028  
PBE0/ECP(Ru)|6-31+G(d,p) 
Ru-C2 2.215 0.415 Ru-C6 2.244 0.378 Ru-C6 2.251 0.387 Ru-C6 2.222 0.393 
Ru-C3 2.28 0.295 Ru-C9 2.201 0.435 Ru-C17 2.325 0.27 Ru-C19 2.182 0.449 
Ru-C4 2.221 0.405 Ru-C7 2.229 0.442 Ru-C9 2.215 0.404 Ru-C10 2.239 0.419 
Ru-C6 2.28 0.295 Ru-C18 2.282 0.309 Ru-C14 2.216 0.413 Ru-C21 2.28 0.308 
Ru-C7 2.221 0.405 Ru-C14 2.309 0.305 Ru-C10 2.208 0.408 Ru-C11 2.235 0.418 
Ru-C9 2.215 0.415 Ru-C17 2.187 0.478 Ru-C16 2.268 0.31 Ru-C18 2.326 0.307 
Ru-P11 2.332 0.854 Ru-P11 2.362 0.799 Ru-P13 2.341 0.853 Ru-P12 2.368 0.789 
Ru-Cl5 2.443 0.853 Ru-O8 2.254 0.413 Ru-Cl19 2.451 0.837 Ru-O16 2.259 0.408 
Ru-Cl17 2.443 0.853 Ru-Cl19 2.423 0.934 Ru-Cl20 2.447 0.836 Ru-Cl23 2.437 0.912 
 
 
 
 
4  
5  
6  
7  
8  
9  
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Table 3.24: The polarization of the bonding interaction of Ru(II) with ligand atoms 
 
Bonds (NBO %) Polarization of Pair Atoms  
Complex 1 
Ru- P11 (37.49%) 0.6123*Ru → (62.51%) 0.7906* P11 
Complex 2    
Ru- P11 (35.61%) 0.5967*Ru → (64.39%) 0.8024* P11 
Ru-Cl19 (24.42%) 0.4941*Ru → (75.58%) 0.8694*Cl19  
Complex 3    
Ru- P13 (30.40%) 0.5514*Ru → (69.60%) 0.8343* P13 
Ru-Cl19 (22.81%) 0.4776*Ru → (77.19%) 0.8786*Cl19 
Ru-Cl20 (22.72%) 0.4767*Ru → (77.28%) 0.8791*Cl20 
Complex 4    
Ru- P12 (36.46%) 0.6038*Ru → (63.54%) 0.7971* P12 
 Polarization coefficient cA is the values with starred superscript and the square of it is percentage of the NBO (cA-squared) 
on each hybrid orbitals (in parentheses). 
 
Table 3.25: The delocalization orbitals with their second perturbation energies (E
(2)
). 
 
Complex 1 Complex 2 Complex 3 Complex 4 
Donor Acceptor E(2) Donor Acceptor E(2) Donor Acceptor E(2) Donor Acceptor E(2) 
90. LP 
(2)Ru 
 378. 
BD*(2) 
C3-C6 22.42 
87. LP 
(2)Ru 
90. LP (1) 
C6 14.91 
 1. BD 
(1)Ru-
P13 
460. 
BD*(1)Ru-
Cl19 11.88 
102. LP 
(2)Ru 
 494. 
BD*(2) 
C11-C19 10.06 
 91. LP 
(3)Ru 
 375. 
BD*(2) 
C2-C4 25.07 
87. LP 
(2)Ru 
 100. 
LP*(1) C7 11.99 
 1. BD 
(1)Ru-
P13 
461. 
BD*(1)Ru-
Cl20 11.88 
102. LP 
(2)Ru 
 509. 
BD*(2) 
C18-C21 18.79 
91. LP 
(3)Ru 
 385. 
BD*(2) 
C7-C9 25.08 
87. LP 
(2)Ru 
 101. 
LP*(1) C9 23 
107. LP 
(2)Ru 
 111. LP (1) 
C10 18.88 
103. LP 
(3)Ru 
 480. 
BD*(2) 
C6-C10 22.1 
4. BD (2) 
C2-C4 
103. 
LP*(4)Ru 67.13 
87. LP 
(2)Ru 
 409. 
BD*(2) 
C14-C18 19.88 
107. LP 
(2)Ru 
 119. 
LP*(1) C6 29.14 
103. LP 
(3)Ru 
 494. 
BD*(2) 
C11-C19 21.2 
4. BD (2) 
C2-C4 
104. 
LP*(5)Ru 20.9 
88. LP 
(3)Ru 
90. LP (1) 
C6 10.98 
107. LP 
(2)Ru 
 498. 
BD*(2) 
C16-C17 19.25 
15. BD 
(2) C6-
C10 
115. 
LP*(4)Ru 64.38 
4. BD (2) 
C2-C4 
372. 
BD*(1)Ru
-P11 10.22 
88. LP 
(3)Ru 
95. LP (1) 
C17 46.13 
108. LP 
(3)Ru 
 111. LP (1) 
C10 38 
15. BD 
(2) C6-
C10 
116. 
LP*(5)Ru 16.97 
6. BD (1) 
C3-C6 
372. 
BD*(1)Ru
-P11 10.83 
88. LP 
(3)Ru 
 100. 
LP*(1) C7 49.06 
108. LP 
(3)Ru 
 119. 
LP*(1) C6 16.16 
15. BD 
(2) C6-
C10 
466. 
BD*(1)Ru-
P12 14.65 
7. BD (2) 
C3-C6 
372. 
BD*(1)Ru
-P11 39.87 
88. LP 
(3)Ru 
 101. 
LP*(1) C9 41.74 
108. LP 
(3)Ru 
 483. 
BD*(2) 
C9-C14 31.27 
16. BD 
(1) C6-
C11 
116. 
LP*(5)Ru 10.69 
374 
14. BD (2) 
C7-C9 
103. 
LP*(4)Ru 67.15 
15. BD 
(1) C6-C7 
378. 
BD*(1)Ru
-Cl19 13.76 
17. BD 
(1) C6-
C10 
461. 
BD*(1)Ru-
Cl20 15.15 
29. BD 
(2) C11-
C19 
115. 
LP*(4)Ru 69.89 
14. BD (2) 
C7-C9 
104. 
LP*(5)Ru 20.9 
22. BD 
(1) C9-
C17 
 99. 
LP*(4)Ru 14.48 
24. BD 
(1) C9-
C14 
460. 
BD*(1)Ru-
Cl19 16.07 
29. BD 
(2) C11-
C19 
116. 
LP*(5)Ru 23.38 
14. BD (2) 
C7-C9 
372. 
BD*(1)Ru
-P11 10.21 
33. BD 
(2) C14-
C18 
377. 
BD*(1)Ru
-P11 35.44 
25. BD 
(2) C9-
C14 
460. 
BD*(1)Ru-
Cl19 52.3 
44. BD 
(2) C18-
C21 
466. 
BD*(1)Ru-
P12 38.6 
92. LP 
(1)Cl5 
 103. 
LP*(4)Ru 10.93 
 95. LP 
(1) C17 
99. 
LP*(4)Ru 45.96 
39. BD 
(1) C16-
C17 
459. 
BD*(1)Ru-
P13 11.35 
108. LP 
(2) O16 
 115. 
LP*(4)Ru 22.23 
92. LP 
(1)Cl5 
 104. 
LP*(5)Ru 13.01 
95. LP (1) 
C17 
 378. 
BD*(1)Ru
-Cl19 13.17 
40. BD 
(2) C16-
C17 
459. 
BD*(1)Ru-
P13 31.97 
108. LP 
(2) O16 
 116. 
LP*(5)Ru 33.01 
95. LP 
(4)Cl5 
 103. 
LP*(4)Ru 
105.1
8 
92. LP (2) 
O 8 
99. 
LP*(4)Ru 51.52 
111. LP 
(1) C10 
 461. 
BD*(1)Ru-
Cl20 41.72 
111. LP 
(1)Cl23 
 115. 
LP*(4)Ru 12.65 
95. LP 
(4)Cl5 
 104. 
LP*(5)Ru 54.32       
111. LP 
(1)Cl23 
 116. 
LP*(5)Ru 11.17 
95. LP 
(4)Cl5 
 372. 
BD*(1)Ru
-P11 13.89       
114. LP 
(4)Cl23 
 115. 
LP*(4)Ru 
104.3
4 
98. LP 
(1)Cl17 
 103. 
LP*(4)Ru 10.93       
114. LP 
(4)Cl23 
 116. 
LP*(5)Ru 44.64 
98. LP 
(1)Cl17 
 104. 
LP*(5)Ru 13.01       
114. LP 
(4)Cl23 
 466. 
BD*(1)Ru-
P12 12.83 
101. LP 
(4)Cl17 
 103. 
LP*(4)Ru 
105.1
6          
101. LP 
(4)Cl17 
 104. 
LP*(5)Ru 54.31          
101. LP 
(4)Cl17 
 372. 
BD*(1)Ru
-P11 13.89          
The orbital analyses in the table are defined in terms of the second perturbation energy or stability energy (E(2) in kcal/mol). 
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Table 3.26: The amount of electron transferred to the acceptor orbitals and their energy level values for 
the four complexes 
 
Complex 1 Complex 2 Complex 3 Complex 4 
Acceptor e
-
 Energy Acceptor e
-
 Energy Acceptor e
-
 Energy Acceptor e
-
 Energy 
103. 
LP*(4)Ru 0.86632 
-
0.23304 
99. 
LP*(4)Ru 0.34162 -0.12373 
459. 
BD*(1)R
u-P13 0.28052 0.0264 
115. 
LP*(4)Ru 0.7717 -0.34383 
104. 
LP*(5)Ru 0.29265 0.09026 
377. 
BD*(1)R
u-P11 0.36076 -0.18575 
460. 
BD*(1)R
u-Cl19 0.31342 -0.0177 
116. 
LP*(5)Ru 0.25086 -0.04602 
372. 
BD*(1)Ru
-P11 0.4201 
-
0.08239 
378. 
BD*(1)R
u-Cl19 0.3616 -0.20458 
461. 
BD*(1)R
u-Cl20 0.31388 -0.01498 
466. 
BD*(1)R
u-P12 0.41636 -0.20332 
375. 
BD*(2) 
C2-C4 0.3873 -0.0176 
100. 
LP*(1) 
C7 0.95425 -0.319 
119. 
LP*(1) 
C6 0.97701 -0.1717 
480. 
BD*(2) 
C6-C10 0.38112 -0.14052 
378. 
BD*(2) 
C3-C6 0.30743 
-
0.00519 
101. 
LP*(1) 
C9 0.94513 -0.31816 
483. 
BD*(2) 
C9-C14 0.3977 -0.01059 
494. 
BD*(2) 
C11-C19 0.39198 -0.13302 
385. 
BD*(2) 
C7-C9 0.38731 -0.0176 
409. 
BD*(2) 
C14-C18 0.2906 -0.14131 
498. 
BD*(2) 
C16-C17 0.31534 0.00534 
509. 
BD*(2) 
C18-C21 0.31948 -0.12782 
 
 
 
 
 
Table 3.27: The NEDA analysis of the complexes showing the contribution of different factors to the 
total interaction energies (i.e. stability energies) 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
ES  -613.65 -232.72 -195.41 -1180.24 
POL  -1005.45 -755.32 -631.22 -1056.91 
XC  -865.43 -200.66 -178.08 -923.35 
DEF 2694.41 1567.78 1317.34 3295.35 
SE 488.65 373.76 312.37 454.75 
Electrical 
(ES+POL+SE)  -1130.45 -614.27 -514.26 -1782.4 
 Charge 
Transfer (CT)  -661.56 -472.22 -351.67 -1441.76 
Core 
(XC+DEF-SE)  1340.33 993.36 826.89 1917.24 
 Total 
Interaction (E)  -451.67 -93.14 -39.04 -1306.93 
 
 
Table 3.28: The induced energy and dipole of each fragment of ligands coordinated to metal through 
376 
NEDA analysis for the four complexes 
 
  Fragment 1 Fragment 2 Fragment 3 Fragment 4 
1 E(ind) -1.292 -1.506 -0.748 -0.748 
 Dipole (ind) 24.135 0.854 1.163 1.163 
2 E(ind) -0.652 -1.388 -0.458 
 Dipole (ind) 6.816 0.927 0.544 
3 E(ind) -0.576 -1.524  
 Dipole (ind) 0.655 1.133  
4 E(ind) -1.411 -1.420 -1.695 -0.726 
 Dipole (ind) 28.107 1.755 14.771 1.135 
 
 
 
Table 3.29: The QTAIM properties of selected bonds in complex 1, 2, 3 and 4 that are associated with 
metal using DGDZVP 
Complex 1 
 r r  K 
BPL-
GBL_I V G L GBL_I Ven |V/G| 
Ru1 - P11 0.096 0.147 0.156 0.030 0.005 -0.097 0.067 -0.037 4.408 -7.633 1.450 
Ru1 - C2 0.077 0.247 0.585 0.014 0.014 -0.091 0.076 -0.062 4.186 -11.882 1.189 
Ru1 - C4 0.077 0.263 1.723 0.014 0.037 -0.093 0.079 -0.066 4.198 -12.781 1.170 
Ru1 - C9 0.077 0.247 0.584 0.014 0.014 -0.091 0.076 -0.062 4.186 -11.880 1.189 
Ru1 - C7 0.077 0.263 1.728 0.014 0.037 -0.093 0.079 -0.066 4.198 -12.783 1.170 
Ru1 - Cl5 0.064 0.208 0.194 0.007 0.003 -0.067 0.059 -0.052 4.616 -10.204 1.122 
Ru1 - Cl17 0.064 0.208 0.194 0.007 0.003 -0.067 0.059 -0.052 4.616 -10.205 1.122 
Complex 2 
Ru1 - P11 0.092 0.131 0.147 0.028 0.002 -0.089 0.061 -0.033 4.463 -6.546 1.463 
Ru1 - C7 0.076 0.227 0.394 0.015 0.015 -0.086 0.071 -0.057 4.212 -10.511 1.206 
Ru1 - C9 0.081 0.249 0.744 0.016 0.014 -0.095 0.079 -0.062 4.160 -11.938 1.209 
Ru1 - C17 0.081 0.250 0.496 0.017 0.017 -0.096 0.079 -0.063 4.133 -11.911 1.211 
Ru1 - O8 0.054 0.311 0.504 -0.004 0.005 -0.070 0.074 -0.078 4.260 -14.561 0.946 
Ru1 - Cl19 0.067 0.218 0.298 0.008 0.003 -0.071 0.063 -0.054 4.580 -10.442 1.133 
Complex 3 
Ru1 - P13 0.094 0.151 0.162 0.029 0.006 -0.095 0.067 -0.038 4.424 -8.327 1.433 
Ru1 - C9 0.077 0.258 0.981 0.015 0.020 -0.094 0.079 -0.065 4.187 -13.648 1.184 
Ru1 - C10 0.078 0.248 0.476 0.015 0.016 -0.092 0.077 -0.062 4.173 -13.001 1.197 
Ru1 - C14 0.077 0.241 0.623 0.015 0.015 -0.090 0.075 -0.060 4.188 -12.683 1.199 
Ru1 - Cl19 0.063 0.206 0.219 0.007 0.004 -0.065 0.058 -0.052 4.632 -10.869 1.117 
Ru1 - Cl20 0.063 0.209 0.182 0.007 0.003 -0.066 0.059 -0.052 4.624 -11.039 1.118 
Complex 4 
Ru1 - P12 0.090 0.138 0.154 0.027 0.003 -0.088 0.061 -0.034 4.475 -7.374 1.439 
377 
Ru1 - C6 0.078 0.243 0.868 0.015 0.016 -0.091 0.076 -0.061 4.199 -12.578 1.198 
Ru1 - C11 0.074 0.262 3.945 0.012 0.029 -0.089 0.077 -0.065 4.223 -13.605 1.150 
Ru1 - C10 0.073 0.250 1.462 0.012 0.026 -0.087 0.075 -0.063 4.231 -12.862 1.161 
Ru1 - C19 0.084 0.228 0.279 0.020 0.011 -0.096 0.077 -0.057 4.123 -11.721 1.257 
Ru1 - O16 0.054 0.305 0.490 -0.004 0.006 -0.069 0.073 -0.076 4.268 -15.482 0.950 
Ru1 - Cl23 0.065 0.215 0.313 0.008 0.003 -0.069 0.061 -0.054 4.605 -11.089 1.124 
Ven=Laplacian of the electron-nuclear attractive contribution to virial field, r= Laplacian of the electron density. 
 
 
Table 3.30: The QTAIM properties of selected bonds in complex 1, 2, 3 and 4 that are associated with 
metal using 3-21G 
Complex 1 
 r r  K 
BPL-
GBL_I V G L GBL_I Ven |V/G| 
Ru1 - P11 0.090 0.150 0.104 0.027 0.008 -0.091 0.065 -0.038 4.408 -7.737 1.418 
Ru1 - C2 0.075 0.268 0.240 0.011 0.014 -0.089 0.078 -0.067 4.186 -12.842 1.140 
Ru1 - C4 0.074 0.285 0.543 0.010 0.019 -0.091 0.081 -0.071 4.198 -13.801 1.121 
Ru1 - C7 0.074 0.285 0.544 0.010 0.019 -0.091 0.081 -0.071 4.198 -13.803 1.121 
Ru1 - C9 0.075 0.268 0.240 0.011 0.014 -0.089 0.078 -0.067 4.186 -12.841 1.140 
Ru1 - Cl5 0.063 0.206 0.167 0.007 0.001 -0.065 0.058 -0.051 4.616 -10.030 1.117 
Ru1 - Cl17 0.063 0.206 0.167 0.007 0.001 -0.065 0.058 -0.051 4.616 -10.030 1.117 
Complex 2 
Ru1 - P11 0.086 0.136 0.101 0.025 0.003 -0.083 0.059 -0.034 4.463 -6.746 1.422 
Ru1 - C6 0.071 0.284 2.624 0.007 0.048 -0.086 0.078 -0.071 4.240 -13.389 1.094 
Ru1 - C7 0.074 0.248 0.168 0.011 0.015 -0.084 0.073 -0.062 4.212 -11.473 1.148 
Ru1 - C9 0.079 0.270 0.295 0.012 0.014 -0.092 0.080 -0.068 4.160 -12.885 1.155 
Ru1 - C17 0.079 0.273 0.178 0.013 0.018 -0.094 0.081 -0.068 4.133 -12.968 1.156 
Ru1 - O8 0.059 0.295 0.349 0.007 0.005 -0.087 0.081 -0.074 4.260 -13.772 1.086 
Ru1 - Cl19 0.066 0.212 0.220 0.008 0.004 -0.070 0.061 -0.053 4.579 -10.127 1.136 
Complex 3 
Ru1 - P13 0.088 0.154 0.110 0.026 0.009 -0.090 0.064 -0.039 4.424 -8.486 1.400 
Ru1 - C6 0.071 0.274 1.012 0.008 0.023 -0.085 0.077 -0.068 4.254 -14.381 1.107 
Ru1 - C9 0.075 0.283 0.394 0.010 0.018 -0.092 0.081 -0.071 4.187 -14.913 1.128 
Ru1 - C10 0.076 0.272 0.183 0.011 0.014 -0.090 0.079 -0.068 4.173 -14.209 1.143 
Ru1 - C14 0.075 0.262 0.276 0.011 0.013 -0.088 0.077 -0.066 4.188 -13.769 1.145 
Ru1 - Cl19 0.061 0.205 0.192 0.006 0.001 -0.064 0.057 -0.051 4.632 -10.728 1.110 
Ru1 - Cl20 0.062 0.206 0.154 0.006 0.001 -0.065 0.058 -0.052 4.624 -10.861 1.112 
Complex 4 
Ru1 - P12 0.084 0.142 0.103 0.024 0.004 -0.083 0.059 -0.036 4.475 -7.569 1.400 
Ru1 - C6 0.076 0.266 0.372 0.011 0.012 -0.088 0.077 -0.066 4.199 -13.683 1.142 
Ru1 - C11 0.072 0.276 1.018 0.009 0.024 -0.087 0.078 -0.069 4.223 -14.275 1.113 
Ru1 - C10 0.071 0.267 0.592 0.009 0.023 -0.084 0.075 -0.067 4.231 -13.640 1.116 
Ru1 - C19 0.082 0.257 0.090 0.015 0.012 -0.093 0.079 -0.064 4.123 -13.179 1.186 
Ru1 - O16 0.059 0.289 0.350 0.007 0.005 -0.086 0.079 -0.072 4.268 -14.667 1.089 
Ru1 - Cl23 0.064 0.211 0.230 0.007 0.004 -0.068 0.060 -0.053 4.605 -10.815 1.123 
Table 3.31: The correlation in the properties of the electron density critical point analysis of complexes 
378 
1, 2, 3 and 4 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
 r
r
 
Ve
n r
r
 
Ve
n r
r
 
Ve
n r
r
 
Ve
n 
r 1.00 -0.94 -0.72 0.95 1.00 -0.92 -0.73 0.92 1.00 -0.93 -0.60 0.93 1.00 -0.90 -0.54 0.89 
r -0.94 1.00 0.66 -0.99 -0.92 1.00 0.73 -0.99 -0.93 1.00 0.57 -0.97 -0.90 1.00 0.52 -0.98 
Ellipti
city -0.72 0.66 1.00 -0.67 -0.73 0.73 1.00 -0.74 -0.60 0.57 1.00 -0.56 -0.54 0.52 1.00 -0.51 
K 0.99 -0.96 -0.72 0.98 0.94 -0.97 -0.71 0.98 0.98 -0.96 -0.60 0.96 0.94 -0.97 -0.52 0.97 
BPL-
GBL_
I -0.63 0.44 0.80 -0.43 -0.58 0.44 0.52 -0.44 -0.64 0.49 0.46 -0.47 -0.66 0.47 0.62 -0.45 
V -0.96 0.86 0.72 -0.90 -0.91 0.89 0.66 -0.92 -0.95 0.85 0.58 -0.88 -0.93 0.90 0.49 -0.92 
G 0.15 0.14 -0.20 -0.05 0.02 0.21 0.15 -0.12 0.24 0.07 -0.14 0.03 0.27 0.00 -0.06 0.08 
L 0.94 -1.00 -0.66 0.99 0.92 -1.00 -0.73 0.99 0.93 -1.00 -0.57 0.97 0.90 -1.00 -0.52 0.98 
GBL_
I -0.95 0.95 0.71 -0.92 -0.92 0.94 0.72 -0.91 -0.95 0.95 0.61 -0.90 -0.93 0.90 0.57 -0.85 
Ven 0.95 -0.99 -0.67 1.00 0.92 -0.99 -0.74 1.00 0.93 -0.97 -0.56 1.00 0.89 -0.98 -0.51 1.00 
|V/G| 0.73 -0.87 -0.54 0.80 0.71 -0.83 -0.64 0.77 0.76 -0.89 -0.50 0.81 0.78 -0.87 -0.45 0.80 
 
 
 
Table 3.32: Selected atomic properties derived through QTAIM analysis for complex 1, 2, 3 and 4 
using DGDZVP 
 
 
Complex 1 
 q(A) L(A) K(A) 
KScaled
(A) Ee(A)
Intra(
A)|
Bond(
A)| (A)| N(A) (A) 
%(A
)
(A,A
')
(A,
A') 
Vol(A
)
ZZ(A
) 
Ru1 0.77 0.00 
4435.
29 
-
4445.
63 
-
4435.
29 0.41 1.60 1.70 43.23 40.56 93.81 2.68 6.19 
108.1
0 -6.80 
C2 -0.06 
-1.94E-
04 37.84 -37.93 -37.84 0.11 0.13 0.07 6.06 3.96 65.42 2.10 34.58 71.99 -10.67 
C3 -0.04 
-9.00E-
05 37.83 -37.92 -37.83 0.13 0.12 0.07 6.04 3.96 65.52 2.08 34.48 74.58 -6.58 
C4 -0.07 
-1.75E-
04 37.83 -37.92 -37.83 0.10 0.06 0.06 6.07 3.97 65.40 2.10 34.60 73.72 -10.43 
C6 -0.04 8.70E-05 37.83 -37.92 -37.83 0.13 0.12 0.07 6.04 3.96 65.52 2.08 34.48 74.49 -6.57 
C7 -0.07 
-1.43E-
04 37.83 -37.92 -37.83 0.10 0.06 0.06 6.07 3.97 65.40 2.10 34.60 73.67 -10.40 
C9 -0.06 
-2.27E-
04 37.84 -37.93 -37.84 0.11 0.13 0.07 6.06 3.96 65.42 2.10 34.58 72.00 -10.63 
P11 1.51 
-6.77E-
04 
340.0
2 
-
340.8
1 
-
340.0
2 1.40 0.34 1.07 13.49 11.56 85.67 1.93 14.33 79.09 -10.43 
Cl5 -0.58 1.05E-04 459.4 - - 0.13 1.27 1.36 17.58 16.96 96.47 0.62 3.53 239.7 -26.11 
379 
1 460.4
8 
459.4
1 
5 
Cl17 -0.58 1.03E-04 
459.4
1 
-
460.4
8 
-
459.4
1 0.13 1.27 1.36 17.58 16.96 96.47 0.62 3.53 
239.7
5 -26.11 
Complex 2 
Ru1 0.77 
-3.17E-
04 
4435.
24 
-
4445.
98 
-
4435.
24 0.38 0.92 1.06 43.23 40.65 94.04 2.58 5.96 112.07 -5.80 
C6 -0.05 
-1.00E-
05 37.83 -37.92 -37.83 0.13 0.08 0.09 6.05 3.96 65.52 2.09 34.48 74.04 -8.04 
C7 -0.07 
-2.46E-
04 37.84 -37.93 -37.84 0.11 0.06 0.06 6.07 3.97 65.51 2.09 34.49 72.85 -12.96 
C9 -0.06 
-1.09E-
04 37.84 -37.93 -37.84 0.09 0.09 0.11 6.06 3.96 65.41 2.09 34.59 70.53 -11.30 
C14 -0.05 4.20E-05 37.83 -37.92 -37.83 0.13 0.08 0.06 6.05 3.97 65.65 2.08 34.35 76.53 -7.23 
C17 -0.06 
-3.69E-
04 37.85 -37.94 -37.85 0.12 0.11 0.08 6.06 3.97 65.50 2.09 34.50 71.93 -11.11 
C18 -0.02 1.22E-04 37.83 -37.92 -37.83 0.13 0.13 0.06 6.02 3.95 65.56 2.07 34.44 72.70 -6.69 
P11 1.31 
-3.08E-
04 
340.1
3 
-
340.9
6 
-
340.1
3 1.32 0.97 0.37 13.69 11.70 85.45 1.99 14.55 88.25 -11.43 
O8 -1.17 4.40E-05 75.21 -75.39 -75.21 0.31 0.90 0.61 9.17 8.24 89.89 0.93 10.11 
120.8
5 -12.65 
Cl19 -0.54 6.20E-05 
459.4
3 
-
460.5
4 
-
459.4
3 0.06 1.23 1.20 17.54 16.88 96.21 0.67 3.79 
228.2
1 -26.04 
Complex 3 
Ru1 0.75 5.80E-05 
4435.
21 
-
4446.
21 
-
4435.
21 0.42 1.61 1.66 43.25 40.58 93.85 2.66 6.15 
108.9
7 -1.02 
C9 -0.08 2.05E-04 37.85 -37.95 -37.85 0.09 0.02 0.07 6.08 3.97 65.37 2.11 34.63 72.50 -10.29 
C10 -0.07 
-2.39E-
04 37.86 -37.95 -37.86 0.09 0.07 0.03 6.07 3.97 65.35 2.10 34.65 70.76 -12.64 
C14 -0.07 
-9.64E-
04 37.86 -37.95 -37.86 0.09 0.10 0.05 6.07 3.97 65.35 2.10 34.65 70.15 -10.85 
C16 -0.06 
-1.10E-
05 37.86 -37.95 -37.86 0.10 0.08 0.06 6.06 3.97 65.40 2.10 34.60 71.55 -7.97 
C17 -0.04 1.58E-04 37.86 -37.95 -37.86 0.11 0.16 0.06 6.04 3.91 64.64 2.14 35.36 59.63 -6.69 
P13 1.49 
-6.44E-
04 
340.0
1 
-
340.8
6 
-
340.0
1 1.42 0.21 1.21 13.51 11.58 85.72 1.93 14.28 80.37 -10.30 
Cl19 -0.59 1.22E-04 
459.4
0 
-
460.5
4 
-
459.4
0 0.13 1.42 1.52 17.59 16.97 96.45 0.62 3.55 
238.4
3 -23.78 
Cl20 -0.59 1.12E-04 
459.4
1 
-
460.5
5 
-
459.4
1 0.12 1.06 1.14 17.59 16.94 96.32 0.65 3.68 
233.7
0 -28.24 
Complex 4 
Ru1 0.76 
-6.20E-
05 
4435.
17 
-
4446.
59 
-
4435.
17 0.38 0.77 0.82 43.24 40.67 94.06 2.57 5.94 112.67 11.03 
380 
C6 -0.06 
-1.85E-
04 37.85 -37.95 -37.85 0.09 0.08 0.11 6.06 3.96 65.37 2.10 34.63 70.51 -9.00 
C10 -0.08 1.71E-04 37.86 -37.95 -37.86 0.11 0.10 0.12 6.08 3.98 65.49 2.10 34.51 73.04 -10.70 
C11 -0.05 1.09E-04 37.85 -37.95 -37.85 0.11 0.09 0.04 6.05 3.91 64.58 2.14 35.42 60.21 -9.43 
C18 -0.05 1.24E-04 37.87 -37.97 -37.87 0.11 0.01 0.12 6.05 3.91 64.67 2.14 35.33 58.48 -6.52 
C19 -0.06 
-3.64E-
04 37.87 -37.96 -37.87 0.09 0.13 0.12 6.06 3.96 65.38 2.10 34.62 68.72 -12.22 
C21 -0.06 2.07E-04 37.85 -37.95 -37.85 0.12 0.12 0.12 6.06 3.97 65.50 2.09 34.50 73.24 -8.31 
P12 1.31 1.50E-05 
340.1
2 
-
341.0
0 
-
340.1
2 1.36 0.77 0.59 13.69 11.71 85.54 1.98 14.46 89.10 -10.46 
O16 -1.17 1.17E-04 75.21 -75.41 -75.21 0.31 0.90 0.62 9.17 8.23 89.78 0.94 10.22 119.64 -13.16 
Cl23 -0.55 7.40E-05 
459.4
3 
-
460.6
1 
-
459.4
3 0.06 1.21 1.19 17.55 16.89 96.23 0.66 3.77 
228.2
0 -23.81 
 
q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %(A) is percentage of average number of electrons localized in 
atom A, %(A,A') is the percentage of electron delocalization index of atom A, KScaled(A) is approximation to virial-based 
total energy of atom A, Intra(A)| is magnitude of Intraatomic dipole moment of atom A, Ee(A) is contribution of atom A to 
electronic energy of molecule, Vol(A) is the volume bounded by an isosurface of the electron density distribution (0.001) 
and by interatomic surfaces of atom A and zz= Out of plane magnetizability contribution of atom A. 
 
 
 
Table 3.33: Selected atomic properties derived through QTAIM analysis for complex 1, 2, 3 and 4 
using 3-21G 
Complex 1 
 q(A) L(A) K(A) 
KScaled
(A) Ee(A)
Intra(
A)|
Bond(
A)| (A)| N(A) (A) 
%(A
)
(A,A
')
(A,
A') 
Vol(A
)
ZZ(A
) 
Ru1 0.61 3.10E-04 
4402.
72 
-
4423.
80 
-
4402.
72 0.38 1.88 1.91 43.39 40.79 94.00 2.60 6.00 
105.5
1 -4.67 
C2 -0.10 
-8.90E-
05 37.61 -37.79 -37.61 0.25 0.22 0.09 6.10 4.02 65.90 2.08 34.10 74.18 -10.60 
C3 -0.09 1.04E-04 37.59 -37.77 -37.59 0.25 0.21 0.11 6.09 4.02 66.00 2.07 34.00 76.48 -6.91 
C4 -0.12 
-7.80E-
05 37.60 -37.78 -37.60 0.23 0.14 0.10 6.12 4.04 65.93 2.09 34.07 76.04 -10.63 
C6 -0.09 
-2.70E-
05 37.59 -37.77 -37.59 0.26 0.21 0.11 6.09 4.02 66.00 2.07 34.00 76.53 -6.91 
C7 -0.13 
-1.41E-
04 37.60 -37.78 -37.60 0.23 0.14 0.10 6.13 4.04 65.93 2.09 34.07 75.99 -10.62 
C9 -0.10 
-9.70E-
05 37.61 -37.79 -37.61 0.25 0.22 0.09 6.10 4.02 65.90 2.08 34.10 74.21 -10.61 
P11 1.19 
-8.00E-
04 
337.9
8 
-
339.6
0 
-
337.9
8 1.14 0.36 1.50 13.81 11.80 85.50 2.00 14.50 85.10 -14.91 
Cl5 -0.55 9.60E-05 
456.6
5 
-
458.8
4 
-
456.6
5 0.17 1.31 1.48 17.55 16.95 96.56 0.60 3.44 
232.4
3 -25.33 
381 
Cl17 -0.55 9.40E-05 
456.6
5 
-
458.8
4 
-
456.6
5 0.17 1.31 1.48 17.55 16.95 96.56 0.60 3.44 
232.4
0 -25.33 
Complex 2 
Ru1 0.66 3.18E-04 
4402.
63 
-
4424.
53 
-
4402.
63 0.31 0.90 0.99 43.34 40.84 94.23 2.50 5.77 
107.7
0 -3.04 
C6 -0.10 1.16E-04 37.59 -37.78 -37.59 0.27 0.15 0.12 6.10 4.02 66.00 2.07 34.00 76.51 -11.14 
C7 -0.12 
-3.12E-
04 37.61 -37.80 -37.61 0.22 0.13 0.10 6.12 4.04 66.06 2.08 33.94 75.90 -11.82 
C9 -0.12 
-3.15E-
04 37.62 -37.80 -37.62 0.22 0.13 0.13 6.12 4.03 65.96 2.08 34.04 73.77 -10.11 
C14 -0.10 1.39E-04 37.59 -37.77 -37.59 0.26 0.16 0.12 6.10 4.03 66.12 2.07 33.88 79.17 -7.57 
C17 -0.10 
-2.73E-
04 37.61 -37.80 -37.61 0.26 0.18 0.11 6.10 4.03 66.01 2.07 33.99 74.92 -10.53 
C18 -0.07 8.10E-05 37.59 -37.78 -37.59 0.26 0.22 0.10 6.07 4.01 66.03 2.06 33.97 75.48 -7.04 
P11 1.02 1.31E-04 
338.0
8 
-
339.7
6 
-
338.0
8 1.06 0.67 0.40 13.98 11.95 85.46 2.03 14.54 93.48 -14.47 
O8 -0.94 1.20E-05 74.50 -74.87 -74.50 0.14 0.66 0.77 8.94 7.90 88.36 1.04 11.64 
100.5
7 -11.58 
Cl19 -0.51 5.70E-05 
456.6
7 
-
458.9
4 
-
456.6
7 0.15 1.13 1.28 17.51 16.86 96.32 0.65 3.68 
225.4
7 -25.46 
Complex 3 
Ru1 0.61 
-2.19E-
04 
4402.
64 
-
4424.
27 
-
4402.
64 0.38 1.62 1.67 43.39 40.81 94.04 2.59 5.96 
106.2
6 1.22 
C6 -0.09 4.70E-05 37.61 -37.79 -37.61 0.12 0.21 0.09 6.09 3.95 64.85 2.14 35.15 62.00 -9.97 
C9 -0.13 5.00E-06 37.62 -37.81 -37.62 0.22 0.11 0.11 6.13 4.04 65.88 2.09 34.12 74.45 -9.49 
C10 -0.11 
-3.23E-
04 37.62 -37.81 -37.62 0.23 0.17 0.07 6.11 4.02 65.83 2.09 34.17 72.73 -11.84 
C14 -0.12 
-2.76E-
04 37.62 -37.81 -37.62 0.22 0.19 0.08 6.12 4.03 65.84 2.09 34.16 71.81 -10.51 
C16 -0.11 
-2.92E-
04 37.62 -37.81 -37.62 0.23 0.17 0.10 6.11 4.03 65.88 2.09 34.12 73.50 -8.17 
C17 -0.06 1.29E-04 37.61 -37.79 -37.61 0.19 0.20 0.06 6.06 3.93 64.88 2.13 35.12 59.99 -7.18 
P13 1.18 
-4.25E-
04 
337.9
8 
-
339.6
4 
-
337.9
8 1.17 0.04 1.20 13.82 11.82 85.56 1.99 14.44 86.26 -13.55 
Cl19 -0.56 9.90E-05 
456.6
4 
-
458.8
9 
-
456.6
4 0.18 1.34 1.51 17.56 16.96 96.55 0.61 3.45 
232.1
2 -23.71 
Cl20 -0.56 8.70E-05 
456.6
4 
-
458.8
9 
-
456.6
4 0.18 0.95 1.12 17.56 16.93 96.41 0.63 3.59 
227.2
9 -28.25 
Complex 4 
Ru1 0.66 
-9.94E-
04 
4402.
56 
-
4425.
01 
-
4402.
56 0.32 0.83 0.83 43.34 40.85 94.26 2.49 5.74 
108.2
7 13.22 
C6 -0.12 
-1.33E-
04 37.62 -37.82 -37.62 0.21 0.13 0.14 6.12 4.03 65.89 2.09 34.11 72.94 -9.46 
382 
C10 -0.13 2.99E-04 37.62 -37.81 -37.62 0.23 0.14 0.15 6.13 4.04 65.98 2.08 34.02 74.94 -11.14 
C11 -0.09 
-1.85E-
04 37.62 -37.81 -37.62 0.18 0.14 0.06 6.09 3.95 64.93 2.13 35.07 61.77 -10.48 
C18 -0.08 
-7.89E-
04 37.63 -37.82 -37.63 0.17 0.02 0.17 6.08 3.95 64.97 2.13 35.03 59.74 -7.55 
C19 -0.11 
-1.06E-
04 37.63 -37.83 -37.63 0.23 0.19 0.15 6.11 4.02 65.90 2.08 34.10 71.34 -12.70 
C21 -0.10 
-1.79E-
04 37.61 -37.80 -37.61 0.25 0.20 0.15 6.10 4.02 65.93 2.08 34.07 75.47 -8.71 
P12 1.01 
-1.38E-
04 
338.0
7 
-
339.8
0 
-
338.0
7 1.10 0.44 0.66 13.99 11.96 85.54 2.02 14.46 94.56 -13.89 
O16 -0.94 3.90E-05 74.50 -74.88 -74.50 0.14 0.66 0.77 8.94 7.90 88.30 1.05 11.70 
100.2
7 -12.42 
Cl23 -0.52 6.70E-05 
456.6
6 
-
458.9
9 
-
456.6
6 0.16 1.16 1.31 17.52 16.88 96.34 0.64 3.66 
225.6
9 -23.34 
q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %(A) is percentage of average number of electrons localized in 
atom A, %(A,A') is the percentage of electron delocalization index of atom A, KScaled(A) is approximation to virial-based 
total energy of atom A, Intra(A)| is magnitude of Intraatomic dipole moment of atom A, Ee(A) is contribution of atom A to 
electronic energy of molecule, Vol(A) is the volume bounded by an isosurface of the electron density distribution (0.001) 
and by interatomic surfaces of atom A and zz= Out of plane magnetizability contribution of atom A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.34: The correlation in the atomic properties of complexes 1, 2, 3 and 4. 
 
 Complex 1 Complex 2 Complex 3 Complex 4 
383 
 K(A) Ee(A)
Bond
(A)|
ZZ(A
) K(A) Ee(A)
Bond
(A)|
ZZ(A
) K(A) Ee(A)
Bond
(A)|
ZZ(A
) K(A) Ee(A)
Bond
(A)|
ZZ(A
) 
q(A) 0.26 -0.26 -0.12 0.28 0.25 -0.25 -0.11 0.31 0.26 -0.26 -0.14 0.30 0.25 -0.25 -0.14 0.40 
L(A) 0.07 -0.07 -0.16 0.19 -0.35 0.35 -0.36 0.38 0.03 -0.03 -0.16 0.13 -0.08 0.08 0.10 0.00 
K(A) 1.00 -1.00 0.56 -0.17 1.00 -1.00 0.33 -0.13 1.00 -1.00 0.57 -0.03 1.00 -1.00 0.30 0.35 
KScal
ed(A) -1.00 1.00 -0.56 0.17 -1.00 1.00 -0.33 0.13 -1.00 1.00 -0.57 0.03 -1.00 1.00 -0.30 -0.35 
Ee(A) -1.00 1.00 -0.56 0.17 -1.00 1.00 -0.33 0.13 -1.00 1.00 -0.57 0.03 -1.00 1.00 -0.30 -0.35 
Intra(
A)| 0.11 -0.11 0.52 -0.06 0.11 -0.11 0.75 -0.13 0.13 -0.13 0.52 -0.05 0.13 -0.13 0.73 -0.07 
Bond(
A)| 0.56 -0.56 1.00 -0.57 0.33 -0.33 1.00 -0.54 0.57 -0.57 1.00 -0.48 0.30 -0.30 1.00 -0.38 
(A)| 0.64 -0.64 0.69 -0.66 0.53 -0.53 0.63 -0.60 0.63 -0.63 0.66 -0.52 0.43 -0.43 0.62 -0.38 
N(A) 0.89 -0.89 0.77 -0.56 0.90 -0.90 0.61 -0.51 0.88 -0.88 0.77 -0.46 0.89 -0.89 0.58 -0.09 
(A) 0.90 -0.90 0.76 -0.56 0.91 -0.91 0.59 -0.49 0.90 -0.90 0.77 -0.44 0.91 -0.91 0.56 -0.05 
%(A) 0.45 -0.45 0.79 -0.83 0.40 -0.40 0.72 -0.79 0.44 -0.44 0.76 -0.79 0.40 -0.40 0.69 -0.59 
(A,A'
) 0.33 -0.33 0.46 -0.30 0.33 -0.33 0.51 -0.47 0.30 -0.30 0.43 -0.35 0.30 -0.30 0.45 -0.39 
%(A,
A') -0.45 0.45 -0.79 0.83 -0.40 0.40 -0.72 0.79 -0.44 0.44 -0.76 0.79 -0.40 0.40 -0.69 0.59 
Vol(A) 0.29 -0.29 0.65 -0.94 0.34 -0.34 0.61 -0.90 0.31 -0.31 0.66 -0.87 0.35 -0.35 0.62 -0.65 
 -0.17 0.17 -0.57 1.00 -0.13 0.13 -0.54 1.00 -0.03 0.03 -0.48 1.00 0.35 -0.35 -0.38 1.00 
 
 
 
Table 3.35: The sum total of the computed atomic properties over all the atoms in complexes 1, 2, 3 
and 4 from DGDVZP(Ru)|6-31+G(d,p) systems. 
 
 q(A) L(A) K(A) 
KScaled
(A) Ee(A)
Intra(
A)|
Bond(
A)| (A)| N(A) (A) 
%(A
)
(A,A
')
(A,
A') 
Vol(A
)
ZZ(A
) 
1 0.00 
-
1.05E-
03 
6,322.
29 
-
6,337.
02 
-
6,322.
29 10.42 12.09 10.96 
204.0
0 
158.5
0 58.48 45.50 41.52 
2,541.
90 
-
203.4
4 
2 1.00 
-
6.96E-
04 
5,938.
65 
-
5,953.
02 
-
5,938.
65 10.31 11.75 8.82 
196.0
0 
149.6
7 55.94 46.33 44.06 
2,439.
26 
-
190.7
7 
3 0.00 
-
1.14E-
03 
6,478.
23 
-
6,494.
30 
-
6,478.
23 11.73 12.20 12.53 
236.0
0 
177.6
4 56.73 58.36 43.27 
3,156.
67 
-
247.3
0 
4 1.00 
1.82E-
03 
6,094.
61 
-
6,110.
31 
-
6,094.
61 11.71 11.61 10.45 
228.0
0 
168.8
4 54.86 59.16 45.14 
3,058.
97 
-
219.5
1 
 
Table 3.36: Thermodynamic properties of the complexes in KJ/mol or KJ/mol-K  
PBE0/ECP(Ru,Cl)[6-31G*] 
Complexes E0 E H G TC E CV S KJ/mol- Imaginary No. Nor 
384 
KJ/mol KJ/mol-K K Vib Mode 
1 -2.67E+06 -2.67E+06 -2.67E+06 -2.67E+06 7.51E+02 0.32 0.62 0 102 
2 -3.18E+06 -3.18E+06 -3.18E+06 -3.18E+06 8.15E+02 0.37 0.69 0 114 
3 -3.38E+06 -3.38E+06 -3.38E+06 -3.38E+06 8.48E+02 0.39 0.69 0 120 
4 -2.68E+06 -2.68E+06 -2.68E+06 -2.69E+06 8.08E+02 0.31 0.55 1 108 
5 -3.30E+06 -3.30E+06 -3.30E+06 -3.30E+06 9.52E+02 0.38 0.66 0 129 
PBE0/ECP(Ru)[6-31+G(d,p)] 
1 -3.84E+06 -3.84E+06 -3.84E+06 -3.84E+06 7.49E+02 0.32 0.62 0 102 
2 -4.35E+06 -4.35E+06 -4.35E+06 -4.35E+06 8.13E+02 0.37 0.69 0 114 
3 -4.55E+06 -4.55E+06 -4.55E+06 -4.55E+06 8.46E+02 0.70 0.39 0 120 
4 -2.69E+06 -2.68E+06 -2.68E+06 -2.69E+06 8.06E+02 0.31 0.55 0 108 
5 -3.30E+06 -3.30E+06 -3.30E+06 -3.30E+06 9.49E+02 0.38 0.66 0 129 
 
 
Table 3.37: The total energy of the complexes in KJ/mol computed scaling up the functional and basis 
sets 
Functional/Basis Sets 1 2 3 4 5 
PBE0/ECP(Ru,Cl)[6-31G*] -2.6733E+06 -3.1824E+06 -3.3823E+06 -2.6853E+06 -3.2957E+06 
B3LYP/3-21G -1.5195E+07 -1.5700E+07 -1.5899E+07 -1.4042E+07 -1.4649E+07 
PBE0/ECP(Ru)[6-31+G(d,p)] -3.8441E+06 -4.3515E+06 -4.5514E+06 -2.6858E+06 -3.2962E+06 
B3LYP/ECP(Ru)[6-31+G(d,p)] -1.5265E+07 -1.5773E+07 -1.5973E+07 -1.4107E+07 -1.4718E+07 
MP2/ECP(Ru)[6-31+G(d,p)] -3.8288E+06 -4.3340E+06 -4.5329E+06 -2.6712E+06 -3.2789E+06 
B3LYP/DGDZVP(Ru)[6-31G*] -1.5266E+07 -1.5774E+07 -1.5974E+07 -1.4108E+07 -1.4719E+07 
B3LYP/DGDZVP(Ru)[6-
31+G(d,p)] -1.5265E+07 -1.5773E+07 -1.5973E+07 -1.4107E+07 -1.4718E+07 
B3LYP/acc-pvtz -1.5069E+07 -1.5576E+07 -1.5773E+07 -1.3907E+07 -1.4520E+07 
 
The SCF of the both MP2/DGDZVP(Ru)[6-31+G(d,p) and B3LYP/aug-cc-pVTZ are prohibitively expensive and therefore 
is unconverged 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.38: Bond distances (Å) and bond order of the ruthenium ligand bonds of the complexes 
bpyr dpy pth raz ter 
Pair Dist Order Pair Dist Order Pair Dist Order Pair 
Distan
ce Order Pair Dist Order 
385 
Ru-C9 2.267 0.387 Ru-C7 2.233 0.408 Ru-C13 2.236 0.376 Ru-C2 2.262 0.384 Ru-C20 2.269 0.399 
Ru-C13 2.232 0.428 Ru-C8 2.254 0.371 Ru-C18 2.236 0.375 Ru-C5 2.241 0.435 Ru-C23 2.29 0.361 
Ru-C18 2.236 0.401 Ru-C13 2.277 0.35 Ru-C25 2.261 0.414 Ru-C3 2.252 0.413 Ru-C26 2.269 0.399 
Ru-C10 2.226 0.414 Ru-C18 2.233 0.408 Ru-C14 2.251 0.39 Ru-C6 2.252 0.412 Ru-C18 2.252 0.419 
Ru-C16 2.228 0.405 Ru-C14 2.239 0.36 Ru-C21 2.264 0.411 Ru-C4 2.263 0.384 Ru-C22 2.252 0.419 
Ru-C19 2.222 0.378 Ru-C19 2.254 0.372 Ru-C23 2.253 0.387 Ru-C7 2.242 0.435 Ru-C27 2.289 0.361 
Ru-Cl22 2.394 1.007 Ru-Cl10 2.396 1.052 Ru-Cl7 2.39 0.996 Ru-N10 2.162 0.363 Ru-N14 2.152 0.423 
Ru-N12 2.137 0.361 Ru-N11 2.096 0.431 Ru-N10 2.138 0.371 Ru-N13 2.162 0.363 Ru-N15 2.039 0.47 
Ru-N17 2.139 0.361 Ru-N16 2.096 0.43 Ru-N16 2.138 0.371 Ru-N15 2.084 0.417 Ru-N21 2.153 0.424 
 
 
 
 
Table 3.39: H-bonding properties of the complexes 
 
(r) 2(r) 
Ellipticity K 
BPL - 
GBL_I V G L GBL_I V/G 
Complex 1 
O2···H24 0.0101 0.0388 0.4777 -0.0016 0.1887 -0.0065 0.0081 -0.0097 4.7207 0.7994 
O2···H29 0.0100 0.0384 0.5142 -0.0016 0.1942 -0.0064 0.0080 -0.0096 4.7341 0.7961 
0.0000 
H34···H38 0.0092 0.0403 1.7449 -0.0027 0.5505 -0.0047 0.0074 -0.0101 4.0818 0.6359 
0.0000 
O2···H31 0.0164 0.0614 0.3859 -0.0018 0.1265 -0.0118 0.0136 -0.0154 4.2711 0.8686 
O28···H36 0.0168 0.0625 0.3248 -0.0017 0.1049 -0.0122 0.0139 -0.0156 4.2285 0.8778 
 
 
 
 
 
 
 
 
 
Table 3.40: The C-H as H-Bonding donor represented with superscript ―*‖ and another C-H in the same 
chemical environment but without taking part in H-Bonding 
Bonds (r) 
2(r) Ellipticity K 
BPL - 
GBL_I V G L GBL_I V/G 
386 
Complex 1 
*C5 - H24 0.2878 -1.1061 0.0325 0.3084 3.98E-04 -0.3403 0.0319 0.2765 2.0107 10.6741 
*C15 - H29 0.2877 -1.1053 0.0325 0.3082 4.00E-04 -0.3402 0.0319 0.2763 2.0108 10.6583 
C11 - H30 0.2883 -1.1066 0.0263 0.3079 1.09E-04 -0.3391 0.0312 0.2766 2.0123 10.8581 
C21 - H35 0.2884 -1.1074 0.0262 0.3080 1.08E-04 -0.3392 0.0312 0.2768 2.0122 10.8735 
Complex 2 
*C12 - H34 0.2853 -1.0584 0.0099 0.2998 8.50E-05 -0.3349 0.0351 0.2646 2.0199 9.5281 
*C21 - H38 0.2845 -1.0570 0.0088 0.2987 1.47E-04 -0.3332 0.0345 0.2643 2.0224 9.6668 
C3 - H27 0.2846 -1.0676 0.0088 0.2998 3.50E-05 -0.3328 0.0329 0.2669 2.0223 10.1006 
C22 - H39 0.2850 -1.0639 0.0101 0.2998 1.20E-05 -0.3337 0.0339 0.2660 2.0206 9.8550 
Complex 3 
*C14 - H31 0.2886 -1.1003 0.0080 0.3076 7.00E-05 -0.3402 0.0326 0.2751 2.0160 10.4485 
*C23 - H36 0.2888 -1.1040 0.0081 0.3084 6.80E-05 -0.3409 0.0324 0.2760 2.0155 10.5077 
C21 - H35 0.2832 -1.0352 0.0102 0.2941 1.80E-05 -0.3294 0.0353 0.2588 2.0245 9.3285 
C25 - H37 0.2833 -1.0361 0.0096 0.2942 1.80E-05 -0.3294 0.0352 0.2590 2.0246 9.3567 
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Table 3.41: The second order perturbation of NBO donor and acceptor orbitals 
bpy dipy phth raz ter 
obt Donor obt Acceptor E
(2)
 obt Donor obt Acceptor E
(2)
 obt Donor obt Acceptor E
(2)
 obt Donor obt Acceptor E
(2)
 obt Donor obt Acceptor E
(2) 
87 n(2)Ru  423
*(2) 
C18C19 26.81 95 n(1)Ru  109 n(2) N16  12.9 103 n(2)Ru  488
*(2) 
C13C14 18.25 91 n(2)Ru  398
*(2) 
C2C4 23.17 103 n(1)Ru  114 n(2) N21  10.29 
88 n(3)Ru  403 *(2) C9C13 18.9 96 n(2)Ru  456
*(2) 
C7C13 
10.8
1 103 n(2)Ru  500
*(2) 
C18C23 19.23 92 n(3)Ru  401
*(2) 
C3C5 19.8 104 n(2)Ru  519
*(2) 
C23C27 21.54 
88 n(3)Ru  406
*(2) 
C10C16 22.02 96 n(2)Ru  459
*(2) 
C8C14 
18.5
7 104 n(3)Ru  506
*(2) 
C21C25 25.94 92 n(3)Ru  408
*(2) 
C6C7 19.5 105 n(3)Ru  507
*(2) 
C18C20 18.5 
95 n(1) N12  102 n*(4)Ru  14.03 97 n(3)Ru  475
*(2) 
C18C19 
21.4
1 114 n(1) N10  121 n*(4)Ru  16.2 2 (1) C2C4  99 n*(5)Ru  12.32 105 n(3)Ru  516
*(2) 
C22C26 18.81 
95 n(1) N12  103 n*(5)Ru  58.16 107 n(1) N11  115 n*(4)Ru  18.1 114 n(1) N10  122 n*(5)Ru  59.16 3 (2) C2C4  99 n*(5)Ru  89.65 111 n(1) N14  115 n*(4)Ru  57.71 
95 n(1) N12  104 n*(6)Ru  33.36 107 n(1) N11  116 n*(5)Ru  
70.4
5 114 n(1) N10  123 n*(6)Ru  27.99 3 (2) C2C4  100 n*(6)Ru  15.13 111 n(1) N14  116 n*(5)Ru  17.3 
97 n(1) N17  102 n*(4)Ru  14.78 107 n(1) N11  117 n*(6)Ru  
32.2
1 115 n(1) N16  121 n*(4)Ru  16.38 6 (2) C3C5  98 n*(4)Ru  70.5 111 n(1) N14  117 n*(6)Ru  27.05 
97 n(1) N17  103 n*(5)Ru  57.21 13
(1) 
C7C8 116 n*(5)Ru  
12.2
7 115 n(1) N16  122 n*(5)Ru  59.19 6 (2) C3C5  99 n*(5)Ru  19.76 112 n(1) N15  116 n*(5)Ru  118.46 
97 n(1) N17  104 n*(6)Ru  33.1 15
(2) 
C7C13 115 n*(4)Ru  69.11 115 n(1) N16  123 n*(6)Ru  28.02 6 (2) C3C5  100 n*(6)Ru  13.45 112 n(1) N15  117 n*(6)Ru  25.6 
16
(1) 
C9C13 102 n*(4)Ru  10.59 15
(2) 
C7C13 116 n*(5)Ru  11.66 107 n(1)Cl7  121 n*(4)Ru  17.59 13 (2) C6C7  98 n*(4)Ru  70.86 113 n(1) N21  115 n*(4)Ru  63.65 
17
(2) 
C9C13 102 n*(4)Ru  87.37 15
(2) 
C7C13 117 n*(6)Ru  
10.8
4 108 n(2)Cl7  121 n*(4)Ru  17.78 13 (2) C6C7  99 n*(5)Ru  19.52 113 n(1) N21  116 n*(5)Ru  11.61 
19
(1) 
C10C16 103 n*(5)Ru  11.48 18
(2) 
C8C14 115 n*(4)Ru  
47.1
6 108 n(2)Cl7  123 n*(6)Ru  10.2 13 (2) C6C7  100 n*(6)Ru  13.47 113 n(1) N21  117 n*(6)Ru  26.95 
20
(2) 
C10C16 103 n*(5)Ru  77.73 18
(2) 
C8C14 116 n*(5)Ru  
28.6
3 110 n(4)Cl7  121 n*(4)Ru  185.27 93 n(1) N10  98 n*(4)Ru  48.83 35
(2) 
C18C20 115 n*(4)Ru  70.99 
20
(2) 
C10C16 104 n*(6)Ru  16.06 18
(2) 
C8C14 117 n*(6)Ru  17.11 110 n(4)Cl7  123 n*(6)Ru  37.72 93 n(1) N10  99 n*(5)Ru  9.9 35
(2) 
C18C20 116 n*(5)Ru  15.15 
25
(1) 
C13C18 103 n*(5)Ru  10.83 33
(1) 
C18C19 116 n*(5)Ru  
10.7
1 22
(2) 
C13C14 121 n*(4)Ru  20.94 93 n(1) N10  100 n*(6)Ru  28.72 35
(2) 
C18C20 117 n*(6)Ru  13.12 
37
(2) 
C18C19 102 n*(4)Ru  32.3 34
(2) 
C18C19 116 n*(5)Ru  
73.2
4 22
(2) 
C13C14 122 n*(5)Ru  70.12 95 n(1) N13  98 n*(4)Ru  48.81 44
(2) 
C22C26 115 n*(4)Ru  63.72 
37
(2) 
C18C19 103 n*(5)Ru  52.5 34
(2) 
C18C19 117 n*(6)Ru  
15.2
6 22
(2) 
C13C14 123 n*(6)Ru  15.69 95 n(1) N13  99 n*(5)Ru  9.86 44
(2) 
C22C26 116 n*(5)Ru  22.29 
37
(2) 
C18C19 104 n*(6)Ru  16.34 103 n(1)Cl10  115 n*(4)Ru  
16.4
9 34
(2) 
C18C23 121 n*(4)Ru  22.57 95 n(1) N13  100 n*(6)Ru  28.71 44
(2) 
C22C26 117 n*(6)Ru  13.12 
98 n(1)Cl22  102 n*(4)Ru  17.04 104 n(2)Cl10  115 n*(4)Ru  
16.9
3 34
(2) 
C18C23 122 n*(5)Ru  68.06 96 n(1) N15  99 n*(5)Ru  102.44 46
(1) 
C23C27 116 n*(5)Ru  11.73 
99 n(2)Cl22  102 n*(4)Ru  17.79 106 n(4)Cl10  115 n*(4)Ru  
201.
91 34
(2) 
C18C23 123 n*(6)Ru  15.72 96 n(1) N15  100 n*(6)Ru  25.01 47
(2) 
C23C27 116 n*(5)Ru  80.31 
101 n(4)Cl22  102 n*(4)Ru  197.12 106 n(4)Cl10  117 n*(6)Ru  
36.4
3 39
(1) 
C21C25 121 n*(4)Ru  11.6      47
(2) 
C23C27 117 n*(6)Ru  14.63 
101 n(4)Cl22  104 n*(6)Ru  36.26      40
(2) 
C21C25 121 n*(4)Ru  96.13          
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Table 3.42: The amount of electron transferred to the acceptor orbitals and their energy level values for 
the five complexes 
1 2 3 
Ob
t Acceptor e Energy Obt Acceptor e Energy Obt Acceptor e Energy 
10
2  n*(4)Ru  0.87434 0.35967 115 n*(4)Ru  0.87533 0.35947 121 n*(4)Ru  0.86496 0.34522 
10
3  n*(5)Ru  0.74736 0.33432 116 n*(5)Ru  0.75181 0.33217 122 n*(5)Ru  0.74216 0.31543 
10
4  n*(6)Ru  0.21177 0.01293 117 n*(6)Ru  0.21035 0.01637 123 n*(6)Ru  0.20406 0.02081 
40
3  *(2) C9C13 0.36325 0.14514 456 *(2) C7C13 0.39975 0.14684 488
*(2) 
C13C14 0.32278 0.10755 
40
6  *(2) C10C16 0.35698 0.13511 459 *(2) C8C14 0.38484 0.13694 500
*(2) 
C18C23 0.32044 0.10717 
42
3  *(2) C18C19 0.33342 0.13002 475
*(2) 
C18C19 0.41816 0.14586 506
*(2) 
C21C25 0.34831 0.12365 
            
 4    5       
Ob
t Acceptor e Energy Obt Acceptor e Energy     
98 n*(4)Ru  0.76334 0.4648 115  n*(4)Ru  0.77615 0.45347     
99 n*(5)Ru  0.75292 0.46237 116  n*(5)Ru  0.77258 0.45078     
10
0  n*(6)Ru  0.18956 0.12562 117  n*(6)Ru  0.18824 0.11449     
39
8  *(2) C2C4 0.30837 0.25545 114  n(2) N 21  1.31156 0.47767     
40
1  *(2) C3C5 0.31954 0.25861 507 
 *(2) 
C18C20 0.31805 0.24868     
40
8  *(2) C6C7 0.31948 0.25857 516 
 *(2) 
C22C26 0.31775 0.24853     
    519 
 *(2) 
C23C27 0.30475 0.24754     
 
Table 3.43: The induced energy and dipole of each fragment of ligands coordinated to metal through 
NEDA analysis for the five complexes 
Complexes  Fragment 1 Fragment 2  Fragment 3 Fragment 4 
1 E(ind) -0.8162 -1.7613 -1.5040 -0.7680 
 Dipole (ind) 0.3878 7.4842 1.1558 1.0618 
2 E(ind) -0.8371 -2.0440 -1.4205 -0.7389 
 Dipole (ind) 0.3398 5.0347 1.0371 1.0819 
3 E(ind) -0.8263 2.1367 -0.7788 -1.4994 
 Dipole (ind) 0.4199 11.5244 1.0331 1.3137 
4 E(ind) -0.8337 -1.2962 -1.7371  
 Dipole (ind) 0.3263 1.1486 6.7520  
5 E(ind) -0.8695 -2.2202 -1.3309  
 Dipole (ind) 0.3455 6.2617 1.2446  
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Table 3.44: The NEDA analysis of the complexes showing the contribution of different factors to the 
total interaction energies (i.e. stability energies) 
 1 2 3 4 5 
SE 818.92 760 835.99 747.73 794.78 
ES -825.88 -1121.16 -1087.51 -362.65 -589.75 
POL -1630.15 -1513.15 -1666.82 -1490.34 -1582.56 
XC -316.08 -307.19 -324.34 -272.18 -285.7 
Electrical (Elec= 
ES+POL+SE)  -1637.11 -1874.31 -1918.35 -1105.26 -1377.52 
Charge Transfer 
(CT)  -1197.82 -1566.92 -1559.06 -721.95 -1107.53 
Core (XC+DEF-
SE)  1908.05 2095.8 2128.62 1406.67 1693.56 
Total Interaction 
(E=Elec + CT + 
Core)  -926.89 -1345.43 -1348.79 -420.55 -791.49 
 
The components of energy are defines in terms of electrostatic interaction (ES); polarization (POL); electrical self-energy 
(SE); exchange interaction (XC); deformation energy (DEF), Electrical (ES+POL+SE), Core (XC+DEF-SE) and Total 
Interaction energy which is the final net H-bond energy (E = Electrical + Core + CT) 
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Table 3.45: Selected bond properties involving ruthenium or hydrogen bond (Bonds with superscript 
―#‖) obtained through QTAIM analysis of DGDZVP(Ru)[6-31+G(d,p)] basis set type of systems. 
Complex 1 
Bonds (r) 
2(r) Ellipticity K 
BPL - 
GBL_I V G L GBL_I V/G 
Ru1 - C10 0.077 0.235 0.621 0.015 1.50E-02 -0.088 0.073 -0.059 4.210 1.200 
Ru1 - C13 0.077 0.231 0.658 0.015 1.84E-02 -0.088 0.073 -0.058 4.220 1.200 
Ru1 - C19 0.078 0.237 1.030 0.015 1.99E-02 -0.089 0.074 -0.059 4.200 1.200 
Ru1 - Cl22 0.073 0.216 0.162 0.011 1.06E-03 -0.075 0.065 -0.054 4.520 1.160 
Ru1 - N17 0.082 0.415 0.428 0.005 1.88E-03 -0.114 0.109 -0.104 4.040 1.050 
Ru1 - N12 0.082 0.417 0.417 0.005 2.00E-03 -0.114 0.109 -0.104 4.040 1.050 
Complex 2 
Ru1 - C7 0.077 0.222 0.399 0.015 9.17E-03 -0.086 0.071 -0.056 4.220 1.220 
Ru1 - C14 0.076 0.223 0.786 0.014 1.17E-02 -0.084 0.070 -0.056 4.230 1.200 
Ru1 - C18 0.077 0.222 0.400 0.015 9.20E-03 -0.086 0.071 -0.056 4.220 1.220 
Ru1 - Cl10 0.073 0.214 0.172 0.011 6.59E-04 -0.075 0.064 -0.053 4.530 1.170 
Ru1 - N11 0.094 0.445 0.319 0.011 5.10E-03 -0.133 0.122 -0.111 3.960 1.090 
Ru1 - N16 0.093 0.446 0.319 0.011 5.36E-03 -0.133 0.122 -0.111 3.960 1.090 
Complex 3 
Ru1 - C13 0.074 0.248 1.930 0.012 5.19E-02 -0.086 0.074 -0.062 4.230 1.160 
Ru1 - C14 0.072 0.240 1.600 0.011 3.01E-02 -0.083 0.071 -0.060 4.250 1.160 
Ru1 - C18 0.074 0.246 1.800 0.012 4.85E-02 -0.086 0.074 -0.062 4.230 1.170 
Ru1 - C23 0.072 0.241 2.010 0.011 3.73E-02 -0.082 0.071 -0.060 4.260 1.150 
Ru1 - C21 0.071 0.241 2.940 0.011 8.17E-02 -0.081 0.071 -0.060 4.280 1.150 
Ru1 - C25 0.071 0.238 2.000 0.011 5.91E-02 -0.082 0.070 -0.059 4.270 1.160 
Ru1 - Cl7 0.073 0.222 0.195 0.011 7.90E-05 -0.077 0.066 -0.055 4.520 1.160 
Ru1 - N10 0.083 0.418 0.434 0.006 3.61E-03 -0.116 0.110 -0.105 4.040 1.050 
Ru1 - N16 0.082 0.418 0.439 0.006 3.50E-03 -0.116 0.110 -0.105 4.040 1.050 
Complex 4 
Ru1 - C2 0.070 0.240 9.190 0.009 1.67E-01 -0.079 0.069 -0.060 4.280 1.130 
Ru1 - C3 0.072 0.235 1.560 0.012 2.42E-02 -0.082 0.070 -0.059 4.260 1.170 
Ru1 - C4 0.070 0.241 14.500 0.009 1.92E-01 -0.079 0.069 -0.060 4.280 1.130 
Ru1 - C5 0.075 0.241 1.670 0.013 3.95E-02 -0.087 0.074 -0.060 4.240 1.180 
Ru1 - C6 0.073 0.234 1.530 0.012 2.38E-02 -0.082 0.070 -0.059 4.260 1.170 
Ru1 - C7 0.075 0.242 1.720 0.013 4.08E-02 -0.087 0.074 -0.060 4.240 1.180 
Ru1 - N10 0.080 0.372 0.185 0.006 2.11E-02 -0.105 0.099 -0.093 4.090 1.060 
Ru1 - N13 0.080 0.372 0.185 0.006 2.11E-02 -0.105 0.099 -0.093 4.090 1.060 
Ru1 - N15 0.097 0.433 0.314 0.013 1.50E-02 -0.135 0.122 -0.108 3.940 1.110 
Complex 5 
Ru1 - C18 0.073 0.238 1.790 0.012 4.69E-02 -0.084 0.072 -0.060 4.260 1.170 
Ru1 - C20 0.070 0.227 1.520 0.011 2.19E-02 -0.078 0.068 -0.057 4.290 1.160 
Ru1 - C22 0.073 0.238 1.720 0.013 4.50E-02 -0.084 0.072 -0.059 4.260 1.170 
Ru1 - C26 0.070 0.228 1.550 0.011 2.23E-02 -0.078 0.068 -0.057 4.290 1.160 
Ru1 - N14 0.084 0.372 0.146 0.008 1.83E-02 -0.109 0.101 -0.093 4.070 1.080 
Ru1 - N15 0.109 0.469 0.285 0.021 9.59E-03 -0.158 0.138 -0.117 3.850 1.150 
Ru1 - N21 0.084 0.371 0.144 0.008 1.83E-02 -0.109 0.101 -0.093 4.070 1.080 
(r) is electron density,  is the Laplancian of (r), BPL – GBL_I is Bond strain, V is virial field (potential energy 
density), G is Lagrangian form of kinetic energy density, K is hamiltonian form of kinetic energy density, L (i.e. K – G) is 
lagrangian density which is (-1/4)  while ―Ratio‖ is V/G i.e. PE/KE (the higher its magnitude the stronger the Bond). 
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Table 3.46: Selected bond properties involving ruthenium or hydrogen bond (Bonds with superscript 
―#‖) obtained through QTAIM analysis of 3-21G basis set type of systems. 
Complex 1 
Bonds (r) 
2(r) Ellipticity K 
BPL - 
GBL_I V G L GBL_I V/G 
Ru1 - C9 6.88E-02 2.75E-01 1.41E+00 7.05E-03 3.42E-02 -8.28E-02 7.58E-02 -6.87E-02 4.26E+00 1.09E+00 
Ru1 - C10 7.31E-02 2.61E-01 3.77E-01 9.55E-03 1.79E-02 -8.43E-02 7.47E-02 -6.52E-02 4.22E+00 1.13E+00 
Ru1 - C13 7.36E-02 2.58E-01 3.43E-01 9.97E-03 1.53E-02 -8.45E-02 7.46E-02 -6.46E-02 4.22E+00 1.13E+00 
Ru1 - C16 7.24E-02 2.78E-01 7.42E-01 8.74E-03 2.80E-02 -8.69E-02 7.81E-02 -6.94E-02 4.21E+00 1.11E+00 
Ru1 - C18 7.00E-02 2.81E-01 1.10E+00 7.53E-03 3.15E-02 -8.52E-02 7.77E-02 -7.02E-02 4.23E+00 1.10E+00 
Ru1 - C19 7.45E-02 2.61E-01 4.84E-01 1.02E-02 1.71E-02 -8.56E-02 7.54E-02 -6.52E-02 4.20E+00 1.14E+00 
Ru1 - Cl22 6.39E-02 1.89E-01 1.38E-01 7.52E-03 1.02E-03 -6.23E-02 5.48E-02 -4.72E-02 4.62E+00 1.14E+00 
Ru1 - N12 8.34E-02 4.05E-01 3.50E-01 5.05E-03 3.38E-03 -1.11E-01 1.06E-01 -1.01E-01 4.03E+00 1.05E+00 
Ru1 - N17 8.35E-02 4.09E-01 3.60E-01 4.98E-03 3.48E-03 -1.12E-01 1.07E-01 -1.02E-01 4.03E+00 1.05E+00 
O2 - H24# 1.68E-02 7.59E-02 2.73E-01 -2.33E-03 5.97E-02 -1.43E-02 1.66E-02 -1.90E-02 4.30E+00 8.60E-01 
Complex 2 
Ru1 - C7 7.50E-02 2.48E-01 1.82E-01 1.10E-02 9.64E-03 -8.41E-02 7.31E-02 -6.20E-02 4.21E+00 1.15E+00 
Ru1 - C8 6.73E-02 2.88E-01 2.43E+00 6.45E-03 3.28E-02 -8.50E-02 7.86E-02 -7.21E-02 4.25E+00 1.08E+00 
Ru1 - C13 6.58E-02 2.83E-01 4.46E+00 5.63E-03 3.10E-02 -8.21E-02 7.65E-02 -7.08E-02 4.29E+00 1.07E+00 
Ru1 - C14 7.41E-02 2.46E-01 4.02E-01 1.05E-02 1.15E-02 -8.25E-02 7.19E-02 -6.14E-02 4.22E+00 1.15E+00 
Ru1 - C19 6.73E-02 2.88E-01 2.44E+00 6.45E-03 3.36E-02 -8.50E-02 7.85E-02 -7.21E-02 4.25E+00 1.08E+00 
Ru1 - C18 7.50E-02 2.48E-01 1.82E-01 1.10E-02 9.69E-03 -8.41E-02 7.31E-02 -6.21E-02 4.21E+00 1.15E+00 
Ru1 - Cl10 6.39E-02 1.88E-01 1.38E-01 7.53E-03 4.15E-04 -6.20E-02 5.44E-02 -4.69E-02 4.62E+00 1.14E+00 
Ru1 - N11 9.24E-02 4.34E-01 2.67E-01 7.79E-03 6.65E-03 -1.24E-01 1.16E-01 -1.09E-01 3.97E+00 1.07E+00 
Ru1 - N16 9.24E-02 4.35E-01 2.66E-01 7.77E-03 6.94E-03 -1.24E-01 1.16E-01 -1.09E-01 3.97E+00 1.07E+00 
Complex 3 
Ru1 - C13 7.25E-02 2.66E-01 6.54E-01 9.16E-03 2.49E-02 -8.48E-02 7.56E-02 -6.65E-02 4.22E+00 1.12E+00 
Ru1 - C14 7.01E-02 2.58E-01 6.34E-01 8.05E-03 2.16E-02 -8.06E-02 7.25E-02 -6.45E-02 4.25E+00 1.11E+00 
Ru1 - C18 7.30E-02 2.62E-01 5.70E-01 9.58E-03 2.18E-02 -8.47E-02 7.51E-02 -6.55E-02 4.22E+00 1.13E+00 
Ru1 - C23 6.93E-02 2.61E-01 8.28E-01 7.55E-03 2.54E-02 -8.02E-02 7.27E-02 -6.51E-02 4.26E+00 1.10E+00 
Ru1 - C21 6.93E-02 2.60E-01 7.20E-01 7.71E-03 2.33E-02 -8.04E-02 7.27E-02 -6.50E-02 4.27E+00 1.11E+00 
Ru1 - C25 7.01E-02 2.57E-01 5.49E-01 8.21E-03 2.01E-02 -8.06E-02 7.24E-02 -6.42E-02 4.26E+00 1.11E+00 
Ru1 - Cl7 6.39E-02 1.93E-01 1.65E-01 7.45E-03 7.57E-04 -6.31E-02 5.57E-02 -4.82E-02 4.61E+00 1.13E+00 
Ru1 - N10 8.14E-02 4.03E-01 3.71E-01 4.63E-03 3.42E-03 -1.10E-01 1.05E-01 -1.01E-01 4.06E+00 1.04E+00 
Ru1 - N16 8.26E-02 4.08E-01 3.72E-01 4.93E-03 3.48E-03 -1.12E-01 1.07E-01 -1.02E-01 4.04E+00 1.05E+00 
O2 - H31# 1.60E-02 7.57E-02 7.35E-01 -2.64E-03 1.49E-01 -1.37E-02 1.63E-02 -1.89E-02 4.35E+00 8.38E-01 
O28 - H36# 1.82E-02 8.48E-02 3.61E-01 -2.29E-03 5.16E-02 -1.66E-02 1.89E-02 -2.12E-02 4.20E+00 8.79E-01 
Complex 4 
Ru1 - C2 6.81E-02 2.50E-01 8.34E-01 7.33E-03 3.16E-02 -7.71E-02 6.98E-02 -6.24E-02 4.27E+00 1.11E+00 
Ru1 - C3 7.01E-02 2.51E-01 6.89E-01 8.28E-03 2.14E-02 -7.94E-02 7.11E-02 -6.28E-02 4.25E+00 1.12E+00 
Ru1 - C4 6.80E-02 2.50E-01 8.52E-01 7.29E-03 3.21E-02 -7.71E-02 6.98E-02 -6.25E-02 4.27E+00 1.10E+00 
Ru1 - N15 9.48E-02 4.31E-01 2.81E-01 8.44E-03 1.65E-02 -1.25E-01 1.16E-01 -1.08E-01 3.95E+00 1.07E+00 
Ru1 - C5 7.19E-02 2.63E-01 5.67E-01 8.84E-03 2.32E-02 -8.35E-02 7.46E-02 -6.58E-02 4.23E+00 1.12E+00 
Ru1 - C6 7.01E-02 2.51E-01 6.77E-01 8.31E-03 2.12E-02 -7.93E-02 7.10E-02 -6.27E-02 4.25E+00 1.12E+00 
Ru1 - C7 7.19E-02 2.63E-01 5.80E-01 8.78E-03 2.35E-02 -8.34E-02 7.46E-02 -6.59E-02 4.23E+00 1.12E+00 
Ru1 - N10 7.92E-02 3.70E-01 2.39E-01 4.45E-03 1.84E-02 -1.01E-01 9.69E-02 -9.24E-02 4.09E+00 1.05E+00 
Ru1 - N13 7.91E-02 3.69E-01 2.39E-01 4.45E-03 1.84E-02 -1.01E-01 9.68E-02 -9.24E-02 4.09E+00 1.05E+00 
Complex 5 
Ru1 - C18 7.03E-02 2.60E-01 6.01E-01 8.16E-03 2.34E-02 -8.13E-02 7.31E-02 -6.50E-02 4.25E+00 1.11E+00 
Ru1 - C20 6.77E-02 2.44E-01 7.06E-01 7.52E-03 2.08E-02 -7.60E-02 6.85E-02 -6.10E-02 4.29E+00 1.11E+00 
Ru1 - C22 7.03E-02 2.60E-01 5.91E-01 8.20E-03 2.31E-02 -8.13E-02 7.31E-02 -6.49E-02 4.25E+00 1.11E+00 
Ru1 - C23 6.44E-02 2.42E-01 1.52E+00 5.76E-03 5.04E-02 -7.20E-02 6.62E-02 -6.05E-02 4.33E+00 1.09E+00 
Ru1 - C27 6.45E-02 2.42E-01 1.48E+00 5.81E-03 4.95E-02 -7.20E-02 6.62E-02 -6.04E-02 4.33E+00 1.09E+00 
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Ru1 - C26 6.77E-02 2.44E-01 7.14E-01 7.51E-03 2.10E-02 -7.61E-02 6.85E-02 -6.10E-02 4.29E+00 1.11E+00 
Ru1 - N14 8.27E-02 3.71E-01 1.83E-01 5.61E-03 1.65E-02 -1.04E-01 9.85E-02 -9.28E-02 4.08E+00 1.06E+00 
Ru1 - N15 1.06E-01 4.68E-01 2.60E-01 1.30E-02 1.17E-02 -1.43E-01 1.30E-01 -1.17E-01 3.86E+00 1.10E+00 
Ru1 - N21 8.26E-02 3.70E-01 1.81E-01 5.60E-03 1.65E-02 -1.04E-01 9.82E-02 -9.26E-02 4.08E+00 1.06E+00 
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Table 3.47: Selected bond properties involving ruthenium or hydrogen bond (Bonds with superscript 
―#‖) obtained through QTAIM analysis of ECP(Ru)[6-31+G(d,p)] basis set type of systems. 
Complex 1 
Bonds (r) 
2(r) Ellipticity K 
BPL - 
GBL_I V G L GBL_I V/G 
Ru1 - C19 7.99E-02 2.16E-01 1.04E+00 1.92E-02 1.50E-02 -9.24E-02 7.31E-02 -5.39E-02 4.20E+00 1.26E+00 
Ru1 - C10 7.88E-02 2.13E-01 6.80E-01 1.90E-02 1.80E-02 -9.10E-02 7.21E-02 -5.31E-02 4.21E+00 1.26E+00 
Ru1 - C13 7.87E-02 2.11E-01 7.01E-01 1.89E-02 1.88E-02 -9.05E-02 7.16E-02 -5.27E-02 4.22E+00 1.26E+00 
Ru1 - C18 7.45E-02 2.46E-01 4.50E+00 1.50E-02 4.94E-02 -9.17E-02 7.66E-02 -6.16E-02 4.23E+00 1.20E+00 
Ru1 - C16 7.65E-02 2.44E-01 3.71E+00 1.60E-02 6.56E-02 -9.28E-02 7.68E-02 -6.09E-02 4.21E+00 1.21E+00 
Ru1 - Cl22 7.48E-02 1.84E-01 1.34E-01 1.54E-02 1.27E-03 -7.69E-02 6.15E-02 -4.61E-02 4.52E+00 1.25E+00 
Ru1 - N17 8.41E-02 3.65E-01 3.74E-01 1.10E-02 2.72E-03 -1.13E-01 1.02E-01 -9.13E-02 4.04E+00 1.11E+00 
Ru1 - N12 8.46E-02 3.67E-01 3.65E-01 1.12E-02 2.97E-03 -1.14E-01 1.03E-01 -9.18E-02 4.04E+00 1.11E+00 
O2 - H24# 1.01E-02 3.87E-02 5.82E-01 -1.65E-03 2.04E-01 -6.37E-03 8.02E-03 -9.67E-03 4.72E+00 7.94E-01 
O2 - H29# 1.00E-02 3.83E-02 6.32E-01 -1.66E-03 2.11E-01 -6.26E-03 7.92E-03 -9.58E-03 4.73E+00 7.91E-01 
Complex 2 
Ru1 - C7 7.86E-02 2.02E-01 4.65E-01 1.93E-02 9.77E-03 -8.92E-02 6.99E-02 -5.05E-02 4.22E+00 1.28E+00 
Ru1 - C14 7.78E-02 2.04E-01 8.95E-01 1.82E-02 1.04E-02 -8.74E-02 6.92E-02 -5.09E-02 4.23E+00 1.26E+00 
Ru1 - C18 7.85E-02 2.02E-01 4.66E-01 1.93E-02 9.88E-03 -8.92E-02 6.99E-02 -5.06E-02 4.22E+00 1.28E+00 
Ru1 - Cl10 7.47E-02 1.82E-01 1.35E-01 1.54E-02 6.75E-04 -7.62E-02 6.08E-02 -4.54E-02 4.53E+00 1.25E+00 
Ru1 - N11 9.63E-02 3.90E-01 2.81E-01 1.76E-02 7.50E-03 -1.33E-01 1.15E-01 -9.76E-02 3.96E+00 1.15E+00 
Ru1 - N16 9.62E-02 3.91E-01 2.82E-01 1.76E-02 7.86E-03 -1.33E-01 1.15E-01 -9.77E-02 3.96E+00 1.15E+00 
H34 - H38# 9.33E-03 4.07E-02 2.60E+00 -2.74E-03 6.30E-01 -4.69E-03 7.43E-03 -1.02E-02 4.08E+00 6.32E-01 
Complex 3 
Ru1 - C13 7.67E-02 2.23E-01 1.64E+00 1.70E-02 3.30E-02 -8.98E-02 7.28E-02 -5.59E-02 4.23E+00 1.23E+00 
Ru1 - C14 7.43E-02 2.17E-01 1.48E+00 1.58E-02 2.56E-02 -8.59E-02 7.01E-02 -5.43E-02 4.25E+00 1.23E+00 
Ru1 - C18 7.68E-02 2.22E-01 1.57E+00 1.71E-02 3.14E-02 -8.95E-02 7.25E-02 -5.54E-02 4.23E+00 1.24E+00 
Ru1 - C23 7.38E-02 2.19E-01 1.73E+00 1.54E-02 2.83E-02 -8.55E-02 7.01E-02 -5.47E-02 4.26E+00 1.22E+00 
Ru1 - C21 7.27E-02 2.21E-01 2.31E+00 1.45E-02 4.99E-02 -8.41E-02 6.96E-02 -5.52E-02 4.28E+00 1.21E+00 
Ru1 - C25 7.31E-02 2.18E-01 1.79E+00 1.49E-02 4.02E-02 -8.43E-02 6.94E-02 -5.45E-02 4.27E+00 1.21E+00 
Ru1 - Cl7 7.50E-02 1.88E-01 1.41E-01 1.55E-02 6.90E-05 -7.80E-02 6.26E-02 -4.71E-02 4.52E+00 1.25E+00 
Ru1 - N10 8.54E-02 3.66E-01 3.58E-01 1.23E-02 3.22E-03 -1.16E-01 1.04E-01 -9.14E-02 4.04E+00 1.12E+00 
Ru1 - N16 8.54E-02 3.66E-01 3.61E-01 1.23E-02 3.18E-03 -1.16E-01 1.04E-01 -9.14E-02 4.04E+00 1.12E+00 
O2 - H31# 1.65E-02 6.08E-02 4.07E-01 -1.82E-03 1.29E-01 -1.16E-02 1.34E-02 -1.52E-02 4.27E+00 8.64E-01 
O28 - H36# 1.69E-02 6.18E-02 3.41E-01 -1.74E-03 1.06E-01 -1.20E-02 1.37E-02 -1.55E-02 4.23E+00 8.73E-01 
Complex 4 
Ru1 - C2 7.22E-02 2.18E-01 3.44E+00 1.39E-02 7.45E-02 -8.23E-02 6.84E-02 -5.45E-02 4.28E+00 1.20E+00 
Ru1 - C3 7.48E-02 2.11E-01 1.49E+00 1.62E-02 2.51E-02 -8.53E-02 6.90E-02 -5.28E-02 4.26E+00 1.23E+00 
Ru1 - C4 7.21E-02 2.18E-01 3.66E+00 1.38E-02 7.78E-02 -8.23E-02 6.84E-02 -5.46E-02 4.28E+00 1.20E+00 
Ru1 - C5 7.67E-02 2.21E-01 1.46E+00 1.72E-02 3.16E-02 -8.96E-02 7.24E-02 -5.52E-02 4.24E+00 1.24E+00 
Ru1 - C6 7.48E-02 2.11E-01 1.46E+00 1.63E-02 2.47E-02 -8.52E-02 6.90E-02 -5.27E-02 4.26E+00 1.24E+00 
Ru1 - C7 7.67E-02 2.21E-01 1.50E+00 1.71E-02 3.22E-02 -8.96E-02 7.24E-02 -5.53E-02 4.24E+00 1.24E+00 
Ru1 - N10 8.22E-02 3.29E-01 1.93E-01 1.17E-02 2.05E-02 -1.06E-01 9.41E-02 -8.24E-02 4.09E+00 1.12E+00 
Ru1 - N15 9.93E-02 3.83E-01 3.00E-01 1.97E-02 1.87E-02 -1.35E-01 1.16E-01 -9.59E-02 3.94E+00 1.17E+00 
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Ru1 - N13 8.21E-02 3.29E-01 1.93E-01 1.17E-02 2.05E-02 -1.06E-01 9.40E-02 -8.23E-02 4.09E+00 1.12E+00 
Complex 5 
Ru1 - C18 7.48E-02 2.18E-01 1.51E+00 1.62E-02 3.13E-02 -8.69E-02 7.07E-02 -5.45E-02 4.26E+00 1.23E+00 
Ru1 - C20 7.22E-02 2.05E-01 1.50E+00 1.50E-02 2.22E-02 -8.13E-02 6.63E-02 -5.13E-02 4.29E+00 1.23E+00 
Ru1 - C22 7.49E-02 2.18E-01 1.47E+00 1.63E-02 3.04E-02 -8.70E-02 7.07E-02 -5.44E-02 4.26E+00 1.23E+00 
Ru1 - C26 7.22E-02 2.06E-01 1.52E+00 1.50E-02 2.24E-02 -8.14E-02 6.64E-02 -5.14E-02 4.29E+00 1.23E+00 
Ru1 - N14 8.63E-02 3.26E-01 1.53E-01 1.40E-02 1.68E-02 -1.09E-01 9.55E-02 -8.15E-02 4.07E+00 1.15E+00 
Ru1 - N15 1.12E-01 4.15E-01 2.63E-01 2.71E-02 1.17E-02 -1.58E-01 1.31E-01 -1.04E-01 3.85E+00 1.21E+00 
Ru1 - N21 8.62E-02 3.25E-01 1.51E-01 1.39E-02 1.69E-02 -1.09E-01 9.52E-02 -8.13E-02 4.07E+00 1.15E+00 
 
 
Table 3.48: The correlation between the computed Bond properties of complexes 1 to 5 
 1 2 3 4 5 
 
2(r) 
Ellipti
city 
GBL_
I 
2(r) 
Elliptic
ity GBL_I 
2(r) 
Elliptic
ity GBL_I 
2(r) 
Elliptic
ity GBL_I 
2(r) 
Elliptic
ity GBL_I 
(r) -0.71 -0.71 -0.89 -0.65 -0.67 -0.86 -0.73 -0.69 -0.90 -0.88 -0.54 -0.88 -0.77 -0.73 -0.84 
2(r) 1.00 0.74 0.87 1.00 0.51 0.83 1.00 0.64 0.87 1.00 0.48 0.96 1.00 0.64 0.89 
Ellipticity 0.74 1.00 0.81 0.51 1.00 0.66 0.64 1.00 0.73 0.48 1.00 0.54 0.64 1.00 0.78 
K -0.54 -0.63 -0.76 -0.49 -0.51 -0.72 -0.59 -0.60 -0.79 -0.74 -0.46 -0.75 -0.59 -0.58 -0.69 
BPL.GBL
_I 0.35 0.41 0.59 0.23 0.87 0.32 0.55 0.62 0.70 0.58 0.98 0.62 0.73 0.89 0.82 
V 0.17 0.39 0.49 0.11 0.35 0.44 0.24 0.42 0.54 0.44 0.35 0.48 0.22 0.38 0.39 
G 0.29 -0.04 -0.09 0.33 -0.11 -0.06 0.24 -0.11 -0.12 0.12 -0.10 0.05 0.27 -0.06 0.05 
L -1.00 -0.74 -0.87 -1.00 -0.51 -0.83 -1.00 -0.64 -0.87 -1.00 -0.48 -0.96 -1.00 -0.64 -0.89 
GBL_I 0.87 0.81 1.00 0.83 0.66 1.00 0.87 0.73 1.00 0.96 0.54 1.00 0.89 0.78 1.00 
V/G -0.82 -0.67 -0.77 -0.78 -0.52 -0.78 -0.80 -0.51 -0.80 -0.75 -0.31 -0.79 -0.74 -0.50 -0.80 
 
 
Table 3.49: The Intra and inter atomic properties of atoms involve in Metal-Ligand and hydrogen 
bonding (atoms with superscript ―#‖) of systems treated with DGDZVP(Ru)[6-31+G(d,p)] basis 
set using QTAIM analysis 
Complex 1 
 q(A) L(A) K(A) 
K_Scale
d(A) Intra(A) Bond(A) |(A)| N(A) LI(A) 
%Loc(A
) 
DI(A,A'
)/2 
%Deloc
(A,A') 
Vol(A),0
.001 
Ru1 0.950 0.001 
4440.00
0 
-
4450.00
0 0.126 1.140 1.200 43.100 40.500 94.100 2.540 5.900 101.000 
C9 -0.063 0.000 37.800 -37.900 0.126 0.035 0.093 6.060 3.970 65.600 2.090 34.400 73.800 
C10 -0.047 0.000 37.800 -37.900 0.089 0.080 0.061 6.050 3.960 65.500 2.090 34.500 71.400 
C13 -0.050 0.000 37.800 -37.900 0.089 0.090 0.102 6.050 3.960 65.500 2.090 34.500 71.600 
C16 -0.051 0.000 37.800 -37.900 0.134 0.099 0.055 6.050 3.970 65.600 2.080 34.400 73.700 
C18 -0.058 0.000 37.800 -37.900 0.127 0.084 0.068 6.060 3.980 65.600 2.080 34.400 74.800 
C19 -0.029 0.000 37.800 -37.900 0.118 0.136 0.102 6.030 3.950 65.500 2.080 34.500 69.900 
Cl22 -0.527 0.000 459.000 
-
461.000 0.061 1.260 1.290 17.500 16.900 96.300 0.646 3.680 232.000 
N12 -0.759 0.000 54.800 -54.900 0.695 0.810 0.658 7.760 5.900 76.100 1.860 23.900 78.100 
N17 -0.759 0.000 54.800 -54.900 0.695 0.790 0.617 7.760 5.900 76.100 1.860 23.900 78.000 
Complex 2 
Ru1 0.959 0.000 
4440.00
0 
-
4450.00
0 0.085 1.120 1.180 43.000 40.500 94.000 2.570 5.960 104.000 
C7 -0.053 0.000 37.800 -38.000 0.075 0.066 0.061 6.050 3.960 65.400 2.090 34.600 70.100 
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C8 -0.063 0.000 37.800 -37.900 0.137 0.079 0.082 6.060 3.980 65.600 2.080 34.400 74.600 
C13 -0.053 0.000 37.800 -37.900 0.146 0.068 0.078 6.050 3.970 65.600 2.080 34.400 76.400 
C14 -0.027 -0.001 37.800 -37.900 0.111 0.144 0.092 6.030 3.950 65.500 2.080 34.500 69.600 
C18 -0.054 -0.001 37.800 -38.000 0.073 0.087 0.093 6.050 3.960 65.400 2.090 34.600 70.200 
C19 -0.063 0.000 37.800 -37.900 0.137 0.066 0.074 6.060 3.980 65.600 2.080 34.400 74.600 
Cl10 -0.521 0.000 459.000 
-
461.000 0.019 1.250 1.260 17.500 16.900 96.400 0.623 3.560 237.000 
N11 -1.220 0.000 55.100 -55.200 0.223 0.743 0.542 8.220 6.360 77.400 1.860 22.600 82.100 
N16 -1.220 0.000 55.100 -55.200 0.224 0.710 0.510 8.220 6.360 77.400 1.860 22.600 82.100 
Complex 3 
Ru1 0.955 0.000 
4440.00
0 
-
4450.00
0 0.090 0.833 0.840 43.000 40.500 94.100 2.520 5.860 99.900 
C13 -0.040 0.000 37.800 -38.000 0.121 0.145 0.081 6.040 3.960 65.500 2.080 34.500 70.600 
C14 -0.049 0.000 37.900 -38.000 0.121 0.281 0.400 6.050 3.970 65.600 2.080 34.400 69.800 
C18 -0.040 0.000 37.800 -38.000 0.118 0.136 0.086 6.040 3.960 65.500 2.080 34.500 70.700 
C21 -0.060 0.000 37.800 -38.000 0.099 0.102 0.132 6.060 3.970 65.500 2.090 34.500 73.600 
C23 -0.050 0.000 37.900 -38.000 0.128 0.287 0.412 6.050 3.970 65.600 2.080 34.400 70.200 
C25 -0.059 0.000 37.800 -38.000 0.096 0.113 0.140 6.060 3.970 65.500 2.090 34.500 73.300 
Cl7 -0.533 0.000 459.000 
-
461.000 0.035 1.270 1.300 17.500 16.900 96.400 0.631 3.600 236.000 
N10 -1.200 0.000 55.000 -55.200 0.200 1.140 0.947 8.200 6.360 77.500 1.840 22.500 83.000 
N16 -1.200 0.000 55.000 -55.200 0.201 1.100 0.912 8.200 6.360 77.500 1.840 22.500 83.000 
Complex 4 
Ru1 0.992 -0.001 
4430.00
0 
-
4450.00
0 0.147 0.442 0.399 43.000 40.600 94.300 2.460 5.710 110.000 
C2 -0.046 0.000 37.800 -37.900 0.132 0.071 0.066 6.050 3.970 65.600 2.080 34.400 73.300 
C3 -0.044 0.000 37.800 -37.900 0.107 0.081 0.066 6.040 3.960 65.600 2.080 34.400 70.700 
C4 -0.046 0.000 37.800 -37.900 0.133 0.087 0.092 6.050 3.970 65.600 2.080 34.400 73.400 
C5 -0.034 0.000 37.800 -37.900 0.127 0.096 0.091 6.030 3.960 65.600 2.080 34.400 72.700 
C6 -0.044 0.000 37.800 -37.900 0.106 0.088 0.081 6.040 3.960 65.600 2.080 34.400 70.600 
C7 -0.034 0.000 37.800 -37.900 0.127 0.100 0.098 6.030 3.960 65.600 2.080 34.400 72.600 
N10 -0.771 0.000 54.700 -54.900 0.728 0.796 0.594 7.770 5.950 76.600 1.820 23.400 82.900 
N13 -0.771 0.000 54.700 -54.900 0.728 0.791 0.581 7.770 5.950 76.600 1.820 23.400 82.900 
N15 -1.240 0.000 55.100 -55.300 0.186 0.447 0.331 8.240 6.400 77.700 1.840 22.300 80.600 
Complex 5 
Ru1 0.982 0.001 
4430.00
0 
-
4450.00
0 0.192 0.583 0.562 43.000 40.500 94.200 2.500 5.820 108.000 
C18 -0.036 0.000 37.800 -37.900 0.126 0.082 0.056 6.040 3.960 65.600 2.080 34.400 72.600 
C20 -0.048 0.000 37.800 -38.000 0.106 0.095 0.089 6.050 3.970 65.600 2.080 34.400 70.900 
C22 -0.036 0.000 37.800 -37.900 0.127 0.085 0.063 6.040 3.960 65.600 2.080 34.400 72.600 
C23 -0.049 0.000 37.800 -37.900 0.132 0.068 0.081 6.050 3.970 65.600 2.080 34.400 73.000 
C26 -0.048 -0.001 37.800 -38.000 0.107 0.128 0.127 6.050 3.970 65.600 2.080 34.400 71.000 
C27 -0.049 0.000 37.800 -37.900 0.131 0.091 0.107 6.050 3.970 65.600 2.080 34.400 72.900 
N14 -1.230 0.000 55.000 -55.200 0.199 0.621 0.462 8.230 6.400 77.800 1.830 22.200 85.800 
N15 -1.230 0.000 55.100 -55.300 0.216 0.369 0.232 8.230 6.350 77.200 1.880 22.800 79.000 
N21 -1.230 0.000 55.000 -55.200 0.199 0.517 0.370 8.230 6.400 77.800 1.830 22.200 85.800 
 q(A) is net charge of atom A, L(A) is Lagrangian of Atom A, N(A) is average number of electrons in atom A, K(A) is 
electronic kinetic energy of atom A (Hamiltonian Form), %Loc(A) is percentage of average number of electrons localized in 
atom A, K_Scaled(A) is approximation to virial-based total energy of atom A, Intra(A) is magnitude of Intraatomic dipole 
moment of atom A, Ee(A) is contribution of atom A to electronic energy of molecule, %Deloc(A,A') is the percentage of 
electron delocalization index of atom A and Vol(A) is the volume bounded by an isosurface of the electron density 
distribution (0.001) and by interatomic surfaces of atom A. 
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Table 3.50: The Intra and inter atomic properties of atoms involve in Metal-Ligand and hydrogen 
bonding (atoms with superscript ―#‖) of systems treated with 3-21G basis set using QTAIM 
analysis 
 
Complex 1 
 q(A) L(A) K(A) 
K_Scale
d(A) Intra(A) Bond(A) |(A)| N(A) LI(A) 
%Loc(A
) 
DI(A,A'
)/2 
%Deloc
(A,A') 
Vol(A),0
.001 
Ru1 
8.63E-
01 
5.52E-
04 
4.40E+0
3 
-
4.43E+0
3 
9.01E-
02 
1.10E+0
0 
1.19E+0
0 
4.31E+0
1 
4.07E+0
1 
9.43E+0
1 
2.46E+0
0 
5.71E+0
0 
9.73E+0
1 
C9 
-1.14E-
01 
-7.00E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.51E-
01 
1.18E-
01 
1.35E-
01 
6.11E+0
0 
4.04E+0
0 
6.60E+0
1 
2.08E+0
0 
3.40E+0
1 
7.66E+0
1 
C10 
-1.04E-
01 
-1.97E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.26E-
01 
1.65E-
01 
9.47E-
02 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.49E+0
1 
C13 
-1.09E-
01 
-1.11E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.25E-
01 
1.41E-
01 
1.16E-
01 
6.11E+0
0 
4.03E+0
0 
6.60E+0
1 
2.08E+0
0 
3.40E+0
1 
7.52E+0
1 
C16 
-9.09E-
02 
-5.60E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.72E-
01 
2.03E-
01 
9.32E-
02 
6.09E+0
0 
4.02E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.57E+0
1 
C18 
-1.04E-
01 
-4.80E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.56E-
01 
1.64E-
01 
1.14E-
01 
6.10E+0
0 
4.04E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.71E+0
1 
C19 
-8.40E-
02 
-1.10E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.53E-
01 
2.18E-
01 
9.99E-
02 
6.08E+0
0 
4.02E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.33E+0
1 
Cl22 
-4.89E-
01 
6.20E-
05 
4.57E+0
2 
-
4.59E+0
2 
1.50E-
01 
1.18E+0
0 
1.33E+0
0 
1.75E+0
1 
1.69E+0
1 
9.65E+0
1 
6.10E-
01 
3.49E+0
0 
2.29E+0
2 
N12 
-6.13E-
01 
4.00E-
05 
5.43E+0
1 
-
5.45E+0
1 
6.55E-
01 
5.13E-
01 
6.53E-
01 
7.61E+0
0 
5.75E+0
0 
7.56E+0
1 
1.86E+0
0 
2.44E+0
1 
7.39E+0
1 
N17 
-6.03E-
01 
1.41E-
04 
5.43E+0
1 
-
5.45E+0
1 
6.57E-
01 
6.91E-
01 
8.83E-
01 
7.60E+0
0 
5.74E+0
0 
7.55E+0
1 
1.86E+0
0 
2.45E+0
1 
7.39E+0
1 
O2# 
-8.53E-
01 
8.40E-
05 
7.47E+0
1 
-
7.51E+0
1 
1.11E-
01 
1.01E+0
0 
9.06E-
01 
8.85E+0
0 
7.78E+0
0 
8.79E+0
1 
1.07E+0
0 
1.21E+0
1 
1.04E+0
2 
H24# 
2.00E-
01 
3.70E-
05 
5.27E-
01 
-5.30E-
01 
1.25E-
01 
4.02E-
01 
4.44E-
01 
8.00E-
01 
2.92E-
01 
3.66E+0
1 
5.07E-
01 
6.34E+0
1 
3.41E+0
1 
Complex 2 
Ru1 
8.62E-
01 
4.02E-
04 
4.40E+0
3 
-
4.43E+0
3 
7.85E-
02 
1.09E+0
0 
1.17E+0
0 
4.31E+0
1 
4.06E+0
1 
9.42E+0
1 
2.49E+0
0 
5.78E+0
0 
9.91E+0
1 
C7 
-1.16E-
01 
-8.10E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.00E-
01 
1.33E-
01 
8.08E-
02 
6.12E+0
0 
4.04E+0
0 
6.60E+0
1 
2.08E+0
0 
3.40E+0
1 
7.31E+0
1 
C8 
-1.05E-
01 
8.60E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.75E-
01 
1.67E-
01 
1.24E-
01 
6.11E+0
0 
4.04E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.72E+0
1 
C13 
-9.59E-
02 
1.57E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.85E-
01 
1.60E-
01 
1.31E-
01 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.87E+0
1 
C14 
-8.33E-
02 
7.10E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.40E-
01 
2.33E-
01 
8.95E-
02 
6.08E+0
0 
4.02E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.24E+0
1 
C18 -1.16E- -8.80E- 3.76E+0 - 1.99E- 1.29E- 1.08E- 6.12E+0 4.04E+0 6.60E+0 2.08E+0 3.40E+0 7.32E+0
309 
01 05 1 3.78E+0
1 
01 01 01 0 0 1 0 1 1 
C19 
-1.05E-
01 
5.90E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.75E-
01 
1.55E-
01 
1.36E-
01 
6.11E+0
0 
4.04E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.73E+0
1 
Cl10 
-4.78E-
01 
9.30E-
05 
4.57E+0
2 
-
4.59E+0
2 
1.41E-
01 
1.15E+0
0 
1.29E+0
0 
1.75E+0
1 
1.69E+0
1 
9.66E+0
1 
5.87E-
01 
3.36E+0
0 
2.34E+0
2 
N11 
-9.49E-
01 
5.00E-
05 
5.45E+0
1 
-
5.48E+0
1 
1.37E-
01 
5.27E-
01 
6.40E-
01 
7.95E+0
0 
6.07E+0
0 
7.63E+0
1 
1.88E+0
0 
2.37E+0
1 
7.74E+0
1 
N16 
-9.49E-
01 
6.00E-
05 
5.45E+0
1 
-
5.48E+0
1 
1.39E-
01 
4.93E-
01 
6.04E-
01 
7.95E+0
0 
6.07E+0
0 
7.63E+0
1 
1.88E+0
0 
2.37E+0
1 
7.75E+0
1 
Complex 3 
Ru1 
8.73E-
01 
-6.31E-
04 
4.40E+0
3 
-
4.43E+0
3 
8.46E-
02 
7.78E-
01 
8.55E-
01 
4.31E+0
1 
4.07E+0
1 
9.43E+0
1 
2.45E+0
0 
5.67E+0
0 
9.61E+0
1 
C13 
-7.91E-
02 
-2.80E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.67E-
01 
2.44E-
01 
8.53E-
02 
6.08E+0
0 
4.01E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.32E+0
1 
C14 
-9.33E-
02 
-4.90E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.41E-
01 
1.75E-
01 
4.11E-
01 
6.09E+0
0 
4.02E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.21E+0
1 
C18 
-8.72E-
02 
8.60E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.57E-
01 
2.22E-
01 
9.86E-
02 
6.09E+0
0 
4.02E+0
0 
6.60E+0
1 
2.07E+0
0 
3.40E+0
1 
7.36E+0
1 
C21 
-1.18E-
01 
-3.70E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.29E-
01 
1.33E-
01 
1.79E-
01 
6.12E+0
0 
4.04E+0
0 
6.61E+0
1 
2.08E+0
0 
3.39E+0
1 
7.64E+0
1 
C23 
-9.43E-
02 
-8.40E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.66E-
01 
1.53E-
01 
4.09E-
01 
6.09E+0
0 
4.03E+0
0 
6.61E+0
1 
2.06E+0
0 
3.39E+0
1 
7.27E+0
1 
C25 
-1.17E-
01 
1.72E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.23E-
01 
1.37E-
01 
1.83E-
01 
6.12E+0
0 
4.04E+0
0 
6.61E+0
1 
2.08E+0
0 
3.39E+0
1 
7.61E+0
1 
Cl7 
-4.97E-
01 
7.30E-
05 
4.57E+0
2 
-
4.59E+0
2 
1.53E-
01 
1.20E+0
0 
1.35E+0
0 
1.75E+0
1 
1.69E+0
1 
9.66E+0
1 
5.90E-
01 
3.37E+0
0 
2.32E+0
2 
N10 
-9.26E-
01 
2.83E-
04 
5.44E+0
1 
-
5.47E+0
1 
1.73E-
01 
7.90E-
01 
9.41E-
01 
7.93E+0
0 
6.06E+0
0 
7.65E+0
1 
1.86E+0
0 
2.35E+0
1 
7.82E+0
1 
N16 
-9.30E-
01 
2.81E-
04 
5.45E+0
1 
-
5.47E+0
1 
1.71E-
01 
7.70E-
01 
9.13E-
01 
7.93E+0
0 
6.06E+0
0 
7.65E+0
1 
1.87E+0
0 
2.35E+0
1 
7.78E+0
1 
O2# 
-8.96E-
01 
1.68E-
04 
7.47E+0
1 
-
7.51E+0
1 
7.76E-
02 
1.00E+0
0 
9.29E-
01 
8.90E+0
0 
7.80E+0
0 
8.77E+0
1 
1.09E+0
0 
1.23E+0
1 
1.04E+0
2 
O28# 
-8.94E-
01 
1.36E-
04 
7.47E+0
1 
-
7.51E+0
1 
8.16E-
02 
9.64E-
01 
8.86E-
01 
8.89E+0
0 
7.81E+0
0 
8.78E+0
1 
1.09E+0
0 
1.22E+0
1 
1.05E+0
2 
H31# 
1.61E-
01 
3.80E-
05 
5.47E-
01 
-5.50E-
01 
1.38E-
01 
2.93E-
01 
3.16E-
01 
8.39E-
01 
3.19E-
01 
3.80E+0
1 
5.20E-
01 
6.20E+0
1 
3.65E+0
1 
H36# 
1.77E-
01 
1.80E-
05 
5.41E-
01 
-5.44E-
01 
1.34E-
01 
2.70E-
01 
3.08E-
01 
8.23E-
01 
3.05E-
01 
3.71E+0
1 
5.17E-
01 
6.29E+0
1 
3.48E+0
1 
Complex 4 
Ru1 
9.46E-
01 
-2.96E-
04 
4.40E+0
3 
-
4.43E+0
3 
1.27E-
01 
5.11E-
01 
4.45E-
01 
4.31E+0
1 
4.07E+0
1 
9.45E+0
1 
2.38E+0
0 
5.52E+0
0 
1.02E+0
2 
C2 
-9.53E-
02 
9.40E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.55E-
01 
1.64E-
01 
9.19E-
02 
6.10E+0
0 
4.03E+0
0 
6.62E+0
1 
2.06E+0
0 
3.38E+0
1 
7.64E+0
1 
C3 
-9.30E-
02 
-9.30E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.35E-
01 
1.60E-
01 
1.09E-
01 
6.09E+0
0 
4.03E+0
0 
6.61E+0
1 
2.06E+0
0 
3.39E+0
1 
7.35E+0
1 
310 
C4 
-9.54E-
02 
-5.80E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.56E-
01 
1.61E-
01 
1.18E-
01 
6.10E+0
0 
4.03E+0
0 
6.62E+0
1 
2.06E+0
0 
3.38E+0
1 
7.65E+0
1 
C5 
-8.74E-
02 
-7.70E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.58E-
01 
1.66E-
01 
1.29E-
01 
6.09E+0
0 
4.03E+0
0 
6.62E+0
1 
2.06E+0
0 
3.38E+0
1 
7.61E+0
1 
C6 
-9.30E-
02 
-5.60E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.34E-
01 
1.58E-
01 
1.27E-
01 
6.09E+0
0 
4.03E+0
0 
6.61E+0
1 
2.06E+0
0 
3.39E+0
1 
7.35E+0
1 
C7 
-8.74E-
02 
-8.00E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.59E-
01 
1.62E-
01 
1.46E-
01 
6.09E+0
0 
4.03E+0
0 
6.62E+0
1 
2.06E+0
0 
3.38E+0
1 
7.61E+0
1 
N10 
-6.07E-
01 
1.22E-
04 
5.42E+0
1 
-
5.45E+0
1 
6.88E-
01 
5.32E-
01 
6.51E-
01 
7.61E+0
0 
5.78E+0
0 
7.60E+0
1 
1.82E+0
0 
2.40E+0
1 
7.84E+0
1 
N13 
-6.07E-
01 
-4.29E-
04 
5.42E+0
1 
-
5.45E+0
1 
6.88E-
01 
5.29E-
01 
6.36E-
01 
7.61E+0
0 
5.78E+0
0 
7.60E+0
1 
1.82E+0
0 
2.40E+0
1 
7.84E+0
1 
N15 
-9.65E-
01 
1.70E-
04 
5.46E+0
1 
-
5.49E+0
1 
1.51E-
01 
2.33E-
01 
3.83E-
01 
7.97E+0
0 
6.10E+0
0 
7.66E+0
1 
1.86E+0
0 
2.34E+0
1 
7.53E+0
1 
Complex 5 
Ru1 
9.26E-
01 
9.21E-
04 
4.40E+0
3 
-
4.43E+0
3 
1.55E-
01 
4.97E-
01 
4.94E-
01 
4.31E+0
1 
4.06E+0
1 
9.44E+0
1 
2.43E+0
0 
5.63E+0
0 
1.01E+0
2 
C18 
-8.75E-
02 
-2.80E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.57E-
01 
1.80E-
01 
7.76E-
02 
6.09E+0
0 
4.03E+0
0 
6.61E+0
1 
2.06E+0
0 
3.39E+0
1 
7.60E+0
1 
C20 
-9.77E-
02 
-1.45E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.30E-
01 
1.54E-
01 
9.89E-
02 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.36E+0
1 
C22 
-8.70E-
02 
7.70E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.57E-
01 
1.74E-
01 
9.16E-
02 
6.09E+0
0 
4.03E+0
0 
6.61E+0
1 
2.06E+0
0 
3.39E+0
1 
7.59E+0
1 
C23 
-1.01E-
01 
-4.40E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.49E-
01 
1.46E-
01 
1.18E-
01 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.60E+0
1 
C26 
-9.72E-
02 
-2.40E-
05 
3.76E+0
1 
-
3.78E+0
1 
2.30E-
01 
1.53E-
01 
1.14E-
01 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.36E+0
1 
C27 
-1.01E-
01 
-1.10E-
04 
3.76E+0
1 
-
3.78E+0
1 
2.48E-
01 
1.47E-
01 
1.38E-
01 
6.10E+0
0 
4.03E+0
0 
6.61E+0
1 
2.07E+0
0 
3.39E+0
1 
7.59E+0
1 
N14 
-9.58E-
01 
1.32E-
04 
5.44E+0
1 
-
5.47E+0
1 
1.96E-
01 
3.93E-
01 
5.43E-
01 
7.96E+0
0 
6.10E+0
0 
7.67E+0
1 
1.85E+0
0 
2.33E+0
1 
8.06E+0
1 
N15 
-9.52E-
01 
3.41E-
04 
5.46E+0
1 
-
5.49E+0
1 
1.07E-
01 
1.73E-
01 
2.78E-
01 
7.95E+0
0 
6.05E+0
0 
7.61E+0
1 
1.90E+0
0 
2.39E+0
1 
7.36E+0
1 
N21 
-9.59E-
01 
8.90E-
05 
5.44E+0
1 
-
5.47E+0
1 
1.96E-
01 
2.96E-
01 
4.49E-
01 
7.96E+0
0 
6.11E+0
0 
7.67E+0
1 
1.85E+0
0 
2.33E+0
1 
8.06E+0
1 
 
 
Table 3.51: The Intra and inter atomic properties of atoms involve in Metal-Ligand and hydrogen 
bonding (atoms with superscript ―#‖) of systems treated with ECP(Ru)[6-31+G(d,p)] basis set 
using QTAIM analysis 
 
Complex 1 
 q(A) L(A) K(A) 
K_Scale
d(A) Intra(A) Bond(A) |(A)| N(A) LI(A) 
%Loc(A
) 
DI(A,A'
)/2 
%Deloc
(A,A') 
Vol(A),0
.001 
311 
Ru1 
9.40E-
01 
2.84E-
04 
3.27E+0
1 
-
3.43E+0
1 
1.37E-
01 
1.02E+0
0 
1.07E+0
0 
1.51E+0
1 
1.24E+0
1 
8.21E+0
1 
2.70E+0
0 
1.79E+0
1 
1.03E+0
2 
C9 
-7.56E-
02 
2.30E-
05 
3.78E+0
1 
-
3.97E+0
1 
1.42E-
01 
4.25E-
02 
1.03E-
01 
6.08E+0
0 
3.98E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.39E+0
1 
C10 
-5.98E-
02 
-2.78E-
04 
3.78E+0
1 
-
3.97E+0
1 
1.04E-
01 
8.99E-
02 
5.74E-
02 
6.06E+0
0 
3.97E+0
0 
6.55E+0
1 
2.09E+0
0 
3.45E+0
1 
7.16E+0
1 
C13 
-6.39E-
02 
-2.07E-
04 
3.78E+0
1 
-
3.97E+0
1 
1.09E-
01 
9.96E-
02 
1.06E-
01 
6.06E+0
0 
3.97E+0
0 
6.55E+0
1 
2.09E+0
0 
3.45E+0
1 
7.18E+0
1 
C16 
-6.54E-
02 
1.51E-
04 
3.78E+0
1 
-
3.97E+0
1 
1.47E-
01 
1.03E-
01 
8.08E-
02 
6.07E+0
0 
3.98E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.37E+0
1 
C18 
-7.15E-
02 
2.20E-
05 
3.78E+0
1 
-
3.97E+0
1 
1.40E-
01 
9.20E-
02 
9.33E-
02 
6.07E+0
0 
3.98E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.47E+0
1 
C19 
-4.23E-
02 
-2.32E-
04 
3.78E+0
1 
-
3.97E+0
1 
1.25E-
01 
1.33E-
01 
8.09E-
02 
6.04E+0
0 
3.96E+0
0 
6.55E+0
1 
2.09E+0
0 
3.45E+0
1 
7.01E+0
1 
Cl22 
-4.92E-
01 
6.40E-
05 
4.59E+0
2 
-
4.82E+0
2 
4.86E-
02 
1.17E+0
0 
1.16E+0
0 
1.75E+0
1 
1.68E+0
1 
9.61E+0
1 
6.81E-
01 
3.89E+0
0 
2.30E+0
2 
N12 
-7.26E-
01 
2.69E-
04 
5.47E+0
1 
-
5.74E+0
1 
6.62E-
01 
7.84E-
01 
6.76E-
01 
7.73E+0
0 
5.84E+0
0 
7.56E+0
1 
1.89E+0
0 
2.44E+0
1 
7.72E+0
1 
N17 
-7.26E-
01 
2.02E-
04 
5.47E+0
1 
-
5.74E+0
1 
6.63E-
01 
7.63E-
01 
6.36E-
01 
7.73E+0
0 
5.84E+0
0 
7.56E+0
1 
1.89E+0
0 
2.44E+0
1 
7.72E+0
1 
O2# 
-
1.13E+0
0 
7.20E-
05 
7.54E+0
1 
-
7.90E+0
1 
5.41E-
01 
1.46E+0
0 
1.00E+0
0 
9.13E+0
0 
8.15E+0
0 
8.92E+0
1 
9.82E-
01 
1.08E+0
1 
1.29E+0
2 
H24# 
1.28E-
01 
1.60E-
05 
5.64E-
01 
-5.92E-
01 
1.07E-
01 
4.19E-
01 
4.61E-
01 
8.72E-
01 
3.40E-
01 
3.90E+0
1 
5.32E-
01 
6.10E+0
1 
4.04E+0
1 
H29# 
1.27E-
01 
2.30E-
05 
5.64E-
01 
-5.92E-
01 
1.07E-
01 
4.30E-
01 
4.72E-
01 
8.73E-
01 
3.41E-
01 
3.90E+0
1 
5.32E-
01 
6.10E+0
1 
4.04E+0
1 
Complex 2 
Ru1 
9.57E-
01 
4.83E-
04 
3.27E+0
1 
-
3.41E+0
1 
9.03E-
02 
1.00E+0
0 
1.06E+0
0 
1.50E+0
1 
1.23E+0
1 
8.18E+0
1 
2.73E+0
0 
1.82E+0
1 
1.05E+0
2 
C7 
-6.65E-
02 
4.00E-
05 
3.78E+0
1 
-
3.95E+0
1 
9.49E-
02 
8.37E-
02 
7.96E-
02 
6.07E+0
0 
3.97E+0
0 
6.54E+0
1 
2.10E+0
0 
3.46E+0
1 
7.04E+0
1 
C8 
-7.69E-
02 
-1.02E-
04 
3.78E+0
1 
-
3.95E+0
1 
1.50E-
01 
8.40E-
02 
9.09E-
02 
6.08E+0
0 
3.99E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.49E+0
1 
C13 
-6.59E-
02 
-2.96E-
04 
3.78E+0
1 
-
3.95E+0
1 
1.58E-
01 
7.62E-
02 
8.29E-
02 
6.07E+0
0 
3.98E+0
0 
6.57E+0
1 
2.08E+0
0 
3.43E+0
1 
7.67E+0
1 
C14 
-4.00E-
02 
-5.43E-
04 
3.78E+0
1 
-
3.95E+0
1 
1.19E-
01 
1.43E-
01 
9.34E-
02 
6.04E+0
0 
3.96E+0
0 
6.55E+0
1 
2.08E+0
0 
3.45E+0
1 
6.99E+0
1 
C18 
-6.67E-
02 
1.40E-
05 
3.78E+0
1 
-
3.95E+0
1 
9.40E-
02 
1.02E-
01 
1.05E-
01 
6.07E+0
0 
3.97E+0
0 
6.54E+0
1 
2.10E+0
0 
3.46E+0
1 
7.04E+0
1 
C19 
-7.67E-
02 
2.55E-
04 
3.78E+0
1 
-
3.95E+0
1 
1.50E-
01 
7.10E-
02 
8.19E-
02 
6.08E+0
0 
3.99E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.48E+0
1 
Cl10 
-4.84E-
01 
6.80E-
05 
4.59E+0
2 
-
4.79E+0
2 
3.25E-
02 
1.15E+0
0 
1.12E+0
0 
1.75E+0
1 
1.68E+0
1 
9.62E+0
1 
6.57E-
01 
3.76E+0
0 
2.34E+0
2 
N11 
-
1.16E+0
0 
6.60E-
05 
5.50E+0
1 
-
5.74E+0
1 
1.93E-
01 
6.93E-
01 
5.24E-
01 
8.16E+0
0 
6.27E+0
0 
7.69E+0
1 
1.89E+0
0 
2.31E+0
1 
8.10E+0
1 
312 
N16 
-
1.16E+0
0 
2.46E-
04 
5.50E+0
1 
-
5.74E+0
1 
1.95E-
01 
6.59E-
01 
4.90E-
01 
8.16E+0
0 
6.27E+0
0 
7.69E+0
1 
1.89E+0
0 
2.31E+0
1 
8.09E+0
1 
H34# 
9.67E-
02 
9.50E-
05 
5.81E-
01 
-6.06E-
01 
1.11E-
01 
5.69E-
02 
6.89E-
02 
9.03E-
01 
3.58E-
01 
3.96E+0
1 
5.45E-
01 
6.04E+0
1 
4.09E+0
1 
H38# 
1.03E-
01 
7.70E-
05 
5.76E-
01 
-6.01E-
01 
1.15E-
01 
6.54E-
02 
5.26E-
02 
8.97E-
01 
3.53E-
01 
3.93E+0
1 
5.45E-
01 
6.07E+0
1 
4.10E+0
1 
Complex 3 
Ru1 
9.59E-
01 
2.52E-
04 
3.27E+0
1 
-
3.41E+0
1 
9.73E-
02 
7.73E-
01 
7.69E-
01 
1.50E+0
1 
1.23E+0
1 
8.20E+0
1 
2.71E+0
0 
1.80E+0
1 
1.01E+0
2 
C13 
-5.37E-
02 
-6.10E-
05 
3.78E+0
1 
-
3.94E+0
1 
1.31E-
01 
1.45E-
01 
7.69E-
02 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.08E+0
1 
C14 
-6.12E-
02 
-1.90E-
04 
3.78E+0
1 
-
3.94E+0
1 
1.29E-
01 
2.77E-
01 
4.01E-
01 
6.06E+0
0 
3.97E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
6.99E+0
1 
C18 
-5.33E-
02 
-1.48E-
04 
3.78E+0
1 
-
3.94E+0
1 
1.29E-
01 
1.38E-
01 
8.25E-
02 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.09E+0
1 
C21 
-7.24E-
02 
-1.20E-
04 
3.78E+0
1 
-
3.94E+0
1 
1.18E-
01 
1.10E-
01 
1.34E-
01 
6.07E+0
0 
3.98E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.38E+0
1 
C23 
-6.28E-
02 
-2.92E-
04 
3.78E+0
1 
-
3.94E+0
1 
1.35E-
01 
2.83E-
01 
4.12E-
01 
6.06E+0
0 
3.98E+0
0 
6.56E+0
1 
2.09E+0
0 
3.44E+0
1 
7.02E+0
1 
C25 
-7.20E-
02 
-2.53E-
04 
3.78E+0
1 
-
3.94E+0
1 
1.15E-
01 
1.20E-
01 
1.42E-
01 
6.07E+0
0 
3.98E+0
0 
6.55E+0
1 
2.09E+0
0 
3.45E+0
1 
7.35E+0
1 
Cl7 
-4.94E-
01 
8.90E-
05 
4.59E+0
2 
-
4.78E+0
2 
7.56E-
03 
1.17E+0
0 
1.16E+0
0 
1.75E+0
1 
1.68E+0
1 
9.62E+0
1 
6.69E-
01 
3.83E+0
0 
2.33E+0
2 
N10 
-
1.14E+0
0 
2.23E-
04 
5.49E+0
1 
-
5.72E+0
1 
1.71E-
01 
1.06E+0
0 
9.04E-
01 
8.14E+0
0 
6.27E+0
0 
7.70E+0
1 
1.87E+0
0 
2.30E+0
1 
8.19E+0
1 
N16 
-
1.14E+0
0 
5.60E-
05 
5.49E+0
1 
-
5.72E+0
1 
1.72E-
01 
1.03E+0
0 
8.69E-
01 
8.14E+0
0 
6.27E+0
0 
7.70E+0
1 
1.87E+0
0 
2.30E+0
1 
8.18E+0
1 
O2# 
-
1.15E+0
0 
1.11E-
04 
7.54E+0
1 
-
7.85E+0
1 
5.23E-
01 
1.38E+0
0 
8.93E-
01 
9.15E+0
0 
8.14E+0
0 
8.90E+0
1 
1.01E+0
0 
1.10E+0
1 
1.27E+0
2 
O28# 
-
1.15E+0
0 
1.17E-
04 
7.54E+0
1 
-
7.85E+0
1 
5.23E-
01 
1.37E+0
0 
8.78E-
01 
9.15E+0
0 
8.14E+0
0 
8.90E+0
1 
1.01E+0
0 
1.10E+0
1 
1.27E+0
2 
H31# 
1.18E-
01 
2.20E-
05 
5.75E-
01 
-5.99E-
01 
1.13E-
01 
3.22E-
01 
3.52E-
01 
8.82E-
01 
3.43E-
01 
3.89E+0
1 
5.39E-
01 
6.11E+0
1 
3.91E+0
1 
H36# 
1.22E-
01 
3.20E-
05 
5.74E-
01 
-5.98E-
01 
1.12E-
01 
3.21E-
01 
3.54E-
01 
8.78E-
01 
3.40E-
01 
3.87E+0
1 
5.39E-
01 
6.13E+0
1 
3.86E+0
1 
Complex 4 
Ru1 
9.82E-
01 
-8.61E-
04 
3.27E+0
1 
-
3.50E+0
1 
1.46E-
01 
3.81E-
01 
3.23E-
01 
1.50E+0
1 
1.24E+0
1 
8.25E+0
1 
2.63E+0
0 
1.75E+0
1 
1.12E+0
2 
C2 
-5.75E-
02 
-2.60E-
05 
3.78E+0
1 
-
4.05E+0
1 
1.48E-
01 
7.65E-
02 
7.55E-
02 
6.06E+0
0 
3.98E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.36E+0
1 
C3 
-5.54E-
02 
-2.19E-
04 
3.78E+0
1 
-
4.05E+0
1 
1.22E-
01 
8.73E-
02 
7.39E-
02 
6.06E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.08E+0
1 
C4 
-5.77E-
02 
-3.00E-
05 
3.78E+0
1 
-
4.05E+0
1 
1.48E-
01 
9.24E-
02 
9.46E-
02 
6.06E+0
0 
3.98E+0
0 
6.57E+0
1 
2.08E+0
0 
3.43E+0
1 
7.36E+0
1 
C5 
-4.58E-
02 
-9.20E-
05 
3.78E+0
1 
-
4.05E+0
1 
1.42E-
01 
1.02E-
01 
9.35E-
02 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.27E+0
1 
C6 -5.55E- -3.53E- 3.78E+0 - 1.21E- 9.59E- 8.67E- 6.06E+0 3.97E+0 6.56E+0 2.08E+0 3.44E+0 7.07E+0
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02 04 1 4.05E+0
1 
01 02 02 0 0 1 0 1 1 
C7 
-4.61E-
02 
-7.90E-
05 
3.78E+0
1 
-
4.05E+0
1 
1.43E-
01 
1.08E-
01 
1.01E-
01 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.27E+0
1 
N10 
-7.38E-
01 
2.73E-
04 
5.47E+0
1 
-
5.85E+0
1 
6.93E-
01 
7.59E-
01 
5.90E-
01 
7.74E+0
0 
5.89E+0
0 
7.61E+0
1 
1.85E+0
0 
2.39E+0
1 
8.21E+0
1 
N13 
-7.38E-
01 
2.80E-
04 
5.47E+0
1 
-
5.85E+0
1 
6.93E-
01 
7.53E-
01 
5.75E-
01 
7.74E+0
0 
5.89E+0
0 
7.61E+0
1 
1.85E+0
0 
2.39E+0
1 
8.21E+0
1 
N15 
-
1.18E+0
0 
4.18E-
04 
5.51E+0
1 
-
5.89E+0
1 
1.58E-
01 
4.22E-
01 
3.23E-
01 
8.18E+0
0 
6.30E+0
0 
7.71E+0
1 
1.87E+0
0 
2.29E+0
1 
7.93E+0
1 
Complex 5 
Ru1 
9.80E-
01 
1.36E-
03 
3.27E+0
1 
-
3.46E+0
1 
1.99E-
01 
5.46E-
01 
5.13E-
01 
1.50E+0
1 
1.23E+0
1 
8.21E+0
1 
2.69E+0
0 
1.79E+0
1 
1.09E+0
2 
C18 
-4.88E-
02 
-3.90E-
04 
3.78E+0
1 
-
4.00E+0
1 
1.42E-
01 
9.08E-
02 
6.77E-
02 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.28E+0
1 
C20 
-5.86E-
02 
-3.20E-
05 
3.78E+0
1 
-
4.00E+0
1 
1.19E-
01 
1.16E-
01 
1.08E-
01 
6.06E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.09E+0
1 
C22 
-4.81E-
02 
4.30E-
05 
3.78E+0
1 
-
4.00E+0
1 
1.42E-
01 
9.31E-
02 
6.63E-
02 
6.05E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.26E+0
1 
C23 
-6.19E-
02 
-2.73E-
04 
3.78E+0
1 
-
4.00E+0
1 
1.49E-
01 
7.92E-
02 
1.00E-
01 
6.06E+0
0 
3.98E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.32E+0
1 
C26 
-5.90E-
02 
-3.44E-
04 
3.78E+0
1 
-
4.00E+0
1 
1.20E-
01 
1.23E-
01 
1.17E-
01 
6.06E+0
0 
3.97E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.11E+0
1 
C27 
-6.16E-
02 
-2.82E-
04 
3.78E+0
1 
-
4.00E+0
1 
1.47E-
01 
7.98E-
02 
9.87E-
02 
6.06E+0
0 
3.98E+0
0 
6.56E+0
1 
2.08E+0
0 
3.44E+0
1 
7.31E+0
1 
N14 
-
1.17E+0
0 
2.33E-
04 
5.49E+0
1 
-
5.81E+0
1 
1.77E-
01 
5.85E-
01 
4.48E-
01 
8.17E+0
0 
6.31E+0
0 
7.72E+0
1 
1.86E+0
0 
2.28E+0
1 
8.46E+0
1 
N15 
-
1.17E+0
0 
4.56E-
04 
5.51E+0
1 
-
5.82E+0
1 
1.85E-
01 
3.33E-
01 
2.20E-
01 
8.17E+0
0 
6.26E+0
0 
7.66E+0
1 
1.91E+0
0 
2.34E+0
1 
7.77E+0
1 
N21 
-
1.17E+0
0 
2.77E-
04 
5.49E+0
1 
-
5.81E+0
1 
1.77E-
01 
4.82E-
01 
3.55E-
01 
8.17E+0
0 
6.31E+0
0 
7.72E+0
1 
1.86E+0
0 
2.28E+0
1 
8.46E+0
1 
 
 
 
 
Table 3.52: Correlation between the computed atomic properties for complexes 1 to 5 
 
 1 2 3 4 5 
 |Bond(A)| 
Vol(A), 
0.001 |Bond(A)| 
Vol(A), 
0.001 |Bond(A)| 
Vol(A), 
0.001 |Bond(A)| 
Vol(A), 
0.001 |Bond(A)| 
Vol(A), 
0.001 
q(A) -0.40 -0.45 -0.31 -0.56 -0.45 -0.57 -0.15 -0.17 -0.21 -0.50 
L(A) 0.48 0.23 0.23 0.05 0.44 0.23 -0.11 -0.21 0.22 0.12 
K(A) 0.36 0.25 0.28 0.23 0.21 0.22 0.14 0.44 0.16 0.32 
K_Scaled(
A) -0.36 -0.25 -0.28 -0.23 -0.21 -0.22 -0.14 -0.44 -0.16 -0.32 
|Intra(A)| 0.46 0.09 0.53 0.01 0.50 -0.04 0.92 0.36 0.65 0.17 
314 
|Bond(A)| 1.00 0.65 1.00 0.67 1.00 0.65 1.00 0.50 1.00 0.61 
|(A)| 0.89 0.68 0.92 0.81 0.88 0.75 0.80 0.59 0.92 0.71 
N(A) 0.60 0.57 0.54 0.58 0.49 0.57 0.37 0.72 0.38 0.63 
LI(A) 0.61 0.58 0.55 0.59 0.51 0.58 0.33 0.66 0.38 0.60 
%Loc(A) 0.73 0.80 0.73 0.83 0.71 0.82 0.68 0.94 0.64 0.93 
DI(A,A')/2 0.22 0.25 0.07 0.19 0.06 0.19 0.53 0.91 0.21 0.63 
%Deloc(A,
A') -0.73 -0.80 -0.73 -0.83 -0.71 -0.82 -0.68 -0.94 -0.64 -0.93 
Vol(A), 
0.001 0.65 1.00 0.67 1.00 0.65 1.00 0.50 1.00 0.61 1.00 
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Table 3.53: The thermodynamic properties and number of vibrational modes  
 E0 KJ/mol E KJ/mol H KJ/mol G KJ/mol 
CV 
KJ/mol-K 
S KJ/mol-
K Imaginary 
No. Nor 
Vib Mode 
1 
-3.73E+06 -3.73E+06 -3.73E+06 -3.73E+06 
0.51 0.82 0 183 
2 
-3.32E+06 -3.32E+06 -3.32E+06 -3.32E+06 
0.44 0.75 0 153 
3 
-2.41E+06 -2.41E+06 -2.41E+06 -2.41E+06 
0.39 0.67 1 141 
The notations in this Table are Zero-point energy (E0) , Total energy (E), Enthalpy (H), Gibb free energy (G), Constant 
volume molar heat capacity (CV) and Entropy (S). 
13  
14  
15  
16  
17  
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Table 3.54: Total hyperpolarizability, band gap, dipole moments and isotropic polarizability of 
complexes 1, 2 and 3 when mixed basis set (SBKJC VDZ with ECP and 6-31g*) and single basis 
set 3-21g were used. 
 B3lyp/3-21g pb0/SBKJC VDZ(6-31g*) 
  ß in esu 
(1x10-30) 
Gap 
KJ/mol 
Dipole 
Debye 
Isot. pol. 
Bohr**3 
 ß esu 
(1x10-30) 
Gap 
KJ/mol 
Dipole 
Debye 
Isot. pol. 
Bohr**3 
1 20.43 382.40 7.3726 122.81 22.17 209.46 8.11 134.32 
2 19.63 366.26 10.9667 101.84 21.60 212.95 10.66 111.52 
3 19.56 366.36 7.9075 110.73 20.48 208.94 7.37 121.14 
3** 18.74 362.66 7.6025 110.73     
The superscript ―**‖ represent the computation with polarized basis set 3-21g**. 
Table 3.55: The effect of the four Ramsey terms in determining the shielding tensor of complexes 2 and 
3 using the functional B3LYP and all electron basis set 3-21g 
Complex 2 
 FC (HZ) SD  PSO  DSO J (HZ) 
Ru-C -2.20 -0.02 -1.32 -0.04 -3.58 
 -2.37 0.02 -1.41 -0.04 -3.78 
 -2.45 -0.13 -1.37 -0.04 -3.98 
 -2.46 0.10 -1.32 -0.04 -3.72 
 -2.80 -0.02 -1.08 -0.04 -3.94 
 -2.96 0.14 -1.09 -0.04 -3.94 
Ru-P -73.12 -0.87 4.62 -0.06 -69.43 
Ru-bO 6.77 1.16 10.22 0.02 18.17 
 6.69 1.19 10.58 0.02 18.49 
Complex 3 
 FC (HZ) SD  PSO  DSO J (HZ) 
Ru-C -1.67 0.10 -0.96 -0.04 -2.56 
 -2.09 0.01 -1.14 -0.04 -3.26 
 -2.46 -0.16 -1.72 -0.04 -4.38 
 -2.63 -0.04 -1.67 -0.04 -4.38 
 -2.96 -0.01 -1.66 -0.04 -4.66 
 -3.16 0.04 -2.10 -0.04 -5.26 
Ru-P -61.68 -1.17 2.79 -0.06 -60.12 
Ru-Cl -0.94 -2.03 -19.73 -0.01 -22.71 
 -1.16 -2.14 -20.18 -0.01 -23.48 
316 
 
Table 3.56: The effect of the four Ramsey terms in determining the shielding tensor of complex 3 using 
the hybrid DFT functional B3LYP and polarized all electron basis set 3-21g** 
 FC (HZ) SD  PSO  DSO J (HZ) 
Ru-C -1.60 0.11 -0.91 -0.04 -2.44 
 -2.03 0.01 -1.08 -0.04 -3.13 
 -2.42 -0.16 -1.69 -0.04 -4.30 
 -2.59 -0.03 -1.64 -0.04 -4.31 
 -3.00 0.00 -1.65 -0.04 -4.68 
 -3.19 0.04 -2.08 -0.04 -5.26 
Ru-P -62.54 -1.17 4.55 -0.06 -59.22 
Ru-Cl -0.64 -2.09 -19.82 -0.01 -22.56 
 -0.89 -2.19 -20.22 -0.01 -23.30 
Table 3.57: The correlation of Isotropic, Anisotropic, charges of all atoms and four Ramsey terms of all 
atoms to Ru atom. 
Isotropic/ Anisotropy Charges FC SD PSO DSO J 
2 -0.16 -0.30 -0.60 -0.15 0.35 -0.11 -0.52 
3 0.91 -0.39 -0.24 -0.96 -0.90 -0.07 -0.64 
3** 0.92 -0.47 -0.19 -0.95 -0.89 -0.06 -0.61 
Anisotropy/ Charges FC SD PSO DSO J  
2 -0.46 0.09 0.52 0.38 0.12 0.19  
3 -0.41 -0.04 -0.85 -0.95 -0.15 -0.47  
3** -0.46 -0.10 -0.87 -0.92 -0.18 -0.53  
Charges/ FC SD PSO DSO J   
2 -0.30 -0.38 -0.12 -0.21 -0.34   
3 -0.33 0.12 0.33 -0.10 -0.16   
3** -0.34 0.21 0.44 -0.09 -0.12   
FC/ SD PSO DSO J    
2 0.59 -0.14 0.34 0.97    
3 0.36 -0.11 0.34 0.89    
3** 0.34 -0.18 0.34 0.88    
SD/ PSO DSO J     
2 0.67 0.36 0.74     
3 0.87 0.10 0.74     
3** 0.85 0.10 0.73     
PSO/ DSO J DSO/ J    
2 0.26 0.09 2 0.41    
3 0.02 0.36 3 0.33    
3** 0.00 0.31 3** 0.33    
The sign ―/‖ stands for correlation with the factors of the row and superscript ―**‖ stands for the case where polarized basis 
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set 3-21g** is used 
Table 3.58: The effect of the four Ramsey terms in determining the shielding tensor of complex 3 using 
the DFT functional pb0 and ECP basis set SBKJC VDZ for Ru, P and Cl while all electron basis 
set 6-31g* is used for other atoms  
 FC (HZ) SD  PSO  DSO J (HZ) 
Ru-C -1.84E-006 3.28E-003 -2.58E-001 -3.01E-002 -2.84E-001 
 -3.23E-006 2.07E-002 -2.28E-001 -3.07E-002 -2.38E-001 
 -3.62E-006 1.70E-002 -2.50E-001 -2.93E-002 -2.63E-001 
 -4.47E-006 2.21E-002 -3.00E-001 -2.92E-002 -3.07E-001 
 2.58E-006 2.17E-002 -1.81E-001 -2.84E-002 -1.88E-001 
 6.37E-006 3.35E-002 -1.52E-001 -2.97E-002 -1.48E-001 
Ru-P 0.00E+000 -5.47E-003 -5.77E-003 -4.98E-002 -6.10E-002 
Ru-Cl 0.00E+000 -9.32E-003 -2.04E-001 -8.22E-003 -2.22E-001 
 0.00E+000 -1.03E-002 -2.06E-001 -8.43E-003 -2.24E-001 
18  
Table 3.59: Correlation of the charges, dipole, magnetizabilities and nmr shielding of complex 2 and 3 
q(A) Intra_Iso(A) Bond_Iso(A) Iso(A) Intra(A) Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A) 
2 0.53 -0.19 0.33 0.4 -0.16 -0.31 -0.26 0.22 -0.26 
3 0.55 -0.11 0.45 0.21 -0.17 -0.29 -0.44 0.1 -0.44 
Intra_Iso(A) Bond_Iso(A) Iso(A) Intra(A) Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A)  
2 -0.49 0.49 -0.09 0.22 0.06 -0.91 0.14 -0.91  
3 -0.25 0.78 -0.02 -0.18 -0.24 -0.93 0.29 -0.93  
Bond_Iso(A) Iso(A) Intra(A) Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A)   
2 0.52 -0.33 -0.56 -0.48 0.68 -0.74 0.67   
3 0.41 -0.32 -0.63 -0.54 0.53 -0.7 0.52   
Iso(A) Intra(A) Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A)    
2 -0.42 -0.35 -0.42 -0.22 -0.6 -0.22    
3 -0.23 -0.57 -0.57 -0.54 -0.18 -0.54    
Intra(A) Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A)     
2 0.28 0.24 0.09 0.27 0.09     
3 0.38 0.27 0 0.22 0.01     
Bond(A) (A) Iso(A,A) Iso(A',A) Iso(A)  (A) Iso(A,A) Iso(A',A) Iso(A) 
2 0.81 -0.52 0.13 -0.52  2 -0.4 -0.05 -0.4 
3 0.76 -0.12 0.16 -0.12  3 -0.06 -0.01 -0.06 
Iso(A,A) Iso(A',A) Iso(A)  Iso(A',A) Iso(A)     
2 -0.19 1  2 -0.18     
3 -0.37 1  3 -0.36     
The magnetic properties are define in terms of q(A)=Total charge on atom A; Intra_Iso(A)= Intraatomic Magnetizability 
Contribution of Atom A (cgs-ppm ); Bond_Iso(A) = Bonding Magnetizability Contribution of Atom A; Iso(A)= Total 
Magnetizability Contribution of Atom A (Intra(A) + Bond(A)); Intra(A) = Intraatomic Dipole Moment Contribution of Atom 
A; Bond(A) = Bonding Dipole Moment Contribution of Atom A; (A) =Total Dipole Moment Contribution of Atom A 
(Intra(A) + Bond(A)); Iso(A,A)=The intraatomic shielding tensor; Iso(A',A)= Total Induced Magnetic Field on Nucleus A 
by other nuclei A'; Iso(A)= Total Magnetic shielding tensor of atom A. 
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Table 3.60: The sum over of the charges, dipole, magnetizabilities and nmr shielding of complexes 2 
and 3. 
Complexe
s q(A)
Intra_Iso(A
)
Bond_Iso(A
) Iso(A) |Intra(A)| |Bond(A)| |(A)| Iso(A,A) Iso(A',A) Iso(A) 
2 0.00 -114.56 -147.91 -262.47 13.65 16.25 15.92 1391.42 653.97 2045.39 
3 0.00 -132.96 -143.11 -276.07 12.23 11.72 12.62 3538.67 604.26 4142.93 
 
 
Table 3.61: The charges, dipole, magnetizabilities and nmr shielding of selected atoms in complexes 2 
 Orapta q(A)
Intra_Is
oIntra_Iso_I
soIntra_Iso(
A)
Bond_I
soBond_Iso(
A) _Iso(A) Intra(A) Bond(A) (A)
_Iso(A,A
)
_Iso(A',
A) _Iso(A) 
 Ru1 0.85 19.65 -24.07 -4.41 0.37 1.83 1.65 -2459.77 23.85 -2435.92 
arene C2 -0.11 -3.39 -6.03 -9.42 0.24 0.18 0.10 94.61 21.65 116.26 
 C5 -0.12 -3.20 -6.01 -9.22 0.22 0.16 0.11 91.07 21.67 112.74 
 C6 -0.07 -2.56 -6.89 -9.45 0.16 0.30 0.16 87.83 24.41 112.24 
 C7 -0.08 -2.37 -6.89 -9.26 0.19 0.20 0.05 82.99 24.32 107.32 
 C8 -0.14 -3.73 -6.33 -10.05 0.22 0.11 0.14 105.93 24.05 129.98 
 C10 -0.15 -3.63 -6.28 -9.92 0.20 0.10 0.13 107.39 24.17 131.56 
 H45* 0.04 -1.20 -0.26 -1.46 0.16 0.15 0.31 21.18 10.01 31.19 
bidentate O12 -0.92 -6.95 -3.12 -10.07 0.14 0.97 1.05 166.70 8.86 175.56 
 O16 -0.92 -7.05 -3.11 -10.17 0.15 1.02 1.10 174.13 9.04 183.17 
 O11u -0.87 -5.10 -1.45 -6.55 0.09 1.29 1.20 -112.27 5.00 -107.26 
 O23u -0.87 -5.12 -1.45 -6.57 0.09 1.29 1.20 -111.17 5.00 -106.17 
 C15* 1.14 -0.77 -3.48 -4.25 0.61 0.67 0.58 41.09 15.30 56.39 
PTA P17 0.82 -7.65 -7.25 -14.90 1.05 0.21 1.18 493.74 12.28 506.03 
 N18 -0.86 -5.98 -3.44 -9.42 0.37 0.50 0.85 211.19 11.96 223.15 
 N22 -0.85 -6.02 -3.17 -9.19 0.38 0.48 0.86 215.23 11.67 226.89 
 N26 -0.86 -5.97 -3.08 -9.06 0.37 0.46 0.83 210.59 11.93 222.53 
 H41* 0.11 -0.98 -1.35 -2.33 0.15 0.35 0.43 19.69 9.10 28.79 
 H51* 0.07 -1.11 -0.23 -1.34 0.16 0.22 0.12 20.49 8.45 28.94 
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Table 3.62: The charges, dipole, magnetizabilities and nmr shielding of selected atoms in complexes 3 
 Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) Intra(A) Bond(A) (A)
_Iso(A,A
)
_Iso(A',
A) _Iso(A) 
 Ru1 0.64 19.74 -23.48 -3.74 0.37 1.39 1.48 -2469.14 25.92 -2443.22 
arene C6 -0.09 -2.66 -6.76 -9.42 0.12 0.17 0.05 92.92 25.77 118.68 
 C9 -0.13 -3.73 -6.51 -10.24 0.23 0.11 0.14 108.03 24.53 132.55 
 C10 -0.11 -3.47 -6.33 -9.81 0.24 0.17 0.10 101.25 24.12 125.37 
 C14 -0.12 -3.44 -6.88 -10.32 0.23 0.18 0.09 101.98 23.93 125.91 
 C16 -0.12 -3.18 -6.71 -9.89 0.23 0.18 0.11 93.18 21.89 115.07 
 C17 -0.06 -2.15 -4.16 -6.32 0.19 0.05 0.15 73.89 22.72 96.61 
 C2* -0.06 -4.69 -5.07 -9.76 0.21 0.22 0.06 163.69 15.51 179.20 
 H46* 0.09 -1.03 -1.84 -2.88 0.15 0.30 0.42 19.98 9.77 29.74 
mono Cl19 -0.58 -23.11 -3.05 -26.16 0.14 1.40 1.54 1191.50 4.08 1195.58 
 Cl20 -0.57 -22.80 -6.68 -29.48 0.14 0.66 0.79 1197.51 4.37 1201.88 
pta P13 0.86 -7.07 -6.37 -13.43 1.02 0.11 0.96 481.97 12.18 494.15 
 N4 -0.85 -5.95 -3.25 -9.20 0.38 0.47 0.85 208.64 11.71 220.35 
 N5 -0.85 -5.95 -3.05 -9.00 0.38 0.47 0.85 209.40 11.64 221.04 
 N15 -0.86 -5.91 -3.46 -9.37 0.37 0.48 0.84 204.84 11.84 216.69 
 H29* 0.06 -1.07 -1.25 -2.32 0.16 0.07 0.09 20.56 7.97 28.52 
 H43* 0.11 -0.96 -1.59 -2.55 0.15 0.36 0.42 19.46 8.66 28.12 
The atoms with ―*‖ shows those that are involve in HB 
Table 3.63: The thermodynamic properties and number of vibrational modes  
Complex 
E0 KJ/mol E KJ/mol H KJ/mol G KJ/mol 
CV KJ/mol-
K S KJ/mol-K Imaginary 
No. Nor Vib 
Mode 
1 -2.00E+06 -2.00E+06 -2.00E+06 -2.00E+06 0.31 0.59 0 105 
2 -2.16E+06 -2.16E+06 -2.16E+06 -2.16E+06 0.31 0.57 1 111 
3 -2.41E+06 -2.41E+06 -2.41E+06 -2.41E+06 0.39 0.67 1 141 
4 -2.57E+06 -2.57E+06 -2.57E+06 -2.57E+06 0.42 0.73 0 147 
5 -2.10E+06 -2.10E+06 -2.10E+06 -2.10E+06 0.33 0.59 1 114 
6 -2.26E+06 -2.26E+06 -2.26E+06 -2.26E+06 0.35 0.62 0 120 
7 -2.88E+06 -2.88E+06 -2.88E+06 -2.88E+06 0.36 0.67 0 114 
8 -3.04E+06 -3.04E+06 -3.04E+06 -3.04E+06 0.38 0.66 0 120 
Cl -3.93E+04 -3.93E+04 -3.93E+04 -3.93E+04 0.01 0.15 0 0 
H2O -2.00E+05 -2.00E+05 -2.00E+05 -2.00E+05 0.03 0.19 0 3 
 
 
Table 3.64: The change in the thermodynamic properties due to hydrolysis 
KJ/mol H G S 
(2+Cl) – (1+H2O) 4.18E+02 4.38E+02 -6.63E-02 
(4+Cl) – (3+H2O) 4.06E+02 4.01E+02 1.94E-02 
(6+Cl) – (5+H2O) 4.16E+02 4.20E+02 -1.39E-02 
(8+Cl) – (7+H2O) 4.32E+02 4.46E+02 -4.55E-02 
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Table 3.65: Total hyperpolarizability, band gap, and isotropic polarizability of complexes 1, 2, 3, 4, 5, 
6, 7 and 8 when mixed basis set (SBKJC VDZ with ECP and 6-31g*) and single basis set 3-21g 
were used. 
 B3lyp/3-21g PBE0/mixes basis 
 
 ß in esu 
(1x10-30) Gap in KJ/mol 
Iso. pol. 
Bohr**3 
 ß in esu 
(1x10-30) Gap in KJ/mol 
Iso. pol. 
Bohr**3 
1 19.24 363.37 88.84 19.95 208.86 226.9 
2 34.39 264.76 93.65 56.74 132.01 227.56 
3 19.56 362.00 110.73 20.48 208.94 277.85 
4 32.96 274.39 115.47 53.30 140.81 277.87 
5 19.59 362.98 91.97 19.92 208.73 238.95 
6 33.06 268.64 95.74 52.99 135.27 238.02 
7 22.10 335.91 93.2 23.50 196.39 240.87 
8 39.21 237.42 97.72 66.97 111.85 243.51 
 
 
Table 3.66: The effect of the four Ramsey terms in determining the shielding tensor of complexes using 
the functional b3lyp and all electron basis set 3-21g 
 Bond FC (HZ)  SD  PSO DSO J (HZ)  
Complex 1 
arene Ru-C -2.40E+000 -5.31E-002 -1.47E+000 -3.32E-002 -3.96E+000 
  -1.87E+000 3.75E-002 -9.03E-001 -3.11E-002 -2.77E+000 
  -2.95E+000 3.56E-002 -1.82E+000 -3.30E-002 -4.77E+000 
  -1.87E+000 3.83E-002 -9.02E-001 -3.11E-002 -2.77E+000 
  -2.95E+000 3.63E-002 -1.82E+000 -3.30E-002 -4.77E+000 
  -2.40E+000 -5.36E-002 -1.47E+000 -3.32E-002 -3.96E+000 
mono Ru-Cl17 -1.04E+000 -2.17E+000 -2.06E+001 -9.64E-003 -2.38E+001 
 Ru-Cl5 -1.04E+000 -2.17E+000 -2.06E+001 -9.64E-003 -2.38E+001 
pta Ru-P -6.07E+001 -1.35E+000 2.59E+000 -5.63E-002 -5.96E+001 
Complex 2 
arene Ru-C -2.93E+000 2.93E-002 -1.76E+000 -3.12E-002 -4.69E+000 
  -2.37E+000 -1.19E-001 -2.10E+000 -3.12E-002 -4.62E+000 
  -3.58E+000 -1.22E-001 -2.13E+000 -3.28E-002 -5.87E+000 
  -1.28E+000 1.21E-002 -1.26E+000 -2.87E-002 -2.56E+000 
  -3.52E+000 -2.43E-001 -2.22E+000 -3.33E-002 -6.01E+000 
  -1.52E+000 1.33E-002 -1.06E+000 -2.93E-002 -2.60E+000 
mono Ru-O 2.86E+000 6.28E-001 3.83E+000 1.58E-002 7.33E+000 
 Ru-Cl# -4.80E-001 -1.72E+000 -1.68E+001 -9.07E-003 -1.90E+001 
pta Ru-P -5.69E+001 -1.77E+000 -1.53E+000 -5.24E-002 -6.02E+001 
Complex 3 
arene Ru-C -2.96E+00 -5.29E-03 -1.66E+00 -3.78E-02 -4.66E+00 
  -3.16E+00 3.61E-02 -2.10E+00 -3.64E-02 -5.26E+00 
  -2.63E+00 -3.71E-02 -1.67E+00 -3.67E-02 -4.38E+00 
  -2.46E+00 -1.64E-01 -1.72E+00 -3.75E-02 -4.38E+00 
  -2.09E+00 6.41E-03 -1.14E+00 -3.57E-02 -3.26E+00 
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  -1.67E+00 1.05E-01 -9.58E-01 -3.68E-02 -2.56E+00 
mono Ru-Cl19 -9.41E-01 -2.03E+00 -1.97E+01 -1.02E-02 -2.27E+01 
 Ru-Cl20 -1.16E+00 -2.14E+00 -2.02E+01 -1.04E-02 -2.35E+01 
pta Ru-P13 -6.17E+01 -1.17E+00 2.79E+00 -5.83E-02 -6.01E+01 
Complex 4 
arene Ru-C -2.94E+000 -1.24E-001 -1.97E+000 -3.53E-002 -5.07E+000 
  -2.69E+000 -1.05E-001 -2.43E+000 -3.57E-002 -5.26E+000 
  -3.75E+000 1.90E-003 -2.12E+000 -3.72E-002 -5.91E+000 
  -1.17E+000 -1.07E-001 -1.40E+000 -3.53E-002 -2.71E+000 
  -3.42E+000 -3.16E-001 -2.27E+000 -3.68E-002 -6.04E+000 
  -1.76E+000 1.22E-001 -1.19E+000 -3.36E-002 -2.86E+000 
mono Ru-O 2.49E+000 6.09E-001 3.87E+000 1.70E-002 6.98E+000 
 Ru-Cl# -5.27E-001 -1.55E+000 -1.56E+001 -9.63E-003 -1.77E+001 
pta Ru-P12 -5.92E+001 -1.51E+000 -7.70E-001 -5.49E-002 -6.15E+001 
Complex 5 
arene Ru-C -2.48E+000 -1.62E-001 -1.40E+000 -3.43E-002 -4.07E+000 
  -2.90E+000 8.62E-002 -2.06E+000 -3.43E-002 -4.91E+000 
  -1.93E+000 8.87E-002 -9.31E-001 -3.17E-002 -2.80E+000 
  -3.00E+000 5.25E-003 -1.60E+000 -3.64E-002 -4.63E+000 
  -2.09E+000 -1.04E-001 -9.20E-001 -3.25E-002 -3.14E+000 
  -2.39E+000 6.14E-002 -1.75E+000 -3.48E-002 -4.12E+000 
mono Ru-Cl2# -9.94E-001 -2.17E+000 -2.06E+001 -9.75E-003 -2.37E+001 
 Ru-Cl20 -1.04E+000 -2.12E+000 -2.04E+001 -9.82E-003 -2.36E+001 
pta Ru-P -6.19E+001 -1.29E+000 2.48E+000 -5.70E-002 -6.07E+001 
Complex 6 
arene Ru-C -2.80E+000 -5.44E-002 -1.94E+000 -3.32E-002 -4.83E+000 
  -2.61E+000 -1.05E-001 -2.16E+000 -3.22E-002 -4.91E+000 
  -3.72E+000 -2.97E-002 -1.97E+000 -3.60E-002 -5.76E+000 
  -1.35E+000 -5.93E-002 -1.39E+000 -2.95E-002 -2.83E+000 
  -3.39E+000 -2.52E-001 -2.36E+000 -3.52E-002 -6.05E+000 
  -1.67E+000 2.29E-002 -1.01E+000 -3.01E-002 -2.69E+000 
mono Ru-O11 2.53E+000 6.07E-001 3.80E+000 1.60E-002 6.95E+000 
 Ru-Cl20# -5.34E-001 -1.64E+000 -1.64E+001 -9.26E-003 -1.86E+001 
pta Ru-P12 -5.90E+001 -1.71E+000 -1.33E+000 -5.36E-002 -6.21E+001 
Complex 7 
arene Ru-C -2.76E+000 1.04E-001 -1.72E+000 -3.74E-002 -4.42E+000 
  -2.36E+000 -3.98E-002 -1.53E+000 -3.54E-002 -3.96E+000 
  -3.71E+000 1.63E-001 -1.61E+000 -4.39E-002 -5.20E+000 
  -1.66E+000 3.89E-002 -7.43E-001 -3.31E-002 -2.40E+000 
  -2.16E+000 -4.85E-002 -1.50E+000 -3.83E-002 -3.74E+000 
  -1.86E+000 6.14E-002 -8.73E-001 -3.33E-002 -2.71E+000 
mono Ru-Cl11# -1.08E+000 -2.21E+000 -2.14E+001 -1.02E-002 -2.47E+001 
 Ru-Cl23 -9.40E-001 -2.30E+000 -2.16E+001 -1.05E-002 -2.48E+001 
pta Ru-P14 -5.96E+001 -1.56E+000 9.82E-001 -6.04E-002 -6.03E+001 
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Table 3.67: The correlation within the four Ramsey terms that were used in determining the shielding 
tensor of the complexes 1, 2, 3, 4, 5, 6 and 7 using the functional b3lyp and all electron basis set 3-
21g  
FC* SD PSO DSO J.HZ. 
1 0.38 -0.12 0.43 0.88 
2 0.7 0.08 0.37 0.95 
3 0.36 -0.11 0.34 0.89 
4 0.67 0.06 0.3 0.96 
5 0.37 -0.11 0.39 0.89 
6 0.7 0.07 0.34 0.96 
7 0.41 -0.05 0.38 0.87 
     
SD* PSO DSO J.HZ.  
1 0.86 0.14 0.77  
2 0.74 0.27 0.87  
3 0.87 0.1 0.74  
4 0.73 0.23 0.84  
5 0.86 0.12 0.75  
6 0.73 0.26 0.87  
7 0.83 0.04 0.78  
     
PSO* DSO J.HZ. DSO* J.HZ. 
1 0.01 0.37 1 0.4 
2 0.2 0.38 2 0.4 
3 0.02 0.36 3 0.33 
4 0.19 0.34 4 0.33 
5 0.01 0.36 5 0.37 
6 0.2 0.36 6 0.38 
7 0 0.44 7 0.33 
The superscript ―*‖ stands for the correlation of the factor with the rest of the factors on the same row except where another 
one appears. 
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Table 3.68: J_XY is X component of the first-order net current vector induced in the molecule by a 
uniform magnetic field along the Y axis in atomic units from QTAIM for complexes 1, 2, 3, 4, 5, 6 
and 7 
 
 1 2 3 4 5 6 7 
J_XX  3.52E-08 -4.65E-04 -2.75E-04 -4.17E-04 2.07E-04 -2.76E-04 1.51E-04 
J_YX  1.23E-06 1.63E-04 1.72E-03 -1.05E-04 5.79E-04 -7.38E-05 1.21E-03 
J_ZX  1.67E-03 -4.10E-04 1.26E-03 8.27E-04 1.48E-03 2.95E-04 7.35E-04 
J_XY  -6.03E-07 9.87E-04 -1.29E-03 8.57E-05 -1.50E-04 -7.05E-04 -3.81E-04 
J_YY  -1.00E-07 6.47E-07 3.36E-04 -3.13E-04 3.92E-05 -9.09E-05 -1.79E-04 
J_ZY  8.24E-04 -3.39E-03 -1.07E-03 -2.26E-03 -1.03E-03 -3.29E-03 -9.54E-04 
J_XZ  -5.19E-04 -9.73E-04 -1.12E-04 9.10E-04 -1.43E-04 1.80E-03 -1.02E-04 
J_YZ  -1.42E-03 2.14E-03 6.07E-04 2.15E-03 6.64E-04 2.39E-03 1.65E-03 
J_ZZ  8.85E-03 1.14E-02 1.12E-02 1.30E-02 1.12E-02 1.14E-02 1.16E-02 
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Table 3.69: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 1 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.64 17.13 -26.98 -9.85 0.38 1.85 1.94 -2172.26 26.08 -2146.18 5274.66 
C2 -0.10 -3.47 -6.19 -9.66 0.25 0.21 0.06 100.03 23.86 123.89 118.23 
C3 -0.09 -3.32 -6.07 -9.40 0.26 0.23 0.06 91.92 21.68 113.61 131.16 
C4 -0.13 -3.72 -6.43 -10.15 0.23 0.13 0.11 107.86 24.39 132.25 108.80 
C6 -0.09 -3.32 -6.08 -9.40 0.26 0.23 0.06 91.94 21.68 113.62 131.15 
C7 -0.13 -3.72 -6.44 -10.16 0.23 0.13 0.11 107.87 24.39 132.26 108.80 
C9 -0.10 -3.47 -6.20 -9.67 0.25 0.21 0.06 100.02 23.86 123.88 118.24 
Cl17 -0.56 -23.02 -2.99 -26.01 0.14 1.37 1.50 1192.99 4.19 1197.18 411.30 
Cl5 -0.56 -23.02 -2.99 -26.01 0.14 1.37 1.50 1193.03 4.19 1197.22 411.35 
P11 0.88 -6.92 -8.08 -14.99 1.00 0.50 1.49 478.93 12.13 491.06 49.27 
N16 -0.85 -5.92 -3.16 -9.09 0.38 0.48 0.85 206.92 11.60 218.52 24.48 
N10 -0.85 -5.92 -3.16 -9.08 0.38 0.48 0.85 206.92 11.60 218.52 24.47 
N18 -0.86 -5.88 -3.15 -9.03 0.37 0.46 0.83 202.83 11.78 214.61 28.90 
The magnetic properties are define in terms of q(A)=Total charge on atom A; Intra_Iso(A)= Intraatomic Magnetizability 
Contribution of Atom A ( cgs-ppm ); Bond_Iso(A) = Bonding Magnetizability Contribution of Atom A; _Iso(A)= Total 
Magnetizability Contribution of Atom A (Intra(A) + Bond(A)); Intra(A) = Intraatomic Dipole Moment Contribution of Atom 
A; Bond(A) = Bonding Dipole Moment Contribution of Atom A; (A) =Total Dipole Moment Contribution of Atom A 
(Intra(A) + Bond(A)); _Iso(A,A)=The Intraatomic shielding tensor; _Iso(A',A)= Total Induced Magnetic Field on Nucleus A 
by other nuclei A'; _Iso(A)= Total Magnetic shielding tensor of atom A. The superscript ―*‖ stands for the correlation of the 
factor with the rest of the factors on the same row except where another one appears. 
 
 
Table 3.70: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 2 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.68 22.05 -23.81 -1.76 0.31 0.85 0.96 -2855.76 25.32 -2830.44 5682.70 
C6 -0.10 -3.56 -6.48 -10.04 0.26 0.15 0.11 103.76 23.94 127.69 119.61 
C7 -0.12 -3.64 -6.64 -10.28 0.24 0.14 0.11 103.50 23.85 127.35 112.19 
C9 -0.11 -3.67 -6.90 -10.57 0.24 0.14 0.12 108.55 25.44 133.98 114.53 
C14 -0.11 -3.43 -7.49 -10.92 0.24 0.15 0.12 93.72 21.71 115.43 127.89 
C17 -0.10 -3.62 -7.52 -11.14 0.26 0.20 0.08 107.49 25.33 132.82 113.11 
C18 -0.07 -3.18 -4.33 -7.51 0.27 0.22 0.09 89.67 21.59 111.25 137.72 
O8 -0.93 -9.13 -2.85 -11.98 0.13 0.66 0.74 357.06 9.88 366.94 169.65 
Cl19# -0.52 -22.16 -3.59 -25.76 0.11 1.20 1.29 1066.93 4.18 1071.11 627.58 
H39* 0.51 -0.47 -0.83 -1.30 0.15 0.35 0.40 13.84 18.08 31.92 18.56 
P11 0.72 -7.34 -7.44 -14.79 0.93 0.62 0.33 465.02 10.76 475.78 86.83 
N10 -0.85 -5.69 -2.93 -8.61 0.35 0.45 0.80 191.35 11.42 202.77 42.54 
N2 -0.85 -5.66 -2.96 -8.62 0.36 0.45 0.81 189.80 11.23 201.03 45.90 
N12 -0.85 -5.68 -2.95 -8.64 0.36 0.45 0.81 190.54 11.33 201.88 41.49 
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Table 3.71: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 3 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.64 19.74 -23.48 -3.74 0.37 1.39 1.48 -2469.14 25.92 -2443.22 5352.17 
C6 -0.09 -2.66 -6.76 -9.42 0.12 0.17 0.05 92.92 25.77 118.68 119.23 
C9 -0.13 -3.73 -6.51 -10.24 0.23 0.11 0.14 108.03 24.53 132.55 91.39 
C10 -0.11 -3.47 -6.33 -9.81 0.24 0.17 0.10 101.25 24.12 125.37 99.04 
C14 -0.12 -3.44 -6.88 -10.32 0.23 0.18 0.09 101.98 23.93 125.91 108.16 
C16 -0.12 -3.18 -6.71 -9.89 0.23 0.18 0.11 93.18 21.89 115.07 113.71 
C17 -0.06 -2.15 -4.16 -6.32 0.19 0.05 0.15 73.89 22.72 96.61 136.40 
C2* -0.06 -4.69 -5.07 -9.76 0.21 0.22 0.06 163.69 15.51 179.20 33.03 
H46* 0.09 -1.03 -1.84 -2.88 0.15 0.30 0.42 19.98 9.77 29.74 9.24 
Cl19 -0.58 -23.11 -3.05 -26.16 0.14 1.40 1.54 1191.50 4.08 1195.58 423.85 
Cl20 -0.57 -22.80 -6.68 -29.48 0.14 0.66 0.79 1197.51 4.37 1201.88 413.29 
P13 0.86 -7.07 -6.37 -13.43 1.02 0.11 0.96 481.97 12.18 494.15 40.48 
N4 -0.85 -5.95 -3.25 -9.20 0.38 0.47 0.85 208.64 11.71 220.35 22.80 
N5 -0.85 -5.95 -3.05 -9.00 0.38 0.47 0.85 209.40 11.64 221.04 23.93 
N15 -0.86 -5.91 -3.46 -9.37 0.37 0.48 0.84 204.84 11.84 216.69 26.24 
H29* 0.06 -1.07 -1.25 -2.32 0.16 0.07 0.09 20.56 7.97 28.52 7.38 
H43* 0.11 -0.96 -1.59 -2.55 0.15 0.36 0.42 19.46 8.66 28.12 8.76 
 
 
Table 3.72: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 4 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.68 23.69 -20.31 3.38 0.31 0.84 0.85 -3024.52 25.27 -2999.25 5722.50 
C6 -0.11 -3.44 -6.63 -10.07 0.23 0.13 0.13 101.94 24.15 126.09 101.34 
C10 -0.13 -3.71 -8.04 -11.75 0.22 0.13 0.13 108.63 24.14 132.77 101.98 
C11 -0.09 -2.68 -7.28 -9.96 0.17 0.07 0.14 94.23 26.95 121.18 126.57 
C18 -0.08 -2.06 -5.20 -7.26 0.18 0.12 0.06 71.21 23.14 94.35 137.73 
C19 -0.11 -3.46 -8.15 -11.61 0.24 0.18 0.12 104.19 25.25 129.44 94.91 
C21 -0.10 -3.21 -4.78 -8.00 0.25 0.18 0.11 94.13 21.65 115.78 114.93 
C7* -0.06 -4.79 -5.72 -10.51 0.25 0.19 0.16 165.34 15.82 181.16 34.35 
H31* 0.06 -1.20 -1.09 -2.29 0.16 0.07 0.21 21.07 9.57 30.64 7.88 
H39* 0.01 -1.30 -1.79 -3.09 0.16 0.12 0.10 21.72 10.25 31.97 6.80 
O16 -0.93 -9.11 -3.96 -13.07 0.13 0.69 0.75 353.42 9.98 363.40 163.45 
Cl23# -0.54 -22.35 -3.67 -26.02 0.11 1.22 1.32 1072.63 4.11 1076.74 602.88 
H50* 0.49 -0.52 -1.26 -1.78 0.15 0.14 0.08 15.52 15.78 31.30 19.15 
H51* 0.50 -0.47 -0.95 -1.43 0.15 0.32 0.38 13.81 18.29 32.10 19.30 
P12 0.73 -7.52 -6.77 -14.29 0.96 0.26 0.70 477.46 10.96 488.42 65.95 
N2 -0.85 -5.74 -2.99 -8.72 0.36 0.45 0.81 195.39 11.31 206.69 39.66 
N8 -0.85 -5.76 -3.17 -8.93 0.36 0.45 0.81 195.98 11.48 207.46 34.05 
N9 -0.85 -5.78 -2.93 -8.72 0.36 0.45 0.81 198.20 11.54 209.74 34.91 
H26* 0.07 -1.09 -1.02 -2.11 0.16 0.10 0.09 20.46 7.28 27.74 5.96 
H35* 0.07 -1.07 -1.58 -2.65 0.16 0.06 0.10 20.36 7.84 28.20 5.35 
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Table 3.73: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 5 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.65 18.61 -25.14 -6.53 0.39 1.56 1.71 -2345.90 25.97 -2319.93 5313.01 
C6 -0.11 -3.37 -6.14 -9.51 0.25 0.21 0.07 97.78 23.80 121.58 116.49 
C9 -0.13 -3.74 -6.32 -10.06 0.23 0.12 0.12 107.84 24.25 132.10 95.56 
C10 -0.09 -3.44 -6.09 -9.53 0.27 0.23 0.07 94.64 21.69 116.33 129.12 
C14 -0.09 -2.58 -6.72 -9.30 0.12 0.16 0.04 90.63 25.57 116.20 122.22 
C16 -0.10 -3.24 -6.04 -9.28 0.26 0.23 0.07 90.66 22.00 112.66 129.03 
C19 -0.11 -3.52 -6.12 -9.64 0.24 0.18 0.08 102.28 23.87 126.15 102.06 
C18* -0.06 -4.69 -5.08 -9.77 0.21 0.22 0.09 163.28 15.45 178.73 33.91 
Cl2# -0.57 -23.04 -4.20 -27.24 0.14 1.13 1.26 1197.33 4.27 1201.60 395.17 
Cl20 -0.57 -23.06 -2.98 -26.03 0.14 1.38 1.51 1193.59 4.13 1197.72 416.52 
P11 0.86 -7.10 -6.45 -13.54 1.02 0.18 0.90 482.52 11.99 494.50 39.20 
N5 -0.85 -5.93 -3.05 -8.98 0.38 0.47 0.85 207.96 11.63 219.59 24.26 
N7 -0.86 -5.90 -3.35 -9.25 0.37 0.49 0.84 204.07 11.84 215.91 27.50 
N15 -0.85 -5.95 -3.24 -9.19 0.38 0.47 0.84 208.95 11.67 220.62 24.12 
H25* 0.12 -0.95 -1.32 -2.28 0.15 0.44 0.50 19.43 8.70 28.13 7.97 
H37* 0.06 -1.07 -1.22 -2.29 0.16 0.10 0.09 20.56 7.84 28.40 7.67 
 
 
 
Table 3.74: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 6 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.68 23.15 -22.34 0.82 0.31 0.72 0.78 -2970.53 25.12 -2945.40 5733.05 
C2 -0.11 -3.46 -6.28 -9.74 0.24 0.13 0.12 102.45 23.77 126.22 106.28 
C3 -0.12 -3.69 -6.58 -10.27 0.24 0.15 0.12 104.89 23.98 128.87 107.88 
C7 -0.09 -2.58 -6.94 -9.52 0.16 0.07 0.21 91.48 26.60 118.08 129.93 
C8 -0.11 -3.45 -7.45 -10.90 0.24 0.14 0.12 94.36 22.00 116.37 125.75 
C13 -0.11 -3.53 -7.30 -10.83 0.24 0.18 0.11 106.84 25.21 132.05 98.20 
C14 -0.08 -3.23 -4.31 -7.54 0.27 0.22 0.09 90.79 21.76 112.55 133.93 
C6* -0.06 -4.78 -5.35 -10.13 0.25 0.20 0.24 164.78 15.66 180.44 33.68 
H26* 0.06 -1.19 -1.04 -2.23 0.16 0.09 0.23 21.04 9.44 30.48 7.55 
O11 -0.93 -9.12 -2.85 -11.97 0.13 0.67 0.75 356.99 10.01 367.00 170.49 
Cl20# -0.53 -22.24 -3.59 -25.83 0.11 1.21 1.31 1069.96 4.10 1074.06 624.88 
H41* 0.51 -0.47 -0.83 -1.30 0.15 0.35 0.41 13.88 18.24 32.12 18.46 
P12 0.73 -7.44 -6.57 -14.00 0.94 0.43 0.51 469.82 10.77 480.59 76.75 
N15 -0.85 -5.72 -3.09 -8.81 0.36 0.45 0.81 193.31 11.41 204.72 37.10 
N16 -0.85 -5.73 -2.88 -8.61 0.35 0.45 0.81 194.52 11.50 206.02 38.83 
N5 -0.85 -5.69 -2.94 -8.63 0.36 0.45 0.81 191.98 11.26 203.24 44.04 
H23* 0.07 -1.09 -0.98 -2.06 0.16 0.12 0.09 20.44 7.18 27.62 5.98 
H33* 0.07 -1.06 -1.41 -2.46 0.16 0.10 0.08 20.32 7.72 28.04 5.82 
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Table 3.75: The charges, magnetizability contribution, dipole, magnetic shielding tensor and anisotropy 
of some selected atoms in complexes 7 
Atom  q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
Ru1 0.65 17.24 -23.87 -6.64 0.40 1.85 2.08 -2148.92 26.26 -2122.67 5122.76 
C6 -0.10 -3.69 -6.34 -10.03 0.28 0.22 0.07 108.41 24.34 132.74 105.68 
C8 -0.09 -3.45 -6.50 -9.95 0.26 0.25 0.02 100.02 23.76 123.77 118.80 
C12 -0.11 -3.10 -6.72 -9.82 0.10 0.12 0.21 99.58 25.32 124.90 90.09 
C17 -0.09 -3.24 -7.24 -10.48 0.26 0.29 0.05 89.86 21.53 111.38 135.87 
C21 -0.08 -3.43 -7.23 -10.66 0.28 0.30 0.03 102.49 23.84 126.33 112.53 
C22 -0.08 -3.35 -4.29 -7.64 0.28 0.23 0.11 92.87 21.58 114.44 131.45 
F7* -0.52 -6.91 -2.43 -9.33 0.07 0.53 0.47 281.25 3.59 284.84 133.19 
F18* -0.50 -6.90 -1.45 -8.35 0.07 0.68 0.61 272.91 4.03 276.95 120.71 
F9 -0.49 -6.83 -1.06 -7.90 0.08 0.77 0.69 256.09 4.03 260.12 120.24 
Cl11# -0.55 -22.77 -4.23 -27.00 0.14 1.10 1.23 1171.99 4.38 1176.36 416.09 
Cl23 -0.55 -22.78 -3.08 -25.86 0.14 1.33 1.46 1168.89 4.30 1173.19 423.99 
P14 0.84 -7.00 -6.25 -13.25 0.98 0.50 0.48 473.02 12.00 485.02 55.06 
N15 -0.85 -5.86 -3.08 -8.93 0.37 0.47 0.84 201.41 11.66 213.07 30.75 
N13 -0.86 -5.85 -3.29 -9.15 0.37 0.47 0.83 200.41 11.78 212.19 31.52 
N2 -0.85 -5.87 -3.00 -8.88 0.38 0.47 0.84 203.56 11.58 215.14 27.72 
H25* 0.07 -1.10 -1.16 -2.26 0.16 0.18 0.30 20.50 7.71 28.21 5.99 
H32* 0.11 -0.96 -1.37 -2.34 0.15 0.34 0.39 19.53 8.52 28.04 8.08 
H34* 0.08 -1.05 -1.59 -2.63 0.15 0.26 0.37 20.32 7.95 28.27 8.66 
 
 
 
Table 3.76: The sum total of the charges, magnetizability contribution, dipole, magnetic shielding 
tensor and anisotropy over all atoms in complexes 1, 2, 3, 4, 5, 6 and 7 
 q(A)
Intra_Iso(
A)
Bond_Iso(
A) _Iso(A) |Intra(A)| 
|Bond(A)
| |(A)|
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Anisotro
py 
raptaB 0.001 -110.750 -117.580 -228.330 10.478 11.915 11.699 
3038.48
2 453.272 
3491.75
4 7253.739 
raptaBh2
0 1.000 -91.203 -115.337 -206.540 10.470 10.873 8.596 
1359.16
6 485.857 
1845.02
4 7767.755 
raptaC -0.001 -132.964 -143.111 -276.075 12.231 11.723 12.618 
3538.67
3 604.259 
4142.93
2 7475.581 
raptaCh2
o 0.999 -114.947 -142.820 -257.767 12.299 11.078 10.343 
2006.52
9 640.884 
2647.41
2 7882.425 
raptaT 0.000 -115.510 -123.627 -239.137 10.910 12.036 11.422 
3068.98
3 491.212 
3560.19
4 7300.437 
raptaTh2
o 0.998 -96.468 -121.308 -217.776 10.945 10.860 9.233 
1454.30
7 524.732 
1979.03
9 7825.634 
raptaTcf3 0.000 -128.347 -124.585 -252.932 11.055 15.261 13.282 
3834.68
1 476.175 
4310.85
6 7487.330 
 
 
Table 3.77: Correlation of the charges, magnetizability contribution, dipole, magnetic shielding tensor 
and anisotropy of complexes 1, 2, 3, 4, 5, 6 and 7 
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qA*
Intra_Iso(A
)
Bond_Iso(
A) _Iso(A) Intra(A) Bond(A) (A) _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y 
raptaB 0.55 -0.21 0.38 0.21 -0.1 -0.18 -0.44 0.12 -0.44 0.25 
raptaBh2o 0.54 -0.13 0.46 0.15 -0.18 -0.52 -0.38 0.11 -0.38 0.23 
raptaC 0.55 -0.11 0.45 0.21 -0.17 -0.29 -0.44 0.1 -0.44 0.25 
raptaCh2o 0.54 -0.06 0.5 0.16 -0.25 -0.47 -0.38 0.09 -0.38 0.24 
raptaT 0.55 -0.17 0.43 0.21 -0.18 -0.29 -0.44 0.11 -0.44 0.25 
raptaTh2o 0.54 -0.1 0.49 0.15 -0.24 -0.54 -0.38 0.1 -0.38 0.23 
raptaTcf3 0.53 -0.16 0.42 0.38 -0.12 -0.29 -0.4 0.28 -0.39 0.19 
           
Intra_Iso(A
)*
Bond_Iso(
A) _Iso(A) Intra(A) Bond(A) (A) _Iso(AA) _Iso(A'A) _Iso(A) 
Anisotrop
y  
raptaB -0.36 0.71 0 -0.23 -0.29 -0.93 0.32 -0.93 0.47  
raptaBh2o -0.44 0.7 -0.08 -0.26 -0.23 -0.92 0.27 -0.92 0.65  
raptaC -0.25 0.78 -0.02 -0.18 -0.24 -0.93 0.29 -0.93 0.51  
raptaCh2o -0.34 0.77 -0.08 -0.23 -0.28 -0.93 0.24 -0.93 0.67  
raptaT -0.34 0.75 -0.01 -0.23 -0.27 -0.93 0.32 -0.93 0.5  
raptaTh2o -0.43 0.74 -0.08 -0.3 -0.31 -0.93 0.27 -0.93 0.67  
raptaTcf3 -0.34 0.77 0.08 -0.19 -0.19 -0.93 0.37 -0.93 0.47  
           
Bond_Iso(A
)* _Iso(A) Intra(A) Bond(A) (A) _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y   
raptaB 0.4 -0.37 -0.68 -0.59 0.62 -0.7 0.62 -0.88   
raptaBh2o 0.34 -0.33 -0.49 -0.4 0.68 -0.7 0.68 -0.84   
raptaC 0.41 -0.32 -0.63 -0.54 0.53 -0.7 0.52 -0.83   
raptaCh2o 0.34 -0.32 -0.47 -0.37 0.58 -0.75 0.58 -0.76   
raptaT 0.36 -0.34 -0.64 -0.55 0.61 -0.71 0.6 -0.87   
raptaTh2o 0.3 -0.32 -0.42 -0.35 0.67 -0.71 0.66 -0.82   
raptaTcf3 0.34 -0.33 -0.67 -0.58 0.6 -0.7 0.59 -0.86   
           
_Iso(A)* Intra(A) Bond(A) (A) _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y    
raptaB -0.28 -0.75 -0.73 -0.44 -0.22 -0.45 -0.2    
raptaBh2o -0.35 -0.67 -0.56 -0.42 -0.28 -0.43 0.01    
raptaC -0.23 -0.57 -0.57 -0.54 -0.18 -0.54 -0.05    
raptaCh2o -0.3 -0.55 -0.53 -0.53 -0.27 -0.53 0.15    
raptaT -0.25 -0.68 -0.66 -0.5 -0.18 -0.5 -0.11    
raptaTh2o -0.32 -0.64 -0.6 -0.48 -0.25 -0.49 0.09    
raptaTcf3 -0.15 -0.65 -0.58 -0.52 -0.11 -0.53 -0.12    
           
Intra(A)* Bond(A) (A) _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y     
raptaB 0.32 0.29 0 0.31 0 0.08     
raptaBh2o 0.56 0 0.05 0.24 0.06 0.03     
raptaC 0.38 0.27 0 0.22 0.01 0.09     
raptaCh2o 0.47 0.16 0.04 0.17 0.05 0.05     
raptaT 0.32 0.22 -0.01 0.26 0 0.09     
raptaTh2o 0.51 0.05 0.05 0.2 0.05 0.04     
raptaTcf3 0.3 0.05 -0.05 0.39 -0.04 0.08     
           
Bond(A)* (A) _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y      
raptaB 0.85 -0.1 0.18 -0.1 0.69      
raptaBh2o 0.68 -0.03 0.15 -0.03 0.4      
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raptaC 0.76 -0.12 0.16 -0.12 0.6      
raptaCh2o 0.69 -0.07 0.12 -0.07 0.42      
raptaT 0.82 -0.09 0.16 -0.09 0.63      
raptaTh2o 0.67 0.01 0.11 0.01 0.35      
raptaTcf3 0.86 -0.13 0.12 -0.13 0.68      
           
(A)* _Iso(AA) _Iso(A'A)_Iso(A) 
Anisotrop
y  
_Iso(AA)
* _Iso(A'A) _Iso(A) 
Anisotrop
y  
raptaB -0.02 0.01 -0.02 0.6  raptaB -0.41 1 -0.75  
raptaBh2o -0.11 -0.01 -0.11 0.46  
raptaBh2
o -0.35 1 -0.89  
raptaC -0.06 -0.01 -0.06 0.56  raptaC -0.37 1 -0.78  
raptaCh2o -0.04 -0.05 -0.04 0.39  
raptaCh2
o -0.31 1 -0.89  
raptaT -0.05 -0.03 -0.05 0.6  raptaT -0.4 1 -0.77  
raptaTh2o -0.01 -0.02 -0.01 0.37  
raptaTh2
o -0.33 1 -0.89  
raptaTcf3 -0.15 -0.04 -0.15 0.69  raptaTcf3 -0.42 1 -0.75  
           
_Iso(A'A)
* _Iso(A) 
Anisotrop
y  _Iso(A)* 
Anisotrop
y      
raptaB -0.39 0.38  raptaB -0.75      
raptaBh2o -0.33 0.35  
raptaBh2
o -0.89      
raptaC -0.36 0.35  raptaC -0.78      
raptaCh2o -0.3 0.33  
raptaCh2
o -0.89      
raptaT -0.39 0.37  raptaT -0.77      
raptaTh2o -0.32 0.34  
raptaTh2
o -0.89      
raptaTcf3 -0.4 0.35  raptaTcf3 -0.75      
 
 
 
 
20  
21  
22  
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Table 3.78: The selected bond lengths and angles of interest with the percentage of the alignment of 
each complexes optimized using different basis sets ECP(Ru,Cl)|6-31G* and ECP(Ru)|6-
31+G(d,p). 
 
  1 2 3 4 5 
Ru-Cl ECP(Ru,Cl)|6-31G* 2.444 2.444 2.390   
 ECP(Ru)|6-31+G(d,p) 2.394 2.396 2.440   
Ru-N ECP(Ru,Cl)|6-31G* 2.133, 2.134 2.10, 2.10 2.140, 2.146 2.166, 2.166, 
*2.089 
2.157, 2.158, 
*2.045 
 ECP(Ru)|6-31+G(d,p) 2.137,2.139 2.096, 2.096 2.138, 2.138 2.162, 2.162, 
*2.084 
2.152, 2.153, 
*2.039 
Ru-C ranges ECP(Ru,Cl)|6-31G* 2.225 - 2.234 2.229 - 2.251 2.233 – 2.252 2.240 – 2.251 2.251 – 2.268 
 ECP(Ru)|6-31+G(d,p) 2.222 – 2.232 2.233 – 2.254 2.236 – 2.253 2.241 – 2.252 2.252 – 2.269 
N-Ru-N ECP(Ru,Cl)|6-31G* 83.045 76.995 77.375 107.984, *72.054, 
*72.051 
108.839, *73.521, 
*73.568 
 ECP(Ru)|6-31+G(d,p) 82.809 77.116 77.317 107.855, *72.159, 
*72.158 
108.654, *73.632, 
*73.672 
RMSD of 
atoms in Å 
 0.068 0.004 0.017 0.011 0.01 
The values for the complexes 4 and 5 with superscript ―*‖ indicated their association with the middle nitrogen of their tridentate. 
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Table 3.79: The assignment of the IR vibrations to different bonds in the complexes 
 
Vibrations Complex Assignment 
3600-3625 1, 2, 3, 5 O-H of carboxylic 
1758-1784 1, 2, 3, 5 C=O [[Carusoetal2012]] of carboxylic 
1050-1150 1, 2, 3, 5 O-C stretches (2-bands) 
735-745 1, 2, 4, 5 O-H bend (out-of-plane) 
3228 1, 4 C-H asymmetric vibration peculiar to 
pyrazol-1-ly unit  
3050-3161 all C-H arene asymmetric vibration 
1419  all charge transfer Ru-L [[Rajapakseetal2009]] 
C-C 
arene v(C-H) stretches  
1337 All but prominent in complex 2 C-N stretches  
   
597 complex 3 i.e. effect of carbonyl unit being 
very close to metal 
Charge transfer 
614-642 Complex 1, 2, 3, 5 O-H bend (out-of-plane) of carboxylic unit 
300 Complex 1, 2, 3, 5 Peculiar to carboxylic 
1477 4 Ru-L charge transfer [[Ombergetal1997]],  
C-C, C-N 
1419 all Ru-L charge transfer [[Ombergetal1997]], 
C-C, C-N 
700  1,2,3 Ru-Cl 
751 2,4,5 with pyridine has peculiar Ru-N(py)  
847  3  Ru-N(phen) 
731 1, 4 Ru-N(pz) 
765 4,5 (strong) Ru-N(py) should result from the strong long 
bond of Ru with mid pyridine unit 
797 all Ru-C 
3161  2,4,5 v(C-H) antisymmetric stretches (py) 
3224  1,4 v(C-H) antisymmetric stretches (pz) 
505 5 Ru-N(py) close to 424-428 assigned to 
v(Ru-S) [[Carusoetal2012]] 
300 all Bond deformations 
 
  
 
 
 
 
 
 
 
Table 3.80: The values of the Ramsey terms that define all the metal-ligand spin spin coupling of the 
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complexes from two different systems treated with DGDZVP(Ru)|6-31+G(d,p) and 3-21G 
respectively  
 
DGDZVP(Ru)|6-31+G(d,p) 3-21G 
Complex 1 Complex 1 
 FC  SD PSO DSO J (HZ)  FC  SD PSO DSO J (HZ) 
Ru-C9 
-
7.06E+00
0 
3.62E-
001 
-
1.71E+00
0 
-3.20E-
002 
-
8.44E+00
0 Ru-C9 
-
2.15E+00
0 
1.81E-
001 
-
1.74E+00
0 
-3.21E-
002 
-
3.74E+00
0 
Ru-C10 
-
7.83E+00
0 
-3.13E-
001 
-
1.67E+00
0 
-3.37E-
002 
-
9.85E+00
0 Ru-C10 
-
2.32E+00
0 
-2.63E-
001 
-
1.65E+00
0 
-3.31E-
002 
-
4.26E+00
0 
Ru-C13 
-
7.44E+00
0 
-2.17E-
001 
-
1.53E+00
0 
-3.37E-
002 
-
9.22E+00
0 Ru-C13 
-
2.14E+00
0 
-1.73E-
001 
-
1.60E+00
0 
-3.32E-
002 
-
3.95E+00
0 
Ru-C16 
-
9.25E+00
0 
2.82E-
001 
-
1.38E+00
0 
-3.31E-
002 
-
1.04E+00
1 Ru-C16 
-
2.76E+00
0 
9.19E-
002 
-
1.31E+00
0 
-3.30E-
002 
-
4.01E+00
0 
Ru-C18 
-
8.82E+00
0 
2.44E-
001 
-
1.74E+00
0 
-3.29E-
002 
-
1.03E+00
1 Ru-C18 
-
2.54E+00
0 
7.33E-
002 
-
1.69E+00
0 
-3.26E-
002 
-
4.19E+00
0 
Ru-C19 
-
8.16E+00
0 
-3.04E-
001 
-
1.04E+00
0 
-3.34E-
002 
-
9.53E+00
0 Ru-C19 
-
2.55E+00
0 
-2.52E-
001 
-
1.12E+00
0 
-3.31E-
002 
-
3.96E+00
0 
Ru-Cl22 
-
1.57E+00
0 
-
2.33E+00
0 
-
2.32E+00
1 
-9.87E-
003 
-
2.71E+00
1 Ru-Cl22 
-
1.11E+00
0 
-
2.49E+00
0 
-
2.20E+00
1 
-9.88E-
003 
-
2.56E+00
1 
Ru-N12 
-
1.24E+00
1 
-1.01E-
001 
-7.08E-
001 
-1.46E-
002 
-
1.32E+00
1 Ru-N12 
-
8.92E+00
0 
-1.07E-
001 
-6.04E-
001 
-1.42E-
002 
-
9.65E+00
0 
Ru-N17 
-
1.22E+00
1 
-1.03E-
001 
-6.93E-
001 
-1.46E-
002 
-
1.30E+00
1 Ru-N17 
-
8.86E+00
0 
-1.04E-
001 
-5.18E-
001 
-1.42E-
002 
-
9.49E+00
0 
Complex 2 Complex 2 
Ru-C7 
-
7.31E+00
0 
-3.58E-
001 
-
1.31E+00
0 
-3.33E-
002 
-
9.01E+00
0 Ru-C7 
-
2.42E+00
0 
-3.80E-
001 
-
1.32E+00
0 
-3.31E-
002 
-
4.16E+00
0 
Ru-C8 
-
8.36E+00
0 
4.45E-
001 
-
1.26E+00
0 
-3.21E-
002 
-
9.21E+00
0 Ru-C8 
-
2.76E+00
0 
3.22E-
001 
-
1.26E+00
0 
-3.19E-
002 
-
3.74E+00
0 
Ru-C13 
-
6.18E+00
0 
4.40E-
001 
-
1.71E+00
0 
-3.08E-
002 
-
7.47E+00
0 Ru-C13 
-
2.13E+00
0 
3.39E-
001 
-
1.73E+00
0 
-3.07E-
002 
-
3.55E+00
0 
Ru-C14 
-
7.30E+00
0 
-4.17E-
001 
-8.50E-
001 
-3.30E-
002 
-
8.61E+00
0 Ru-C14 
-
2.11E+00
0 
-4.33E-
001 
-9.09E-
001 
-3.29E-
002 
-
3.48E+00
0 
Ru-C18 
-
7.30E+00
0 
-3.58E-
001 
-
1.31E+00
0 
-3.33E-
002 
-
9.01E+00
0 Ru-C18 
-
2.42E+00
0 
-3.80E-
001 
-
1.33E+00
0 
-3.30E-
002 
-
4.17E+00
0 
Ru-C19 
-
8.34E+00
0 
4.46E-
001 
-
1.26E+00
0 
-3.21E-
002 
-
9.18E+00
0 Ru-C19 
-
2.75E+00
0 
3.23E-
001 
-
1.26E+00
0 
-3.19E-
002 
-
3.72E+00
0 
Ru-Cl10 
-
1.17E+00
0 
-
2.36E+00
0 
-
2.40E+00
1 
-9.72E-
003 
-
2.76E+00
1 Ru-Cl10 
-9.17E-
001 
-
2.48E+00
0 
-
2.26E+00
1 
-9.71E-
003 
-
2.60E+00
1 
Ru-N11 
-
1.28E+00
1 
-8.72E-
002 
-2.53E-
002 
-1.41E-
002 
-
1.29E+00
1 Ru-N11 
-
8.59E+00
0 
-1.01E-
001 
1.99E-
003 
-1.37E-
002 
-
8.71E+00
0 
Ru-N16 
-
1.28E+00
1 
-8.64E-
002 
-9.98E-
003 
-1.41E-
002 
-
1.29E+00
1 Ru-N16 
-
8.59E+00
0 
-1.01E-
001 
1.20E-
002 
-1.37E-
002 
-
8.69E+00
0 
Complex 3 Complex 3 
Ru-C13 - -1.31E- - -3.59E- - Ru-C13 - -6.54E- - -3.59E- -
333 
8.75E+00
0 
002 1.30E+00
0 
002 1.01E+00
1 
2.83E+00
0 
002 1.31E+00
0 
002 4.25E+00
0 
Ru-C14 
-
7.71E+00
0 
-7.27E-
002 
-
1.84E+00
0 
-3.59E-
002 
-
9.66E+00
0 Ru-C14 
-
2.42E+00
0 
-1.44E-
001 
-
1.79E+00
0 
-3.58E-
002 
-
4.39E+00
0 
Ru-C18 
-
8.63E+00
0 
-5.35E-
002 
-
1.29E+00
0 
-3.58E-
002 
-
1.00E+00
1 Ru-C18 
-
2.79E+00
0 
-1.41E-
001 
-
1.33E+00
0 
-3.58E-
002 
-
4.29E+00
0 
Ru-C21 
-
7.02E+00
0 
-2.37E-
003 
-
1.63E+00
0 
-3.47E-
002 
-
8.68E+00
0 Ru-C21 
-
2.02E+00
0 
-5.09E-
002 
-
1.68E+00
0 
-3.45E-
002 
-
3.79E+00
0 
Ru-C23 
-
7.68E+00
0 
-2.66E-
002 
-
1.86E+00
0 
-3.57E-
002 
-
9.60E+00
0 Ru-C23 
-
2.40E+00
0 
-7.16E-
002 
-
1.88E+00
0 
-3.55E-
002 
-
4.38E+00
0 
Ru-C25 
-
7.09E+00
0 
-4.84E-
002 
-
1.62E+00
0 
-3.48E-
002 
-
8.80E+00
0 Ru-C25 
-
2.13E+00
0 
-1.25E-
001 
-
1.70E+00
0 
-3.47E-
002 
-
3.98E+00
0 
Ru-Cl7 
-
2.06E+00
0 
-
2.04E+00
0 
-
2.29E+00
1 
-1.11E-
002 
-
2.70E+00
1 Ru-Cl7 
-
1.45E+00
0 
-
2.17E+00
0 
-
2.19E+00
1 
-1.11E-
002 
-
2.55E+00
1 
Ru-N10 
-
1.15E+00
1 
-5.83E-
002 
3.27E-
001 
-1.49E-
002 
-
1.13E+00
1 Ru-N10 
-
8.07E+00
0 
-6.77E-
002 
3.26E-
001 
-1.45E-
002 
-
7.83E+00
0 
Ru-N16 
-
1.15E+00
1 
-6.05E-
002 
3.14E-
001 
-1.49E-
002 
-
1.13E+00
1 Ru-N16 
-
8.01E+00
0 
-7.72E-
002 
2.97E-
001 
-1.46E-
002 
-
7.80E+00
0 
Complex 4 Complex 4 
Ru-C2 
-
7.36E+00
0 
-2.69E-
003 
-
1.17E+00
0 
-3.17E-
002 
-
8.56E+00
0 Ru-C2 
-
2.45E+00
0 
-6.12E-
002 
-
1.30E+00
0 
-3.17E-
002 
-
3.84E+00
0 
Ru-C3 
-
6.27E+00
0 
-1.82E-
001 
-
1.65E+00
0 
-3.24E-
002 
-
8.13E+00
0 Ru-C3 
-
1.53E+00
0 
-2.32E-
001 
-
1.69E+00
0 
-3.24E-
002 
-
3.48E+00
0 
Ru-C4 
-
7.37E+00
0 
6.30E-
003 
-
1.16E+00
0 
-3.17E-
002 
-
8.56E+00
0 Ru-C4 
-
2.46E+00
0 
-5.27E-
002 
-
1.30E+00
0 
-3.17E-
002 
-
3.84E+00
0 
Ru-C5 
-
7.96E+00
0 
-7.38E-
002 
-
2.60E+00
0 
-3.23E-
002 
-
1.07E+00
1 Ru-C5 
-
2.91E+00
0 
-1.26E-
001 
-
2.50E+00
0 
-3.22E-
002 
-
5.57E+00
0 
Ru-C6 
-
6.26E+00
0 
-1.90E-
001 
-
1.64E+00
0 
-3.24E-
002 
-
8.13E+00
0 Ru-C6 
-
1.53E+00
0 
-2.40E-
001 
-
1.68E+00
0 
-3.24E-
002 
-
3.48E+00
0 
Ru-C7 
-
7.95E+00
0 
-6.55E-
002 
-
2.60E+00
0 
-3.23E-
002 
-
1.06E+00
1 Ru-C7 
-
2.90E+00
0 
-1.19E-
001 
-
2.51E+00
0 
-3.22E-
002 
-
5.55E+00
0 
Ru-N10 
-
1.28E+00
1 
3.65E-
002 
-7.79E-
001 
-1.33E-
002 
-
1.35E+00
1 Ru-N10 
-
8.84E+00
0 
2.47E-
002 
-6.00E-
001 
-1.30E-
002 
-
9.43E+00
0 
Ru-N13 
-
1.28E+00
1 
3.67E-
002 
-7.79E-
001 
-1.33E-
002 
-
1.35E+00
1 Ru-N13 
-
8.84E+00
0 
2.50E-
002 
-5.99E-
001 
-1.30E-
002 
-
9.43E+00
0 
Ru-N15 
-
1.07E+00
1 
-1.64E-
001 
-6.73E-
001 
-1.47E-
002 
-
1.16E+00
1 Ru-N15 
-
6.86E+00
0 
-1.59E-
001 
-4.56E-
001 
-1.45E-
002 
-
7.49E+00
0 
 Complex 5 Complex 5 
Ru-C18 
-
7.94E+00
0 
-8.67E-
003 
-
2.14E+00
0 
-3.26E-
002 
-
1.01E+00
1 Ru-C18 
-
2.81E+00
0 
-6.52E-
002 
-
2.07E+00
0 
-3.25E-
002 
-
4.98E+00
0 
Ru-C20 
-
6.08E+00
0 
-1.52E-
001 
-
1.42E+00
0 
-3.27E-
002 
-
7.69E+00
0 Ru-C20 
-
1.43E+00
0 
-1.99E-
001 
-
1.45E+00
0 
-3.26E-
002 
-
3.11E+00
0 
Ru-C22 
-
7.95E+00
0 
-1.74E-
002 
-
2.14E+00
0 
-3.26E-
002 
-
1.01E+00
1 Ru-C22 
-
2.82E+00
0 
-7.17E-
002 
-
2.07E+00
0 
-3.25E-
002 
-
4.99E+00
0 
Ru-C23 - 7.09E- -8.44E- -3.18E- - Ru-C23 - 1.27E- -9.64E- -3.17E- -
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6.77E+00
0 
002 001 002 7.57E+00
0 
2.28E+00
0 
002 001 002 3.26E+00
0 
Ru-C26 
-
6.10E+00
0 
-1.46E-
001 
-
1.43E+00
0 
-3.27E-
002 
-
7.71E+00
0 Ru-C26 
-
1.43E+00
0 
-1.96E-
001 
-
1.45E+00
0 
-3.26E-
002 
-
3.11E+00
0 
Ru-C27 
-
6.75E+00
0 
6.16E-
002 
-8.46E-
001 
-3.18E-
002 
-
7.57E+00
0 Ru-C27 
-
2.27E+00
0 
6.47E-
003 
-9.66E-
001 
-3.17E-
002 
-
3.26E+00
0 
Ru-N14 
-
1.27E+00
1 
1.90E-
002 
-2.15E-
001 
-1.33E-
002 
-
1.29E+00
1 Ru-N14 
-
8.69E+00
0 
5.82E-
003 
-9.55E-
002 
-1.30E-
002 
-
8.80E+00
0 
Ru-N15 
-
1.24E+00
1 
-1.60E-
001 
-3.08E-
001 
-1.50E-
002 
-
1.29E+00
1 Ru-N15 
-
7.90E+00
0 
-1.68E-
001 
-1.85E-
001 
-1.48E-
002 
-
8.26E+00
0 
Ru-N21 
-
1.27E+00
1 
1.81E-
002 
-2.34E-
001 
-1.33E-
002 
-
1.30E+00
1 Ru-N21 
-
8.71E+00
0 
5.23E-
003 
-1.08E-
001 
-1.30E-
002 
-
8.82E+00
0 
 
 
Table 3.81: The values of the Ramsey terms that define all the metal-ligand spin spin coupling of the 
complexes from two different systems treated with ECP(Ru)|6-31+G(d,p) and ECP(Ru,Cl)|6-31G* 
respectively  
 
 
Ramsey 
Terms 
ECP(6-
31+G(d,p
)     
ECP(6-
31G*) 
Ramsey 
Terms    
Complex 1 Complex 1 
 
FC (HZ) 
for Ru SD for Ru 
PSO for 
Ru 
DSO for 
Ru 
J (HZ) for 
Ru  
FC (HZ) 
for Ru SD for Ru 
PSO for 
Ru 
DSO for 
Ru 
J (HZ) for 
Ru 
Ru-C9 
-3.67E-
006 
4.55E-
002 
-2.43E-
001 
-3.18E-
002 
-2.29E-
001 Ru-C9 
-1.79E-
006 
3.65E-
002 
-2.55E-
001 
-3.00E-
002 
-2.48E-
001 
Ru-C10 
-6.04E-
006 
-2.15E-
002 
-2.38E-
001 
-3.35E-
002 
-2.93E-
001 Ru-C10 
0.00E+00
0 
-1.41E-
002 
-2.43E-
001 
-3.06E-
002 
-2.88E-
001 
Ru-C13 
-6.00E-
006 
-7.58E-
003 
-2.17E-
001 
-3.35E-
002 
-2.58E-
001 Ru-C13 
-2.90E-
006 
8.14E-
004 
-2.34E-
001 
-3.09E-
002 
-2.64E-
001 
Ru-C16 
-3.66E-
006 
4.04E-
002 
-2.09E-
001 
-3.29E-
002 
-2.01E-
001 Ru-C16 
0.00E+00
0 
3.01E-
002 
-2.00E-
001 
-2.98E-
002 
-2.00E-
001 
Ru-C18 
-3.00E-
006 
3.33E-
002 
-2.52E-
001 
-3.27E-
002 
-2.52E-
001 Ru-C18 
1.33E-
006 
2.31E-
002 
-2.51E-
001 
-2.99E-
002 
-2.58E-
001 
Ru-C19 
-6.44E-
006 
-1.89E-
002 
-1.57E-
001 
-3.32E-
002 
-2.09E-
001 Ru-C19 
0.00E+00
0 
-9.33E-
003 
-1.69E-
001 
-2.98E-
002 
-2.08E-
001 
Ru-Cl22 
0.00E+00
0 
-1.71E-
001 
-
3.17E+00
0 
-9.93E-
003 
-
3.35E+00
0 Ru-Cl22 
0.00E+00
0 
-1.17E-
002 
-2.17E-
001 
-9.88E-
003 
-2.38E-
001 
Ru-N12 
-3.55E-
006 
-3.63E-
003 
-9.07E-
002 
-1.46E-
002 
-1.09E-
001 Ru-N12 
1.35E-
006 
-4.11E-
003 
-1.09E-
001 
-1.37E-
002 
-1.27E-
001 
Ru-N17 
-3.49E-
006 
-3.73E-
003 
-8.93E-
002 
-1.46E-
002 
-1.08E-
001 Ru-N17 
1.18E-
006 
-3.82E-
003 
-9.36E-
002 
-1.37E-
002 
-1.11E-
001 
Complex 2 Complex 2 
Ru-C7 
-8.10E-
006 
-2.42E-
002 
-1.86E-
001 
-3.31E-
002 
-2.43E-
001 Ru-C7 
-5.02E-
006 
-2.49E-
002 
-1.95E-
001 
-3.06E-
002 
-2.51E-
001 
Ru-C8 
-7.05E-
006 
5.42E-
002 
-1.89E-
001 
-3.18E-
002 
-1.67E-
001 Ru-C8 
0.00E+00
0 
5.35E-
002 
-1.94E-
001 
-2.89E-
002 
-1.69E-
001 
Ru-C13 
-6.10E-
006 
5.10E-
002 
-2.39E-
001 
-3.06E-
002 
-2.19E-
001 Ru-C13 
-5.93E-
006 
5.09E-
002 
-2.56E-
001 
-2.86E-
002 
-2.34E-
001 
Ru-C14 
-4.52E-
006 
-2.90E-
002 
-1.27E-
001 
-3.28E-
002 
-1.89E-
001 Ru-C14 
-1.35E-
006 
-2.96E-
002 
-1.36E-
001 
-2.95E-
002 
-1.96E-
001 
Ru-C18 
-8.10E-
006 
-2.42E-
002 
-1.87E-
001 
-3.31E-
002 
-2.44E-
001 Ru-C18 
-5.03E-
006 
-2.49E-
002 
-1.96E-
001 
-3.06E-
002 
-2.51E-
001 
Ru-C19 
-7.04E-
006 
5.42E-
002 
-1.88E-
001 
-3.18E-
002 
-1.66E-
001 Ru-C19 
0.00E+00
0 
5.36E-
002 
-1.93E-
001 
-2.89E-
002 
-1.69E-
001 
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Ru-Cl10 
0.00E+00
0 
-1.69E-
001 
-
3.28E+00
0 
-9.78E-
003 
-
3.46E+00
0 Ru-Cl10 
0.00E+00
0 
-1.10E-
002 
-2.25E-
001 
-9.74E-
003 
-2.46E-
001 
Ru-N11 
-3.33E-
006 
-3.49E-
003 
8.27E-
003 
-1.41E-
002 
-9.33E-
003 Ru-N11 
0.00E+00
0 
-3.67E-
003 
4.69E-
004 
-1.30E-
002 
-1.62E-
002 
Ru-N16 
-3.28E-
006 
-3.57E-
003 
1.05E-
002 
-1.41E-
002 
-7.21E-
003 Ru-N16 
0.00E+00
0 
-3.73E-
003 
2.52E-
003 
-1.30E-
002 
-1.42E-
002 
Complex 3 Complex 3 
Ru-C13 
-6.29E-
006 
8.47E-
003 
-1.86E-
001 
-3.57E-
002 
-2.13E-
001 Ru-C13 
0.00E+00
0 
9.88E-
003 
-1.87E-
001 
-3.27E-
002 
-2.10E-
001 
Ru-C14 
-7.82E-
006 
2.83E-
003 
-2.47E-
001 
-3.56E-
002 
-2.79E-
001 Ru-C14 
-1.39E-
006 
8.60E-
004 
-2.42E-
001 
-3.31E-
002 
-2.74E-
001 
Ru-C18 
-6.23E-
006 
4.71E-
003 
-1.84E-
001 
-3.56E-
002 
-2.15E-
001 Ru-C18 
1.32E-
006 
1.50E-
003 
-1.89E-
001 
-3.26E-
002 
-2.20E-
001 
Ru-C21 
-7.37E-
006 
1.06E-
002 
-2.25E-
001 
-3.45E-
002 
-2.49E-
001 Ru-C21 
-2.65E-
006 
1.08E-
002 
-2.40E-
001 
-3.24E-
002 
-2.61E-
001 
Ru-C23 
-7.69E-
006 
7.47E-
003 
-2.49E-
001 
-3.55E-
002 
-2.77E-
001 Ru-C23 
-1.47E-
006 
9.20E-
003 
-2.54E-
001 
-3.29E-
002 
-2.78E-
001 
Ru-C25 
-7.51E-
006 
6.02E-
003 
-2.24E-
001 
-3.46E-
002 
-2.53E-
001 Ru-C25 
-2.80E-
006 
2.72E-
003 
-2.41E-
001 
-3.25E-
002 
-2.71E-
001 
Ru-Cl7 
0.00E+00
0 
-1.24E-
001 
-
3.06E+00
0 
-1.11E-
002 
-
3.20E+00
0 Ru-Cl7 
0.00E+00
0 
-7.99E-
003 
-2.11E-
001 
-1.11E-
002 
-2.30E-
001 
Ru-N10 
-3.25E-
006 
-2.18E-
003 
6.56E-
002 
-1.49E-
002 
4.85E-
002 Ru-N10 
-1.10E-
006 
-1.94E-
003 
6.08E-
002 
-1.39E-
002 
4.50E-
002 
Ru-N16 
-3.25E-
006 
-2.24E-
003 
6.39E-
002 
-1.49E-
002 
4.67E-
002 Ru-N16 
-1.02E-
006 
-2.53E-
003 
5.75E-
002 
-1.39E-
002 4.11E-002 
Complex 4 Complex 4 
Ru-C2 
-3.54E-
006 
8.88E-
003 
-1.74E-
001 
-3.14E-
002 
-1.97E-
001 Ru-C2 
5.22E-
006 
8.93E-
003 
-1.80E-
001 
-3.13E-
002 
-2.03E-
001 
Ru-C3 
-8.33E-
006 
-8.29E-
003 
-2.29E-
001 
-3.22E-
002 
-2.70E-
001 Ru-C3 
-2.18E-
006 
-8.75E-
003 
-2.34E-
001 
-3.21E-
002 
-2.74E-
001 
Ru-C4 
-3.54E-
006 
9.73E-
003 
-1.74E-
001 
-3.14E-
002 
-1.96E-
001 Ru-C4 
5.25E-
006 
9.81E-
003 
-1.80E-
001 
-3.13E-
002 
-2.02E-
001 
Ru-C5 
-7.34E-
006 
1.34E-
004 
-3.43E-
001 
-3.22E-
002 
-3.75E-
001 Ru-C5 
0.00E+00
0 
-5.09E-
004 
-3.47E-
001 
-3.21E-
002 
-3.80E-
001 
Ru-C6 
-8.31E-
006 
-9.04E-
003 
-2.28E-
001 
-3.22E-
002 
-2.69E-
001 Ru-C6 
-2.17E-
006 
-9.54E-
003 
-2.32E-
001 
-3.21E-
002 
-2.74E-
001 
Ru-C7 
-7.33E-
006 
9.98E-
004 
-3.44E-
001 
-3.22E-
002 
-3.75E-
001 Ru-C7 
0.00E+00
0 
3.83E-
004 
-3.48E-
001 
-3.21E-
002 
-3.79E-
001 
Ru-N10 
-3.37E-
006 
1.11E-
002 
-1.07E-
001 
-1.34E-
002 
-1.09E-
001 Ru-N10 
0.00E+00
0 
1.10E-
002 
-1.10E-
001 
-1.33E-
002 
-1.13E-
001 
Ru-N13 
-3.37E-
006 
1.11E-
002 
-1.07E-
001 
-1.34E-
002 
-1.09E-
001 Ru-N13 
0.00E+00
0 
1.10E-
002 
-1.10E-
001 
-1.33E-
002 
-1.13E-
001 
Ru-N15 
-2.89E-
006 
-1.15E-
002 
-6.88E-
002 
-1.47E-
002 
-9.51E-
002 Ru-N15 
0.00E+00
0 
-1.17E-
002 
-7.21E-
002 
-1.47E-
002 
-9.84E-
002 
Complex 5 Complex 5 
Ru-C18 
-6.68E-
006 
7.27E-
003 
-2.86E-
001 
-3.25E-
002 
-3.11E-
001 Ru-C18 
0.00E+00
0 
6.50E-
003 
-2.91E-
001 
-3.24E-
002 
-3.17E-
001 
Ru-C20 
-7.65E-
006 
-5.87E-
003 
-2.02E-
001 
-3.24E-
002 
-2.40E-
001 Ru-C20 
0.00E+00
0 
-6.18E-
003 
-2.07E-
001 
-3.23E-
002 
-2.45E-
001 
Ru-C22 
-6.70E-
006 
6.32E-
003 
-2.86E-
001 
-3.25E-
002 
-3.12E-
001 Ru-C22 
0.00E+00
0 
5.75E-
003 
-2.91E-
001 
-3.24E-
002 
-3.17E-
001 
Ru-C23 
-2.90E-
006 
1.57E-
002 
-1.33E-
001 
-3.14E-
002 
-1.49E-
001 Ru-C23 
4.56E-
006 
1.59E-
002 
-1.40E-
001 
-3.13E-
002 
-1.55E-
001 
Ru-C26 
-7.62E-
006 
-5.40E-
003 
-2.02E-
001 
-3.24E-
002 
-2.40E-
001 Ru-C26 
0.00E+00
0 
-5.95E-
003 
-2.07E-
001 
-3.23E-
002 
-2.45E-
001 
Ru-C27 
-2.93E-
006 
1.49E-
002 
-1.33E-
001 
-3.14E-
002 
-1.50E-
001 Ru-C27 
4.62E-
006 
1.54E-
002 
-1.40E-
001 
-3.13E-
002 
-1.56E-
001 
Ru-N14 
-3.40E-
006 
1.07E-
002 
-1.97E-
002 
-1.33E-
002 
-2.23E-
002 Ru-N14 
-1.06E-
006 
1.08E-
002 
-2.29E-
002 
-1.33E-
002 
-2.54E-
002 
Ru-N15 
-3.65E-
006 
-1.37E-
002 
-1.20E-
002 
-1.51E-
002 
-4.08E-
002 Ru-N15 
0.00E+00
0 
-1.41E-
002 
-1.94E-
002 
-1.50E-
002 
-4.84E-
002 
Ru-N21 
-3.39E-
006 
1.07E-
002 
-2.23E-
002 
-1.33E-
002 
-2.50E-
002 Ru-N21 
-1.08E-
006 
1.08E-
002 
-2.54E-
002 
-1.33E-
002 
-2.79E-
002 
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Table 3.82: Correlation of computed Ramsey Terms to the spin spin coupling over all atoms in each of 
the complexes 
 
 1 2 3 4 5 
 J(HZ) J(HZ) J(HZ) J(HZ) J(HZ) 
FC 0.71 0.68 0.71 0.99 0.99 
SD 0.66 0.64 0.72 0.28 0.15 
PSO 0.77 0.77 0.77 0.76 0.64 
DSO 0.24 0.34 0.47 0.59 0.48 
J(HZ) 1.00 1.00 1.00 1.00 1.00 
 
 
 
 
Table 3.83: The atomic NMR magnetazability and shielding for the selected atoms in the complexes 
using combined basis set DGDZVP(Ru)|6-31+G(d,p) 
 
Complex 1 
 q(A) 
Vol(A),
0.001 L(A) K(A) LI(A) 
DI(A,
A')/2
Intra_Iso
(A)
Bond_Is
o(A)
_Iso(A
) (A)
_Iso(A
,A)
_Iso(A'
,A)
_Iso(A
) 
Isotrop
ic 
Anisotr
opy 
Ru1 
9.50E-
01 
1.01E+
02 
6.36E-
04 
4.44E+
03 
4.05E+
01 
2.54E+
00 
2.24E+
01 
-
2.27E+
01 
-3.35E-
01 
1.20E+
00 
-
3.51E+
03 
2.52E+
01 
-
3.49E+
03 
-
3.49E+
03 
6.16E+
03 
C9 
-6.26E-
02 
7.38E+
01 
-5.40E-
05 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
3.09E+
00 
-
4.98E+
00 
-
8.07E+
00 
9.26E-
02 
8.50E+
01 
2.29E+
01 
1.08E+
02 
1.08E+
02 
1.28E+
02 
C10 
-4.68E-
02 
7.14E+
01 
-3.51E-
04 
3.78E+
01 
3.96E+
00 
2.09E+
00 
-
2.65E+
00 
-
9.19E+
00 
-
1.18E+
01 
6.08E-
02 
7.30E+
01 
2.35E+
01 
9.65E+
01 
9.65E+
01 
1.35E+
02 
C13 
-4.96E-
02 
7.16E+
01 
7.50E-
05 
3.78E+
01 
3.96E+
00 
2.09E+
00 
-
2.68E+
00 
-
9.21E+
00 
-
1.19E+
01 
1.02E-
01 
7.55E+
01 
2.33E+
01 
9.88E+
01 
9.88E+
01 
1.31E+
02 
C16 
-5.13E-
02 
7.37E+
01 
-1.58E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
3.09E+
00 
-
4.90E+
00 
-
7.99E+
00 
5.52E-
02 
8.44E+
01 
2.30E+
01 
1.07E+
02 
1.07E+
02 
1.32E+
02 
C18 
-5.82E-
02 
7.48E+
01 
-1.32E-
04 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
3.22E+
00 
-
4.95E+
00 
-
8.17E+
00 
6.78E-
02 
8.75E+
01 
2.35E+
01 
1.11E+
02 
1.11E+
02 
1.27E+
02 
C19 
-2.85E-
02 
6.99E+
01 
6.90E-
05 
3.78E+
01 
3.95E+
00 
2.08E+
00 
-
2.34E+
00 
-
9.02E+
00 
-
1.14E+
01 
1.02E-
01 
6.40E+
01 
2.25E+
01 
8.65E+
01 
8.65E+
01 
1.51E+
02 
Cl22 
-5.27E-
01 
2.32E+
02 
8.30E-
05 
4.59E+
02 
1.69E+
01 
6.46E-
01 
-
2.15E+
01 
-
3.69E+
00 
-
2.52E+
01 
1.29E+
00 
1.06E+
03 
4.24E+
00 
1.06E+
03 
1.06E+
03 
5.20E+
02 
N12 
-7.59E-
01 
7.81E+
01 
2.16E-
04 
5.48E+
01 
5.90E+
00 
1.86E+
00 
-
3.51E+
00 
-
6.63E+
00 
-
1.01E+
01 
6.58E-
01 
-
3.46E+
00 
1.70E+
01 
1.35E+
01 
1.35E+
01 
1.92E+
02 
N17 
-7.59E-
01 
7.80E+
01 
2.41E-
04 
5.48E+
01 
5.90E+
00 
1.86E+
00 
-
3.50E+
00 
-
6.64E+
00 
-
1.01E+
01 
6.17E-
01 
-
3.94E+
00 
1.69E+
01 
1.29E+
01 
1.29E+
01 
1.93E+
02 
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O2 
-
1.17E+
00 
1.30E+
02 
8.20E-
05 
7.54E+
01 
8.23E+
00 
9.47E-
01 
-
6.12E+
00 
-
3.48E+
00 
-
9.60E+
00 
1.03E+
00 
-
9.64E+
01 
2.41E+
00 
-
9.40E+
01 
-
9.40E+
01 
5.67E+
02 
H24 
1.23E-
01 
4.05E+
01 
2.40E-
05 
5.68E-
01 
3.45E-
01 
5.32E-
01 
-9.18E-
01 
-
1.36E+
00 
-
2.28E+
00 
4.80E-
01 
1.77E+
01 
5.68E+
00 
2.33E+
01 
2.33E+
01 
6.65E+
00 
H29 
1.23E-
01 
4.06E+
01 
2.60E-
05 
5.68E-
01 
3.45E-
01 
5.32E-
01 
-9.20E-
01 
-
1.36E+
00 
-
2.29E+
00 
4.92E-
01 
1.77E+
01 
5.67E+
00 
2.33E+
01 
2.33E+
01 
6.63E+
00 
Complex 2 
Ru1 
9.59E-
01 
1.04E+
02 
2.47E-
04 
4.44E+
03 
4.05E+
01 
2.57E+
00 
2.00E+
01 
-
2.28E+
01 
-
2.79E+
00 
1.18E+
00 
-
3.12E+
03 
2.45E+
01 
-
3.09E+
03 
-
3.09E+
03 
5.61E+
03 
C7 
-5.32E-
02 
7.01E+
01 
-2.27E-
04 
3.78E+
01 
3.96E+
00 
2.09E+
00 
-
2.53E+
00 
-
9.07E+
00 
-
1.16E+
01 
6.14E-
02 
6.95E+
01 
2.28E+
01 
9.23E+
01 
9.23E+
01 
1.38E+
02 
C8 
-6.29E-
02 
7.46E+
01 
9.20E-
05 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
3.26E+
00 
-
4.86E+
00 
-
8.12E+
00 
8.23E-
02 
8.88E+
01 
2.26E+
01 
1.11E+
02 
1.11E+
02 
1.30E+
02 
C13 
-5.29E-
02 
7.64E+
01 
-6.00E-
06 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
3.20E+
00 
-
4.90E+
00 
-
8.10E+
00 
7.84E-
02 
8.70E+
01 
2.27E+
01 
1.10E+
02 
1.10E+
02 
1.30E+
02 
C14 
-2.67E-
02 
6.96E+
01 
-5.71E-
04 
3.78E+
01 
3.95E+
00 
2.08E+
00 
-
2.13E+
00 
-
8.85E+
00 
-
1.10E+
01 
9.18E-
02 
5.83E+
01 
2.19E+
01 
8.02E+
01 
8.02E+
01 
1.57E+
02 
C18 
-5.42E-
02 
7.02E+
01 
-8.17E-
04 
3.78E+
01 
3.96E+
00 
2.09E+
00 
-
2.53E+
00 
-
9.07E+
00 
-
1.16E+
01 
9.29E-
02 
6.96E+
01 
2.29E+
01 
9.24E+
01 
9.24E+
01 
1.37E+
02 
C19 
-6.30E-
02 
7.46E+
01 
9.00E-
05 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
3.26E+
00 
-
4.86E+
00 
-
8.12E+
00 
7.40E-
02 
8.89E+
01 
2.26E+
01 
1.11E+
02 
1.11E+
02 
1.30E+
02 
Cl10 
-5.21E-
01 
2.37E+
02 
8.60E-
05 
4.59E+
02 
1.69E+
01 
6.23E-
01 
-
2.20E+
01 
-
3.76E+
00 
-
2.57E+
01 
1.26E+
00 
1.10E+
03 
4.72E+
00 
1.10E+
03 
1.10E+
03 
4.20E+
02 
N11 
-
1.22E+
00 
8.21E+
01 
8.40E-
05 
5.51E+
01 
6.36E+
00 
1.86E+
00 
-
3.55E+
00 
-
7.30E+
00 
-
1.09E+
01 
5.42E-
01 
-
3.05E+
01 
1.29E+
01 
-
1.76E+
01 
-
1.76E+
01 
3.87E+
02 
N16 
-
1.22E+
00 
8.21E+
01 
1.68E-
04 
5.51E+
01 
6.36E+
00 
1.86E+
00 
-
3.54E+
00 
-
7.32E+
00 
-
1.09E+
01 
5.10E-
01 
-
3.11E+
01 
1.29E+
01 
-
1.82E+
01 
-
1.82E+
01 
3.89E+
02 
H34 
8.99E-
02 
4.09E+
01 
8.10E-
05 
5.87E-
01 
3.64E-
01 
5.46E-
01 
-9.14E-
01 
-
1.27E+
00 
-
2.19E+
00 
6.96E-
02 
1.82E+
01 
4.25E+
00 
2.25E+
01 
2.25E+
01 
1.07E+
01 
H38 
9.65E-
02 
4.10E+
01 
5.80E-
05 
5.81E-
01 
3.59E-
01 
5.45E-
01 
-9.15E-
01 
-
1.28E+
00 
-
2.19E+
00 
5.34E-
02 
1.81E+
01 
4.22E+
00 
2.23E+
01 
2.23E+
01 
1.01E+
01 
Complex 3 
Ru1 
9.55E-
01 
9.99E+
01 
3.57E-
04 
4.44E+
03 
4.05E+
01 
2.52E+
00 
2.45E+
01 
-
2.56E+
01 
-
1.05E+
00 
8.40E-
01 
-
3.76E+
03 
2.39E+
01 
-
3.73E+
03 
-
3.73E+
03 
6.00E+
03 
C13 
-4.01E-
02 
7.06E+
01 
-1.19E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.72E+
00 
-
6.38E+
00 
-
9.11E+
00 
8.08E-
02 
7.46E+
01 
2.26E+
01 
9.72E+
01 
9.72E+
01 
1.39E+
02 
C14 
-4.85E-
02 
6.98E+
01 
-1.15E-
04 
3.79E+
01 
3.97E+
00 
2.08E+
00 
-
2.69E+
00 
-
6.81E+
00 
-
9.50E+
00 
4.00E-
01 
7.44E+
01 
2.31E+
01 
9.75E+
01 
9.75E+
01 
1.39E+
02 
C18 
-3.97E-
02 
7.07E+
01 
-9.40E-
05 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.69E+
00 
-
6.38E+
00 
-
9.06E+
00 
8.56E-
02 
7.35E+
01 
2.26E+
01 
9.61E+
01 
9.61E+
01 
1.40E+
02 
C21 
-5.97E-
02 
7.36E+
01 
-6.60E-
05 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.89E+
00 
-
6.48E+
00 
-
9.37E+
00 
1.32E-
01 
7.88E+
01 
2.31E+
01 
1.02E+
02 
1.02E+
02 
1.34E+
02 
C23 
-5.00E-
02 
7.02E+
01 
-1.81E-
04 
3.79E+
01 
3.97E+
00 
2.08E+
00 
-
2.73E+
00 
-
6.81E+
00 
-
9.53E+
00 
4.12E-
01 
7.53E+
01 
2.31E+
01 
9.84E+
01 
9.84E+
01 
1.39E+
02 
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C25 
-5.93E-
02 
7.33E+
01 
-2.62E-
04 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.87E+
00 
-
6.46E+
00 
-
9.33E+
00 
1.40E-
01 
7.81E+
01 
2.32E+
01 
1.01E+
02 
1.01E+
02 
1.34E+
02 
Cl7 
-5.33E-
01 
2.36E+
02 
1.08E-
04 
4.59E+
02 
1.69E+
01 
6.31E-
01 
-
2.18E+
01 
-
3.57E+
00 
-
2.54E+
01 
1.30E+
00 
1.08E+
03 
4.16E+
00 
1.09E+
03 
1.09E+
03 
5.79E+
02 
N10 
-
1.20E+
00 
8.30E+
01 
2.90E-
04 
5.50E+
01 
6.36E+
00 
1.84E+
00 
-
3.65E+
00 
-
7.31E+
00 
-
1.10E+
01 
9.47E-
01 
-
2.31E+
01 
1.21E+
01 
-
1.11E+
01 
-
1.11E+
01 
3.83E+
02 
N16 
-
1.20E+
00 
8.30E+
01 
8.80E-
05 
5.50E+
01 
6.36E+
00 
1.84E+
00 
-
3.65E+
00 
-
7.31E+
00 
-
1.10E+
01 
9.12E-
01 
-
2.24E+
01 
1.21E+
01 
-
1.03E+
01 
-
1.03E+
01 
3.81E+
02 
O2 
-
1.19E+
00 
1.28E+
02 
1.16E-
04 
7.54E+
01 
8.22E+
00 
9.69E-
01 
-
6.05E+
00 
-
2.15E+
00 
-
8.20E+
00 
9.26E-
01 
-
8.06E+
01 
2.34E+
00 
-
7.83E+
01 
-
7.83E+
01 
5.28E+
02 
O28 
-
1.19E+
00 
1.28E+
02 
1.27E-
04 
7.54E+
01 
8.23E+
00 
9.67E-
01 
-
6.07E+
00 
-
2.15E+
00 
-
8.22E+
00 
9.10E-
01 
-
8.12E+
01 
2.31E+
00 
-
7.89E+
01 
-
7.89E+
01 
5.26E+
02 
H31 
1.12E-
01 
3.92E+
01 
-2.90E-
05 
5.80E-
01 
3.48E-
01 
5.39E-
01 
-9.26E-
01 
-
1.24E+
00 
-
2.16E+
00 
3.59E-
01 
1.82E+
01 
6.49E+
00 
2.47E+
01 
2.47E+
01 
6.46E+
00 
H36 
1.17E-
01 
3.87E+
01 
2.90E-
05 
5.79E-
01 
3.45E-
01 
5.39E-
01 
-9.12E-
01 
-
1.23E+
00 
-
2.15E+
00 
3.62E-
01 
1.81E+
01 
6.49E+
00 
2.46E+
01 
2.46E+
01 
6.83E+
00 
Complex 4 
Ru1 
9.92E-
01 
1.10E+
02 
-9.65E-
04 
4.43E+
03 
4.06E+
01 
2.46E+
00 
2.65E+
01 
-
2.59E+
01 
5.96E-
01 
3.99E-
01 
-
4.14E+
03 
2.40E+
01 
-
4.12E+
03 
-
4.12E+
03 
6.61E+
03 
C2 
-4.55E-
02 
7.33E+
01 
1.09E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.80E+
00 
-
6.45E+
00 
-
9.25E+
00 
6.59E-
02 
7.44E+
01 
2.23E+
01 
9.67E+
01 
9.67E+
01 
1.37E+
02 
C3 
-4.44E-
02 
7.07E+
01 
-1.18E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.70E+
00 
-
6.37E+
00 
-
9.07E+
00 
6.64E-
02 
7.52E+
01 
2.36E+
01 
9.87E+
01 
9.87E+
01 
1.40E+
02 
C4 
-4.58E-
02 
7.34E+
01 
-6.00E-
06 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.81E+
00 
-
6.45E+
00 
-
9.26E+
00 
9.17E-
02 
7.46E+
01 
2.23E+
01 
9.69E+
01 
9.69E+
01 
1.37E+
02 
C5 
-3.39E-
02 
7.27E+
01 
-2.15E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.84E+
00 
-
6.43E+
00 
-
9.27E+
00 
9.10E-
02 
8.08E+
01 
2.38E+
01 
1.05E+
02 
1.05E+
02 
1.35E+
02 
C6 
-4.44E-
02 
7.06E+
01 
-1.85E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.69E+
00 
-
6.37E+
00 
-
9.05E+
00 
8.10E-
02 
7.49E+
01 
2.36E+
01 
9.84E+
01 
9.84E+
01 
1.40E+
02 
C7 
-3.40E-
02 
7.26E+
01 
-7.40E-
05 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.85E+
00 
-
6.42E+
00 
-
9.27E+
00 
9.80E-
02 
8.10E+
01 
2.38E+
01 
1.05E+
02 
1.05E+
02 
1.35E+
02 
N10 
-7.71E-
01 
8.29E+
01 
7.40E-
05 
5.47E+
01 
5.95E+
00 
1.82E+
00 
-
3.69E+
00 
-
6.67E+
00 
-
1.04E+
01 
5.94E-
01 
-
4.52E+
00 
1.51E+
01 
1.06E+
01 
1.06E+
01 
1.47E+
02 
N13 
-7.71E-
01 
8.29E+
01 
3.03E-
04 
5.47E+
01 
5.95E+
00 
1.82E+
00 
-
3.69E+
00 
-
6.68E+
00 
-
1.04E+
01 
5.81E-
01 
-
4.53E+
00 
1.51E+
01 
1.06E+
01 
1.06E+
01 
1.47E+
02 
N15 
-
1.24E+
00 
8.06E+
01 
4.25E-
04 
5.51E+
01 
6.40E+
00 
1.84E+
00 
-
4.55E+
00 
-
6.84E+
00 
-
1.14E+
01 
3.31E-
01 
4.37E+
01 
1.25E+
01 
5.62E+
01 
5.62E+
01 
2.20E+
02 
Complex 5 
Ru1 
9.82E-
01 
1.08E+
02 
1.20E-
03 
4.43E+
03 
4.05E+
01 
2.50E+
00 
2.53E+
01 
-
2.34E+
01 
1.86E+
00 
5.62E-
01 
-
3.94E+
03 
2.31E+
01 
-
3.92E+
03 
-
3.92E+
03 
5.35E+
03 
C18 
-3.61E-
02 
7.26E+
01 
-3.09E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.80E+
00 
-
7.46E+
00 
-
1.03E+
01 
5.62E-
02 
7.91E+
01 
2.29E+
01 
1.02E+
02 
1.02E+
02 
1.38E+
02 
C20 
-4.79E-
02 
7.09E+
01 
-3.12E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.67E+
00 
-
8.73E+
00 
-
1.14E+
01 
8.92E-
02 
7.42E+
01 
2.28E+
01 
9.70E+
01 
9.70E+
01 
1.42E+
02 
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C22 
-3.57E-
02 
7.26E+
01 
-1.31E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.79E+
00 
-
7.45E+
00 
-
1.02E+
01 
6.26E-
02 
7.89E+
01 
2.29E+
01 
1.02E+
02 
1.02E+
02 
1.38E+
02 
C23 
-4.91E-
02 
7.30E+
01 
4.00E-
06 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.72E+
00 
-
3.64E+
00 
-
6.36E+
00 
8.07E-
02 
7.14E+
01 
2.16E+
01 
9.29E+
01 
9.29E+
01 
1.42E+
02 
C26 
-4.81E-
02 
7.10E+
01 
-6.86E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.67E+
00 
-
8.72E+
00 
-
1.14E+
01 
1.27E-
01 
7.44E+
01 
2.28E+
01 
9.72E+
01 
9.72E+
01 
1.41E+
02 
C27 
-4.90E-
02 
7.29E+
01 
-1.03E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.71E+
00 
-
3.64E+
00 
-
6.35E+
00 
1.07E-
01 
7.11E+
01 
2.16E+
01 
9.26E+
01 
9.26E+
01 
1.43E+
02 
N14 
-
1.23E+
00 
8.58E+
01 
2.21E-
04 
5.50E+
01 
6.40E+
00 
1.83E+
00 
-
3.88E+
00 
-
7.35E+
00 
-
1.12E+
01 
4.62E-
01 
-
1.31E+
01 
1.19E+
01 
-
1.24E+
00 
-
1.24E+
00 
3.37E+
02 
N15 
-
1.23E+
00 
7.90E+
01 
4.56E-
04 
5.51E+
01 
6.35E+
00 
1.88E+
00 
-
3.71E+
00 
-
7.16E+
00 
-
1.09E+
01 
2.32E-
01 
-
1.01E+
01 
1.22E+
01 
2.12E+
00 
2.12E+
00 
3.05E+
02 
N21 
-
1.23E+
00 
8.58E+
01 
2.75E-
04 
5.50E+
01 
6.40E+
00 
1.83E+
00 
-
3.89E+
00 
-
7.37E+
00 
-
1.13E+
01 
3.70E-
01 
-
1.23E+
01 
1.19E+
01 
-4.32E-
01 
-4.31E-
01 
3.35E+
02 
q(A) is total charge on atom A, Vol(A) is the volume bounded by an isosurface of the electron density distribution (0.001) 
and by interatomic surfaces of atom A; K(A) is electronic kinetic energy of atom A (Hamiltonian Form), Loc(A) is number 
of electrons localized in atom A, K_Scaled(A) is approximation to virial-based total energy of atom A, Deloc(A,A') is 
number of electron delocalization from atom A, Intra_Iso(A) is Intraatomic magnetizability contribution of atom A (cgs-ppm); 
Bond_Iso(A) is Bonding magnetizability contribution of atom A; _Iso(A) is total magnetizability contribution of atom A (i.e. 
magnetizability isotropic); (A) is total dipole moment contribution of atom A; _Iso(A,A) is the Intraatomic shielding 
tensor; _Iso(A',A) is total induced magnetic field on nucleus a by other nuclei A'; _Iso(A) is total magnetic shielding tensor 
of atom A (i.e. nmr shielding isotropic). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.84: The correlation of the computed atomic NMR properties of the complexes 
 Complex 1 Complex 2 Complex 3 Complex 4 Complex 5 
 _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) _Iso(A) 
q(A) -0.30 0.53 -0.25 0.52 -0.25 0.54 -0.33 0.56 -0.25 0.58 
Vol(A), 0.07 -0.83 0.10 -0.84 0.07 -0.85 -0.39 -0.68 -0.28 -0.64 
340 
0.001 
K(A) -0.93 0.10 -0.91 0.01 -0.93 0.08 -1.00 0.24 -1.00 0.26 
K_Scaled(
A) 0.93 -0.10 0.91 -0.01 0.93 -0.08 1.00 -0.24 1.00 -0.26 
LI(A) -0.75 -0.27 -0.72 -0.36 -0.75 -0.30 -0.94 -0.04 -0.92 -0.05 
DI(A,A')/2 -0.28 -0.40 -0.27 -0.38 -0.25 -0.40 -0.21 -0.78 -0.20 -0.67 
Intra_Iso(A) -0.89 0.68 -0.86 0.66 -0.88 0.65 -0.98 0.45 -0.94 0.50 
Bond_Iso(A) 0.71 0.30 0.68 0.35 0.75 0.25 0.81 0.31 0.73 0.37 
_Iso(A) -0.37 1.00 -0.33 1.00 -0.35 1.00 -0.29 1.00 -0.31 1.00 
|(A)| -0.29 -0.42 -0.25 -0.48 -0.14 -0.57 -0.33 -0.44 -0.28 -0.26 
_Iso(A,A) 1.00 -0.37 1.00 -0.32 1.00 -0.34 1.00 -0.28 1.00 -0.30 
_Iso(A',A) -0.31 -0.31 -0.30 -0.28 -0.28 -0.26 -0.25 -0.71 -0.25 -0.57 
_Iso(A) 1.00 -0.37 1.00 -0.33 1.00 -0.35 1.00 -0.29 1.00 -0.31 
Anisotropy -0.93 0.08 -0.92 -0.01 -0.93 0.04 -1.00 0.21 -0.99 0.17 
 
 
Table 3.85: The atomic NMR magnetazability and shielding for the selected atoms in the complexes 
using combined basis sets 3-21G 
Complex 1 
 q(A) 
Vol(A),
0.001 L(A) K(A) LI(A) 
DI(A,
A')/2
Intra_Iso
(A)
Bond_Is
o(A)
_Iso(A
) (A)
_Iso(A
,A)
_Iso(A'
,A)
_Iso(A
) 
Isotrop
ic 
Anisotr
opy 
Ru1 
8.63E-
01 
9.73E+
01 
5.52E-
04 
4.40E+
03 
4.07E+
01 
2.46E+
00 
2.47E+
01 
-
2.50E+
01 
-2.65E-
01 
1.19E+
00 
-
3.10E+
03 
2.41E+
01 
-
3.07E+
03 
-
3.07E+
03 
6.03E+
03 
C9 
-1.14E-
01 
7.66E+
01 
-7.00E-
05 
3.76E+
01 
4.04E+
00 
2.08E+
00 
-
3.64E+
00 
-
6.30E+
00 
-
9.95E+
00 
1.35E-
01 
1.04E+
02 
2.27E+
01 
1.26E+
02 
1.26E+
02 
1.19E+
02 
C10 
-1.04E-
01 
7.49E+
01 
-1.97E-
04 
3.76E+
01 
4.03E+
00 
2.07E+
00 
-
3.35E+
00 
-
6.23E+
00 
-
9.58E+
00 
9.47E-
02 
9.56E+
01 
2.30E+
01 
1.19E+
02 
1.19E+
02 
1.24E+
02 
C13 
-1.09E-
01 
7.52E+
01 
-1.11E-
04 
3.76E+
01 
4.03E+
00 
2.08E+
00 
-
3.37E+
00 
-
6.24E+
00 
-
9.61E+
00 
1.16E-
01 
9.77E+
01 
2.28E+
01 
1.20E+
02 
1.20E+
02 
1.21E+
02 
C16 
-9.09E-
02 
7.57E+
01 
-5.60E-
05 
3.76E+
01 
4.02E+
00 
2.07E+
00 
-
3.52E+
00 
-
6.13E+
00 
-
9.66E+
00 
9.32E-
02 
1.00E+
02 
2.24E+
01 
1.23E+
02 
1.23E+
02 
1.26E+
02 
C18 
-1.04E-
01 
7.71E+
01 
-4.80E-
05 
3.76E+
01 
4.04E+
00 
2.07E+
00 
-
3.71E+
00 
-
6.23E+
00 
-
9.94E+
00 
1.14E-
01 
1.04E+
02 
2.30E+
01 
1.27E+
02 
1.27E+
02 
1.21E+
02 
C19 
-8.40E-
02 
7.33E+
01 
-1.10E-
04 
3.76E+
01 
4.02E+
00 
2.07E+
00 
-
3.05E+
00 
-
6.06E+
00 
-
9.11E+
00 
9.99E-
02 
8.86E+
01 
2.21E+
01 
1.11E+
02 
1.11E+
02 
1.35E+
02 
Cl22 
-4.89E-
01 
2.29E+
02 
6.20E-
05 
4.57E+
02 
1.69E+
01 
6.10E-
01 
-
2.15E+
01 
-
3.19E+
00 
-
2.47E+
01 
1.33E+
00 
9.98E+
02 
3.76E+
00 
1.00E+
03 
1.00E+
03 
4.24E+
02 
N12 
-6.13E-
01 
7.39E+
01 
4.00E-
05 
5.43E+
01 
5.75E+
00 
1.86E+
00 
-
3.74E+
00 
-
6.36E+
00 
-
1.01E+
01 
6.53E-
01 
2.36E+
01 
1.74E+
01 
4.10E+
01 
4.10E+
01 
1.58E+
02 
N17 
-6.03E-
01 
7.39E+
01 
1.41E-
04 
5.43E+
01 
5.74E+
00 
1.86E+
00 
-
3.68E+
00 
-
6.52E+
00 
-
1.02E+
01 
8.83E-
01 
1.93E+
01 
1.74E+
01 
3.66E+
01 
3.66E+
01 
1.68E+
02 
O2 
-8.53E-
01 
1.04E+
02 
8.40E-
05 
7.47E+
01 
7.78E+
00 
1.07E+
00 
-
5.00E+
00 
-
2.28E+
00 
-
7.27E+
00 
9.06E-
01 
-
9.86E+
01 
4.65E+
00 
-
9.40E+
01 
-
9.40E+
01 
5.71E+
02 
H24 
2.00E-
01 
3.41E+
01 
3.70E-
05 
5.27E-
01 
2.92E-
01 
5.07E-
01 
-8.31E-
01 
-9.37E-
01 
-
1.77E+
00 
4.44E-
01 
1.80E+
01 
5.96E+
00 
2.40E+
01 
2.40E+
01 
6.47E+
00 
H29 1.55E- 3.93E+ 4.10E- 5.43E- 3.30E- 5.14E- -9.62E- -4.06E- - 3.57E- 1.90E+ 6.38E+ 2.54E+ 2.54E+ 5.79E+
341 
01 01 05 01 01 01 01 01 1.37E+
00 
02 01 00 01 01 00 
Complex 2 
Ru1 
8.62E-
01 
9.91E+
01 
4.02E-
04 
4.40E+
03 
4.06E+
01 
2.49E+
00 
2.21E+
01 
-
2.48E+
01 
-
2.66E+
00 
1.17E+
00 
-
2.71E+
03 
2.35E+
01 
-
2.69E+
03 
-
2.69E+
03 
5.42E+
03 
C7 
-1.16E-
01 
7.31E+
01 
-8.10E-
05 
3.76E+
01 
4.04E+
00 
2.08E+
00 
-
3.14E+
00 
-
6.11E+
00 
-
9.25E+
00 
8.08E-
02 
9.07E+
01 
2.25E+
01 
1.13E+
02 
1.13E+
02 
1.27E+
02 
C8 
-1.05E-
01 
7.72E+
01 
8.60E-
05 
3.76E+
01 
4.04E+
00 
2.07E+
00 
-
3.83E+
00 
-
6.13E+
00 
-
9.96E+
00 
1.24E-
01 
1.07E+
02 
2.23E+
01 
1.29E+
02 
1.29E+
02 
1.23E+
02 
C13 
-9.59E-
02 
7.87E+
01 
1.57E-
04 
3.76E+
01 
4.03E+
00 
2.07E+
00 
-
3.78E+
00 
-
6.21E+
00 
-
9.99E+
00 
1.31E-
01 
1.05E+
02 
2.24E+
01 
1.28E+
02 
1.28E+
02 
1.24E+
02 
C14 
-8.33E-
02 
7.24E+
01 
7.10E-
05 
3.76E+
01 
4.02E+
00 
2.07E+
00 
-
2.78E+
00 
-
5.96E+
00 
-
8.74E+
00 
8.95E-
02 
8.18E+
01 
2.17E+
01 
1.03E+
02 
1.03E+
02 
1.41E+
02 
C18 
-1.16E-
01 
7.32E+
01 
-8.80E-
05 
3.76E+
01 
4.04E+
00 
2.08E+
00 
-
3.15E+
00 
-
6.13E+
00 
-
9.27E+
00 
1.08E-
01 
9.08E+
01 
2.25E+
01 
1.13E+
02 
1.13E+
02 
1.27E+
02 
C19 
-1.05E-
01 
7.73E+
01 
5.90E-
05 
3.76E+
01 
4.04E+
00 
2.07E+
00 
-
3.83E+
00 
-
6.15E+
00 
-
9.97E+
00 
1.36E-
01 
1.07E+
02 
2.23E+
01 
1.29E+
02 
1.29E+
02 
1.23E+
02 
Cl10 
-4.78E-
01 
2.34E+
02 
9.30E-
05 
4.57E+
02 
1.69E+
01 
5.87E-
01 
-
2.19E+
01 
-
3.41E+
00 
-
2.53E+
01 
1.29E+
00 
1.03E+
03 
4.26E+
00 
1.03E+
03 
1.03E+
03 
3.66E+
02 
N11 
-9.49E-
01 
7.74E+
01 
5.00E-
05 
5.45E+
01 
6.07E+
00 
1.88E+
00 
-
3.67E+
00 
-
6.91E+
00 
-
1.06E+
01 
6.40E-
01 
1.00E+
00 
1.39E+
01 
1.49E+
01 
1.49E+
01 
3.56E+
02 
N16 
-9.49E-
01 
7.75E+
01 
6.00E-
05 
5.45E+
01 
6.07E+
00 
1.88E+
00 
-
3.67E+
00 
-
6.90E+
00 
-
1.06E+
01 
6.04E-
01 
4.94E-
01 
1.39E+
01 
1.44E+
01 
1.44E+
01 
3.58E+
02 
H34 
1.49E-
01 
3.72E+
01 
3.70E-
05 
5.50E-
01 
3.27E-
01 
5.25E-
01 
-9.03E-
01 
-4.11E-
01 
-
1.31E+
00 
3.97E-
02 
1.89E+
01 
4.77E+
00 
2.37E+
01 
2.37E+
01 
1.00E+
01 
H38 
1.51E-
01 
3.74E+
01 
8.50E-
05 
5.47E-
01 
3.24E-
01 
5.25E-
01 
-9.09E-
01 
-4.18E-
01 
-
1.33E+
00 
4.12E-
02 
1.88E+
01 
4.70E+
00 
2.35E+
01 
2.35E+
01 
9.30E+
00 
Complex 3 
Ru1 
8.73E-
01 
9.61E+
01 
-6.31E-
04 
4.40E+
03 
4.07E+
01 
2.45E+
00 
2.73E+
01 
-
2.50E+
01 
2.30E+
00 
8.55E-
01 
-
3.41E+
03 
2.29E+
01 
-
3.38E+
03 
-
3.38E+
03 
5.84E+
03 
C13 
-7.91E-
02 
7.32E+
01 
-2.80E-
05 
3.76E+
01 
4.01E+
00 
2.07E+
00 
-
3.29E+
00 
-
6.18E+
00 
-
9.47E+
00 
8.53E-
02 
9.47E+
01 
2.23E+
01 
1.17E+
02 
1.17E+
02 
1.29E+
02 
C14 
-9.33E-
02 
7.21E+
01 
-4.90E-
05 
3.76E+
01 
4.02E+
00 
2.07E+
00 
-
3.27E+
00 
-
6.65E+
00 
-
9.92E+
00 
4.11E-
01 
9.41E+
01 
2.29E+
01 
1.17E+
02 
1.17E+
02 
1.27E+
02 
C18 
-8.72E-
02 
7.36E+
01 
8.60E-
05 
3.76E+
01 
4.02E+
00 
2.07E+
00 
-
3.26E+
00 
-
6.21E+
00 
-
9.47E+
00 
9.86E-
02 
9.37E+
01 
2.23E+
01 
1.16E+
02 
1.16E+
02 
1.29E+
02 
C21 
-1.18E-
01 
7.64E+
01 
-3.70E-
05 
3.76E+
01 
4.04E+
00 
2.08E+
00 
-
3.50E+
00 
-
6.31E+
00 
-
9.81E+
00 
1.79E-
01 
9.88E+
01 
2.29E+
01 
1.22E+
02 
1.22E+
02 
1.25E+
02 
C23 
-9.43E-
02 
7.27E+
01 
-8.40E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.35E+
00 
-
6.66E+
00 
-
1.00E+
01 
4.09E-
01 
9.62E+
01 
2.29E+
01 
1.19E+
02 
1.19E+
02 
1.29E+
02 
C25 
-1.17E-
01 
7.61E+
01 
1.72E-
04 
3.76E+
01 
4.04E+
00 
2.08E+
00 
-
3.46E+
00 
-
6.30E+
00 
-
9.76E+
00 
1.83E-
01 
9.81E+
01 
2.30E+
01 
1.21E+
02 
1.21E+
02 
1.25E+
02 
Cl7 
-4.97E-
01 
2.32E+
02 
7.30E-
05 
4.57E+
02 
1.69E+
01 
5.90E-
01 
-
2.18E+
01 
-
3.20E+
00 
-
2.50E+
01 
1.35E+
00 
1.01E+
03 
3.77E+
00 
1.02E+
03 
1.02E+
03 
4.99E+
02 
N10 -9.26E- 7.82E+ 2.83E- 5.44E+ 6.06E+ 1.86E+ - - - 9.41E- 2.92E+ 1.31E+ 1.60E+ 1.60E+ 3.60E+
342 
01 01 04 01 00 00 3.72E+
00 
7.07E+
00 
1.08E+
01 
01 00 01 01 01 02 
N16 
-9.30E-
01 
7.78E+
01 
2.81E-
04 
5.45E+
01 
6.06E+
00 
1.87E+
00 
-
3.73E+
00 
-
6.99E+
00 
-
1.07E+
01 
9.13E-
01 
4.52E+
00 
1.31E+
01 
1.76E+
01 
1.76E+
01 
3.55E+
02 
O2 
-8.96E-
01 
1.04E+
02 
1.68E-
04 
7.47E+
01 
7.80E+
00 
1.09E+
00 
-
5.04E+
00 
-
2.27E+
00 
-
7.31E+
00 
9.29E-
01 
-
7.73E+
01 
4.31E+
00 
-
7.30E+
01 
-
7.30E+
01 
5.56E+
02 
O28 
-8.94E-
01 
1.05E+
02 
1.36E-
04 
7.47E+
01 
7.81E+
00 
1.09E+
00 
-
5.06E+
00 
-
2.21E+
00 
-
7.27E+
00 
8.86E-
01 
-
8.26E+
01 
4.19E+
00 
-
7.84E+
01 
-
7.84E+
01 
5.53E+
02 
H31 
1.61E-
01 
3.65E+
01 
3.80E-
05 
5.47E-
01 
3.19E-
01 
5.20E-
01 
-9.69E-
01 
-
1.06E+
00 
-
2.03E+
00 
3.16E-
01 
1.93E+
01 
7.78E+
00 
2.71E+
01 
2.71E+
01 
5.20E+
00 
H36 
1.77E-
01 
3.48E+
01 
1.80E-
05 
5.41E-
01 
3.05E-
01 
5.17E-
01 
-9.20E-
01 
-
1.05E+
00 
-
1.98E+
00 
3.08E-
01 
1.89E+
01 
7.65E+
00 
2.66E+
01 
2.66E+
01 
6.36E+
00 
Complex 4 
Ru1 
9.46E-
01 
1.02E+
02 
-2.96E-
04 
4.40E+
03 
4.07E+
01 
2.38E+
00 
2.97E+
01 
-
2.51E+
01 
4.51E+
00 
4.45E-
01 
-
3.77E+
03 
2.31E+
01 
-
3.75E+
03 
-
3.75E+
03 
6.50E+
03 
C2 
-9.53E-
02 
7.64E+
01 
9.40E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.39E+
00 
-
6.18E+
00 
-
9.57E+
00 
9.19E-
02 
9.45E+
01 
2.19E+
01 
1.16E+
02 
1.16E+
02 
1.28E+
02 
C3 
-9.30E-
02 
7.35E+
01 
-9.30E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.29E+
00 
-
6.17E+
00 
-
9.46E+
00 
1.09E-
01 
9.52E+
01 
2.33E+
01 
1.18E+
02 
1.18E+
02 
1.32E+
02 
C4 
-9.54E-
02 
7.65E+
01 
-5.80E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.40E+
00 
-
6.18E+
00 
-
9.58E+
00 
1.18E-
01 
9.46E+
01 
2.19E+
01 
1.17E+
02 
1.17E+
02 
1.28E+
02 
C5 
-8.74E-
02 
7.61E+
01 
-7.70E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.50E+
00 
-
6.23E+
00 
-
9.73E+
00 
1.29E-
01 
1.01E+
02 
2.36E+
01 
1.25E+
02 
1.25E+
02 
1.26E+
02 
C6 
-9.30E-
02 
7.35E+
01 
-5.60E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.28E+
00 
-
6.16E+
00 
-
9.45E+
00 
1.27E-
01 
9.49E+
01 
2.33E+
01 
1.18E+
02 
1.18E+
02 
1.32E+
02 
C7 
-8.74E-
02 
7.61E+
01 
-8.00E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.51E+
00 
-
6.23E+
00 
-
9.74E+
00 
1.46E-
01 
1.01E+
02 
2.36E+
01 
1.25E+
02 
1.25E+
02 
1.26E+
02 
N10 
-6.07E-
01 
7.84E+
01 
1.22E-
04 
5.42E+
01 
5.78E+
00 
1.82E+
00 
-
3.84E+
00 
-
6.59E+
00 
-
1.04E+
01 
6.51E-
01 
1.74E+
01 
1.59E+
01 
3.33E+
01 
3.33E+
01 
1.33E+
02 
N13 
-6.07E-
01 
7.84E+
01 
-4.29E-
04 
5.42E+
01 
5.78E+
00 
1.82E+
00 
-
3.84E+
00 
-
6.59E+
00 
-
1.04E+
01 
6.36E-
01 
1.74E+
01 
1.59E+
01 
3.33E+
01 
3.33E+
01 
1.33E+
02 
N15 
-9.65E-
01 
7.53E+
01 
1.70E-
04 
5.46E+
01 
6.10E+
00 
1.86E+
00 
-
4.55E+
00 
-
6.58E+
00 
-
1.11E+
01 
3.83E-
01 
6.20E+
01 
1.36E+
01 
7.56E+
01 
7.56E+
01 
2.10E+
02 
Complex 5 
Ru1 
9.26E-
01 
1.01E+
02 
9.21E-
04 
4.40E+
03 
4.06E+
01 
2.43E+
00 
2.82E+
01 
-
2.44E+
01 
3.84E+
00 
4.94E-
01 
-
3.57E+
03 
2.23E+
01 
-
3.55E+
03 
-
3.55E+
03 
5.25E+
03 
C18 
-8.75E-
02 
7.60E+
01 
-2.80E-
04 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.44E+
00 
-
6.11E+
00 
-
9.55E+
00 
7.76E-
02 
9.92E+
01 
2.27E+
01 
1.22E+
02 
1.22E+
02 
1.29E+
02 
C20 
-9.77E-
02 
7.36E+
01 
-1.45E-
04 
3.76E+
01 
4.03E+
00 
2.07E+
00 
-
3.26E+
00 
-
6.04E+
00 
-
9.29E+
00 
9.89E-
02 
9.45E+
01 
2.26E+
01 
1.17E+
02 
1.17E+
02 
1.32E+
02 
C22 
-8.70E-
02 
7.59E+
01 
7.70E-
05 
3.76E+
01 
4.03E+
00 
2.06E+
00 
-
3.43E+
00 
-
6.10E+
00 
-
9.53E+
00 
9.16E-
02 
9.91E+
01 
2.27E+
01 
1.22E+
02 
1.22E+
02 
1.29E+
02 
C23 
-1.01E-
01 
7.60E+
01 
-4.40E-
05 
3.76E+
01 
4.03E+
00 
2.07E+
00 
-
3.31E+
00 
-
6.03E+
00 
-
9.34E+
00 
1.18E-
01 
9.15E+
01 
2.12E+
01 
1.13E+
02 
1.13E+
02 
1.33E+
02 
C26 -9.72E- 7.36E+ -2.40E- 3.76E+ 4.03E+ 2.07E+ - - - 1.14E- 9.46E+ 2.26E+ 1.17E+ 1.17E+ 1.32E+
343 
02 01 05 01 00 00 3.26E+
00 
6.03E+
00 
9.29E+
00 
01 01 01 02 02 02 
C27 
-1.01E-
01 
7.59E+
01 
-1.10E-
04 
3.76E+
01 
4.03E+
00 
2.07E+
00 
-
3.30E+
00 
-
6.03E+
00 
-
9.33E+
00 
1.38E-
01 
9.13E+
01 
2.12E+
01 
1.13E+
02 
1.13E+
02 
1.33E+
02 
N14 
-9.58E-
01 
8.06E+
01 
1.32E-
04 
5.44E+
01 
6.10E+
00 
1.85E+
00 
-
3.97E+
00 
-
7.06E+
00 
-
1.10E+
01 
5.43E-
01 
1.27E+
01 
1.30E+
01 
2.57E+
01 
2.57E+
01 
3.17E+
02 
N15 
-9.52E-
01 
7.36E+
01 
3.41E-
04 
5.46E+
01 
6.05E+
00 
1.90E+
00 
-
3.79E+
00 
-
6.70E+
00 
-
1.05E+
01 
2.78E-
01 
1.69E+
01 
1.34E+
01 
3.04E+
01 
3.04E+
01 
2.83E+
02 
N21 
-9.59E-
01 
8.06E+
01 
8.90E-
05 
5.44E+
01 
6.11E+
00 
1.85E+
00 
-
3.97E+
00 
-
7.07E+
00 
-
1.10E+
01 
4.49E-
01 
1.32E+
01 
1.30E+
01 
2.62E+
01 
2.62E+
01 
3.16E+
02 
 
 
Table 3.86: The atomic NMR magnetazability and shielding for the selected atoms in the complexes 
using combined basis sets ECP(Ru)|6-31+G(d,p) 
Complex 1 
q(A) 
Vol(A),
0.001 L(A) K(A) LI(A) 
DI(A,A
')/2
Intra_Iso
(A)
Bond_Iso
(A) _Iso(A) (A)
_Iso(A,
A)
_Iso(A',
A) _Iso(A) 
Isotropi
c 
Anisotr
opy 
9.40E-
01 
1.03E+
02 
2.84E-
04 
3.27E+
01 
1.24E+
01 
2.70E+
00 
1.42E+
01 
-
4.48E+
01 
-
3.06E+
01 
1.07E+
00 
1.52E+
03 
2.53E+
01 
1.55E+
03 
-
4.41E+
02 
6.61E+
02 
-7.56E-
02 
7.39E+
01 
2.30E-
05 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
3.04E+
00 
-
6.24E+
00 
-
9.29E+
00 
1.03E-
01 
8.71E+
01 
1.29E+
01 
1.00E+
02 
1.10E+
02 
1.21E+
02 
-5.98E-
02 
7.16E+
01 
-2.78E-
04 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.69E+
00 
-
6.57E+
00 
-
9.26E+
00 
5.74E-
02 
7.77E+
01 
-
7.36E+
00 
7.04E+
01 
1.01E+
02 
1.28E+
02 
-6.39E-
02 
7.18E+
01 
-2.07E-
04 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.75E+
00 
-
8.16E+
00 
-
1.09E+
01 
1.06E-
01 
8.19E+
01 
6.66E+
00 
8.85E+
01 
1.05E+
02 
1.23E+
02 
-6.54E-
02 
7.37E+
01 
1.51E-
04 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
3.07E+
00 
-
2.09E+
00 
-
5.16E+
00 
8.08E-
02 
8.69E+
01 
-
3.55E+
01 
5.14E+
01 
1.09E+
02 
1.26E+
02 
-7.15E-
02 
7.47E+
01 
2.20E-
05 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
3.17E+
00 
-
3.53E+
00 
-
6.70E+
00 
9.33E-
02 
8.93E+
01 
-
2.09E+
01 
6.84E+
01 
1.12E+
02 
1.21E+
02 
-4.23E-
02 
7.01E+
01 
-2.32E-
04 
3.78E+
01 
3.96E+
00 
2.09E+
00 
-
2.42E+
00 
7.31E-
01 
-
1.69E+
00 
8.09E-
02 
7.01E+
01 
-
4.33E+
01 
2.68E+
01 
9.18E+
01 
1.43E+
02 
-4.92E-
01 
2.30E+
02 
6.40E-
05 
4.59E+
02 
1.68E+
01 
6.81E-
01 
-
2.03E+
01 
-
3.56E+
00 
-
2.38E+
01 
1.16E+
00 
9.04E+
02 
-
3.28E+
00 
9.01E+
02 
9.08E+
02 
5.31E+
02 
-7.26E-
01 
7.72E+
01 
2.69E-
04 
5.47E+
01 
5.84E+
00 
1.89E+
00 
-
3.36E+
00 
-
3.66E+
01 
-
3.99E+
01 
6.76E-
01 
2.99E+
00 
6.84E+
01 
7.13E+
01 
1.95E+
01 
1.73E+
02 
-7.26E-
01 
7.72E+
01 
2.02E-
04 
5.47E+
01 
5.84E+
00 
1.89E+
00 
-
3.36E+
00 
-
3.86E+
01 
-
4.19E+
01 
6.36E-
01 
2.77E+
00 
6.84E+
01 
7.12E+
01 
1.93E+
01 
1.74E+
02 
-
1.13E+
00 
1.29E+
02 
7.20E-
05 
7.54E+
01 
8.15E+
00 
9.82E-
01 
-
5.90E+
00 
-
4.31E+
00 
-
1.02E+
01 
1.00E+
00 
-
8.96E+
01 
1.29E+
01 
-
7.67E+
01 
-
8.70E+
01 
5.43E+
02 
1.28E-
01 
4.04E+
01 
1.60E-
05 
5.64E-
01 
3.40E-
01 
5.32E-
01 
-9.11E-
01 
-
2.81E+
00 
-
3.72E+
00 
4.61E-
01 
1.75E+
01 
1.67E+
01 
3.42E+
01 
2.32E+
01 
6.57E+
00 
1.27E-
01 
4.04E+
01 
2.30E-
05 
5.64E-
01 
3.41E-
01 
5.32E-
01 
-9.13E-
01 
-
3.04E+
00 
-
3.95E+
00 
4.72E-
01 
1.75E+
01 
1.67E+
01 
3.43E+
01 
2.33E+
01 
6.51E+
00 
Complex 2 
344 
9.57E-
01 
1.05E+
02 
4.83E-
04 
3.27E+
01 
1.23E+
01 
2.73E+
00 
1.23E+
01 
-
6.54E+
01 
-
5.31E+
01 
1.06E+
00 
1.53E+
03 
2.44E+
01 
1.56E+
03 
-
4.29E+
02 
5.46E+
02 
-6.65E-
02 
7.04E+
01 
4.00E-
05 
3.78E+
01 
3.97E+
00 
2.10E+
00 
-
2.58E+
00 
-
1.72E+
00 
-
4.30E+
00 
7.96E-
02 
7.53E+
01 
-
3.11E+
01 
4.43E+
01 
9.75E+
01 
1.31E+
02 
-7.69E-
02 
7.49E+
01 
-1.02E-
04 
3.78E+
01 
3.99E+
00 
2.09E+
00 
-
3.19E+
00 
-
4.54E+
00 
-
7.73E+
00 
9.09E-
02 
8.97E+
01 
-
5.68E+
01 
3.29E+
01 
1.11E+
02 
1.26E+
02 
-6.59E-
02 
7.67E+
01 
-2.96E-
04 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
3.15E+
00 
-
6.68E+
00 
-
9.83E+
00 
8.29E-
02 
8.70E+
01 
-
1.67E+
01 
7.03E+
01 
1.09E+
02 
1.26E+
02 
-4.00E-
02 
6.99E+
01 
-5.43E-
04 
3.78E+
01 
3.96E+
00 
2.08E+
00 
-
2.20E+
00 
4.69E+
00 
2.49E+
00 
9.34E-
02 
6.43E+
01 
-
7.19E+
01 
-
7.61E+
00 
8.54E+
01 
1.50E+
02 
-6.67E-
02 
7.04E+
01 
1.40E-
05 
3.78E+
01 
3.97E+
00 
2.10E+
00 
-
2.58E+
00 
3.40E-
01 
-
2.24E+
00 
1.05E-
01 
7.54E+
01 
-
3.10E+
01 
4.45E+
01 
9.75E+
01 
1.30E+
02 
-7.67E-
02 
7.48E+
01 
2.55E-
04 
3.78E+
01 
3.99E+
00 
2.09E+
00 
-
3.19E+
00 
-
3.50E+
00 
-
6.69E+
00 
8.19E-
02 
8.98E+
01 
-
5.67E+
01 
3.31E+
01 
1.11E+
02 
1.26E+
02 
-4.84E-
01 
2.34E+
02 
6.80E-
05 
4.59E+
02 
1.68E+
01 
6.57E-
01 
-
2.08E+
01 
-
4.12E+
00 
-
2.49E+
01 
1.12E+
00 
9.50E+
02 
1.89E+
01 
9.69E+
02 
9.55E+
02 
4.05E+
02 
-
1.16E+
00 
8.10E+
01 
6.60E-
05 
5.50E+
01 
6.27E+
00 
1.89E+
00 
-
3.34E+
00 
-
5.67E+
01 
-
6.00E+
01 
5.24E-
01 
-
2.40E+
01 
9.76E+
01 
7.36E+
01 
-
1.13E+
01 
3.45E+
02 
-
1.16E+
00 
8.09E+
01 
2.46E-
04 
5.50E+
01 
6.27E+
00 
1.89E+
00 
-
3.34E+
00 
-
5.92E+
01 
-
6.25E+
01 
4.90E-
01 
-
2.44E+
01 
9.81E+
01 
7.37E+
01 
-
1.17E+
01 
3.47E+
02 
9.67E-
02 
4.09E+
01 
9.50E-
05 
5.81E-
01 
3.58E-
01 
5.45E-
01 
-9.04E-
01 
-
1.89E+
00 
-
2.80E+
00 
6.89E-
02 
1.80E+
01 
2.20E+
01 
4.00E+
01 
2.23E+
01 
1.05E+
01 
1.03E-
01 
4.10E+
01 
7.70E-
05 
5.76E-
01 
3.53E-
01 
5.45E-
01 
-9.10E-
01 
-
1.87E+
00 
-
2.78E+
00 
5.26E-
02 
1.79E+
01 
2.19E+
01 
3.98E+
01 
2.22E+
01 
9.71E+
00 
Complex 3 
9.59E-
01 
1.01E+
02 
2.52E-
04 
3.27E+
01 
1.23E+
01 
2.71E+
00 
1.57E+
01 
-
2.51E+
01 
-
9.33E+
00 
7.69E-
01 
1.45E+
03 
2.38E+
01 
1.47E+
03 
-
5.15E+
02 
5.85E+
02 
-5.37E-
02 
7.08E+
01 
-6.10E-
05 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.74E+
00 
-
1.78E+
00 
-
4.52E+
00 
7.69E-
02 
7.80E+
01 
-
3.43E+
01 
4.37E+
01 
9.77E+
01 
1.36E+
02 
-6.12E-
02 
6.99E+
01 
-1.90E-
04 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.66E+
00 
-
1.16E+
00 
-
3.81E+
00 
4.01E-
01 
7.74E+
01 
-
1.80E+
01 
5.94E+
01 
9.83E+
01 
1.35E+
02 
-5.33E-
02 
7.09E+
01 
-1.48E-
04 
3.78E+
01 
3.97E+
00 
2.09E+
00 
-
2.71E+
00 
-8.01E-
01 
-
3.52E+
00 
8.25E-
02 
7.71E+
01 
-
3.46E+
01 
4.25E+
01 
9.68E+
01 
1.37E+
02 
-7.24E-
02 
7.38E+
01 
-1.20E-
04 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
2.90E+
00 
-
3.34E+
00 
-
6.24E+
00 
1.34E-
01 
8.08E+
01 
-
2.52E+
00 
7.83E+
01 
1.02E+
02 
1.32E+
02 
-6.28E-
02 
7.02E+
01 
-2.92E-
04 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
2.69E+
00 
-3.87E-
01 
-
3.08E+
00 
4.12E-
01 
7.80E+
01 
-
1.87E+
01 
5.94E+
01 
9.88E+
01 
1.36E+
02 
-7.20E-
02 
7.35E+
01 
-2.53E-
04 
3.78E+
01 
3.98E+
00 
2.09E+
00 
-
2.88E+
00 
-
2.91E+
00 
-
5.79E+
00 
1.42E-
01 
8.04E+
01 
-
2.87E+
00 
7.76E+
01 
1.02E+
02 
1.32E+
02 
-4.94E-
01 
2.33E+
02 
8.90E-
05 
4.59E+
02 
1.68E+
01 
6.69E-
01 
-
2.04E+
01 
-
3.83E+
00 
-
2.42E+
01 
1.16E+
00 
9.18E+
02 
1.43E+
01 
9.32E+
02 
9.23E+
02 
6.30E+
02 
-
1.14E+
00 
8.19E+
01 
2.23E-
04 
5.49E+
01 
6.27E+
00 
1.87E+
00 
-
3.46E+
00 
-
3.07E+
01 
-
3.42E+
01 
9.04E-
01 
-
1.84E+
01 
6.25E+
01 
4.41E+
01 
-
4.93E+
00 
3.41E+
02 
- 8.18E+ 5.60E- 5.49E+ 6.27E+ 1.87E+ - - - 8.69E- - 6.25E+ 4.46E+ - 3.41E+
345 
1.14E+
00 
01 05 01 00 00 3.46E+
00 
3.25E+
01 
3.60E+
01 
01 1.79E+
01 
01 01 4.43E+
00 
02 
-
1.15E+
00 
1.27E+
02 
1.11E-
04 
7.54E+
01 
8.14E+
00 
1.01E+
00 
-
5.80E+
00 
-
1.14E+
01 
-
1.72E+
01 
8.93E-
01 
-
7.45E+
01 
-1.02E-
01 
-
7.46E+
01 
-
7.20E+
01 
5.01E+
02 
-
1.15E+
00 
1.27E+
02 
1.17E-
04 
7.54E+
01 
8.14E+
00 
1.01E+
00 
-
5.82E+
00 
-
1.19E+
01 
-
1.77E+
01 
8.78E-
01 
-
7.53E+
01 
-5.23E-
02 
-
7.54E+
01 
-
7.28E+
01 
4.99E+
02 
1.18E-
01 
3.91E+
01 
2.20E-
05 
5.75E-
01 
3.43E-
01 
5.39E-
01 
-9.17E-
01 
-
5.56E+
00 
-
6.48E+
00 
3.52E-
01 
1.80E+
01 
-
9.34E+
00 
8.68E+
00 
2.41E+
01 
6.77E+
00 
1.22E-
01 
3.86E+
01 
3.20E-
05 
5.74E-
01 
3.40E-
01 
5.39E-
01 
-9.03E-
01 
-
5.80E+
00 
-
6.70E+
00 
3.54E-
01 
1.79E+
01 
-
9.83E+
00 
8.07E+
00 
2.40E+
01 
7.09E+
00 
Complex 4 
9.82E-
01 
1.12E+
02 
-8.61E-
04 
3.27E+
01 
1.24E+
01 
2.63E+
00 
1.72E+
01 
-
3.72E+
01 
-
2.00E+
01 
3.23E-
01 
1.38E+
03 
2.40E+
01 
1.41E+
03 
-
5.81E+
02 
7.13E+
02 
-5.75E-
02 
7.36E+
01 
-2.60E-
05 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
2.80E+
00 
-
3.30E+
00 
-
6.10E+
00 
7.55E-
02 
7.77E+
01 
-
2.22E+
01 
5.55E+
01 
9.86E+
01 
1.32E+
02 
-5.54E-
02 
7.08E+
01 
-2.19E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.71E+
00 
-
3.84E+
00 
-
6.55E+
00 
7.39E-
02 
7.94E+
01 
-
7.69E+
00 
7.17E+
01 
1.02E+
02 
1.32E+
02 
-5.77E-
02 
7.36E+
01 
-3.00E-
05 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
2.81E+
00 
-
2.41E+
00 
-
5.22E+
00 
9.46E-
02 
7.79E+
01 
-
2.22E+
01 
5.57E+
01 
9.87E+
01 
1.32E+
02 
-4.58E-
02 
7.27E+
01 
-9.20E-
05 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.85E+
00 
-
5.17E+
00 
-
8.02E+
00 
9.35E-
02 
8.34E+
01 
6.44E+
00 
8.98E+
01 
1.07E+
02 
1.31E+
02 
-5.55E-
02 
7.07E+
01 
-3.53E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.71E+
00 
-
3.48E+
00 
-
6.19E+
00 
8.67E-
02 
7.92E+
01 
-
7.80E+
00 
7.14E+
01 
1.02E+
02 
1.32E+
02 
-4.61E-
02 
7.27E+
01 
-7.90E-
05 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.85E+
00 
-
4.95E+
00 
-
7.80E+
00 
1.01E-
01 
8.35E+
01 
6.38E+
00 
8.99E+
01 
1.07E+
02 
1.31E+
02 
-7.38E-
01 
8.21E+
01 
2.73E-
04 
5.47E+
01 
5.89E+
00 
1.85E+
00 
-
3.51E+
00 
-
1.44E+
01 
-
1.79E+
01 
5.90E-
01 
1.80E+
00 
3.50E+
01 
3.68E+
01 
1.66E+
01 
1.21E+
02 
-7.38E-
01 
8.21E+
01 
2.80E-
04 
5.47E+
01 
5.89E+
00 
1.85E+
00 
-
3.51E+
00 
-
1.46E+
01 
-
1.81E+
01 
5.75E-
01 
1.80E+
00 
3.50E+
01 
3.68E+
01 
1.66E+
01 
1.21E+
02 
-
1.18E+
00 
7.93E+
01 
4.18E-
04 
5.51E+
01 
6.30E+
00 
1.87E+
00 
-
4.22E+
00 
-
2.86E+
01 
-
3.28E+
01 
3.23E-
01 
3.98E+
01 
6.59E+
01 
1.06E+
02 
5.34E+
01 
1.95E+
02 
Complex 5 
9.80E-
01 
1.09E+
02 
1.36E-
03 
3.27E+
01 
1.23E+
01 
2.69E+
00 
1.65E+
01 
-
5.14E+
01 
-
3.49E+
01 
5.13E-
01 
1.36E+
03 
2.32E+
01 
1.38E+
03 
-
6.08E+
02 
4.66E+
02 
-4.88E-
02 
7.28E+
01 
-3.90E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.82E+
00 
-
5.26E+
00 
-
8.08E+
00 
6.77E-
02 
8.26E+
01 
-
1.05E+
00 
8.15E+
01 
1.04E+
02 
1.33E+
02 
-5.86E-
02 
7.09E+
01 
-3.20E-
05 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.72E+
00 
-
1.28E+
00 
-
4.00E+
00 
1.08E-
01 
7.85E+
01 
-
2.39E+
01 
5.46E+
01 
9.99E+
01 
1.34E+
02 
-4.81E-
02 
7.26E+
01 
4.30E-
05 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.81E+
00 
-
5.08E+
00 
-
7.89E+
00 
6.63E-
02 
8.24E+
01 
-
1.02E+
00 
8.14E+
01 
1.04E+
02 
1.33E+
02 
-6.19E-
02 
7.32E+
01 
-2.73E-
04 
3.78E+
01 
3.98E+
00 
2.08E+
00 
-
2.73E+
00 
-
2.89E+
00 
-
5.62E+
00 
1.00E-
01 
7.44E+
01 
-
4.68E+
01 
2.76E+
01 
9.43E+
01 
1.38E+
02 
-5.90E-
02 
7.11E+
01 
-3.44E-
04 
3.78E+
01 
3.97E+
00 
2.08E+
00 
-
2.72E+
00 
-
1.14E+
00 
-
3.86E+
00 
1.17E-
01 
7.88E+
01 
-
2.38E+
01 
5.49E+
01 
1.00E+
02 
1.34E+
02 
-6.16E- 7.31E+ -2.82E- 3.78E+ 3.98E+ 2.08E+ - - - 9.87E- 7.42E+ - 2.74E+ 9.40E+ 1.38E+
346 
02 01 04 01 00 00 2.73E+
00 
2.89E+
00 
5.62E+
00 
02 01 4.68E+
01 
01 01 02 
-
1.17E+
00 
8.46E+
01 
2.33E-
04 
5.49E+
01 
6.31E+
00 
1.86E+
00 
-
3.60E+
00 
-
2.02E+
01 
-
2.38E+
01 
4.48E-
01 
-
6.06E+
00 
4.15E+
01 
3.55E+
01 
6.43E+
00 
2.96E+
02 
-
1.17E+
00 
7.77E+
01 
4.56E-
04 
5.51E+
01 
6.26E+
00 
1.91E+
00 
-
3.45E+
00 
-
4.33E+
01 
-
4.68E+
01 
2.20E-
01 
-
9.09E+
00 
1.00E+
02 
9.11E+
01 
4.13E+
00 
2.62E+
02 
-
1.17E+
00 
8.46E+
01 
2.77E-
04 
5.49E+
01 
6.31E+
00 
1.86E+
00 
-
3.61E+
00 
-
2.10E+
01 
-
2.46E+
01 
3.55E-
01 
-
5.54E+
00 
4.13E+
01 
3.57E+
01 
6.90E+
00 
2.94E+
02 
 
 
 
Table 3.87: The fitted properties of the factors used in the proposed isotropic shielding model 
 1 2 3 4 5 
(Intercept)  2.98E+001 3.95E+001 3.89E+001 -1.01E+002 35.19 
abs(q(A)) -5.40E+001 -5.43E+001 -5.37E+001 4.22E+001 -5.32E+001 
K(A)  4.04E+000 3.92E+000 3.97E+000 -1.35E+001 3.34 
(K_Scaled(A))2 -1.01E-003 -9.74E-004 -1.01E-003 2.64E-003 -8.96E-004 
LI(A)  -3.52E+001 -2.97E+001 -3.15E+001 7.71E+001 -2.43E+001 
DI(A,A')/2  2.42E+001 3.81E+000 5.61E+000 1.89E+002 3.96E+000 
 R-squared 0.9968 0.9941 0.9966 0.9998 0.9974 
p-value 2.20E-016 2.20E-016 2.20E-016 2.20E-016 2.20E-016 
Min residue -92.515 -104.098 -93.863 -37.232 -113.183 
Max residue 117.752 114.178 100.135 12.616 117.111 
 









Table 3.88: The conductive properties of the complexes 
ECP|6-31G* 
 Dipole      
 ß in esu 
(1x10-30) 
Gap in 
KJ/mol  KJ/mol 
bpyrazace 3.36 216.91 21.47 23.65 49.34 4.52E+00 5.19 156.35 78.17 
dpynic 6.60 279.95 178.26 178.69 75.21 1.35E-02 21.58 173.10 86.55 
phth 7.71 293.04 -57.11 147.14 9193.44 1.06E-02 14.22 159.95 79.97 
razol 2.78 239.30 120.99 132.10 1405.16 6.07E-03 4.43 221.67 110.84 
terpy 5.41 304.08 176.09 179.75 651.20 1.69E-02 4.66 210.70 105.35 
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3-21G 
bpyrazace 6.78 191.82 30.93 42.17 410.65 -20.57 4.13 395.11 197.56 
dpynic 6.60 248.11 157.78 157.85 12.16 -31.83 11.98 314.14 157.07 
phth 8.43 262.55 -55.83 134.05 7426.85 -30.48 7.26 294.69 147.34 
razol 3.15 218.38 112.59 126.98 1723.92 -20.91 3.08 391.80 195.90 
terpy 4.96 274.65 165.37 170.87 923.74 -29.41 2.81 366.20 183.10 
DGDZVP|6-31+G(d,p) 
bpyrazace 6.85 224.50 -26.12 41.27 510.43 -8.50 3.60 405.87 202.93 
dpynic 6.85 290.46 157.90 158.15 39.09 -17.15 12.96 307.11 153.55 
phth 8.28 303.87 124.09 125.04 118.04 -16.09 6.66 301.63 150.82 
razol 2.47 246.42 106.75 117.33 1184.90 -9.55 2.75 390.01 195.00 
terpy 6.07 311.90 156.81 160.52 588.77 -14.47 3.12 358.54 179.27 
ECP|6-31+G(d,p) 
bpyrazace 5.80 233.00 -29.28 48.32 738.82 -1.89E-03  238.15 119.08 
dpynic 5.89 307.61 179.09 179.83 133.67 6.16E-04  165.29 82.64 
phth 6.95 319.96 138.24 138.69 62.08 -7.98E-04  162.12 81.06 
razol 1.83 255.97 115.41 124.10 1040.71 -2.24E-04  221.85 110.92 
terpy 4.65 326.37 168.22 170.74 427.26 2.45E-03  218.62 109.31 
 
 
 
Table 3.89: The binding activities of the Ru(II)-based complexes as predicted suing Glide package 
  CatB 
DNA-
Gyrase HDAC7 HP-NCP KINASE rHA RNR Top11 TrXR TS 
1 CraptaC -2.14 -1.68 -1.41 -2.67 -3.45  -1.51  -1.70 -1.00 
2 OraptaC -2.19 -2.19 -2.38 -2.15 -4.44 -2.12 -0.55  -2.69 -3.71 
3 raptaB-H2O -4.04 -3.18 -2.16 -3.41 -3.10 -2.40 -3.52 -5.68  -4.10 
4 raptaC-H2O -3.56 -2.49 -3.35 -2.99 -2.61 -2.61 -3.64 -3.97 -2.37 -2.82 
5 raptaT-H2O -3.98 -2.48 -2.61 -2.87 -3.38 -2.23 -3.75 -4.75 -2.57 -3.76 
6 piano -4.35 -3.41 -3.72 -3.29 -3.48 -3.75 -3.40 -4.96 -3.45 -3.94 
7 ragly -2.92 -3.63 -2.73 -3.90 -4.83 -3.35 -2.06 -4.42 -2.88 -3.32 
8 etdiaglydmso -2.57 -2.88 -2.12 -4.17 -4.02  -2.42 -3.79 -3.60 -3.52 
9 radipyrazoic -4.93 -3.88 -3.40 -5.11 -3.12 -3.10 -7.10 -5.15 -4.43 -4.10 
10 radipyrdioic -3.22 -4.60 -4.06 -4.00 -5.97 -3.57 -6.87 -3.87 -4.69 -4.00 
11 raphendioic -4.37 -4.39 -2.62 -3.20 -4.30 -3.85 -4.71 -4.58 -3.33 -4.97 
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Table 3.90: The binding activities of the Ru(II)-based complexes as predicted suing Autodock package 
  CatB 
DNA_G
yrase HDAC7 HP-NCP KINASE rHA RNR top11 TrXR TS 
1 CraptaC -9.29 -8.92 -8.33 -7.11 -6.57 -6.49 -5.49 -4.47 -5.22 -8.05 
2 OraptaC -9.11 -8.35 -7.93 -7.59 -6.44 -5.52 -5.16 -5.6 -5.96 -7.15 
3 raptaBh2o -7.16 -6.21 -6.95 -6.78 -6.3 -4.72 -3.79 -4.41 -5.1 -5.46 
4 raptaCh2o -8.15 -6.58 -6.63 -6.75 -6.21 -5.11 -3.89 -4.14 -4.78 -5.17 
5 raptaTh2o -7.27 -6.26 -6.61 -7.01 -6.32 -5.04 -3.62 -4.42 -5.05 -5.52 
6 piano -5.83 -5.56 -6.49 -7.31 -6.45 -5.35 -3.72 -4.53 -4.72 -4.26 
7 ragly -5.63 -5.05 -5.77 -6.6 -5.08 -4.88 -3.64 -4.38 -5.04 -4.5 
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8 etdiaglydmso -9.34 -7.57 -8.63 -8.5 -7.92 -6.37 -4.02 -6.46 -6.3 -5.62 
9 radipyrazoic -4.49 -3.77 -3.84 -3.94 -3.4 -4.3 -4.93 -4.73 -4.17 -4.5 
10 radipyrdioic -3.68 -4.4 -2.5 -5.01 -5.33 -6.09 -5.65 -6 -6.24 -4.91 
11 raphendioic -5.3 -5.58 -3.48 -5.49 -4.77 -6.52 -5.47 -5.48 -4.93 -5.04 
12 rCpbkdmso -6.16 -5.6 -6.05 -4.85 -4.18 -4.63 -4.69 -4.35 -4.39 -4.73 
 
Table 3.91: The correlation between the ranking of the complexes activity as predicted from Autodock 
and Glide packages. 
 
 Autodock/Glide 
CatB -0.65 
DNA-Gyrase -0.86 
HDAC7 -0.69 
HP-NCP -0.55 
KINASE -0.12 
rHA 0.46 
RNR 0.24 
TopII -0.55 
TrXR 0.11 
TS -0.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.92: The interaction of the binding site residues with first two rank best inhibitors complexes 
from the three docking methods defining the Complex-receptor existing Hydrogen bond (HB) and 
Metal-Receptor (MR) possible interactions with residues within the range of 4.5Å. 
Receptor Autodock  Glide 
CatB etdiaglydmso
a{[HB: 2.31 Å (H1@NH2EtNH2)-
(O@CO CYC 26D)], [HB: 1.72 Å (H2@NH2EtNH2)-
(O@COOH GLU 122E)], [HB: 1.93 Å 
(H@NH2CH2COO)-(O@COOH GLU 122E)], [HB: 
2.73 Å (N@NH2CH2COO)-(H@COOH GLU 122E)], 
[HB: 2.87 Å (O@NH2CH2COO)-(S@CH2S CYS 
29D)], [HB: 2.13 Å (O@NH2CH2COO)-(H@NH 
radipyrazoica{[HB: 1.82 Å (H@COOH)-(O@COO GLU 
122E)], [MR: 3.66Å (H@ar TRP 221E)]}; 
raphendioicb{[HB: 1.63 Å (H@COOH)-(O@COO GLU 
122E)], [MR: 4.27 Å (H@ar TRP 221E)]}; 
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CYS 29D)], [MR: 3.38 Å (O@COOH GLU 122 E)], 
[MR: 4.36 Å (CH GLY 27 D)]}; 
CraptaCb{[HB: 1.92 Å (O@COO)-(H@im HIS 111E)], 
MR: 4.07Å (ar TRP 221E)}; 
DNA-Gyrase CraptaC
a {[HB: 1.74Å (O@COO)-(H@NH VAL 
120A)]; [MR: 4.35Å (NH2 ASN 46A)};  
OraptaCb {[HB: 1.78Å (O@COO)-(H@NH VAL 
120A)], [MR: 4.41Å (CO GLY 117A)], [MR: 4.48Å 
(CH2 GLY 119A)]}; 
radipyrdioica {[HB: 2.12 Å (H@COOH1)-(O@CO ASP 
49A)]; [HB: 1.92 Å (O@COOH2)-(H@NH GLY 
77A)];[HB: 2.08 Å (H@COOH2)-(O@CO ASP 73A)]; 
raphendioicb {[HB: 1.67 Å (H@COOH1)-(O@COO ASP 
49A)], [HB: 2.48 Å (H@COOH2)-(O@COO ASP 73A)], 
[MR: 4.14Å (CH2 ASN 46A)], [MR: 4.09 Å (CH2 
ILE78A)]} 
HDAC7 etdiaglydmso
a{[HB: 1.67 Å (H@NH2EtNH2)-
(O@COO ASP 626 A)], [MR: 4.06 Å (COO ASP 626 
A)]}; 
CraptaCb{MR: 3.53Å (COO ASP 626 A)}; 
radipyrdioica {[HB: 1.58 Å (H@COOH)-(O@COO ASP 
626A)], [MR: 3.59 Å (H@CH2 PHE 738 A)], [MR: 4.45 Å 
(H@NH PHE 738 A)], [MR: 4.36 Å (O@CO PRO 
809 A)], [MR: 4.47 Å (H@CH2 PRO 809 A)]}; 
pianob {[HB: 2.10 Å (H@NH2)-(O@CO PRO 809 A)], 
[MR: 4.11 Å (H@CH3 LEU 810 A)], [MR: 4.29 Å 
(O@CO PRO 809 A)], [MR: 4.35 Å (H1,2@CH2 PHE 
738 A)]} 
HP-NCP etdiaglydmsoa{[HB: 1.98 Å (O@dmso)-(H@NH 
ASP 478 A)], [MR: 3.96 Å (O@COO GLU 532 A)], 
[MR: 4.42Å (O@COO ASP 478 A)]}; 
OraptaCb {[IT: 2.90 (N@PTA)-(O@COO GLU 
64G)],[MR: 3.73Å (COO GLU 61G)]},  
radipyrazoica {[HB: 2.12 Å (O@COOH)-(H@COOH 
GLU 61 G)], [MR: 4.50 Å (H@COOH ASP 90 G)]}; 
etdiaglydmsob {[HB: 2.09 Å (O@COOH)-(HN@im HIS 
106H)]} 
KINASE etdiaglydmso
a{[HB: 2.15 Å (H@NH2EtNH2
1)-
(O@COO GLU 68 H)], [HB: 1.76 Å 
(H@NH2EtNH2
2)-(O@COO ASP 65 H)], [MR: 4.06 
Å (CH2COO ASP 65 H)]}; 
CraptaCb {[HB: 1.36 (O@COO)- (H@im HIS 
584A)]}; 
radipyrdioica {[HB: 2.55 Å (H@COOH1)-(O@CO CYS 
531A)], [HB: 2.10 Å (O@COOH1)-(H@NH CYS 531A)], 
[HB: 2.67 Å (O@COOH2)-(H@OH THR 528A)], 
[MR: 3.88 Å (H@CH3 VAL 470 A)], [MR: 4.28 Å 
(H@ar PHE 582 A)]}; 
raglyb {[HB: 1.99 Å (O@COO)-(H@NH ASP 593 A)], 
[MR: 4.05 Å (H@CH3 LEU 513 A)], [MR: 3.60 Å 
(H@NH ASP 593 A)], [MR: 3.40 Å (H@CH2 LYS 482 
A)], [MR: 4.06 Å (H@NH3 LYS 482 A)]} 
rHA raphendioica {[HB: 2.15 Å (H@COOH1)-
(H@COO GLU 425 A)], [HB: 1.72 Å (H@COOH2)-
(O@CO PRO 113 A)], [HB: 1.92 Å (O@COOH2)-
(H@NH ARG 145 A)], [MR: 4.45 Å (CH2 ARG 145 
A)]}; 
CraptaCb {[MR: 4.05Å (NH2 ASN 109A)], [MR: 
4.21Å (COOH GLU 425A)]}; 
raphendioica {[HB: 2.20 Å (O@COOH1)-(H@NH2 ARG 
145 A)], [HB: 2.23 Å (O@COOH1)-(H@OH GLU 141 
A)], [HB: 1.84 Å (O@COOH2)-(H@NH3 LYS 137 
A)], [HB: 1.67 Å (H@COOH2)-(O@COOH GLU 37 
A)], [MR: 4.45 Å (H@NH3 LYS 137 A)]}; 
pianob {[HB: 1.99 Å (H@NH2)-(O@COOH ASP 107 
A)], [MR: 4.32 Å (O@COOH ASP 107 A)], [MR: 4.45 
Å (H@NH2 ASN 111 A)]} 
RNR radipyrdioica {[HB: 2.32 Å (H@COOH1)-(O@CO 
ARG 251A)], [HB: 2.60 Å (O1@COOH2)-(H@NH 
THR 209 A)], [HB: 1.99 Å (O1@COOH2)-(H@OH 
SER 625A)], [HB: 2.13 Å (O2@COOH2)-(H@NH 
SER 625A)], [HB: 2.26 Å (O2@COOH2)-(H@NH 
THR 624 A)], [HB: 2.43 Å (O2@COOH2)-(H@NH 
GLU 623 A)]}; 
CraptaCb {[HB: 1.99Å (O@COO)- (H@NH THR 
209A)], [HB: 2.55Å (N@PTA)- (H@COOH GLU 
441A], } 
radipyrazoica {[HB: 2.09 Å (O1@COOH1)-(H@NH GLU 
633 A)], [HB: 1.89 Å (O1@COOH)-(H@NH THR 624 
A)], [HB: 1.95 Å (O2@COOH)-(H@NH SER 625 
A)], [MR: 3.59 Å (CH3 LEU 464 A)], [MR: 4.46 Å 
(H@CH2 SER 224 A)]}; 
radipyrdioicb {[HB: 2.51 Å (O1@COOH1)-(H@NH3 LYS 
154A)], [HB: 2.31 Å (O2@COOH1)-(H@NH3 LYS 
154A)], [HB: 2.50 Å (O2@COOH1)-(H@OH THR 209 
A)], [HB: 1.70 Å (H@COOH2)-(H@OH THR 624 A)], 
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[HB: 1.44 Å (H@COOH2)-(H@OH SER 224 A)], [MR: 
3.90 Å (H@CH2OH SER 224 A)]} 
TopII etdiaglydmso
a{[HB: 2.17 Å (O@NH2CH2COO)-
(H@NH LEU 124 A)], [MR: 3.85 Å (im HIS 123 
A)]}; 
radipyrdioicb {[HB: 1.79 Å (H@COOH1)-(O@CO 
PHE 362 A)], [HB: 2.00 Å (H@COOH2)-(O@CO 
THR 27 A)]} 
raptaB-H2O
a{[HB: 1.83Å (H@H2O)- (O@OH SER 
128A)], [HB: 2.04Å (H@H2O)- (O@CO ASN 
129A)], [IT: 2.97Å (N@PTA)- (O@CO ASN 70A)], 
[MR: 3.66Å (NH SER 128A)]}, 
radipyrazoicb {[HB: 2.28 Å (O@COOH)-(H@NH3 LYS 
147 A)], [HB: 2.23 Å (H@COOH)-(O@CO ASN 70 A)], 
[MR: 4.31 Å (H@CH3 ILE 120A)], [MR: 4.01 Å 
(H@OH SER 128 A)]}; 
TrXR etdiaglydmso
a{[HB: 1.83 Å (H@NH2EtNH2)-
(O@CO THR 161 A)], [MR: 3.66 Å (CO THR 161 
A)], [MR: 3.97 Å (O@CO PHE 43 A)], [MR: 4.21 Å 
(H@NH PHE 43 A)], [MR: 4.15 Å (H@NH GLY 
20 A)]}; 
radipyrdioicb {[HB: 2.30Å (H@COOH1)-(O@CO LEU 
41 A)], [HB: 1.91 Å (H@COOH2)-(O@CO ALA 160 
A)], [HB: 2.11 Å (O1@COOH2)-(H@NH GLY 24 
A)], HB: 2.43 Å (O2@COOH2)-(H@NH GLY 23 
A)], [MR: 3.82 Å (H@NH2 ARG 164 A)], [MR: 
4.33 Å (O@CO THR 161 A)], [MR: 4.00 Å 
(H@NH TRP 53 A)], [MR: 4.10 Å (NH THR 58 A)], 
[MR: 3.41 Å (OH THR 58 A)]} 
radipyrdioica {[HB: 1.92 Å (O@COOH)-(H@COOH 
GLU 163 A)], [HB: 2.22 Å (H@COOH)-(O@CO 
ARG 293 A)], [MR: 3.81 Å (H@NH2 ARG 166 A)]}; 
radipyrazoicb {[HB: 2.60 Å (O@COOH)-(H@COOH 
GLU 163 A)], [HB: 2.29 Å (O@COOH)-(H@NH2 ARG 
166 A)]} 
TS CraptaCa {[no HB and MR]}, 
OraptaCb {[HB: 1.86Å (O@COO)-(H@SH CYS 
198A], [HB: 2.22Å (CO)-(H@NH ASP 221A], 
[MR: 4.14Å (CH2 GLY 225A)]} 
raphendioica {[HB: 2.91 Å (O@COOH)-(H@NH2 ASN 
229 A)], [MR: 3.94 Å (H@NH2 ASN 229 A)]} 
raptaB-H2O
b{[HB: 1.69Å (H@H2O)- (H@OH ASP 
257A)], [MR: 3.73Å (OH SER 219A)]} 
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Table 3.93: The docking result of the metal-based complexes against ten receptors using Glide package 
in Maestro.  
 
  CatB 
DNA-
Gyrase HDAC7 HP-NCP KINASE rHA RNR Top11 TrxR TS 
1 carbo-rapta-C -2.14 -1.68 -1.41 -2.67 -3.45 -0.97 -1.51  -1.70 -1.00 
2 
rapta-C-
COOH -1.24 -1.67  -1.35   -0.88  -2.12 -1.22 
3 rapta-C-(OH)2 -2.50 -2.14 -1.38 -3.02 -3.26 -1.49 -2.52 -3.12 -2.84 -1.91 
4 
rapta-C-
NH2(OH) -2.12 -1.88 -1.63 -1.99 -3.49  -1.16 -3.03 -2.44 -1.65 
5 oxalo-rapta-C -2.19 -2.19 -2.38 -2.15 -4.44 -2.12 -0.55  -2.69 -3.71 
6 raC-NH2 -2.68 -2.51 -1.93 -3.56 -5.17 -2.91 -1.80 -3.44 -2.92 -2.93 
7 rapta-B -3.59 -2.53 -2.30 -2.84 -3.20 -2.49 -2.88 -3.75 -2.54 -1.74 
8 rapta-B-H2O -4.04 -3.18 -2.16 -3.41 -3.10 -2.40 -3.52 -5.68  -4.10 
9 rapta-B-H -4.01 -2.63 -2.83 -3.03 -4.06 -2.96 -2.81 -4.67 -3.16 -2.56 
11 rapta-C -3.36 -2.34 -2.62 -2.46 -3.31 -1.88 -3.32 -4.18 -2.49 -3.09 
12 rapta-C-H2O -3.56 -2.49 -3.35 -2.99 -2.61 -2.61 -3.64 -3.97 -2.37 -2.82 
13 rapta-C-H -3.68 -3.08 -3.44 -2.79 -4.34 -2.66 -3.82 -5.09 -3.00 -3.06 
14 rapta-T -3.25 -2.65  -2.71 -2.39 -2.01 -2.53 -3.91 -2.56 -2.74 
15 rapta-Ta-CH3 -3.21 -2.19 -2.44 -2.64 -2.25 -2.34 -3.41 -3.74 -2.84 -3.21 
16 rapta-Ta-NH2 -3.05 -2.56 -3.06 -2.97 -3.96 -2.68 -4.15 -4.76 -2.73 -3.22 
17 rapta-Ta-OH -3.83 -3.16 -3.19 -3.55 -3.24 -3.35 -4.75 -5.02 -2.87 -4.16 
18 rapta-T-CF3 -3.81 -2.21 -2.58 -2.33 -2.13 -2.31 -3.99 -4.19 -1.91 -2.73 
19 
rapta-T-
CF3(H2O) -3.92 -2.35 -2.43 -2.65 -2.47 -2.08 -4.21 -3.95 -2.56 -3.36 
20 rapta-T-H2O -3.98 -2.48 -2.61 -2.87 -3.38 -2.23 -3.75 -4.75 -2.57 -3.76 
21 rClCOO-NH3 -3.18 -2.20 -1.92 -2.95 -3.79 -3.82 -1.96 -2.76 -3.79 -3.19 
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Table 3.94: The docking prediction for metal-based complexes using Gold 
 
  CatB 
DNA-
Gyrase HDAC7 HP-NCP KINASE rHA RNR Top11 TrxR TS 
1 
 carbo-rapta-
C 50.37 40.79 -39.09 21.56 39 36.51 51.46 41.13 34.48 42.45 
2 
 rapta-C-
COOH 40.53 47.59 30.82 30.46 35.37 33.26 43.02 45.21 38.67 45.48 
3 
 rapta-C-
(OH)2 45.53 39.29 37.14 21.63 42.04 39.06 38.54 60.73 41.92 52.63 
4 
 rapta-C-
NH2(OH) 53.29 46.78 39.97 32.2 39.68 43.75 40.18 64.48 40.31 51.22 
5 
 oxalo-rapta-
C 40.94 42.48 18.01 25.28 42.51 46.79 46.62 49.95 40.75 40.28 
6  raC-NH2 32.39 26.92 30.46 25.81 27.59 29.22 24.97 30.63 35.56 30.02 
7  rapta-B 45.14 31.96 32.91 22.01 34.92 29.49 28.93 41.53 37.1 34.2 
8  rapta-B-H2O 45.94 32.76 32.4 26.36 40.14 31.73 29.32 42.14 32.71 31.72 
9  rapta-B-H 45.08 32.04 38.21  40.34 33.89  41.4  40.08 
10  rapta-B-NH2 47.66 37.76 40 28.61 42.27 42.57 36.13 47.9 48.6 38.03 
11  rapta-C 44.84 41.05 1.63 24.02 46.02 35.18 27.07 53.56 33.47 38.49 
12  rapta-C-H2O 40.34 39.56 10.84 26.19 42.19 36.96 36.94 52.18 37.26 37.39 
13  rapta-C-H 47.22 39.11 32.49 15.25 43.03 39.26 24.33 51.92 32.93 39.36 
14  rapta-T 41.09 34.83 34.43 22.33 38.57 31.1 28.8 46.48 40.48 34.66 
15  rapta-Ta-CH3 50.09 38.46 38.59 25.11 39.04 35.87 29.64 48.55 30.9 38.84 
16  rapta-Ta-NH2 50.46 44.05 34.02 30.56 46.61 39.58 41.03 53.8 35.93 38.7 
17  rapta-Ta-OH 49.51 43.87 -4.38 28.01 38.15 34.39 42 49.75 36.91 40.75 
18  rapta-T-CF3 45.33 32.37 33.2 22.83 39.65 30.95 31.99 43.82 37.93 35.02 
19 
 rapta-T-
CF3(H2O) 46.03 27.52 29.51 26.64 43.79 29.8 34.39 45.61 30.34 31.96 
20  rapta-T-H2O 45.13 33.69 26.55 26.86 44.12 29.71 37.95 46.1 28.8 34.72 
21 
 rClCOO-
NH3 35.59 38.42 38.51 28.92 32.83 32.54 33.89 40.86 39.64 48.42 
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Table 3.95: The docking prediction for metal-based complexes using Autodock. 
 
  CatB 
DNA-
Gyrase HDAC7 HP-NCP KINASE rHA RNR Top11 TrxR TS 
1 carbo-rapta-C -9.29 -8.92 -8.33 -3.93 -6.57 -6.49 -5.49 -4.94 -3.04 -8.05 
2 
rapta-C-
COOH -8.33 -6.63 -7.68 -3.06 -5.51 -5.02 -4.12 -2.63 -5.32 -6.66 
3 
rapta-C-
(OH)2 -9.96 -7.9 -8.1 -3.46 -6.65 -5.58 -4 -3.82 -6.43 -6.27 
4 
rapta-C-
NH2(OH) -9.42 -6.79 -7.37 -2.95 -6.16 -5.25 -3.73 -3.1 -6.22 -5.79 
5 oxalo-rapta-C -9.11 -8.35 -7.93 -3.66 -6.44 -5.52 -5.16 -3.8 -7.26 -7.15 
6 raC-NH2 -3.22 -2.72 -3.69 -2.11 -3.41 -2.96 -2.94 -1.84 -2.78 -2.73 
7 rapta-B -5.01 -3.95 -4.09 -2.61 -3.82 -4.11 -2.65 -2.38 -2.84 -3.89 
8 rapta-B-H2O -7.16 -6.21 -6.95 -2.98 -6.3 -4.72 -3.79 -3.22 -5.69 -5.46 
9 rapta-B-H -4.83 -4.77 -5.07 -2.71 -4.81 -4.4 -2.83 -2.42 -3.03 -4.01 
10 rapta-B-NH2 -7.09 -5.65 -6.76 -2.76 -5.76 -4.23 -3.31 -2.54 -4.24 -4.68 
11 rapta-C -5.73 -5.36 -5.2 -3.08 -4.71 -4.34 -3.46 -3.18 -2.18 -4.65 
12 rapta-C-H2O -8.15 -6.58 -6.63 -3.61 -6.21 -5.11 -3.89 -2.78 -5.87 -5.17 
13 rapta-C-H -5.44 -5.14 -5.1 -2.83 -4.69 -4.24 -2.99 -2.65 -3.46 -4.32 
14 rapta-T -7.1 -6.15 -6.23 -2.79 -5.32 -4.62 -3.74 -3.23 -4.67 -5.31 
15 rapta-Ta-CH3 -5.42 -4.94 -4.49 -3.04 -4.18 -4.48 -3.68 -2.86 -2.64 -4.13 
16 rapta-Ta-NH2 -5.02 -4.76 -4.37 -2.96 -4 -4.21 -3.11 -2.7 -2.5 -3.77 
17 rapta-Ta-OH -7.15 -7.03 -7.51 -5.14 -6.48 -5.83 -5.32 -3.98 -4.58 -5.99 
18 rapta-T-CF3 -5.02 -4.59 -4.98 -1.86 -4.33 -3.89 -2.8 -2.04 -1.77 -3.91 
19 
rapta-T-
CF3(H2O) -6.57 -5.86 -5.91 -2.31 -5.87 -4.34 -3.07 -2.53 -4.41 -4.76 
20 rapta-T-H2O -7.27 -6.26 -6.61 -2.9 -6.32 -5.04 -3.62 -3.23 -4.89 -5.52 
21 rClCOO-NH3 -5.74 -4.88 -5.57 -2.78 -5.32 -4.81 -3.37 -3.09 -4.25 -3.85 
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Table 3.96: The interaction of the binding site residues with first two rank best inhibitors complexes 
from the three docking methods defining the Complex-receptor existing Hydrogen bond (HB) and 
Metal-Receptor (MR) possible interactions with residues within the range of 4.5Å. 
No 
Metho
d Receptor Interactions 
1 
Autod
ock  
 
CatBb{[HB: 1.92 Å (O@COO)-(H@imHIS 111E)], MR:4.07Å (arTRP 221E)};  
Gyrasea{[HB:1.74Å (O@COO)-(H@NHVAL 120A)]; [MR:4.35Å (NH2ASN 46A)};  
HDAC7a{[MR:3.52Å (COOH ASP 626A)]}; 
Kinaseb{[HB:1.36 (O@COO)- (H@imHIS 584A)]}; 
rHAa{[MR:4.05Å (NH2 ASN 109A)], [MR:4.21Å (COOH GLU 425A)]}; 
RNRa {[HB:1.99Å (O@COO)- (H@NHTHR 209A)], [HB:2.55Å (N@PTA)- (H@COOHGLU 441A], } 
TSa {[no HB and MR]} 
Gold 
CatBb{[MR: 4.32Å (arTRP 221E)]}; 
RNRa {[MR:3.83Å (HOTHR 209A)]} 
3 
 
 
 
 
Autod
ock  
CatBa{[HB:1.59Å (OH1)-(O@COOGLU 122E)], [HB:1.52Å (OH2)-(O@COOH GLU 122E)], [HB:2.52Å (HO2)-
(H@NH2GLN 23D)], [MR:3.88Å (CH2GLY 121E)}; 
HDAC7b{[HB:1.69 (OH)-(O@COOASP 626A)],[MR:4.37Å (arPHE 738A)], [MR:4.39Å (COOH ASP 626A) ] ; 
HP-NCPa{[HB:2.22 (OH)-(O@COOGLU 64G)],[MR:2.83Å (COOGLU 64G)], [MR:4.19Å (COOGLU 61G) ]}  
Kinasea{[HB:1.96Å (H@OH1)-(O@COOH ASP 586A)], [HB:2.54Å (H@HO2)-(O@COOH ASP 586A)], 
[HB:3.02Å (O@HO2)-(H@COOH ASP 586A)], } 
Gold  
Gyrasea{[MR:4.48Å (COO GLU 50A)], } 
Top11b { [HB:2.11Å (O@OH)- (H@NH SER 128A)], [MR:3.97Å (CHSER 127A)], [MR:4.23Å (CO 
ASN 71A)]} 
TrxRb{ [HB:1.73Å (O@OH)-(H@NH2 ARG 166A)], [MR:3.67Å (NH2ARG 166A)]} 
TSa {[HB:1.11Å (O@OH1)-(H@NH2ARG 218A], [HB:2.30Å (O@OH
1)-(H@OH SER 219A], 
[HB:2.52Å (O@OH2)-(H@NH2ARG 23A)][MR:3.47Å (CH2ARG 23A)], [MR:3.20Å (NH2ARG 218A)]} 
4 
Autod
ock  
CatBa{[HB: 1.44 Å (NH2)-(O@COOH GLU 122E)], MR:3.23Å (CH2 GLY 29D)};  
Gyraseb{HB: 1.87 Å (OH)-(H@NH2 ASN 46A)], [MR:2.07Å (CH2ASN 46A)], [MR:4.17Å (CH3ILE 78A)]} 
HDAC7a{[MR:1.87Å (arPHE 679A)], [MR:3.73Å (im HIS 709A) ] } 
TSb {[HB:2.57Å (N@PTA)-(H@OH SER 219A], [MR:2.90Å (SH CYS 198A)], [MR:3.48Å 
(CH3LEU 195A)]} 
5 
 
 
Autod
ock  
HP-NCPa{[IT:2.90 (N@PTA)-(O@COOGLU 64G)],[MR:3.73Å (COOGLU 61G)]} 
Gyraseb{[HB:1.78Å (O@COO)-(H@NHVAL 120A)], [MR:4.41Å (COGLY 117A)], [MR:4.48Å (CH2GLY 
119A)]}; 
Top11a{[HB:2.08Å (O@COO)-(H@OHSER 128A)], [MR:3.18Å (COOGLU 134A)]} 
TrxRa{[HB:1.83Å (O@COO)-(H@NHSER 386A)], [MR:3.96Å (COGLY 38A)]} 
TSb {[HB:1.86Å (O@COO)-(H@SHCYS 198A], [HB:2.22Å (CO)-(H@NH ASP 221A], [MR:4.14Å 
(CH2GLY 225A)]} 
Gold 
rHAa {[HB:1.68Å (O@COO)-(H@NH2ASN 111A], [HB:2.08Å (O@COO)-(H@NH ASN 111A], 
[MR:3.20Å (CH2 GLN 33A)]} 
RNRb {[HB:1.86Å (O@COO1)- (H@NH GLU 623A)], [HB:1.98Å (O@COO1)- (H@NH THR 
624A)], HB:2.56Å (O@COO1) - (H@OH THR 624A)], HB:1.98Å (O@COO2)- (H@OH SER 
625A)], [IT:2.81Å (N@PTA)- (O@COPRO 621A], [MR:3.40Å (HOTHR 209A)]} 
6 Glide 
HP-NCPa{[MR:2.42Å (NH3 LYS 113H)]} 
Kinasea{[MR:3.01Å (NH ASP 593A) ]}  
8 Glide 
CatBa{[HB:1.96Å (H@H2O)-(O@COOGLU 122E)]} 
Gyrasea{[HB:1.67Å (H@H2O)-(O@COO ASP 49A)]} 
Top11a{[HB:1.83Å (H@H2O)- (O@OHSER 128A)], [HB:2.04Å (H@H2O)- (O@CO ASN 129A)], 
[IT:2.97Å (N@PTA)- (O@CO ASN 70A)], [MR:3.66Å (NH SER 128A)]} 
TSb{[HB:1.69Å (H@H2O)- (H@OHASP 257A)], [MR:3.73Å (OH SER 219A)]} 
9 Glide 
CatBb{[MR:3.09Å (CH2 GLY121E)], [MR:4.29Å (COOH GLY122E)]} 
TrxRb{[MR:3.42Å OH SER 199A]} 
10 Gold 
rHAb { [MR:1.55Å (CH3@S(CH3) MET 87A)]} 
TrxRa{ [MR:4.18Å (ar@ph TYR 200A)]} 
12 
Autod
ock   
Glide HDAC7
b{[HB:1.64Å (H@H2O)-(O@COOASP 626A)]} 
13 Glide 
HDAC7a{[MR:3.21Å (ar PHE 679A)], [MR:4.42Å (CH3 LEV 810A)]} 
Kinasea{[MR:3.33Å (ar PHE 582A) ], [MR:3.30Å (CH3ILE 462A) ] }  
Top11b{[MR:4.10Å (CH2ASN 70A)], [MR:3.78Å (CH3 ILE 104A)]} 
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15 Gold HDAC7b{[MR:2.80Å (arPHE 679A)], [MR:3.52Å (im HIS 709A) ]  
16 Gold 
HP-NCPb{[HB: 1.69Å(NH2@ar)-(O@COOH GLU 61G)]} 
Kinasea{[MR:4.24Å (ar TRP 530A) ], [MR:4.34Å (ar PHE 582A) ] }  
17 
 
 
 
 
 
 
Autod
ock  
HP-NCPa{[HB:2.044Å(OH@ar)-(O@COTHR 101G)]};  
rHAb {[HB:1.88Å (OH@ar)-(O@COPRO 113A], [HB:2.02Å (HO@ar)-(H@NH ARG 145A], [HB:2.11Å 
(HO@ar)-(H@NH LEU 115A], [HB:2.44Å (N@PTA)-(H@COOH GLU 425A]}; 
RNRb {[HB:1.89Å (HO@ar)-(H@NH SER 625A]} 
Top11b {[no HB and MR]} 
Glide 
Gyraseb{[MR:3.26Å (CH2 ILE 78A)], [MR:3.99Å (CH2 ASN 46A)]} 
Top11b{[HB:1.69Å (OH@ar)- (O@COASP 73A)], [MR:4.33Å (COO GLU 134A)]} 
rHAb {[HB:1.77Å (OH@ar)-(O@CO PRO 110A]} 
RNRa{[HB:1.80Å (OH@ar)- (O@OHSER 625A)], [HB:1.86Å (OH@ar)- (H@NHSER 625A)], 
[MR:4.08Å (H@OH THR 209A)]} 
TSa{[HB:2.63Å (OH@ar)- (H@NH3ARG 23A)], [MR:4.39Å (NH2 ASP 221A)], [MR:3.43Å (SH 
CYS 198A)]} 
19 Glide RNR
b{[HB andMR]} 
20 Gold Kinase
a{[MR:2.83Å (ar PHE 582A) ], [MR:3.46Å (CH3VAL 470A)] }  
 
21 
Autod
ock 
TrxRb {[HB:1.70Å (H@NH3)-(O
1@COOGLU 341A], [HB:2.32Å (H@NH3)-(O
2@COOGLU 341A)], 
[HB:1.70Å (H@NH3)-(O@COARG 293A], [MR: 3.26Å (COOGLU 341A)], [MR: 3.88Å (COOARG 
166A)], [MR: 4.09Å (NH3LYS 315A)]} 
Glide 
rHAa {[HB:1.74Å (O@COO1)-(H@NH2ARG 144A], [HB:2.03Å (O@COO
2)-(H@NH2ARG 145A], 
[HB:1.95Å (O@COO)-(H@OH GLU 141A]} 
TrxRa {[HB:2.62Å (H@NH3)-(O@CO VAL 291A], [HB:1.85Å (O@COO)-(H@NH ALA 198A], 
[MR:3.27Å NH2ARG 221A], [MR:3.81Å CH2ARG 226A]} 
The type of the interaction: MR(Metal-Receptor define for any receptor residue within the range of 4.50Å), HB(Hydrogen 
bond Interaction) and IT (interaction predicted to be also HB). The signs im (imidazole group), ar (arene group which in 
some residues like TRP is part of benzopyrole), @ (part of). The superscript ―a‖ and ―b‖ on each receptors indicate the 
ranking of the ligand as first and second respectively, while superscript ―1‖ and ―2‖ indicates first and second respectively 
of the same functional group that exist on a residue, {} separate different receptor, [] separate different interaction in the 
same receptor while () define the atom with its residue that is involved in the interaction. 
 
 
 
 
Table 3.97. The correlation of the docking result using Autodock, Gold and Glide Packages 
 
 
Autodock VS 
Gold 
Autodock VS 
Glide Gold VS Glide 
CatB 0.27 -0.50 0.10 
DNA-Gyrase 0.54 -0.32 -0.33 
HDAC7 -0.13 -0.33 -0.38 
HP-NCP 0.24 -0.17 -0.18 
KINASE 0.32 -0.17 -0.26 
rHA 0.45 -0.37 -0.20 
RNR 0.76 -0.32 -0.36 
topoII 0.41 -0.06 -0.11 
TrxR 0.32 0.13 0.07 
TS 0.42 -0.28 -0.46 
 
 
 
Table 3.98. The statistical results of the QSAR analysis called COMSIA of the Glide docked result.  
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Fact
ors  
 
gaus
s 
 
gaus
e 
 
gaus
h  gausa  gausd  S.D   R^2  
 R^2-
CV 
 R^2-
Scramb
le 
 
Stabilit
y  F   P 
CatB 1 0.53 0.15 0.22 0.06 0.05 0.33 0.85 0.41 0.39 0.66 
138.
8 1.83E-011 
DNA-
Gyrase 1 0.52 0.17 0.19 0.08 0.04 0.53 0.53 0.19 0.39 0.86 27.2 2.41E-005 
HDAC7 1 0.5 0.14 0.19 0.07 0.1 0.42 0.65 0.04 0.45 0.58 41.3 1.82E-006 
HP-NCP 1 0.59 0.14 0.19 0.04 0.03 0.42 0.71 0.35 0.38 0.77 58.5 6.88E-008 
KINASE 1 0.63 0.08 0.16 0.07 0.06 0.68 0.49 0.25 0.35 0.94 21.8 1.07E-004 
rHA 1 0.53 0.16 0.22 0.04 0.05 0.41 0.72 0.02 0.55 0.48 52.9 3.68E-007 
RNR 1 0.63 0.13 0.15 0.05 0.04 1 0.62 0.39 0.45 0.93 38.7 2.00E-006 
topoII 1 0.43 0.18 0.18 0.07 0.14 0.45 0.65 0.27 0.45 0.72 38.4 3.78E-006 
TrxR 1 0.48 0.15 0.23 0.08 0.06 0.32 0.8 0.03 0.55 0.31 92.6 1.57E-009 
TS 1 0.6 0.16 0.15 0.05 0.03 0.7 0.49 0.27 0.36 0.94 23.4 6.35E-005 
 
 
 
 
Table 3.99: The two best binding metallocomponds of each receptors from Molegro and Autodock 
showing the existing Hydrogen bond (HB) (in Å) and Metal-Residues (MR) interactions with 
binding site residues 
 
DNA-1 
Molegro metallocompound 10a {[HB: 2.39 O(COOH)i H(DC 18.B)], [HB: 1.91 H(COOH)ii 
N7(DG 16.B)]}; 
metallocompound 12 {[HB: 2.32 O(COOH) H(DA 17.B)], [HB: 1.44 H(COOH) 
O6(DG 7.A)]} 
Molegro-Constrain metallocompound 10a {[HB: 1.71 O(COOH)i H(DC 2.A)], [HB: 1.89 H(COOH)i 
O6(DG 23.B)], [HB: 1.66 H(H2O) O6(DG 23.B)], [HB: 2.01 H(H2O) N7(DG 23.B)], 
[MR 4.49 N7(DG 34.B)], [MR 4.60 N7(DA 22.B)]}; 
metallocompound 9a {[HB: 2.05 H(COOH)i O6(DG 23.B)], [HB: 2.02 H(COOH)ii 
OP2(DG 23.B)], [HB: 2.11 H(H2O)
 N7(DA 22.B)], [MR 4.60 N7(DA 22.B)]}; 
Autodock metallocompound 9a {[HB: 2.00 H(COOH)i OP1(DT 5.A)], [HB: 1.65 H(COOH)ii 
OP2(DA 15.B)]} 
metallocompound 4a {[HB: 1.81 H(NH2)
i
 OP1(DG 6.A)], [HB: 1.70 H(NH2)
ii
 
OP2(DG 7.A)], [MR 3.32 O(DG 6.A)], [MR 3.88 O(DG 6.A)]} 
DNA-2 Molegro Metallocompound 10a {[HB: 1.92 O(COOH)i H(DG 7.T)], [HB: 1.76 H(COOH)i 
O4(DT 8.T)], [HB: 2.16 H(COOH)ii O3(DC 9.T)]};  
metallocompound 1a {[HB: 1.75 H(COOH) O2(DC 8.P)], [HB: 2.12 H(H2O)
 O4(DT 
8.T)]} 
Molegro-Constrain metallocompound 12 {[HB: 1.57 H(COOH) O6(DG 5.P)], [HB: 2.50 O(COOH) 
H(DC 9.T)], [HB: 2.80 O(COOH) H(DA 6.P)], [MR 3.64 N7(DG 6.T)], [MR 4.21 
N7(DG 7.T)]}; 
metallocompound 1 {[HB: 1.95 N(arene) H(DA 6.P)], [MR 3.91 N7(DG 7.T)]} 
Autodock metallocompound 1a {[HB: 1.79 H(COOH) OP2(DG 6.T)]}; 
metallocompound 4a {[HB: 1.76 H(H2O) OP2(DG 7.T)], [HB: 1.96 H(NH2)
i O3(DG 
6.T)], [HB: 1.84 H(NH2)
i OP1(DG 6.T)]} 
CatB Molegro metallocompound 12 {[HB: 1.66 H(COOH) O(GLY 24 D)]} 
metallocompound 1 {[HB: 2.21 H(COOH) O(MET 196 E)]} 
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Molegro-Constrain metallocompound 1a {[HB: 3.28 N(arene) SG(CYS 29D)], [HB: 2.61 H(COOH) 
O(GLY 198E)], [MR 4.60 SG(CYS 29D)]} 
metallocompound 8a {[MR 4.60 SG(CYS 29D)]} 
Autodock metallocompound 10a {[HB: 2.99 O(COOH)i SG(CYS 29 D)], [HB: 2.76 O(COOH)i 
H(GLN 23 D)], [HB: 1.70 H(COOH)i OE1(GLN 23D)], [HB: 2.14 H(COOH)ii 
OE2(GLU 122D)]}; 
metallocompound 1a {[HB: 1.72 H(COOH) OE1(GLU 122 E)], HB: 1.72 H(COOH) 
OE2(GLU 122E)]} 
Gyrase Molegro metallocompound 10 {[HB: 2.17 H(COOH) O(ASP 73A)]} 
metallocompound 11 {[none]} 
Molegro-Constrain metallocompound 10a {[HB: 2.24 H(COOH)i OD2(ASP 49A)], [HB: 1.92 
H(COOH)ii O(GLY 117A)], MR: 4.60 ND2(ASP 46 A)]} 
metallocompound 9a {[HB: 1.50 H(H2O) OD1(ASP 46A)], [HB: 2.08 H(COOH)
i 
O(ASP 46A)], [HB: 1.84 H(COOH)ii O(ASP 45A)], MR: 4.27 ND2(ASP 46 A)]}; 
Autodock metallocompound 12 {[HB: 2.11 H(COOH) O(ASP 73A)], [HB: 1.81 H(COOH) 
O(ASP 73A)], [HB: 2.00 O(COOH) H(GLY 77A)]}; 
metallocompound 9a {[HB: 1.90 O(H2O) HD22(ASN 46A)], [HB: 1.63 H(COOH)
i 
O(LYS 103 A)], [HB: 2.05 O(COOH)ii H(ALA 100 A)], [HB: 1.65 H(COOH)ii 
O(ILE 94 A)], [HB: 2.14 O(COOH)
ii
 H(SER 121 A)]} 
 
HDAC7 
Molegro metallocompound 1 {[HB: 1.82 N(arene) H(imi@HIS 709A)], [HB: 1.87 O(COOH) 
H(imi@HIS 669A)]}; 
metallocompound 12 {[HB: 2.36 H(COOH) O(ASP 707A)]} 
Molegro-Constrain metallocompound 10a {[HB: 1.89 H(COOH)i O(GLY 678A)], [HB: 2.43 O(COOH)i 
H(CYS 680A)], [HB: 1.99 O(COOH)i HE2(HIS 669A)], [MR: 3.43 NE2(HIS 
709A)]} 
metallocompound 11 {[MR: 3.60 N(HIS 709A)]} 
Autodock metallocompound 1a {[HB: 1.63 H(COOH) OD1(ASP 626A)], [HB: 1.90 H(H2O) 
OD1(ASP 626A)]}; 
metallocompound 9a {[HB: 1.80 O(COOH)i H(PHE 738A)], [HB: 1.79 H(COOH)i 
O(PRO 809 A)]} 
HP-NCP Molegro metallocompound 1a {[none]} 
metallocompound 11 {[MR: 3.38 OE(GLU 56G)]} 
Molegro-Constrain metallocompound 10a {[HB: 1.75 H(COOH)i OE1(GLU 92 G)], [[HB: 2.17 
H(COOH)ii NE2(HIS 106 H)], [MR: 4.36 OE1(GLU 61 H)], MR: 4.44 NE2(HIS 106 
H)]} 
metallocompound 11 {[MR: 4.36 OE1(GLU 61 H)], [MR: 4.60 NE2(HIS 106 H)]} 
Autodock metallocompound 4a {[HB: 1.67 H(H2O) OE2(GLU 61 G)], [HB: 1.67 H(H2O) 
OE1(GLU 64G)]}; 
metallocompound 5a {[MR: 2.90 OE2(GLU 61 G)]} 
BRAF 
Kinase 
Molegro metallocompound 1a {[HB: 2.09 H(COOH) O(ASN 579A)]}; 
metallocompound 12 {[HB: 2.59 H(COOH) O(CYS 531A)], [HB: 1.66 O(COOH) 
H(CYS 531A)]} 
Molegro-Constrain metallocompound 1 {[HB: 2.04 N(arene) H(SER 535A)], [MR: 4.61 SG(CYS 531 
A)]} 
metallocompound 8 {[MR: 4.61 SG(CYS 531 A)]} 
Autodock metallocompound 4a {[HB: 1.91 H(NH2)
i OD2(ASP 478A)], [HB: 2.03 H(H2O) 
OD2(ASP 478A)], [HB: 1.84 H(NH2)
ii OE2(GLU 532A)], [HB: 1.94 H(H2O) 
OE2(GLU 532A)]}; 
metallocompound 5a {[none]} 
rHA Molegro metallocompound 10 {[HB: 2.24 O(COOH)i H(ARG 117A)], [HB: 2.05 O(COOH)ii 
H(ARG 186A)]}; 
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metallocompound 12 {[HB: 2.16 H(COOH) O(ASP 108A)], [MR: 4.27 O(SER 
193A)]} 
Molegro-Constrain metallocompound 10a {[HB: 2.12 H(COOH)i OE2(GLU 37A)], [HB: 1.68 
O(COOH)ii H(ARG 144A)], [HB: 1.82 H(COOH)ii O(GLN 33A)], [MR: 4.59 
NH1(ARG 144A)]} 
metallocompound 2 {[HB: 1.91 O(COO)i H(ARG 144A)], [HB: 1.91 O(COO)i 
H(ARG 144A)], [MR: 4.59 NH1(ARG 144A)]}; 
Autodock metallocompound 10 {[MR: 1.78 NZ(LYS 195A)], [MR: 4.52 NH2(ARG 222A)]}; 
metallocompound 4a {[HB: 1.85 H(H2O) OD2(ASP 38A)], [HB: 1.73 H(H2O) 
OH(TYR 84A)], [HB: 1.85 H(NH2)
i OD2(ASP 34A)]} 
RNR Molegro metallocompound 1a {[HB: 1.59 H(H2O) O(PRO 621A)], [HB: 1.98 H(COOH) 
OE1(GLU 441A)], [HB: 2.39 O(COOH) HD22(ASN 437A)]}; 
metallocompound 3 {[HB: 1.88 O(COO)i H(GLU 623A)], [HB: 1.92 O(COO)i 
H(SER 625A)], [HB: 2.34 O(COO)ii H(THR 209A)]} 
Molegro-Constrain metallocompound 1a {[HB: 2.22 H(COOH) O(SER 224B)], [MR: 4.17 SG(CYS 
439A)]}; 
metallocompound 10 {[HB: 2.27 H(COOH)i O(PRO 621A)], [HB: 2.16 H(COOH)ii 
O(SER 224A)], [MR: 4.26 S(CYS 439A)]} 
Autodock metallocompound 1a {[HB: 1.68 H(COOH) OE1(GLU 623A)], [HB: 2.00 O(H2O) 
H(ARG 639A)], [MR: 3.69 NH2(ARG 639A)]}; 
metallocompound 12 {[HB: 2.60 O(COOH) H(GLU 623A)], [HB: 1.95 O(COOH) 
N(SER 625A)], [HB: 2.02 O(COOH) HG(SER 625A)], [HB: 1.77 H(COOH) 
OG1(THR 209A)]} 
TopII Molegro metallocompound 1 {[HB: 2.15 H(COOH) O(GLN 365B)], [HB: 3.38 O(COOH) 
O(THR 27A)]} 
metallocompound 10 {none}; 
Molegro-Constrain metallocompound 10a {[HB: 2.47 H(COOH) O(ILE 15A)], [MR: 4.60 NE2(HIS 
20B)]}; 
metallocompound 1a {[MR: 4.60 NE2(HIS 20B)]} 
Autodock metallocompound 5 {[HB: 2.21 O(COO) H(GLY)], [HB: 2.57 O(COO) NH2(GLN 
365A)], [HB: 2.53 O(COO) NH3(LYS 367A)], [HB: 2.09 O(COO) H(ASN 142A)], 
[HB: 2.37 O(COO) H(ARG 141A)]}; 
metallocompound 9a {[HB: 1.90 H(COOH)i OD1(ASN 70A)], [HB: 1.88 O(COOH)i 
HZ1(LYS 147A)], [HB: 1.85 H(COOH)ii OD1(ASN 129A)], [HB: 2.15 O(COOH)ii 
HD21(ASN 129A)]} 
TrXR Molegro metallocompound 10 {[HB: 1.77 O(COOH)i O(ALA 198A)], [HB: 2.60 O(COOH)ii 
H(ARG 166A)], [HB: 2.19 O(COOH)ii H(ARG 166A)]}; 
metallocompound 1 {[HB: 2.14 H(COOH) O(SER 222A)], [HB: 1.75 O(COOH) 
OH(SER 222A)]} 
Molegro-Constrain metallocompound 9a {[HB: 2.27 O(COOH)i HZ1(LYS 67A)], [HB: 2.10 H(COOH)ii 
O(THR 373A)], [MR: 3.59 SG(CYS 64A)], [MR: 4.60 SG(CYS 59A)]} 
metallocompound 8a {[HB: 1.63 H(COOH) OD2(ASP 334A)], [HB: 2.11 O(COOH) 
HH21(ARG 293A)], [HB: 1.85 O(COOH) HE(ARG 293A)], [MR: 3.06 SG(CYS 
64A)], [MR: 4.60 SG(CYS 59A)]} 
Autodock metallocompound 5a {[HB: 1.96 H(NH2) O(GLU 341A)], [HB: 1.89 H(NH2) 
OH(TYR 200A)], [HB: 2.10 O(COO) H(THR 343A)], [HB: 2.13 O(COO) H(THR 
343A)], [HB: 2.02 H(H2O) OD1(ASP 334A)], [HB: 2.48 H(H2O) OD2(ASP 334A)]} 
metallocompound 12 {[HB: 1.69 H(COOH) O(GLU 341A)], [HB: 1.98 O(COOH) 
NH3(LYS 315A)], [MR: 3.47 H(LEU 340A)]}; 
TS Molegro metallocompound 12 {[HB: 2.22 H(COOH) O(SER 232A)]}; 
metallocompound 10 {[HB: 1.53 O(COOH) H(ASN 229A)]} 
Molegro-Constrain metallocompound 10a {[HB: 2.40 O(COOH) H(CYS 198A)], [HB: 1.86 O(COOH) 
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HH(TYR 146A)], [MR: 4.60 S(CYS 198A)]} 
metallocompound 1 {[HB: 2.13 H(COOH) O(SER 219A)], [HB: 2.70 O(COOH) 
H(ARG 218A)], [HB: 2.39 O(COOH) H(ARG 218A)], [HB: 2.38 O(COOH) 
H(ARG 23A)], [HB: 1.56 O(COOH) H(ARG 23A)], [MR: 3.55 S(CYS 198A)]}; 
Autodock metallocompound 9a {[HB: 1.82 H(COOH)i O(SER 219A)], [HB: 1.97 O(COOH)i 
H(ASP 221A)], [HB: 2.45 O(COOH)i HG(CYS 198A)], [HB: 2.08 O(COOH)ii 
HD21(ASN 229A)], [HB: 1.63 H(COOH)ii OE2(GLU 60A)]}; 
metallocompound 5a {[HB: 2.36 O(COO) HH(TYR 146A)], [HB: 1.71 H(H2O) 
OE1(GLU 60A)]} 
 
 
 
 
 
Table 3.100(a): The binding energy of the metallocompounds from the Autodock docking 
 
DNA-
1 DNA-2 CatB 
DNA_
Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
KINA
SE rHA  RNR  topoII TrxR TS 
1 -4.32 -3.3 -4.26 -3.68 -3.15 -3.44 -3.25 -3.45 -3.15 -3 -3.43 -3.03 
2 -2.47 -3.08 -3.38 -3.21 -2.64 -3.43 -3.79 -4.19 -3.71 -2.65 -3.35 -4.14 
3 -2.73 -2.5 -3.43 -3.49 -2.5 -3.82 -3.29 -3.91 -3.49 -3.84 -3.35 -3.7 
4 -4.67 -3.88 -3.98 -3.49 -3.92 -4.16 -3.65 -3.86 -2.85 -3.05 -3.21 -2.84 
5 -2.93 -2.7 -3.27 -3.01 -3.02 -3.54 -3.39 -3.62 -3.07 -4.08 -3.39 -3.21 
6 -2.29 -1.9 -1.24 -1.31 -1.77 -2.46 -2.37 -2.32 -2.45 -1.62 -2.19 -1.31 
7 -2.82 -2.79 -3.42 -3.38 -3.1 -2.59 -3.97 -3.97 -3.6 -3.47 -2.79 -2.96 
8 -2.24 -3.41 -2.92 -3.09 -2.59 -3.29 -3.39 -3.4 -3.25 -3.03 -3.43 -2.53 
9 -4.27 -3.73 -4.02 -3.24 -3.5 -3.63 -3.66 -3.34 -3.39 -3.1 -3.92 -3.67 
10 -5.13 -4.94 -5.19 -4.86 -3.78 -5.14 -4.48 -5.24 -4.03 -3.86 -4.24 -4.51 
11 -5.02 -3.81 -4.5 -3.68 -4.01 -3.85 -3.12 -2.98 -2.43 -2.19 -2.91 -3.65 
12 -5.97 -4.65 -5.77 -5.12 -5.1 -4.56 -4.37 -4.16 -4.19 -3.4 -4.31 -5.23 
13 -2.5 -2.44 -3.35 -2.94 -2.78 -2.84 -3.13 -3.38 -2.88 -2.88 -2.86 -2.78 
14 -3.04 -3.14 -3.55 -3.54 -2.72 -3.83 -3.41 -4.29 -3.52 -3.98 -3.79 -3.7 
15 -2.43 -2.56 -3.38 -3.1 -2.82 -3.05 -3.27 -3.39 -3.09 -3.13 -2.83 -2.96 
16 -1.63 -1.87 -2.23 -2.15 -1.66 -2.22 -2.08 -2.59 -2.41 -2.08 -2.11 -2.4 
cisplatin -2.23 -2.94 -2.15 -1.34 -1.98 -2.18 -2.56 -1.65 -1.93 -1.95 -2.4 -1.23 
co-crystallized 
compounds   -5.49 -8.68 -4.35    -7.01 -12.48 -4.79 -9.19 
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Table 3.100(b): The binding energy of the metallocompounds from the Autodock docking of hydrolytic 
complexes 
 DNA-1 DNA-2 CatB 
DNA_
Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
KINAS
E rHA  RNR  topoII TrxR TS 
1a -6.53 -5.65 -6.47 -4.67 -5.97 -4.95 -4.97 -4.04 -4.39 -3.16 -4.26 -4.9 
4a -6.85 -5.87 -6.29 -4.82 -5.55 -5.58 -5.27 -4.54 -3.16 -3.47 -4.23 -4.72 
5a -5.58 -4.75 -5.65 -4.55 -5.08 -5.26 -4.98 -4.33 -4.13 -3.96  -5.35 
6a -5.35 -3.6 -3.6 -2.3 -3.39 -4.51 -4.26 -2.6 -2.37 -2.38 -3.54 -2.96 
8a -6.44 -5.03 -5.78 -4.76 -5.25 -5.22 -3.96 -4.02 -3.02 -3.06 -2.98 -4.2 
9a -6.98 -5.96 -6.19 -5.03 -5.56 -5.05 -4.77 -3.3 -3.95 -4.07 -3.94 -6.09 
10a -6.38 -5.22 -6.7 -4.61 -5.21 -4.58 -4.03 -4.48 -3.49 -3.51 -4.17 -5.26 
13a -4.86 -4.06 -5.19 -4.05 -4.81 -4.29 -3.59 -3.74 -3.32 -3.65 -3.61 -3.39 
14a -4.39 -3.75 -4.84 -4.19 -4.59 -4.32 -3.33 -3.99 -3.65 -3.73 -3.76 -3.17 
15a -4.86 -4.03 -4.38 -3.8 -4.79 -4.27 -3.64 -3.41 -3.14 -3.6 -3.65 -3.05 
16a -4.12 -3.24 -3.1 -3.28 -3.75 -3.62 -3.1 -2.91 -2.16 -2.77 -2.65 -2.31 
Cisp-
W1 -4.31 -3.98 -2.1 -0.99 -2.55 -3.37 -3.25 -1.73 -1.04 -1.15 -2.63 -1.45 
Cisp-
W2 -4.92 -4.4 -2.15 -0.93 -2.76 -3.18 -3.47 -1.72 0.02 -0.33 -1.79 -1.2 
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Table 3.101(a): The binding energy of the metallocompounds from the relax Molgro docking 
 DNA-1 DNA-2 CatB Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
1 -137.57 -133.77 -136.37 -131.99 -166.09 -111.45 -118.79 -142.13 -126.87 -154.82 -137.87 -127.39 
2 -113.84 -106.15 -124.88 -110.82 -127.16 -94.13 -110.31 -113.18 -98.90 -121.50 -103.71 -114.61 
3 -116.96 -97.09 -114.43 -103.00 -110.06 -91.82 -105.79 -135.47 -124.93 -118.69 -104.43 -111.20 
4 -77.36 -77.97 -72.59 -79.89 -83.51 -68.21 -67.34 -85.02 -74.88 -74.75 -75.04 -75.89 
5 -71.22 -82.12 -78.61 -73.09 -90.05 -68.85 -74.96 -86.25 -83.41 -84.15 -82.63 -79.76 
6 -86.14 -81.39 -88.78 -84.63 -95.90 -75.53 -84.76 -97.60 -88.56 -92.57 -100.22 -79.41 
7 -87.95 -84.94 -93.69 -94.11 -102.98 -75.06 -99.78 -100.28 -92.07 -97.69 -106.18 -83.43 
8 -119.77 -111.18 -118.67 -110.79 -107.93 -96.84 -117.76 -126.06 -116.02 -115.67 -121.37 -111.59 
9 -124.03 -122.96 -125.25 -126.26 -131.56 -101.43 -115.00 -119.84 -106.90 -129.34 -119.82 -118.59 
10 -141.56 -126.74 -135.89 -142.43 -147.55 -107.85 -114.94 -147.15 -121.72 -129.66 -138.35 -129.75 
11 -143.11 -142.45 -131.53 -140.36 -157.61 -117.62 -114.61 -133.71 -114.68 -128.89 -121.04 -127.35 
12 -153.94 -129.90 -144.21 -138.83 -160.63 -104.74 -122.12 -142.37 -113.66 -129.13 -120.89 -135.47 
13 -62.98 -67.16 -83.32 -70.45 -90.53 -63.02 -73.54 -73.40 -74.49 -82.38 -70.73 -77.41 
14 -82.56 -85.26 -100.23 -85.99 -113.53 -71.41 -89.94 -97.88 -91.04 -102.67 -89.64 -85.02 
15 -66.45 -67.86 -89.21 -70.59 -101.13 -62.61 -74.58 -78.25 -81.13 -84.18 -78.17 -84.17 
16 -73.52 -76.16 -95.70 -80.20 -94.92 -71.53 -87.20 -87.77 -80.40 -93.80 -84.48 -87.89 
cisplati
n -47.86 -44.53 -38.09 -46.03 -45.22 -46.40 -39.91 -43.53 -40.83 -43.89 -38.82 -39.79 
co-
crystalli
zed 
compou
nds   -117.36 -162.48 -70.17  -121.74  -152.80 -192.15 -160.24 -106.57 
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Table 3.101(b): The binding energy of the metallocompounds from the relax Molgro docking for 
hydrolytic 
 
 DNA-1 DNA-2 CatB Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
1a -150.05 -145.76 -128.02 -136.31 -106.38 -129.59 -122.79 -137.56 -125.01 -84.25 -131.96 -127.11 
4a -94.36 -98.02 -77.65 -81.91 -81.50 -76.86 -61.37 -80.77 -73.66 -75.59 -87.09 -79.70 
5a -88.43 -96.33 -82.01 -76.01 -86.05 -75.74 -68.95 -87.31 -80.07 -82.79 -87.95 -86.37 
6a -100.04 -95.69 -91.02 -89.94 -96.65 -73.28 -85.05 -104.25 -86.02 -81.42 -99.80 -82.86 
8a -146.26 -127.46 -126.15 -136.28 -129.26 -113.66 -113.13 -129.33 -113.82 -116.42 -111.76 -118.85 
9a -144.54 -125.87 -123.34 -120.42 -90.58 -106.68 -109.38 -127.80 -106.99 -44.91 -131.76 -120.86 
10a -161.33 -145.84 -131.71 -142.22 -158.93 -113.82 -110.56 -121.54 -120.44 -79.33 -122.11 -126.24 
13a -77.52 -81.55 -90.06 -75.72 -94.57 -71.10 -71.20 -74.88 -80.32 -88.55 -71.37 -79.81 
14a -96.88 -106.30 -105.80 -99.03 -110.38 -80.03 -95.53 -86.14 -94.44 -106.7 -94.05 -86.26 
15a -84.66 -86.84 -91.02 -82.81 -101.74 -74.49 -74.40 -78.79 -83.59 -95.58 -80 -75.33 
16a -89.62 -89.80 -98.32 -85.32 -106.94 -81.19 -85.06 -90.37 -82.83 -99.96 -81.1 -84.77 
Cisp-
W1 -62.38 -58.09 -46.27 -50.24 -44.07 -44.94 -35.32 -44.08 -41.17 -42.72 -44.55 -42.56 
Cisp-
W2 -84.39 -70.95 -45.17 -57.47 -43.45 -42.73 -28.77 -37.91 -43.82 -42.74 -44.54 -41.68 
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Table 3.102(a): The binding affinities of the metallocompounds from the covalent constrain Molegro 
docking 
 
 DNA-1 DNA-2 CatB Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
1 -116.11 -128.23 -99.45 -107.80 -133.48 -95.08 -105.04 -27.44 -121.13 -43.60 -67.44 -110.86 
2 -97.80 -85.91 -82.34 -84.02 -74.26 -72.24 -10.28 -86.36 -99.26 -8.38 -14.82 -98.92 
3 -78.05 -72.06 -74.09 -72.94 -66.77 -76.14 -58.45 10.16 -90.08 -72.78 -40.92 -81.43 
4 -68.50 -61.59 -67.53 -50.22 -71.28 -61.87 -63.35 -43.68 -60.08 -38.15 -39.06 -54.89 
5 -61.04 -58.83 -63.33 -57.28 -76.44 -58.64 -70.82 26.31 -65.84 -44.97 -41.88 -61.54 
6 -71.93 -66.06 -72.19 -62.16 -94.46 -61.01 -65.64 -70.29 -71.03 -43.94 -47.54 -69.91 
7 -70.49 -65.18 -75.95 -67.76 -96.59 -67.18 -69.16 15.13 -75.00 -63.31 -53.38 -70.06 
8 -90.84 -88.44 -79.93 -82.66 -83.25 -81.53 -96.36 -2.29 -96.45 -49.40 -63.45 -102.19 
9 -111.80 -117.06 -99.06 -110.65 -87.96 -78.92 -79.57 -49.97 -104.49 -70.13 -62.38 -92.44 
10 -122.46 -117.40 -90.07 -90.46 -141.61 -102.69 -74.46 -88.52 -113.02 -47.87 -45.13 -99.57 
11 -124.47 -125.50 -111.86 -104.70 -144.86 -104.53 -92.96 -85.74 -107.52 -50.71 -91.01 -98.64 
12 -125.54 -129.90 -104.35 -107.26 -112.43 -97.12 -75.51 -66.29 -106.43 -8.28 -66.59 -91.48 
13 -49.78 -49.53 -60.05 -48.08 -55.13 -46.22 -59.27 -47.94 -62.99 -56.55 -28.91 -58.53 
14 -66.71 -68.14 -79.05 -65.58 -66.86 -51.48 -50.64 19.86 -77.96 0.00 -52.96 -78.21 
15 -54.61 -55.65 -64.40 -58.80 -58.83 -53.29 -63.23 -55.84 -64.54 -57.33 -36.73 -65.11 
16 -65.29 -64.79 -70.31 -68.07 -72.82 -58.20 -58.63 -66.45 -73.20 -37.72 -35.54 -71.26 
Cisplati
n -38.97 -34.23 -43.49 -33.31 -49.14 -29.06 -36.20 -26.49 -30.79 -35.58 -33.00 -30.63 
co-
crystalli
zed 
compou
nds   -132.12 -120.11 -73.24 -30.80 -94.68  -126.37 -115.68 -144.33 -95.40 
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Table 3.102(b): The binding affinities of the metallocompounds from the covalent constrain Molegro 
docking of hydrolytic complexes 
 DNA-1 DNA-2 CatB Gyrase 
HDAC
7 
HP-
NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
1a -126.70 -122.83 -127.33 -117.35 -99.20 -104.06 -86.78 -7.23 -113.75 -81.83 -101.44 -108.38 
4a -85.71 -72.54 -69.40 -65.33 -81.49 29.93 -59.98 36.01 -59.88 -39.37 -63.58 -53.49 
5a -77.64 -71.78 -68.57 -63.59 -86.11 -57.75 -67.38 29.87 -63.13 -47.71 -67.64 -64.37 
6a -94.75 -84.34 -81.49 -74.57 -96.64 -66.72 -64.99 24.66 -76.07 -54.41 -69.31 -73.20 
8a -128.21 -111.69 -110.41 -112.41 -129.27 -99.85 -92.82 -78.11 -110.43 -69.52 -103.76 -94.83 
9a -134.05 -125.46 -103.79 -119.20 -65.16 -81.50 -74.88 -52.63 -106.48 -68.35 -118.89 -100.43 
10a -135.60 -126.76 -116.86 -120.84 -158.92 -115.24 -72.50 -91.28 -110.44 -82.45 -84.59 -113.85 
13a -63.52 -63.46 -69.71 -57.52 -73.39 -60.84 -58.70 35.82 -67.58 -59.59 -33.43 -55.79 
14a -84.65 -78.01 -92.77 -69.23 -74.84 -60.37 -54.22 23.16 -82.70 -5.71 -11.37 -78.60 
15a -71.57 -68.76 -75.77 -66.29 -72.91 -66.99 -64.27 -37.41 -72.72 -66.08 -36.32 -62.97 
16a -74.70 -74.07 -73.81 -74.55 -72.88 -69.08 -60.26 -34.70 -76.95 -46.59 -42.19 -66.71 
Cisp-
W1 -62.37 -45.20 -40.91 -36.93 -43.65 -35.62 -32.23 -31.06 -35.91 -29.93 -34.13 -29.65 
Cisp-
W2 -78.38 -55.98 -34.03 -38.27 -43.46 -40.96 -29.51 -24.29 -32.68 -25.48 -32.34 -26.43 
 
 
 
Table 3.103: The docking results of metallocompounds with available experimental activities. 
 
CatB 
 Experiment Moldock-non Moldock-cons Autodock 
RAPTATh2o 1.5 -91.0243 -75.7655 -4.38 
RAPTACh2o 2.5 -105.798 -92.7676 -4.84 
CRAPTAC 5 -124.877 -82.3353 -3.38 
ORAPTAC 200 -114.427 -74.0878 -3.43 
RAPTABh2o 200 -90.0599 -69.7078 -5.19 
TrXR 
CRAPTAC 4.6 -103.714 -14.8246 -3.35 
ORAPTAC 32.5 -104.425 -40.9218 -3.35 
RAPTACh2o 37.1 -94.0454 -52.9618 -3.76 
RAPTATh2o 144 -80.0042 -36.727 -3.65 
RAPTABh2o 200 -71.3701 -28.9068 -3.61 
 
 
 
Table 3.104(a):The correlation of the factors that determine the biding interaction of the 
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metallocompounds with the receptors using Molgro docking (unconstrained cocking) 
 
 4DL7 CatB Gyrase HDAC7 HP-NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
E.Inter.pr
otein.liga
nd. 0.28 0.91 0.93 0.93 0.89 0.89 0.93 0.92 0.81 0.90 0.90 
E.Intertot
al 0.84 0.91 0.93 0.93 0.89 0.89 0.93 0.92 0.81 0.90 0.90 
E.Intra.st
eric. 0.12 0.42 0.39 0.46 0.68 0.49 0.66 0.58 0.45 0.31 0.55 
E.Intra.to
rs. 0.26 -0.01 -0.11 0.07 0.20 0.05 0.15 -0.11 -0.10 -0.53 0.14 
E.Intra.to
rs.ligand
atoms. 0.16 0.37 0.30 0.43 0.65 0.46 0.63 0.51 0.36 -0.01 0.52 
E.Intra.v
dw. -0.91 -0.77 -0.82 -0.79 -0.67 -0.65 -0.69 -0.50 -0.32 -0.58 -0.74 
Electro -0.35 0.22 0.45 -0.14 -0.07 -0.04 -0.12 0.61 -0.19 0.26 0.07 
ElectroL
ong -0.76 0.20 0.31 -0.08 -0.21 -0.06 -0.29 0.36 -0.20 0.53 0.51 
HBond -0.47 0.20 0.17 -0.44 0.03 -0.14 0.11 0.34 0.13 0.71 0.31 
HeavyAt
oms -0.71 -0.91 -0.82 -0.84 -0.80 -0.85 -0.76 -0.78 -0.52 -0.82 -0.84 
LE1 -0.13 -0.50 -0.20 -0.39 -0.21 -0.39 -0.11 -0.27 -0.23 -0.22 -0.30 
LE3 -0.11 -0.63 -0.39 -0.45 -0.43 -0.41 -0.42 -0.27 -0.40 -0.52 -0.11 
MW -0.51 -0.69 -0.65 -0.64 -0.60 -0.67 -0.54 -0.53 -0.13 -0.71 -0.56 
N -0.51 -0.57 -0.35 -0.63 -0.59 -0.49 -0.47 -0.63 -0.60 -0.64 -0.53 
NoHBon
d90 -0.35 0.19 0.15 -0.15 0.08 0.01 0.22 0.64 0.45 0.74 0.31 
PoseEner
gy 0.80 0.99 0.99 0.99 0.99 0.99 1.00 0.99 0.99 0.99 0.99 
RerankS
core 0.81 0.69 0.48 0.08 0.52 0.54 0.32 0.85 -0.23 0.38 0.53 
Steric 0.48 0.85 0.90 0.94 0.89 0.87 0.92 0.77 0.80 0.85 0.86 
Torsions -0.31 -0.31 -0.55 -0.20 -0.41 -0.45 -0.38 -0.65 -0.27 -0.70 -0.37 
VdW.LJ
12.6. 0.32 -0.01 -0.17 -0.30 -0.11 0.04 -0.29 0.35 -0.34 -0.37 0.20 
halogen 0.26 0.38 0.50 0.29 0.40 0.40 0.45 0.50 0.51 0.50 0.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.104(b):The correlation of the factors that determine the binding interaction of the 
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metallocompounds with the receptors using Molgro docking (constrained cocking) 
 
 4DL7 CatB Gyrase HDAC7 HP-NCP 
BRAF 
Kinase rHA RNR TopII TrXR TS 
E.Inter.pr
otein.liga
nd. -0.43 0.87 0.87 0.94 0.83 -0.17 0.31 0.89 0.67 0.52 0.85 
E.Intertot
al 0.82 0.87 0.87 0.94 0.83 -0.17 0.31 0.89 0.67 0.52 0.85 
E.Intra.st
eric. 0.15 0.32 0.25 0.67 0.71 -0.39 0.29 0.53 -0.04 -0.18 0.61 
E.Intra.to
rs. 0.30 0.14 -0.01 0.46 0.35 -0.05 -0.21 -0.21 -0.25 -0.51 -0.04 
E.Intra.to
rs.ligand
atoms. 0.21 0.31 0.22 0.68 0.70 -0.37 0.22 0.44 -0.09 -0.28 0.54 
E.Intra.v
dw. -0.71 -0.55 -0.79 -0.55 -0.65 -0.55 -0.43 -0.58 0.00 -0.71 -0.51 
E.SoftCo
nstraintP
enalty 0.14 0.15 0.46 -0.01 -0.37 0.76 0.89 NA 0.33 0.41 -0.45 
Electro 0.05 0.57 -0.33 -0.24 -0.07 -0.24 -0.10 0.19 0.06 -0.01 0.31 
ElectroL
ong -0.73 0.18 -0.33 0.16 0.72 0.17 0.08 -0.31 0.16 -0.33 -0.36 
HBond 0.04 0.10 0.42 0.12 0.10 0.15 0.25 0.53 0.17 0.62 0.34 
HeavyAt
oms -0.53 -0.71 -0.81 -0.47 -0.65 -0.37 -0.71 -0.84 0.15 -0.67 -0.82 
LE1 0.08 -0.10 -0.20 0.16 0.06 0.78 0.79 -0.14 0.72 0.40 -0.10 
LE3 -0.02 -0.15 -0.25 0.09 0.17 -0.42 -0.59 -0.54 0.45 -0.09 -0.47 
MW -0.39 -0.35 -0.67 -0.23 -0.40 -0.50 -0.75 -0.61 0.39 -0.57 -0.55 
N -0.26 -0.42 -0.38 -0.41 -0.49 -0.18 -0.43 -0.63 -0.08 -0.73 -0.57 
NoHBon
d90 0.36 0.40 0.47 0.30 0.13 0.21 0.24 0.70 0.18 0.70 0.31 
PoseEner
gy 0.83 0.99 0.99 0.99 0.99 1.00 0.99 0.99 0.99 0.99 0.98 
RerankS
core 0.07 0.05 0.10 0.25 0.66 -0.40 -0.45 0.34 0.46 -0.03 -0.02 
Steric -0.20 0.81 0.85 0.92 0.72 -0.19 0.25 0.87 0.64 0.54 0.79 
Torsions -0.25 -0.62 -0.55 -0.04 -0.16 -0.17 -0.62 -0.63 -0.17 -0.70 -0.51 
VdW.LJ
12.6. -0.11 -0.20 -0.23 0.08 0.48 -0.38 -0.44 -0.36 0.41 -0.17 -0.36 
halogen 0.37 0.44 0.38 0.35 0.45 -0.32 0.14 0.44 0.17 0.33 0.38 
 
 
 
 
 
 
 
Table 4.1: Assignment of the prominent IR picks of the ligands using the PED method 
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dmpz bdmpzm 
Freq Intensity Vibration Vibration Freq 
Intensit
y Vibration Vibration 
3589.12 58.84 υ(NH)  3007.49 24.96 υ(CH)  
3080.63 14.85 υ(CH)  2979.19 43.12 υ(CH)  
3039.59 15.12 υ(CH)  2979.69 31.47 υ(CH) υ(CH) 
3029.52 13.11 υ(CH)  2972.01 36.22 υ(CH) υ(CH) 
2979.22 32.22 υ(CH)  2968.49 32.95 υ(CH) υ(CH) 
2972.32 42.98 υ(CH)  1564.26 42.14 υ(CC) υ(CC) 
1574.91 41.03 υ(CC) β(HNN) 1560.38 42.94 υ(CC)  
1462.75 8.13 β(CNN) β(HCH) 1446.85 19.42 β(CNN) β(HCH) 
1450.17 6.67 β(HCH) τ(HCCC) 1444.59 32.48 β(CNN) β(HCH) 
1438.24 5.59 β(HCH) τ(HCCC) 1424.05 37.84 β(HCH) β(HCH) 
1437.84 12.07 β(HCH) τ(HCCN) 1414.81 26.55 β(HCH) β(HCH) 
1409.03 36.57 β(CNN) β(HCH) 1413.02 45.24 β(HCH) β(HCH) 
1270.94 16.64 υ(NC) β(HNN) 1392.69 19.24 υ(NC) β(HCN) 
1159.57 14.56 υ(NN) υ(NC) 1343.57 55.23 β(HCH) τ(HCNC) 
981.5 16.75 β(CNN) τ(HCCC) 1294.06 110.65 υ(NC) β(HCN) 
764.89 43.89 τ(HCCC)  1251.9 37.26 υ(NC)  
656.84 4.66 τ(CNNC)  792.24 20.33 υ(CC) υ(CC) 
631.81 25.35 τ(CCNN)  760.76 24.87 τ(HCCC) τ(HCCC) 
453.74 45.71 τ(HNNC)  760.33 24.34 τ(HCCC) τ(HCCC) 
175.21 4.78 ο(CCNC)  666.26 26.51 β(CNN) β(CNN) 
bdmpza bdcpzm 
3629.27 65.03 υ(OH)  3645.72 97.92 υ(OH)  
2987.94 25.11 υ(CH)  1791.4 199.66 υ(OC)  
2981.16 35.35 υ(CH) υ(CH) 1780.25 376.25 υ(OC)  
2979.61 60.08 υ(CH) υ(CH) 1771.02 324.55 υ(OC)  
1774.89 212.51 υ(OC)  1752.4 224.79 υ(OC)  
1565.7 45.07 υ(CC) β(HCC) 1432.98 68.69 β(CNN) τ(HCNC) 
1562.87 45.09 υ(CC) β(HCC) 1327.66 89.51 υ(NN)  
1418.12 53.16 β(HCH) β(HCH) 1285.01 237.63 υ(OC) β(HOC) 
1412.14 52.72 β(HCH) β(HCH) 1272.6 188.17 υ(OC) β(HOC) 
1385.44 33.5 υ(NC)  1262.45 139.57 υ(NN) β(HOC) 
1382.52 29.6 υ(CC) τ(HCCO) 1237.44 369.46 υ(CC) β(HOC) 
1295.36 172.05 υ(NC) τ(HCCO) 1225.77 432.86 υ(OC) β(HOC) 
1204.93 26.43 υ(NC) β(CNN) 1204.6 100.07 υ(NN) β(HCN) 
1161.02 35.66 υ(NN)  1125.64 238.72 β(HOC) β(HCC) 
1102.19 177.16 υ(OC) β(HOC) 1102.65 107.68 υ(OC) β(HCC) 
855.36 40.86 υ(CC) υ(NC) 1083.83 75.29 υ(OC) β(HCC) 
814.87 41.6 β(CCN) ο(CNNC) 1066.37 69.13 υ(OC)  
738.61 30.95 υ(CC) β(CNN) 500.48 123.33 τ(HOCC)  
664.37 103.74 τ(HOCC)  457.1 86.89 β(OCO) τ(HOCC) 
368 
605.52 30.88 β(OCO) τ(CCNN) 448.41 64.62 β(OCC) β(OCC) 
Greek letters υ, β, τ, ο denote stretching, bending, tortion and out of plane modes respectively 
 
 
Table 4.2: The experimental H- and C-NMR shift in ligands bdmpzm and bdmpza 
 
1
H-NMR (dmso-d6)
 1
H-NMR (CHCl3-d, 250.00 MHz) 
dmpz   bdmpzm   bdmpza 
2.11 (s, 3H, C3CH3) 2.44 (s, 6H, 
C3CH3)  
1.703 (1.94) (s, 6H, C3CH3) [[Díez-
Barraetal2002]] 
2.11 (s, 3H, C5CH3)  2.44 (s, 6H, 
C5CH3)  
2.21 (2.21) (s, 6H, C5CH3) [[Díez-
Barraetal2002]] 
5.73 (s, H, H4) 5.86 (s, 2H, H4) 5.88 (5.82) (s, 2H, H4) [[Díez-
Barraetal2002]] 
11.99 (s, H, H1) 6.13, 7.27  (s, 2H, CH2)  7.27 (7.27) (s, 1H, CHCOOH) 
[[Burzlaffetal2001]] 
     7.45  (s, 1H, COOH) 
  
13
C- NMR (CHCl3-d, 62.5 MHz) 
  11.13, 
13.54 
(CH3)  11.42, 12.03, 
13.54 (11.40, 
14.50) 
(CH3) 
[[Burzlaffetal2001]] 
  60.46 (CH2)   
  106.78, 
140.46, 
148.58 
(Cpz) 104.37, 
106.78, 144.37, 
147.98 
(Cpz) 
    169.71 (165.90) (CO2H) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3: The computed H-NMR shifts from the direct subtractions of TMS isotropic and from fitting 
equation 
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dmpz bdmpzm bdmpza bdcpzm 
 direct fitted  direct fitted  direct fitted  direct fitted 
H8 2.291 2.745 H16 2.35 2.8 H19 5.96 6.31 H24 6.89 7.21 
H9 2.141 2.599 H17 5.94 6.29 H20 2.06 2.52 H25 6.56 6.88 
H10 2.13 2.59 H18 2.05 2.51 H21 1.65 2.12 H26 7.03 7.34 
H11 5.99 6.33 H19 1.68 2.15 H22 2.14 2.6 H27 6.46 6.78 
H12 2.14 2.6 H20 2.11 2.57 H23 5.97 6.31 H28 6.29 6.63 
H13 2.2 2.66 H21 5.96 6.3 H24 2.13 2.59 H29 5.76 6.11 
H14 2.16 2.62 H22 2.16 2.62 H25 2.1 2.56 H30 7.39 7.69 
H15 8.68 8.94 H23 2.1 2.56 H26 2.01 2.47 H31 6.34 6.68 
   H24 2.28 2.74 H27 2.26 2.71    
   H25 2.05 2.51 H28 2.52 2.97    
   H26 2.2 2.66 H29 2.24 2.69    
   H27 2.23 2.69 H30 7.37 7.67    
   H28 1.99 2.45 H31 6.53 6.86    
   H29 2.29 2.75 H32 2.19 2.65    
   H30 5.62 5.97 H33 2.37 2.82    
   H31 6.12 6.46 H34 2.23 2.69    
 
 
 
Table 4.4: The computed C-NMR shifts from the direct subtractions of TMS isotropic and fitted 
equation 
 
dmpz bdmpzm bdmpza bdcpzm 
 direct fitted  direct fitted  direct fitted  direct fitted 
C1 15.67 6.747 C1 102.5 90.36 C1 104.8 92.66 C4 151.7 137.7 
C3 147.8 134 C2 13.42 4.575 C2 14.52 5.637 C5 109.1 96.77 
C5 101.1 89.08 C3 15.41 6.499 C3 15.24 6.332 C6 154.3 140.2 
C6 134 120.7 C4 137.2 123.7 C4 139.6 126.1 C7 138.5 125 
C7 11.87 3.082 C5 148.1 134.3 C5 148.4 134.5 C8 109.4 97.09 
   C6 104.4 92.22 C6 105.9 93.66 C11 130 117 
   C7 12.78 3.967 C7 12.98 4.155 C13 143 129 
   C8 135.9 122.6 C8 137.9 124.4 C14 153 139 
   C9 15.35 6.435 C9 15.18 6.276 C15 141 127 
   C10 145 131 C10 146 132 C16 155 141 
   C15 63.1 52.5 C16 78.5 67.2 C21 68 57.1 
      C17 166 152    
 
 
Table 4.5:The four Ramsey terms of the N-N bonds in the ligands 
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dmpz 
 FC SD PSO DSO J 
*N2-N4 -4.957 -0.039 -1.046 0.024 -6.018 
bdmpzm 
N11-*N12 -5.306 -0.028 -1.095 0.031 -6.398 
N13-*N14 -5.120 -0.037 -0.155 0.031 -6.182 
*N12···*N14 0.081 -0.001 -0.002 0.004 0.081 
bdmpza  
N12-*N13 -5.483 -0.029 -1.054 0.033 -6.534 
N14-*N15 -5.156 -0.036 -1.009 0.032 -6.169 
*N13···*N15 0.039 0.000 -0.003 0.004 0.039 
bdcpzm 
N18-*N20 -4.341 -0.005 -1.510 0.032 -5.824 
*N19-N17 -4.901 -0.010 -1.462 0.033 -6.339 
*N19···*N20 0.112 0.000 -0.001 0.007 0.116 
The N atoms with superscript ―*‖ represent the lone pair centre for the metal coordination  
 
 
 
 
Table 4.6: The bonds properties of the four ligands 
 
Bonds 
GBL_I 
(au) 
BPL - 
GBL_I (r) 2(r)  V G 

Ven V/G 
dmpz          
*N2 - N4 2.570 1.02E-03 0.360 -0.671 0.128 -0.557 0.194 13.189 2.863 
bdmpzm          
N11 - *N12 2.577 8.71E-04 0.357 -0.652 0.127 -0.553 0.195 18.473 2.836 
N13 - *N14 2.582 5.42E-04 0.355 -0.643 0.132 -0.546 0.193 17.834 2.835 
bdmpza          
N14 - *N15 2.592 4.55E-04 0.351 -0.628 0.133 -0.537 0.190 19.486 2.826 
N12 - *N13 2.590 6.24E-04 0.352 -0.630 0.129 -0.540 0.191 19.751 2.824 
bacpzpm          
N17 - *N19 2.537 1.24E-03 0.375 -0.705 0.134 -0.598 0.211 25.172 2.835 
N18 - *N20 2.532 9.13E-04 0.378 -0.726 0.138 -0.603 0.211 25.088 2.860 
 
 
 
 
Table 4.7: The QTAIM and NBO properties of the nitrogen atoms that are available (*N) and not 
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available (N) for metal coordination. 
 
Atom  q(A) 
|intra(
A)|
bond(
A)| |(A)| 
Vol(A
),0.00
1
Intra_Is
o(A)
bond_Is
o(A)
Iso(A
) zz(A)
Iso(A,
A)
Iso(A'
,A)
Iso(A
) 
Anisot
ropy Occ 
Energ
y 
dmpz                
*N2 -0.70 0.78 0.98 1.19 119.04 -3.98 -3.91 -7.90 -14.20 -55.57 11.55 -44.01 
295.5
7 
1.946
15 
-
0.388
47 
N4 -0.84 0.60 0.81 0.21 92.40 -4.43 -4.60 -9.03 -13.75 53.52 12.24 65.76 94.68 
1.581
42 
-
0.253
92 
Total 0.00 4.28 3.43 3.06 
952.3
3 -32.62 -32.93 -65.55 -89.63 
620.5
2 
169.7
7 
790.2
9 
849.4
6   
bdmpz
m                
N11 -0.816 0.564 0.809 0.271 
69.56
5 -3.331 -5.397 -8.728 
-
12.46
7 
37.56
8 
12.92
8 
50.49
6 
116.54
93 
1.567
8 
-
0.256
69 
*N12 -0.698 0.769 0.986 1.142 
115.45
1 -3.695 -3.877 -7.572 
-
11.987 
-
62.46
7 11.339 
-
51.12
8 
294.8
341 
1.945
46 
-
0.389
88 
N13 -0.810 0.561 0.809 0.282 
70.71
3 -3.367 -5.211 -8.578 -7.438 
35.20
6 13.119 
48.32
5 
113.75
68 
1.566
63 
-
0.248
96 
*N14 -0.707 0.774 0.989 1.171 
116.23
9 -3.681 -3.916 -7.597 -6.661 
-
69.65
1 11.219 
-
58.43
2 
252.5
809 
1.946
18 
-
0.389
05 
Total 0.000 8.882 7.083 6.257 
1923.
584 
-
64.15
4 
-
71.12
4 
-
135.2
78 
-
144.8
12 
1300.
711 
350.2
16 
1650.
927 
1704.
9506   
bdmpz
a                
N12 -0.797 0.558 0.750 0.216 
68.78
2 -3.431 -5.208 -8.638 
-
10.69
9 
42.14
3 
12.61
3 
54.75
7 
107.6
403 
1.581
65 
-
0.265
22 
*N13 -0.706 0.766 1.016 1.145 
114.50
5 -3.587 -3.847 -7.434 
-
10.43
3 
-
70.14
2 11.171 
-
58.97
1 
266.5
736 
1.945
9 
-
0.398
75 
N14 -0.797 0.552 0.772 0.246 
67.97
1 -3.386 -5.156 -8.541 -6.152 
34.36
1 
12.91
8 
47.27
9 
110.36
55 
1.575
31 
-
0.251
83 
*N15 -0.720 0.773 1.013 1.179 
115.67
1 -3.703 -3.885 -7.589 -5.217 
-
68.28
7 11.233 
-
57.05
3 
240.2
67 
1.946
28 
-
0.393
73 
Total 0.000 
10.39
1 11.077 8.396 
2149.1
19 
-
75.75
9 
-
75.08
2 
-
150.8
41 
-
148.6
98 
1318.
551 
370.5
33 
1689.
083 
2476.
2381   
bdcpz
m                
N17 -0.756 0.540 0.747 0.287 
68.06
0 -3.110 -5.514 -8.623 
-
13.08
4 
27.88
9 
13.09
9 
40.98
8 
135.3
961 
1.522
97 
-
0.313
78 
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N18 -0.744 0.533 0.708 0.236 
66.44
9 -3.049 -5.408 -8.458 -5.950 
19.93
3 
13.13
3 
33.06
6 
146.3
104 
1.513
1 
-
0.313
74 
*N19 -0.590 0.705 0.821 0.976 
106.6
63 -2.900 -4.097 -6.997 
-
12.40
3 
-
86.52
3 
12.31
5 
-
74.20
8 
365.0
761 
1.945
36 
-
0.443
07 
*N20 -0.575 0.702 0.819 0.974 
107.6
57 -2.685 -4.037 -6.722 -4.822 
-
108.5
64 11.575 
-
96.98
9 
359.7
227 
1.946
03 
-
0.449
13 
Total 0.000 
13.24
1 
21.04
0 
13.19
5 
2253.
555 
-
86.53
0 
-
67.76
9 
-
154.2
98 
-
163.6
30 
694.6
06 
284.5
39 
979.1
45 
4947.
7465   
 
 
 
Table 4.8: The Laplacian of electron density and the NMR J_coupling of the intramolecular H-bonding 
in the ligands 
 
bdmpzm   bdmpza   bdcpzm   
 (r) J_Coupling  
(r) J_Coupling  
(r) J_Coupling 
N11···H19 0.022 3.30E-002 C2···C17 0.034 2.49E-002 O2···H30 0.052 -5.10E-002 
H24···H28 0.017 7.13E-001 
O11···H2
8 0.022 -3.07E-001 O9···H30 0.037 -3.37E-001 
   
N12···H2
1 0.024 3.99E-002    
   
O18···H3
2 0.028 -1.91E-001    
   
H28···H3
3 0.025 7.86E-001    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.9: The electronic excitation of the ligands showing their triplet and singlet transitions 
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dmpz 
  f transitions 
Triplet-A 298.67 0 HOMO→L+1 (116%), H-1→L+5 (4%), HOMO→L+5 (3%),  
Triplet-A 249.49 0 H-1→L+1 (102%), H-1→L+7 (2%), HOMO→L+5 (3%),  
Triplet-A 224.30 0 HOMO→LUMO (98%),  
Singlet-A 222.61 0.0001 HOMO→LUMO (98%),  
Singlet-A 214.55 0.0001 H-1→LUMO (96%),  
Singlet-A 213.36 0.0241 H-1→L+1 (61%), HOMO→L+5 (18%), HOMO→L+1 (2%), HOMO→L+4 (5%), 
 bdmpzm  
Triplet-A 303.69 0 H-2→L+1 (98%), H-2→LUMO (2%), H-2→L+2 (2%), H-2→L+3 (2%), 
Triplet-A 302.55 0 H-1→L+2 (11%), HOMO→L+2 (76%), H-3→L+2 (2%), H-2→L+1 (2%), 
Triplet-A 261.18 0 H-3→L+1 (57%), H-1→L+1 (21%), HOMO→L+1 (20%), H-3→L+2 (2%), 
Singlet-A 256.50 0.0028 HOMO→LUMO (83%),  
Singlet-A 228.08 0.0033 H-1→LUMO (86%), HOMO→L+1 (3%),  
Singlet-A 227.46 0.0092 H-2→LUMO (55%), HOMO→L+1 (34%), H-1→LUMO (4%),  
 bdmpza 
Triplet-A 311.63 0 HOMO→LUMO (30%), HOMO→L+4 (65%), H-2→L+4 (2%), HOMO→L+1 (3%), 
Triplet-A 308.62 0 H-2→L+1 (14%), H-2→L+2 (88%), H-3→L+8 (2%), H-2→L+3 (3%), 
Triplet-A 281.41 0 H-1→LUMO (81%), HOMO→LUMO (10%), H-6→LUMO (2%), H-1→L+4 (4%), 
Singlet-A 279.59 0.0005 HOMO→LUMO (95%), H-1→LUMO (4%),  
Singlet-A 272.98 0.027 H-1→LUMO (92%), HOMO→LUMO (4%),  
Singlet-A 268.01 0.0003 H-2→LUMO (96%),  
bdcpzm  
Triplet-A 352.51 0 H-4→LUMO (24%), H-2→LUMO (10%), H-1→L+1 (23%), HOMO→L+1 (31%), 
Triplet-A 351.31 0 H-4→LUMO (33%), H-2→LUMO (18%), H-1→L+1 (17%), HOMO→L+1 (24%), 
Triplet-A 299.77 0 H-1→L+1 (35%), HOMO→L+3 (36%), H-5→L+1 (8%), H-4→L+1 (9%), 
Singlet-A 298.17 0.0031 H-1→L+1 (17%), HOMO→LUMO (12%), HOMO→L+1 (14%), HOMO→L+3 
(20%), 
Singlet-A 286.59 0.0003 H-7→LUMO (17%), H-3→LUMO (11%), H-2→LUMO (10%), HOMO→LUMO 
(23%), 
Singlet-A 282.21 0.0099 H-6→L+1 (23%), H-5→L+1 (10%), H-1→L+1 (20%), HOMO→L+1 (12%), 
 
 
 
 
 
 
 
 
 
Table 4.10: The molecular orbital (MO) contribution of the nitrogen atom(s) ―*N‖ available for metal 
374 
coordination and nitrogen atom ―N‖ in dmpz not available for metal coordination.  
 
 
dmpz 
MO eV *N2 N4 others 
L+5 1.03 11 0 89 
L+4 1.02 3 -5 104 
L+3 0.76 26 -37 112 
L+2 0.52 15 -54 140 
L+1 0.27 21 21 58 
LUMO -0.08 -104 13 191 
HOMO -6.49 38 3 59 
H-1 -6.7 1 28 71 
H-2 -7.84 70 9 22 
H-3 -9.93 4 1 96 
H-4 -10.49 8 5 88 
H-5 -10.61 9 23 69 
H-6 -11.13 1 7 92 
H-7 -11.4 6 3 91 
bdmpzm 
MO eV *N12 *N14 others 
L+5 0.51 3 53 44 
L+4 0.42 15 9 75 
L+3 0.36 5 -19 115 
L+2 0.21 10 17 74 
L+1 -0.05 18 -1 83 
LUMO -0.28 -40 -32 174 
HOMO -6.38 2 28 70 
H-1 -6.53 1 6 93 
H-2 -6.64 35 2 63 
H-3 -6.84 1 2 98 
H-4 -7.78 15 53 32 
H-5 -7.91 50 14 36 
H-6 -9.86 0 3 97 
H-7 -10.01 3 1 96 
bdmpza 
MO eV *N13 *N15 others 
L+5 0.39 -4 -29 135 
L+4 0.2 0 18 83 
L+3 0.09 -9 0 111 
L+2 -0.22 24 -3 80 
L+1 -0.45 -11 -9 122 
LUMO -1.24 9 1 91 
HOMO -6.46 2 34 64 
H-1 -6.61 1 1 98 
375 
H-2 -6.82 35 2 63 
H-3 -7.05 0 1 99 
H-4 -7.91 2 63 35 
H-5 -8.09 63 3 34 
H-6 -8.59 2 1 97 
H-7 -9.67 0 0 100 
bdcpzm 
MO eV *N20 *N19 others 
L+5 -0.88 -18 0 120 
L+4 -1.03 4 -40 137 
L+3 -1.82 0 8 92 
L+2 -2.08 12 1 87 
L+1 -2.48 0 19 81 
LUMO -2.74 19 0 81 
HOMO -8.12 0 13 86 
H-1 -8.22 2 10 87 
H-2 -8.42 7 2 91 
H-3 -8.5 1 0 98 
H-4 -8.56 18 1 81 
H-5 -8.76 1 2 97 
H-6 -8.86 1 12 88 
H-7 -9.07 2 0 97 
 
 
 
 
Table 4.11: The non-linear conductive properties of the ligands 
 
 Dipole      
 ß in esu 
(1x10-30) HOMO LUMO 
Gap in 
KJ/mol 
Non-
Valence 
Lewis 
Orbitals 
dmpz 2.61 74.42 -21.68 40.15 570.80 -43.15 0.34 -0.23835 -0.0029 618.28 1.87% 
bdmpzm 4.02 162.68 10.35 61.51 1838.25 -4.98 1.36 -0.2345 -0.0103 588.78 1.84% 
bdmpza 3.59 182.12 6.52 52.67 1365.72 -6.60 2.47 -0.2374 -0.0455 503.87 1.83% 
bdcpzm 3.42 196.10 -22.50 88.84 3692.83 -8.99 1.31 -0.2984 -0.1006 519.29 2.23% 
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Table 4.12: Assignment of the prominent IR picks of the ligands using the PED method 
pz bpzm 
3601.64 74.41 υ(NH)  3003.03 25.78 υ(CH) υ(CH) 
3203.74 1.7 υ(CH) υ(CH) 1516.54 19.02 υ(CC)  
3193.24 2.19 υ(CH) υ(CH) 1507.74 21.96 υ(CC) β(HCC) 
1518.85 5.49 β(HNN) υ(CC) 1436.15 24.83 υ(NC) β(HCC) 
1444.72 6.06 β(HNN) υ(NC) 1409.7 10.65 υ(NC) β(CNN) 
1401.82 10.65 β(HCN) υ(NC) 1404.78 27.48 υ(NC) β(CNN) 
1341.32 3.61 β(HCC) υ(NC) 1349.45 75.51 τ(HCNC)  
1245.72 3.32 β(HNN) β(HCN) 1312.28 47.45 υ(NC) τ(HCNC) 
1154.22 0.83 β(HCC) υ(NN) 1299.08 33.65 υ(NC) υ(NC) 
1124.08 17.65 β(HCN) υ(NC) 1205.13 22.97 β(HCC) β(HCN) 
1031.5 11.21 β(HCC) β(CNN) 1189.67 21.56 β(HCN)  
1024.07 36.48 β(HCC) β(CNN) 1082.75 21.57 β(HCC) β(NNC) 
908.49 3.33 β(CCN) β(CNN) 1078.25 19.56 β(HCC) β(CNN) 
886.66 7.58 β(CNN)  1045.82 19.31 β(HCC)  
848.44 7.16 τ(HCNN)  1033.64 30.12 υ(NN) β(HCC) 
795.2 15.77 τ(HCNN)  958.08 15.84 υ(NN) β(CNN) 
716.49 103.29 τ(HCCN)  759.18 28.62 υ(NN) β(NCN) 
668.81 18.72 τ(CCNN)  732.76 53.57 υ(NC) β(NNC) 
509.76 52.85 τ(HNNC)  720.53 44.07 τ(HCCN)  
    717.43 74.71 τ(HCCN)  
bpza bpzpya  
3617.19 67.3 υ(OH)  1773.99 246.25 υ(OC)  
1761.24 201.93 υ(OC)  1590.32 109.86 υ(CC) β(HCC) 
1511.96 24.72 υ(CC) β(HCC) 1576.91 288.13 υ(CC)  
1404.28 36.29 υ(NC) β(CCN) 1523.44 89.91 υ(CC)  
1398.39 39.14 υ(NC) β(CCN) 1520.84 102.81 υ(CC)  
1363.89 49.98 υ(OC) β(HCC) 1469.66 47.37 υ(NC)  
1303.66 111.35 υ(NC) υ(NC) 1429.18 299.82 υ(NC)  
1269.37 24.85 υ(NC) β(HOC) 1402.85 338.61 υ(NC) β(CCN) 
1197.96 53.15 υ(NN) β(HCN) 1398.32 192.84 υ(CC)  
1188.49 40.96 β(HOC) β(HCN) 1362.55 50.55 υ(CC) β(HCC) 
1102.94 234.02 υ(OC) β(HOC) 1266.95 325.58 υ(OC) β(HOC) 
1076.39 29.98 υ(NC) β(HCC) 1255.47 92.5 υ(CC) β(HOC) 
1033.2 38.2 υ(NN) β(HCC) 1241.24 84.13 υ(NN) β(HCC) 
819.44 30.4 β(CNN) ο(CNNC) 1145.19 60.4 υ(NN) β(HCC) 
819.98 28.03 β(CCN) τ(HOCC) 1031.32 94.3 υ(NN) β(HCC) 
735.45 96.35 τ(HCCN)  944.81 76.94 υ(NC) υ(NN) 
725.23 75.06 τ(HCCN)  779.35 77.51 υ(NC) β(CCC) 
705.81 121.4 υ(NC) τ(HOCC) 716.71 33.69 τ(HCCC)  
659.97 26.01 β(OCO) ο(CCNN) 709.34 71.44 τ(HCCC)  
632.85 67.27 β(OCO) τ(CNNC) 483.01 49.64 τ(HOCC)  
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Greek letters υ, β, τ, ο denote stretching, bending, tortion and out of plane modes respectively 
 
 
Table 4.13: The experimental H- and C-NMR shift in ligands bpzm and bpza 
pz
 
1
H-NMR (dmso-d6) 
bpzm
 
1
H- NMR (CHCl3-d, 250.00 MHz) 
bpza
 
1
H- NMR (CHCl3-d, 250.00 MHz) 
6.25 (t, 2H, H4) [[Díez-
Barraetal2002]] 
5.89 
(5.82) 
(t, 2H, H4) [[Díez-
Barraetal2002]] 
6.37 
(6.39) 
(t, 2H, H4), (dd, 2H, 3 JH-H = 1.9 Hz, 
3JH-H =1.6 Hz, Hpz) 
[[Burzlaffetal2001]] 
7.60  (d, 2H, H5) 7.28  (d, 2H, H5) 7.81 
(7.84) 
(d, 2H, H5), (d, 2H, 3JH-H =1.3 Hz, 
Hpz) [[Burzlaffetal2001]] 
7.60  (d, 2H, H3) 7.28  (d, 2H, H3) 7.65 
(7.57) 
(d, 2H, H3), (d, 2H, 3 JH-H = 2.0 Hz, 
Hpz) [[Burzlaffetal2001]] 
12.81 (s, H, NH) 6.41 
(6.28) 
(s, 1H, CH2) [[Díez-
Barraetal2002]] 
7.22 
(7.27) 
(s, 1H, CHCOOH) 
[[Burzlaffetal2001]] 
    7.20  (s, 1H, COOH) 
  13C- NMR (CHCl3-d, 62.50 MHz)  
13
C- NMR (CHCl3-d, 62.50 MHz) 
  77.00 (s, CH2) 74.18 
(74.70) 
(s, CH) [[Burzlaffetal2001]] 
  104.67, 
104.97, 
133.85 
(Cpz) 107.44 
130.58 
132.82 
(Cpz) 
    140.94 
(165.90) 
(s, CO2H) [[Burzlaffetal2001]] 
 
 
 
 
Table 4.14: The computed H-NMR shifts from the direct subtractions of TMS isotropic and from fitting 
equation 
 
pz bpzm bpza bpzpya 
 direct fitted  direct fitted  direct fitted  direct fitted 
H6 7.76 8.05 H12 6.49 6.82 H15 7.58 7.87 H20 7.02 7.34 
H7 9.51 9.75 H13 7.69 7.98 H16 6.42 6.75 H21 6.89 7.20 
H8 6.43 6.76 H14 7.77 8.06 H17 7.58 7.87 H22 7.93 8.22 
H9 7.47 7.77 H15 6.34 6.67 H18 6.42 6.75 H23 7.84 8.13 
   H16 7.07 7.38 H19 8.37 8.64 H24 8.11 8.39 
   H17 7.59 7.89 H20 8.37 8.64 H25 6.66 6.98 
   H18 5.83 6.18 H21 7.29 7.59 H26 6.67 6.99 
   H19 6.51 6.84 H22 6.52 6.85 H27 7.97 8.26 
         H28 7.95 8.23 
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Table 4.15: The computed C-NMR shifts from the direct subtractions of TMS isotropic and fitted 
equation 
 
pz bpzm bpza bpzpya 
 direct fitted  direct fitted  direct fitted  direct fitted 
C2 136.51 123.11 C1 103.42 91.25 C1 136.95 123.53 C2 160.13 145.86 
C4 101.65 89.54 C2 126.27 113.25 C2 104.95 92.71 C4 140.97 127.41 
C5 121.46 108.62 C3 139.04 125.55 C3 136.95 123.53 C5 101.05 88.96 
   C4 103.82 91.63 C4 104.95 92.71 C6 107.47 95.15 
   C5 120.87 108.05 C7 123.41 110.49 C7 152.00 138.02 
   C7 135.70 122.33 C8 123.41 110.50 C8 151.87 137.90 
   C11 68.41 57.53 C11 76.49 65.31 C11 122.47 109.59 
      C13 166.09 151.60 C13 123.51 110.59 
         C16 106.40 94.11 
         C17 106.61 94.32 
         C18 140.40 126.86 
         C19 140.64 127.09 
 
 
  
Table 4.16: The four Ramsey terms of the N-N bonds in the ligands 
 
pz 
 FC SD PSO DSO J 
*N1-N3 -5.220 -0.018 -1.197 0.022 -6.414 
bpzm 
N6-*N8 -5.492 -0.010 -1.215 0.029 -6.688 
N9-*N10 -5.265 -0.017 -1.222 0.028 -6.476 
*N8-*N10 0.018 0.000 0.000 0.000 0.018 
bpza 
*N5-N9 -5.753 -0.023 -1.162 0.030 -6.908 
*N6-N10 -5.753 -0.023 -1.162 0.030 -6.908 
*N5-*N6 0.032 0.000 0.001 0.003 0.035 
bpzpya 
N10-*N14 -5.793 0.005 -1.150 0.030 -6.908 
N12-*N15 -5.776 0.009 -1.129 0.030 -6.867 
*N14-*N15 0.009 0.001 -0.002 0.004 0.011 
Npy-*N14 0.541 0.003 0.014 0.008 0.566 
Npy-*N15 0.607 0.010 0.015 0.009 0.641 
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Table 4.17: The *N-N bond and H-bond properties of the ligands 
 
pz 
Bonds 
GBL_I 
(au) 
BPL - 
GBL_I (r) 2(r)  V G 

Ven V/G 
*N1 - N3 2.560 1.06E-03 0.364 -0.680 0.131 -0.569 0.200 11.646 2.852 
bpzm 
N6 - *N8 2.569 7.63E-04 0.361 -0.659 0.130 -0.562 0.199 15.718 2.830 
N9 - *N10 2.566 7.17E-04 0.362 -0.661 0.135 -0.566 0.200 15.541 2.826 
bpza 
*N5 - N9 2.578 5.87E-04 0.356 -0.640 0.129 -0.553 0.196 17.204 2.816 
*N6 - N10 2.578 5.87E-04 0.356 -0.640 0.129 -0.553 0.196 17.204 2.816 
#O12···H19 4.890 0.2281 0.009 0.035 0.756 -0.006 0.007 -0.693 0.810 
#O12···H20 4.890 0.2280 0.009 0.035 0.755 -0.006 0.007 -0.693 0.810 
bpzpya 
N10 - *N14 2.580 8.35E-04 0.355 -0.635 0.112 -0.550 0.196 18.235 2.811 
N12 - *N15 2.583 8.26E-04 0.354 -0.633 0.108 -0.548 0.195 18.161 2.812 
The bonds with ―#‖ represent the H-bonds while an atom with ―*‖ represent the nitrogen atom on pyrazole that is available 
for metal coordination. 
 
 
 
 
Table 4.18: The QTAIM and NBO properties of the nitrogen atoms that are available (*N) and not 
available (N) for metal coordination. 
 
pz                
Atom  q(A) 
|intra(
A)|
bond(
A)| |(A)| 
Vol(A
),0.00
1
Intra_Is
o(A)
bond_Is
o(A)
Iso(A
) zz(A)
Iso(A,
A)
Iso(A'
,A)
Iso(A
) 
Anisot
ropy Occ 
Energ
y 
*N1 -0.68 0.78 0.95 1.16 119.03 -3.92 -4.44 -8.36 -15.79 -62.54 12.31 -50.23 
352.3
1 
1.946
72 
-
0.3991
7 
N3 -0.83 0.62 0.79 0.17 93.03 -4.41 -5.18 -9.60 -15.43 47.91 12.98 60.89 
126.3
4 
1.561
42 
-
0.2634
7 
Total 0.00 3.61 3.11 2.30 
629.6
7 -20.31 -24.21 -44.51 -74.36 221.44 97.48 
318.9
1 
860.5
2   
bpzm                
N6 -0.828 0.578 0.814 0.282 
70.33
7 -3.292 -5.747 -9.038 -7.925 29.574 
13.47
0 
43.04
4 
136.5
8 
1.553
82 
-
0.2728
9 
*N8 -0.682 0.767 0.974 1.129 
116.79
2 -3.670 -4.313 -7.983 -5.944 
-
71.654 11.792 
-
59.86
2 
336.5
0 
1.946
6 
-
0.4081
4 
N9 -0.806 0.577 0.815 0.287 
72.03
7 -3.231 -5.649 -8.880 
-
14.03
0 24.643 
13.68
9 
38.33
2 
130.2
7 
1.546
06 
-
0.2618
7 
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*N10 -0.690 0.775 0.963 1.155 
117.06
4 -3.801 -4.333 -8.135 
-
14.03
8 
-
67.342 
12.00
1 
-
55.34
2 
317.0
4 
1.946
45 
-
0.4021
1 
Total 0.000 7.626 6.632 4.879 
1293.
130 
-
39.87
5 
-
51.93
9 
-
91.81
4 
-
106.81
1 
499.09
4 
203.4
63 
702.5
57 
1701.
86   
bpza                
*N5 -0.687 0.765 0.986 1.133 
116.40
2 -3.653 -4.274 -7.927 -5.486 
-
72.499 11.779 
-
60.72
0 
304.8
2 
1.947
17 
-
0.4094
3 
*N6 -0.687 0.765 0.985 1.133 
116.39
9 -3.653 -4.275 -7.928 -5.487 
-
72.498 11.779 
-
60.71
9 
304.8
2 
1.947
17 
-
0.4094
4 
N9 -0.807 0.569 0.779 0.257 
70.68
9 -3.270 -5.515 -8.785 -6.248 24.740 
13.41
5 
38.15
5 
125.4
3 
1.559
34 
-
0.2711
7 
N10 -0.807 0.569 0.779 0.257 
70.60
6 -3.269 -5.516 -8.785 -6.249 24.742 
13.41
6 
38.15
8 
125.4
3 
1.559
34 
-
0.2711
7 
Total 0.000 9.101 10.499 7.032 
1529.
574 
-
51.92
8 
-
55.39
5 
-
107.3
22 
-
79.85
5 
551.85
0 
221.9
53 
773.8
04 
2412.
24 
 
  
bpzpy                 
*Npy -1.112 0.054 0.944 0.907 
109.0
16 -4.083 -4.337 -8.420 
-
16.47
3 
-
34.897 7.237 
-
27.66
0 
436.1
6 
1.896
76 
-
0.3552
9 
N10 -0.840 0.572 0.738 0.166 
73.05
5 -3.150 -5.450 -8.599 
-
12.75
4 15.536 
10.78
1 
26.31
7 
134.6
5 
1.534
1 
-
0.2763
2 
N12 -0.841 0.571 0.738 0.170 
73.51
3 -3.174 -5.269 -8.443 
-
13.37
1 16.260 
10.55
7 
26.81
8 
131.5
8 
1.531
72 
-
0.2741
6 
*N14 -0.653 0.766 1.003 1.062 
112.74
8 -3.473 -4.180 -7.653 
-
12.72
2 
-
73.521 
10.80
6 
-
62.71
5 
349.8
9 
1.946
52 
-
0.4069
8 
*N15 -0.656 0.768 1.013 1.061 
112.41
5 -3.510 -4.096 -7.606 
-
13.65
5 
-
70.411 
10.66
2 
-
59.74
9 
352.4
1 
1.946
58 
-
0.4043
2 
Total 0.000 
10.39
6 12.224 8.071 
1989.
531 
-
63.17
3 
-
78.12
5 
-
141.2
98 
-
221.2
00 
649.80
5 
273.1
83 
922.9
88 
3638.
08   
 
 
 
 
 
 
 
 
 
 
Table 4.19: The electronic excitation of the ligands showing their triplet and singlet transitions  
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Ligang State Wavelength f Transitions  
pz Triplet-A 290.64 0 
H-1→L+1 (16%); HOMO→L+1 (104%); H-1→L+4 (7%); HOMO→L+9 
(2%) 
 Triplet-A 244.49 0 H-1→L+1 (94%); HOMO→L+1 (15%); HOMO→L+4 (3%);  
 Triplet-A 211.04 0 H-2→L+1 (95%); H-2→L+4 (8%); HOMO→LUMO (3%);  
 Singlet-A 207.98 0.0071 HOMO→LUMO (99%);  
 Singlet-A 206.79 0 H-1→LUMO (93%);  
 Singlet-A 205.26 0.0551 
H-1→L+1 (40%); HOMO→L+1 (29%); HOMO→L+4 (11%); H-1→L+4 
(3%) 
bpzm Triplet-A 297.73 0 
H-2→LUMO (60%); H-2→L+1 (24%); H-1→LUMO (19%); H-
3→LUMO (8%)  
 Triplet-A 296.03 0 
H-1→L+1 (12%); HOMO→LUMO (17%); HOMO→L+1 (42%); 
HOMO→L+2 (22%) 
 Triplet-A 257.18 0 
H-1→LUMO (14%); H-1→L+1 (35%); H-1→L+2 (15%); HOMO→L+1 
(14%) 
 Singlet-A 255.04 0.0024 HOMO→LUMO (75%); HOMO→L+1 (8%);  
 Singlet-A 214.20 0.0592 H-1→LUMO (90%); H-2→LUMO (3%);  
 Singlet-A 214.03 0.0073 H-2→LUMO (11%); H-1→L+1 (76%);  
bpzcooh Triplet-A 307.69 0 
H-1→LUMO (18%); H-1→L+3 (19%); HOMO→L+1 (47%); 
HOMO→L+2 (10%) 
 Triplet-A 307.03 0 
H-1→L+1 (32%); HOMO→LUMO (28%); HOMO→L+3 (24%); H-
3→L+1 (7%)  
 Triplet-A 265.21 0 
H-6→LUMO (14%); H-3→LUMO (40%); H-2→L+1 (20%); H-
1→LUMO (19%) 
 Singlet-A 264.41 0.001 HOMO→LUMO (93%);  
 Singlet-A 253.16 0.0145 H-1→LUMO (87%) H-6→LUMO (3%); H-3→LUMO (4%);  
 Singlet-A 248.42 0.0342 H-2→LUMO (94%);  
bpzpya Triplet-A 406.98 0 HOMO→LUMO (104%); H-8→LUMO (2%);  
 Triplet-A 386.82 0 
H-3→LUMO (10%); HOMO→L+1 (82%); H-9→LUMO (7%); H-
9→L+1 (3%)  
 Triplet-A 349.08 0 
H-1→LUMO (40%); H-1→L+1 (32%); H-1→L+2 (15%); H-2→L+1 
(4%)  
 Singlet-A 338.64 0.1315 HOMO→LUMO (88%);  
 Singlet-A 334.79 0.001 H-1→LUMO (88%);  
 Singlet-A 322.55 0.0012 H-2→LUMO (89%); H-3→LUMO (3%); ;  
 
 
 
 
 
 
 
 
 
 
 
 
 
382 
Table 4.20: The molecular orbital (MO) contribution of the nitrogen atom(s) ―*N‖ available for metal 
coordination and nitrogen atom ―N‖ in pz not available for metal coordination.  
 
pz      
MO eV *N1 N3 others  
L+5 1.41 -39 10 130 
L+4 1.18 -4 0 106 
L+3 0.82 71 -86 116 
L+2 0.67 -18 15 105 
L+1 -0.02 26 14 60 
LUMO -0.05 -54 -23 179 
HOMO -6.98 32 1 66 
H-1 -7.26 7 32 61 
H-2 -8.18 77 4 19 
H-3 -11.03 3 2 95 
H-4 -11.83 7 10 82 
H-5 -12 23 45 33 
H-6 -12.24 13 16 71 
H-7 -14.97 10 12 77 
bpzm      
MO eV *N8 *N10 others  
L+5 0.69 37 9 55 
L+4 0.51 -6 1 106 
L+3 0.46 -4 -19 125 
L+2 0.07 -41 -9 152 
L+1 -0.37 2 6 93 
LUMO -0.54 18 4 78 
HOMO -7 0 29 71 
H-1 -7.05 5 6 89 
H-2 -7.33 28 2 70 
H-3 -7.5 5 2 93 
H-4 -8.25 2 73 25 
H-5 -8.42 73 2 25 
H-6 -10.89 2 6 92 
H-7 -11.03 2 3 95 
bpza      
MO eV *N5 *N6 others  
L+5 0.47 -22 -21 145 
L+4 0.25 -23 -23 148 
L+3 0.15 13 13 75 
L+2 -0.37 -6 -6 114 
L+1 -0.71 8 8 84 
LUMO -1.45 1 1 99 
HOMO -7.11 17 16 67 
H-1 -7.26 12 15 73 
H-2 -7.27 4 2 95 
H-3 -7.58 7 7 87 
H-4 -8.38 37 34 29 
H-5 -8.48 36 39 25 
H-6 -8.92 2 2 97 
H-7 -9.9 0 0 100 
bpzpya      
MO eV *N9 *N15 *N14 others 
L+5 0.23 2 2 -32 129 
L+4 0.05 -6 -48 4 153 
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L+3 -0.83 0 4 -3 100 
L+2 -0.86 4 5 -5 97 
L+1 -2.01 1 3 4 92 
LUMO -2.66 16 0 0 85 
HOMO -6.93 0 0 0 100 
H-1 -7.31 2 28 1 69 
H-2 -7.39 1 3 29 67 
H-3 -7.54 11 5 6 77 
H-4 -7.99 36 26 12 25 
H-5 -8.37 1 28 47 25 
H-6 -8.41 3 3 0 94 
H-7 -8.78 35 19 18 28 
 
 
Table 4.21: The non-linear conductive properties of the ligands 
 Dipole
ii
    
 ß in esu 
(1x10-30) HOMO LUMO 
Gap in 
KJ/mol 
Non-Valence 
Lewis Orbitals 
pz 2.42 47.89 -10.40 23.80 229.13 -29.52 0.86 -0.2564 -0.0017 668.85 2.46% 
bpzm 3.58 109.44 5.65 46.37 1059.23 -2.61 1.69 -0.2571 -0.0200 622.64 2.36% 
bpza 2.76 129.47 3.57 26.01 332.00 -4.45 2.40 -0.2612 -0.0536 545.07 2.22% 
bpzpya 3.21 205.34 -80.24 160.82 9712.52 -8.53 11.21 -0.2546 -0.0979 411.44 2.61% 
 
 
 
Table 4.22: Assignment of the prominent IR picks of the ligands using the PED method 
apz phpz bphpzm bphpza 
Freq Int Vibration Freq Int Vibration Freq Int Vibration Freq Int Vibration 
3648
.54 
82.4
2 υ(OH),  
3593.
44 
98.3
1 υ(NH) 
3129.0
9 25.59 υ(CH) 
3616.3
3 77.78 υ(OH) 
3540
.35 
131.
49 υ(NH),  
3138.
03 
20.3
4 
υ(CH), 
υ(CH) 
3000.6
4 31.33 υ(CH), υ(CH) 
1760.1
7 
205.6
1 υ(OC) 
1768
.92 
305.
06 υ(OC),  
3128.
31 
27.4
2 υ(CH) 
1494.6
5 41.23 υ(CC), υ(CC) 
1495.1
8 44.25 β(HCC) 
1757
.84 
373.
2 υ(OC),  
1610.
48 
10.6
6 
υ(CC), 
β(HCC) 
1458.9
2 29.35 
β(HCC), 
τ(HCNC) 
1360.9
7 31.16 υ(NC), β(HCC) 
1537
.16 
42.2
9 
υ(CC), 
β(HNN) 
1498.
5 
13.1
5 
β(HCC), 
υ(CC) 
1396.4
7 25.73 
υ(NC), 
β(HCH) 
1319.1
4 
161.6
9 
β(HCC), 
τ(HCCO) 
1442
.47 
69.3
5 
β(CNN), 
υ(NN) 
1450.
73 28.8 
β(HCC), 
β(CNN) 
1331.1
9 51.15 
β(HCN), 
τ(HCNC) 
1294.6
5 31.53 
υ(NN), 
β(HCC) 
1390
.89 
83.5
5 
β(HNN), 
υ(NC) 
1189.
52 7.56 
υ(NC), 
β(HNN) 
1323.9
8 
179.7
4 
υ(NN), 
τ(HCNC) 
1218.1
4 
120.2
9 υ(NC), β(HCC) 
1325
.35 
153.
82 υ(NC),  
1114.
88 
19.4
5 
υ(NC), 
β(HCC) 
1269.8
8 31.67 
υ(NN), 
β(HOC) 
1192.5
5 70.32 β(HCC) 
1282
.98 
192.
1 
υ(OC), 
β(HOC) 
1077.
18 
10.7
3 
υ(CC), 
β(HCC) 
1221.4
4 65.93 
β(HCC), 
β(HCC) 
1183.4
1 78.99 
υ(NN), 
τ(HCCO) 
1222
.05 
175.
36 
β(HOC), 
υ(NN) 
1062.
24 
18.4
1 
υ(NC), 
β(HCC) 
1211.5
5 38.26 υ(CC), β(HCC) 
1109.4
5 
186.7
6 
υ(OC), 
β(HOC) 
384 
1141.
69 
81.8
9 
β(HOC), 
β(HCC) 
1034.
58 
12.2
1 
υ(NN), 
β(HCC) 
1173.9
1 33.52 
β(HCN), 
τ(HCNC) 1088.7 60.09 
β(HCC), 
β(NCN) 
1102.
96 
265.
59 
υ(OC), 
β(HOC) 
1023.
39 6.59 υ(CC) 
1078.5
2 28.76 
β(HCC), 
β(HCC) 1080.2 31.23 υ(CC), β(HCC) 
1071
.28 
48.8
1 
υ(OC), 
β(HCC) 
923.2
8 7.89 β(CNN) 
1076.9
1 27.27 υ(CC), β(HCC) 
1078.2
4 43.6 β(HCC) 
991.
97 
58.7
5 
υ(OC), 
β(CNN) 
761.5
3 11.5 
τ(HCCC), 
τ(CCCC) 
1037.5
2 44.66 
β(HCC), 
β(HCC) 
1036.0
2 59.94 β(HCC) 
750.
49 
44.9
9 τ(HOCC),  
718.1
2 
133.
94 τ(HCCC) 769.06 56.23 
υ(NC), 
β(CNN) 817.08 35.99 
ο(OCOC), 
τ(HCCC) 
728.
5 
40.0
5 
ο(OCOC), 
τ(HNNC) 
676.4
3 29.4 
τ(HCCC), 
τ(CCCC) 735.51 60.47 
υ(NN), 
β(CNN) 735.44 
132.7
6 
τ(HCCC), 
τ(HCCC) 
715.
8 
36.1
4 
υ(OC), 
β(CCO) 
673.8
6 8.15 
υ(CC), 
β(CCC) 723.81 72.56 
τ(HCCC), 
τ(HCCC) 722.11 113.5 τ(HCCC) 
689.
66 
42.4
2 τ(HNNC),  
635.0
7 8.11 τ(HNNC) 718.87 99.7 
τ(HCCC), 
τ(HCCC) 709.32 
139.5
6 
ο(OCOC), 
τ(HOCC) 
558.
04 
84.8
2 
τ(HOCC), 
τ(CNNC) 
500.1
3 
20.0
6 τ(HNNC) 675.37 27.06 
τ(CCCC), 
τ(HCCC) 675.51 44.08 τ(HCCC) 
432.
8 
76.9
5 τ(HOCC),        647.56 74.3 
ο(CCNN), 
β(OCO) 
bpzpy bmpzpy bdcpzpy  
1592
.97 
209.
02 υ(CC),  
2979.
18 43.5 υ(CH) 
3647.9
9 97.65 υ(OH)    
1585
.64 
121.
33 
υ(CC), 
β(HCC) 
2974.
42 
61.5
8 
υ(CH), 
υ(CH) 
3646.9
9 
101.6
5 υ(OH)    
1518
.25 
138.
22 
υ(CC), 
β(HCN) 
1586.
88 
164.
64 
υ(CC), 
β(HCC) 
1784.3
3 
237.1
4 υ(OC)    
1466
.34 
53.0
7 
υ(NC), 
β(HCC) 
1585.
83 
139.
1 υ(CC) 
1770.7
8 
184.5
1 υ(OC)    
1443
.46 
372.
02 
υ(NC), 
β(HCC) 
1562.
89 
142.
13 
υ(CC), 
υ(CC) 1764.3 
328.2
2 υ(OC)    
1408
.63 
60.0
9 
υ(CC), 
β(HCC) 
1472.
69 
62.8
9 
υ(NC), 
β(HCH) 
1761.1
7 
380.4
6 υ(OC)    
1408 
55.3
8 
β(CCN), 
β(HCC) 
1448.
29 
56.1
4 
β(HCH), 
τ(HCCC) 
1463.4
3 
102.8
1 
υ(NC), 
β(HCC)    
1398
.39 
120.
44 
υ(NC), 
β(HCN) 
1445.
37 
177.
85 
β(HCH), 
β(HCH) 
1428.0
8 90.81 
υ(CC), 
β(CNN)    
1384
.99 
28.6
2 
υ(NC), 
β(HCC) 
1434.
61 
203.
98 
β(HCH), 
τ(HCCN) 
1423.6
8 
295.1
5 υ(CC), β(HCC)    
1347
.29 
22.4
5 
υ(NC), 
β(CCN) 
1430.
85 
88.0
6 
υ(CC), 
β(HCH) 
1407.6
2 
156.6
9 υ(NC)    
1319
.78 
24.0
8 
υ(NC), 
β(CCN) 
1405.
69 
34.1
3 
υ(NC), 
β(HCH) 
1291.7
2 
103.1
5 β(HOC)    
1261
.65 
60.8
7 
υ(NN), 
β(HCC) 
1375.
64 
34.5
9 
υ(NC), 
β(HCH) 
1282.2
1 
186.1
3 
β(HOC), 
β(HOC)    
1190.
14 
18.0
5 
υ(NC), 
β(HCN) 
1371.
04 
62.8
8 β(HCH) 
1268.9
2 
263.0
3 υ(CC)    
1153.
82 
46.7
4 β(HCC),  
1368.
17 
83.0
5 
υ(NC), 
β(HCH) 
1258.6
8 
236.5
5 
υ(NN), 
β(HOC)    
1031
.61 
91.1
9 
υ(NN), 
β(HCC) 
1350.
11 
48.4
2 
υ(NC), 
β(HCH) 1247.5 90.14 υ(NN)    
944. 67.3 υ(NN), 1345. 36.0 υ(NC) 1130.4 117.1 β(HOC),    
385 
02 2 β(CCN) 36 3 7 2 β(HCC) 
799.
06 
22.3
4 τ(HCNN),  
1110.
01 
36.8
6 
υ(NC), 
β(NCN) 
1115.6
6 
375.5
7 
υ(OC), 
β(HOC)    
778.
87 
39.6
6 
τ(HCCC), 
τ(CNCC) 
790.0
1 
46.2
2 
τ(CNCC), 
τ(HCCC) 
1098.5
2 
227.4
6 
υ(OC), 
β(OCO)    
762.
8 
65.5
6 
β(CCC), 
β(CNN) 
760.0
5 
35.8
3 τ(HCCC) 
1091.9
4 
152.9
7 υ(CC), β(HCC)    
715.
31 
131.
94 τ(HCCC),  
723.3
6 
57.0
6 
υ(NC), 
β(CNN) 1041.4 
221.8
6 
υ(OC), 
β(CCN)    
 
Greek letters υ, β, τ, ο denote stretching, bending, tortion and out of plane modes respectively 
 
Table 4.23: The experimental 
13
C-NMR shifts obtained using d-chloroform as solvent 
 
 bphpza  bpzpy  bdmpzpy 
CH3   13.724, 14.892 
CHCOOH 74.015 
(74.70 
[[Burzlaffet
al2001]]) 
  
C4  105.040 108.27 109.791 
Cpx-meta  128.582 110.898 113.879 
C5  128.947 125.188 138.991 
Cph 131.867   
Cpx-para  126.392 127.158 124.683 
C3  132.232 140.791 140.743 
Cpx-ortho 126.210 142.926 150.671 
CHCOOH 153.219   
The subscript ―px‖ represent the phenyl (ph) in bphpza and pyridine (pyr) in bpzpy and bdmpzpy. The value in bracket is 
from the cited reference for similar molecule. 
 
 
 
 
 
 
 
 
Table 4.24: The computed 
13
C-NMR shifts from the direct and fitting methods 
dcpz phpz bphpzm bphpza bpzpy  bmpzpy bdcpzpy 
 Direct 
Fittin
g  
Dir
ect 
Fitt
ing  
Direc
t 
Fittin
g  
Dire
ct 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g 
386 
C3 
153.8
0 
139.7
6 C1 
125
.13 
112
.15 C1 
124.5
7 
111.6
1 C1 
101.
91 89.79 C2 
151.3
8 
137.4
3 C2 
151.6
8 
137.7
2 C3 
156.6
1 
142.4
7 
C4 
131.3
5 
118.1
4 C2 
121
.91 
109
.05 C2 
121.3
4 
108.5
0 C2 
125.
17 
112.1
9 C3 
151.3
7 
137.4
2 C3 
151.6
8 
137.7
2 C5 
141.6
9 
128.1
0 
C6 
104.0
6 91.86 C5 
123
.46 
110
.54 C3 
100.3
4 88.28 C3 
151.
20 
137.2
6 C4 
135.4
0 
122.0
4 C4 
133.2
8 
120.0
0 C7 
157.2
0 
143.0
4 
C8 
143.6
8 
130.0
2 C6 
132
.05 
118
.81 C4 
100.7
7 88.69 C4 
102.
19 90.06 C5 
106.7
4 94.44 C5 
111.8
0 99.31 
C1
1 
143.0
5 
129.4
1 
C9 
156.5
7 
142.4
3 C7 
150
.31 
136
.40 C5 
128.1
0 
115.0
2 C5 
124.
97 
112.0
0 C6 
106.7
2 94.42 C6 
111.7
9 99.31 
C1
2 
109.8
4 97.43 
   C8 
124
.48 
111
.53 C6 
121.2
7 
108.4
3 C6 
121.
44 
108.6
0 C9 
122.8
1 
109.9
2 C9 15.11 6.20 
C1
5 
131.7
5 
118.5
2 
   C9 
123
.36 
110
.45 C7 
124.5
1 
111.5
6 C8 
124.
58 
111.6
2 
C1
1 
122.8
0 
109.9
1 
C1
0 15.11 6.20 
C1
7 
148.0
7 
134.2
4 
   
C1
0 
121
.21 
108
.38 C8 
122.7
0 
109.8
1 
C1
0 
150.
23 
136.3
2 
C1
3 
139.6
0 
126.0
8 
C1
1 
136.6
4 
123.2
4 
C1
8 
148.6
2 
134.7
7 
   C11 
98.
83 
86.
83 C9 
124.1
3 
111.1
9 
C1
1 
131.
18 
117.9
8 
C1
4 
139.6
0 
126.0
8 
C1
3 
136.6
4 
123.2
4 
C1
9 
109.0
6 96.67 
      
C1
0 
131.1
0 
117.9
0 
C1
4 
123.
84 
110.9
1 
C1
5 
105.3
1 93.06 
C1
5 
148.6
5 
134.8
0 
C2
1 
152.9
2 
138.9
2 
      C11 
153.0
1 
139.0
0 
C1
6 
76.6
5 65.47 
C1
6 
105.3
1 93.07 
C1
6 
148.6
5 
134.8
0 
C2
2 
136.2
3 
122.8
5 
      
C1
2 
149.8
1 
135.9
2 
C1
7 
122.
72 
109.8
3    
C1
7 
105.7
1 93.45 
C2
4 
116.9
9 
104.3
1 
      
C1
3 
131.8
2 
118.6
0 
C1
8 
165.
95 
151.4
6    
C1
8 
105.7
1 93.45 
C2
5 
157.3
6 
143.1
9 
      
C1
5 
123.3
4 
110.4
3 
C1
9 
125.
34 
112.3
6    
C1
9 15.49 6.57 
C2
6 
112.4
1 99.90 
      
C1
7 
125.4
5 
112.4
6 
C2
1 
130.
94 
117.7
5    
C2
0 15.49 6.57 
C2
7 
136.2
9 
122.9
0 
      
C1
8 
122.8
2 
109.9
3 
C2
2 
121.
44 
108.6
0          
      
C2
1 
122.3
0 
109.4
2 
C2
3 
124.
54 
111.5
9          
      
C2
2 68.32 57.44 
C2
4 
124.
02 
111.0
8          
      
C2
3 
125.2
3 
112.2
4 
C2
5 
125.
37 
112.3
8          
         
C2
6 
122.
70 
109.8
1          
 
 
 
 
Table 4.25: The experimental 
1
H-NMR shifts using d-chloroform 
  bphpza  bpzpy  bdmpzpy 
CH3   2.317, 2.673 
387 
COOH  6.452   
C4-H  7.174 6.497 6.040 
CHCOO  7.354   
Cpx-para-H  7.369 7.376 7.461 
Cpx-meta-H  7.429 7.292 7.309 
fCpx-ortho-H  7.520 7.681 7.647 
C5-H  7.790 7.952  
cCpx-ortho-H  7.850   
C3-H   8.561  
The subscript ―px‖ represent the phenyl (ph) in bphpza and pyridine (pyr) in bpzpy and bdmpzpy. Also, the superscript ―c‖ 
and ―f‖ on Cph-ortho mean close to and far from the nitrogen which is the coordination centre of the pyrazole.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.26: The computed 
1
H-NMR shifts from the direct and fitting methods 
 
388 
dcpz phpz bphpzm bphpza bpzpy  bmpzpy bdcpzpy 
 
Dire
ct 
Fittin
g  
Dir
ect 
Fitt
ing  
Direc
t 
Fittin
g  
Dire
ct 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g 
H1
2 6.54 6.87 
H1
2 
7.4
1 
7.7
1 
H2
4 7.43 7.73 
H2
7 6.84 7.15 
H1
7 7.75 8.04 
H2
1 2.07 2.53 
H2
9 6.25 6.59 
H1
3 6.91 7.23 
H1
3 
8.6
4 
8.9
1 
H2
5 7.73 8.02 
H2
8 8.43 8.70 
H1
8 7.10 7.41 
H2
2 7.75 8.04 
H3
0 7.20 7.51 
H1
4 6.16 6.50 
H1
4 
7.3
0 
7.6
0 
H2
6 6.88 7.20 
H2
9 6.80 7.12 
H1
9 7.11 7.41 
H2
3 6.99 7.30 
H3
1 6.29 6.63 
H1
5 
10.7
4 10.94 
H1
5 
7.4
8 
7.7
8 
H2
7 6.71 7.03 
H3
0 7.67 7.96 
H2
0 7.90 8.19 
H2
4 6.99 7.30 
H3
2 7.11 7.42 
   
H1
6 
7.3
8 
7.6
9 
H2
8 7.69 7.98 
H3
1 8.21 8.48 
H2
1 7.91 8.19 
H2
5 2.22 2.67 
H3
3 6.78 7.10 
   
H1
7 
7.7
2 
8.0
1 
H2
9 7.40 7.70 
H3
2 7.40 7.70 
H2
2 7.92 8.20 
H2
6 2.41 2.86 
H3
4 7.20 7.51 
   
H1
8 
6.8
4 
7.1
6 
H3
0 7.68 7.97 
H3
3 7.32 7.63 
H2
3 7.92 8.20 
H2
7 2.52 2.96 
H3
5 8.38 8.65 
   
H1
9 
9.3
2 
9.5
6 
H3
1 7.00 7.31 
H3
4 7.27 7.57 
H2
4 6.59 6.92 
H2
8 2.40 2.85 
H3
6 7.98 8.26 
      
H3
2 7.33 7.63 
H3
5 8.67 8.93 
H2
5 6.59 6.92 
H2
9 2.22 2.67 
H3
7 6.81 7.12 
      
H3
3 7.31 7.61 
H3
6 7.50 7.80    
H3
0 6.22 6.55    
      
H3
4 7.44 7.74 
H3
7 6.56 6.89    
H3
1 6.22 6.55    
      
H3
5 8.57 8.84 
H3
8 7.69 7.98    
H3
2 2.51 2.96    
      
H3
6 5.83 6.18 
H3
9 7.40 7.70    
H3
3 2.21 2.66    
      
H3
7 8.63 8.90 
H4
0 7.32 7.62    
H3
4 2.21 2.67    
      
H3
8 7.48 7.78 
H4
1 7.48 7.78    
H3
5 2.40 2.85    
      
H3
9 6.49 6.82 
H4
2 8.63 8.90    
H3
6 2.41 2.86    
               
H3
7 2.07 2.53    
 
 
  
 
 
 
 
 
Table 4.27: The computed 
15
N-NMR shifts from the direct and fitting methods 
389 
dcpz phpz bphpzm bphpza bpzpy  bmpzpy bdcpzpy 
 
Dire
ct 
Fittin
g  
Dir
ect 
Fitt
ing  
Direc
t 
Fittin
g  
Dire
ct 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g  
Direc
t 
Fittin
g 
N5 
-
173.
52 
-
194.1
5 
*N
3 
-
88.
00 
-
113
.25 
N1
4 
-
178.8
1 
-
199.1
5 N7 
-
173.
01 
-
193.6
6 
pyr
N1 
-
106.4
3 
-
130.6
8 
pyrN
1 
-
84.25 
-
109.7
0 
*N
6 
-
32.73 
-
60.96 
*N
7 
-
45.7
8 
-
73.31 N4 
-
193
.87 
-
213
.40 
N1
6 
-
171.4
9 
-
192.2
3 
*N
9 
-
78.6
1 
-
104.3
6 N7 
-
154.1
5 
-
175.8
2 N7 
-
161.8
7 
-
183.1
3 
*N
9 
-
65.32 
-
91.80 
      
*N
19 
-
79.52 
-
105.2
2 
N1
2 
-
171.
53 
-
192.2
7 N8 
-
154.1
6 
-
175.8
3 N8 
-
161.8
7 
-
183.1
3 
pyr
N1
0 
-
109.5
5 
-
133.6
3 
      
*N
20 
-
84.46 
-
109.9
0 
*N
15 
-
79.2
0 
-
104.9
2 
*N
10 
-
67.33 
-
93.70 
*N
12 
-
70.52 
-
96.71 
N1
4 
-
147.5
5 
-
169.5
8 
            
*N
12 
-
67.32 
-
93.68 
*N
14 
-
70.52 
-
96.71 
N1
6 
-
153.3
3 
-
175.0
4 
 
Table 4.28:The four Ramsey terms of the N-N bonds in the ligands 
dcpz 
 FC SD PSO DSO J 
N5-*N7 -3.947 0.000 -1.564 0.025 -5.486 
phpz 
*N3-N4 -4.535 -0.053 -1.175 0.024 -5.739 
bphpzm 
N14-*N19 -4.832 -0.044 -1.177 0.031 -6.022 
N16-*N20 -4.499 -0.051 -1.205 0.030 -5.725 
*N19-*N20 0.014 0.000 -0.001 0.000 0.014 
bphpza 
N7-*N9 -5.000 -0.056 -1.139 0.032 -6.163 
N12-*N15 -4.940 -0.060 -1.128 0.032 -6.096 
*N9-*N15 0.025 0.000 -0.001 0.004 0.027 
bpzpy 
N7-*N12 -5.712 0.005 -1.167 0.029 -6.844 
N8-*N10 -5.712 0.005 -1.167 0.029 -6.844 
*N10-*N12 0.006 0.000 -0.002 0.004 0.008 
pyN1-*N10 0.531 0.004 0.016 0.008 0.559 
pyN1-*N12 0.530 0.004 0.016 0.008 0.558 
bdmpzpy 
N7-*N14 -5.548 -0.015 -1.034 0.031 -6.566 
N8-*N12 -5.549 -0.015 -1.034 0.031 -6.566 
*N12-*N14 0.003 0.000 -0.002 0.004 0.005 
pyN1-*N12 0.478 -0.005 -0.001 0.008 0.481 
pyN1-*N14 0.478 -0.005 -0.001 0.008 0.480 
bdcpzpy 
*N6-*N9 -0.001 0.000 0.000 -0.001 -0.002 
*N6-pyN10 0.497 -0.013 0.008 0.010 0.502 
*N6-N14 -4.517 0.020 -1.526 0.033 -5.990 
*N9-pyN10 0.350 0.007 0.030 -0.003 0.384 
*N9-N16 -4.608 -0.008 -1.316 0.033 -5.900 
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Table 4.29: The *N-N bond and H-bond properties of the ligands 
 
apz 
Bonds 
GBL_I 
(au) 
BPL - 
GBL_I (r) 2(r)  V G 

Ven V/G 
N5 - *N7 2.514 1.50E-03 0.386 -0.768 0.137 -0.623 0.215 18.251 2.891 
phpz 
*N3 - N4 2.552 1.15E-03 0.368 -0.699 0.137 -0.577 0.201 15.401 2.869 
bphpzm 
N14 - *N19 2.562 8.32E-04 0.363 -0.673 0.135 -0.567 0.199 21.260 2.844 
N16 - *N20 2.556 8.36E-04 0.366 -0.680 0.140 -0.574 0.202 21.317 2.842 
bphpza 
N7 - *N9 2.569 6.84E-04 0.360 -0.658 0.134 -0.559 0.198 22.852 2.832 
N12 - *N15 2.570 6.41E-04 0.359 -0.656 0.135 -0.559 0.197 22.803 2.831 
bpzpy 
N8 - *N10 2.578 8.62E-04 0.356 -0.639 0.114 -0.552 0.196 17.120 2.815 
N7 - *N12 2.578 8.62E-04 0.356 -0.639 0.114 -0.552 0.196 17.121 2.815 
bmpzpy 
N8 - *N12 2.590 8.22E-04 0.351 -0.624 0.118 -0.538 0.191 19.062 2.818 
N7 - *N14 2.590 8.22E-04 0.351 -0.624 0.118 -0.538 0.191 19.063 2.818 
bdcpzpy 
N6 - N14 2.537 1.20E-03 0.375 -0.712 0.134 -0.598 0.210 26.683 2.849 
N9 - N16 2.550 9.91E-04 0.369 -0.693 0.125 -0.582 0.205 24.986 2.847 
 
 
 
 
Table 4.30: The QTAIM and NBO properties of the nitrogen atoms that are available (*N) and not 
available (N) for metal coordination. 
 
apz 
Atom  q(A) 
|intra(
A)|
bond(
A)| |(A)| 
Vol(A
),0.00
1
Intra_Is
o(A)
bond_Is
o(A)
Iso(A
) zz(A)
Iso(A,
A)
Iso(A'
,A)
Iso(A
) 
Anisot
ropy Occ 
Energ
y 
N5 -0.77 0.58 0.77 0.24 87.00 -3.97 -4.82 -8.78 -14.17 32.48 12.08 44.56 
146.3
4 
1.501
21 
-
0.300
83 
*N7 -0.56 0.70 0.74 0.98 110.03 -2.96 -4.11 -7.07 -14.66 -95.22 12.03 -83.18 
409.3
8 
1.946
21 
-
0.436
17 
Total 0.00 6.34 10.47 6.90 
1119.4
0 -44.29 -32.12 -76.41 
-
113.48 
361.0
2 
137.1
2 
498.1
4 
2440.
20   
phpz 
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*N3 -0.66 0.74 0.92 1.13 113.65 -3.70 -3.93 -7.63 -14.21 -52.01 11.05 -40.96 
328.9
3 
1.943
37 
-
0.398
9 
N4 -0.82 0.62 0.79 0.17 92.72 -4.40 -4.78 -9.18 -14.16 52.51 12.39 64.90 117.40 
1.558
71 
-
0.267
06 
Total 0.00 4.53 3.32 3.15 
1297.
55 -37.95 -54.03 -91.98 
-
156.7
4 
617.9
5 
194.6
0 
812.5
5 
1832.
26   
bphpzm 
N14 -0.826 0.583 0.811 0.273 69.83 -3.328 -5.412 -8.741 
-
12.16
0 
36.88
6 
12.95
8 
49.84
3 
123.0
147 
1.554
59 
-
0.276
59 
N16 -0.797 0.584 0.818 0.289 71.77 -3.228 -5.296 -8.524 -5.813 
29.38
9 
13.13
8 
42.52
7 
116.59
39 
1.542
85 
-
0.265
37 
*N19 -0.671 0.731 0.951 1.116 112.09 -3.475 -3.877 -7.352 
-
11.668 
-
59.95
8 
10.51
0 
-
49.44
8 
312.0
204 
1.943
81 
-
0.407
61 
*N20 -0.677 0.738 0.928 1.138 112.21 -3.617 -3.895 -7.513 -4.970 
-
55.24
8 
10.74
0 
-
44.50
7 
299.3
827 
1.943
49 
-
0.401
37 
Total 0.000 9.474 7.152 6.585 
2629.
01 
-
75.08
7 
-
112.69
1 
-
187.7
78 
-
202.2
74 
1296.
134 
397.7
61 
1693.
895 
3653.
2171   
bphpza 
N7 -0.803 0.577 0.775 0.257 70.50 -3.291 -5.200 -8.491 -8.983 
31.17
2 
12.86
5 
44.03
8 
115.04
4 
1.944
5 
-
0.408
08 
*N9 -0.674 0.731 0.958 1.119 111.58 -3.477 -3.861 -7.337 -8.488 
-
60.85
9 
10.50
2 
-
50.35
7 
285.9
892 
1.556
58 
-
0.2721
1 
N12 -0.799 0.571 0.783 0.226 69.98 -3.261 -5.279 -8.540 -7.281 
29.66
1 
12.90
5 
42.56
6 
113.27
64   
*N15 -0.677 0.732 0.967 1.127 111.57 -3.487 -3.856 -7.343 -6.542 
-
60.26
5 
10.49
7 
-
49.76
8 
278.4
442 
1.944
54 
-
0.407
21 
Total 0.002 
10.96
0 11.139 8.735 
2864.
42 
-
87.22
0 
-
116.49
6 
-
203.7
16 
-
198.8
15 
1347.
838 
416.7
58 
1764.
596 
4365.
6132   
bpzpy 
pyN1 -1.126 0.046 0.958 0.931 110.02 -4.225 -4.442 -8.667 
-
16.67
6 
-
29.86
5 7.329 
-
22.53
6 
423.1
244 
1.897
26 
-
0.340
6 
N7 -0.840 0.576 0.764 0.194 73.12 -3.123 -5.335 -8.458 
-
12.89
9 
14.43
5 
10.74
9 
25.18
4 
136.5
511 
1.530
84 
-
0.262
67 
N8 -0.840 0.576 0.764 0.193 73.09 -3.123 -5.339 -8.462 
-
12.91
6 
14.44
4 
10.74
6 
25.19
0 
136.5
213 
1.530
83 
-
0.262
69 
*N10 -0.655 0.768 0.983 1.066 113.07 -3.501 -4.162 -7.663 
-
13.15
9 
-
72.48
7 
10.85
4 
-
61.63
3 
351.3
237 
1.946
7 
-
0.394
93 
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*N12 -0.655 0.768 0.983 1.066 113.09 -3.501 -4.159 -7.660 
-
13.14
0 
-
72.50
0 
10.85
6 
-
61.64
4 
351.2
671 
1.946
7 
-
0.394
93 
Total 0.000 8.871 8.299 5.856 
1751.
24 
-
51.311 
-
73.40
4 
-
124.7
15 
-
199.3
99 
581.4
70 
254.3
78 
835.8
48 
2838.
5704   
bmpzpy 
pyN1 -1.121 0.057 0.956 0.944 111.11 -3.947 -4.623 -8.570 
-
15.29
2 
-
52.45
0 7.734 
-
44.71
7 
435.9
292 
1.900
56 
-
0.338
5 
N7 -0.836 0.562 0.764 0.207 72.31 -3.225 -5.144 -8.369 
-
12.15
0 
22.54
4 
10.36
2 
32.90
5 
116.61
21 
1.554
71 
-
0.251
68 
N8 -0.836 0.562 0.764 0.208 72.34 -3.225 -5.148 -8.373 
-
12.15
6 
22.54
6 
10.36
2 
32.90
7 
116.60
45 
1.554
65 
-
0.251
68 
*N12 -0.681 0.765 1.007 1.108 112.86 -3.536 -3.823 -7.359 
-
11.679 
-
68.86
4 
10.41
9 
-
58.44
6 
283.0
056 
1.946
33 
-
0.384
43 
*N14 -0.681 0.765 1.007 1.108 112.89 -3.536 -3.820 -7.356 
-
11.673 
-
68.86
4 
10.41
7 
-
58.44
7 
283.0
162 
1.946
33 
-
0.384
43 
Total 0.001 
10.10
7 8.876 7.304 
2383.
12 
-
74.99
9 
-
94.03
2 
-
169.0
31 
-
227.9
20 
1338.
409 
401.5
25 
1739.
934 
2848.
6794   
bdcpzpy 
*N6 -0.568 0.705 0.785 0.949 
107.0
08 -2.585 -3.957 -6.541 
-
11.433 
-
107.3
50 11.118 
-
96.23
2 
378.8
421 
1.946
63 
-
0.436
94 
*N9 -0.618 0.714 0.824 1.006 
107.5
23 -3.155 -3.900 -7.056 
-
10.61
5 
-
74.42
6 
10.78
5 
-
63.64
1 
350.7
135 
1.943
12 
-
0.433
33 
pyN10 -1.188 0.045 0.966 0.926 
105.1
96 -4.112 -4.784 -8.897 
-
15.20
9 
-
27.34
6 7.929 
-
19.41
7 
394.8
674 
1.890
35 
-
0.377
5 
N14 -0.766 0.549 0.755 0.283 
70.13
4 -2.915 -5.017 -7.932 
-
11.447 8.119 
10.46
7 
18.58
6 
156.3
873 
1.497
14 
-
0.300
68 
N16 -0.800 0.552 0.866 0.363 
71.35
6 -2.990 -4.965 -7.955 
-
10.14
4 
14.06
8 
10.29
2 
24.36
0 
134.4
276   
Total -0.002 
14.65
2 
23.91
2 
15.04
2 
2722.
229 
-
98.47
7 
-
88.93
3 
-
187.4
10 
-
249.8
24 
784.2
00 
336.6
32 
1120.8
32 
6037.
6538   
 
 
 
 
Table 4.31: The electronic excitation of the ligands showing their triplet and singlet transitions 
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Ligang State Wavelength f Transitions  
apz Triplet-A 342.05 0 
HOMO→LUMO (100%); H-2→LUMO (8%); H-2→L+1 (6%); 
HOMO→L+1 (9%) 
 Triplet-A 286.65 0 H-2→LUMO (90%); HOMO→L+1 (18%); 
 Triplet-A 282.89 0 
H-3→LUMO (75%); H-1→LUMO (22%); H-3→L+1 (5%); H-
3→L+8 (2%) 
 Singlet-A 278.48 0 
H-3→LUMO (45%); H-1→LUMO (35%); H-3→L+1 (4%); H-
1→L+1 (3%) 
 Singlet-A 267.06 0 H-3→LUMO (13%); H-1→L+1 (74%); 
 Singlet-A 257.58 0.0307 
H-2→LUMO (38%); HOMO→LUMO (21%); HOMO→L+1 
(25%); H-2→L+1 (4%) 
phpz Triplet-A 392.39 0 
H-1→L+1 (16%); HOMO→LUMO (107%); H-3→L+11 (3%); H-
2→L+4 (4%) 
 Triplet-A 300.57 0 
H-3→LUMO (11%); H-2→LUMO (12%); H-2→L+1 (10%); H-
1→L+1 (36%) 
 Triplet-A 292.00 0 
H-1→LUMO (29%); HOMO→L+1 (55%); H-2→LUMO (6%); H-
1→L+1 (5%) 
 Singlet-A 276.51 0.0284 
H-1→LUMO (33%); HOMO→LUMO (10%); HOMO→L+1 
(49%);8-→8 (0) 
 Singlet-A 270.94 0.3149 
HOMO→LUMO (66%); H-1→LUMO (5%); H-1→L+1 (3%); 
HOMO→L+1 (7%) 
 Singlet-A 259.01 0.0013 HOMO→L+2 (88%);11-→-95 (-106);11-→27 (16);78-→168 (90) 
bphpzm Triplet-A 396.80 0 H-2→L+3 (11%); HOMO→L+1 (102%); H-2→L+4 (4%); 
 Triplet-A 394.73 0 
H-3→L+2 (13%); H-1→LUMO (104%); H-5→LUMO (2%); H-
5→L+5 (3%) 
 Triplet-A 304.68 0 
H-6→L+1 (11%); H-2→L+3 (18%); HOMO→L+3 (21%); H-
5→LUMO (3%) 
 Singlet-A 304.16 0.0099 HOMO→LUMO (89%); 
 Singlet-A 293.09 0.5388 
H-1→LUMO (21%); HOMO→L+1 (48%); H-2→L+1 (3%); 
HOMO→L+3 (5%) 
 Singlet-A 285.71 0.0588 
H-2→L+1 (19%); H-1→LUMO (15%); H-1→L+2 (11%); 
HOMO→L+3 (26%) 
bphpza Triplet-A 399.17 0 
H-1→L+1 (10%); H-1→L+2 (14%); HOMO→LUMO (14%); 
HOMO→L+1 (37%) 
  Triplet-A 398.24 0 
H-1→LUMO (11%); H-1→L+1 (40%); H-1→L+2 (14%); 
HOMO→LUMO (11%) 
 Triplet-A 314.89 0 
H-2→L+5 (11%); HOMO→LUMO (40%); H-7→L+1 (2%); H-
6→LUMO (4%) 
 Singlet-A 303.52 0.0608 HOMO→LUMO (93%); 
 Singlet-A 302.26 0.1404 H-1→LUMO (92%); 
 Singlet-A 299.56 0.2834 HOMO→L+1 (81%); 
bpzpy Triplet-A 372.77 0 
HOMO→L+1 (95%); H-8→L+1 (8%); H-7→LUMO (9%); H-
3→LUMO (7%) 
 Triplet-A 336.13 0 
H-1→L+1 (10%); HOMO→LUMO (71%); H-3→L+1 (8%); H-
2→LUMO (9%) 
 Triplet-A 330.05 0 
H-2→L+1 (53%); H-1→LUMO (26%); H-1→L+3 (13%); H-
3→LUMO (4%) 
 Singlet-A 327.49 0.1405 HOMO→LUMO (75%); H-7→L+1 (3%); H-3→L+1 (4%); 
 Singlet-A 283.79 0.1472 HOMO→L+1 (78%); 
 Singlet-A 283.01 0.0025 H-4→LUMO (11%); H-1→LUMO (68%); H-3→LUMO (7%); 
394 
bmpzpy Triplet-A 365.15 0 
H-8→LUMO (13%); H-7→L+1 (16%); HOMO→L+1 (83%); H-
3→LUMO (7%) 
 Triplet-A 339.28 0 
H-1→L+1 (20%); HOMO→LUMO (63%); H-7→LUMO (3%); H-
2→LUMO (7%) 
 Triplet-A 334.68 0 
H-2→L+1 (41%); H-1→LUMO (34%); H-1→L+4 (19%); H-
2→L+6 (6%) 
 Singlet-A 331.82 0.1454 HOMO→LUMO (81%); H-8→L+1 (3%); 
 Singlet-A 295.94 0.0026 H-1→LUMO (91%); 
 Singlet-A 295.40 0.0006 H-2→LUMO (87%); H-1→L+1 (4%); 
bdcpzpy Triplet-A 382.00 0 
HOMO→LUMO (51%); HOMO→L+1 (36%); H-9→L+3 (5%); H-
4→LUMO (2%) 
 Triplet-A 356.50 0 
H-1→L+1 (62%); H-6→L+1 (6%); H-3→LUMO (3%); H-
2→LUMO (6%) 
 Triplet-A 354.64 0 
H-4→LUMO (21%); H-3→LUMO (33%); H-2→LUMO (33%); H-
5→LUMO (3%) 
 Singlet-A 334.57 0.0563 HOMO→LUMO (73%); HOMO→L+1 (8%) 
 Singlet-A 300.35 0.2795 HOMO→L+1 (66%); H-1→LUMO (6%); HOMO→LUMO (5%);; 
 Singlet-A 291.27 0.0499 H-1→LUMO (84%); HOMO→L+1 (4%) 
 
Table 4.32: The molecular orbital (MO) contribution of the nitrogen atom(s) ―*N‖ available for metal 
coordination.  
 
dcpz 
 eV N5 *N7 others  
L+5 0.93 7 6 87  
L+4 0.18 -1 -81 184  
L+3 -0.24 -33 21 113  
L+2 -0.83 -1 -13 116  
L+1 -1.88 3 13 85  
LUMO -2.37 15 18 68  
HOMO -8.2 5 28 67  
H-1 -8.32 0 0 100  
H-2 -8.51 24 2 74  
H-3 -8.78 0 3 98  
H-4 -9.36 12 65 22  
H-5 -9.49 1 0 99  
H-6 -9.73 0 2 98  
H-7 -11.65 1 1 98  
phpz 
 eV *N3 N4 others  
L+5 0.56 3 -6 103  
L+4 0.27 10 6 84  
L+3 0.24 -5 1 105  
L+2 -0.14 -94 27 168  
L+1 -0.38 1 1 98  
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LUMO -0.93 17 6 78  
HOMO -6.12 11 11 78  
H-1 -6.85 2 1 97  
H-2 -7.1 24 3 73  
H-3 -8.06 3 17 80  
H-4 -8.2 74 2 24  
H-5 -9.35 6 0 95  
H-6 -9.53 1 0 99  
H-7 -10.06 0 5 95  
bphpzm 
 eV *N20 *N19 others  
L+5 -0.1 0 4 95  
L+4 -0.26 -22 -19 143  
L+3 -0.44 0 0 102  
L+2 -0.56 0 1 99  
L+1 -1.01 16 0 84  
LUMO -1.19 1 19 80  
HOMO -6.09 9 0 91  
H-1 -6.33 1 10 89  
H-2 -6.86 3 0 97  
H-3 -7 0 1 99  
H-4 -7.1 24 0 76  
H-5 -7.36 0 25 76  
H-6 -7.98 2 1 97  
H-7 -8.23 9 2 89  
bphpza 
 eV *N9 *N15 others  
L+5 -0.43 0 -11 113  
L+4 -0.45 -1 -8 111  
L+3 -0.59 -2 -10 114  
L+2 -0.88 4 2 94  
L+1 -1.21 12 9 79  
LUMO -1.54 1 2 97  
HOMO -6.19 3 7 90  
H-1 -6.34 7 4 89  
H-2 -6.94 0 2 98  
H-3 -6.97 1 0 99  
H-4 -7.2 6 18 77  
H-5 -7.34 18 6 76  
H-6 -8.08 2 2 96  
H-7 -8.2 4 5 90  
bpzpy 
 eV *N12 pyN1 *N10 others 
L+5 0.43 -14 4 -14 126 
L+4 0.13 -21 -5 -21 150 
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L+3 -0.11 1 -1 1 99 
L+2 -0.3 -8 -14 -8 133 
L+1 -1.53 4 0 4 92 
LUMO -1.53 0 22 1 77 
HOMO -6.57 0 0 0 100 
H-1 -7.03 14 3 14 69 
H-2 -7.06 18 0 18 65 
H-3 -7.22 5 12 5 78 
H-4 -7.67 16 44 16 25 
H-5 -8.06 38 0 38 24 
H-6 -8.33 22 28 22 28 
H-7 -8.61 3 20 3 74 
bdmpzpy 
 eV *N12 pyN1 *N14 others 
L+5 0.37 -9 -1 -9 122 
L+4 0.21 4 2 4 90 
L+3 0.05 -27 -8 -27 166 
L+2 -0.27 -20 -34 -20 177 
L+1 -1.23 2 1 2 95 
LUMO -1.39 -1 23 -1 82 
HOMO -6.27 1 0 1 98 
H-1 -6.48 19 2 18 61 
H-2 -6.52 17 0 18 66 
H-3 -6.7 0 7 0 93 
H-4 -7.51 20 33 20 28 
H-5 -7.7 35 0 35 31 
H-6 -7.96 16 38 16 29 
H-7 -8.07 2 0 2 95 
bdcpzpy 
 ev *N6 *N9 pyN10 others 
L+5 0.9 4 3 0 94 
L+4 1.28 3 2 1 94 
L+3 1.71 3 10 3 84 
L+2 1.96 0 1 4 95 
L+1 2.39 17 10 0 72 
LUMO 2.66 1 2 18 80 
HOMO 7.4 0 1 0 99 
H-1 7.72 23 0 0 77 
H-2 8.18 1 4 9 85 
H-3 8.2 1 1 9 88 
H-4 8.32 0 10 7 83 
H-5 8.38 0 0 2 98 
H-6 8.5 11 4 0 85 
H-7 8.7 0 2 3 95 
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Table 4.24: Assignment of the prominent IR picks of the ligands using the PED method 
bpyr dmbpyr dcbpyr 
Freq Int Vibration Freq Int Vibration Freq Int Vibration 
3143.4
3 5.05 υ(CH)  3118.65 41.42 υ(CH) υ(CH) 3647.4 86.05 υ(OH)  
3142.7
5 30.16 υ(CH)  3116.37 14.03 υ(CH)  3645.65 85.75 υ(OH)  
3134.7
9 13.82 υ(CH)  3088.13 29.71 υ(CH)  3096.08 29.02 υ(CH)  
3132.0
7 17.5 υ(CH)  3087.84 19.95 υ(CH)  1744.04 
334.4
1 υ(OC)  
3119.9
5 5.07 υ(CH)  3070.06 13.34 υ(CH)  1741.81 
245.5
5 υ(OC)  
3090.2
3 28.13 υ(CH)  3070.44 13.05 υ(CH)  1572.05 70.3 υ(CC)  
3090.6
2 24.68 υ(CH)  2978.88 24.74 υ(CH)  1392.35 91.63 υ(CC) β(CCC) 
1587.3
5 73.62 υ(CC)  2978.41 23.91 υ(CH)  1380.49 67.75 
β(HCC
) β(CCC) 
1565.8
5 28 β(HCC) υ(CC) 1595.18 107.12 υ(CC)  1338.5 77.81 υ(CC) υ(CC) 
1451.6
8 23.93 υ(CC) β(HCN) 1593.63 53.65 υ(CC) β(HCC) 1329.35 96.32 
β(HOC
) β(HCC) 
1417.8
4 46.82 β(HCC) β(HCN) 1566.58 39.07 υ(CC)  1326.49 61.18 υ(CC) 
β(HOC
) 
1406.3
3 5.39 υ(CC) β(HCC) 1557 22.82 υ(CC)  1161.06 
137.9
3 υ(CC) 
β(HOC
) 
1098.1
6 7.81 υ(CC) β(HCC) 1465.43 13.55 υ(NC) β(HCC) 1155.19 
237.4
5 υ(OC) 
β(HOC
) 
1046.0
8 4.91 υ(CC) β(HCN) 1445.53 18.18 β(HCH) τ(HCCC) 1102.11 
181.0
4 υ(OC) 
β(HOC
) 
1027.0
9 6.73 υ(NC) β(CNC) 1444.81 35.34 β(HCH) τ(HCCC) 1074.17 69.53 υ(OC) 
β(HCN
) 
744.48 56.45 τ(HCCC) τ(CNCC) 1439.54 12.14 β(HCH) τ(HCCC) 745.09 93.14 
ο(OCO
C)  
730.88 45.01 τ(HCCC) τ(CNCC) 1381.38 24.81 β(HCC) β(CCC) 720.87 33.62 
τ(CNC
C) 
τ(CCC
N) 
726.81 6.91 τ(HCCN)  823.66 13.46 υ(CC) β(CCC) 620.36 69.44 
β(OCO
)  
645.27 10.12 β(CCC)  802.64 48.58 τ(HCCN)  611.02 73.83 
β(OCO
)  
599.47 4.75 β(CCN)  453.07 12.19 β(CCC)  603.91 
133.0
8 
τ(HOC
C)  
phn dmphn dcphn 
3138.1
6 45.44 υ(CH)  3126.2 45.38 υ(CH)  3649.77 86.6 υ(OH)  
3120.9
6 28.98 υ(CH)  3119.75 30.12 υ(CH)  3640.32 76.75 υ(OH)  
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3110.9
3 15.51 υ(CH)  3106.11 14.2 υ(CH)  1767.58 
231.6
6 υ(OC)  
3084.6 28.94 υ(CH) υ(CH) 3036.88 21.24 υ(CH)  1722.58 
365.4
7 υ(OC)  
3083.8
7 24.55 υ(CH) υ(CH) 2975.23 29.21 υ(CH)  1538.22 29.18 υ(CC) β(CCC) 
1613.6
2 5.08 υ(CC)  2975.35 20.15 υ(CH)  1356.59 86.46 υ(OC) 
β(HOC
) 
1605.9
2 8.72 υ(CC) β(HCC) 1614.77 23.96 υ(CC)  1343.39 40.17 υ(CC)  
1590.9 9.33 υ(CC)  1611.46 46.86 υ(CC)  1306.66 99.84 υ(OC) 
β(HOC
) 
1545.1
8 15.24 υ(CC)  1592.78 42.92 υ(CC)  1180.71 53.61 υ(CC) 
β(HOC
) 
1496.3
4 33.73 υ(NC) β(HCN) 1505.6 42.69 β(HCC) β(CCN) 1159.87 56.72 
β(HOC
) β(HCC) 
1492.4
1 10.95 υ(CC) β(HCC) 1488.26 59.39 υ(CC) β(HCC) 1122.75 31.96 υ(CC) β(HCC) 
1412.1
8 34.45 β(HCN)  1438.53 17.5 β(HCH) τ(HCCC) 1104.38 
373.6
7 υ(OC) υ(OC) 
1309.5 4.02 υ(NC) β(HCN) 1428.8 41.44 β(HCH) τ(HCCC) 1100.11 
143.1
2 υ(OC) β(HCC) 
1123.4
9 8.48 υ(CC) β(HCC) 1408.6 27.37 β(HCC)  1059.25 83.8 υ(OC) β(CCC) 
1082.3
3 11.71 υ(CC) β(HCC) 1329.45 16.21 υ(NC)  855.9 60.43 
τ(HCC
C)  
822.69 71.33 τ(HCCC)  1191.94 14.41 β(HCC) β(HCC) 720.14 
104.5
4 
ο(OCO
C)  
741.12 22 τ(HCCC)  1129.38 13.64 β(HCC)  682.65 35.9 υ(OC) β(CCC) 
726.96 30.06 τ(CCCC) τ(CCCC) 986.59 11.92 β(HCH) τ(HCCC) 614.04 109.4 
τ(HOC
C)  
606.94 6.66 β(CCC)  832.79 68.55 τ(HCCC)  583.83 36.97 
β(OCO
) β(CCC) 
94.16 5.41 τ(CCNC)  537.97 13.36 τ(CCCN) τ(CCCN) 493.83 34.35 
τ(CCN
C)  
Greek letters υ, β, τ, ο denote stretching, bending, tortion and out of plane modes respectively 
 
 
 
 
 
 
Table 4.33: The non-linear conductive properties of the ligands 
 
 Dipole       ß in esu HOMO LUMO Gap in Non-
399 
(1x10-
30) 
KJ/mol Valence 
Lewis 
Orbitals 
dcpz 3.55 92.52 -3.31 75.16 2819.12 -49.97 1.84 -0.3015 -0.0870 563.27 2.32% 
phpz 2.49 124.37 -90.01 102.87 1240.26 -65.22 3.40 -0.2250 -0.0341 500.97 2.79% 
bphpzm 3.21 273.88 -9.61 172.79 14881.42 -8.31 2.71 -0.2240 -0.0436 473.61 2.73% 
bphpza 2.35 296.55 -48.38 133.87 7790.76 -11.62 4.19 -0.2273 -0.0569 447.56 2.84% 
bpzpy 5.16 179.84 -78.73 143.88 7251.88 -6.22 7.91 -0.2412 -0.0564 485.39 2.76% 
bmpzpy 5.19 233.64 -78.06 141.62 6981.98 -9.33 10.05 -0.2306 -0.0513 470.74 2.27% 
bdcpzpy 4.66 267.46 -135.11 175.81 6327.24 -13.55 2.99 -0.2717 -0.0976 457.20 2.72% 
 
Table 4.34: Assignment of the prominent IR picks of the ligands using the PED method 
bpyr dmbpyr dcbpyr 
Freq Int Vibration Freq Int Vibration Freq Int Vibration 
3143.4
3 5.05 υ(CH)  3118.65 41.42 υ(CH) υ(CH) 3647.4 86.05 υ(OH)  
3142.7
5 30.16 υ(CH)  3116.37 14.03 υ(CH)  3645.65 85.75 υ(OH)  
3134.7
9 13.82 υ(CH)  3088.13 29.71 υ(CH)  3096.08 29.02 υ(CH)  
3132.0
7 17.5 υ(CH)  3087.84 19.95 υ(CH)  1744.04 
334.4
1 υ(OC)  
3119.9
5 5.07 υ(CH)  3070.06 13.34 υ(CH)  1741.81 
245.5
5 υ(OC)  
3090.2
3 28.13 υ(CH)  3070.44 13.05 υ(CH)  1572.05 70.3 υ(CC)  
3090.6
2 24.68 υ(CH)  2978.88 24.74 υ(CH)  1392.35 91.63 υ(CC) β(CCC) 
1587.3
5 73.62 υ(CC)  2978.41 23.91 υ(CH)  1380.49 67.75 
β(HCC
) β(CCC) 
1565.8
5 28 β(HCC) υ(CC) 1595.18 107.12 υ(CC)  1338.5 77.81 υ(CC) υ(CC) 
1451.6
8 23.93 υ(CC) β(HCN) 1593.63 53.65 υ(CC) β(HCC) 1329.35 96.32 
β(HOC
) β(HCC) 
1417.8
4 46.82 β(HCC) β(HCN) 1566.58 39.07 υ(CC)  1326.49 61.18 υ(CC) 
β(HOC
) 
1406.3
3 5.39 υ(CC) β(HCC) 1557 22.82 υ(CC)  1161.06 
137.9
3 υ(CC) 
β(HOC
) 
1098.1
6 7.81 υ(CC) β(HCC) 1465.43 13.55 υ(NC) β(HCC) 1155.19 
237.4
5 υ(OC) 
β(HOC
) 
1046.0
8 4.91 υ(CC) β(HCN) 1445.53 18.18 β(HCH) τ(HCCC) 1102.11 
181.0
4 υ(OC) 
β(HOC
) 
1027.0
9 6.73 υ(NC) β(CNC) 1444.81 35.34 β(HCH) τ(HCCC) 1074.17 69.53 υ(OC) 
β(HCN
) 
744.48 56.45 τ(HCCC) τ(CNCC) 1439.54 12.14 β(HCH) τ(HCCC) 745.09 93.14 
ο(OCO
C)  
730.88 45.01 τ(HCCC) τ(CNCC) 1381.38 24.81 β(HCC) β(CCC) 720.87 33.62 
τ(CNC
C) 
τ(CCC
N) 
726.81 6.91 τ(HCCN)  823.66 13.46 υ(CC) β(CCC) 620.36 69.44 β(OCO  
400 
) 
645.27 10.12 β(CCC)  802.64 48.58 τ(HCCN)  611.02 73.83 
β(OCO
)  
599.47 4.75 β(CCN)  453.07 12.19 β(CCC)  603.91 
133.0
8 
τ(HOC
C)  
phn dmphn dcphn 
3138.1
6 45.44 υ(CH)  3126.2 45.38 υ(CH)  3649.77 86.6 υ(OH)  
3120.9
6 28.98 υ(CH)  3119.75 30.12 υ(CH)  3640.32 76.75 υ(OH)  
3110.9
3 15.51 υ(CH)  3106.11 14.2 υ(CH)  1767.58 
231.6
6 υ(OC)  
3084.6 28.94 υ(CH) υ(CH) 3036.88 21.24 υ(CH)  1722.58 
365.4
7 υ(OC)  
3083.8
7 24.55 υ(CH) υ(CH) 2975.23 29.21 υ(CH)  1538.22 29.18 υ(CC) β(CCC) 
1613.6
2 5.08 υ(CC)  2975.35 20.15 υ(CH)  1356.59 86.46 υ(OC) 
β(HOC
) 
1605.9
2 8.72 υ(CC) β(HCC) 1614.77 23.96 υ(CC)  1343.39 40.17 υ(CC)  
1590.9 9.33 υ(CC)  1611.46 46.86 υ(CC)  1306.66 99.84 υ(OC) 
β(HOC
) 
1545.1
8 15.24 υ(CC)  1592.78 42.92 υ(CC)  1180.71 53.61 υ(CC) 
β(HOC
) 
1496.3
4 33.73 υ(NC) β(HCN) 1505.6 42.69 β(HCC) β(CCN) 1159.87 56.72 
β(HOC
) β(HCC) 
1492.4
1 10.95 υ(CC) β(HCC) 1488.26 59.39 υ(CC) β(HCC) 1122.75 31.96 υ(CC) β(HCC) 
1412.1
8 34.45 β(HCN)  1438.53 17.5 β(HCH) τ(HCCC) 1104.38 
373.6
7 υ(OC) υ(OC) 
1309.5 4.02 υ(NC) β(HCN) 1428.8 41.44 β(HCH) τ(HCCC) 1100.11 
143.1
2 υ(OC) β(HCC) 
1123.4
9 8.48 υ(CC) β(HCC) 1408.6 27.37 β(HCC)  1059.25 83.8 υ(OC) β(CCC) 
1082.3
3 11.71 υ(CC) β(HCC) 1329.45 16.21 υ(NC)  855.9 60.43 
τ(HCC
C)  
822.69 71.33 τ(HCCC)  1191.94 14.41 β(HCC) β(HCC) 720.14 
104.5
4 
ο(OCO
C)  
741.12 22 τ(HCCC)  1129.38 13.64 β(HCC)  682.65 35.9 υ(OC) β(CCC) 
726.96 30.06 τ(CCCC) τ(CCCC) 986.59 11.92 β(HCH) τ(HCCC) 614.04 109.4 
τ(HOC
C)  
606.94 6.66 β(CCC)  832.79 68.55 τ(HCCC)  583.83 36.97 
β(OCO
) β(CCC) 
94.16 5.41 τ(CCNC)  537.97 13.36 τ(CCCN) τ(CCCN) 493.83 34.35 
τ(CCN
C)  
Greek letters υ, β, τ, ο denote stretching, bending, tortion and out of plane modes respectively 
Table 4.35: The experimental 
1
H-NMR shifts obtained in d-dmso 
 
401 
1H-NMR d-dmso dmbpyr  phn dmphn 
CH3 2.40 to 2.50  2.49 to 2.79 
Cpx-meta-H 7.27 7.77 7.62 
Cbase-H  7.99 7.86 
Cpx-para-H 8.22 8.50 8.34 
Cpx-ortho-H 8.52 9.10  
The subscript ―px‖ represent the pyridine (pyr) in dmbpyr and phenanthroline (phn) in phn and dmphn.  
 
Table 4.36: The computed 
1
H-NMR shifts from the direct and fitting methods 
bpyr dmbpyr dcbpyr phn dmphn dcphn 
 Direct Fitting  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g 
H1
3 7.25 7.55 H15 7.14 7.45 H19 6.46 6.79 H15 7.80 8.09 H17 7.70 7.99 H21 7.96 8.25 
H1
4 7.74 8.03 H16 8.84 9.10 H20 7.92 8.21 H16 7.80 8.09 H18 7.70 7.99 H22 7.96 8.24 
H1
5 9.01 9.26 H17 7.41 7.71 H21 9.16 9.40 H17 8.15 8.42 H19 8.04 8.32 H23 8.28 8.56 
H1
6 7.58 7.87 H18 7.40 7.70 H22 9.03 9.28 H18 8.15 8.42 H20 8.04 8.32 H24 8.29 8.56 
H1
7 7.58 7.87 H19 8.84 9.10 H23 8.94 9.20 H19 7.64 7.93 H21 7.59 7.88 H25 8.90 9.16 
H1
8 7.74 8.03 H20 7.16 7.47 H24 6.50 6.82 H20 9.31 9.55 H22 7.59 7.88 H26 8.71 8.97 
H1
9 9.01 9.26 H21 2.45 2.90 H25 9.16 9.41 H21 7.64 7.93 H23 2.87 3.30 H27 6.64 6.96 
H2
0 7.25 7.55 H22 2.61 3.05 H26 8.12 8.40 H22 9.31 9.55 H24 2.97 3.40 H28 6.52 6.85 
   H23 2.02 2.49       H25 2.87 3.30    
   H24 2.57 3.02       H26 2.97 3.40    
   H25 2.56 3.01       H27 2.87 3.30    
   H26 1.96 2.42       H28 2.87 3.30    
 
 
 
 
Table 4.37: The computed 
15
N-NMR shifts from the direct and fitting methods 
bpyr dmbpyr dcbpyr phn dmphn dcphn 
402 
 Direct Fitting  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g  Direct 
Fittin
g 
N5 -56.78 -83.71 N6 -64.74 
-
91.24 N8 -42.27 -69.99 N10 -61.81 
-
88.47 N10 -68.36 
-
94.67 N11 -55.77 
-
82.76 
N9 -56.78 -83.71 N10 -64.86 
-
91.36 N12 -42.77 -70.46 N12 -61.81 
-
88.47 N12 -68.36 
-
94.67 N13 -47.70 
-
75.12 
 
 
 
Table 4.38: The computed 
13
C-NMR shifts from the direct and fitting methods 
bpyr dmbpyr dcbpyr phn dmphn dcphn 
 Direct Fitting  Direct 
Fittin
g  Direct Fitting  
Dire
ct Fitting  Direct Fitting  Direct 
Fittin
g 
C1 
117.9
2 105.21 C1 22.39 
13.2
2 C2 163.99 149.58 C1 
123.
89 110.95 C1 122.60 109.72 C1 126.09 
113.0
8 
C2 
131.3
8 118.17 C2 118.63 
105.
90 C4 118.69 105.95 C2 
123.
89 110.95 C2 122.60 109.72 C2 125.54 
112.5
4 
C3 
148.5
5 134.71 C3 143.88 
130.
21 C5 133.40 120.12 C3 
131.
24 118.04 C3 131.45 118.24 C3 132.06 
118.8
3 
C4 
118.7
5 106.00 C4 148.01 
134.
19 C6 149.71 135.83 C4 
126.
48 113.45 C4 124.55 111.59 C4 127.83 
114.7
6 
C6 
158.3
6 144.16 C5 119.89 
107.
11 C7 117.92 105.21 C5 
126.
48 113.45 C5 124.55 111.59 C5 127.40 
114.3
3 
C7 
158.3
7 144.16 C7 158.80 
144.
57 C9 154.65 140.58 C6 
118.
16 105.44 C6 117.89 105.18 C6 122.09 
109.2
2 
C8 
118.7
5 106.01 C8 158.84 
144.
62 C10 154.31 140.25 C7 
146.
33 132.56 C7 145.13 131.41 C7 145.40 
131.6
7 
C10 
131.3
8 118.17 C9 119.90 
107.
12 C11 116.51 103.85 C8 
131.
24 118.04 C8 131.45 118.24 C8 132.18 
118.9
4 
C11 
148.5
5 134.71 C11 143.87 
130.
20 C14 133.65 120.35 C9 
146.
33 132.56 C9 145.13 131.41 C9 145.86 
132.1
2 
C12 
117.9
2 105.21 C12 147.91 
134.
09 C15 149.74 135.85 C11 
147.
21 133.42 C11 157.20 143.04 C12 145.97 
132.2
2 
   C13 22.37 
13.2
0 C16 163.59 149.19 C13 
118.
16 105.44 C13 117.89 105.18 C14 121.57 
108.7
2 
   C14 118.63 
105.
89 C17 120.76 107.94 C14 
147.
22 133.42 C14 26.60 17.27 C15 165.16 
150.7
0 
            C15 157.20 143.04 C16 145.38 
131.6
6 
            C16 26.60 17.27 C18 159.69 
145.4
3 
 
 
 
Table 4.39: The four Ramsey terms of the N-N bonds in the ligands 
403 
 
bpyr 
 FC SD PSO DSO J 
N5-C6 1.989 0.416 -3.589 0.087 -1.097 
C7-N9 1.989 0.416 -3.589 0.087 -1.096 
N5-N9 0.518 0.004 0.038 0.007 0.566 
dmbpyr 
N6-C7 1.982 0.421 -3.577 0.088 -1.087 
C8-N10 2.008 0.424 -3.589 0.088 -1.069 
N6-N10 0.532 0.003 0.035 0.007 0.578 
dcbpyr 
N8-C9 1.990 0.428 -3.608 0.089 -1.100 
C10-N12 1.973 0.436 -3.624 0.089 -1.126 
N8-N12 0.547 0.108 0.072 0.008 0.736 
phn 
C7-N10 -0.615 0.336 -3.197 0.092 -3.384 
C9-N12 -0.615 0.336 -3.197 0.092 -3.385 
N10-N12 0.379 0.101 0.069 0.008 0.557 
dmphn 
C7-N10 0.440 0.309 -3.081 0.096 -2.236 
C9-N12 0.440 0.309 -3.081 0.096 -2.236 
N10-N12 0.402 0.087 0.061 0.009 0.559 
dcphn 
C7-N11 2.208 0.373 -3.312 0.100 -0.631 
C9-N13 1.880 0.382 -3.334 0.099 -0.973 
N11-N13 0.262 0.117 0.070 0.010 0.458 
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Table 4.40: The selected bond properties of the ligands 
 
bpyr 
Bonds 
GBL_I 
(au) 
BPL - 
GBL_I (r) 2(r)  V G 

Ven V/G 
N5 - C6 2.556 2.14E-03 0.337 -1.110 0.117 -0.768 0.245 27.266 3.132 
C6 - C7 2.827 4.10E-05 0.269 -0.684 0.095 -0.289 0.059 15.819 4.909 
C7 - N9 2.556 2.14E-03 0.337 -1.110 0.117 -0.768 0.245 27.266 3.132 
dmbpyr 
N6 - C7 2.554 2.02E-03 0.338 -1.116 0.117 -0.769 0.245 29.385 3.140 
C7 - C8 2.827 3.50E-05 0.269 -0.684 0.093 -0.288 0.059 17.046 4.913 
C8 - N10 2.554 2.02E-03 0.338 -1.116 0.118 -0.770 0.246 29.384 3.136 
dcbpyr 
N8 - C9 2.559 2.26E-03 0.337 -1.112 0.111 -0.763 0.242 32.328 3.148 
C9 - C10 2.837 3.20E-05 0.265 -0.661 0.118 -0.282 0.058 18.332 4.825 
C10 - N12 2.556 2.27E-03 0.338 -1.114 0.114 -0.768 0.245 32.379 3.137 
phn 
C7 - C9 2.764 1.05E-04 0.284 -0.737 0.163 -0.326 0.071 18.877 4.597 
C7 - N10 2.569 2.24E-03 0.333 -1.115 0.105 -0.725 0.223 29.368 3.249 
C9 - N12 2.569 2.24E-03 0.333 -1.115 0.105 -0.725 0.223 29.368 3.249 
dmphn 
C7 - C9 2.763 1.43E-04 0.284 -0.737 0.165 -0.327 0.072 20.278 4.577 
C7 - N10 2.571 2.40E-03 0.332 -1.112 0.100 -0.719 0.220 31.585 3.261 
C9 - N12 2.571 2.40E-03 0.332 -1.112 0.100 -0.719 0.220 31.585 3.262 
dcphn 
C7 - C9 2.770 9.90E-05 0.283 -0.732 0.159 -0.323 0.070 22.303 4.616 
C7 - N11 2.557 2.52E-03 0.336 -1.095 0.110 -0.767 0.247 34.792 3.109 
C9 - N13 2.555 2.58E-03 0.336 -1.093 0.110 -0.776 0.251 34.763 3.088 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.41: The QTAIM and NBO properties of the nitrogen atoms that are available (N) for metal 
405 
coordination. 
 
bpyr 
Atom  q(A) 
|intra(
A)|
bond(
A)| |(A)| 
Vol(A
),0.00
1
Intra_Is
o(A)
bond_Is
o(A)
Iso(A
) zz(A)
Iso(A,
A)
Iso(A'
,A)
Iso(A
) 
Anisot
ropy Occ 
Energ
y 
N5 -1.152 0.087 1.009 1.045 
117.97
4 -3.771 -4.810 -8.581 
-
16.86
7 
-
79.85
0 7.666 
-
72.18
5 
533.9
352 
1.921
04 
-
0.329
18 
N9 -1.152 0.087 1.009 1.045 
117.95
6 -3.771 -4.808 -8.578 
-
16.86
5 
-
79.85
5 7.666 
-
72.18
9 
533.9
434 
1.921
03 
-
0.329
16 
Total 0.000 4.233 4.612 3.680 
1395.
438 
-
35.90
3 
-
58.63
1 
-
94.53
4 
-
161.8
03 
423.3
56 
181.7
63 
605.11
9 
2758.
7677   
dmbpyr 
N6 -1.154 0.086 1.015 1.060 
118.50
6 -3.913 -4.723 -8.636 
-
16.61
4 
-
71.97
1 7.746 
-
64.22
5 
525.9
265 
1.920
45 
-
0.326
04 
N10 -1.154 0.084 1.016 1.060 
118.52
0 -3.914 -4.717 -8.631 
-
16.55
2 
-
71.84
8 7.745 
-
64.10
3 
525.8
694 
1.920
43 
-
0.326
05 
Total 0.000 4.785 5.035 4.623 
1714.
945 
-
48.00
0 
-
69.31
8 
-
117.31
8 
-
181.7
36 
802.1
85 
255.8
62 
1058.
047 
2807.
9105   
dcbpyr 
N8 -1.136 0.095 0.989 0.991 
114.83
3 -3.457 -4.631 -8.088 
-
18.06
9 
-
94.08
4 7.390 
-
86.69
4 
576.2
422 
1.920
65 
-
0.340
82 
N12 -1.137 0.090 0.991 0.994 
114.83
2 -3.465 -4.630 -8.095 
-
18.08
6 
-
93.59
5 7.399 
-
86.19
6 
575.4
809 
1.920
83 
-
0.339
91 
Total -0.002 7.336 
13.70
1 8.388 
1867.
198 
-
60.24
0 
-
66.52
9 
-
126.7
69 
-
217.1
34 
582.7
24 
219.8
13 
802.5
37 
4369.
5752   
phn 
N10 -1.152 0.142 1.012 1.021 
116.80
8 -3.775 -5.244 -9.019 
-
19.67
5 
-
74.49
8 7.342 
-
67.15
6 
543.2
858 
1.918
56 
-
0.325
82 
N12 -1.152 0.142 1.012 1.021 
116.80
8 -3.775 -5.241 -9.015 
-
19.66
9 
-
74.49
4 7.341 
-
67.15
3 
543.2
735 
1.918
55 
-
0.325
82 
Total 0.000 4.340 4.675 3.698 
1537.
415 
-
39.46
5 
-
80.75
8 
-
120.2
23 
-
237.7
32 
541.8
31 
216.2
57 
758.0
88 
3083.
1443   
dmphn 
N10 -1.158 0.129 1.004 1.026 
115.37
1 -3.808 -5.056 -8.864 
-
19.16
9 
-
67.82
3 7.219 
-
60.60
4 
498.0
169 
1.917
09 
-
0.318
24 
N12 -1.158 0.129 1.004 1.026 
115.40
6 -3.808 -5.055 -8.863 
-
19.16
6 
-
67.82
3 7.220 
-
60.60
3 
498.0
145 
1.917
06 
-
0.318
21 
406 
Total 0.000 4.968 4.979 4.550 
1857.
125 
-
52.08
5 
-
90.32
0 
-
142.4
05 
-
256.3
19 
928.1
69 
288.4
64 
1216.
633 
3107.
6483   
dcphn 
N11 -1.120 0.074 0.969 0.928 
109.7
78 -3.401 -5.313 -8.714 
-
19.73
7 
-
80.71
3 7.516 
-
73.19
7 
549.7
021 
1.916
75 
-
0.338
37 
N13 -1.118 0.066 0.965 0.927 
110.48
6 -3.320 -5.311 -8.631 
-
19.84
3 
-
88.77
2 7.507 
-
81.26
5 
561.5
419 
1.915
57 
-
0.336
94 
Total 0.000 7.287 13.117 8.275 
2018.
455 
-
64.30
6 
-
89.42
7 
-
153.7
33 
-
282.9
50 
684.4
09 
256.5
60 
940.9
69 
4655.
9297   
 
 
 
 
 
Table 4.42: The electronic excitation of the ligands showing their triplet and singlet transitions 
 
Ligang State Wavelength f Transitions  
bpyr Triplet-A 375.68 0 
HOMO→LUMO (89%); HOMO→L+1 (11%); H-5→L+2 (4%); H-
5→L+4 (5%) 
 Triplet-A 330.04 0 H-2→L+2 (14%); H-1→LUMO (76%); H-1→L+1 (11%); 
 Triplet-A 318.93 0 H-2→LUMO (66%); H-2→L+1 (11%); H-1→L+2 (28%); 
 Singlet-A 313.99 0.0004 H-1→LUMO (87%); 
 Singlet-A 292.28 0.0041 H-2→LUMO (86%); H-1→L+2 (2%); 
 Singlet-A 288.92 0 H-2→L+2 (22%); H-1→L+1 (63%); 
dmbpyr Triplet-A 377.46 0 
H-5→L+4 (10%); H-3→L+2 (10%); HOMO→LUMO (91%); H-
4→LUMO (5%) 
 Triplet-A 324.56 0 
H-1→LUMO (71%); H-5→LUMO (6%); H-4→L+2 (6%); H-
3→L+1 (4%) 
  Triplet-A 316.39 0 
H-5→LUMO (36%); H-4→L+2 (20%); H-3→L+1 (26%); H-
1→LUMO (10%) 
 Singlet-A 312.71 0.0005 H-1→LUMO (87%); 
 Singlet-A 287.66 0.0044 H-2→LUMO (88%); 
 Singlet-A 286.60 0.3159 
HOMO→LUMO (68%); H-4→LUMO (6%); H-4→L+1 (2%); 
HOMO→L+1 (7%) 
dcbpyr Triplet-A 425.81 0 
H-4→LUMO (13%); HOMO→LUMO (69%); HOMO→L+2 
(35%); H-7→L+1 (7%) 
 Triplet-A 407.32 0 H-2→L+1 (11%); H-1→LUMO (92%); H-1→L+6 (3%); 
 Triplet-A 369.47 0 H-2→LUMO (59%); H-1→L+1 (43%); H-2→L+6 (3%); 
 Singlet-A 360.69 0 H-1→LUMO (88%); H-2→L+1 (2%); 
 Singlet-A 348.79 0.1497 HOMO→LUMO (76%); H-4→L+2 (4%); HOMO→L+2 (3%); 
 Singlet-A 338.25 0.0028 H-2→LUMO (48%); H-1→L+1 (37%); 
phn Triplet-A' 450.90 0 
H-2→L+1 (21%); HOMO→LUMO (103%); H-6→L+10 (2%); H-
5→L+4 (3%) 
 Triplet-A' 361.34 0 HOMO→L+1 (99%); H-4→LUMO (6%); H-4→L+4 (2%);5-→11 
407 
(6) 
 Triplet-A" 359.10 0 
H-3→LUMO (13%); H-1→L+1 (86%); H-3→L+4 (3%); H-1→L+2 
(5%) 
  
Singlet-
A" 344.24 0 H-1→L+1 (83%); H-3→LUMO (2%);35-→11 (-24);35-→11 (-24) 
 Singlet-A' 325.89 0.0003 H-2→LUMO (28%); HOMO→L+1 (66%);4-→9 (5);4-→9 (5) 
 
Singlet-
A" 321.38 0.0013 H-1→LUMO (90%); H-3→L+1 (2%);35-→4 (-31);35-→4 (-31) 
dmphn Triplet-A 449.21 0 
H-1→LUMO (22%); HOMO→L+1 (100%); H-5→L+4 (3%); H-
4→LUMO (4%) 
 Triplet-A 370.29 0 HOMO→LUMO (104%); H-4→L+1 (4%);5-→10 (5);5-→10 (5) 
 Triplet-A 352.06 0 
H-3→L+1 (10%); H-2→LUMO (87%); H-3→L+4 (3%); H-2→L+2 
(6%) 
 Singlet-A 349.04 0.0013 H-1→L+1 (22%); HOMO→LUMO (68%);4-→9 (5);4-→9 (5) 
 Singlet-A 326.74 0 H-2→LUMO (89%);35-→10 (-25);35-→10 (-25);29-→80 (51) 
 Singlet-A 317.39 0.0011 H-2→L+1 (89%);35-→4 (-31);35-→4 (-31);29-→92 (63) 
dcphn Triplet-A 489.24 0 
HOMO→LUMO (108%); H-10→L+5 (3%); H-7→L+3 (2%); H-
6→L+1 (5%) 
 Triplet-A 392.59 0 
H-3→L+1 (12%); H-1→LUMO (74%); H-1→L+1 (11%); H-
3→L+2 (3%) 
 Triplet-A 382.38 0 
H-3→LUMO (37%); H-1→L+1 (48%); H-3→L+1 (9%); H-3→L+5 
(2%) 
 Singlet-A 371.54 0.0005 H-1→LUMO (87%);21-→5 (-16);38-→5 (-33);40-→90 (50) 
 Singlet-A 358.76 0.1912 HOMO→LUMO (71%); H-2→L+1 (9%);4-→7 (3);3-→6 (3) 
 Singlet-A 351.69 0.0002 
H-3→LUMO (57%); H-1→L+1 (23%); H-1→L+2 (6%);38-→8 (-
30) 
 
 
 










Table 4.43: The molecular orbital (MO) contribution of the nitrogen atom(s) ―N‖ available for metal 
coordination.  
408 
 
 
bpyr 
 eV N9 N5 others 
L+5 0.14 -7 -7 116 
L+4 0.03 -1 0 103 
L+3 -0.12 -11 -11 124 
L+2 -0.94 10 10 81 
L+1 -1 5 5 90 
LUMO -1.6 10 10 80 
HOMO -6.81 2 2 96 
H-1 -7.02 36 36 29 
H-2 -7.22 34 34 32 
H-3 -7.78 6 6 88 
H-4 -7.97 16 15 69 
H-5 -8.19 7 8 85 
H-6 -9.98 5 5 90 
H-7 -10.45 5 5 90 
dmbpyr 
 eV N10 N6 others 
L+5 0.19 -4 -4 111 
L+4 0.03 1 1 99 
L+3 -0.08 -11 -12 125 
L+2 -0.74 10 8 83 
L+1 -0.8 4 6 90 
LUMO -1.47 9 9 82 
HOMO -6.66 3 3 95 
H-1 -6.9 35 36 29 
H-2 -7.08 34 33 33 
H-3 -7.54 10 11 79 
H-4 -7.56 14 13 73 
H-5 -7.8 2 2 96 
H-6 -9.63 4 4 92 
H-7 -10.1 3 3 93 
dcbpyr 
 eV N8 N12 others 
L+5 -0.25 -1 -3 106 
L+4 -0.36 -8 -3 113 
L+3 -0.42 2 2 96 
L+2 -1.9 0 0 99 
L+1 -2.21 5 7 87 
LUMO -2.7 12 10 77 
HOMO -7.13 2 2 95 
H-1 -7.26 34 38 28 
H-2 -7.79 35 31 34 
409 
H-3 -8.34 10 6 84 
H-4 -8.36 10 17 72 
H-5 -8.41 0 2 98 
H-6 -8.48 2 0 97 
H-7 -8.74 5 3 93 
phn 
 eV N12 N10 others 
L+5 0.13 -6 -6 114 
L+4 0.03 4 4 91 
L+3 -0.05 -6 -6 113 
L+2 -0.64 4 4 92 
L+1 -1.76 12 12 77 
LUMO -1.82 4 4 92 
HOMO -6.51 4 4 92 
H-1 -6.84 35 35 30 
H-2 -6.89 4 4 92 
H-3 -7.31 34 34 33 
H-4 -8.19 14 14 71 
H-5 -8.39 2 2 95 
H-6 -9.4 10 10 80 
H-7 -9.86 4 4 92 
dmphn 
 eV N12 N10 others 
L+5 0.18 -12 -12 126 
L+4 0.11 3 3 93 
L+3 0.02 -7 -7 115 
L+2 -0.47 5 5 90 
L+1 -1.57 4 4 92 
LUMO -1.6 10 10 80 
HOMO -6.23 5 5 90 
H-1 -6.65 2 2 95 
H-2 -6.67 35 35 29 
H-3 -7.14 34 34 33 
H-4 -7.92 17 17 65 
H-5 -8.14 1 1 97 
H-6 -9.06 11 11 77 
H-7 -9.64 4 4 92 
dcphn 
 eV N13 N11 others 
L+5 -0.19 5 5 90 
L+4 -0.27 -6 -4 112 
L+3 -0.53 1 1 98 
L+2 -1.84 2 2 97 
L+1 -2.17 15 16 69 
LUMO -2.76 5 5 90 
410 
HOMO -6.99 4 3 93 
H-1 -7.28 21 38 40 
H-2 -7.34 4 5 91 
H-3 -7.7 46 13 41 
H-4 -7.93 2 0 98 
H-5 -8.23 0 18 82 
H-6 -8.6 13 13 74 
H-7 -8.73 1 1 97 
 
 
 
 
Table 4.44: The non-linear conductive properties of the ligands 
 
 Dipole      
 ß in esu 
(1x10-
30) HOMO LUMO 
Gap in 
KJ/mol 
Non-
Valence 
Lewis 
Orbitals 
bpyr 3.24 136.67 -7.32 112.51 6302.94 -3.49 0.48 -0.2501 -0.0586 502.88 2.98% 
dmbpyr 3.99 166.03 5.71 123.62 7624.68 -5.31 0.49 -0.2447 -0.0541 500.41 2.59% 
dcbpyr 2.67 184.39 -129.75 165.79 5326.43 -7.13 1.61 -0.2622 -0.0990 428.47 2.67% 
phn 3.43 165.31 -129.38 152.69 3287.10 -3.79 0.35 -0.2391 -0.0668 452.54 2.85% 
dmphn 2.30 197.84 -134.72 168.35 5095.27 -5.96 2.94 -0.2289 -0.0588 446.54 2.49% 
dcphn 6.06 218.27 -149.89 200.47 8861.17 -8.22 6.48 -0.2569 -0.1015 407.98 3.31% 
 
 
 
Table 5.1: The synthesised complexes and their starting materials 
 
 Starting Material mmol Solvent Product % yield 
ST1 RuCl3·3H2O 7.62 dmso RuCl2(dmso)4 40.04 
ST2 RuCl3·3H2O 7.016 Ethanol [(cym)RuCl2]2 60.20 
ST3 RuCl3·3H2O 11.2 Hcl Ru(bdmpzm)Cl4 47.50 
ST4 RuCl3·3H2O 1.2 Hcl Ru(bpzm)Cl4 62.86 
C1 RuCl3·3H2O 0.237 DMF [Ru(bpzm)3]
2+ 20.06 
C2 RuCl3·3H2O 0.33 DMF [Ru(bpza)3]
2+ 24.94 
C3 RuCl3·3H2O 0.702 EtOH [Ru(bdmpzm)3]
2+ 18.45 
C4 RuCl3·3H2O 0.333 DMF [Ru(bdmpza)3]
2+ 16.89 
C5 RuCl3·3H2O 0.622 EtOH Ru(bpzm)2Cl2 23.69 
C6 RuCl2(dmso)4 0.5 DMF Ru(bpza)2Cl2 68.30 
C7 RuCl3·3H2O 2.85 EtOH Ru(bdmpzm)2Cl2 60.79 
C8 RuCl2(dmso)4 0.5 DMF Ru(bdmpza)2Cl2 59.83 
C9 RuCl2(dmso)4 0.5 DMF Ru(bpza)(bdmpza)Cl2 52.45 
411 
C10 Ru(bdmpzm)Cl4 0.5 CH2Cl2 Ru(bpza)(bdmpzm)Cl2 80.26 
C11 RuCl2(dmso)4 0.4 DMF Ru(bpza)(bphpza)Cl2 30.77 
C12 RuCl2(dmso)4 0.5 DMF Ru(bpza)(bpyr)Cl2 81.75 
C13 RuCl2(dmso)4 0.5 DMF Ru(bpza)(dmbpyr)Cl2 67.76 
C14 RuCl2(dmso)4 0.5 DMF Ru(bpza)(phn)Cl2 74.62 
C15 RuCl2(dmso)4 0.5 DMF Ru(bpza)(dmphn)Cl2 37.77 
C16 Ru(bdmpzm)Cl4 0.4 THF  Ru(bdmpzm)(bdmpza)Cl2 53.52 
C17 RuCl2(dmso)4 0.4 DMF Ru(bdmpza)(bphpza)Cl2 28.22 
C18 RuCl2(dmso)4 0.5 DMF Ru(bdmpza)(pyr)Cl2 15.15 
C19 RuCl2(dmso)4 0.5 DMF Ru(bdmpza)(bmpyr)Cl2 24.12 
C20 RuCl2(dmso)4 0.5 DMF Ru(bdmpza)(dmphn)Cl2 15.96 
C21 Ru(bdmpzm)Cl4 0.4 DMF Ru(bdmpzm)(bpzm)Cl2 50.68 
C22 Ru(bdmpzm)Cl4 0.4 DMF Ru(bdmpzm)(bphpza)Cl2 54.95 
C23 Ru(bdmpzm)Cl4 0.4 Toluene [Ru(bdmpzm)(bpzpy)Cl]
+ 27.44 
C24 Ru(bdmpzm)Cl4 0.4 THF  [Ru(bdmpzm)(bdmpzpy)Cl]
+ 15.00 
C25 [(cym)RuCl2]2 0.09 Methanol (cym)Ru(pz)Cl2 80.15 
C26 [(cym)RuCl2]2 0.09 Methanol (cym)Ru(dmpz)Cl2 78.71 
C27 [(cym)RuCl2]2 0.08 Methanol (cym)Ru(dcpz)Cl2 28.39 
C28 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(bpzm)Cl]
+ 92.31 
C29 [(cym)RuCl2]2 0.1633 CH3CN [(cym)Ru(bpza)Cl]
+ 20.58 
C30 [(cym)RuCl2]2 0.1633 CH3CN [(cym)Ru(bmpzm)Cl]
+ 24.87 
C31 [(cym)RuCl2]2 0.088 CH3CN [(cym)Ru(bmpza)Cl]
+ 44.50 
C32 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(bphpza)Cl]
+ 62.44 
C33 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(pyr)Cl]
+ 25.16 
C34 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(phn)Cl]
+ 97.62 
C35 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(bmpyr)Cl]
+ 90.33 
C36 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(dmphn)Cl]
+ 58.39 
C37 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(dcbpyr)Cl]
+ 36.65 
C38 [(cym)RuCl2]2 0.1633 CH3CN [(cym)Ru(dcphn)Cl]
+ 41.47 
C39 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(bpzpy)]
2+ 75.06 
C40 [(cym)RuCl2]2 0.1633 Methanol [(cym)Ru(bdmpzpy)]
2+ 43.97 
 
 
 
 
 
 
 
 
 
Table 5.2: The calculated and the found elemental analysis of the synthesised complexes (those in red is 
an indication of the presence of impurities). 
 
  Calculat   Found   
412 
ed 
  C H S C H S 
ST1 RuCl2(dmso)4 19.83 4.99 26.47 20.04 4.418 25.822 
  C H N C H N 
ST2 [(cym)RuCl2]2 39.23 4.61 0 39.31 4.61 0 
ST3 Ru(bdmpzm)Cl4 29.55 3.61 12.53 30.06 4.14 12.32 
ST4 Ru(bpzm)Cl4 21.5 2.06 14.33 21.06 2.028 14.65 
C1 [Ru(bpzm)3]
2+ 30.19 2.9 20.12 24.944 1.922 17.706 
C2 [Ru(bpza)3]
2+ 29.79 2.5 17.37 30.28 2.743 18.92 
C3 [Ru(bdmpzm)3]
2+ 39.49 4.82 16.74 39.514 4.665 16.093 
C4 [Ru(bdmpza)3]
2+ 38.07 4.26 14.8 38.63 4.451 14.618 
C5 Ru(bpzm)2Cl2 35.91 3.44 23.93 28.422 2.12 17.914 
C6 Ru(bpza)2Cl2 34.54 2.9 20.14 34.581 3 20.186 
C7 Ru(bdmpzm)2Cl2 45.52 5.56 19.3 35.438 3.881 15.263 
C8 Ru(bdmpza)2Cl2 43.12 4.82 16.76 43.435 4.964 17.089 
C9 Ru(bpza)(bdmpza)Cl2 39.22 3.95 18.3 39.112 4.477 18.494 
C10 Ru(bpza)(bdmpzm)Cl2 40.15 4.26 19.71 40.21 4.685 19.76 
C11 Ru(bpza)(bphpza)Cl2 47.47 3.41 15.82 47.903 3.364 15.834 
C12 Ru(bpza)(bpyr)Cl2 41.55 3.1 16.15 41.87 3.9 16.77 
C13 Ru(bpza)(dmbpyr)Cl2 43.8 3.68 15.32 43.95 3.933 15.202 
C14 Ru(bpza)(phn)Cl2 44.13 2.96 15.44 41.34 4.138 15.3 
C15 Ru(bpza)(dmphn)Cl2 46.16 3.52 14.68 45.876 2.91 14.237 
C16 Ru(bdmpzm)(bdmpza)Cl2 44.23 5.16 17.94 37.639 2.909 14.467 
C17 Ru(bdmpza)(bphpza)Cl2 50.27 4.22 14.65 50.35 4.641 14.899 
C18 Ru(bdmpza)(pyr)Cl2 45.84 4.2 14.58 46.092 4.014 14.082 
C19 Ru(bdmpza)(dmbpyr)Cl2 47.69 4.67 13.9 47.17 4.23 13.43 
C20 Ru(bdmpza)(dmphn)Cl2 49.69 4.49 13.37 49.605 4.221 13.983 
C21 Ru(bdmpzm)(bpzm)Cl2 41.23 4.61 21.37 32.4 4.819 18.11 
C22 Ru(bdmpzm)(bphpza)Cl2 51.67 4.48 15.55 41.92 5.992 14.15 
C23 [Ru(bdmpzm)(bpzpy)Cl]+ 37.91 3.62 18.09 30.914 2.455 12.897 
C24 [Ru(bdmpzm)(bdmpzpy)Cl]+ 41.47 4.42 16.74    
C25 (cym)Ru(pz)Cl2 41.72 4.85 7.48 41.9 4.587 7.52 
C26 (cym)Ru(dmpz)Cl2 44.78 5.51 6.96    
C27 (cym)Ru(dcpz)Cl2 38.97 3.92 6.06 38.8 3.947 6.29 
C28 [(cym)Ru(bpzm)Cl]+ 36.21 3.93 9.94 36.57 3.856 10.31 
C29 [(cym)Ru(bpza)Cl]+ 35.57 3.65 9.22    
C30 [(cym)Ru(bmpzm)Cl]+ 40.68 4.88 9.04 40.45 4.785 8.82 
C31 [(cym)Ru(bmpza)Cl]+ 39.8 4.55 8.44 39.59 4.258 7.91 
C32 [(cym)Ru(bphpza)Cl]+ 47.41 3.98 7.37 47.93 3.971 7.46 
C33 [(cym)Ru(pyr)Cl]+ 42 3.88 4.9    
C34 [(cym)Ru(phn)Cl]+ 44.34 3.72 4.7 44.11 3.796 4.77 
C35 [(cym)Ru(dmbpyr)Cl]+ 44.04 4.37 4.67 44.14 4.593 4.71 
C36 [(cym)Ru(dmphn)Cl]+ 46.2 4.2 4.49 46.23 4.264 4.52 
C37 [(cym)Ru(bcpyr)Cl]+ 40.04 3.36 4.25 32.1 3.931 0.44 
C38 [(cym)Ru(dcphn)Cl]+ 53.48 4.11 5.2 31.25 3.298 1.7 
413 
C39 [(cym)Ru(bpzpy)]2+ 42.64 3.92 11.84 34.19 3.035 6.45 
C40 [(cym)Ru(bdmpzpy)]2+ 46.37 4.82 10.81 33.55 3.912 0.31 
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Table 5.3: The Assignment of the prominent IR binbrations of the complexes using PED 
 
Freq. Int. Assignment Freq. Int. Assignment Freq. Int. Assignment Freq. Int. Assignment 
ST1=RuCl2(dmso)4 ST2=[(cym)RuCl2]2 ST3=Ru(bdmpzm)Cl4 ST4=Ru(bpzm)Cl4 
2990.83 31.92  (CH), (CH) 2977.67 48.48  (CH), (CH) 2981.45 31.04  (CH), (CH) 1431.77 46.62  (CNN), (CC) 
1297.12 37.04  (HCH), (HCH) 2970.37 51.44  (CH), (CH) 2948.76 63.82  (CH),  1430.68 35.89  (CC), (CNN) 
1073.25 205.33  (SO),  292.65 31.67  (RuCl),  1573.86 34.88  (CC), (HCC) 1392.46 38.38  (HCN), (HCNN) 
1057.31 178.88  (SO), (SO)    1559.01 30.39  (CC), (HCC) 1276.72 87.78  (NN), (NC) 
1053.2 77.73  (SO), (SO)    1488.05 39.34  (CC),  1273.39 40.96  (NC),  
1048.07 115.72  (SO),     1480.42 56.69  (CC),  1054.09 53.68  (HCC), (CC) 
1006.64 156.25  (HCSRu), (HCSRu)    1410.75 35.55  (HCH), (HCH) 724.46 56.88  (HCCC), (HCCN) 
1005.51 33.81  (HCSRu), (HCSRu)    1400.26 57.88  (HCH), (HCH) 720.71 30.89  (HCCN), (HCCC) 
396.76 35.95  (CSO), (OSC)    1283.49 76.79  (NC),  398.75 30.94  (CNRu), (HCNN) 
389.15 32.13  (ORuCS), (OSC)    1234.99 37.93  (CC), (CNN) 329.21 70.52  (RuCl),  
385.99 42.04  (OCRuS), (CSO)    349.5 38.95  (RuCl), (RuCl) 263.75 36.39  (RuCl),  
      314.34 59.24  (RuCl),     
      304.36 31.9  (RuCl), (RuCl)    
C1=[Ru(bpzm)3]
2+
 C2=[Ru(bpza)3]
2+
 C3=[Ru(bdmpzm)3]
2+
 C4=[Ru(bdmpza)3]
2+ 
1432.38 60.2  (CNN),  3601.02 174.07  (OH),  1587.69 55.41  (CC), (CC) 3618.09 125.4  (OH),  
1427.35 30.14  (CNN), (NC) 1852.3 262.85  (OC),  1579.57 56.63  (CC),  3604.23 116.37  (OH),  
1273.27 101.41  (NN), (NC) 1850.11 135.19  (OC),  1575.63 41.83  (CCN), (CC) 3534.02 124.76  (OH),  
1270.05 33.21  (NN), (NC) 1805.59 175.33  (OC),  1567.04 40.66  (CC), (CC) 2959.06 187  (CH),  
1266.49 94.76  (NN), (NC) 1436.28 60.29  (CNN),  1565.07 42.39  (CC), (CC) 1827.63 147.97  (OC),  
1263.23 35.28  (NN),  1303.7 128.23  (HCCO), (NC) 1450.93 36.06  (HCH), (HCH) 1820.18 283.5  (OC),  
1055.04 32.92  (HCC), (HCC) 1295.93 68.3  (HCCO), (NC) 1422.65 38.84  (HCH),  1594.42 57.37  (CC),  
739.93 79.43  (HCCN), (HCCC) 1293.39 115.31  (HCCO), (NC) 1419.67 56.42  (HCH),  1588.7 52.01  (CC), (CC) 
738.04 42.84  (HCCN), (HCCC) 1263.45 205.11  (OC), (HOC) 1418.1 37.12  (HCH), (HCH) 1570.42 62.83  (CC), (CC) 
736.92 63.29  (HCCN), (HCCC) 1259.28 211.91  (OC), (HCC) 1403.46 58.45  (NC), (CCN) 1421.03 51.69  (HCH), (HCH) 
735.31 75.8  (HCCN), (HCCC) 1251.82 189.39  (OC), (HCC) 1283.75 102.0  (NC),  1386.22 60.16  (NC),  
415 
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730.87 47.33  (HCCN), (HCCC) 1187.99 58.39  (HCC),  1281.33 32.83  (CNC), (NC) 1380.67 65.5  (NC),  
   1126.66 144.6  (OC), (HOC) 1274.33 83.5  (NN),  1314.46 51.1  (CNN), (HCCO) 
   743.95 99.49  (HCCC), (HCCN) 1269.59 89.69  (HCN), (NC) 1304.11 129.28  (HCCO), (NC) 
   743 59.83  (HCCC), (HCCN) 1257.14 87.05  (HCN),  1301.94 142.95  (HCCO), (NC) 
   743.5 57.73  (HCCC), (HCCN) 1246.09 47.32  (HCN), (HCNN) 1255.07 182.68  (HOC), (OC) 
   721.76 73.88  (HOCC),  1218.28 41.9  (CNN), (NN) 1252.55 122.03  (HCC), (NN) 
   649.73 75.66  (OCO),     1230.72 79.93  (HCC),  
   517 97.66  (HOCC),     1138.65 140.28  (HOC), (OC) 
   506.85 97.03  (HOCC),     676.27 93.93  (HOCC),  
C5=Ru(bpzm)2Cl2 C6=Ru(bpza)2Cl2 C7=Ru(bdmpzm)2Cl2 C8=(bdmpza)2RuCl2 
2939.91 195.3  (CH), (CH) 3633.31 104.73  (OH),  3006.97 45.51  (CH), (CH) 3641.06 81.38  (OH),  
1459.06 57.41  (NC),  3548.58 147.96  (OH),  2977.61 77.42  (CH), (CH) 3633.85 52.72  (OH),  
1394.03 57.76  (HCH), (HCH) 2828.24 244.11  (CH),  2973.91 98.35  (CH), (CH) 2975.54 35.52  (CH), (CH) 
1338.51 38.4  (CC), (HCNN) 2645.38 559.78  (CH),  2970.65 62.47  (CH), (CH) 2967.85 42.08  (CH), (CH) 
1260.79 46.79  (CC), (NC) 1788.95 214.02  (OC),  2954.54 61.87  (CH), (CH) 2696.89 352.03  (CH),  
1102.3 101.33  (CNN),  1763.94 318.82  (OC),  1586.77 59.22  (CC),  1792.86 170.15  (OC),  
1088.85 41.71  (CNN), (CCN) 1368.07 56.83  (CC), (HCC) 1577.4 38.07  (CC),  1779.29 258.86  (OC),  
695.39 126.68  (HCCC), (HCCC) 1307.09 68.47  (HCCO), (NC) 1431.28 51.32  (HCH), (HCH) 1597.25 36  (CC),  
691.96 95.01  (HCCC), (HCCC) 1289.27 340.21  (OC), (HOC) 1415.06 42.41  (HCH), (HCH) 1425.93 43.98  (HCH),  
   1128.27 214.94  (OC), (HOC) 1305.68 
119.2
9  (NN),  1314.64 108.02  (HCCO), (HOC) 
   1089.69 66.4  (HCC), (CNN) 1304.44 37.05  (NC),  1310.12 43.05  (NC),  
   1085.94 54.79  (HCC), (CCN) 1190.34 86.62  (CNN), (NN) 1171.17 63.47  (NN),  
   717.54 60.28  (HCCN), (HCCC)    1147.71 53.72  (HCC), (HCC) 
   714.29 62.9  (HCCN), (HCCC)    1142.9 146.74  (OC), (HCC) 
   712.85 70.28  (HCCC), (HCCN)    1120.64 84.96  (OC), (HOC) 
   696.84 46.35  (HCCC), (HCCN)    636.27 79.17  (OCO), (HOCC) 
   669.5 47.02  (HOCC), (CNCN)    621.27 47.5  (CCNN),  
   640.46 84.91  (HOCC), (CNRuN)    612.69 35.3  (OCO), (CCNN) 
416 
   633.36 48.7  (CNRuN), (OCO)    574.81 35.95  (OCO), (OCOC) 
   604.32 62.13  (HOCC),     455.61 40.52  (HOCC),  
C9=Ru(bpza)(bdmpza)Cl2 C10=Ru(bpza)(bdmpzm)Cl2 C11=Ru(bpza)(bphpza)Cl2 C12=Ru(bpza)(bpyr)Cl2 
3651.58 65.32  (OH),  3629.1 61.16  (OH),  3645.1 66.81  (OH),  3492.17 244.99  (OH),  
3638.45 81.23  (OH),  2983.13 33.55  (CH), (CH) 3637.73 89.19  (OH),  2831.22 283.24  (CH),  
2993.25 67.41  (CH), (CH) 2970.66 77.55  (CH), (CH) 3130.89 50.82  (CH), (CH) 1786.83 233.3  (OC),  
2558.36 709.61  (CH),  1777.95 205.59  (OC),  3124.53 78.41  (CH), (CH) 1472.35 41.36  (CC), (CC) 
1812.42 173.7  (OC),  1582.94 32.75  (CC), (CC) 3120.02 44.36  (CH), (CH) 1446.66 51.37  (CC), (HCC) 
1783.21 275.37  (OC),  1468.34 34.74  (NC), (CNN) 2637.58 
507.2
5  (CH),  1409.89 35.1  (NC), (HCC) 
1394.81 47.99  (NC), (CNN) 1420.62 37.85  (HCH), (CNN) 1806.51 
205.8
7  (OC),  1327.29 48.45  (NC), (NC) 
1317.34 80.07  (HCCO),  1384.73 36.06  (NC), (CNN) 1785.07 
269.0
5  (OC),  1304.07 43  (HCCO), (CC) 
1155.15 52.23  (OC), (HCC) 1300.69 84.9  (NC), (CNC) 1377.62 49.47  (HCCO), (NC) 1300.85 299.49  (HOC),  
1143.57 145.31  (OC), (HCC) 1290.13 31.29  (NC),  1328.18 83.97  (HCCO), (NC) 1221.05 42.03  (NN),  
1131.66 131.08  (OC), (HOC) 1167.53 51.96  (CC),  1201.35 48.21  (NC), (HCC) 1088.05 32.63  (NC), (CCN) 
1114.3 67.85  (NN), (HOC) 1137.26 35.76  (HCC),  1133.94 
252.4
1  (OC), (HOC) 1086.46 34.9  (NC), (CNN) 
1098.1 44.75  (HCC), (CNN) 1130.03 93.83  (OC), (HOC) 1130.99 
125.5
5  (OC), (HOC) 1015.56 41.49  (CCN), (CCC) 
685.54 50.89  (HCCN), (HCCC) 1096.98 51.17  (NC), (HCC) 1096.86 65.2  (HCC),  950.17 38.02  (NC), (CNN) 
674.19 118.19  (HOCC), (OCO) 944.06 35.82  (NC), (CCN) 730.67 68.35  (HCCC), (HCCN) 733.34 72.39  (HCCC), (HCCC) 
654.08 42.18  (HOCC), (CNRuN) 682.84 118.14  (HCCC), (HCCN) 684.72 50.89  (NRuCN), (CCC) 723.19 61.38  (HCCN), (HCCN) 
642.8 58.71  (CNNC),  669.77 50.6  (HCCN), (HCCC) 683.48 46.45  (HCCN), (HCCC) 719.38 58.9  (HCCN), (HCCN) 
632.32 43.18  (CCNN), (OCO) 650.8 38.5  (CNRuN),  671.51 92.99  (CCNN), (OCO) 706.51 32.33  (CCNC), (CCCC) 
566.74 66.35  (HOCC), (OCO) 602.36 66.42  (HOCC), (CNNRu) 664.08 46.52  (HOCC), (CCC) 615.17 45.19  (OCOC), (NC) 
   478.78 42.22  (HOCC), (CNC) 647.38 91.73  (OCO), (HOCC)    
C13=Ru(bpza)(dmbpyr)Cl2 C14=Ru(bpza)(phn)Cl2 C15=Ru(bpza)(dmphn)Cl2 C16=Ru(bdmpza)(bdmpzm)Cl2 
3477.54 275.9  (OH),  3491.17 258.43  (OH),  3335.07 
514.7
8  (OH),  2982.61 31.8  (CH), (CH) 
2979.88 50.03  (CH), (CH) 2834.08 297.79  (CH),  2897.62 
286.0
3  (CH),  2976.56 33.25  (CH), (CH) 
2979.73 36.01  (CH), (CH) 1786.95 241.28  (OC),  1782.08 287.3  (OC),  2974.21 62.74  (CH), (CH) 
417 
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2832.28 287.7  (CH),  1505.81 34.21  (CC), (NC) 1458.91 30.49  (HCH), (HCH) 2946.37 
1023.2
5  (OH),  
1786.2 241.1  (OC),  1326.97 47.42  (NC), (OC) 1454.03 37.65  (HCH), (HCH) 1762.11 275.83  (OC), (OC) 
1464.59 49.81  (HCC), (HCC) 1303.98 99.38  (HCCO), (NC) 1351.06 30.15  (HCCO), (NC) 1586.95 61.92  (CC),  
1447.99 52.02  (HCH), (HCH) 1299.92 238.86  (HOC),  1342.59 
153.5
8  (OC), (HOC) 1467.18 30.68  (CNN), (CC) 
1446.54 34.91  (HCH), (HCH) 1219.96 43.07  (NN),  1315.85 70.55  (NC), (HOC) 1324.59 75.04  (OC), (HCC) 
1327.26 48.58  (NC), (HOC) 1188.89 36.58  (HCC), (HCC) 1282.8 31.81  (HCCO), (NC) 1322.44 93.39  (HCCO), (OC) 
1303.11 32.35  (HCCO), (CC) 1087.37 39.91  (CNN),  1208.69 44.03  (NC), (HCC) 1304.41 77.21  (CNC), (NC) 
1301.78 282.78  (OC), (HOC) 1085.72 40.39  (HCC), (CNN) 1093.35 59.55  (HCC), (CNN) 1256.37 33.02  (OC), (HCC) 
1219.45 44.39  (NN),  950.1 39.87  (CNN),  827.16 64.02  (HCCC), (HCCC) 1229.37 52.06  (HCC),  
1087.68 35.97  (NC), (CCN) 817.35 61.33  (HCCC), (HCCC) 736.33 40.22  (HCCC), (HCCN) 1178.58 53.63  (CNN),  
1085.75 33.83  (NC), (CNN) 723.28 55.05  (HCCC), (HCCN) 726.42 70.22  (HCCC), (HCCN) 1173.41 112.65  (HOC),  
1015.64 52.36  (CCN), (CCC) 718.21 62.77  (HCCC), (HCCN) 722.6 33.29  (HOCC),  808.69 31.69  (HOCC),  
949.57 45.14  (NC), (CNN) 701.97 40.76  (CCCC),  689.93 31.81  (CNRuN), (OCO)    
800.09 44.71  (HCCN), (HCCC) 681.72 31.54  (OCO),        
721.77 54.79  (HCCN), (HCCN) 615.16 44.95  (NC), (COOC)       
717.75 67.76  (HCCN), (HCCN)  wih         
617.76 42.33  (OCOC), (NC)  IR         
C17=Ru(bdmpza)(bphpza)Cl2 C18=Ru(bdmpza)(pyr)Cl2 C19=Ru(bdmpza)(dmbpyr)Cl2 C20=Ru(bdmpza)(dmphn)Cl2 
3649.66 65.36  (OH),  3253.9 578.32  (OH),  3188.99 
737.6
8  (OH),  3239.32 624.12  (OH),  
3458.99 248.2  (OH),  2982.88 49.68  (CH), (CH) 2979.19 48.65  (CH), (CH) 2841.16 300.27  (CH),  
3186.79 58.24  (CH),  2819.62 328.3  (CH),  2977.92 55.05  (CH), (CH) 1805.94 323.83  (OC),  
3046.21 95.09  (CH),  1808.14 323.11  (OC),  2976.49 32.74  (CH), (CH) 1574.04 37.31  (CC),  
1800.67 177.95  (OC),  1572.24 30.11  (CC), (HCC) 2816.97 
342.1
2  (CH),  1451.35 44.56  (CC),  
1785.54 119.13  (OC),  1569.79 30.79  (CC), (CCN) 1782.56 
379.4
8  (OC),  1409.81 58.03  (NC), (HCH) 
1499.11 46.21  (CC), (HCC) 1475.94 34.86  (CC), (CC) 1564.68 32.61  (CC), (HCC) 1394.86 42.24  (CNN), (NC) 
1336.81 59.69  (OC), (HOC) 1413.44 34.81  (NC), (HCC) 1471.08 32.03  (CC), (CC) 1352.05 201.81  (OC), (HOC) 
1271.98 48.68  (NN), (NC) 1406.58 72.78  (NC), (HCH) 1447.7 41.01  (HCH),  1327.57 30.92  (NC),  
418 
1219.7 162.72  (NC), (HCC) 1391.15 50.33  (NC), (CNN) 1446.11 30.65  (HCH), (HCH) 1293.57 41.92  (HCCO), (HCC) 
1183.48 125.5  (NC), (HCC) 1353.02 213.07  (OC), (HOC) 1445.24 39.56  (CNN), (HCH) 1209.21 44.53  (NNC), (NC) 
1136.59 87.51  (OC), (HOC) 1298.79 50.33  (HCCO), (HCC) 1397.89 78.99  (NC), (HCH) 1201.51 37.27  (CNN), (OC) 
1129.09 155.49  (OC), (HOC) 1212.07 43.38  (CC), (CNN) 1387.19 44.9  (CNN), (NC) 1183.27 30.97  (OC),  
798.2 101.75  (CCO), (NC) 1205.08 36.58  (OC), (CNN) 1344.45 
167.3
4  (OC), (HOC) 825.03 49.61  (HCCC), (HCCC) 
763.65 70.55  (HCCC), (HCCC) 1182.75 33.6  (OC),  1297.28 53.6  (HCCO), (HCC) 716.15 30.75  (HOCC),  
745.58 61.98  (HCCC), (HCCC) 1016.19 32.46  (CCN), (CCC) 1205.09 37.1  (NC),     
736.02 96.91  (HCCN), (HCCC) 736.03 68.94  (HCCC), (HCCC) 1172.34 47.15  (OC),     
676.36 67.25  (CCC), (OCOC) 713.39 36.22  (HOCC),  1014.26 51.59  (CCN),     
669.06 49.42  (CCC), (OCOC)    730.32 33.99  (HOCC),     
637.13 61.15  (HOCC), (CCNN)          
C21=Ru(bdmpzm)(bpzm)Cl2 C22=Ru(bdmpzm)(bphpza)Cl2 C23=[Ru(bdmpzm)(bpzpy)Cl]
+
 C24=[Ru(bdmpzm)(bdmpzpy)Cl]
+ 
2972.94 93.03  (CH), (CH) 3622.65 78.43  (OH),  1569.48 45.54  (CC),  1593.19 73.48  (CC),  
2965.16 96.03  (CH), (CH) 3139.44 41.52  (CH), (CH) 1477.9 
100.8
3  (NC),  1461.05 137.28  (CC),  
2942.81 189.07  (CH),  3128.63 39.77  (CH), (CH) 1464.04 38.21  (NC),  1456.31 32.78  (HCH), (NC) 
1568.44 49.38  (CC),  3105.92 54.75  (CH),  1462.23 94.79  (NC),  1451.32 33.48  (HCH),  
1452.64 45.25  (NC), (HCN) 2971.82 46.95  (CH), (CH) 1423.85 56.38  (NC), (CNN) 1442.23 37.55  (HCH),  
1450.45 33.79  (CNN),  2929.67 63.36  (CH),  1414.85 59.42  (HCH), (HCH) 1421.36 33.48  (HCH), (HCNN) 
1448.6 31.93  (NC), (CNN) 1778.14 186.36  (OC),  1379.19 39.48  (NC), (CNN) 1414.87 36.18  (NC),  
1392.97 33.56  (HCH),  1475.56 41.84  (CNN), (NC) 1269.05 
130.7
2  (CC), (NN) 1413.42 35.47  (NC), (HCH) 
1273.37 42.12  (CC), (NC) 1402.77 67.06  (HCC), (NNC) 741.37 84.13  (HCCC), (CCCN) 1389.5 32.08  (NC),  
1269.05 50.26  (HCNN), (HCN) 1304.23 69.67  (NC),  710.32 60.86  (HCCN), (HCCC) 1385.63 33.23  (CNN), (NC) 
1096.38 49.57  (CNN), (CNN) 1279.64 36.31  (NNC),  708.25 34.5  (HCCN), (HCCC) 1269.17 72.54  (HCN), (NC) 
689.36 112.67  (HCCC), (HCCC) 1202.81 68.93  (NC), (HCC)    1267.86 39.81  (HCC),  
   1166.78 65.91  (NN), (HCC)    732.91 50.39  (HCCC), (HCCC) 
   1135.19 201.18  (OC), (HOC)       
   740.14 68.06  (HCCC), (HCCN)       
   731.02 76.81  (HCCC), (HCCN)       
   722.56 50.81  (HOCC), (OCOC)       
   691.91 38.16  (CCCC), (CCCC)       
419 
   651.43 60.32  (OCO),        
C25=(cym)Ru(pz)Cl2 C26=(cym)Ru(dmpz)Cl2 C27=(cym)Ru(dcpz)Cl2 C28=[(cym)Ru(bpzm)Cl]
+ 
3215.83 411.47  (NH),  3205.04 528.11  (NH),  3648.48 82.86  (OH),  1427.04 46.63  (CC), (CNN) 
3211.75 47.57  (CH), (CH) 3058.23 31.11  (CH), (CH) 3647.51 
126.2
4  (OH),  1268.91 102.16  (CC), (CNN) 
3052.57 33.61  (CH), (CH) 3051.41 30.2  (CH), (CH) 3022.26 624.5  (NH),  1054.44 31.03  (NN), (HCC) 
2972.77 39.98  (CH), (CH) 2971.62 38.99  (CH), (CH) 2973.82 32.54  (CH), (CH) 725.2 75.49  (HCCN), (HCCC) 
1268.55 48.94  (HNC), (HCC) 1568.37 55.99  (CC), (HNC) 1752.45 
222.9
6  (OC),  723.11 58.71  (HCCN), (HCCC) 
1146.18 60.92  (CC), (HNC) 1473.48 37.39  (CC), (CNN) 1743.12 
307.1
4  (OC),     
1052.3 43.69  (CC), (HCC) 1413.81 35.74  (CC), (HCH) 1544.48 36.73  (CC), (HNC)    
745.25 64.64  (HNCC), (HCCC) 1287.25 81.15  (NC), (HNC) 1445.7 73.08  (CNN), (CNN)    
   1212.62 48.54  (NN),  1397.03 
270.4
1  (NC), (CC)    
   769.55 49.97  (HNCC), (HCCC) 1335.25 
150.9
4  (NC), (HOC)    
      1250.52 74.95  (NC), (HNC)    
      1122.32 
213.7
4  (OC), (HOC)    
      1114.57 
525.4
6  (OC), (HOC)    
      1074.23 41.23  (OC), (HCC)    
      990.41 96.91  (CNN), (CNN)    
      744.13 52.14  (OCOC), (HCCN)    
      704.98 54.74  (CC), (OCO)    
      664.41 58.52  (OC), (OCO)    
      630.5 55.47  (HOCC),     
      538.7 92.33  (HOCC),     
C29=[(cym)Ru(bpza)Cl]
+
 C30=[(cym)Ru(bdmpzm)Cl]
+
 C31=[(cym)Ru(bdmpza)Cl]
+
 C32=[(cym)Ru(bphpza)Cl]
+ 
3605.32 143.34  (OH),  1564.4 54.02  (CC),  3622.41 
124.5
7  (OH),  3609.1 144.95  (OH),  
1784.78 197.75  (OC),  1472.1 40.29  (HCH), (HCH) 2884.86 
150.3
5  (CH),  1798.55 171.22  (OC),  
1428.05 56.05  (NC), (CNN) 1463.55 64.84  (NC), (NC) 1785.58 248.7  (OC),  1531.34 38.76  (CC), (NC) 
420 
1366.39 38.58  (OC), (HCC) 1412.71 56.71  (HCH),  1560.93 60.36  (CC),  1528.97 45.11  (CC), (CC) 
1298.12 101.5  (HCCO), (NC) 1382.34 44.5  (NC), (CNN) 1469.82 37.5  (HCH), (HCH) 1492.64 42.54  (CC),  
1218.94 40.89  (NN), (HCC) 1274.78 166.3  (NN), (NC) 1461.43 32.65  (HCH), (HCH) 1417.34 43.78  (NNC),  
1186.93 60.15  (HOC), (HCC)    1406.57 51.2  (HCH),  1414.33 39.75  (NC), (NNC) 
1113.64 182.34  (OC), (HOC)    1387.57 41.95  (HCCO), (NC) 1378.56 58.02  (OC), (HOC) 
1055.87 42.52  (HCC), (HCC)    1382.15 77.16  (NC), (CNN) 1364.62 41.94  (HCCO), (NC) 
732.67 65.49  (HCCN), (HCCC)    1341.09 34.32  (CC), (HOC) 1310.77 82.76  (HCCO), (NN) 
731.32 89.39  (HCCN), (HCCC)    1299.81 
118.3
1  (HCCO),  1205.49 118.13  (NN), (HCC) 
702.21 81.28  (HOCC),     1216.91 30.96  (CC), (NC) 1193.04 100.24  (HCC), (HOC) 
646.42 62.94  (OCO),     1156.78 45.01  (NN), (HCC) 1127.71 84.92  (HCCC), (OC) 
      1146.53 80.97  (NN), (HCC) 1127.45 52.8  (OC),  
      1114.4 96.4  (OC), (HOC) 1055.54 57.83  (HCC), (HCC) 
      1040.3 31.67  (HCCC), (CCCC) 761.15 38.85  (HCCN), (HCCC) 
      664.69 76.35  (HOCC),  753.46 38.96  (HCCC), (CCCC) 
      639.79 52.65  (HCCN), (CRuNN) 749.49 62.31  (HCCC), (HCCC) 
      629.09 32.73  (CCNN), (OCO) 722.32 93  (HOCC),  
         646.76 72.85  (OCO), (CCRuC) 
C33=[(cym)Ru(pyr)Cl]
+
 C34=[(cym)Ru(phn)Cl]
+
 C35=[(cym)Ru(dmbpyr)Cl]
+
 C36=[(cym)Ru(dmphn)Cl]
+ 
1451.2 47.12  (HCH),  828.92 69.56  (HCCC), (HCCC) 1617.92 39.12  (CC), (CC) 1470.29 36.23  (HCH),  
744.08 105.85  (HCCN), (HCCN) 705.98 30.15  (CCCC), (CCCC) 1613.28 64.52  (CC),  1433.68 33.54  (HCH), (HCH) 
      1472.36 42.94  (HCC), (CCN) 843.77 69.93  (HCCC), (HCCC) 
      1446.05 41.56  (HCH), (HCH)    
      803.72 52.32  (HCCN), (HCCC)    
C37=[(cym)Ru(dcbpyr)Cl]
+
 C38=[(cym)Ru(dcphn)Cl]
+
 C39=[(cym)Ru(bpzpy)]
2+
 C40=[(cym)Ru(bdmpzpy)]
2+ 
3638.79 165.81  (OH),  3642 132.23  (OH),  3233.18 44.92  (CH), (CH) 1599.35 197.54  (CC),  
3636.65 163.62  (OH),  3621.21 137.04  (OH),  1601.46 
109.8
3  (CC),  1555.03 46.23  (CC), (CC) 
1757.79 295.03  (OC),  1762.92 149.96  (OC),  1491.84 30.05  (CC), (HCC) 1479.77 222.05  (NC), (NC) 
1754.02 260.13  (OC),  1756.71 159.64  (OC),  1473.32 
192.7
1  (NC), (HCC) 1439.6 183.78  (CNN), (HCH) 
1425.02 42.59  (CC),  1350.96 43.71  (CC),  1470.61 58.38  (NC), (NC) 1418.46 55.5  (HCH), (HCH) 
1405.45 60.3  (CC), (CC) 1330.36 83.37  (OC), (HOC) 1420.24 138.3  (NC), (CNN) 1406.86 103.47  (NC), (HCH) 
421 
1338.23 190.5  (OC), (HOC) 1314.51 93.4  (OC), (HOC) 1350.7 32.78  (NC), (HCC) 1385.66 30.49  (HCC), (HCC) 
1338.93 166.04  (OC), (HOC) 1171.42 56.28  (CC), (HOC) 1041.15 60.65  (HCC), (HCC) 1375.42 44.74  (NC), (NC) 
1158.53 136.2  (HOC), (HCC) 1164.2 57.15  (CC), (HCC) 763.64 98.32  (HCCC), (HCCC) 1341.79 32.41  (NC), (HCC) 
1152.18 266.35  (CC), (HOC) 1128.34 237.34  (OC), (HOC) 735.16 78.82  (HCCC), (HCCN) 753.98 42.36  (HCCC), (HCCC) 
1110.98 143.69  (OC),  1117.83 231.53  (OC), (HOC)       
1091.3 131.81  (OC),  1068.98 192.57  (OC), (CNC)       
750.13 87.33  (HCCN), (OCOC) 854.91 68.38  (HCCC), (HCCC)       
702.56 49.37  (CCCN), (OCOC) 709.12 35.5  (OCOC),        
631.8 62.91  (OCO),  677.52 50.27  (OCO),        
622.26 40.75  (OCO),  609.48 39.79  (HOCC), (HOCC)       
614.65 133.04  (HOCC),  582.12 36.73  (HOCC), (CCC)       
   560.46 39.32  (OCO), (CCC)       
 
The symbols υ, β, τ, ο denote stretching, bending, torsional and out of plane modes respectively 
 
Table 5.4: The Assignment of he IR bibraions ha are associaed wih he Ru aom in he complexes using PED 
 
Freq. Int. Assignment Freq. Int. Assignment Freq. Int. Assignment Freq. Int. Assignment 
ST1=RuCl2(dmso)4 ST2=[(cym)RuCl2]2 ST3=Ru(bdmpzm)Cl4 ST4=Ru(bpzm)Cl4 
1030.6
8 24.87  (HCSRu), (HCSRu) 1015.28 11.92  (HCCRu), (HCCRu) 349.5 38.95  (RuCl), (RuCl) 631.93 6.06  (RuCNN),  
1006.6
4 
156.2
5  (HCSRu), (HCSRu) 1013.62 16.43  (HCCRu), (HCCRu) 314.34 59.24  (RuCl),  398.75 30.94  (CNRu), (HCNN) 
1005.5
1 33.81  (HCSRu), (HCSRu) 842.24 16.85  (HCCRu), (HCCRu) 304.36 31.9  (RuCl), (RuCl) 359.96 17.61  (RuCl),  
951.31 18.35  (SO), (HCSRu) 830.57 28.76  (HCCRu),  183.7 5.16  (RuN),  354.84 8.36  (RuCl), (CNC) 
389.15 32.13  (ORuCS), (OSC) 292.65 31.67  (RuCl),  139.14 2.5  (ClRuCl),  329.21 70.52  (RuCl),  
385.99 42.04  (OCRuS), (CSO) 283.21 13.24  (RuCl), (RuCl) 101.06 5.33  (ClRuCl),  302.05 26.02  (RuCl),  
356.92 18.31  (OCRuS), (CSO) 253.57 20.47  (RuCl), (RuCl)    263.75 36.39  (RuCl),  
349.17 15.71  (ORuCS), (OSC) 244.83 8.14  (RuCl), (ClRuCl)    239.02 5.19  (RuN),  
422 
284.2 17.88  (RuCl), (CSRu) 239.06 21.45  (RuCl), (ClRuCl)    221.32 4.24  (CNRu), (ClNNRu) 
252.99 18.07  (OCRuS), (RuCl) 199.49 13.23  (CCRuCl), (RuCl)       
C1=[Ru(bpzm)3]2+ C2=[Ru(bpza)3]2+ C3=[Ru(bdmpzm)3]2+ C4=[Ru(bdmpza)3]2+ 
640.02 4.63  (CRuNN),  638.02 21.36  (CNRuN),  649.77 2.12  (NCNRu),  652.5 21.58  (CNNC), (CRuNN) 
634.98 6.65  (CNNC), (CRuNN) 634.26 3.41  (CNRuN),  647.7 2.31  (NCNRu),  649.78 5.42  (CNRuN),  
632.86 3.34  (CNNC), (CRuNN) 630.38 15.01  (CNNC), (CNRuN)    217.91 3.42  (RuN),  
393.64 2.96  (CNC), (RuN) 619.76 3.01  (CNNC), (CNRuN)       
356.89 4.77  (NRuN), (RuN) 362.55 3.2  (RuN),        
330.98 3.44  (NRuN), (RuN) 300.92 3  (RuN),        
295.43 3.65  (RuN), (RuN) 198.86 2.41  (RuN),        
294.03 4.33  (RuN),  36.16 2.98  (CNNRu), (OCCN)       
203.6 3.01  (NNNRu), (NNRu)          
167.85 2.87  (NRuN), (RuN)          
C5=Ru(bpzm)2Cl2 C6=(bpza)2RuCl2 C7=Ru(bdmpzm)2Cl2 C8=(bdmpza)2RuCl2 
391.35 14.65  (RuN), (NRuN) 648.9 19.95  (CNRuN),  650.39 4.73  (CNNC), (CRuNN) 680.11 28.9  (HOCC), (CRuNN) 
335.63 14.26  (RuCl), (RuCl) 640.46 84.91  (HOCC), (CNRuN) 284.02 2.53  (CCC), (ClNNRu) 651.9 17.75  (CCNC), (CRuNN) 
291.85 18.93  (RuN), (CNRu) 633.36 48.7  (CNRuN), (OCO) 282.68 18.99  (CCC), (RuCl) 293.22 4.19  (CCC), (RuCl) 
221.02 5.19  (NNRuN), (NRuN) 384.25 8.85  (RuN),  227.59 3.43  (NNRu),  282.23 21.09  (RuCl),  
203.64 12.29  (RuCl), (CNRu) 377.61 5.98  (NNRu),  223.16 3.45  (CNRuN), (CCNC) 178.91 3.23  (CNNRu),  
176.44 3.98  (RuN), (NRuN) 309.93 10.97  (RuCl),  198.96 2.83  (CNNRu), (RuN) 145.03 2.09  (ClNNRu),  
130.32 3.56  (ClNClRu), (ClRuN) 284.13 7.8  (RuN), (RuN) 161.9 4.43  (RuN), (RuN) 131.69 2.31  (ClNNRu),  
111.48 4.03  (NNRuN), (NNRuN) 216.41 10.26  (NRuN), (ClRuCl) 142.83 2.62  (ClRuN), (CCNC) 106.06 3.96  (ClRuCl), (NNRuN) 
63.53 4.47  (ClNClRu), (ClRuN) 203.48 7.63  (RuCl),  90.45 3.05  (ClNClRu), (CNRuN) 99.84 6.16  (ClNClRu),  
62.19 5.92  (CNNRu), (CNNRu) 175.84 10.05  (ClNClRu), (ClRuCl) 62.62 4.39  (CNNRu), (NNNRu)    
C9=Ru(bpza)(bdmpza)Cl2 C10=Ru(bpza)(bdmpzm)Cl2 C11=Ru(bpza)(bphpza)Cl2 C12=Ru(bpza)(bpyr)Cl2 
654.08 42.18  (HOCC), (CNRuN) 650.8 38.5  (CNRuN),  684.72 50.89  (NRuCN), (CCC) 386.44 8.1  (NNRu),  
306.53 11.73  (RuCl),  640.59 10.78  (HCCN), (CRuNN) 394.88 9  (RuN), (RuN) 320.63 12.32  (RuCl),  
270.98 6.06  (CCC), (RuCl) 602.36 66.42  (HOCC), (CNNRu) 383.81 3.2  (NRuN),  312.31 13.98  (RuCl),  
236.71 4.83  (RuNC),  296.03 8.59  (CCC), (RuCl) 308.32 10.46  (RuCl),  296.12 3.82  (RuN), (RuN) 
423 
211.8 9.06  (NRuNN), (RuCl) 286.98 18.77  (RuCl),  285.78 3.65  (RuN),  228.88 11.6  (RuCl), (NNRu) 
188.47 4.26  (NNRu), (CCNC) 223.82 5.79  (RuCl),  237.77 6.99  (RuCl), (CNRu) 199.08 6.49  (RuCl), (ClRuCl) 
156.68 3.41  (ClNClRu),  216.79 7.04  (CNNRu),  213.12 7.41  (NNRuN), (RuCl) 175.53 3.87  (NNRuN), (ClRuCl) 
152.37 5.52  (ClRuCl),  202.41 4.71  (CNNRu),  192.03 6.45  (CCN), (ClNClRu) 106.18 6.49  (ClRuCl),  
44.79 2.22  (ClRuCl), (CNNC) 169.12 4.27  (RuN),  148.28 7.87  (ClRuCl),  88.63 5.03  (CNCC), (RuCCN) 
   123.78 4.63  (ClRuCl), (ClNClRu) 145.76 3.45  (ClRuCl), (RuN) 57.1 11.99  (CNNRu), (CNNC) 
C13=Ru(bpza)(dmbpyr)Cl2 C14=Ru(bpza)(phn)Cl2 C15=Ru(bpza)(dmphn)Cl2 C16=Ru(bdmpza)(bdmpzm)Cl2 
391.4 7.27  (RuN),  392.36 5.01  (RuN), (NRuN) 711.28 7.81  (CCCC), (CRuCN) 660.92 2.45  (CRuNN),  
293.75 20.93  (RuCl), (CCC) 315.46 24.68  (RuCl),  689.93 31.81  (CNRuN), (OCO) 283.63 16.82  (RuCl),  
286.13 4.81  (RuN), (RuN) 264.69 11.13  (RuN), (CNRu) 673.38 5.07  (CNRuN), (OCO) 278.39 2.94  (CCO), (RuCl) 
280.95 12.79  (RuCl),  227.22 6.04  (CCNRu), (CCCN) 321.41 3.87  (CNCC), (RuCl) 241.64 2.89  (ClRuCl), (RuN) 
237.07 9.37  (RuCl),  221.12 7.52  (ClRuN),  309.11 14.42  (RuCl),  232.77 3.69  (RuCl),  
189.03 4.39  (RuCl), (NNRu) 202.69 2.73  (RuCl), (NRuN) 268.68 3.63  (NRuN),  192.36 10.17  (ClRuCl), (CNNRu) 
177.31 5.4  (NNRuN), (RuN) 176.3 4.49  (NNRuN), (ClRuCl) 194.33 5.3  (RuCl),  155.78 4.09  (RuN),  
121.34 4.98  (ClNClRu), (CCN) 115.42 4.83  (RuClClN),  123.62 5.76  (ClNClRu), (CCN) 149.06 2.65  (ClNClRu),  
105.35 10.19  (NNRuN), (ClRuCl) 107.18 6.4  (ClRuCl),  112.51 10.5  (ClRuCl),  76.13 3.14  (ClRuCl), (ClNNRu) 
52.84 11.47  (CNNC), (NNNRu) 54.46 10.25  (CNRuN), (NRuCN) 99.37 6.5  (CRuCN),  67.91 4.67  (CNNRu),  
C17=Ru(bdmpza)(bphpza)Cl2 C18=Ru(bdmpza)(pyr)Cl2 C19=Ru(bdmpza)(dmbpyr)Cl2 C20=Ru(bdmpza)(dmphn)Cl2 
658.67 9.81  (CRuNN),  649.8 6.79  (CNCC), (CRuNN) 668.44 24  (CNRuN), (OCO) 653.05 3.26  (CNRuN),  
644.74 8.74  (CRuNN), (CRuNN) 486 3.34  (NNNRu),  412.5 6.06  (OCC), (NRuN) 419.01 7.05  (NRuN), (CCNC) 
341.4 3.43  (RuCl),  332.36 6.91  (RuCl),  348.68 2.79  (CNRuN), (CNCC) 349.09 7.3  (NRuN), (CCNC) 
313.85 5.22  (RuCl),  298.84 14.54  (RuCl),  296.78 4.44  (RuCl),  311.92 9.78  (RuCl),  
302.85 15.95  (RuCl),  223.83 7.31  (NNRu),  276.93 13.37  (RuCl),  287.2 8.04  (CCC), (RuCl) 
262.7 4.82  (CCN), (CNNRu) 189.25 5.44  (RuCl),  224.67 10.73  (RuCl),  251.9 3.83  (RuN),  
208.14 9.47  (RuN), (RuCl) 188.5 5.49  (ClNNRu), (NNNRu) 204.21 2.19  (CNRuN),  205.69 7.44  (ClRuCl), (RuCl) 
147.31 5.43  (ClRuN), (ClNClRu) 144.42 7.35  (ClRuCl), (ClNClRu) 189.86 5.15  (ClNNRu), (RuN) 192.9 3.58  (RuCl),  
134.09 3.32  (ClRuCl),  116.5 3.67  (RuN),  173.43 3.57  (ClNNRu),  149.93 13.65  (ClRuCl),  
123.13 4.14  (ClRuCl),  66.82 4.05  (CNNRu),  137.38 5.66  (RuN),  129.55 3.88  (ClRuN),  
C21=Ru(bdmpzm)(bpzm)Cl2 C22=Ru(bdmpzm)(bphpza)Cl2 C23=[Ru(bdmpzm)(bpzpy)Cl]+ C24=[Ru(bdmpzm)(bdmpzpy)Cl]+ 
648.12 3.55  (CNRuN),  654.97 4.67  (HCCN), (CNRuN) 645.64 2.67  (CNRuN), (CNRuN) 672.07 8.53  (RuN), (CCC) 
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382.22 4.73  (RuN), (CNRu) 286.78 16.84  (RuCl),  641.64 3.93  (HCCN), (CNRuN) 647.84 2.27  (CCNC), (CNRuN) 
335.39 6.15  (RuN), (NRuN) 250.22 2.12  (CNNRu), (RuCl) 636.13 5.23  (CNRuN), (CNRuN) 646.76 2.18  (CNRuN), (CNRuN) 
304.8 8.89  (RuCl),  240.94 3.87  (CNNRu), (RuCl) 635.35 4.52  (CCNN), (CNRuN) 309.34 6.34  (RuCl),  
259.7 10.85  (RuCl), (NRuN) 235.85 2.95  (RuCl), (NNRu) 349.26 3.88  (RuN), (RuCl)    
245.06 4.74  (CNNRu), (CCNC) 234.3 2.34  (RuCl),  329.89 7.11  (RuN),     
212.28 12.16  (RuCl),  216.35 3.98  (CNNRu),  286.41 8.84  (CCC), (RuNC)    
151.17 4.94  (RuCl), (NNRu) 160.11 2.67  (CNNRu),  235.65 4.22  (CCNC), (RuCl)    
118.62 3.32  (ClRuN), (CCNC) 101.58 2.25  (ClRuCl), (ClNClRu) 51.84 2.67  (NNRuN), (CNNRu)    
60.98 5.48  (CNNRu), (CNNRu)          
C25=(cym)Ru(pz)Cl2 C26=(cym)Ru(dmpz)Cl2 C27=(cym)Ru(dcpz)Cl2 C28=[(cym)Ru(bpzm)Cl]+ 
1012.1
4 12.92  (HCCRu), (HCCRu) 1010.99 10.74  (HCCRu), (HCCRu) 1015.58 10.91  (HCCRu), (HCCRu) 
1369.3
2 8.5  (HCCRu),  
838.81 18.94  (HCCRu), (HCCRu) 848.45 4.62  (HCCRu), (HCCRu) 844.4 30.05  (HCCRu), (HCCRu) 
1316.0
2 5.96  (HCC), (HCCRu) 
597.36 8.81  (CCNN), (CNNRu) 831.94 21.88  (HCCRu), (HCCRu) 654.47 15.05  (CRuNN), (HOCC) 
1005.5
4 16.15  (HCCRu), (HCCRu) 
286.8 20.18  (RuCl),  638.19 3.77  (CNRuN), (CCRuC) 641.54 7.65  (CRuCC),  848.3 16.45  (HCCRu), (HCCRu) 
273.87 9.65  (RuCl),  291.41 5.23  (RuN), (CCC) 544.18 10.41  (CCRuC), (CCC) 648.06 5.63  (CCRuC), (CRuCC) 
232.08 14.37  (RuCl), (NCCRu) 288.98 12.23  (RuCl), (CCC) 286.84 19.17  (RuCl),  438.88 5.25  (CRuCC), (CCRu) 
228.63 3.85  (RuN), (CRuCC) 262.51 14.52  (RuCl), (RuCl) 267.19 7.65  (RuCl), (CCO) 308.35 8.49  (RuC), (RuCl) 
211.41 3.6  (RuN), (CCC) 244.61 8.06  (RuCl), (CCC) 241.46 14.73  (RuCl), (CCO) 297.62 9.78  (RuCl), (CCC) 
182.45 6.73  (ClCClRu),  219.11 8.29  (CNNRu), (CCC) 213.18 9.12  (CRuCC), (CRuNN) 252.47 7.61  (RuN), (RuN) 
125.82 3.56  (ClRuN), (ClCNRu) 92.61 5.09  (CCRuC), (CCC) 196.82 5.29  (ClCClRu), (ClRuCl) 226.8 3.48  (CNNRu), (RuN) 
C29=[(cym)Ru(bpza)Cl]+ C30=[(cym)Ru(bdmpzm)Cl]+ C31=[(cym)Ru(bdmpza)Cl]+ C32=[(cym)Ru(bphpza)Cl]+ 
1006.8
2 15.14  (HCCRu), (HCCRu) 1364.32 5.84  (HCCRu), (CC) 1008.01 15.7  (HCCRu), (HCCRu) 
1013.9
5 15.58  (HCCRu), (HCCRu) 
848.28 15.5  (HCCRu), (HCCRu) 1006.88 16.18  (HCCRu), (HCCRu) 851.61 23.44  (HCCRu), (HCCRu) 890.22 4  (HCCRu), (HCCRu) 
648.61 13.08  (CCRuC), (OCO) 876.52 12.52  (HCCRu), (CC) 649.16 9.12  (CCRuC), (CCRuC) 867.06 18.69  (HCCRu), (HCCRu) 
628.22 22.52  (CNRuN), (OCO) 848.74 16.06  (HCCRu), (HCCRu) 639.79 52.65  (HCCN), (CRuNN) 702.5 3.72  (HCCN), (NCRuN) 
438.8 5.53  (RuC), (CCRu) 650.55 12.81  (CCRuC),  633.88 14.14  (HCCN), (CRuNN) 649.45 15.57  (OCO), (CCRuC) 
376.33 6.24  (CC), (NRuN) 541.18 5.96  (CCRuC),  427.31 3.45  (CCRuC), (CCRu) 646.76 72.85  (OCO), (CCRuC) 
304.91 7.65  (RuC), (RuCl) 377.2 4.68  (CCC), (RuC) 396.79 3.25  (NRuN),  293.41 11.9  (RuCl),  
296.92 9.56  (RuCl), (CCC) 310.53 7.83  (RuC),  295.16 11.24  (RuCl),  213.7 4.81  (HCCC), (CRuCC) 
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249.56 3.44  (RuN),  294.48 11.25  (RuCl),  218.78 3.78  (CNNRu),  111.38 6.03  (CCRuC),  
219.53 6.88  (CCRuC), (CNNRu) 234.89 8.69  (NRuN), (ClCNRu) 106.69 3.65  (NNRu), (CNNC) 109.34 5.47  (CCCRu), (ClCNRu) 
C33=[(cym)Ru(pyr)Cl]+ C34=[(cym)Ru(phn)Cl]+ C35=[(cym)Ru(dmbpyr)Cl]+ C36=[(cym)Ru(dmphn)Cl]+ 
1013.9
1 17.24  (HCH), (HCCRu) 1366.9 15.09  (HCCRu),  1009.61 14.54  (HCCRu), (HCH) 
1309.4
8 7.89  (HCCRu), (HCC) 
869.72 2.87  (HCCRu), (HCCRu) 1350.11 7.47  (HCCRu),  1007.33 7.84  (HCCRu), (NC) 
1004.3
9 10.35  (HCCRu), (HCCRu) 
841.74 16.35  (HCCRu), (HCCRu) 1309.54 8.6  (HCCRu), (HCC) 868.19 3.56  (HCCRu), (HCCRu) 
1002.5
1 22.44  (HCCRu), (HCCRu) 
316.53 5.82  (RuCl), (CCC) 1010.82 18.81  (HCCRu), (HCCRu) 844.53 16.07  (HCCRu), (HCCRu) 835.49 16.48  (HCCRu), (HCCRu) 
299.23 11.86  (RuCl),  842.21 15.06  (HCCRu), (HCCRu) 642.63 2.51  (CCRuC), (CCRu) 642.95 6.42  (CCRuC),  
271.58 3.3  (RuN), (CNRu) 378.96 3.66  (CCRuC), (CCRuC) 397.02 2.78  (CCRuC), (RuC) 415.44 4.45  (CCRuC), (RuC) 
228.35 2.5  (CCRu),  352.83 4.26  (RuC),  294.43 8.06  (CCNRu), (RuCl) 350.33 3.41  (RuCl), (CCRu) 
210.86 4.34  (CCRuC), (CCC) 315.28 7.05  (RuCl),  292.83 6.61  (RuCl),  313.28 4.76  (CCCC), (RuCl) 
150.16 2.1  (ClRuN), (HCCRu) 288.2 10.16  (RuCl),  287.95 8.88  (CCNRu), (RuCl) 295.67 6.23  (RuCl),  
92.18 4.41  (CCRuN), (CCNC) 96.42 5.64  (CCNRu), (CCRuN) 172.77 2.72  (CCRuC), (CCC) 95.57 3.51  (CCRuC), (CCRuC) 
C37=[(cym)Ru(dcbpyr)Cl]+ C38=[(cym)Ru(dcphn)Cl]+ C39=[(cym)Ru(bpzpy)]2+ C40=[(cym)Ru(bdmpzpy)]2+ 
1011.2
3 22.05  (HCCRu), (HCH) 1442.31 12.57  (HCCRu), (HCH) 1001.57 25.94  (HCCRu), (HCCRu) 995.83 28.76  (HCCRu), (HCCRu) 
876.47 6.74  (HCCRu), (CC) 1008.94 25.43  (HCCRu), (HCCRu) 947.26 6.15  (HCCRu), (HCCRu) 847.63 14.36  (HCCRu), (HCCRu) 
846.87 13.24  (HCCRu), (HCCRu) 840.76 17.98  (HCCRu), (HCCRu) 941.51 24.36  (HCCRu), (NC) 664.54 2.15  (RuN), (CNC) 
552.13 6.28  (CRuCC), (CCO) 558.1 5.12  (CCRuC),  854.88 11.58  (HCCRu), (HCCRu) 644.17 7.32  (CCRuC), (CRuCC) 
473.71 12.75  (CRuCN), (CRuCN) 479.7 4.38  (CCCC), (CRuCN) 649.2 13.61  (CCRuC), (CCRuC) 629.01 7.26  (CNRuN),  
425.98 11.08  (CRuCC), (CCN) 349.51 9.47  (CCRuC), (RuC) 630.94 4.43  (CNRuN), (NNCN) 427.75 8.14  (CCC), (CCRuC) 
413.68 7.06  (CCCN), (CRuCN) 316.12 5.78  (CC), (RuCl) 583.43 10.43  (CNRuN),  385.63 2.3  (CRuCC),  
384.42 12.16  (CRuCC),  310.25 4.48  (RuCl), (OCC) 571.91 7.11  (CNRuN),  382.18 2.34  (CRuCC), (RuC) 
291.45 11.93  (RuCl),  293.54 11.27  (RuCl),  373.7 6.51  (RuC), (CCC) 340.45 2.86  (CCC), (RuC) 
270.92 10.62  (CCNRu), (RuCl) 215.29 6.45  (CCRuC),  310.73 5.14  (RuN), (CCC) 248.71 2.4  (RuN),  
 
The symbols υ, β, τ, ο denote stretching, bending, torsional and out of plane modes respectively 
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Table 5.5: The experimental and the theoretical 
1
H-NMR chemical shift of the complexes 
 
ST1=RuCl2(dmso)4 
C12=Ru(bpza)(bpyr)Cl2 
cd3od C26=(cym)Ru(dmpz)Cl2 
 Direct Fitting Exp.  Direct Fitting Exp.  Direct Fitting Exp. 
CH3 
2.1997 to 
4.4991 
2.65631 to 
4.88673  C4-H 6.5058 6.83323 6.7 CH3 
0.9433 to 
3.0466 
1.4376 
to 
3.4778 
1.3256 
to 
2.8615 
ST2=[(cym)RuCl2]2 Cboth-H  
7.3994 to 
9.6078 
7.70002 to 
9.84217 
7.45 to 
9.60 Ccym-H 3.4544 3.87337 3.3273 
CH3 
0.6235 to 
3.3231 
1.12739 to 
3.74601 
0.085 to 
2.6817  COOH 8.6863 8.94831 8.7 C4-H 5.9241 6.26898 6.0605 
Ccym-H 
2.9233, 
4.0558 
3.3582, 
4.45673 
3.2095 
m CHOO 11.6051 11.7795 10.15 Cothers-H 
4.6375 to 
5.1353 
5.02098 
to 
5.50384 
5.4900 
to 
6.2804  
Cothers-
H 
4.1213 to 
5.6738 
4.52026 to 
6.02619 
5.3889 
to 
5.7844 
C13=Ru(bpza)(bmpyr)Cl2 
cd3od NH 12.3505 12.5026 6.1769 
     Direct Fitting Exp. C27=(cym)Ru(dcpz)Cl2 
CH3 
0.6235 to 
3.3231 
1.12739 to 
3.74601 
0.085 to 
2.6817   
2.161 to 
2.7532 
2.61877 to 
3.1932 
1.3 to 
3.5, 4.65 CH3 
0.7938 to 
2.9881 
1.29259 
to 
3.42106 
0.31 to 
2.25 
Ccy-H 
2.9233, 
4.0558 
3.3582, 
4.45673 
3.2095 
m C4-H 6.4838 6.81189 6.2 Ccym-H 3.4442 3.86347 3.5 
Cothers
-H 
4.1213 to 
5.6738 
4.52026 to 
6.02619 
5.3889 
to 
5.7844 
Cpyr-
metal-H 
7.285 to 
8.0257 
7.58905 to 
8.30753 
7.2 to 
7.75 COOH 
6.0912, 
6.3032 
6.43106, 
6.6367 6.49 
ST3=Ru(bdmpzm)Cl4 
dmso-d6 Cpz-H 
8.2894 to 
8.3592 
8.56332 to 
8.63102 
8.25 to 
8.50 
Cothers-
H 
5.1843 to 
7.4766 
5.55137 
to 
7.7749 
5.25 to 
8.10 
CH3 
1.343 to 
2.3934 
1.82531 to 
2.8442 
-3.493 
to 
2.5136 COOH 8.7815 9.04066 8.65 NH 14.1274 14.2262  
CH3 
3.2122 to 
5.1828 
3.63843 to 
5.54992  Cpyr-H 9.4605 9.69929 
9.25, 
9.48 
C28=[(cym)Ru(bpzm)Cl]
+
 
cd3od 
CH2  
4.7697, 
10.6551 
5.14921, 
10.858 
8.35, 
15.3879 CHOO 11.6333 11.8069 9.8 CH3 
1.1682 to 
2.8348 
1.65575 
to 
3.27236 
1.10250 
to 
2.8002 
C4-H 
6.0259, 
6.425 
6.36772, 
6.75485 6.85 
C14=Ru(bpza)(phn)Cl2 
cd3od Ccym-H 3.7071 4.11849 2.9194 
ST4=Ru(bpzm)Cl4 
dmso-d6 C4-H 
6.3707, 
6.3904 
6.70218, 
6.72129 
6.30, 
6.75 Cothers-H 
5.0375 to 
8.0385 
5.40898 
to 
8.31995 
5.8779 
to 
8.2705 
C3-H 
-1.8609 
to 1.067  
-1.28247 
to 0.51239  
1.4-
2.60 Cboth-H  
7.5782 to 
9.9948 
7.87345 to 
10.2176 
7.45-
10.00 CH2 
5.4604, 
6.163 
5.81919, 
6.50071 6.2793 
C4-H 
5.0695, 
5.6906 
5.44001, 
6.04248 
5.90, 
6.10 COOH 8.4649 8.73355 8.7 C4-H 
6.6671, 
6.6916 
6.98969, 
7.01345 
6.4228 
m 
C5-H 
9.7245, 
10.1933 
9.95537, 
10.4101 
7.95, 
8.25 CHOO 12.0857 12.2457 10.5 C29=[(cym)Ru(bpza)Cl]+  
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CH2 
11.1008, 
18.5331 
11.2904, 
18.4997 
6.60, 
8.65 
C15=Ru(bpza)(dmphn)Cl2 
cd3od CH3 
1.1805 to 
2.883 
1.66769 
to 
3.31911 
1.25-
1.89 
C1=[Ru(bpzm)3]
2+
 
dmso-d6 CH3 
2.4337 to 
4.237 
2.88329 to 
4.63249 1.3-3.75  Ccym-H 3.7585 4.16835 3.25 t 
C3-H & 
CH2 
close to 
Ru   
1.9202 
to 
3.36128 C4-H 
6.2744 to 
6.3412 
6.60877 to 
6.67356 6.75 Cothers-H 
5.0384 to 
8.076 
5.40985 
to 
8.35632 
4.5 to 
8.47 
CH2 
5.6819 to 
6.2487 
6.03404 to 
6.58384 
6.2825, 
6.3981, 
6.5036 Cboth-H  
7.531 to 
9.5706 
7.82767 to 
9.80608 
7.45 to 
8.35 C4-H 
6.6248, 
6.6443 
6.94866, 
6.96757 6.75 
C3-H 
6.2753 to 
7.8025 
6.60964 to 
8.09103 
6.584, 
7.3887 
d COOH 9.5706 9.80608 8.4 CHOO 7.0123 7.32453 7.45 
C4-H 
6.8616 to 
7.2786 
7.17835 to 
7.58284 
7.1258, 
8.3405 CHOO 12.2029 12.3594 8.75 COOH 7.558 7.85386 7.75 
C5-H 
8.1088 to 
8.3001 
8.38814 to 
8.5737 
8.9862 
d C16=Ru(bdmpza)(bdmpzm)Cl2 
C30=[(cym)Ru(bdmpzm)Cl]
+
 
cd3od 
C2=[Ru(bpza)3]
2+
 
cd3od CH3 
1.7417-
3.0087 
2.21205-
3.44104  CH3 
1.1465 to 
3.4373 
1.63471 
to 
3.85678 
1.1911 
to 
2.5440 
CHOO 
5.7556, 
6.6172, 
6.9762 
6.10553, 
6.94128, 
7.28951 7.2 CH2 5.1546 5.52256  Ccym-H 3.5759 3.99122 3.3235 
C3-H 
6.0137-
8.2067 
6.35589-
8.4831 
3.3, 
4.55, 
6.62 
CHCO
O 6.8879 7.20386  
Ccym-
others-H 
5.1312 to 
5.2828 
5.49986 
to 
5.64692 
4.5858 
to 
5.9934 
C4-H 
6.683-
8.3555 
7.00511-
8.62744 8.3 C4-H 
6.0986-
6.3274 
6.43824-
6.66018  CH2 
5.4869, 
5.5524 
5.84489, 
5.90843 6.2284 
COOH 
6.6619, 
6.9636, 
7.7326 
6.98464,7.
27729, 
8.02322 7.45 OH 12.3233 12.4762  C4-H 
6.2582, 
6.2691 
6.59305, 
6.60363 
6.4599, 
6.4984 
C5-H 
8.2618 to 
8.473 
8.53655 to 
8.74141 8.6 C17=Ru(bdmpza)(bphpza)Cl2 
C31=[(cym)Ru(bdmpza)Cl]
+
 
cd3od 
C3=[Ru(bdmpzm)3]
2+ CH3 
1.2658 to 
4.7416 
1.75043 
to 
5.12195 
0.0005 to 
4.5 CH3 
1.0621 to 
3.481 
1.55284 
to 
3.89917 
1.25 to 
2.80 
CH3 
0.0444 to 
0.7554 
0.565668-
1.25534 
0.45 
j=4.064
5 C4-H 
5.6465 to 
6.6277 
5.99971 to 
6.95147 
6.2 to 
6.70 Ccym-H 3.7142 4.12537 3.35 
CH3 
1.2721 to 
2.7988 
1.75654 to 
3.23744 
1.40 to 
3.6 COOH 
6.1607, 
6.7229 
6.49848, 
7.04381 6 Cothers-H 
5.1197 to 
6.3315 
5.48871 
to 
6.66416 
5.25 to 
6.25 
CH2 
4.9514 to 
5.591 
5.32546 to 
5.94587 
4.5-
5.90  
CHCO
O 
4.5957, 
9.0467 
4.98043, 
9.2979 
5.10, 
8.45 COOH 7.0006 7.31318 7.2 
C4-H 
6.0905 to 
6.4874 
6.43039 to 
6.81538 
6.10-
7.50 
Cothers
-H 
6.3964 to 
11.204 
6.72711 to 
11.3905 
6.30 to 
8.30 CHOO 8.1368 8.4153 7.35 
C4=[Ru(bdmpza)3]
2+
 C18=Ru(bdmpza)(pyr)Cl2 C32=[(cym)Ru(bphpza)Cl]
+ 
CH3 
-0.3125 
to 3.3415 
0.219475 
to 3.76386 
1.37 to 
3.25 CH3 
1.8435 to 
4.4619 
2.3108 to 
4.85064 
-1.25 to 
4.5 CH3 
0.1214 to 
2.6711 
0.64035
8 to 
0.8934 
to 
428 
3.11357 2.2399 
COOH 
6.3312 to 
7.1473 
6.66386 to 
7.45548 
6.20 to 
6.30 C4-H 
5.9843, 
6.1466 
6.32737, 
6.4848 5.8 Ccym-H 2.8585 3.29535 3.3232 
CHCO
O 
5.9573 to 
8.4983 
6.30118 to 
8.76595 
4.57 to 
7.5 COOH 10.0172 10.2393 8.8 CHOO 6.6128 6.93702 6.8836 
C4-H 
6.1631 to 
6.6569 
6.50081 to 
6.97979 
5.85 to 
6.75 
CHCO
O 11.5059 11.6833 8.85 COOH 7.3528 7.65482 7.7363 
C5=Ru(bpzm)2Cl2 
dmso-d6 
Cothers
-H 
7.2448 to 
10.0188 
7.55006 to 
10.2408 
7.25 to 
8.75 C4-H 
6.4789, 
6.5177 
6.80713, 
6.84477 6.7599 d 
CH2 
close to 
Ru    
1.2475 
to 
2.6256 C19=Ru(bdmpza)(bmpyr)Cl2 
Cothers
-H 
3.9623 to 
8.1705 
4.36603 
to 
8.44798 
3.8948 
to 
8.2431  
CH2 5.0856 5.45563 5.45 CH3 
1.9143 to 
4.2396 
2.37947 to 
4.63501 
0.7 to 
4.50 
C33=[(cym)Ru(bpyr)Cl]
+
 
cd3od 
C4-H 
6.4822 to 
6.4824 
6.81033 to 
6.81053 
6.2832 
to 6.398 C4-H 
6.0131, 
6.1564 
6.35531, 
6.49431 5.75-6.2 CH3 
0.18 to 
3.6035 
0.6972 
to 
4.01799 
0.351 to 
2.6466  
C5-H 
7.6729 to 
7.6731 
7.96531 to 
7.96551 
7.3900 
d Cpyr-H 
7.1533 to 
9.8071 
7.4613 to 
10.0355 
7.00 to 
8.25 Ccym-H 2.3908 2.84168 
3.3236 
m 
C3-H 
8.5384 to 
8.5387 
8.80485 to 
8.80514 8.25 COOH 10.3983 10.609 9.3 Cothers-H 
5.092 to 
9.1109 
5.46184 
to 
9.36017 
5.8573 
to 
9.4875  
CH2 
close to 
Cl 
9.9078 to 
9.9087 
10.1332 to 
10.134 9.12 CHOO 11.5308 11.7075 9.8 
C34=[(cym)Ru(phn)Cl]
+
 
ch3od  
C6=(bpza)2RuCl2 
cd3od C20=Ru(bdmpza)(dmphn)Cl2 CH3 
-0.1573 
to 3.6117 
ch3 
0.37001
9 to 
4.02595 
0.992 to 
2.6694 
CH4-H 
6.4986 to 
6.5308 
6.82624 to 
6.85748 
6.45 to 
6.55 CH3 
1.8295 to 
4.4504 
2.29722 
to 
4.83949 
0.0005 to 
3.6 Ccym-H 2.4358 2.88533 
3.3236 
m 
COOH 
6.8246, 
8.2115 
7.14246, 
8.48775 7.25 C4 
5.9292, 
6.0762 
6.27392, 
6.41651 4.5 Cothers-H 
5.2484 to 
9.3954 
5.61355 
to 
9.63614 
6.0115 
to 
9.8329  
CH  
8.0113 to 
8.8952 
8.29356 to 
9.15094 
7.75 to 
8.25 COOH 10.4203 10.6303 7.9 
C35=[(cym)Ru(dmbpyr)Cl]
+
 
cd3od 
CHCO
O 
11.4349, 
12.0581 
11.6145, 
12.219 8.5 
CHCO
O 11.8696 12.0361 8.62 CH3 
0.2371 to 
3.6452 
0.75258
7 to 
4.05844 
1.0543 
to 
2.6370  
C7=Ru(bdmpzm)2Cl2 
dmso-d6 Cothers 
7.4764 to 
8.0595 
7.77471 to 
8.34032 
7.15 to 
8.50 Ccym-H 2.3218 2.77475 
3.3237 
m 
CH3 
1.7889 to 
2.8282 
2.25783 to 
3.26595 
0.5318 
to 
2.4231 C21=Ru(bdmpzm)(bpzm)Cl2 Cothers-H 
4.9021 to 
8.9136 
5.27764 
to 
9.16879 
4.5896 
to 
9.2728  
CH2 
5.0994 to 
7.3616 
5.46902 to 
7.66335 
5.8128, 
7.4897 CH3 
2.0064 to 
4.6144 
2.46881 to 
4.99857 
0.03 to 
4.5 
C36=[(cym)Ru(dmphn)Cl]
+
 
cd3od  
C4-H 
6.1307 to 
6.1448 
6.46938 to 
6.48306 6.0301 CH2 
5.1876 to 
10.0813 
5.55457 
to 
10.3015 5.85 CH3 
-0.6152 
to 3.9726 
ch3 
-
0.07414
4 to 
4.37602 
0.7511 
to 
4.5859 
429 
ch3 
CH2 
close to 
Cl   12.2183 C4-H 
6.178 to 
6.5853 
6.51526 to 
6.91034 
6.2 to 
6.60 Ccym-H 1.8429 2.31021 
3.3234 
m 
C8=(bdmpza)2RuCl2 
cd3od 
Cmeta/orth
o 
7.7364 to 
8.6686 
8.02691 to 
8.93114 
7.7 to 
8.15 Cothers-H 
5.0622 to 
8.2611 
5.43293 
to 
8.53587 
5.9516 
to 
8.6379 
CH3 
1.5949 to 
3.2835 
2.06965 to 
3.70759 
1.3034 
to 
3.3233 C22=Ru(bdmpzm)(bphpza)Cl2 
C37=[(cym)Ru(dcbpyr)Cl]
+
 
cd3od 
OH 
5.9067 to 
6.0811 
6.2521-
6.42127 6.326 CH3 
1.3819 to 
3.2435 
1.86304 to 
3.66879 
0.5 to 
3.00 CH3 
0.1123 to 
3.5295 
0.63153
1 to 
3.94622 
1.3425 
to 
2.7960  
C4-H 
5.9004 to 
6.1089 
6.24599 to 
6.44823  CH2 
4.9123, 
5.4407 
5.28753, 
5.80008 4.4 Ccym-H 2.4061 2.85652 3.3238 
CHCO
O 
5.7043-
10.395 
6.05577-
10.6058  C4-H 
5.3841 to 
6.4622 
5.74518 to 
6.79093 
5.65 to 
6.50 Cothers-H 
5.1496 to 
9.2194 
5.51771 
to 
9.46542 
5.5010 
to 
5.8967 
C9=Ru(bpza)(bdmpza)Cl2 
cd3od COOH 6.5342 6.86077 6.5 COOH 
7.1791, 
7.2009 
7.48633, 
7.50747 ? 
CH3 
1.7475-
3.4751 
2.21767-
3.89345 
1.75-
3.4 CHOO 9.1972 9.44388 8.5 C38=[(cym)Ru(dcphn)Cl]+ 
C4-H 
5.9985-
6.5453 
6.34114-
6.87154 6.6 
Cothers-
H 
6.6881 to 
9.7762 
7.01006 to 
10.0055 
6.75 to 
7.60 CH3 
-0.9366 
to 3.5554  
-
0.38590
2 to 
3.97134  
1.3585 
to 
2.7951 
COOH 
6.4373, 
6.5145 
6.76678, 
6.84166 7.4 
C23=[Ru(bdmpzm)(bpzpy)Cl]
+
 
dmso-d6 Ccym-H 1.5631 2.03881 
3.3231 
m 
CHCO
O 
6.1833, 
12.8142 
6.5204, 
12.9524 8, 8.3 CH3 
1.235 to 
3.5675 
1.72055 to 
3.98308 
1.2433 to 
2.90009 Cothers-H 
4.7001 to 
9.035 
5.0817 
to 
9.28655 
5.5746 
to 
5.8970 
C10=Ru(bpza)(bdmpzm)Cl2 
cd3od CH2 
5.4281, 
6.083 
5.78786, 
6.42311 5.8132 COOH 
7.0155, 
7.4272 
7.32764, 
7.72698 5.5014 
CH3 
1.8912, 
3.3983 
2.35706, 
3.81895 
1.37-
3.38 C4-H 
6.0487 to 
6.92 
6.38984 to 
7.235 6.0305 
C39=[(cym)Ru(bpzpy)]
2+
 
cd3od 
CH2 
4.9934, 
6.4977 
5.3662, 
6.82537 6.37 
Cothers-
H 
7.2819 to 
8.453 
7.58604 to 
8.72201 
7.0168 to 
8.52 CH3 
-0.5245 
to 2.8097 
ch3 
0.01383
5 to 
3.24801 
0.351 to 
2.6204  
CHOO 6.1258 6.46463 7.6 C24=[Ru(bdmpzm)(bdmpzpy)Cl]+ Ccy-H 2.4369 2.88639 3.3235 
COOH 6.2759 6.61022 7.9 CH3 
1.1462 to 
3.6205 
1.63441 to 
4.03449 
0.004 to 
3.3812 
Cothers
-H 
5.2069 to 
8.6766 
5.57329 
to 
8.9389 
4.5856 
to 
8.9094 
C4-H 
6.1501 to 
6.5986 
6.4882 to 
6.92324 
6.25, 
7.45 CH2 
5.2537, 
5.6886 
5.61869, 
6.04054 4.4731 C4-H 
7.3245, 
7.3853 
7.62737, 
7.68634 7.0475 t 
Cmeta/
auto-H  
7.7382 to 
8.573 
8.02865 to 
8.83841 
7.12-
9.38 C4-H 
5.8014 to 
6.29 
6.14996 to 
6.6239  
C40=[(cym)Ru(bdmpzpy)]
2+
 
cd3od 
C11=Ru(bpza)(bphpza)Cl2 
Cothers-
H 
7.1411 to 
7.7839 
7.44947 to 
8.07298  CH3 
0.3559 to 
3.2041 
0.86782
3 to 
3.63058 
0.85 to 
2.7960 
C4-H 
5.604 to 
6.4217 
5.95848 to 
6.75165 
6.1814-
6.6143 C25=(cym)Ru(pz)Cl2 Ccym-H 2.0242 2.48607 
3.3238 
m 
430 
CHOO 
5.8653, 
12.6296 
6.21194, 
12.7733 6.1814 CH3 0.8757 1.37203 
0.9154 to 
3.1464 C4-H 
4.9929 to 
8.4043 
5.36571 
to 
8.67477 
5.5016 
to 
5.8976 
COOH 
6.3765, 
6.4681 
6.70781, 
6.79666 6.6471 Ccym-H 3.4953 3.91304 3.3234 
Cothers-
H 
6.7504, 
6.9064 
7.07049, 
7.22181 
5.7087, 
5.7245 
Cother-H 
6.8428 to 
9.6636 
7.16012 to 
9.89629 
7.2158 
to 
8.0988 
Cothers-
H 
4.5919 to 
7.5216 
4.97674 to 
7.81855 
5.4703 to 
8.0428     
    NH 12.5956 12.7403 8.2872     
 
 
 
 
Table 5.6: The theoretical 
13
C-NMR chemical shift of the complexes 
ST1=RuCl2(dmso)4 C14=Ru(bpza)(phn)Cl2 C28=[(cym)Ru(bpzm)Cl]
+ 
 Direct Fitting  Direct Fitting  Direct Fitting 
CH3 
47.3626 to 
52.04 
37.2616 to 
41.766 CHCOOH 72.3495 61.324 CH3 
18.7789 to 
26.512 
9.73552 to 
17.1825 
ST2=[(cym)RuCl2]2 C4 
104.598, 
104.781 
92.3792, 
92.5556 Ccym-H 36.0267 26.3452 
CH3 
18.3165 to 
27.773 
9.29023 to 
18.3968 Cothers 
118.162 to 
152.403 
105.442 to 
138.415 CH2 62.6565 51.9896 
Ccym-H 
33.3454, 
35.0746 
23.7631, 
25.4283 COOH 159.984 145.716 Carene 
79.0071 to 
121.491 
67.7353 to 
108.647 
Carene 
69.7615 to 
113.633 
58.8318 to 
101.08 C15=Ru(bpza)(dmphn)Cl2 C4 
107.453, 
107.537 
95.1291, 
95.21 
ST3=Ru(bdmpzm)Cl4 CH3 
30.0523 to 
30.2331 
20.5918 to 
20.7659 Cothers 
129.475 to 
147.91 
116.335 to 
134.089 
CH3 
12.0589 to 
27.3709 
3.26416 to 
18.0096 CHCOOH 70.4106 59.4568 C29=[(cym)Ru(bpza)Cl]+ 
CH2 55.7778 45.3655 C4 
104.07, 
104.37 
91.8708, 
92.1595 CH3 
18.7987 to 
26.2205 
9.75459 to 
16.9018 
C4 
107.921, 
108.993 
95.5792, 
96.6112 COOH 162.12 147.773 Ccym-H 36.0429 26.3608 
Cothers 
136.032, 
172.764 
122.65, 
158.023 Cothers 
120.089 to 
168.434 
107.297 to 
153.853 CHCOO 71.5687 60.5721 
ST4=Ru(bpzm)Cl4 C16=Ru(bdmpza)(bdmpzm)Cl2 Carene 
79.2783 to 
121.155 
67.9964 to 
108.324 
CH2 79.9513 68.6445 CH3 
13.3197 to 
20.7833 
4.47831 to 
11.6658 C4 
107.458, 
107.572 
95.1331, 
95.2432 
C4 
95.5082, 
96.9653 
83.6258, 
85.029 CHCOOH 
60.2745 to 
74.936 
49.6958 to 
63.8148 COOH 160.552 146.263 
Cothers 131.453 to 118.24 to C4 107.241 to 94.9241 to Cothers 129.599 to 116.456 to 
431 
135.939 122.561 111.998 99.5058 148.559 134.714 
C1=[Ru(bpzm)3]
2+ COOH 160.593 146.302 C30=[(cym)Ru(bdmpzm)Cl]+ 
CH2 
63.5237 to 
63.9444 
52.8248 to 
53.2299 Cothers 
137.258 to 
169.654 
123.831 to 
155.028 CH3 
12.657 to 
27.073 
3.84013 to 
17.7227 
C4 
109.026 to 
109.907 
96.6435 to 
97.4917 C17=Ru(bdmpza)(bphpza)Cl2 Ccym-H 37.1282 27.4059 
Cothers 
133.046 to 
146.798 
119.775 to 
133.018 CH3 
13.7964 to 
36.648 
4.93737 to 
26.9435 CH2 56.1486 45.7225 
C2=[Ru(bpza)3]
2+ C4 
115.879 to 
118.399 
103.243 to 
105.669 Carene 
73.5806 to 
130.166 
62.5096 to 
117.001 
CHCOOH 
71.8574 to 
77.5718 
60.8501 to 
66.3531 COOH 
157.57, 
164.584 
143.391, 
150.146 C4 
109.509, 
109.657 
97.1087, 
97.2507 
C4 
107.834 to 
110.422 
95.4951 to 
97.9879 CHCOO 
74.8581, 
77.9388 
63.7398, 
66.7065 Cothers 
141.036 to 
157.607 
127.469 to 
143.427 
Cothers 
131.594 to 
147.735 
118.377 to 
133.921 Cothers 
120.072 to 
181.055 
107.28 to 
166.008 
C31=[(cym)Ru(bdmpza)Cl]
+ 
CH3 
15.5562 to 26.8291 
6.63206 to 17.4879 COOH 
149.397 to 
157.702 
135.52 to 
143.518 C18=Ru(bdmpza)(pyr)Cl2 
C3=[Ru(bdmpzm)3]
2+ CH3 
14.0957 to 
18.5064 
5.2256 to 
9.4731 Ccym-H 36.7463 27.0381 
CH3 
11.8745 to 
18.0226 
3.08658 to 
9.0072 C4 
107.828, 
108.928 
95.4901, 
96.5493 CHCOO 73.5519 62.4819 
CH2 
56.2528 to 
60.0261 
45.8229 to 
49.4566 COOH 162.054 147.709 Carene 
73.8723 to 
130.694 
62.7905 to 
117.51 
C4 
109.542 to 
113.508 
97.14 to 
100.96 CHCOO 74.0061 62.9193 C4 
110.787, 
112.756 
98.3396, 
100.236 
Cothers 
142.488 to 
167.162 
128.868 to 
152.629 Cothers 
116.682 to 
157.968 
104.017 to 
143.775 Cothers 
142.338 to 
159.196 
128.723 to 
144.958 
C4=[Ru(bdmpza)3]
2+
 C19=Ru(bdmpza)(bmpyr)Cl2 COOH 159.875 145.611 
CH3 
12.2106 to 
19.4121 
3.41025 to 
10.3453 CH3 
14.3045 to 
22.2162 
5.42667 to 
13.0456 C32=[(cym)Ru(bphpza)Cl]+ 
CHCOO 
70.0217 to 
72.7851 
59.0823 to 
61.7435 CHCOOH 73.9388 62.8545 CH3 
18.7785 to 
26.2859 
9.73514 to 
16.9648 
COOH 
155.401 to 
156.647 
141.303 to 
142.502 C4 
108.002 to 
109.163 
95.6571 to 
96.7759 Ccym-H 35.3002 25.6455 
C4 
110.559 to 
114.307 
98.1199 to 
101.729 Cothers 
118.276 to 
157.95 
105.551 to 
143.757 CHCOO 72.2393 61.2179 
Cothers 
145.417 to 
166.575 
131.688 to 
152.063 COOH 162.358 148.003 Carene 
73.5694 to 
127.554 
62.4988 to 
114.486 
C5=Ru(bpzm)2Cl2 C20=Ru(bdmpza)(dmphn)Cl2 C4 
109.993 to 
110.92 
97.5747 to 
98.4673 
CH2 
65.3462, 
65.3487 
54.5798, 
54.5822 CH3 
14.1904 to 
26.9404 
5.3168 to 
17.595 COOH 158.471 144.259 
C4 
103.088 to 
103.09 
90.9252 to 
90.9271 C4 
107.877, 
108.065 
95.5369, 
95.7176 Cothers 
123.334 to 
164.701 
110.422 to 
150.259 
Cothers 
126.328 to 
144.377 
113.305 to 
130.686 COOH 162.363 148.007 C33=[(cym)Ru(bpyr)Cl]+ 
C6=(bpza)2RuCl2 CHCOO 74.6515 63.5408 CH3 
19.1232 to 
27.0098 
10.0671 to 
17.6619 
432 
CHCOOH 
72.1369, 
74.386 
61.1193, 
63.2852 Cothers 
118.888 to 
168.237 
106.141 to 
153.663 Ccym-H 35.8508 26.1758 
C4 
104.04 to 
104.713 
91.8415 to 
92.4899 C21=Ru(bdmpzm)(bpzm)Cl2 Carene 
85.0657 to 
111.04 
73.5697 to 
98.5827 
Cothers 
126.704 to 
145.995 
113.667 to 
132.244 CH3 
13.4804 to 
18.6111 
4.63307 to 
9.57393 Cothers 
119.835 to 
151.834 
107.053 to 
137.868 
COOH 
161.287 to 
163.813 
146.971 to 
149.404 CH2 
59.0564 to 
64.6519 
48.5228 to 
53.9112 C34=[(cym)Ru(phn)Cl]+ 
C7=Ru(bdmpzm)2Cl2 C4 
103.728 to 
107.549 
91.5415 to 
95.2214 CH3 
18.7032 to 
26.9675 
9.66262 to 
17.6211 
CH3 
13.3833 to 
21.1533 
4.53956 to 
12.0221 Cothers 
127.706 to 
157.332 
114.633 to 
143.162 Ccym-H 35.7585 26.0869 
CH2 
60.0465, 
60.0466 
49.4762, 
49.4763 C22=Ru(bdmpzm)(bphpza)Cl2 Carene 
84.4084 to 
110.293 
72.9367 to 
97.8634 
C4 
107.205 to 
110.517 
94.8901 to 
98.0791 CH3 
12.8977 to 
23.1103 
4.07193 to 
13.9067 Cothers 
122.069 to 
150.257 
109.204 to 
136.349 
Cothers 
136.267 to 
166.561 
122.877 to 
152.049 CHCOOH 
61.9346 to 
72.5808 
51.2945 to 
61.5468 C35=[(cym)Ru(bmpyr)Cl]+ 
C8=Ru(bdmpza)2Cl2 C4 
108.846 to 
112.139 
96.47 to 
99.6411 CH3 
19.3161 to 
27.2417 
10.2528 to 
17.8852 
CH3 
13.0639 to 
21.9522 
4.23198 to 
12.7914 COOH 163.992 149.576 Ccym-H 36.101 26.4167 
CHCOOH 
70.9543 to 
75.2078 
59.9804 to 
64.0766 Cothers 
121.102 to 
172.733 
108.272 to 
157.994 Carene 
84.4764 to 
116.693 
73.0022 to 
104.027 
C4 
108.44 to 
111.769 
96.0794 to 
99.2849 C23=[Ru(bdmpzm)(bpzpy)Cl]+ Cothers 
120.585 to 
151.507 
107.775 to 
137.553 
COOH 
160.161 to 
161.017 
145.887 to 
146.71 CH3 
12.5549 to 
18.8141 
3.74181 to 
9.76942 C36=[(cym)Ru(dmphn)Cl]+ 
Cothers 
135.815 to 
173.386 
122.441 to 
158.622 CH2 55.8971 45.4803 CH3 
18.9445 to 
28.653 
9.89499 to 
19.2443 
C9=Ru(bpza)(bdmpza)Cl2 Cpyr-meta 
102.3, 
104.445 
90.1667, 
92.2315 Ccym-H 35.2764 25.6226 
CH3 
15.5098 to 
18.9948 
6.58738 to 
9.94343 C4 
108.984, 
109.543 
96.6032, 
97.1411 Carene 
80.3863 to 
120.244 
69.0634 to 
107.447 
CHCOOH 
73.82, 
75.4064 
62.7401, 
64.2678 Cothers 
126.207 to 
158.756 
113.188 to 
144.533 Cothers 
123.3 to 
163.651 
110.39 to 
149.248 
C4 
103.767, 
108.817 
91.5787, 
96.4426 C24=[Ru(bdmpzm)(bdmpzpy)Cl]+ C37=[(cym)Ru(dcbpyr)Cl]+ 
Cothers 
128.885 to 
157.716 
115.767 to 
143.532 CH3 
11.907, 
18.3856 
3.11788, 
9.35677 CH3 
19.0201 to 
27.1085 
9.9678 to 
17.7569 
COOH 
162.388, 
163.275 
148.031, 
148.885 CH2 56.1542 45.7279 Ccym-H 35.9646 26.2853 
C10=Ru(bpza)(bdmpzm)Cl2 Cpyr-meta 
100.451, 
102.543 
88.3857, 
90.4004 Carene 
85.8985 to 
112.987 
74.3717 to 
100.458 
CH3 
13.2915 to 
22.1584 
4.45115 to 
12.99 C4 
108.089 to 
109.407 
95.7413 to 
97.0107 Cothers 
120.263 to 
152.049 
107.464 to 
138.075 
CH2 61.2872 50.671 Cothers 
133.53 to 
159.222 
120.241 to 
144.983 COOH 
159.41 to 
159.976 
145.163 to 
145.708 
CHCOOH 76.4295 65.253 C25=(cym)Ru(pz)Cl2 C38=[(cym)Ru(dcphn)Cl]+ 
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C4 
104.57 to 
111.54 
92.3521 to 
99.0647 CH3 
19.2194 to 
26.5616 
10.1597 to 
17.2303 CH3 
18.5994 to 
28.6687 
9.56266 to 
19.2594 
COOH 162.81 148.437 Ccym-H 34.6488 25.0182 Ccym-H 36.6414 26.9371 
Cothers 
128.089 to 
166.493 
115.001 to 
151.984 C4 102.958 90.7997 Carene 
85.3531 to 
118.217 
73.8465 to 
105.494 
C11=Ru(bpza)(bphpza)Cl2 Carene 
76.6877 to 
108.219 
65.5017 to 
95.8662 Cothers 
125.413 to 
155.32 
112.424 to 
141.224 
CHCOOH 
73.9941, 
75.3019 
62.9078, 
64.1672 Cothers 
122.235, 
135.042 
109.363, 
121.697 COOH 
160.975 to 
164.542 
146.67 to 
150.105 
C4 
103.105 to 
107.7 
90.9412 to 
95.3662 C26=(cym)Ru(dmpz)Cl2 C39=[(cym)Ru(bpzpy)]
2+ 
Cothers 
121.575 to 
161.444 
108.728 to 
147.122 CH3 
11.7005 to 
26.7558 
2.91902 to 
17.4173 CH3 
17.5248, 
27.4515 
8.52782, 
18.0872 
COOH 
160.185 to 
162.003 
145.91 to 
147.66 Ccym-H 34.8921 25.2525 Ccym-H 37.4655 27.7307 
C12=Ru(bpza)(bpyr)Cl2 C4 105.316 93.0707 Cpyr-meta 
107.246 to 
107.524 
94.929 to 
95.1972 
CHCOOH 71.8354 60.8289 Carene 
80.5659 to 
107.099 
69.2364 to 
94.7875 Carene 
77.3561 to 
127.122 
66.1454 to 
114.07 
C4 104.52 92.3043 Cothers 
137.421, 
150.238 
123.988, 
136.33 C4 
113.882 to 
114.335 
101.32 to 
101.756 
Cothers 
117.342 to 
156.954 
104.652 to 
142.798 C27=(cym)Ru(dcpz)Cl2 Cothers 
130.487 to 
151.771 
117.31 to 
137.807 
COOH 161.254 146.939 CH3 
18.91 to 
26.4946 
9.86177 to 
17.1657 C40=[(cym)Ru(bdmpzpy)]2+ 
C13=Ru(bpza)(dmbpyr)Cl2 Ccym-H 35.169 25.5192 CH3 
15.2042 to 
27.3715 
6.29308 to 
18.0102 
CH3 22.2139 13.0434 Carene 
76.3656 to 
114.84 
65.1915 to 
102.242 Ccym-H 35.6869 26.0179 
CHCOOH 71.8527 60.8456 C4 114.258 101.682 Cpyr-meta 
105.05 to 
106.165 
92.8141 to 
93.8887 
C4 104.425 92.2132 Cothers 
129.729, 
139.425 
116.58, 
125.918 Carene 
80.0787 to 
114.876 
68.7672 to 
102.277 
Cothers 
118.415 to 
156.586 
105.685 to 
142.444 COOH 
154.51, 
159.353 
140.444, 
145.108 C4 
113.327, 
114.411 
100.786, 
101.829 
COOH 161.36 147.041    Cothers 
143.64 to 
165.472 
129.977 to 
151.001 
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Table 5.7: The theoretical 
15
N-NMR chemical shift of the complexes 
ST3=Ru(bdmpzm)Cl4 C13=Ru(bpza)(bmpyr)Cl2 C25=(cym)Ru(pz)Cl2 
 Direct Fitting  Direct Fitting  Direct Fitting 
N13 
 -181.495, -
181.049 
-201.692, -
201.271 N21 
 -166.733, -
166.733 
-187.728, -
187.728 N6 -175.844 -196.347 
*N15 
 -156.809, -
144.702 
-178.34, -
166.887 *N22 
 -92.9174, -
92.9148 
-117.898, -
117.896 *N7 -136.851 -159.459 
ST4=Ru(bpzm)Cl4 **N15 
 -80.3983, -
80.3983 
-106.055, -
106.055 C26=(cym)Ru(dmpz)Cl2 
N6 
 -157.105 to 
-148.771 
-178.62 to -
170.736 C14=Ru(bpza)(phn)Cl2 N14 -179.772 -200.062 
*N9 
 -142.573 to 
-116.768 
-164.873 to 
-140.461 N26 
 -167.658, -
167.039 
-188.603, -
188.017 *N10 -144.371 -166.573 
C1=[Ru(bpzm)3]
2+ *N25 
 -97.1494, -
95.5598 
-121.902, -
120.398 C27=(cym)Ru(dcpz)Cl2 
N11 
 -176.048 to 
-171.199 
-196.54 to -
191.952 **N14 
 -75.3446, -
75.2441 
-101.274, -
101.179 N6 -149.63 -171.549 
*N15 
 -130.373 to 
-123.828 
-153.331 to 
-147.139 C15=Ru(bpza)(dmphn)Cl2 *N8 -103.087 -127.518 
C2=[Ru(bpza)3]
2+ N19 
 -165.185, -
161.526 
-186.264, -
182.802 C28=[(cym)Ru(bpzm)Cl]+ 
N20 
 -176.97 to -
173.766 
-197.412 to 
-194.381 *N21 
 -92.9129, -
92.7386 
-117.894, -
117.729 N7 
 -177.922, -
177.858 
-198.312, -
198.252 
*N24 
 -134.993 to 
-121.229 
-157.702 to 
-144.681 **N13 
 -89.8653, -
89.6946 
-115.011, -
114.849 *N6 
 -138.632, -
137.807 
-161.144, -
160.363 
C3=[Ru(bdmpzm)3]
2+
 C16=Ru(bdmpza)(bdmpzm)Cl2 C29=[(cym)Ru(bpza)Cl]
+ 
N10 
 -183.353 to 
-176.566 
-203.45 to -
197.03 N19 
 -181.222 to 
-176.065 
-201.435 to 
-196.556 N7 
 -177.432, -
176.844 
-197.849, -
197.293 
*N29 
 -141.777 to 
-128.006 
-164.119 to 
-151.092 *N11 
 -121.603 to 
-85.4027 
-145.035 to 
-110.789 *N6 
 -138.416, -
137.287 
-160.94, -
159.871 
C4=[Ru(bdmpza)3]
2+
 C17=Ru(bdmpza)(bphpza)Cl2 C30=[(cym)Ru(bdmpzm)Cl]
+ 
N 
-187.441 to 
-175.14 
-207.318 to 
-195.68 N 
-181.563 to 
-167.398 
-201.757 to 
-188.356 N21 
 -182.473, -
182.278 
-202.618, -
202.433 
*N 
-148.996 to 
-127.453 
-170.948 to 
-150.569 *N 
-148.271 to 
-78.279 
-170.263 to 
-104.05 *N10 
 -153.084, -
152.365 
-174.816, -
174.136 
C5=Ru(bpzm)2Cl2 C18=Ru(bdmpza)(bpyr)Cl2 C31=[(cym)Ru(bdmpza)Cl]
+
 
N20 
 -165.549 to 
-165.544 
-186.607 to 
-186.603 N 
-173.395, -
171.84 
-194.03, -
192.558 N14 
 -181.13, -
176.366 
-201.347, -
196.841 
*N12 
 -96.7244 to 
-96.7137 
-121.5 to -
121.489 *N 
-105.426, -
104.475 
-129.731, -
128.831 *N13 
 -148.759, -
142.106 
-170.724, -
164.431 
C6=(bpza)2RuCl2 **N 
-71.0856, -
68.9597 
-97.2452, -
95.2341 C32=[(cym)Ru(bphpza)Cl]+ 
N11 
 -168.083 to 
-165.971 
-189.004 to 
-187.007 C19=Ru(bdmpza)(bmpyr)Cl2 N12 
 -178.776, -
178.136 
-199.121, -
198.515 
*N25 
 -99.8158 to 
-95.1468 
-124.424 to 
-120.007 N21 
 -172.97, -
171.239 
-193.628, -
191.99 *N18 
 -143.577, -
139.581 
-165.822, -
162.041 
C7=Ru(bdmpzm)2Cl2 *N22  -102.059, - -126.546, - C33=[(cym)Ru(bpyr)Cl]
+ 
435 
101.685 126.192 
N12 
 -175.653 to 
-172.202 
-196.166 to 
-192.902 **N17 
 -79.6672, -
77.6318 
-105.363, -
103.438 N14 
 -117.649, -
117.001 
-141.294, -
140.681 
*N14 
 -109.383 to 
-82.5676 
-133.474 to 
-108.107 C20=Ru(bdmpza)(dmphn)Cl2 C34=[(cym)Ru(phn)Cl]
+ 
C8=(bdmpza)2RuCl2 N 
-175.591, -
172.745 
-196.107, -
193.415 N20 
 -122.033, -
121.999 
-145.442, -
145.409 
N22 
 -182.799 to 
-174.672 
-202.926 to 
-195.238 *N 
-104.192, -
103.005 
-128.564, -
127.441 C35=[(cym)Ru(dmbpyr)Cl]+ 
*N26 
 -108.623 to 
-75.8315 
-132.756 to 
-101.735 **N 
-82.9872, -
80.2264 
-108.504, -
105.892 N16 
 -127.587, -
126.295 
-150.696, -
149.473 
C9=Ru(bpza)(bdmpza)Cl2 C21=Ru(bdmpzm)(bpzm)Cl2 C36=[(cym)Ru(dmphn)Cl]
+ 
N12 
 -173.823 to 
-170.386 
-194.435 to 
-191.184 N17 
 -171.251 to 
-169.201 
-192.002 to 
-190.062 N16 
 -127.805, -
127.479 
-150.902, -
150.593 
*N11 
 -105.216 to 
-95.5199 
-129.533 to 
-120.36 *N12 
 -106.409 to 
-91.2202 
-130.662 to 
-116.293 C37=[(cym)Ru(dcbpyr)Cl]+ 
C10=Ru(bpza)(bdmpzm)Cl2 C22=Ru(bdmpzm)(bphpza)Cl2 N18 
 -107.593, -
106.867 
-131.781, -
131.094 
N21 
 -181.444 to 
-173.345 
-201.645 to 
-193.983 N32 
 -179.023 to 
-171.119 
-199.354 to 
-191.877 C38=[(cym)Ru(dcphn)Cl]+ 
*N13 
 -109.567 to 
-71.3737 
-133.649 to 
-97.5178 *N35 
 -117.541 to 
-80.3074 
-141.192 to 
-105.969 N17 
 -113.457, -
108.732 
-137.328, -
132.858 
C11=Ru(bpza)(bphpza)Cl2 C23=[Ru(bdmpzm)(bpzpy)Cl]
+
 C39=[(cym)Ru(bpzpy)]
2+ 
N35 
 -177.488 to 
-167.536 
-197.902 to 
-188.488 N8 
 -181.61, -
146.035 
-201.801, -
168.147 N14 
 -152.866, -
152.189 
-174.609, -
173.969 
*N20 
 -111.161 to 
-102.287 
-135.156 to 
-126.762 *N21 
 -135.611, -
93.6459 
-158.287, -
118.587 *N10 
 -132.773, -
129.918 
-155.602, -
152.9 
C12=Ru(bpza)(bpyr)Cl2 **N22 -120.774 -144.251 **N20 -180.978 -201.204 
N19 
 -167.14, -
167.14 
-188.112, -
188.113 C24=[Ru(bdmpzm)(bdmpzpy)Cl]+ C40=[(cym)Ru(bdmpzpy)]2+ 
*N21 
 -94.6212, -
94.6204 
-119.51, -
119.509 N23 
 -183.436, -
150.135 
-203.529, -
172.026 N21 
 -157.459, -
157.311 
-178.955, -
178.815 
**N11 
 -71.0549, -
71.0546 
-97.2162, -
97.2159 *N31 
 -133.077, -
100.797 
-155.889, -
125.353 *N8 
 -142.11, -
137.12 
-164.434, -
159.713 
   **N18 -120.52 -144.01 **N23 -184.133 -204.188 
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Table 5.8: The theoretical 
99
Ru-NMR chemical shift of the complexes 
ST1=RuCl2(dmso)4 3377.96 C19=Ru(bdmpza)(bmpyr)Cl2 6333.7 
ST2=[(cym)RuCl2]2 
2654.78, 
2452.7 C20=Ru(bdmpza)(dmphn)Cl2 7265.29 
ST3=Ru(bdmpzm)Cl4 -13438.4 C21=Ru(bdmpzm)(bpzm)Cl2 7914.36 
ST4=Ru(bpzm)Cl4 -40545.6 C22=Ru(bdmpzm)(bphpza)Cl2 9855.22 
C1=[Ru(bpzm)3]
2+ 5526.45 C23=[Ru(bdmpzm)(bpzpy)Cl]+ 5787.75 
C2=[Ru(bpza)3]
2+ 5530.61 C24=[Ru(bdmpzm)(bdmpzpy)Cl]+ 5841.54 
C3=[Ru(bdmpzm)3]
2+ 7790.17 C25=(cym)Ru(pz)Cl2 1679.79 
C4=[Ru(bdmpza)3]
2+ 9015.25 C26=(cym)Ru(dmpz)Cl2 1936.47 
C5=Ru(bpzm)2Cl2 6862.85 C27=(cym)Ru(dcpz)Cl2 2137.24 
C6=(bpza)2RuCl2 6442.06 C28=[(cym)Ru(bpzm)Cl]
+ 1947.45 
C7=Ru(bdmpzm)2Cl2 9268.49 C29=[(cym)Ru(bpza)Cl]
+ 1988.9 
C8=(bdmpza)2RuCl2 9816.82 C30=[(cym)Ru(bdmpzm)Cl]
+ 2236.22 
C9=Ru(bpza)(bdmpza)Cl2 6676.96 C31=[(cym)Ru(bdmpza)Cl]
+ 2347.68 
C10=Ru(bpza)(bdmpzm)Cl2 7639.57 C32=[(cym)Ru(bphpza)Cl]
+ 2515.19 
C11=Ru(bpza)(bphpza)Cl2 7248.84 C33=[(cym)Ru(bpyr)Cl]
+ 1616.12 
C12=Ru(bpza)(bpyr)Cl2 5450.3 C34=[(cym)Ru(phn)Cl]
+ 1606.05 
C13=Ru(bpza)(bmpyr)Cl2 5561.2 C35=[(cym)Ru(dmbpyr)Cl]
+ 1570.07 
C14=Ru(bpza)(phn)Cl2 5831.23 C36=[(cym)Ru(dmphn)Cl]
+ 2118.21 
C15=Ru(bpza)(dmphn)Cl2 8247.75 C37=[(cym)Ru(dcbpyr)Cl]
+ 1589.16 
C16=Ru(bdmpza)(bdmpzm)Cl2 9547.58 C38=[(cym)Ru(dcphn)Cl]
+ 2274.08 
C17=Ru(bdmpza)(bphpza)Cl2 7679.13 C39=[(cym)Ru(bpzpy)]
2+ 2628.34 
C18=Ru(bdmpza)(bpyr)Cl2 6293.47 C40=[(cym)Ru(bdmpzpy)]2+ 2556.3 
 
